(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 27 September 2001 (27.09.2001)

(10) International Publication Number WO 01/070979 A3

- (51) International Patent Classification7: C12N 15/12, C07K 14/47, C12Q 1/68, C07K 16/18, G01N 33/68. 33/574 // A61P 15/08, 35/00
- (21) International Application Number: PCT/US01/09126
- (22) International Filing Date: 21 March 2001 (21.03.2001)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/191,031	21 March 2000 (21.03.2000)	US
60/207,124	25 May 2000 (25.05.2000)	US
60/211,940	15 June 2000 (15.06.2000)	US
60/216,820	7 July 2000 (07.07.2000)	US
60/220,661	25 July 2000 (25.07.2000)	US
60/257,672	21 December 2000 (21.12.2000)	US

- (71) Applicant: MILLENNIUM PHARMACEUTICALS, INC. [US/US]; 75 Sidney Street, Cambridge, MA 02139 (US).
- (72) Inventors: LEE, John; 119 Walnut Street, Somerville, MA 02145 (US). LILLIE, James; 3 WildMeadow Lane, Natick, MA 01760 (US).
- 74) Agents: SMITH, DeAnn, F. et al.; Lahive & Cockfield, LLP, 28 State Street, Boston, MA 02109 (US).

- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- (88) Date of publication of the international search report: 4 July 2002
- (48) Date of publication of this corrected version:

1 August 2002

(15) Information about Correction:

see PCT Gazette No. 31/2002 of 1 August 2002, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: GENES, COMPOSITIONS, KITS, AND METHOD FOR IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF OVARIAN CANCER

(57) Abstract: The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human ovarian cancers. A variety of novel markers are provided, wherein changes in the levels of expression of one or more of the markers is correlated with the presence of ovarian cancer.

- 1 -

COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF OVARIAN CANCER

5

RELATED APPLICATIONS

The present application claims priority to U.S. provisional patent application serial no. 60/191,031 filed on March 21, 2000, U.S. provisional patent application serial no. 60/207,124, filed on May 25, 2000, U.S. provisional patent application serial no. 60/211,940, filed on June 15, 2000, U.S. provisional patent application serial no. 60/216,820, filed on July 7, 2000, U.S. provisional patent application serial no. 60/220,661, filed on July 25, 2000, and U.S. provisional patent application serial no. 60/257,672, filed on December 21, 2000, all of which are expressly incorporated by reference.

15

10

FIELD OF THE INVENTION

The field of the invention is ovarian cancer, including diagnosis, characterization, management, and therapy of ovarian cancer.

BACKGROUND OF THE INVENTION

Ovarian cancer is responsible for significant morbidity and mortality in populations around the world. Ovarian cancer is classified, on the basis of clinical and pathological features, in three groups, namely epithelial ovarian cancer (EOC; >90% of ovarian cancer in Western countries), germ cell tumors (circa 2-3% of ovarian cancer), and stromal ovarian cancer (circa 5% of ovarian cancer; Ozols et al., 1997, Cancer

Principles and Practice of Oncology, 5th ed., DeVita et al., Eds. pp. 1502). Relative to

EOC, germ cell tumors and stromal ovarian cancers are more easily detected and treated at an early stage, translating into higher/better survival rates for patients afflicted with these two types of ovarian cancer.

There are numerous types of ovarian tumors, some of which are benign, and
others of which are malignant. Treatment (including non-treatment) options and
predictions of patient outcome depend on accurate classification of the ovarian cancer.
Ovarian cancers are named according to the type of cells from which the cancer is

15

20

25

30

derived and whether the ovarian cancer is benign or malignant. Recognized histological tumor types include, for example, serous, mucinous, endometrioid, and clear cell tumors. In addition, ovarian cancers are classified according to recognized grade and stage scales.

In grade I, the tumor tissue is well differentiated from normal ovarian tissue. In grade II, tumor tissue is moderately well differentiated. In grade III, the tumor tissue is poorly differentiated from normal tissue, and this grade correlates with a less favorable prognosis than grades I and II. Stage I is generally confined within the capsule surrounding one (stage IA) or both (stage IB) ovaries, although in some stage I (i.e. stage IC) cancers, malignant cells may be detected in ascites, in peritoneal rinse fluid, or on the surface of the ovaries. Stage II involves extension or metastasis of the tumor from one or both ovaries to other pelvic structures. In stage IIA, the tumor extends or has metastasized to the uterus, the fallopian tubes, or both. Stage IIB involves extension of the tumor to the pelvis. Stage IIC is stage IIA or IIB in which malignant cells may be detected in ascites, in peritoneal rinse fluid, or on the surface of the ovaries. In stage III. the tumor comprises at least one malignant extension to the small bowel or the omentum, has formed extrapelvic peritoneal implants of microscopic (stage IIIA) or macroscopic (< 2 centimeter diameter, stage IIIB; > 2 centimeter diameter, stage IIIC) size, or has metastasized to a retroperitoneal or inguinal lymph node (an alternate indicator of stage IIIC). In stage IV, distant (i.e. non-peritoneal) metastases of the tumor can be detected.

The durations of the various stages of ovarian cancer are not presently known, but are believed to be at least about a year each (Richart et al., 1969, Am. J. Obstet. Gynecol. 105:386). Prognosis declines with increasing stage designation. For example, 5-year survival rates for patients diagnosed with stage I, II, III, and IV ovarian cancer are 80%, 57%, 25%, and 8%, respectively.

Despite being the third most prevalent gynecological cancer, ovarian cancer is the leading cause of death among those afflicted with gynecological cancers. The disproportionate mortality of ovarian cancer is attributable to a substantial absence of symptoms among those afflicted with early-stage ovarian cancer and to difficulty diagnosing ovarian cancer at an early stage. Patients afflicted with ovarian cancer most often present with non-specific complaints, such as abnormal vaginal bleeding,

30

gastrointestinal symptoms, urinary tract symptoms, lower abdominal pain, and generalized abdominal distension. These patients rarely present with paraneoplastic symptoms or with symptoms which clearly indicate their affliction. Presently, less than about 40% of patients afflicted with ovarian cancer present with stage I or stage II. Management of ovarian cancer would be significantly enhanced if the disease could be detected at an earlier stage, when treatments are much more generally efficacious.

Ovarian cancer may be diagnosed, in part, by collecting a routine medical history from a patient and by performing physical examination, x-ray examination, and chemical and hematological studies on the patient. Hematological tests which may be indicative of ovarian cancer in a patient include analyses of serum levels of proteins designated CA125 and DF3 and plasma levels of lysophosphatidic acid (LPA). Palpation of the ovaries and ultrasound techniques (particularly including endovaginal ultrasound and color Doppler flow ultrasound techniques) can aid detection of ovarian tumors and differentiation of ovarian cancer from benign ovarian cysts. However, a definitive diagnosis of ovarian cancer typically requires performing exploratory laparotomy of the patient.

Potential tests for the detection of ovarian cancer (e.g., screening, reflex or monitoring) may be characterized by a number of factors. The "sensitivity" of an assay refers to the probability that the test will yield a positive result in an individual afflicted with ovarian cancer. The "specificity" of an assay refers to the probability that the test will yield a negative result in an individual not afflicted with ovarian cancer. The "positive predictive value" (PPV) of an assay is the ratio of true positive results (i.e. positive assay results for patients afflicted with ovarian cancer) to all positive results (i.e. positive assay results for patients afflicted with ovarian cancer + positive assay results for patients not afflicted with ovarian cancer). It has been estimated that in order for an assay to be an appropriate population-wide screening tool for ovarian cancer the assay must have a PPV of at least about 10% (Rosenthal et al., 1998, Sem. Oncol. 25:315-325). It would thus be desirable for a screening assay for detecting ovarian cancer in patients to have a high sensitivity and a high PPV. Monitoring and reflex tests would also require appropriate specifications.

25

30

Owing to the cost, limited sensitivity, and limited specificity of known methods of detecting ovarian cancer, screening is not presently performed for the general population. In addition, the need to perform laparotomy in order to diagnose ovarian cancer in patients who screen positive for indications of ovarian cancer limits the desirability of population-wide screening, such that a PPV even greater than 10% would be desirable.

Prior use of serum CA125 level as a diagnostic marker for ovarian cancer indicated that this method exhibited insufficient specificity for use as a general screening method. Use of a refined algorithm for interpreting CA125 levels in serial retrospective samples obtained from patients improved the specificity of the method without shifting detection of ovarian cancer to an earlier stage (Skakes, 1995, Cancer 76:2004). Screening for LPA to detect gynecological cancers including ovarian cancer exhibited a sensitivity of about 96% and a specificity of about 89%. However, CA125based screening methods and LPA-based screening methods are hampered by the presence of CA125 and LPA, respectively, in the serum of patients afflicted with conditions other than ovarian cancer. For example, serum CA125 levels are known to be associated with menstruation, pregnancy, gastrointestinal and hepatic conditions such as colitis and cirrhosis, pericarditis, renal disease, and various non-ovarian malignancies. Serum LPA is known, for example, to be affected by the presence of non-ovarian gynecological malignancies. A screening method having a greater specificity for ovarian cancer than the current screening methods for CA125 and LPA could provide a population-wide screening for early stage ovarian cancer.

Presently greater than about 60% of ovarian cancers diagnosed in patients are stage III or stage IV cancers. Treatment at these stages is largely limited to cytoreductive surgery (when feasible) and chemotherapy, both of which aim to slow the spread and development of metastasized tumor. Substantially all late stage ovarian cancer patients currently undergo combination chemotherapy as primary treatment, usually a combination of a platinum compound and a taxane. Median survival for responding patients is about one year. Combination chemotherapy involving agents such as doxorubicin, cyclophosphamide, cisplatin, hexamethylmelamine, paclitaxel, and methotrexate may improve survival rates in these groups, relative to single-agent therapies. Various recently-developed chemotherapeutic agents and treatment regimens

have also demonstrated usefulness for treatment of advanced ovarian cancer. For example, use of the topoisomerase I inhibitor topectan, use of amifostine to minimize chemotherapeutic side effects, and use of intraperitoneal chemotherapy for patients having peritoneally implanted tumors have demonstrated at least limited utility.

Presently, however, the 5-year survival rate for patients afflicted with stage III ovarian cancer is 25%, and the survival rate for patients afflicted with stage IV ovarian cancer is 8%.

In summary, the earlier ovarian cancer is detected, the aggressiveness of therapeutic intervention and the side effects associated with therapeutic intervention are minimized. More importantly, the earlier the cancer is detected, the survival rate and quality of life of ovarian cancer patients is enhanced. Thus, a pressing need exists for methods of detecting ovarian cancer as early as possible. There also exists a need for methods of detecting recurrence of ovarian cancer as well as methods for predicting and monitoring the efficacy of treatment. The present invention satisfies these needs.

15

25

30

10

SUMMARY OF THE INVENTION

The invention relates to novel genes associated with ovarian cancer as well as methods of assessing whether a patient is afflicted with ovarian cancer. This method comprises the step of comparing the level of expression of a marker in a patient sample, wherein the marker is listed in Tables 1-2, and the normal level of expression of the marker in a control, e.g., a sample from a patient without ovarian cancer. A significant difference between the level of expression of the marker in the patient sample and the normal level is an indication that the patient is afflicted with ovarian cancer. Preferably, a protein corresponding to the marker is a secreted protein. Alternatively, the marker can correspond to a protein having an extracellular portion, to one which is normally expressed in ovarian tissue at a detectable level, or both.

In one method, the marker(s) are preferably selected such that the positive predictive value of the method is at least about 10%. Also preferred are embodiments of the method wherein the marker is over- or under-expressed by at least two-fold in at least about 20% of stage I ovarian cancer patients, stage II ovarian cancer patients, stage III ovarian cancer patients, grade I ovarian cancer patients, grade I ovarian cancer patients, epithelial

15

20

25

ovarian cancer patients, stromal ovarian cancer patients, germ cell ovarian cancer patients, malignant ovarian cancer patients, benign ovarian patients, serous neoplasm ovarian cancer patients, mucinous neoplasm ovarian cancer patients, endometrioid neoplasm ovarian cancer patients and/or clear cell neoplasm ovarian cancer patients.

In one embodiment of the methods of the present invention, the patient sample is an ovary-associated body fluid. Such fluids include, for example, blood fluids, lymph, ascitic fluids, gynecological fluids, cystic fluids, urine, and fluids collected by peritoneal rinsing. In another embodiment, the sample comprises cells obtained from the patient. In this embodiment, the cells may be found in a fluid selected from the group consisting of a fluid collected by peritoneal rinsing, a fluid collected by uterine rinsing, a uterine fluid, a uterine exudate, a pleural fluid, and an ovarian exudate. In another embodiment, the patient sample is *in vivo*.

In accordance with the methods of the present invention, the level of expression of the marker in a sample can be assessed, for example, by detecting the presence in the sample of:

- a protein corresponding to the marker or fragment of the protein (e.g. using a reagent, such as an antibody, an antibody derivative, or an antibody fragment, which binds specifically with the protein)
- a transcribed polynucleotide (e.g. an mRNA or a cDNA), or fragment thereof, having at least a portion with which the marker is substantially homologous (e.g. by contacting a mixture of transcribed polynucleotides obtained from the sample with a substrate having one or more of the markers listed in Tables 1-2 fixed thereto at selected positions)
- a transcribed polynucleotide or fragment thereof, wherein the polynucleotide anneals with the marker under stringent hybridization conditions.
- a metabolite which is produced directly (i.e., catalyzed) or indirectly by a protein corresponding to the marker

The methods of the present invention are particularly useful for patients with an identified pelvic mass or symptoms associated with ovarian cancer. The methods of the present invention can also be of particular use with patients having an enhanced risk of developing ovarian cancer (e.g., patients having a familial history of ovarian cancer,

10

15

25

30

patients identified as having a mutant oncogene, and patients at least about 50 years of age). The methods of the present invention may further be of particular use in monitoring the efficacy of treatment of an ovarian cancer patient (e.g. the efficacy of chemotherapy).

The methods of the present invention may be performed using a plurality (e.g. 2, 3, 5, or 10 or more) of markers. According to a method involving a plurality of markers, the level of expression in the sample of each of a plurality of markers independently selected from the markers listed in Tables 1-2 is compared with the normal level of expression of each of the plurality of markers in samples of the same type obtained from control humans not afflicted with ovarian cancer. The markers of Tables 1-2 may also be used in combination with known ovarian cancer markers in the methods of the present invention.

In a preferred method of assessing whether a patient is afflicted with ovarian cancer (e.g., new detection ("screening"), detection of recurrence, reflex testing), the method comprises comparing:

- a) the level of expression of a marker in a patient sample, wherein at least one marker is selected from the markers of Tables 1-2, and
- b) the normal level of expression of the marker in a control non-ovarian cancer sample.
- A significant difference between the level of expression of the marker in the patient sample and the normal level is an indication that the patient is afflicted with ovarian cancer.

The methods of the present invention further include a method of assessing the efficacy of a test compound for inhibiting ovarian cancer in a patient. This method comprises comparing:

- a) expression of a marker in a first sample obtained from the patient and maintained in the presence of the test compound, wherein the marker is selected from the group consisting of the markers listed in Tables 1-2, and
- b) expression of the marker in a second sample obtained from the patient and maintained in the absence of the test compound.

15

20

25

A significant difference between the level of expression of the marker in the first sample, relative to the second sample, is an indication that the test compound is efficacious for inhibiting ovarian cancer in the patient. For example, the first and second samples can be portions of a single sample obtained from the patient or portions of pooled samples obtained from the patient.

The invention further relates to a method of assessing the efficacy of a therapy for inhibiting ovarian cancer in a patient. This method comprises comparing:

- a) expression of a marker in a first sample obtained from the patient prior to providing at least a portion of the therapy to the patient, wherein the marker is selected from the group consisting of the markers listed in Tables 1-2, and
- b) expression of the marker in a second sample obtained from the patient following provision of the portion of the therapy.

A significant difference between the level of expression of the marker in the second sample, relative to the first sample, is an indication that the therapy is efficacious for inhibiting ovarian cancer in the patient.

It will be appreciated that in these methods the "therapy" may be any traditional therapy for treating ovarian cancer including, but not limited to, chemotherapy, radiation therapy and surgical removal of tissue, e.g., an ovarian tumor. Thus, the methods of the invention may be used to evaluate a patient before, during and after thereapy, for example, to evaluate the reduction in tumor burden.

The present invention therefore further comprises a method for monitoring the progression of ovarian cancer in a patient, the method comprising:

- a) detecting in a patient sample at a first time point, the expression of a marker, wherein the marker is selected from the group consisting of the markers listed in Tables 1-2;
 - b) repeating step a) at a subsequent time point in time; and
- c) comparing the level of expression detected in steps a) and b), and therefrom monitoring the progression of ovarian cancer in the patient.
- The invention also includes a method of selecting a composition for inhibiting ovarian cancer in a patient. This method comprises the steps of:
 - a) obtaining a sample comprising cancer cells from the patient;

10

15

20

30

- b) separately maintaining aliquots of the sample in the presence of a plurality of test compositions;
- c) comparing expression of a marker listed in Tables 1-2 in each of the aliquots; and
- d) selecting one of the test compositions which alters the level of expression of the marker in the aliquot containing that test composition, relative to other test compositions.

In addition, the invention includes a method of inhibiting ovarian cancer in a patient. This method comprises the steps of:

- a) obtaining a sample comprising cancer cells from the patient;
 - b) separately maintaining aliquots of the sample in the presence of a plurality of test compositions;
 - c) comparing expression of a marker listed in Tables 1-2 in each of the aliquots; and
 - d) administering to the patient at least one of the test compositions which alters the level of expression of the marker in the aliquot containing that test composition, relative to other test compositions.

The invention also includes a kit for assessing whether a patient is afflicted with ovarian cancer. This kit comprises reagents for assessing expression of a marker listed in Tables 1-2.

In another aspect, the invention relates to a kit for assessing the suitability of each of a plurality of compounds for inhibiting an ovarian cancer in a patient. The kit comprises a reagent for assessing expression of a marker listed in Tables 1-2, and may also comprise a plurality of compounds.

In another aspect, the invention relates to a kit for assessing the presence of ovarian cancer cells. This kit comprises an antibody, wherein the antibody binds specifically with a protein corresponding to a marker listed in Tables 1-2. The kit may also comprise a plurality of antibodies, wherein the plurality binds specifically with a protein corresponding to a different marker listed in Tables 1-2.

The invention also includes a kit for assessing the presence of ovarian cancer cells, wherein the kit comprises a nucleic acid probe. The probe binds specifically with a transcribed polynucleotide corresponding to a marker listed in Tables 1-2. The kit

WO 01/070979 PCT/US01/09126

may also comprise a plurality of probes, wherein each of the probes binds specifically with a transcribed polynucleotide corresponding to a different marker listed in Tables 1-2.

The invention further relates to a method of making an isolated hybridoma which produces an antibody useful for assessing whether a patient is afflicted with ovarian cancer. The method comprises isolating a protein corresponding to a marker listed in Tables 1-2, immunizing a mammal using the isolated protein, isolating splenocytes from the immunized mammal, fusing the isolated splenocytes with an immortalized cell line to form hybridomas, and screening individual hybridomas for production of an antibody which specifically binds with the protein to isolate the hybridoma. The invention also includes an antibody produced by this method.

The invention further includes a method of assessing the ovarian carcinogenic potential of a test compound. This method comprises the steps of:

a) maintaining separate aliquots of ovarian cells in the presence and absence of the test compound; and

b) comparing expression of a marker in each of the aliquots.

15

20

25

The marker is selected from those listed in Tables 1-2. A significantly altered level of expression of the marker in the aliquot maintained in the presence of (or exposed to) the test compound, relative to the aliquot maintained in the absence of the test compound, is an indication that the test compound possesses ovarian carcinogenic potential.

Additionally, the invention includes a kit for assessing the ovarian carcinogenic potential of a test compound. The kit comprises ovarian cells and a reagent for assessing expression of a marker in each of the aliquots. The marker is selected from those listed in Tables 1-2.

The invention further relates to a method of treating a patient afflicted with ovarian cancer or at risk of developing ovarian cancer. This method comprises enhancing expression of a marker listed in Tables 1-2 or providing to cells of the patient a protein corresponding to a marker listed in Tables 1-2, wherein the marker is underexpressed in patients afflicted with ovarian cancer. The protein can be provided to the cells, for example, by providing a vector comprising a polynucleotide encoding the protein to the cells.

The invention includes another method of treating a patient afflicted with ovarian cancer or at risk of developing ovarian cancer. This method comprises inhibiting expression or overexpression of a marker listed in Tables 1-2 by, e.g., providing to cells of the patient an antisense oligonucleotide complementary to a polynucleotide corresponding to a marker listed in Tables 1-2, wherein the marker is overexpressed in patients afflicted with ovarian cancer.

It will be appreciated that the methods and kits of the present invention may also include known cancer markers including known ovarian cancer markers. It will further be appreciated that the methods and kits may be used to identify cancers other than ovarian cancer.

DETAILED DESCRIPTION OF THE INVENTION

The invention relates to newly discovered genes associated with the cancerous state of ovarian cells. It has been discovered that the level of expression of individual genes, also referred to as markers, and combinations of these genes, correlates with the presence of ovarian cancer in a patient. Methods are provided for detecting the presence of ovarian cancer in a sample, the absence of ovarian cancer in a sample, the stage of an ovarian cancer, and with other characteristics of ovarian cancer that are relevant to prevention, diagnosis, characterization, and therapy of ovarian cancer in a patient.

20

25

30

10

15

Definitions

As used herein, each of the following terms has the meaning associated with it in this section.

The articles "a" and "an" are used herein to refer to one or to more than one (i.e. to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.

A "marker" is a naturally-occurring polymer corresponding to at least one of the novel nucleic acids listed in Tables 1-2. For example, markers include, without limitation, sense and anti-sense strands of genomic DNA (*i.e.* including any introns occurring therein), RNA generated by transcription of genomic DNA (*i.e.* prior to splicing), RNA generated by splicing of RNA transcribed from genomic DNA, and proteins generated by translation of spliced RNA (*i.e.* including proteins both before and

15

after cleavage of normally cleaved regions such as transmembrane signal sequences). As used herein, "marker" may also include a cDNA made by reverse transcription of an RNA generated by transcription of genomic DNA (including spliced RNA).

The term "probe" refers to any molecule which is capable of selectively binding to a specifically intended target molecule, for example a marker of the invention. Probes can be either synthesized by one skilled in the art, or derived from appropriate biological preparations. For purposes of detection of the target molecule, probes may be specifically designed to be labeled, as described herein. Examples of molecules that can be utilized as probes include, but are not limited to, RNA, DNA, proteins, antibodies, and organic monomers.

An "ovary-associated" body fluid is a fluid which, when in the body of a patient, contacts or passes through ovarian cells or into which cells or proteins shed from ovarian cells e.g., ovarian epithelium, are capable of passing. Exemplary ovary-associated body fluids include blood fluids, lymph, ascites, gynecological fluids, cystic fluid, urine, and fluids collected by peritoneal rinsing.

The "normal" level of expression of a marker is the level of expression of the marker in ovarian cells of a patient, e.g. a human, not afflicted with ovarian cancer.

"Over-expression" and "under-expression" of a marker refer to expression of the marker of a patient at a greater or lesser level, respectively, than normal level of expression of the marker (e.g. at least two-fold greater or lesser level).

As used herein, the term "promoter/regulatory sequence" means a nucleic acid sequence which is required for expression of a gene product operably linked to the promoter/regulatory sequence. In some instances, this sequence may be the core promoter sequence and in other instances, this sequence may also include an enhancer sequence and other regulatory elements which are required for expression of the gene product. The promoter/regulatory sequence may, for example, be one which expresses the gene product in a tissue-specific manner.

A "constitutive" promoter is a nucleotide sequence which, when operably linked with a polynucleotide which encodes or specifies a gene product, causes the gene product to be produced in a living human cell under most or all physiological conditions of the cell.

WO 01/070979

5

10

15

30

An "inducible" promoter is a nucleotide sequence which, when operably linked with a polynucleotide which encodes or specifies a gene product, causes the gene product to be produced in a living human cell substantially only when an inducer which corresponds to the promoter is present in the cell.

A "tissue-specific" promoter is a nucleotide sequence which, when operably linked with a polynucleotide which encodes or specifies a gene product, causes the gene product to be produced in a living human cell substantially only if the cell is a cell of the tissue type corresponding to the promoter.

A "transcribed polynucleotide" is a polynucleotide (e.g. an RNA, a cDNA, or an analog of one of an RNA or cDNA) which is complementary to or homologous with all or a portion of a mature RNA made by transcription of a genomic DNA corresponding to a marker of the invention and normal post-transcriptional processing (e.g. splicing), if any, of the transcript.

"Complementary" refers to the broad concept of sequence complementarity between regions of two nucleic acid strands or between two regions of the same nucleic acid strand. It is known that an adenine residue of a first nucleic acid region is capable of forming specific hydrogen bonds ("base pairing") with a residue of a second nucleic acid region which is antiparallel to the first region if the residue is thymine or uracil. Similarly, it is known that a cytosine residue of a first nucleic acid strand is capable of base pairing with a residue of a second nucleic acid strand which is antiparallel to the first strand if the residue is guanine. A first region of a nucleic acid is complementary to a second region of the same or a different nucleic acid if, when the two regions are arranged in an antiparallel fashion, at least one nucleotide residue of the first region is capable of base pairing with a residue of the second region. Preferably, the first region comprises a first portion and the second region comprises a second portion, whereby, when the first and second portions are arranged in an antiparallel fashion, at least about 50%, and preferably at least about 75%, at least about 90%, or at least about 95% of the nucleotide residues of the first portion are capable of base pairing with nucleotide residues in the second portion. More preferably, all nucleotide residues of the first portion are capable of base pairing with nucleotide residues in the second portion.

20

25

30

"Homologous" as used herein, refers to nucleotide sequence similarity between two regions of the same nucleic acid strand or between regions of two different nucleic acid strands. When a nucleotide residue position in both regions is occupied by the same nucleotide residue, then the regions are homologous at that position. A first region is homologous to a second region if at least one nucleotide residue position of each region is occupied by the same residue. Homology between two regions is expressed in terms of the proportion of nucleotide residue positions of the two regions that are occupied by the same nucleotide residue. By way of example, a region having the nucleotide sequence 5'-TATGGC-3' and a region having the nucleotide sequence 5'-TATGGC-3' share 50% homology. Preferably, the first region comprises a first portion and the second region comprises a second portion, whereby, at least about 50%, and preferably at least about 75%, at least about 90%, or at least about 95% of the nucleotide residue positions of each of the portions are occupied by the same nucleotide residue. More preferably, all nucleotide residue positions of each of the portions are occupied by the same nucleotide residue.

A marker is "fixed" to a substrate if it is covalently or non-covalently associated with the substrate such the substrate can be rinsed with a fluid (e.g. standard saline citrate, pH 7.4) without a substantial fraction of the marker dissociating from the substrate.

As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g. encodes a natural protein).

Expression of a marker in a patient is "significantly" higher or lower than the normal level of expression of a marker if the level of expression of the marker is greater or less, respectively, than the normal level by an amount greater than the standard error of the assay employed to assess expression, and preferably at least twice, and more preferably three, four, five or ten times that amount. Alternately, expression of the marker in the patient can be considered "significantly" higher or lower than the normal level of expression if the level of expression is at least about two, and preferably at least about three, four, or five times, higher or lower, respectively, than the normal level of expression of the marker.

Ovarian cancer is "inhibited" if at least one symptom of the cancer is alleviated, terminated, slowed, or prevented. As used herein, ovarian cancer is also "inhibited" if recurrence or metastasis of the cancer is reduced, slowed, delayed, or prevented.

A kit is any manufacture (e.g. a package or container) comprising at least one reagent, e.g. a probe, for specifically detecting a marker of the invention, the manufacture being promoted, distributed, or sold as a unit for performing the methods of the present invention.

Description

10

15

20

The present invention is based, in part, on identification of novel markers which are over-expressed in ovarian cancer cells as compared to their expression in normal (i.e. non-cancerous) ovarian cells. The markers of the invention correspond to DNA, RNA, and polypeptide molecules which can be detected in one or both of normal and cancerous ovarian cells. The enhanced expression of one or more of these markers in ovarian cells is herein correlated with the cancerous state of the tissue. The invention thus includes compositions, kits, and methods for assessing the cancerous state of ovarian cells (e.g. cells obtained from a human, cultured human cells, archived or preserved human cells and in vivo cells).

The compositions, kits, and methods of the invention have the following uses, among others:

- 1) assessing whether a patient is afflicted with ovarian cancer;
- 2) assessing the stage of ovarian cancer in a human patient;
- 3) assessing the grade of ovarian cancer in a patient;
- 4) assessing the benign or malignant nature of ovarian cancer in a patient;
- 25 ssessing the histological type of neoplasm (e.g. serous, mucinous, endometroid, or clear cell neoplasm) associated with ovarian cancer in a patient;
 - 6) making an isolated hybridoma which produces an antibody useful for assessing whether a patient is afflicted with ovarian cancer;
- 30 7) assessing the presence of ovarian cancer cells:
 - assessing the efficacy of one or more test compounds for inhibiting ovarian cancer in a patient;

10

15

20

25

30

À

- assessing the efficacy of a therapy for inhibiting ovarian cancer in a patient;
- 10) monitoring the progression of ovarian cancer in a patient;
- selecting a composition or therapy for inhibiting ovarian cancer in a patient;
- 12) treating a patient afflicted with ovarian cancer;
- 13) inhibiting ovarian cancer in a patient;
 - 14) assessing the ovarian carcinogenic potential of a test compound; and
- 15) inhibiting an ovarian cancer in a patient at risk for developing ovarian cancer.

The invention thus includes a method of assessing whether a patient is afflicted with ovarian cancer. This method comprises comparing the level of expression of a marker in a patient sample and the normal level of expression of the marker in a control, e.g., a non-ovarian cancer sample. A significant difference between the level of expression of the marker in the patient sample and the normal level is an indication that the patient is afflicted with ovarian cancer. The marker is selected from the group consisting of the markers listed in Tables 1-2.

The polynucleotides set forth in Tables 1-2 represent previously unidentified nucleotide sequences. These nucleotide sequences were identified through subtracted library experiments described herein. Also provided by this invention are polynucleotides that correspond to the polynucleotides of Tables 1-2. In one embodiment, these polynucleotides are obtained by identification of a larger fragment or full-length coding sequence of these polynucleotides. Gene delivery vehicles, host cells, compositions and databases (all described herein) containing these polynucleotides are also provided by this invention.

Any marker or combination of markers listed in Tables 1-2, as well as any known markers in combination with the markers set forth in Tables 1-2, may be used in the compositions, kits, and methods of the present invention. In general, it is preferable to use markers for which the difference between the level of expression of the marker in ovarian cancer cells and the level of expression of the same marker in normal ovarian

30

cells is as great as possible. Although this difference can be as small as the limit of detection of the method for assessing expression of the marker, it is preferred that the difference be at least greater than the standard error of the assessment method, and preferably a difference of at least 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 15-, 20-, 25-, 100-, 500-, 1000-fold or greater.

It is recognized that certain markers correspond to proteins which are secreted from ovarian cells (*i.e.* one or both of normal and cancerous cells) to the extracellular space surrounding the cells. These markers are preferably used in certain embodiments of the compositions, kits, and methods of the invention, owing to the fact that the protein corresponding to each of these markers can be detected in an ovary-associated body fluid sample, which may be more easily collected from a human patient than a tissue biopsy sample. In addition, preferred *in vivo* techniques for detection of a protein corresponding to a marker of the invention include introducing into a subject a labeled antibody directed against the protein. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

It is a simple matter for the skilled artisan to determine whether any particular marker corresponds to a secreted protein. In order to make this determination, the protein corresponding to a marker is expressed in a test cell (e.g. a cell of an ovarian cell line), extracellular fluid is collected, and the presence or absence of the protein in the extracellular fluid is assessed (e.g. using a labeled antibody which binds specifically with the protein).

The following is an example of a method which can be used to detect secretion of a protein corresponding to a marker of the invention. About 8 x 10⁵ 293T cells are incubated at 37°C in wells containing growth medium (Dulbecco's modified Eagle's medium {DMEM} supplemented with 10% fetal bovine serum) under a 5% (v/v) CO₂, 95% air atmosphere to about 60-70% confluence. The cells are then transfected using a standard transfection mixture comprising 2 micrograms of DNA comprising an expression vector encoding the protein and 10 microliters of LipofectAMINETM (GIBCO/BRL Catalog no. 18342-012) per well. The transfection mixture is maintained for about 5 hours, and then replaced with fresh growth medium and maintained in an air atmosphere. Each well is gently rinsed twice with DMEM which does not contain

15

20

25

methionine or cysteine (DMEM-MC; ICN Catalog no. 16-424-54). About 1 milliliter of DMEM-MC and about 50 microcuries of Trans-³⁵STM reagent (ICN Catalog no. 51006) are added to each well. The wells are maintained under the 5% CO₂ atmosphere described above and incubated at 37°C for a selected period. Following incubation, 150 microliters of conditioned medium is removed and centrifuged to remove floating cells and debris. The presence of the protein in the supernatant is an indication that the protein is secreted.

Examples of ovary-associated body fluids include blood fluids (e.g. whole blood, blood serum, blood having platelets removed therefrom, etc.), lymph, ascitic fluids, gynecological fluids (e.g. ovarian, fallopian, and uterine secretions, menses, vaginal douching fluids, fluids used to rinse cervical cell samples, etc.), cystic fluid, urine, and fluids collected by peritoneal rinsing (e.g. fluids applied and collected during laparoscopy or fluids instilled into and withdrawn from the peritoneal cavity of a human patient). In these embodiments, the level of expression of the marker can be assessed by assessing the amount (e.g. absolute amount or concentration) of the marker in an ovary-associated body fluid obtained from a patient. The fluid can, of course, be subjected to a variety of well-known post-collection preparative and storage techniques (e.g. storage, freezing, ultrafiltration, concentration, evaporation, centrifugation, etc.) prior to assessing the amount of the marker in the fluid.

Many ovary-associated body fluids (*i.e.* usually excluding urine) can have ovarian cells, *e.g.* ovarian epithelium, therein, particularly when the ovarian cells are cancerous, and, more particularly, when the ovarian cancer is metastasizing. Cell-containing fluids which can contain ovarian cancer cells include, but are not limited to, peritoneal ascites, fluids collected by peritoneal rinsing, fluids collected by uterine rinsing, uterine fluids such as uterine exudate and menses, pleural fluid, and ovarian exudates. Thus, the compositions, kits, and methods of the invention can be used to detect expression of markers corresponding to proteins having at least one portion which is displayed on the surface of cells which express it. Examples of such proteins are indicated in the Tables herein. Although not every protein having at least one cell-surface portion is indicated in the Tables, it is a simple matter for the skilled artisan to determine whether the protein corresponding to any particular marker comprises a cell-surface protein. For example, immunological methods may be used to detect such

15

20

25

30

proteins on whole cells, or well known computer-based sequence analysis methods (e.g. the SIGNALP program; Nielsen et al., 1997, Protein Engineering 10:1-6) may be used to predict the presence of at least one extracellular domain (i.e. including both secreted proteins and proteins having at least one cell-surface domain). Expression of a marker corresponding to a protein having at least one portion which is displayed on the surface of a cell which expresses it may be detected without necessarily lysing the cell (e.g. using a labeled antibody which binds specifically with a cell-surface domain of the protein).

Expression of a marker of the invention may be assessed by any of a wide variety of well known methods for detecting expression of a transcribed molecule or protein. Non-limiting examples of such methods include immunological methods for detection of secreted, cell-surface, cytoplasmic, or nuclear proteins, protein purification methods, protein function or activity assays, nucleic acid hybridization methods, nucleic acid reverse transcription methods, and nucleic acid amplification methods.

In a preferred embodiment, expression of a marker is assessed using an antibody (e.g. a radio-labeled, chromophore-labeled, fluorophore-labeled, or enzyme-labeled antibody), an antibody derivative (e.g. an antibody conjugated with a substrate or with the protein or ligand of a protein-ligand pair {e.g. biotin-streptavidin}), or an antibody fragment (e.g. a single-chain antibody, an isolated antibody hypervariable domain, etc.) which binds specifically with a protein corresponding to the marker, such as the protein encoded by the open reading frame corresponding to the marker or such a protein which has undergone all or a portion of its normal post-translational modification.

In another preferred embodiment, expression of a marker is assessed by preparing mRNA/cDNA (i.e. a transcribed polynucleotide) from cells in a patient sample, and by hybridizing the mRNA/cDNA with a reference polynucleotide which is a complement of a polynucleotide comprising the marker, and fragments thereof. cDNA can, optionally, be amplified using any of a variety of polymerase chain reaction methods prior to hybridization with the reference polynucleotide; preferably, it is not amplified. Expression of one or more markers can likewise be detected using quantitative PCR to assess the level of expression of the marker(s). Alternatively, any of the many known methods of detecting mutations or variants (e.g. single nucleotide

20

25

30

polymorphisms, deletions, etc.) of a marker of the invention may be used to detect occurrence of a marker in a patient.

In a related embodiment, a mixture of transcribed polynucleotides obtained from the sample is contacted with a substrate having fixed thereto a polynucleotide complementary to or homologous with at least a portion (e.g. at least 7, 10, 15, 20, 25, 30, 40, 50, 100, 500, or more nucleotide residues) of a marker of the invention. If polynucleotides complementary to or homologous with are differentially detectable on the substrate (e.g. detectable using different chromophores or fluorophores, or fixed to different selected positions), then the levels of expression of a plurality of markers can be assessed simultaneously using a single substrate (e.g. a "gene chip" microarray of polynucleotides fixed at selected positions). When a method of assessing marker expression is used which involves hybridization of one nucleic acid with another, it is preferred that the hybridization be performed under stringent hybridization conditions.

Because the compositions, kits, and methods of the invention rely on detection of a difference in expression levels of one or more markers of the invention, it is preferable that the level of expression of the marker is significantly greater than the minimum detection limit of the method used to assess expression in at least one of normal ovarian cells and cancerous ovarian cells.

It is understood that by routine screening of additional patient samples using one or more of the markers of the invention, it will be realized that certain of the markers are over- or under-expressed in cancers of various types, including specific ovarian cancers, as well as other cancers such as breast cancer, cervical cancer, etc. For example, it will be confirmed that some of the markers of the invention are over- or under-expressed in most (i.e. 50% or more) or substantially all (i.e. 80% or more) of ovarian cancer.

Furthermore, it will be confirmed that certain of the markers of the invention are associated with ovarian cancer of various stages (i.e. stage I, II, III, and IV ovarian cancers, as well as subclassifications IA, IB, IC, IIA, IIB, IIC, IIIA, IIIB, and IIIC, using the FIGO Stage Grouping system for primary carcinoma of the ovary; 1987, Am. J. Obstet. Gynecol. 156:236), of various histologic subtypes (e.g. serous, mucinous, endometroid, and clear cell subtypes, as well as subclassifications and alternate classifications adenocarcinoma, papillary adenocarcinoma, papillary cystadenocarcinoma, surface papillary carcinoma, malignant adenofibroma,

WO 01/070979 PCT/US01/09126

- 21 -

cystadenofibroma, adenocarcinoma, cystadenocarcinoma, adenoacanthoma, endometrioid stromal sarcoma, mesodermal (Müllerian) mixed tumor, mesonephroid tumor, malignant carcinoma, Brenner tumor, mixed epithelial tumor, and undifferentiated carcinoma, using the WHO/FIGO system for classification of malignant ovarian tumors; Scully, Atlas of Tumor Pathology, 3d series, Washington DC), and various grades (i.e. grade I {well differentiated}, grade II {moderately well differentiated), and grade III {poorly differentiated from surrounding normal tissue}). In addition, as a greater number of patient samples are assessed for expression of the markers of the invention and the outcomes of the individual patients from whom the samples were obtained are correlated, it will also be confirmed that altered expression of certain of the markers of the invention are strongly correlated with malignant cancers and that altered expression of other markers of the invention are strongly correlated with benign tumors. The compositions, kits, and methods of the invention are thus useful for characterizing one or more of the stage, grade, histological type, and benign/malignant nature of ovarian cancer in patients. In addition, these compositions, kits, and methods can be used to detect and differentiate epithelial, stromal, and germ cell ovarian cancers.

10

15

25

When the compositions, kits, and methods of the invention are used for characterizing one or more of the stage, grade, histological type, and benign/malignant nature of ovarian cancer in a patient, it is preferred that the marker or panel of markers of the invention is selected such that a positive result is obtained in at least about 20%, and preferably at least about 40%, 60%, or 80%, and more preferably in substantially all patients afflicted with an ovarian cancer of the corresponding stage, grade, histological type, or benign/malignant nature. Preferably, the marker or panel of markers of the invention is selected such that a PPV of greater than about 10% is obtained for the general population (more preferably coupled with an assay specificity greater than 99.5%).

When a plurality of markers of the invention are used in the compositions, kits, and methods of the invention, the level of expression of each marker in a patient sample can be compared with the normal level of expression of each of the plurality of markers in non-cancerous samples of the same type, either in a single reaction mixture (i.e. using reagents, such as different fluorescent probes, for each marker) or in individual reaction mixtures corresponding to one or more of the markers. In one embodiment, a

25

significantly enhanced level of expression of more than one of the plurality of markers in the sample, relative to the corresponding normal levels, is an indication that the patient is afflicted with ovarian cancer. In another embodiment, a significantly lower level of expression in the sample of each of the plurality of markers, relative to the corresponding normal levels, is an indication that the patient is afflicted with ovarian cancer. In yet another embodiment, a significantly enhanced level of expression of one or more marks and a significantly lower level of expression of one or more markers in a sample relative to the corresponding normal levels, is an indication that the patient is afflicted with ovarian cancer. When a plurality of markers is used, it is preferred that 2, 3, 4, 5, 8, 10, 12, 15, 20, 30, or 50 or more individual markers be used, wherein fewer markers are preferred.

In order to maximize the sensitivity of the compositions, kits, and methods of the invention (*i.e.* by interference attributable to cells of non-ovarian origin in a patient sample), it is preferable that the marker of the invention used therein be a marker which has a restricted tissue distribution, *e.g.*, normally not expressed in a non-epithelial tissue, and more preferably a marker which is normally not expressed in a non-ovarian tissue.

Only a small number of markers are known to be associated with ovarian cancers (e.g. AKT2, Ki-RAS, ERBB2, c-MYC, RB1, and TP53; Lynch, supra). These markers are not, of course, included among the markers of the invention, although they may be used together with one or more markers of the invention in a panel of markers, for example. It is well known that certain types of genes, such as oncogenes, tumor suppressor genes, growth factor-like genes, protease-like genes, and protein kinase-like genes are often involved with development of cancers of various types. Thus, among the markers of the invention, use of those which correspond to proteins which resemble known proteins encoded by known oncogenes and tumor suppressor genes, and those which correspond to proteins which resemble growth factors, proteases, and protein kinases are preferred.

Known oncogenes and tumor suppressor genes include, for example, abl, abr, akt2, apc, bcl2α, bcl3, bcr, brca1, brca2, cbl, ccnd1, cdc42, cdk4, crk-II, csf1r/fms, dbl, dcc, dpc4/smad4, e-cad, e2f1/rbap, egfr/erbb-1, elk1, elk3, eph, erg, ets1, ets2, fer, fgr/src2, fli1/ergb2, fos, fps/fes, fra1, fra2, fyn, hck, hek, her2/erbb-2/neu, her3/erbb-3, her4/erbb-4, hras1, hst2, hstf1, igfbp2, ink4a, ink4b, int2/fgf3, jun, junb, jund, kip2, kit, kras2a, kras2b, lck, lyn, mas, max, mcc, mdm2, met, mlh1, mmp10, mos,

20

25

30

4.

msh2, msh3, msh6, myb, myba, mybb, myc, mycl1, mycn, nf1, nf2, nme2, nras, p53, pdgfb, phb, pim1, pms1, pms2, ptc, pten, raf1, rap1a, rb1, rel, ret, ros1, ski, src1, tal1, tgfbr2, tgfb3, tgfbr3, thra1, thrb, tiam1, timp3, tjp1, tp53, trk, vav, vhl, vil2, waf1, wnt1, wnt2, wt1, and yes1 (Hesketh, 1997, In: The Oncogene and Tumour Suppressor Gene Facts Book, 2nd Ed., Academic Press; Fishel et al., 1994, Science 266:1403-1405).

Known growth factors include platelet-derived growth factor alpha, plateletderived growth factor beta (simian sarcoma viral {v-sis} oncogene homolog), thrombopoietin (myeloproliferative leukemia virus oncogene ligand, megakaryocyte growth and development factor), erythropoietin, B cell growth factor, macrophage stimulating factor 1 (hepatocyte growth factor-like protein), hepatocyte growth factor (hepapoietin A), insulin-like growth factor 1 (somatomedia C), hepatoma-derived growth factor, amphiregulin (schwannoma-derived growth factor), bone morphogenetic proteins 1, 2, 3, 3 beta, and 4, bone morphogenetic protein 7 (osteogenic protein 1), bone morphogenetic protein 8 (osteogenic protein 2), connective tissue growth factor. connective tissue activation peptide 3, epidermal growth factor (EGF), teratocarcinomaderived growth factor 1, endothelin, endothelin 2, endothelin 3, stromal cell-derived factor 1, vascular endothelial growth factor (VEGF), VEGF-B, VEGF-C, placental growth factor (vascular endothelial growth factor-related protein), transforming growth factor alpha, transforming growth factor beta 1 and its precursors, transforming growth factor beta 2 and its precursors, fibroblast growth factor 1 (acidic), fibroblast growth factor 2 (basic), fibroblast growth factor 5 and its precursors, fibroblast growth factor 6 and its precursors, fibroblast growth factor 7 (keratinocyte growth factor), fibroblast growth factor 8 (androgen-induced), fibroblast growth factor 9 (glia-activating factor), pleiotrophin (heparin binding growth factor 8, neurite growth-promoting factor 1), brain-derived neurotrophic factor, and recombinant glial growth factor 2.

Known proteases include interleukin-1 beta convertase and its precursors, Mch6 and its precursors, Mch2 isoform alpha, Mch4, Cpp32 isoform alpha, Lice2 gamma cysteine protease, Ich-1S, Ich-1L, Ich-2 and its precursors, TY protease, matrix metalloproteinase 1 (interstitial collagenase), matrix metalloproteinase 2 (gelatinase A, 72kD gelatinase, 72kD type IV collagenase), matrix metalloproteinase 7 (matrilysin), matrix metalloproteinase 8 (neutrophil collagenase), matrix metalloproteinase 12 (macrophage elastase), matrix metalloproteinase 13 (collagenase 3), metallopeptidase 1.

30

cysteine-rich metalloprotease (disintegrin) and its precursors, subtilisin-like protease Pc8 and its precursors, chymotrypsin, snake venom-like protease, cathepsin l, cathepsin D (lysosomal aspartyl protease), stromelysin, aminopeptidase N, plasminogen, tissue plasminogen activator, plasminogen activator inhibitor type II, and urokinase-type plasminogen activator.

Known protein kinases include DAP kinase, serine/threonine protein kinases NIK, PK428, Krs-2, SAK, and EMK, interferon-inducible double stranded RNA dependent protein kinase, FAST kinase, AIM1, IPL1-like midbody-associated protein kinase-1, NIMA-like protein kinase 1 (NLK1), the cyclin-dependent kinases (cdk1-10), checkpoint kinase Chk1, Nek3 protein kinase, BMK1 beta kinase, Clk1, Clk2, Clk3, extracellular signal-regulated kinases 1, 3, and 6, cdc28 protein kinase 1, cdc28 protein kinase 2, pLK, Myt1, c-Jun N-terminal kinase 2, Cam kinase 1, the MAP kinases, insulin-stimulated protein kinase 1, beta-adrenergic receptor kinase 2, ribosomal protein S6 kinase, kinase suppressor of ras-1 (KSR1), putative serine/threonine protein kinase Prk, PkB kinase, cAMP-dependent protein kinase, cGMP-dependent protein kinase, type II cGMP-dependent protein kinase, protein kinases Dyrk2, Dyrk3, and Dyrk4, Rhoassociated coiled-coil containing protein kinase p160ROCK, protein tyrosine kinase t-Ror1, Ste20-related kinases, cell adhesion kinase beta, protein kinase 3, stress-activated protein kinase 4, protein kinase Zpk, serine kinase hPAK65, dual specificity mitogenactivated protein kinases 1 and 2, casein kinase I gamma 2, p21-activated protein kinase Pak1, lipid-activated protein kinase PRK2, focal adhesion kinase, dual-specificity tyrosine-phosphorylation regulated kinase, myosin light chain kinase, serine kinases SRPK2, TESK1, and VRK2, B lymphocyte serine/threonine protein kinase, stressactivated protein kinases JNK1 and JNK2, phosphorylase kinase, protein tyrosine kinase Tec, Jak2 kinase, protein kinase Ndr, MEK kinase 3, SHB adaptor protein (a Src homology 2 protein), agammaglobulinaemia protein-tyrosine kinase (Atk), protein kinase ATR, guanylate kinase 1, thrombopoeitin receptor and its precursors, DAG kinase epsilon, and kinases encoded by oncogenes or viral oncogenes such as v-fgr (Gardner-Rasheed), v-abl (Abelson murine leukemia viral oncogene homolog 1), v-arg (Abelson murine leukemia viral oncogene homolog, Abelson-related gene), v-fes and vfps (feline sarcoma viral oncogene and Fujinami avian sarcoma viral oncogene

homologs), proto-oncogene c-cot, oncogene pim-1, and oncogene mas1.

15

25

It is recognized that the compositions, kits, and methods of the invention will be of particular utility to patients having an enhanced risk of developing ovarian cancer and their medical advisors. Patients recognized as having an enhanced risk of developing ovarian cancer include, for example, patients having a familial history of ovarian cancer, patients identified as having a mutant oncogene (i.e. at least one allele), and patients of advancing age (i.e. women older than about 50 or 60 years).

The level of expression of a marker in normal (i.e. non-cancerous) human ovarian tissue can be assessed in a variety of ways. In one embodiment, this normal level of expression is assessed by assessing the level of expression of the marker in a portion of ovarian cells which appears to be non-cancerous and by comparing this normal level of expression with the level of expression in a portion of the ovarian cells which is suspected of being cancerous. For example, when laparoscopy or other medical procedure, reveals the presence of a lump on one portion of a patient's ovary, but not on another portion of the same ovary or on the other ovary, the normal level of expression of a marker may be assessed using one or both or the non-affected ovary and a non-affected portion of the affected ovary, and this normal level of expression may be compared with the level of expression of the same marker in an affected portion (i.e. the lump) of the affected ovary. Alternately, and particularly as further information becomes available as a result of routine performance of the methods described herein, population-average values for normal expression of the markers of the invention may be used. In other embodiments, the 'normal' level of expression of a marker may be determined by assessing expression of the marker in a patient sample obtained from a non-cancer-afflicted patient, from a patient sample obtained from a patient before the suspected onset of ovarian cancer in the patient, from archived patient samples, and the like.

The invention includes compositions, kits, and methods for assessing the presence of ovarian cancer cells in a sample (e.g. an archived tissue sample or a sample obtained from a patient). These compositions, kits, and methods are substantially the same as those described above, except that, where necessary, the compositions, kits, and methods are adapted for use with samples other than patient samples. For example, when the sample to be used is a parafinized, archived human tissue sample, it can be necessary to adjust the ratio of compounds in the compositions of the invention, in the

20

25

30

kits of the invention, or the methods used to assess levels of marker expression in the sample. Such methods are well known in the art and within the skill of the ordinary artisan.

The invention includes a kit for assessing the presence of ovarian cancer cells (e.g. in a sample such as a patient sample). The kit comprises a plurality of reagents, each of which is capable of binding specifically with a nucleic acid or polypeptide corresponding to a marker of the invention. Suitable reagents for binding with a polypeptide corresponding to a marker of the invention include antibodies, antibody derivatives, antibody fragments, and the like. Suitable reagents for binding with a nucleic acid (e.g. a genomic DNA, an mRNA, a spliced mRNA, a cDNA, or the like) include complementary nucleic acids. For example, the nucleic acid reagents may include oligonucleotides (labeled or non-labeled) fixed to a substrate, labeled oligonucleotides not bound with a substrate, pairs of PCR primers, molecular beacon probes, and the like.

The kit of the invention may optionally comprise additional components useful for performing the methods of the invention. By way of example, the kit may comprise fluids (e.g. SSC buffer) suitable for annealing complementary nucleic acids or for binding an antibody with a protein with which it specifically binds, one or more sample compartments, an instructional material which describes performance of a method of the invention, a sample of normal ovarian cells, a sample of ovarian cancer cells, and the like.

The invention also includes a method of making an isolated hybridoma which produces an antibody useful for assessing whether patient is afflicted with an ovarian cancer. In this method, a protein corresponding to a marker of the invention is isolated (e.g. by purification from a cell in which it is expressed or by transcription and translation of a nucleic acid encoding the protein in vivo or in vitro using known methods). A vertebrate, preferably a mammal such as a mouse, rat, rabbit, or sheep, is immunized using the isolated protein. The vertebrate may optionally (and preferably) be immunized at least one additional time with the isolated protein, so that the vertebrate exhibits a robust immune response to the protein. Splenocytes are isolated from the immunized vertebrate and fused with an immortalized cell line to form hybridomas, using any of a variety of methods well known in the art. Hybridomas formed in this

WO 01/070979 PCT/US01/09126

- 27 -

manner are then screened using standard methods to identify one or more hybridomas which produce an antibody which specifically binds with the protein. The invention also includes hybridomas made by this method and antibodies made using such hybridomas.

5

10

15

20

25

30

The invention also includes a method of assessing the efficacy of a test compound for inhibiting ovarian cancer cells. As described above, differences in the level of expression of the markers of the invention correlate with the cancerous state of ovarian cells. Although it is recognized that changes in the levels of expression of certain of the markers of the invention likely result from the cancerous state of ovarian cells, it is likewise recognized that changes in the levels of expression of other of the markers of the invention induce, maintain, and promote the cancerous state of those cells. Thus, compounds which inhibit an ovarian cancer in a patient will cause the level of expression of one or more of the markers of the invention to change to a level nearer the normal level of expression for that marker (*i.e.* the level of expression for the marker in non-cancerous ovarian cells).

This method thus comprises comparing expression of a marker in a first ovarian cell sample and maintained in the presence of the test compound and expression of the marker in a second ovarian cell sample and maintained in the absence of the test compound. A significant alteration in the level of expression of a marker listed in Tables 1-2 is an indication that the test compound inhibits ovarian cancer. The ovarian cell samples may, for example, be aliquots of a single sample of normal ovarian cells obtained from a patient, pooled samples of normal ovarian cells obtained from a patient, cells of a normal ovarian cell line, aliquots of a single sample of ovarian cancer cells obtained from a patient, pooled samples of ovarian cancer cells obtained from a patient, cells of an ovarian cancer cell line, or the like. In one embodiment, the samples are ovarian cancer cells obtained from a patient and a plurality of compounds known to be effective for inhibiting various ovarian cancers are tested in order to identify the compound which is likely to best inhibit the ovarian cancer in the patient.

This method may likewise be used to assess the efficacy of a therapy for inhibiting ovarian cancer in a patient. In this method, the level of expression of one or more markers of the invention in a pair of samples (one subjected to the therapy, the other not subjected to the therapy) is assessed. As with the method of assessing the

WO 01/070979 PCT/US01/09126

10

20

25

30

- 28 -

efficacy of test compounds, if the therapy induces a significant alteration in the level of expression of a marker listed in Tables 1-2 then the therapy is efficacious for inhibiting ovarian cancer. As above, if samples from a selected patient are used in this method, then alternative therapies can be assessed *in vitro* in order to select a therapy most likely to be efficacious for inhibiting ovarian cancer in the patient.

As described herein, ovarian cancer in patients is associated with an altereration in the level of expression of one or more markers listed in Tables 1-2. While, as discussed above, some of these changes in expression level result from occurrence of the ovarian cancer, others of these changes induce, maintain, and promote the cancerous state of ovarian cancer cells. Thus, ovarian cancer characterized by an increase in the level of expression of one or more markers listed in either or both of Tables 1-2 can be inhibited by inhibiting expression of those markers.

Expression of a marker listed in Tables 1-2 can be inhibited in a number of ways generally known in the art. For example, an antisense oligonucleotide can be provided to the ovarian cancer cells in order to inhibit transcription, translation, or both, of the marker(s). Alternately, a polynucleotide encoding an antibody, an antibody derivative, or an antibody fragment, and operably linked with an appropriate promoter/regulator region, can be provided to the cell in order to generate intracellular antibodies which will inhibit the function or activity of the protein corresponding to the marker(s). Using the methods described herein, a variety of molecules, particularly including molecules sufficiently small that they are able to cross the cell membrane, can be screened in order to identify molecules which inhibit expression of the marker(s). The compound so identified can be provided to the patient in order to inhibit expression of the marker(s) in the ovarian cancer cells of the patient.

Expression of a marker listed in Tables 1-2 can be enhanced in a number of ways generally known in the art. For example, a polynucleotide encoding the marker and operably linked with an appropriate promoter/regulator region can be provided to ovarian cancer cells of the patient in order to induce enhanced expression of the protein (and mRNA) corresponding to the marker therein. Alternatively, if the protein is capable of crossing the cell membrane, inserting itself in the cell membrane, or is normally a secreted protein, then expression of the protein can be enhanced by providing

15

the protein (e.g. directly or by way of the bloodstream or another ovary-associated fluid) to ovarian cancer cells in the patient.

As described above, the cancerous state of human ovarian cells is correlated with changes in the levels of expression of the markers of the invention. The invention includes a method for assessing the human ovarian cell carcinogenic potential of a test compound. This method comprises maintaining separate aliquots of human ovarian cells in the presence and absence of the test compound. Expression of a marker of the invention in each of the aliquots is compared. A significant alteration in the level of expression of a marker listed in Tables 1-2 in the aliquot maintained in the presence of the test compound (relative to the aliquot maintained in the absence of the test compound) is an indication that the test compound possesses human ovarian cell carcinogenic potential. The relative carcinogenic potentials of various test compounds can be assessed by comparing the degree of enhancement or inhibition of the level of expression of the relevant markers, by comparing the number of markers for which the level of expression is enhanced or inhibited, or by comparing both.

Various aspects of the invention are described in further detail in the following subsections.

I. Isolated Nucleic Acid Molecules

20 One aspect of the invention pertains to novel isolated nucleic acid molecules that correspond to a marker of the invention, including nucleic acids which encode a polypeptide corresponding to a marker of the invention or a portion of such a polypeptide. Isolated nucleic acids of the invention also include nucleic acid molecules sufficient for use as hybridization probes to identify nucleic acid molecules that 25 correspond to a marker of the invention, including nucleic acids which encode a polypeptide corresponding to a marker of the invention, and fragments of such nucleic acid molecules, e.g., those suitable for use as PCR primers for the amplification or mutation of nucleic acid molecules. As used herein, the term "nucleic acid molecule" is intended to include DNA molecules (e.g., cDNA or genomic DNA) and RNA molecules (e.g., mRNA) and analogs of the DNA or RNA generated using nucleotide analogs. The 30 nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA.

WO 01/070979 PCT/US01/09126

An "isolated" nucleic acid molecule is one which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid molecule. Preferably, an "isolated" nucleic acid molecule is free of sequences (preferably protein-encoding sequences) which naturally flank the nucleic acid (*i.e.*, sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated nucleic acid molecule can contain less than about 5 kB, 4 kB, 3 kB, 2 kB, 1 kB, 0.5 kB or 0.1 kB of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized.

A nucleic acid molecule of the present invention can be isolated using standard molecular biology techniques and the sequence information in the database records described herein. Using all or a portion of such nucleic acid sequences, nucleic acid molecules of the invention can be isolated using standard hybridization and cloning techniques (e.g., as described in Sambrook et al., ed., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).

15

20

25

30

A nucleic acid molecule of the invention can be amplified using cDNA, mRNA, or genomic DNA as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to all or a portion of a nucleic acid molecule of the invention can be prepared by standard synthetic techniques, *e.g.*, using an automated DNA synthesizer.

In another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule which has a nucleotide sequence complementary to the nucleotide sequence of a nucleic acid corresponding to a marker of the invention or to the nucleotide sequence of a nucleic acid encoding a protein which corresponds to a marker of the invention. A nucleic acid molecule which is complementary to a given nucleotide sequence is one which is sufficiently

WO 01/070979

10

15

20

- 31 -

PCT/US01/09126

complementary to the given nucleotide sequence that it can hybridize to the given nucleotide sequence thereby forming a stable duplex.

Moreover, a nucleic acid molecule of the invention can comprise only a portion of a nucleic acid sequence, wherein the full length nucleic acid sequence comprises a marker of the invention or which encodes a polypeptide corresponding to a marker of the invention. Such nucleic acids can be used, for example, as a probe or primer. The probe/primer typically is used as one or more substantially purified oligonucleotides. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 7, preferably about 15, more preferably about 25, 50, 75, 100, 125, 150, 175, 200, 250, 300, 350, or 400 or more consecutive nucleotides of a nucleic acid of the invention.

Probes based on the sequence of a nucleic acid molecule of the invention can be used to detect transcripts or genomic sequences corresponding to one or more markers of the invention. The probe comprises a label group attached thereto, e.g., a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as part of a diagnostic test kit for identifying cells or tissues which misexpress the protein, such as by measuring levels of a nucleic acid molecule encoding the protein in a sample of cells from a subject, e.g., detecting mRNA levels or determining whether a gene encoding the protein has been mutated or deleted.

The invention further encompasses nucleic acid molecules that differ, due to degeneracy of the genetic code, from the nucleotide sequence of nucleic acids encoding a protein which corresponds to a marker of the invention, and thus encode the same protein.

It will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequence can exist within a population (e.g., the human population). Such genetic polymorphisms can exist among individuals within a population due to natural allelic variation. An allele is one of a group of genes which occur alternatively at a given genetic locus. In addition, it will be appreciated that DNA polymorphisms that affect RNA expression levels can also exist that may affect the overall expression level of that gene (e.g., by affecting regulation or degradation).

WO 01/070979 PCT/US01/09126

As used herein, the phrase "allelic variant" refers to a nucleotide sequence which occurs at a given locus or to a polypeptide encoded by the nucleotide sequence.

As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules comprising an open reading frame encoding a polypeptide corresponding to a marker of the invention. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of a given gene. Alternative alleles can be identified by sequencing the gene of interest in a number of different individuals. This can be readily carried out by using hybridization probes to identify the same genetic locus in a variety of individuals. Any and all such nucleotide variations and resulting amino acid polymorphisms or variations that are the result of natural allelic variation and that do not alter the functional activity are intended to be within the scope of the invention.

In another embodiment, an isolated nucleic acid molecule of the invention is at least 7, 15, 20, 25, 30, 40, 60, 80, 100, 150, 200, 250, 300, 350, 400, 450, 550, 650, 700, 800, 900, 1000, 1200, 1400, 1600, 1800, 2000, 2200, 2400, 2600, 2800, 3000, 3500, 15 4000, 4500, or more nucleotides in length and hybridizes under stringent conditions to a nucleic acid corresponding to a marker of the invention or to a nucleic acid encoding a protein corresponding to a marker of the invention. As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 75% (80%, 85%, preferably 90%) identical to each other typically remain hybridized to each other. Such stringent conditions are known to those skilled in the art and can be found in sections 6.3.1-6.3.6 of Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989). A preferred, non-limiting example of stringent hybridization conditions for annealing two single-stranded DNA each of which is at least about 100 bases in length and/or for annealing a single-stranded DNA and a single-stranded RNA each of which is at least about 100 bases in length, are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 50-65°C. Further preferred hybridization conditions are taught in Lockhart, et al., Nature Biotechnology, Volume 14, 1996 August:1675-1680; Breslauer, et al., Proc. Natl. Acad. Sci. USA, Volume 83, 1986 June: 3746-3750; Van Ness, et al., Nucleic Acids Research, Volume 19, No. 19, 1991 September: 5143-5151; McGraw, et al., BioTechniques,

20

30

WO 01/070979 PCT/US01/09126

Volume 8, No. 6 1990: 674-678; and Milner, *et al.*, Nature Biotechnology, Volume 15, 1997 June: 537-541, all expressly incorporated by reference.

In addition to naturally-occurring allelic variants of a nucleic acid molecule of the invention that can exist in the population, the skilled artisan will further appreciate that sequence changes can be introduced by mutation thereby leading to changes in the amino acid sequence of the encoded protein, without altering the biological activity of the protein encoded thereby. For example, one can make nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues. A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequence without altering the biological activity, whereas an "essential" amino acid residue is required for biological activity. For example, amino acid residues that are not conserved or only semi-conserved among homologs of various species may be non-essential for activity and thus would be likely targets for alteration. Alternatively, amino acid residues that are conserved among the homologs of various species (e.g., murine and human) may be essential for activity and thus would not be likely targets for alteration.

10

15

25

30

Accordingly, another aspect of the invention pertains to nucleic acid molecules encoding a polypeptide of the invention that contain changes in amino acid residues that are not essential for activity. Such polypeptides differ in amino acid sequence from the naturally-occurring proteins which correspond to the markers of the invention, yet retain biological activity. In one embodiment, such a protein has an amino acid sequence that is at least about 40% identical, 50%, 60%, 70%, 80%, 90%, 95%, or 98% identical to the amino acid sequence of one of the proteins which correspond to the markers of the invention.

An isolated nucleic acid molecule encoding a variant protein can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of nucleic acids of the invention, such that one or more amino acid residue substitutions, additions, or deletions are introduced into the encoded protein. Mutations can be introduced by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an

15

25

amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Alternatively, mutations can be introduced randomly along all or part of the coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for biological activity to identify mutants that retain activity. Following mutagenesis, the encoded protein can be expressed recombinantly and the activity of the protein can be determined.

The present invention encompasses antisense nucleic acid molecules, *i.e.*, molecules which are complementary to a sense nucleic acid of the invention, *e.g.*, complementary to the coding strand of a double-stranded cDNA molecule corresponding to a marker of the invention or complementary to an mRNA sequence corresponding to a marker of the invention. Accordingly, an antisense nucleic acid of the invention can hydrogen bond to (*i.e.* anneal with) a sense nucleic acid of the invention. The antisense nucleic acid can be complementary to an entire coding strand, or to only a portion thereof, *e.g.*, all or part of the protein coding region (or open reading frame). An antisense nucleic acid molecule can also be antisense to all or part of a noncoding region of the coding strand of a nucleotide sequence encoding a polypeptide of the invention. The non-coding regions ("5' and 3' untranslated regions") are the 5' and 3' sequences which flank the coding region and are not translated into amino acids.

An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 or more nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine

substituted nucleotides can be used. Examples of modified nucleotides which can be used to generate the antisense nucleic acid include 5-fluorouracil, 5-bromouracil, 5chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an 15 expression vector into which a nucleic acid has been sub-cloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

The antisense nucleic acid molecules of the invention are typically administered to a subject or generated *in situ* such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a polypeptide corresponding to a selected marker of the invention to thereby inhibit expression of the marker, *e.g.*, by inhibiting transcription and/or translation. The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule which binds to DNA duplexes, through specific interactions in the major groove of the double helix. Examples of a route of administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site or infusion of the antisense nucleic acid into an ovary-associated body fluid. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, *e.g.*, by linking the antisense nucleic acid molecules

to peptides or antibodies which bind to cell surface receptors or antigens. The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of the antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

An antisense nucleic acid molecule of the invention can be an α-anomeric nucleic acid molecule. An α-anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual α-units, the strands run parallel to each other (Gaultier *et al.*, 1987, *Nucleic Acids Res.* 15:6625-6641). The antisense nucleic acid molecule can also comprise a 2'-o-methylribonucleotide (Inoue *et al.*, 1987, *Nucleic Acids Res.* 15:6131-6148) or a chimeric RNA-DNA analogue (Inoue *et al.*, 1987, *FEBS Lett.* 215:327-330).

The invention also encompasses ribozymes. Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes as described in Haselhoff and Gerlach, 1988, *Nature* 334:585-591) can be used to catalytically cleave mRNA transcripts to thereby inhibit translation of the protein encoded by the mRNA. A ribozyme having specificity for a nucleic acid molecule encoding a polypeptide corresponding to a marker of the invention can be designed based upon the nucleotide sequence of a cDNA corresponding to the marker. For example, a derivative of a *Tetrahymena* L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved (see Cech et al. U.S. Patent No. 4,987,071; and Cech et al. U.S. Patent No. 5,116,742). Alternatively, an mRNA encoding a polypeptide of the invention can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules (see, e.g., Bartel and Szostak, 1993, *Science* 261:1411-1418).

The invention also encompasses nucleic acid molecules which form triple helical structures. For example, expression of a polypeptide of the invention can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the gene encoding the polypeptide (e.g., the promoter and/or enhancer) to form triple helical structures that prevent transcription of the gene in target cells. See generally Helene

- 37 -

(1991) Anticancer Drug Des. 6(6):569-84; Helene (1992) Ann. N.Y. Acad. Sci. 660:27-36; and Maher (1992) Bioassays 14(12):807-15.

In various embodiments, the nucleic acid molecules of the invention can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids (see Hyrup et al., 1996, Bioorganic & Medicinal Chemistry 4(1): 5-23). As used herein, the terms "peptide nucleic acids" or "PNAs" refer to nucleic acid mimics, e.g., DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup et al. (1996), supra; Perry-O'Keefe et al. (1996) Proc. Natl. Acad. Sci. USA 93:14670-675.

PNAs can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, e.g., inducing transcription or translation arrest or inhibiting replication. PNAs can also be used, e.g., in the analysis of single base pair mutations in a gene by, e.g., PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, e.g., S1 nucleases (Hyrup (1996), supra; or as probes or primers for DNA sequence and hybridization (Hyrup, 1996, supra; Perry-O'Keefe et al., 1996, Proc. Natl. Acad. Sci. USA 93:14670-675).

15

25

In another embodiment, PNAs can be modified, e.g., to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras can be generated which can combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes, e.g., RNASE H and DNA polymerases, to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (Hyrup,

25

30

1996, supra). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup (1996), supra, and Finn et al. (1996) Nucleic Acids Res. 24(17):3357-63. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry and modified nucleoside analogs. Compounds such as 5'-(4-methoxytrityl)amino-5'-deoxy-thymidine phosphoramidite can be used as a link between the PNA and the 5' end of DNA (Mag et al., 1989, Nucleic Acids Res. 17:5973-88). PNA monomers are then coupled in a step-wise manner to produce a chimeric molecule with a 5' PNA segment and a 3' DNA segment (Finn et al., 1996, Nucleic Acids Res. 24(17):3357-63). Alternatively, chimeric molecules can be synthesized with a 5' DNA segment and a 3' PNA segment (Peterser et al., 1975, Bioorganic Med. Chem. Lett. 5:1119-11124).

In other embodiments, the oligonucleotide can include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al., 1989, Proc. Natl. Acad. Sci. USA 86:6553-6556; Lemaitre et al., 1987, Proc. Natl. Acad. Sci. USA 84:648-652; PCT Publication No. WO 88/09810) or the blood-brain barrier (see, e.g., PCT Publication No. WO 89/10134). In addition, oligonucleotides can be modified with hybridization-triggered cleavage agents (see, e.g., Krol et al., 1988, Bio/Techniques 6:958-976) or intercalating agents (see, e.g., Zon, 1988, Pharm. Res. 5:539-549). To this end, the oligonucleotide can be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

The invention also includes molecular beacon nucleic acids having at least one region which is complementary to a nucleic acid of the invention, such that the molecular beacon is useful for quantitating the presence of the nucleic acid of the invention in a sample. A "molecular beacon" nucleic acid is a nucleic acid comprising a pair of complementary regions and having a fluorophore and a fluorescent quencher associated therewith. The fluorophore and quencher are associated with different portions of the nucleic acid in such an orientation that when the complementary regions are annealed with one another, fluorescence of the fluorophore is quenched by the quencher. When the complementary regions of the nucleic acid are not annealed with

10

15

20

25

30

one another, fluorescence of the fluorophore is quenched to a lesser degree. Molecular beacon nucleic acids are described, for example, in U.S. Patent 5,876,930.

II. Isolated Proteins and Antibodies

One aspect of the invention pertains to isolated proteins which correspond to individual markers of the invention, and biologically active portions thereof, as well as polypeptide fragments suitable for use as immunogens to raise antibodies directed against a polypeptide corresponding to a marker of the invention. In one embodiment, the native polypeptide corresponding to a marker can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, polypeptides corresponding to a marker of the invention are produced by recombinant DNA techniques. Alternative to recombinant expression, a polypeptide corresponding to a marker of the invention can be synthesized chemically using standard peptide synthesis techniques.

An "isolated" or "purified" protein or biologically active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the protein is derived, or substantially free of chemical. precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of protein in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly produced. Thus, protein that is substantially free of cellular material includes preparations of protein having less than about 30%, 20%, 10%, or 5% (by dry weight) of heterologous protein (also referred to herein as a "contaminating protein"). When the protein or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, 10%, or 5% of the volume of the protein preparation. When the protein is produced by chemical synthesis, it is preferably substantially free of chemical precursors or other chemicals, i.e., it is separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. Accordingly such preparations of the protein have less than about 30%, 20%, 10%, 5% (by dry weight) of chemical precursors or compounds other than the polypeptide of interest.

25

30

Biologically active portions of a polypeptide corresponding to a marker of the invention include polypeptides comprising amino acid sequences sufficiently identical to or derived from the amino acid sequence of the protein corresponding to the marker, which include fewer amino acids than the full length protein, and exhibit at least one activity of the corresponding full-length protein. Typically, biologically active portions comprise a domain or motif with at least one activity of the corresponding protein. A biologically active portion of a protein of the invention can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acids in length. Moreover, other biologically active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of the native form of a polypeptide of the invention.

Preferred polypeptides are encoded by the nucleotide sequences of Tables 1-2. Other useful proteins are substantially identical (e.g., at least about 40%, preferably 50%, 60%, 70%, 80%, 90%, 95%, or 99%) to one of these sequences and retain the functional activity of the protein of the corresponding naturally-occurring protein yet differ in amino acid sequence due to natural allelic variation or mutagenesis.

To determine the percent identity of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % identity = # of identical positions/total # of positions (e.g., overlapping positions) $\times 100$). In one embodiment the two sequences are the same length.

The determination of percent identity between two sequences can be accomplished using a mathematical algorithm. A preferred, non-limiting example of a mathematical algorithm utilized for the comparison of two sequences is the algorithm of Karlin and Altschul (1990) *Proc. Natl. Acad. Sci. USA* 87:2264-2268, modified as in Karlin and Altschul (1993) *Proc. Natl. Acad. Sci. USA* 90:5873-5877. Such an

÷

algorithm is incorporated into the NBLAST and XBLAST programs of Altschul, et al. (1990) J. Mol. Biol. 215:403-410. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to a nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to a protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al. (1997) Nucleic Acids Res. 25:3389-3402. Alternatively, PSI-Blast can be used to perform an iterated search which detects distant relationships between molecules. When utilizing BLAST, Gapped BLAST, and PSI-Blast programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. See http://www.ncbi.nlm.nih.gov. Another preferred, non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller, (1988) CABIOS 4:11-17. Such an algorithm is incorporated into the ALIGN program (version 2.0) which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used. Yet another useful algorithm for identifying regions of local sequence similarity and alignment is the FASTA algorithm as described in Pearson and Lipman (1988) Proc. Natl. Acad. Sci. USA 85:2444-2448. When using the FASTA algorithm for comparing nucleotide or amino acid sequences, a PAM120 weight residue table can, for example, be used with a k-tuple value of 2.

The percent identity between two sequences can be determined using techniques similar to those described above, with or without allowing gaps. In calculating percent identity, only exact matches are counted.

The invention also provides chimeric or fusion proteins corresponding to a marker of the invention. As used herein, a "chimeric protein" or "fusion protein" comprises all or part (preferably a biologically active part) of a polypeptide corresponding to a marker of the invention operably linked to a heterologous polypeptide (*i.e.*, a polypeptide other than the polypeptide corresponding to the marker). Within the fusion protein, the term "operably linked" is intended to indicate that the polypeptide of the invention and the heterologous polypeptide are fused in-frame to each

- 42 -

other. The heterologous polypeptide can be fused to the amino-terminus or the carboxyl-terminus of the polypeptide of the invention.

One useful fusion protein is a GST fusion protein in which a polypeptide corresponding to a marker of the invention is fused to the carboxyl terminus of GST sequences. Such fusion proteins can facilitate the purification of a recombinant polypeptide of the invention.

In another embodiment, the fusion protein contains a heterologous signal sequence at its amino terminus. For example, the native signal sequence of a polypeptide corresponding to a marker of the invention can be removed and replaced with a signal sequence from another protein. For example, the gp67 secretory sequence of the baculovirus envelope protein can be used as a heterologous signal sequence (Ausubel et al., ed., Current Protocols in Molecular Biology, John Wiley & Sons, NY, 1992). Other examples of eukaryotic heterologous signal sequences include the secretory sequences of melittin and human placental alkaline phosphatase (Stratagene; La Jolla, California). In yet another example, useful prokaryotic heterologous signal sequences include the phoA secretory signal (Sambrook et al., supra) and the protein A secretory signal (Pharmacia Biotech; Piscataway, New Jersey).

In yet another embodiment, the fusion protein is an immunoglobulin fusion protein in which all or part of a polypeptide corresponding to a marker of the invention is fused to sequences derived from a member of the immunoglobulin protein family. The immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between a ligand (soluble or membrane-bound) and a protein on the surface of a cell (receptor), to thereby suppress signal transduction *in vivo*. The immunoglobulin fusion protein can be used to affect the bioavailability of a cognate ligand of a polypeptide of the invention. Inhibition of ligand/receptor interaction can be useful therapeutically, both for treating proliferative and differentiative disorders and for modulating (e.g. promoting or inhibiting) cell survival. Moreover, the immunoglobulin fusion proteins of the invention can be used as immunogens to produce antibodies directed against a polypeptide of the invention in a subject, to purify ligands and in screening assays to identify molecules which inhibit the interaction of receptors with ligands.

30

- 43 -

Chimeric and fusion proteins of the invention can be produced by standard recombinant DNA techniques. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and re-amplified to generate a chimeric gene sequence (see, e.g., Ausubel et al., supra). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide). A nucleic acid encoding a polypeptide of the invention can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the polypeptide of the invention.

A signal sequence can be used to facilitate secretion and isolation of the secreted protein or other proteins of interest. Signal sequences are typically characterized by a core of hydrophobic amino acids which are generally cleaved from the mature protein during secretion in one or more cleavage events. Such signal peptides contain processing sites that allow cleavage of the signal sequence from the mature proteins as they pass through the secretory pathway. Thus, the invention pertains to the described polypeptides having a signal sequence, as well as to polypeptides from which the signal sequence has been proteolytically cleaved (i.e., the cleavage products). In one embodiment, a nucleic acid sequence encoding a signal sequence can be operably linked in an expression vector to a protein of interest, such as a protein which is ordinarily not secreted or is otherwise difficult to isolate. The signal sequence directs secretion of the protein, such as from a eukaryotic host into which the expression vector is transformed, and the signal sequence is subsequently or concurrently cleaved. The protein can then be readily purified from the extracellular medium by art recognized methods. Alternatively, the signal sequence can be linked to the protein of interest using a sequence which facilitates purification, such as with a GST domain.

4

The present invention also pertains to variants of the polypeptides corresponding to individual markers of the invention. Such variants have an altered amino acid sequence which can function as either agonists (mimetics) or as antagonists. Variants can be generated by mutagenesis, *e.g.*, discrete point mutation or truncation. An agonist can retain substantially the same, or a subset, of the biological activities of the naturally

30

occurring form of the protein. An antagonist of a protein can inhibit one or more of the activities of the naturally occurring form of the protein by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade which includes the protein of interest. Thus, specific biological effects can be elicited by treatment with a variant of limited function. Treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein can have fewer side effects in a subject relative to treatment with the naturally occurring form of the protein.

Variants of a protein of the invention which function as either agonists 10 (mimetics) or as antagonists can be identified by screening combinatorial libraries of mutants, e.g., truncation mutants, of the protein of the invention for agonist or antagonist activity. In one embodiment, a variegated library of variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential protein sequences is expressible as individual polypeptides. or alternatively, as a set of larger fusion proteins (e.g., for phage display). There are a variety of methods which can be used to produce libraries of potential variants of the polypeptides of the invention from a degenerate oligonucleotide sequence. Methods for 20 synthesizing degenerate oligonucleotides are known in the art (see, e.g., Narang, 1983, Tetrahedron 39:3; Itakura et al., 1984, Annu. Rev. Biochem. 53:323; Itakura et al., 1984, Science 198:1056; Ike et al., 1983 Nucleic Acid Res. 11:477).

In addition, libraries of fragments of the coding sequence of a polypeptide corresponding to a marker of the invention can be used to generate a variegated population of polypeptides for screening and subsequent selection of variants. For example, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of the coding sequence of interest with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA which can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, an expression library can be

20

30

derived which encodes amino terminal and internal fragments of various sizes of the protein of interest.

Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. The most widely used techniques, which are amenable to high through-put analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a technique which enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify variants of a protein of the invention (Arkin and Yourvan, 1992, *Proc. Natl. Acad. Sci. USA 89:7811-7815*; Delgrave *et al.*, 1993, *Protein Engineering* 6(3):327-331).

An isolated polypeptide corresponding to a marker of the invention, or a fragment thereof, can be used as an immunogen to generate antibodies using standard techniques for polyclonal and monoclonal antibody preparation. The full-length polypeptide or protein can be used or, alternatively, the invention provides antigenic peptide fragments for use as immunogens. The antigenic peptide of a protein of the invention comprises at least 8 (preferably 10, 15, 20, or 30 or more) amino acid residues of the amino acid sequence of one of the polypeptides of the invention, and encompasses an epitope of the protein such that an antibody raised against the peptide forms a specific immune complex with a marker of the invention to which the protein corresponds. Preferred epitopes encompassed by the antigenic peptide are regions that are located on the surface of the protein, *e.g.*, hydrophilic regions. Hydrophobicity sequence analysis, hydrophilicity sequence analysis, or similar analyses can be used to identify hydrophilic regions.

An immunogen typically is used to prepare antibodies by immunizing a suitable (i.e. immunocompetent) subject such as a rabbit, goat, mouse, or other mammal or vertebrate. An appropriate immunogenic preparation can contain, for example, recombinantly-expressed or chemically-synthesized polypeptide. The preparation can

- 46 -

further include an adjuvant, such as Freund's complete or incomplete adjuvant, or a similar immunostimulatory agent.

Accordingly, another aspect of the invention pertains to antibodies directed against a polypeptide of the invention. The terms "antibody" and "antibody substance" as used interchangeably herein refer to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, *i.e.*, molecules that contain an antigen binding site which specifically binds an antigen, such as a polypeptide of the invention, e.g., an epitope of a polypeptide of the invention. A molecule which specifically binds to a given polypeptide of the invention is a molecule which binds the polypeptide, but does not substantially bind other molecules in a sample, *e.g.*, a biological sample, which naturally contains the polypeptide. Examples of immunologically active portions of immunoglobulin molecules include F(ab) and F(ab')₂ fragments which can be generated by treating the antibody with an enzyme such as pepsin. The invention provides polyclonal and monoclonal antibodies. The term "monoclonal antibody" or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope.

10

15

20

Polyclonal antibodies can be prepared as described above by immunizing a suitable subject with a polypeptide of the invention as an immunogen. Preferred polyclonal antibody compositions are ones that have been selected for antibodies directed against a polypeptide or polypeptides of the invention. Particularly preferred polyclonal antibody preparations are ones that contain only antibodies directed against a polypeptide or polypeptides of the invention. Particularly preferred immunogen compositions are those that contain no other human proteins such as, for example, immunogen compositions made using a non-human host cell for recombinant expression of a polypeptide of the invention. In such a manner, the only human epitope or epitopes recognized by the resulting antibody compositions raised against this immunogen will be present as part of a polypeptide or polypeptides of the invention.

The antibody titer in the immunized subject can be monitored over time by

standard techniques, such as with an enzyme linked immunosorbent assay (ELISA)

using immobilized polypeptide. If desired, the antibody molecules can be harvested or
isolated from the subject (e.g., from the blood or serum of the subject) and further

purified by well-known techniques, such as protein A chromatography to obtain the IgG fraction. Alternatively, antibodies specific for a protein or polypeptide of the invention can be selected or (e.g., partially purified) or purified by, e.g., affinity chromatography, For example, a recombinantly expressed and purified (or partially purified) protein of the invention is produced as described herein, and covalently or non-covalently coupled to a solid support such as, for example, a chromatography column. The column can then be used to affinity purify antibodies specific for the proteins of the invention from a sample containing antibodies directed against a large number of different epitopes. thereby generating a substantially purified antibody composition, i.e., one that is substantially free of contaminating antibodies. By a substantially purified antibody composition is meant, in this context, that the antibody sample contains at most only 30% (by dry weight) of contaminating antibodies directed against epitopes other than those of the desired protein or polypeptide of the invention, and preferably at most 20%, yet more preferably at most 10%, and most preferably at most 5% (by dry weight) of the sample is contaminating antibodies. A purified antibody composition means that at least 99% of the antibodies in the composition are directed against the desired protein or polypeptide of the invention.

10

15

20

At an appropriate time after immunization, e.g., when the specific antibody titers are highest, antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies by standard techniques, such as the hybridoma technique originally described by Kohler and Milstein (1975) Nature 256:495-497, the human B cell hybridoma technique (see Kozbor et al., 1983, Immunol. Today 4:72), the EBV-hybridoma technique (see Cole et al., pp. 77-96 In Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., 1985) or trioma techniques. The technology for producing hybridomas is well known (see generally Current Protocols in Immunology, Coligan et al. ed., John Wiley & Sons, New York, 1994). Hybridoma cells producing a monoclonal antibody of the invention are detected by screening the hybridoma culture supernatants for antibodies that bind the polypeptide of interest, e.g., using a standard ELISA assay.

Alternative to preparing monoclonal antibody-secreting hybridomas, a monoclonal antibody directed against a polypeptide of the invention can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (e.g., an

antibody phage display library) with the polypeptide of interest. Kits for generating and screening phage display libraries are commercially available (e.g., the Pharmacia Recombinant Phage Antibody System, Catalog No. 27-9400-01; and the Stratagene SurfZAP Phage Display Kit, Catalog No. 240612). Additionally, examples of methods and reagents particularly amenable for use in generating and screening antibody display library can be found in, for example, U.S. Patent No. 5,223,409; PCT Publication No. WO 92/18619; PCT Publication No. WO 91/17271; PCT Publication No. WO 92/20791; PCT Publication No. WO 92/15679; PCT Publication No. WO 93/01288; PCT Publication No. WO 92/01047; PCT Publication No. WO 92/09690; PCT Publication No. WO 90/02809; Fuchs et al. (1991) Bio/Technology 9:1370-1372; Hay et al. (1992) Hum. Antibod. Hybridomas 3:81-85; Huse et al. (1989) Science 246:1275-1281; Griffiths et al. (1993) EMBO J. 12:725-734.

Additionally, recombinant antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region. (See, e.g., Cabilly et al., U.S. Patent No. 4,816,567; and Boss et al., U.S. Patent No. 4,816,397, which are incorporated herein by reference in their entirety.) Humanized antibodies are antibody molecules from non-human species having one or more complementarily determining regions (CDRs) from the non-human species and a framework region from a human immunoglobulin molecule. (See, e.g., Queen, U.S. Patent No. 5,585,089, which is incorporated herein by reference in its entirety.) Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in PCT Publication No. WO 87/02671; European Patent Application 184,187; European Patent Application 171,496; European Patent Application 173,494; PCT Publication No. WO 86/01533; U.S. Patent No. 4,816,567; European Patent Application 125,023; Better et al. (1988) Science 240:1041-1043; Liu et al. (1987) Proc. Natl. Acad. Sci. USA 84:3439-3443; Liu et al. (1987) J. Immunol. 139:3521-3526; Sun et al. (1987) Proc. Natl. Acad. Sci. USA 84:214-218; Nishimura et al. (1987) Cancer Res. 47:999-1005; Wood et al. (1985) Nature 314:446-

10

15

25

449; and Shaw et al. (1988) J. Natl. Cancer Inst. 80:1553-1559); Morrison (1985) Science 229:1202-1207; Oi et al. (1986) Bio/Techniques 4:214; U.S. Patent 5,225,539; Jones et al. (1986) Nature 321:552-525; Verhoeyan et al. (1988) Science 239:1534; and Beidler et al. (1988) J. Immunol. 141:4053-4060.

Antibodies of the invention may be used as therapeutic agents in treating cancers. In a preferred embodiment, completely human antibodies of the invention are used for therapeutic treatment of human cancer patients, particularly those having an ovarian cancer. Such antibodies can be produced, for example, using transgenic mice which are incapable of expressing endogenous immunoglobulin heavy and light chains genes, but which can express human heavy and light chain genes. The transgenic mice are immunized in the normal fashion with a selected antigen, e.g., all or a portion of a polypeptide corresponding to a marker of the invention. Monoclonal antibodies directed against the antigen can be obtained using conventional hybridoma technology. The human immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA and IgE antibodies. For an overview of this technology for producing human antibodies. see Lonberg and Huszar (1995) Int. Rev. Immunol. 13:65-93). For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., U.S. Patent 5,625,126; U.S. Patent 5,633,425; U.S. Patent 5,569,825; U.S. Patent 5,661,016; and U.S. Patent 5,545,806. In addition, companies such as Abgenix, Inc. (Freemont, CA), can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above.

Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a selected non-human monoclonal antibody, e.g., a murine antibody, is used to guide the selection of a completely human antibody recognizing the same epitope (Jespers et al., 1994, Bio/technology 12:899-903).

An antibody directed against a polypeptide corresponding to a marker of the invention (e.g., a monoclonal antibody) can be used to isolate the polypeptide by standard techniques, such as affinity chromatography or immunoprecipitation:

Moreover, such an antibody can be used to detect the marker (e.g., in a cellular lysate or cell supernatant) in order to evaluate the level and pattern of expression of the marker. The antibodies can also be used diagnostically to monitor protein levels in tissues or body fluids (e.g. in an ovary-associated body fluid) as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate. rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ¹²⁵I, ¹³¹I, ³⁵S or ³H.

Further, an antibody (or fragment thereof) can be conjugated to a therapeutic moiety such as a cytotoxin, a therapeutic agent or a radioactive metal ion. A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples include taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclothosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine).

- 51 -

The conjugates of the invention can be used for modifying a given biological response, the drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor, alpha.-interferon, beta.-interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte macrophase colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors.

10

25

Techniques for conjugating such therapeutic moiety to antibodies are well known, see, e.g., Arnon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in Monoclonal Antibodies And Cancer Therapy, Reisfeld et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., "Antibodies For Drug Delivery", in Controlled Drug Delivery (2nd Ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in Monoclonal Antibodies '84: Biological And Clinical Applications, Pinchera et al. (eds.), pp. 475-506 (1985); "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in Monoclonal Antibodies For Cancer Detection And Therapy, Baldwin et al. (eds.), pp. 303-16 (Academic Press 1985), and Thorpe et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", Immunol. Rev., 62:119-58 (1982).

ď,

Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980.

Accordingly, in one aspect, the invention provides substantially purified antibodies or fragments thereof, and non-human antibodies or fragments thereof, which antibodies or fragments specifically bind to a polypeptide comprising an amino acid sequence selected from the group consisting of the amino acid sequences of the present invention, an amino acid sequence encoded by the cDNA of the present invention, a fragment of at least 15 amino acid residues of an amino acid sequence of the present invention, an amino acid sequence which is at least 95% identical to the amino acid sequence of the present invention (wherein the percent identity is determined using the

10

15

25

30

- 52 -

ALIGN program of the GCG software package with a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4) and an amino acid sequence which is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule consisting of the nucleic acid molecules of the present invention, or a complement thereof, under conditions of hybridization of 6X SSC at 45°C and washing in 0.2 X SSC, 0.1% SDS at 65°C. In various embodiments, the substantially purified antibodies of the invention, or fragments thereof, can be human, non-human, chimeric and/or humanized antibodies.

In another aspect, the invention provides non-human antibodies or fragments thereof, which antibodies or fragments specifically bind to a polypeptide comprising an amino acid sequence selected from the group consisting of: the amino acid sequence of the present invention, an amino acid sequence encoded by the cDNA of the present invention, a fragment of at least 15 amino acid residues of the amino acid sequence of the present invention, an amino acid sequence which is at least 95% identical to the amino acid sequence of the present invention (wherein the percent identity is determined using the ALIGN program of the GCG software package with a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4) and an amino acid sequence which is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule consisting of the nucleic acid molecules of the present invention, or a complement thereof, under conditions of hybridization of 6X SSC at 45°C and washing in 0.2 X SSC, 0.1% SDS at 65°C. Such non-human antibodies can be goat, mouse, sheep, horse, chicken, rabbit, or rat antibodies. Alternatively, the non-human antibodies of the invention can be chimeric and/or humanized antibodies. In addition, the nonhuman antibodies of the invention can be polyclonal antibodies or monoclonal antibodies.

In still a further aspect, the invention provides monoclonal antibodies or fragments thereof, which antibodies or fragments specifically bind to a polypeptide comprising an amino acid sequence selected from the group consisting of the amino acid sequences of the present invention, an amino acid sequence encoded by the cDNA of the present invention, a fragment of at least 15 amino acid residues of an amino acid sequence of the present invention, an amino acid sequence which is at least 95% identical to an amino acid sequence of the present invention (wherein the percent

15

20

25

30

identity is determined using the ALIGN program of the GCG software package with a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4) and an amino acid sequence which is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule consisting of the nucleic acid molecules of the present invention, or a complement thereof, under conditions of hybridization of 6X SSC at 45°C and washing in 0.2 X SSC, 0.1% SDS at 65°C. The monoclonal antibodies can be human, humanized, chimeric and/or non-human antibodies.

The substantially purified antibodies or fragments thereof may specifically bind to a signal peptide, a secreted sequence, an extracellular domain, a transmembrane or a cytoplasmic domain or cytoplasmic membrane of a polypeptide of the invention. In a particularly preferred embodiment, the substantially purified antibodies or fragments thereof, the non-human antibodies or fragments thereof, and/or the monoclonal antibodies or fragments thereof, of the invention specifically bind to a secreted sequence or an extracellular domain of the amino acid sequences of the present invention.

Any of the antibodies of the invention can be conjugated to a therapeutic moiety or to a detectable substance. Non-limiting examples of detectable substances that can be conjugated to the antibodies of the invention are an enzyme, a prosthetic group, a fluorescent material, a luminescent material, a bioluminescent material, and a radioactive material.

The invention also provides a kit containing an antibody of the invention conjugated to a detectable substance, and instructions for use. Still another aspect of the invention is a pharmaceutical composition comprising an antibody of the invention and a pharmaceutically acceptable carrier. In preferred embodiments, the pharmaceutical composition contains an antibody of the invention, a therapeutic moiety, and a pharmaceutically acceptable carrier.

Still another aspect of the invention is a method of making an antibody that specifically recognizes a polypeptide of the present invention, the method comprising immunizing a mammal with a polypeptide. The polypeptide used as an immungen comprises an amino acid sequence selected from the group consisting of the amino acid sequence of the present invention, an amino acid sequence encoded by the cDNA of the nucleic acid molecules of the present invention, a fragment of at least 15 amino acid residues of the amino acid sequence of the present invention, an amino acid sequence

which is at least 95% identical to the amino acid sequence of the present invention (wherein the percent identity is determined using the ALIGN program of the GCG software package with a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4) and an amino acid sequence which is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule consisting of the nucleic acid molecules of the present invention, or a complement thereof, under conditions of hybridization of 6X SSC at 45°C and washing in 0.2 X SSC, 0.1% SDS at 65°C.

After immunization, a sample is collected from the mammal that contains an antibody that specifically recognizes the polypeptide. Preferably, the polypeptide is recombinantly produced using a non-human host cell. Optionally, the antibodies can be further purified from the sample using techniques well known to those of skill in the art. The method can further comprise producing a monoclonal antibody- producing cell from the cells of the mammal. Optionally, antibodies are collected from the antibody-producing cell.

15

III. Recombinant Expression Vectors and Host Cells

Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding a polypeptide corresponding to a marker of the invention (or a portion of such a polypeptide). As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors, namely expression vectors, are capable of directing the expression of genes to which they are operably linked. In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids (vectors). However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g.,

- 55 -

replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell. This means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operably linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence (e.g., in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel, Methods in Enzymology: Gene Expression Technology vol. 185, Academic Press, San Diego, CA (1991). Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cell and those which direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, and the like. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein.

45

The recombinant expression vectors of the invention can be designed for

25 expression of a polypeptide corresponding to a marker of the invention in prokaryotic

(e.g., E. coli) or eukaryotic cells (e.g., insect cells {using baculovirus expression

vectors}, yeast cells or mammalian cells). Suitable host cells are discussed further in

Goeddel, supra. Alternatively, the recombinant expression vector can be transcribed

and translated in vitro, for example using T7 promoter regulatory sequences and T7

30 polymerase.

25

30

Expression of proteins in prokaryotes is most often carried out in *E. coli* with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant protein; 2) to increase the solubility of the recombinant protein; and 3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson, 1988, *Gene* 67:31-40), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.

Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc (Amann *et al.*, 1988, Gene 69:301-315) and pET 11d (Studier *et al.*, p. 60-89, In Gene Expression Technology: Methods in Enzymology vol.185, Academic Press, San Diego, CA, 1991). Target gene expression from the pTrc vector relies on host RNA polymerase transcription from a hybrid trp-lac fusion promoter. Target gene expression from the pET 11d vector relies on transcription from a T7 gn10-lac fusion promoter mediated by a co-expressed viral RNA polymerase (T7 gn1). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident prophage harboring a T7 gn1 gene under the transcriptional control of the lacUV 5 promoter.

One strategy to maximize recombinant protein expression in *E. coli* is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, p. 119-128, In *Gene Expression Technology: Methods in Enzymology* vol. 185, Academic Press, San Diego, CA, 1990. Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in *E. coli* (Wada *et al.*, 1992, *Nucleic Acids Res.* 20:2111-2118). Such alteration of

15

nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

In another embodiment, the expression vector is a yeast expression vector. Examples of vectors for expression in yeast *S. cerevisiae* include pYepSec1 (Baldari *et al.*, 1987, *EMBO J.* 6:229-234), pMFa (Kurjan and Herskowitz, 1982, *Cell* 30:933-943), pJRY88 (Schultz *et al.*, 1987, *Gene* 54:113-123), pYES2 (Invitrogen Corporation, San Diego, CA), and pPicZ (Invitrogen Corp, San Diego, CA).

Alternatively, the expression vector is a baculovirus expression vector. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., Sf 9 cells) include the pAc series (Smith et al., 1983, Mol. Cell Biol. 3:2156-2165) and the pVL series (Lucklow and Summers, 1989, Virology 170:31-39).

In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, 1987, *Nature* 329:840) and pMT2PC (Kaufman *et al.*, 1987, *EMBO J.* 6:187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see chapters 16 and 17 of Sambrook *et al.*, *supra*.

In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert et al., 1987, Genes Dev. 1:268-277), lymphoid-specific promoters (Calame and Eaton, 1988, Adv. Immunol. 43:235-275), in particular promoters of T cell receptors (Winoto and Baltimore, 1989, EMBO J. 8:729-733) and immunoglobulins (Banerji et al., 1983, Cell 33:729-740; Queen and Baltimore, 1983, Cell 33:741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle, 1989, Proc. Natl. Acad. Sci. USA 86:5473-5477), pancreas-specific promoters (Edlund et al., 1985, Science 230:912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Patent No. 4,873,316 and European Application Publication No. 264,166). Developmentally-

regulated promoters are also encompassed, for example the murine hox promoters (Kessel and Gruss, 1990, *Science* 249:374-379) and the α-fetoprotein promoter (Camper and Tilghman, 1989, *Genes Dev.* 3:537-546).

The invention further provides a recombinant expression vector comprising a

DNA molecule of the invention cloned into the expression vector in an antisense
orientation. That is, the DNA molecule is operably linked to a regulatory sequence in a
manner which allows for expression (by transcription of the DNA molecule) of an RNA
molecule which is antisense to the mRNA encoding a polypeptide of the invention.
Regulatory sequences operably linked to a nucleic acid cloned in the antisense
orientation can be chosen which direct the continuous expression of the antisense RNA
molecule in a variety of cell types, for instance viral promoters and/or enhancers, or
regulatory sequences can be chosen which direct constitutive, tissue-specific or cell type
specific expression of antisense RNA. The antisense expression vector can be in the
form of a recombinant plasmid, phagemid, or attenuated virus in which antisense nucleic
acids are produced under the control of a high efficiency regulatory region, the activity
of which can be determined by the cell type into which the vector is introduced. For a
discussion of the regulation of gene expression using antisense genes see Weintraub et
al., 1986, Trends in Genetics, Vol. 1(1).

Another aspect of the invention pertains to host cells into which a recombinant

20 expression vector of the invention has been introduced. The terms "host cell" and

"recombinant host cell" are used interchangeably herein. It is understood that such

terms refer not only to the particular subject cell but to the progeny or potential progeny

of such a cell. Because certain modifications may occur in succeeding generations due

to either mutation or environmental influences, such progeny may not, in fact, be

25 identical to the parent cell, but are still included within the scope of the term as used

herein.

A host cell can be any prokaryotic (e.g., E. coli) or eukaryotic cell (e.g., insect cells, yeast or mammalian cells).

Vector DNA can be introduced into prokaryotic or eukaryotic cells via

conventional transformation or transfection techniques. As used herein, the terms
"transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid into a host cell, including calcium

20

25

30

phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, *et al.* (*supra*), and other laboratory manuals.

For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., for resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Preferred selectable markers include those which confer resistance to drugs, such as G418, hygromycin and methotrexate. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die).

A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce a polypeptide corresponding to a marker of the invention. Accordingly, the invention further provides methods for producing a polypeptide corresponding to a marker of the invention using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding a polypeptide of the invention has been introduced) in a suitable medium such that the marker is produced. In another embodiment, the method further comprises isolating the marker polypeptide from the medium or the host cell.

The host cells of the invention can also be used to produce nonhuman transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which a sequences encoding a polypeptide corresponding to a marker of the invention have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous sequences encoding a marker protein of the invention have been introduced into their genome or homologous recombinant animals in which endogenous gene(s) encoding a polypeptide corresponding to a marker of the invention sequences have been altered. Such animals are useful for studying the function and/or activity of the polypeptide corresponding to the marker and for identifying and/or evaluating modulators of polypeptide activity. As used herein, a "transgenic animal" is a non-human animal, preferably a mammal, more

25

30

preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, an "homologous recombinant animal" is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, e.g., an embryonic cell of the animal, prior to development of the animal.

A transgenic animal of the invention can be created by introducing a nucleic acid encoding a polypeptide corresponding to a marker of the invention into the male pronuclei of a fertilized oocyte, e.g., by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably linked to the transgene to direct expression of the polypeptide of the invention to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009, U.S. Patent No. 4,873,191 and in Hogan, Manipulating the Mouse Embryo, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986. Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the transgene in its genome and/or expression of mRNA encoding the transgene in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying the transgene can further be bred to other transgenic animals carrying other transgenes.

To create an homologous recombinant animal, a vector is prepared which contains at least a portion of a gene encoding a polypeptide corresponding to a marker of the invention into which a deletion, addition or substitution has been introduced to

thereby alter, e.g., functionally disrupt, the gene. In a preferred embodiment, the vector is designed such that, upon homologous recombination, the endogenous gene is functionally disrupted (i.e., no longer encodes a functional protein; also referred to as a "knock out" vector). Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous gene is mutated or otherwise altered but still encodes functional protein (e.g., the upstream regulatory region can be altered to thereby alter the expression of the endogenous protein). In the homologous recombination vector, the altered portion of the gene is flanked at its 5' and 3' ends by additional nucleic acid of the gene to allow for homologous recombination to occur 10 between the exogenous gene carried by the vector and an endogenous gene in an embryonic stem cell. The additional flanking nucleic acid sequences are of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5' and 3' ends) are included in the vector (see, e.g., Thomas and Capecchi, 1987, Cell 51:503 for a description of homologous 15 recombination vectors). The vector is introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced gene has homologously recombined with the endogenous gene are selected (see, e.g., Li et al., 1992, Cell 69:915). The selected cells are then injected into a blastocyst of an animal (e.g., a mouse) to form aggregation chimeras (see, e.g., Bradley, Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, Robertson, Ed., IRL, Oxford, 1987, pp. 113-152). A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley (1991) Current Opinion in Bio/Technology 2:823-829 and in PCT Publication NOS. WO 90/11354, WO 91/01140, WO 92/0968, and WO 93/04169.

In another embodiment, transgenic non-human animals can be produced which contain selected systems which allow for regulated expression of the transgene. One example of such a system is the *cre/loxP* recombinase system of bacteriophage P1. For a description of the *cre/loxP* recombinase system, see, e.g., Lakso et al. (1992) *Proc.*

25

Natl. Acad. Sci. USA 89:6232-6236. Another example of a recombinase system is the FLP recombinase system of Saccharomyces cerevisiae (O'Gorman et al., 1991, Science 251:1351-1355). If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

Clones of the non-human transgenic animals described herein can also be
produced according to the methods described in Wilmut *et al.* (1997) *Nature* 385:810-813 and PCT Publication NOS. WO 97/07668 and WO 97/07669.

IV. Pharmaceutical Compositions

The nucleic acid molecules, polypeptides, and antibodies (also referred to herein as "active compounds") corresponding to a marker of the invention can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein the language "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

The invention includes methods for preparing pharmaceutical compositions for modulating the expression or activity of a polypeptide or nucleic acid corresponding to a marker of the invention. Such methods comprise formulating a pharmaceutically acceptable carrier with an agent which modulates expression or activity of a polypeptide or nucleic acid corresponding to a marker of the invention. Such compositions can further include additional active agents. Thus, the invention further includes methods for preparing a pharmaceutical composition by formulating a pharmaceutically

30

acceptable carrier with an agent which modulates expression or activity of a polypeptide or nucleic acid corresponding to a marker of the invention and one or more additional active compounds.

The invention also provides methods (also referred to herein as "screening assays") for identifying modulators, *i.e.*, candidate or test compounds or agents (*e.g.*, peptides, peptidomimetics, peptoids, small molecules or other drugs) which (a) bind to the marker, or (b) have a modulatory (*e.g.*, stimulatory or inhibitory) effect on the activity of the marker or, more specifically, (c) have a modulatory effect on the interactions of the marker with one or more of its natural substrates (*e.g.*, peptide, protein, hormone, co-factor, or nucleic acid), or (d) have a modulatory effect on the expression of the marker. Such assays typically comprise a reaction between the marker and one or more assay components. The other components may be either the test compound itself, or a combination of test compound and a natural binding partner of the marker.

The test compounds of the present invention may be obtained from any available source, including systematic libraries of natural and/or synthetic compounds. Test compounds may also be obtained by any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; peptoid libraries (libraries of molecules having the functionalities of peptides, but with a novel, non-peptide backbone which are resistant to enzymatic degradation but which nevertheless remain bioactive; see, e.g., Zuckermann et al., 1994, J. Med. Chem. 37:2678-85); spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the 'one-bead one-compound' library method; and synthetic library methods using affinity chromatography selection. The biological library and peptoid library approaches are limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam, 1997, Anticancer Drug Des. 12:145).

Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt et al. (1993) Proc. Natl. Acad. Sci. U.S.A. 90:6909; Erb et al. (1994) Proc. Natl. Acad. Sci. USA 91:11422; Zuckermann et al. (1994). J. Med. Chem. 37:2678; Cho et al. (1993) Science 261:1303; Carrell et al. (1994) Angew. Chem.

Int. Ed. Engl. 33:2059; Carell et al. (1994) Angew. Chem. Int. Ed. Engl. 33:2061; and in Gallop et al. (1994) J. Med. Chem. 37:1233.

Libraries of compounds may be presented in solution (e.g., Houghten, 1992, Biotechniques 13:412-421), or on beads (Lam, 1991, Nature 354:82-84), chips (Fodor, 1993, Nature 364:555-556), bacteria and/or spores, (Ladner, USP 5,223,409), plasmids (Cull et al, 1992, Proc Natl Acad Sci USA 89:1865-1869) or on phage (Scott and Smith, 1990, Science 249:386-390; Devlin, 1990, Science 249:404-406; Cwirla et al, 1990, Proc. Natl. Acad. Sci. 87:6378-6382; Felici, 1991, J. Mol. Biol. 222:301-310; Ladner, supra.).

10

15

In one embodiment, the invention provides assays for screening candidate or test compounds which are substrates of a marker or biologically active portion thereof. In another embodiment, the invention provides assays for screening candidate or test compounds which bind to a marker or biologically active portion thereof. Determining the ability of the test compound to directly bind to a marker can be accomplished, for example, by coupling the compound with a radioisotope or enzymatic label such that binding of the compound to the marker can be determined by detecting the labeled marker compound in a complex. For example, compounds (*e.g.*, marker substrates) can be labeled with ¹²⁵I, ³⁵S, ¹⁴C, or ³H, either directly or indirectly, and the radioisotope detected by direct counting of radioemission or by scintillation counting. Alternatively, assay components can be enzymatically labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product.

In another embodiment, the invention provides assays for screening candidate or test compounds which modulate the activity of a marker or a biologically active portion thereof. In all likelihood, the marker can, *in vivo*, interact with one or more molecules, such as but not limited to, peptides, proteins, hormones, cofactors and nucleic acids. For the purposes of this discussion, such cellular and extracellular molecules are referred to herein as "binding partners" or marker "substrate".

One necessary embodiment of the invention in order to facilitate such screening is the use of the marker to identify its natural *in vivo* binding partners. There are many ways to accomplish this which are known to one skilled in the art. One example is the use of the marker protein as "bait protein" in a two-hybrid assay or three-hybrid assay

(see, e.g., U.S. Patent No. 5,283,317; Zervos et al, 1993, Cell 72:223-232; Madura et al, 1993, J. Biol. Chem. 268:12046-12054; Bartel et al, 1993, Biotechniques 14:920-924; Iwabuchi et al, 1993 Oncogene 8:1693-1696; Brent WO94/10300) in order to identify other proteins which bind to or interact with the marker (binding partners) and, therefore, are possibly involved in the natural function of the marker. Such marker binding partners are also likely to be involved in the propagation of signals by the marker or downstream elements of a marker-mediated signaling pathway. Alternatively, such marker binding partners may also be found to be inhibitors of the marker.

The two-hybrid system is based on the modular nature of most transcription 10 factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that encodes a marker protein fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, in vivo, forming a markerdependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) which is operably linked to a transcriptional regulatory site responsive to 20 the transcription factor. Expression of the reporter gene can be readily detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene which encodes the protein which interacts with the marker protein.

In a further embodiment, assays may be devised through the use of the invention for the purpose of identifying compounds which modulate (e.g., affect either positively or negatively) interactions between a marker and its substrates and/or binding partners. Such compounds can include, but are not limited to, molecules such as antibodies, peptides, hormones, oligonucleotides, nucleic acids, and analogs thereof. Such compounds may also be obtained from any available source, including systematic libraries of natural and/or synthetic compounds. The preferred assay components for use in this embodiment is an ovarian cancer marker identified herein, the known binding partner and/or substrate of same, and the test compound. Test compounds can be supplied from any source.

- 66 -

The basic principle of the assay systems used to identify compounds that interfere with the interaction between the marker and its binding partner involves preparing a reaction mixture containing the marker and its binding partner under conditions and for a time sufficient to allow the two products to interact and bind, thus forming a complex. In order to test an agent for inhibitory activity, the reaction mixture is prepared in the presence and absence of the test compound. The test compound can be initially included in the reaction mixture, or can be added at a time subsequent to the addition of the marker and its binding partner. Control reaction mixtures are incubated without the test compound or with a placebo. The formation of any complexes between the marker and its binding partner is then detected. The formation of a complex in the control reaction, but less or no such formation in the reaction mixture containing the test compound, indicates that the compound interferes with the interaction of the marker and its binding partner. Conversely, the formation of more complex in the presence of compound than in the control reaction indicates that the compound may enhance interaction of the marker and its binding partner.

15

The assay for compounds that interfere with the interaction of the marker with its binding partner may be conducted in a heterogeneous or homogeneous format.

Heterogeneous assays involve anchoring either the marker or its binding partner onto a solid phase and detecting complexes anchored to the solid phase at the end of the reaction. In homogeneous assays, the entire reaction is carried out in a liquid phase. In either approach, the order of addition of reactants can be varied to obtain different information about the compounds being tested. For example, test compounds that interfere with the interaction between the markers and the binding partners (e.g., by competition) can be identified by conducting the reaction in the presence of the test substance, i.e., by adding the test substance to the reaction mixture prior to or simultaneously with the marker and its interactive binding partner. Alternatively, test compounds that disrupt preformed complexes, e.g., compounds with higher binding constants that displace one of the components from the complex, can be tested by adding the test compound to the reaction mixture after complexes have been formed. The various formats are briefly described below.

- 67 -

In a heterogeneous assay system, either the marker or its binding partner is anchored onto a solid surface or matrix, while the other corresponding non-anchored component may be labeled, either directly or indirectly. In practice, microtitre plates are often utilized for this approach. The anchored species can be immobilized by a number of methods, either non-covalent or covalent, that are typically well known to one who practices the art. Non-covalent attachment can often be accomplished simply by coating the solid surface with a solution of the marker or its binding partner and drying.

Alternatively, an immobilized antibody specific for the assay component to be anchored can be used for this purpose. Such surfaces can often be prepared in advance and stored.

10

15

30

In related embodiments, a fusion protein can be provided which adds a domain that allows one or both of the assay components to be anchored to a matrix. For example, glutathione-S-transferase/marker fusion proteins or glutathione-S-transferase/binding partner can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtiter plates, which are then combined with the test compound or the test compound and either the non-adsorbed marker or its binding partner, and the mixture incubated under conditions conducive to complex formation (e.g., physiological conditions). Following incubation, the beads or microtiter plate wells are washed to remove any unbound assay components, the immobilized complex assessed either directly or indirectly, for example, as described above. Alternatively, the complexes can be dissociated from the matrix, and the level of marker binding or activity determined using standard techniques.

Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either a marker or a marker binding partner can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated marker protein or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, IL), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). In certain embodiments, the protein-immobilized surfaces can be prepared in advance and stored.

In order to conduct the assay, the corresponding partner of the immobilized assay component is exposed to the coated surface with or without the test compound. After the reaction is complete, unreacted assay components are removed (e.g., by washing)

20

25

and any complexes formed will remain immobilized on the solid surface. The detection of complexes anchored on the solid surface can be accomplished in a number of ways. Where the non-immobilized component is pre-labeled, the detection of label immobilized on the surface indicates that complexes were formed. Where the non-immobilized component is not pre-labeled, an indirect label can be used to detect complexes anchored on the surface; *e.g.*, using a labeled antibody specific for the initially non-immobilized species (the antibody, in turn, can be directly labeled or indirectly labeled with, *e.g.*, a labeled anti-Ig antibody). Depending upon the order of addition of reaction components, test compounds which modulate (inhibit or enhance) complex formation or which disrupt preformed complexes can be detected.

In an alternate embodiment of the invention, a homogeneous assay may be used. This is typically a reaction, analogous to those mentioned above, which is conducted in a liquid phase in the presence or absence of the test compound. The formed complexes are then separated from unreacted components, and the amount of complex formed is determined. As mentioned for heterogeneous assay systems, the order of addition of reactants to the liquid phase can yield information about which test compounds modulate (inhibit or enhance) complex formation and which disrupt preformed complexes.

In such a homogeneous assay, the reaction products may be separated from unreacted assay components by any of a number of standard techniques, including but not limited to: differential centrifugation, chromatography, electrophoresis and immunoprecipitation. In differential centrifugation, complexes of molecules may be separated from uncomplexed molecules through a series of centrifugal steps, due to the different sedimentation equilibria of complexes based on their different sizes and densities (see, for example, Rivas, G., and Minton, A.P., *Trends Biochem Sci* 1993 Aug;18(8):284-7). Standard chromatographic techniques may also be utilized to separate complexed molecules from uncomplexed ones. For example, gel filtration chromatography separates molecules based on size, and through the utilization of an appropriate gel filtration resin in a column format, for example, the relatively larger complex may be separated from the relatively smaller uncomplexed components. Similarly, the relatively different charge properties of the complex as compared to the uncomplexed molecules may be exploited to differentially separate the complex from

30

the remaining individual reactants, for example through the use of ion-exchange chromatography resins. Such resins and chromatographic techniques are well known to one skilled in the art (see, e.g., Heegaard, 1998, J Mol. Recognit. 11:141-148; Hage and Tweed, 1997, J. Chromatogr. B. Biomed. Sci. Appl., 699:499-525). Gel electrophoresis may also be employed to separate complexed molecules from unbound species (see, e.g., Ausubel et al (eds.), In: Current Protocols in Molecular Biology, J. Wiley & Sons, New York. 1999). In this technique, protein or nucleic acid complexes are separated based on size or charge, for example. In order to maintain the binding interaction during the electrophoretic process, nondenaturing gels in the absence of reducing agent are typically preferred, but conditions appropriate to the particular interactants will be well known to one skilled in the art. Immunoprecipitation is another common technique utilized for the isolation of a protein-protein complex from solution (see, e.g., Ausubel et al (eds.), In: Current Protocols in Molecular Biology, J. Wiley & Sons, New York. 1999). In this technique, all proteins binding to an antibody specific to one of the binding molecules are precipitated from solution by conjugating the antibody to a polymer bead that may be readily collected by centrifugation. The bound assay components are released from the beads (through a specific proteolycis event or other technique well known in the art which will not disturb the protein-protein interaction in the complex), and a second immunoprecipitation step is performed, this time utilizing 20 antibodies specific for the correspondingly different interacting assay component. In this manner, only formed complexes should remain attached to the beads. Variations in complex formation in both the presence and the absence of a test compound can be compared, thus offering information about the ability of the compound to modulate interactions between the marker and its binding partner.

Also within the scope of the present invention are methods for direct detection of interactions between the marker and its natural binding partner and/or a test compound in a homogeneous or heterogeneous assay system without further sample manipulation. For example, the technique of fluorescence energy transfer may be utilized (see, e.g., Lakowicz et al, U.S. Patent No. 5,631,169; Stavrianopoulos et al, U.S. Patent No. 4,868,103). Generally, this technique involves the addition of a fluorophore label on a first 'donor' molecule (e.g., marker or test compound) such that its emitted fluorescent energy will be absorbed by a fluorescent label on a second, 'acceptor' molecule (e.g.,

WO 01/070979

15

20

marker or test compound), which in turn is able to fluoresce due to the absorbed energy. Alternately, the 'donor' protein molecule may simply utilize the natural fluorescent energy of tryptophan residues. Labels are chosen that emit different wavelengths of light, such that the 'acceptor' molecule label may be differentiated from that of the 'donor'. Since the efficiency of energy transfer between the labels is related to the distance separating the molecules, spatial relationships between the molecules can be assessed. In a situation in which binding occurs between the molecules, the fluorescent emission of the 'acceptor' molecule label in the assay should be maximal. An FET binding event can be conveniently measured through standard fluorometric detection means well known in the art (e.g., using a fluorimeter). A test substance which either enhances or hinders participation of one of the species in the preformed complex will result in the generation of a signal variant to that of background. In this way, test substances that modulate interactions between a marker and its binding partner can be identified in controlled assays.

In another embodiment, modulators of marker expression are identified in a method wherein a cell is contacted with a candidate compound and the expression of mRNA or protein, corresponding to a marker in the cell, is determined. The level of expression of mRNA or protein in the presence of the candidate compound is compared to the level of expression of mRNA or protein in the absence of the candidate compound. The candidate compound can then be identified as a modulator of marker expression based on this comparison. For example, when expression of marker mRNA or protein is greater (statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of marker mRNA or protein expression. Conversely, when expression of marker mRNA or protein is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of marker mRNA or protein expression. The level of marker mRNA or protein expression in the cells can be determined by methods described herein for detecting marker mRNA or protein.

In another aspect, the invention pertains to a combination of two or more of the assays described herein. For example, a modulating agent can be identified using a cell-based or a cell free assay, and the ability of the agent to modulate the activity of a

- 71 -

marker protein can be further confirmed *in vivo*, *e.g.*, in a whole animal model for cellular transformation and/or tumorigenesis.

This invention further pertains to novel agents identified by the above-described screening assays. Accordingly, it is within the scope of this invention to further use an agent identified as described herein in an appropriate animal model. For example, an agent identified as described herein (e.g., an marker modulating agent, an antisense marker nucleic acid molecule, an marker-specific antibody, or an marker-binding partner) can be used in an animal model to determine the efficacy, toxicity, or side effects of treatment with such an agent. Alternatively, an agent identified as described herein can be used in an animal model to determine the mechanism of action of such an agent. Furthermore, this invention pertains to uses of novel agents identified by the above-described screening assays for treatments as described herein.

It is understood that appropriate doses of small molecule agents and protein or polypeptide agents depends upon a number of factors within the knowledge of the ordinarily skilled physician, veterinarian, or researcher. The dose(s) of these agents will vary, for example, depending upon the identity, size, and condition of the subject or sample being treated, further depending upon the route by which the composition is to be administered, if applicable, and the effect which the practitioner desires the agent to have upon the nucleic acid or polypeptide of the invention. Exemplary doses of a small molecule include milligram or microgram amounts per kilogram of subject or sample weight (e.g. about 1 microgram per kilogram to about 500 milligrams per kilogram, about 100 micrograms per kilogram to about 5 milligrams per kilogram, or about 1 microgram per kilogram to about 50 micrograms per kilogram). Exemplary doses of a protein or polypeptide include gram, milligram or microgram amounts per kilogram of subject or sample weight (e.g. about 1 microgram per kilogram to about 5 grams per kilogram, about 100 micrograms per kilogram to about 500 milligrams per kilogram, or about 1 milligram per kilogram to about 50 milligrams per kilogram). It is furthermore understood that appropriate doses of one of these agents depend upon the potency of the agent with respect to the expression or activity to be modulated. Such appropriate doses can be determined using the assays described herein. When one or more of these agents is to be administered to an animal (e.g. a human) in order to modulate expression or activity of a polypeptide or nucleic acid of the invention, a physician, veterinarian, or

- 72 -

researcher can, for example, prescribe a relatively low dose at first, subsequently increasing the dose until an appropriate response is obtained. In addition, it is understood that the specific dose level for any particular animal subject will depend upon a variety of factors including the activity of the specific agent employed, the age, body weight, general health, gender, and diet of the subject, the time of administration, the route of administration, the rate of excretion, any drug combination, and the degree of expression or activity to be modulated.

A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediamine-tetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampules, disposable syringes or multiple dose vials made of glass or plastic.

10

15

20

30

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL (BASF; Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance

- 73 -

of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a polypeptide or antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium, and then incorporating the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

10

20

25

30

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed.

Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches, and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

30

For administration by inhalation, the compounds are delivered in the form of an aerosol spray from a pressurized container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.

Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid.

Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes having monoclonal antibodies incorporated therein or thereon) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound

and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

For antibodies, the preferred dosage is 0.1 mg/kg to 100 mg/kg of body weight (generally 10 mg/kg to 20 mg/kg). If the antibody is to act in the brain, a dosage of 50 mg/kg to 100 mg/kg is usually appropriate. Generally, partially human antibodies and fully human antibodies have a longer half-life within the human body than other antibodies. Accordingly, lower dosages and less frequent administration is often possible. Modifications such as lipidation can be used to stabilize antibodies and to enhance uptake and tissue penetration (e.g., into the ovarian epithelium). A method for lipidation of antibodies is described by Cruikshank et al. (1997) J. Acquired Immune Deficiency Syndromes and Human Retrovirology 14:193.

The nucleic acid molecules corresponding to a marker of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (U.S. Patent 5,328,470), or by stereotactic injection (see, e.g., Chen et al., 1994, Proc. Natl. Acad. Sci. USA 91:3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g. retroviral vectors, the pharmaceutical preparation can include one or more cells which produce the gene delivery system.

The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

25 V. Predictive Medicine

The present invention pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, pharmacogenomics, and monitoring clinical trails are used for prognostic (predictive) purposes to thereby treat an individual prophylactically. Accordingly, one aspect of the present invention relates to diagnostic assays for determining the level of expression of polypeptides or nucleic acids corresponding to one or more markers of the invention, in order to determine whether an individual is at risk of developing ovarian cancer. Such assays can be used for

15

30

prognostic or predictive purposes to thereby prophylactically treat an individual prior to the onset of the cancer.

Yet another aspect of the invention pertains to monitoring the influence of agents (e.g., drugs or other compounds administered either to inhibit ovarian cancer or to treat or prevent any other disorder {i.e. in order to understand any ovarian carcinogenic effects that such treatment may have}) on the expression or activity of a marker of the invention in clinical trials. These and other agents are described in further detail in the following sections.

A. Diagnostic Assays

An exemplary method for detecting the presence or absence of a polypeptide or nucleic acid corresponding to a marker of the invention in a biological sample involves obtaining a biological sample (e.g. an ovary-associated body fluid) from a test subject and contacting the biological sample with a compound or an agent capable of detecting the polypeptide or nucleic acid (e.g., mRNA, genomic DNA, or cDNA). The detection methods of the invention can thus be used to detect mRNA, protein, cDNA, or genomic DNA, for example, in a biological sample in vitro as well as in vivo. For example, in vitro techniques for detection of mRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detection of a polypeptide corresponding to a marker of the invention include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence. In vitro techniques for detection of genomic DNA include Southern hybridizations. Furthermore, in vivo techniques for detection of a polypeptide corresponding to a marker of the invention include introducing into a subject a labeled antibody directed against the polypeptide. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

A general principle of such diagnostic and prognostic assays involves preparing a sample or reaction mixture that may contain a marker, and a probe, under appropriate conditions and for a time sufficient to allow the marker and probe to interact and bind, thus forming a complex that can be removed and/or detected in the reaction mixture. These assays can be conducted in a variety of ways.

- 77 -

For example, one method to conduct such an assay would involve anchoring the marker or probe onto a solid phase support, also referred to as a substrate, and detecting target marker/probe complexes anchored on the solid phase at the end of the reaction. In one embodiment of such a method, a sample from a subject, which is to be assayed for presence and/or concentration of marker, can be anchored onto a carrier or solid phase support. In another embodiment, the reverse situation is possible, in which the probe can be anchored to a solid phase and a sample from a subject can be allowed to react as an unanchored component of the assay.

There are many established methods for anchoring assay components to a solid phase. These include, without limitation, marker or probe molecules which are immobilized through conjugation of biotin and streptavidin. Such biotinylated assay components can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, IL), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). In certain embodiments, the surfaces with immobilized assay components can be prepared in advance and stored.

10

15

Other suitable carriers or solid phase supports for such assays include any material capable of binding the class of molecule to which the marker or probe belongs. Well-known supports or carriers include, but are not limited to, glass, polystyrene, nylon, polypropylene, nylon, polypropylene, dextran, amylases, natural and modified celluloses, polyacrylamides, gabbros, and magnetite.

In order to conduct assays with the above mentioned approaches, the non-immobilized component is added to the solid phase upon which the second component is anchored. After the reaction is complete, uncomplexed components may be removed (e.g., by washing) under conditions such that any complexes formed will remain immobilized upon the solid phase. The detection of marker/probe complexes anchored to the solid phase can be accomplished in a number of methods outlined herein.

In a preferred embodiment, the probe, when it is the unanchored assay component, can be labeled for the purpose of detection and readout of the assay, either directly or indirectly, with detectable labels discussed herein and which are well-known to one skilled in the art.

15

20

25

30

It is also possible to directly detect marker/probe complex formation without further manipulation or labeling of either component (marker or probe), for example by utilizing the technique of fluorescence energy transfer (see, for example, Lakowicz et al., U.S. Patent No. 5,631,169; Stavrianopoulos, et al., U.S. Patent No. 4,868,103). A fluorophore label on the first, 'donor' molecule is selected such that, upon excitation with incident light of appropriate wavelength, its emitted fluorescent energy will be absorbed by a fluorescent label on a second 'acceptor' molecule, which in turn is able to fluoresce due to the absorbed energy. Alternately, the 'donor' protein molecule may simply utilize the natural fluorescent energy of tryptophan residues. Labels are chosen that emit different wavelengths of light, such that the 'acceptor' molecule label may be differentiated from that of the 'donor'. Since the efficiency of energy transfer between the labels is related to the distance separating the molecules, spatial relationships between the molecules can be assessed. In a situation in which binding occurs between the molecules, the fluorescent emission of the 'acceptor' molecule label in the assay should be maximal. An FET binding event can be conveniently measured through standard fluorometric detection means well known in the art (e.g., using a fluorimeter).

In another embodiment, determination of the ability of a probe to recognize a marker can be accomplished without labeling either assay component (probe or marker) by utilizing a technology such as real-time Biomolecular Interaction Analysis (BIA) (see, e.g., Sjolander, S. and Urbaniczky, C., 1991, Anal. Chem. 63:2338-2345 and Szabo et al., 1995, Curr. Opin. Struct. Biol. 5:699-705). As used herein, "BIA" or "surface plasmon resonance" is a technology for studying biospecific interactions in real time, without labeling any of the interactants (e.g., BIAcore). Changes in the mass at the binding surface (indicative of a binding event) result in alterations of the refractive index of light near the surface (the optical phenomenon of surface plasmon resonance (SPR)), resulting in a detectable signal which can be used as an indication of real-time reactions between biological molecules.

Alternatively, in another embodiment, analogous diagnostic and prognostic assays can be conducted with marker and probe as solutes in a liquid phase. In such an assay, the complexed marker and probe are separated from uncomplexed components by any of a number of standard techniques, including but not limited to: differential centrifugation, chromatography, electrophoresis and immunoprecipitation. In

WO 01/070979

15

20

25

30

- 79 -

PCT/US01/09126

differential centrifugation, marker/probe complexes may be separated from uncomplexed assay components through a series of centrifugal steps, due to the different sedimentation equilibria of complexes based on their different sizes and densities (see, for example, Rivas, G., and Minton, A.P., 1993, *Trends Biochem Sci.* 18(8):284-7).

Standard chromatographic techniques may also be utilized to separate complexed molecules from uncomplexed ones. For example, gel filtration chromatography separates molecules based on size, and through the utilization of an appropriate gel filtration resin in a column format, for example, the relatively larger complex may be separated from the relatively smaller uncomplexed components. Similarly, the relatively different charge properties of the marker/probe complex as compared to the uncomplexed components may be exploited to differentiate the complex from uncomplexed components, for example through the utilization of ion-exchange chromatography resins. Such resins and chromatographic techniques are well known to one skilled in the art (see, e.g., Heegaard, N.H., 1998, J. Mol. Recognit. Winter 11(1-

6):141-8; Hage, D.S., and Tweed, S.A. J Chromatogr B Biomed Sci Appl 1997 Oct 10;699(1-2):499-525). Gel electrophoresis may also be employed to separate complexed assay components from unbound components (see, e.g., Ausubel et al., ed., Current Protocols in Molecular Biology, John Wiley & Sons, New York, 1987-1999). In this technique, protein or nucleic acid complexes are separated based on size or charge, for example. In order to maintain the binding interaction during the electrophoretic process, non-denaturing gel matrix materials and conditions in the absence of reducing agent are typically preferred. Appropriate conditions to the

particular assay and components thereof will be well known to one skilled in the art.

In a particular embodiment, the level of mRNA corresponding to the marker can be determined both by *in situ* and by *in vitro* formats in a biological sample using methods known in the art. The term "biological sample" is intended to include tissues, cells, biological fluids and isolates thereof, isolated from a subject, as well as tissues, cells and fluids present within a subject. Many expression detection methods use isolated RNA. For *in vitro* methods, any RNA isolation technique that does not select against the isolation of mRNA can be utilized for the purification of RNA from ovarian cells (see, *e.g.*, Ausubel *et al.*, ed., *Current Protocols in Molecular Biology*, John Wiley & Sons, New York 1987-1999). Additionally, large numbers of tissue samples can

20

readily be processed using techniques well known to those of skill in the art, such as, for example, the single-step RNA isolation process of Chomczynski (1989, U.S. Patent No. 4,843,155).

The isolated mRNA can be used in hybridization or amplification assays that include, but are not limited to, Southern or Northern analyses, polymerase chain reaction analyses and probe arrays. One preferred diagnostic method for the detection of mRNA levels involves contacting the isolated mRNA with a nucleic acid molecule (probe) that can hybridize to the mRNA encoded by the gene being detected. The nucleic acid probe can be, for example, a full-length cDNA, or a portion thereof, such as an oligonucleotide of at least 7, 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to a mRNA or genomic DNA encoding a marker of the present invention. Other suitable probes for use in the diagnostic assays of the invention are described herein. Hybridization of an mRNA with the probe indicates that the marker in question is being expressed.

In one format, the mRNA is immobilized on a solid surface and contacted with a probe, for example by running the isolated mRNA on an agarose gel and transferring the mRNA from the gel to a membrane, such as nitrocellulose. In an alternative format, the probe(s) are immobilized on a solid surface and the mRNA is contacted with the probe(s), for example, in an Affymetrix gene chip array. A skilled artisan can readily adapt known mRNA detection methods for use in detecting the level of mRNA encoded by the markers of the present invention.

An alternative method for determining the level of mRNA corresponding to a marker of the present invention in a sample involves the process of nucleic acid amplification, e.g., by rtPCR (the experimental embodiment set forth in Mullis, 1987, U.S. Patent No. 4,683,202), ligase chain reaction (Barany, 1991, Proc. Natl. Acad. Sci. USA, 88:189-193), self sustained sequence replication (Guatelli et al., 1990, Proc. Natl. Acad. Sci. USA 87:1874-1878), transcriptional amplification system (Kwoh et al., 1989, Proc. Natl. Acad. Sci. USA 86:1173-1177), Q-Beta Replicase (Lizardi et al., 1988, Bio/Technology 6:1197), rolling circle replication (Lizardi et al., U.S. Patent No. 5,854,033) or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if

- 81 -

such molecules are present in very low numbers. As used herein, amplification primers are defined as being a pair of nucleic acid molecules that can anneal to 5' or 3' regions of a gene (plus and minus strands, respectively, or vice-versa) and contain a short region in between. In general, amplification primers are from about 10 to 30 nucleotides in length and flank a region from about 50 to 200 nucleotides in length. Under appropriate conditions and with appropriate reagents, such primers permit the amplification of a nucleic acid molecule comprising the nucleotide sequence flanked by the primers.

For *in situ* methods, mRNA does not need to be isolated from the ovarian cells prior to detection. In such methods, a cell or tissue sample is prepared/processed using known histological methods. The sample is then immobilized on a support, typically a glass slide, and then contacted with a probe that can hybridize to mRNA that encodes the marker.

As an alternative to making determinations based on the absolute expression level of the marker, determinations may be based on the normalized expression level of the marker. Expression levels are normalized by correcting the absolute expression level of a marker by comparing its expression to the expression of a gene that is not a marker, e.g., a housekeeping gene that is constitutively expressed. Suitable genes for normalization include housekeeping genes such as the actin gene, or epithelial cell-specific genes. This normalization allows the comparison of the expression level in one sample, e.g., a patient sample, to another sample, e.g., a non-ovarian cancer sample, or between samples from different sources.

Alternatively, the expression level can be provided as a relative expression level. To determine a relative expression level of a marker, the level of expression of the marker is determined for 10 or more samples of normal versus cancer cell isolates, preferably 50 or more samples, prior to the determination of the expression level for the sample in question. The mean expression level of each of the genes assayed in the larger number of samples is determined and this is used as a baseline expression level for the marker. The expression level of the marker determined for the test sample (absolute level of expression) is then divided by the mean expression value obtained for that marker. This provides a relative expression level.

30

- 82 -

Preferably, the samples used in the baseline determination will be from ovarian cancer or from non-ovarian cancer cells of ovarian tissue. The choice of the cell source is dependent on the use of the relative expression level. Using expression found in normal tissues as a mean expression score aids in validating whether the marker assayed is ovarian specific (versus normal cells). In addition, as more data is accumulated, the mean expression value can be revised, providing improved relative expression values based on accumulated data. Expression data from ovarian cells provides a means for grading the severity of the ovarian cancer state.

In another embodiment of the present invention, a polypeptide corresponding to a marker is detected. A preferred agent for detecting a polypeptide of the invention is an antibody capable of binding to a polypeptide corresponding to a marker of the invention, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab')₂) can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin.

10

20

25

Proteins from ovarian cells can be isolated using techniques that are well known to those of skill in the art. The protein isolation methods employed can, for example, be such as those described in Harlow and Lane (Harlow and Lane, 1988, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York).

A variety of formats can be employed to determine whether a sample contains a protein that binds to a given antibody. Examples of such formats include, but are not limited to, enzyme immunoassay (EIA), radioimmunoassay (RIA), Western blot analysis and enzyme linked immunoabsorbant assay (ELISA). A skilled artisan can readily adapt known protein/antibody detection methods for use in determining whether ovarian cells express a marker of the present invention.

In one format, antibodies, or antibody fragments, can be used in methods such as Western blots or immunofluorescence techniques to detect the expressed proteins. In such uses, it is generally preferable to immobilize either the antibody or proteins on a solid support. Suitable solid phase supports or carriers include any support capable of binding an antigen or an antibody. Well-known supports or carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, gabbros, and magnetite.

One skilled in the art will know many other suitable carriers for binding antibody or antigen, and will be able to adapt such support for use with the present invention. For example, protein isolated from ovarian cells can be run on a polyacrylamide gel electrophoresis and immobilized onto a solid phase support such as nitrocellulose. The support can then be washed with suitable buffers followed by treatment with the detectably labeled antibody. The solid phase support can then be washed with the buffer a second time to remove unbound antibody. The amount of bound label on the solid support can then be detected by conventional means.

15

25

30

The invention also encompasses kits for detecting the presence of a polypeptide or nucleic acid corresponding to a marker of the invention in a biological sample (e.g. an ovary-associated body fluid such as a urine sample). Such kits can be used to determine if a subject is suffering from or is at increased risk of developing ovarian cancer. For example, the kit can comprise a labeled compound or agent capable of detecting a polypeptide or an mRNA encoding a polypeptide corresponding to a marker of the invention in a biological sample and means for determining the amount of the polypeptide or mRNA in the sample (e.g., an antibody which binds the polypeptide or an oligonucleotide probe which binds to DNA or mRNA encoding the polypeptide). Kits can also include instructions for interpreting the results obtained using the kit.

For antibody-based kits, the kit can comprise, for example: (1) a first antibody (e.g., attached to a solid support) which binds to a polypeptide corresponding to a marker of the invention; and, optionally, (2) a second, different antibody which binds to either the polypeptide or the first antibody and is conjugated to a detectable label.

For oligonucleotide-based kits, the kit can comprise, for example: (1) an oligonucleotide, e.g., a detectably labeled oligonucleotide, which hybridizes to a nucleic acid sequence encoding a polypeptide corresponding to a marker of the invention or (2)

a pair of primers useful for amplifying a nucleic acid molecule corresponding to a marker of the invention. The kit can also comprise, e.g., a buffering agent, a preservative, or a protein stabilizing agent. The kit can further comprise components necessary for detecting the detectable label (e.g., an enzyme or a substrate). The kit can also contain a control sample or a series of control samples which can be assayed and compared to the test sample. Each component of the kit can be enclosed within an individual container and all of the various containers can be within a single package, along with instructions for interpreting the results of the assays performed using the kit.

B. Pharmacogenomics

10

15

20

25

Agents or modulators which have a stimulatory or inhibitory effect on expression of a marker of the invention can be administered to individuals to treat (prophylactically or therapeutically) ovarian cancer in the patient. In conjunction with such treatment, the pharmacogenomics (*i.e.*, the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) of the individual may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, the pharmacogenomics of the individual permits the selection of effective agents (*e.g.*, drugs) for prophylactic or therapeutic treatments based on a consideration of the individual's genotype. Such pharmacogenomics can further be used to determine appropriate dosages and therapeutic regimens.

Accordingly, the level of expression of a marker of the invention in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual.

Pharmacogenomics deals with clinically significant variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See, e.g., Linder (1997) Clin. Chem. 43(2):254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body are referred to as "altered drug action." Genetic conditions transmitted as single factors altering the way the body acts on drugs are referred to as "altered drug metabolism". These pharmacogenetic conditions can occur either as rare defects or as polymorphisms. For example, glucose-6-phosphate

dehydrogenase (G6PD) deficiency is a common inherited enzymopathy in which the main clinical complication is hemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.

As an illustrative embodiment, the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action. The discovery of genetic polymorphisms of drug metabolizing enzymes (e.g., N-acetyltransferase 2 (NAT 2) and cytochrome P450 enzymes CYP2D6 and CYP2C19) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and serious toxicity after taking the standard and safe dose of a drug. 10 These polymorphisms are expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor metabolizer (PM). The prevalence of PM is different among different populations. For example, the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side effects when they receive standard doses. If a metabolite is the active therapeutic moiety, a PM will show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6formed metabolite morphine. The other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of 20 ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification.

Thus, the level of expression of a marker of the invention in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual. In addition, pharmacogenetic studies can be used to apply genotyping of polymorphic alleles encoding drug-metabolizing enzymes to the identification of an individual's drug responsiveness phenotype. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with a modulator of expression of a marker of the invention.

30 C. Monitoring Clinical Trials

Monitoring the influence of agents (e.g., drug compounds) on the level of expression of a marker of the invention can be applied not only in basic drug screening,

15

but also in clinical trials. For example, the effectiveness of an agent to affect marker expression can be monitored in clinical trials of subjects receiving treatment for ovarian cancer. In a preferred embodiment, the present invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) comprising the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression of one or more selected markers of the invention in the pre-administration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression of the marker(s) in the post-administration samples; (v) comparing the level of expression of the marker(s) in the pre-administration sample with the level of expression of the marker(s) in the post-administration sample or samples; and (vi) altering the administration of the agent to the subject accordingly. For example, increased administration of the agent can be desirable to increase expression of the marker(s) to higher levels than detected, i.e., to increase the effectiveness of the agent. Alternatively, decreased administration of the agent can be desirable to decrease expression of the marker(s) to lower levels than detected, i.e., to decrease the effectiveness of the agent.

D. Electronic Apparatus Readable Media and Arrays

Electronic apparatus readable media comprising a marker of the present invention is also provided. As used herein, "electronic apparatus readable media" refers to any suitable medium for storing, holding or containing data or information that can be read and accessed directly by an electronic apparatus. Such media can include, but are not limited to: magnetic storage media, such as floppy discs, hard disc storage medium, and magnetic tape; optical storage media such as compact disc; electronic storage media such as RAM, ROM, EPROM, EEPROM and the like; general hard disks and hybrids of these categories such as magnetic/optical storage media. The medium is adapted or configured for having recorded thereon a marker of the present invention.

As used herein, the term "electronic apparatus" is intended to include any suitable computing or processing apparatus or other device configured or adapted for storing data or information. Examples of electronic apparatus suitable for use with the

present invention include stand-alone computing apparatus; networks, including a local area network (LAN), a wide area network (WAN) Internet, Intranet, and Extranet; electronic appliances such as a personal digital assistants (PDAs), cellular phone, pager and the like; and local and distributed processing systems.

As used herein, "recorded" refers to a process for storing or encoding information on the electronic apparatus readable medium. Those skilled in the art can readily adopt any of the presently known methods for recording information on known media to generate manufactures comprising the markers of the present invention.

5

10

15

25

30

A variety of software programs and formats can be used to store the marker information of the present invention on the electronic apparatus readable medium. For example, the nucleic acid sequence corresponding to the markers can be represented in a word processing text file, formatted in commercially-available software such as WordPerfect and MicroSoft Word, or represented in the form of an ASCII file, stored in a database application, such as DB2, Sybase, Oracle, or the like, as well as in other forms. Any number of dataprocessor structuring formats (e.g., text file or database) may be employed in order to obtain or create a medium having recorded thereon the the markers of the present invention.

By providing the markers of the invention in readable form, one can routinely access the marker sequence information for a variety of purposes. For example, one skilled in the art can use the nucleotide or amino acid sequences of the present invention in readable form to compare a target sequence or target structural motif with the sequence information stored within the data storage means. Search means are used to identify fragments or regions of the sequences of the invention which match a particular target sequence or target motif.

The present invention therefore provides a medium for holding instructions for performing a method for determining whether a subject has ovarian cancer or a pre-disposition to ovarian cancer, wherein the method comprises the steps of determining the presence or absence of a marker and based on the presence or absence of the marker, determining whether the subject has ovarian cancer or a pre-disposition to ovarian cancer and/or recommending a particular treatment for ovarian cancer or pre-ovarian cancer condition.

15

20

25

30

The present invention further provides in an electronic system and/or in a network, a method for determining whether a subject has ovarian cancer or a pre-disposition to ovarian cancer associated with a marker wherein the method comprises the steps of determining the presence or absence of the marker, and based on the presence or absence of the marker, determining whether the subject has ovarian cancer or a pre-disposition to ovarian cancer, and/or recommending a particular treatment for the ovarian cancer or pre-ovarian cancer condition. The method may further comprise the step of receiving phenotypic information associated with the subject and/or acquiring from a network phenotypic information associated with the subject.

The present invention also provides in a network, a method for determining whether a subject has ovarian cancer or a pre-disposition to ovarian cancer associated with a marker, said method comprising the steps of receiving information associated with the marker receiving phenotypic information associated with the subject, acquiring information from the network corresponding to the marker and/or ovarian cancer, and based on one or more of the phenotypic information, the marker, and the acquired information, determining whether the subject has a ovarian cancer or a pre-disposition to ovarian cancer. The method may further comprise the step of recommending a particular treatment for the ovarian cancer or pre-ovarian cancer condition.

The present invention also provides a business method for determining whether a subject has ovarian cancer or a pre-disposition to ovarian cancer, said method comprising the steps of receiving information associated with the marker, receiving phenotypic information associated with the subject, acquiring information from the network corresponding to the marker and/or ovarian cancer, and based on one or more of the phenotypic information, the marker, and the acquired information, determining whether the subject has ovarian cancer or a pre-disposition to ovarian cancer. The method may further comprise the step of recommending a particular treatment for the ovarian cancer or pre-ovarian cancer condition.

The invention also includes an array comprising a marker of the present invention. The array can be used to assay expression of one or more genes in the array. In one embodiment, the array can be used to assay gene expression in a tissue to ascertain tissue specificity of genes in the array. In this manner, up to about 7600 genes

can be simultaneously assayed for expression. This allows a profile to be developed showing a battery of genes specifically expressed in one or more tissues.

In addition to such qualitative determination, the invention allows the quantitation of gene expression. Thus, not only tissue specificity, but also the level of expression of a battery of genes in the tissue is ascertainable. Thus, genes can be grouped on the basis of their tissue expression per se and level of expression in that tissue. This is useful, for example, in ascertaining the relationship of gene expression between or among tissues. Thus, one tissue can be perturbed and the effect on gene expression in a second tissue can be determined. In this context, the effect of one cell type on another cell type in response to a biological stimulus can be determined. Such a determination is useful, for example, to know the effect of cell-cell interaction at the level of gene expression. If an agent is administered therapeutically to treat one cell type but has an undesirable effect on another cell type, the invention provides an assay to determine the molecular basis of the undesirable effect and thus provides the opportunity to co-administer a counteracting agent or otherwise treat the undesired effect. Similarly, even within a single cell type, undesirable biological effects can be determined at the molecular level. Thus, the effects of an agent on expression of other than the target gene can be ascertained and counteracted.

In another embodiment, the array can be used to monitor the time course of expression of one or more genes in the array. This can occur in various biological contexts, as disclosed herein, for example development of ovarian cancer, progression of ovarian cancer, and processes, such a cellular transformation associated with ovarian cancer.

20

25

30

The array is also useful for ascertaining the effect of the expression of a gene on the expression of other genes in the same cell or in different cells. This provides, for example, for a selection of alternate molecular targets for therapeutic intervention if the ultimate or downstream target cannot be regulated.

The array is also useful for ascertaining differential expression patterns of one or more genes in normal and abnormal cells. This provides a battery of genes that could serve as a molecular target for diagnosis or therapeutic intervention.

E. Surrogate Markers

10

15

20

25

The markers of the invention may serve as surrogate markers for one or more disorders or disease states or for conditions leading up to disease states, and in particular, ovarian cancer. As used herein, a "surrogate marker" is an objective biochemical marker which correlates with the absence or presence of a disease or disorder, or with the progression of a disease or disorder (e.g., with the presence or absence of a tumor). The presence or quantity of such markers is independent of the disease. Therefore, these markers may serve to indicate whether a particular course of treatment is effective in lessening a disease state or disorder. Surrogate markers are of particular use when the presence or extent of a disease state or disorder is difficult to assess through standard methodologies (e.g., early stage tumors), or when an assessment of disease progression is desired before a potentially dangerous clinical endpoint is reached (e.g., an assessment of cardiovascular disease may be made using cholesterol levels as a surrogate marker, and an analysis of HIV infection may be made using HIV RNA levels as a surrogate marker, well in advance of the undesirable clinical outcomes of myocardial infarction or fully-developed AIDS). Examples of the use of surrogate markers in the art include: Koomen et al. (2000) J. Mass. Spectrom. 35: 258-264; and James (1994) AIDS Treatment News Archive 209.

The markers of the invention are also useful as pharmacodynamic markers. As used herein, a "pharmacodynamic marker" is an objective biochemical marker which correlates specifically with drug effects. The presence or quantity of a pharmacodynamic marker is not related to the disease state or disorder for which the drug is being administered; therefore, the presence or quantity of the marker is indicative of the presence or activity of the drug in a subject. For example, a pharmacodynamic marker may be indicative of the concentration of the drug in a biological tissue, in that the marker is either expressed or transcribed or not expressed or transcribed in that tissue in relationship to the level of the drug. In this fashion, the distribution or uptake of the drug may be monitored by the pharmacodynamic marker. Similarly, the presence or quantity of the pharmacodynamic marker may be related to the presence or quantity of the metabolic product of a drug, such that the presence or quantity of the marker is indicative of the relative breakdown rate of the drug *in vivo*. Pharmacodynamic markers are of particular use in increasing the sensitivity of detection

of drug effects, particularly when the drug is administered in low doses. Since even a small amount of a drug may be sufficient to activate multiple rounds of marker transcription or expression, the amplified marker may be in a quantity which is more readily detectable than the drug itself. Also, the marker may be more easily detected due to the nature of the marker itself; for example, using the methods described herein, antibodies may be employed in an immune-based detection system for a protein marker, or marker-specific radiolabeled probes may be used to detect a mRNA marker. Furthermore, the use of a pharmacodynamic marker may offer mechanism-based prediction of risk due to drug treatment beyond the range of possible direct observations. Examples of the use of pharmacodynamic markers in the art include: Matsuda et al. US 6,033,862; Hattis et al. (1991) Env. Health Perspect. 90: 229-238; Schentag (1999) Am. J. Health-Syst. Pharm. 56 Suppl. 3: S21-S24; and Nicolau (1999) Am. J. Health-Syst. Pharm. 56 Suppl. 3: S16-S20.

The markers of the invention are also useful as pharmacogenomic markers. As 15 used herein, a "pharmacogenomic marker" is an objective biochemical marker which correlates with a specific clinical drug response or susceptibility in a subject (see, e.g., McLeod et al. (1999) Eur. J. Cancer 35(12): 1650-1652). The presence or quantity of the pharmacogenomic marker is related to the predicted response of the subject to a specific drug or class of drugs prior to administration of the drug. By assessing the presence or quantity of one or more pharmacogenomic markers in a subject, a drug therapy which is most appropriate for the subject, or which is predicted to have a greater degree of success, may be selected. For example, based on the presence or quantity of RNA or protein for specific tumor markers in a subject, a drug or course of treatment may be selected that is optimized for the treatment of the specific tumor likely to be present in the subject. Similarly, the presence or absence of a specific sequence mutation in marker DNA may correlate with drug response. The use of pharmacogenomic markers therefore permits the application of the most appropriate treatment for each subject without having to administer the therapy.

15

20

25

VI. Experimental Protocol

A. Subtracted Libraries

Subtracted libraries are generated using a PCR based method that allows the isolation of clones expressed at higher levels in one population of mRNA (tester) compared to another population (driver). Both tester and driver mRNA populations are converted into cDNA by reverse transcription, and then PCR amplified using the SMART PCR kit from Clontech. Tester and driver cDNAs are then hybridized using the PCR-Select cDNA subtraction kit from Clontech. This technique results in both subtraction and normalization, which is an equalization of copy number of low-abundance and high-abundance sequences. After generation of the subtractive libraries, a group of 96 or more clones from each library is tested to confirm differential expression by reverse Southern hybridization.

To create the subtracted libraries, a first group of regular cDNA libraries was constructed. Library johOa was constructed from a pool of 5 normal ovarian epithelial cell cultures. Library johOb was constructed from a pool of 5 ascites short cultured samples from ovarian cancer patients. Library johOc was constructed from a pool of 6 serous late stage (III/IV) tumor samples. Three subtracted libraries were generated from tumor samples. Library johOd was a subtracted ascites library, where the tester was johOb, and the driver was johOa. The johOe and the johOf library were both subtracted stage III/IV serous tumor libraries. The tester for both of these libraries was johOc, and the driver was a pooled RNA from normal tissues. The tissues used for this driver pool were: kidney, small intestine, prostate, lung, heart, muscle, spleen, pancreas, liver, and lymphocyte. Library cMhOg was the same as the johOc and johOf libraries, with the exception that normal ovary was added to the driver. cMhOh, i, j, and k are all stage I/II subtracted libraries made from pooled tumor RNAs of different histological types (h=serous, I-endometriod, j=clear cell, k=mucinous). The driver was the same for these 4 libraries. It consisted of normal ovarian epithelial RNA and PBML RNA. Of the markers listed in Table 1, SEQ ID NOS: 1-129, 916-1029, 1566-1571 and 1607-1865 were identified in library johOa. Markers identified in johOb include SEO ID NOS: 130-177, 1030-1081, 1572-1574, and 1866-1974. Markers identified in johOc include SEQ ID NOS: 178-269, 1082-1120, 1575-1577, and 1975-2060. Markers identified in johOd include SEQ ID NOS: 270-370, 1121-1304, 1578-1592, and 2061-2244. Markers

- 93 -

identified in johOe include SEQ ID NOS: 371-611, 1305-1416, 1593-1596 and 2245-2487. Markers identified in johOf include SEQ ID NOS: 612-915, 1417-1565, 1597-1606, and 2488-2871. Of the markers listed in Table 1A, SEQ ID NOS: 2872-2976, 3817-3898, 4438-4443 and 4474-4675 were identified in library cMhOg. Markers identified in cMhOh include SEQ ID NOS: 2977-3376, 3899-4072, 4444-4455, and 4676-5303. Markers identified in cMhOi include SEQ ID NOS: 3377-3495, 4073-4158, 4456-4460, and 5304-5637. Markers identified in cMhOj include SEQ ID NOS: 3496-3742, 4195-4390, 4461-4468, and 5638-6197. Markers identified in cMhOk include SEQ ID NOS: 3743-3816, 4391-4437, 4469-4473 and 6198-6398.

10

20

VII. Summary Of The Data Provided In The Tables

Tables 1, 1A, 2 and 3 are being filed concurrently herewith on a compact disc in lieu of paper copies. The compact disc submitted is formatted from an IBM-PC and is compatible with MS-Windows. The disc contains the following four (4) files:

Table1.text, containing 1,223kb, Table1A.text, containing 1,582kb, Table2.text, containing 10,600kb, and Table3.text, containing 568kb. The material on the compact disc, namely Tables 1, 1A, 2 and 3, is expressly incorporated by reference.

Tables 1 and 1A show 6398 novel nucleotide sequences. These 6398 novel sequences were determined to be novel through various BLAST searches of available databases. Of these novel markers, SEQ ID NOS: 1566 – 1606 and 4438-4473 are preferred, SEQ ID NOS: 916-1565 and 3817-4437 are more preferred, and SEQ ID NOS: 1 – 915 and 2872-3816 are most preferred.

The sequences of Tables 1 and 1A were re-interpreted and vector sequences removed and those sequences are set forth in Table 2.

Table 3 correlates the SEQ ID NOS. from Tables 1 and 1A with those of Table 2.

The contents of all references, patents, published patent applications, and databases cited throughout this application are hereby incorporated by reference.

30 Other Embodiments

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention

- 94 -

described herein. Such equivalents are intended to be encompassed by the following claims.

What is claimed is:

5

25

Claims

- 1. An isolated nucleic acid molecule comprising a nucleotide sequence of Tables 1-2, or a complement thereof.
 - 2. A vector which contains the nucleic acid molecule of claim 1.
 - 3. A host cell which contains the nucleic acid molecule of claim 1.
- 4. An isolated polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence of Tables 1-2.
 - 5. An antibody which selectively binds to a polypeptide of claim 4.
- 6. A method for producing a polypeptide comprising culturing the host cell of claim 3 under conditions in which the nucleic acid molecule is expressed.
 - 7. A method for detecting the presence of a polypeptide of claim 4 in a sample comprising:
- a) contacting the sample with a compound which selectively binds to the polypeptide; and
 - b) determining whether the compound binds to the polypeptide in the sample to thereby detect the presence of a polypeptide of claim 4 in the sample.
 - 8. A kit comprising a compound which selectively binds to the polypeptide of claim 4.

- 9. A method for detecting the presence of a nucleic acid molecule of claim 1 in a sample comprising:
 - a) contacting the sample with a nucleic acid probe or primer which selectively hybridizes to the nucleic acid molecule; and
- b) determining whether the nucleic acid probe or primer binds to a nucleic acid molecule in the sample to thereby detect the presence of a nucleic acid molecule of claim 1 in the sample.
- 10. The method of claim 9, wherein the sample comprises mRNA molecules10 and is contacted with a nucleic acid probe.
 - 11. The method of claim 9, wherein the sample is isolated from ovarian tissue.
- 15 12. The method of claim 9, wherein the sample is a tumor sample.
 - 13. A kit comprising a compound which selectively hybridizes to a nucleic acid molecule of claim 1.
- 20 14. A method of assessing whether a patient is afflicted with ovarian cancer, the method comprising comparing:
 - a) the level of expression of a marker in a patient sample, wherein the marker is selected from the group consisting of the markers listed in Tables 1-2, and
- 25 b) the normal level of expression of the marker in a control nonovarian cancer sample,

wherein a significant difference between the level of expression of the marker in the patient sample and the normal level is an indication that the patient is afflicted with ovarian cancer.

30

15. The method of claim 14, wherein the marker corresponds to a secreted protein.

- 16. The method of claim 14, wherein the marker corresponds to a transcribed polynucleotide or portion thereof, wherein the polynucleotide comprises the marker.
- 17. The method of claim 14, wherein the sample comprises cells obtained from the patient.
 - 18. The method of claim 17, wherein the sample is an ovarian tissue sample.
- 19. The method of claim 14, wherein the sample is an ovary-associated body 10 fluid.
 - 20. The method of claim 14, wherein the level of expression of the marker in the sample is assessed by detecting the presence in the sample of a protein or protein fragment corresponding to the marker.

- 21. The method of claim 20, wherein the presence of the protein or protein fragment is detected using a reagent which specifically binds with the protein or protein fragment.
- 20 22. The method of claim 21, wherein the reagent is selected from the group consisting of an antibody, an antibody derivative, and an antibody fragment.
 - 23. The method of claim 14, wherein the level of expression of the marker in the sample is assessed by detecting the presence in the sample of a transcribed polynucleotide or portion thereof, wherein the transcribed polynucleotide comprises the marker.
 - 24. The method of claim 23, wherein the transcribed polynucleotide is an mRNA.

30

25

25. The method of claim 23, wherein the transcribed polynucleotide is a cDNA.

30

- 26. The method of claim 23, wherein the step of detecting further comprises amplifying the transcribed polynucleotide.
- 27. The method of claim 14, wherein the level of expression of the marker in the sample is assessed by detecting the presence in the sample of a transcribed polynucleotide which anneals with the marker or anneals with a portion of a polynucleotide wherein the polynucleotide comprises the marker, under stringent hybridization conditions.
- 10 28. The method of claim 14, wherein the level of expression of the marker in the sample differs from the normal level of expression of the marker in a patient not afflicted with ovarian cancer by a factor of at least about 2.
- 29. The method of claim 14, wherein the level of expression of the marker in the sample differs from the normal level of expression of the marker in a patient not afflicted with ovarian cancer by a factor of at least about 5.
 - 30. The method of claim 14, comprising comparing:
 - a) the level of expression in the sample of each of a plurality of markers independently selected from the markers listed in Tables 1-2, and
 - b) the normal level of expression of each of the plurality of markers in samples of the same type obtained from control humans not afflicted with ovarian cancer,

wherein the level of expression of more than one of the markers is significantly
altered, relative to the corresponding normal levels of expression of the markers, is an
indication that the patient is afflicted with ovarian cancer.

31. The method of claim 30, wherein the level of expression of each of the markers is significantly altered, relative to the corresponding normal levels of expression of the markers, is an indication that the patient is afflicted with ovarian cancer.

- 32. The method of claim 30, wherein the plurality comprises at least three of the markers.
- 33. The method of claim 30, wherein the plurality comprises at least five of the markers.
 - 34. A method for monitoring the progression of ovarian cancer in a patient, the method comprising:
- a) detecting in a patient sample at a first point in time, the expression of a marker, wherein the marker is selected from the group consisting of the markers listed in Tables 1-2;
 - b) repeating step a) at a subsequent point in time; and
 - c) comparing the level of expression detected in steps a) and b), and therefrom monitoring the progression of ovarian cancer.

- 35. The method of claim 34, wherein the marker corresponds to a secreted protein.
- 36. The method of claim 34, wherein the marker corresponds to a transcribed polynucleotide or portion thereof, wherein the polynucleotide comprises the marker.
 - 37. The method of claim 34, wherein the sample comprises cells obtained from the patient.
- 25 38. The method of claim 37, wherein the patient sample is an ovarian tissue sample.
 - 39. The method of claim 34, wherein between the first point in time and the subsequent point in time, the patient has undergone surgery to remove ovarian tissue.

25

- 40. A method of assessing the efficacy of a test compound for inhibiting ovarian cancer in a patient, the method comprising comparing:
 - a) expression of a marker in a first sample obtained from the patient and exposed to the test compound, wherein the marker is selected from the group consisting of the markers listed in Tables 1-2, and
- b) expression of the marker in a second sample obtained from the patient, wherein the sample is not exposed to the test compound, wherein a significantly lower level of expression of the marker in the first sample, relative to the second sample, is an indication that the test compound is efficacious for inhibiting ovarian cancer in the patient.
- 41. The method of claim 40, wherein the first and second samples are portions of a single sample obtained from the patient.
- 15 42. The method of claim 40, wherein the first and second samples are portions of pooled samples obtained from the patient.
 - 43. A method of assessing the efficacy of a therapy for inhibiting ovarian cancer in a patient, the method comprising comparing:
- a) expression of a marker in the first sample obtained from the patient prior to providing at least a portion of the therapy to the patient, wherein the marker is selected from the group consisting of the markers listed in Tables 1-2, and
 - b) expression of the marker in a second sample obtained from the patient following provision of the portion of the therapy,

wherein a significantly lower level of expression of the marker in the second sample, relative to the first sample, is an indication that the therapy is efficacious for inhibiting ovarian cancer in the patient.

5

15

20 .

- 101 -

- 44. A method of selecting a composition for inhibiting ovarian cancer in a patient, the method comprising:
 - a) obtaining a sample comprising cancer cells from the patient;
 - b) separately exposing aliquots of the sample in the presence of a plurality of test compositions;
 - c) comparing expression of a marker in each of the aliquots, wherein the marker is selected from the group consisting of the markers listed in Tables 1-2; and
- d) selecting one of the test compositions which alters the level of
 expression of the marker in the aliquot containing that test composition, relative
 to other test compositions.
 - 45. A method of inhibiting ovarian cancer in a patient, the method comprising:
 - a) obtaining a sample comprising cancer cells from the patient;
 - b) separately maintaining aliquots of the sample in the presence of a plurality of test compositions;
 - c) comparing expression of a marker in each of the aliquots, wherein the marker is selected from the group consisting of the markers listed in Tables 1-2; and
 - d) administering to the patient at least one of the test compositions which alters the level of expression of the marker in the aliquot containing that test composition, relative to other test compositions.
- 46. A kit for assessing whether a patient is afflicted with ovarian cancer, the kit comprising reagents for assessing expression of a marker selected from the group consisting of the markers listed in Tables 1-2.
- 47. A kit for assessing the presence of ovarian cancer cells, the kit
 30 comprising a nucleic acid probe wherein the probe specifically binds with a transcribed polynucleotide corresponding to a marker selected from the group consisting of the markers listed in Tables 1-2.

20

25

- 48. A kit for assessing the suitability of each of a plurality of compounds for inhibiting ovarian cancer in a patient, the kit comprising:
 - a) the plurality of compounds; and
- b) a reagent for assessing expression of a marker selected from the
 group consisting of the markers listed in Tables 1-2.
 - 49. A method of making an isolated hybridoma which produces an antibody useful for assessing whether a patient is afflicted with ovarian cancer, the method comprising:
- isolating a protein or protein fragment corresponding to a marker selected from the group consisting of the markers listed in Tables 1-2;

immunizing a mammal using the isolated protein or protein fragment; isolating splenocytes from the immunized mammal;

fusing the isolated splenocytes with an immortalized cell line to form hybridomas; and

screening individual hybridomas for production of an antibody which specifically binds with the protein or protein fragment to isolate the hybridoma.

- 50. An antibody produced by a hybridoma made by the method of claim 42.
- 51. A kit for assessing the presence of human ovarian cancer cells, the kit comprising an antibody, wherein the antibody specifically binds with a protein or protein fragment corresponding to a marker selected from the group consisting of the markers listed in Tables 1-2.
- 52. A method of assessing the ovarian cell carcinogenic potential of a test compound, the method comprising:
 - a) maintaining separate aliquots of ovarian cells in the presence and absence of the test compound; and
- b) comparing expression of a marker in each of the aliquots, wherein the marker is selected from the group consisting of the markers listed in Tables 1-2,

wherein a significantly altered level of expression of the marker in the aliquot maintained in the presence of the test compound, relative to the aliquot maintained in the absence of the test compound, is an indication that the test compound possesses human ovarian cell carcinogenic potential.

5

53. A kit for assessing the ovarian cell carcinogenic potential of a test compound, the kit comprising ovarian cells and a reagent for assessing expression of a marker, wherein the marker is selected from the group consisting of the markers listed in Tables 1-2.

10

- 54. A method of inhibiting ovarian cancer in a patient at risk for developing ovarian cancer, the method comprising inhibiting expression of a gene corresponding to a marker selected from the markers listed in Tables 1-2.
- 15 55. A method of treating a patient afflicted with ovarian cancer, the method comprising providing to cells of the patient an antisense oligonucleotide complementary to a polynucleotide corresponding to a marker selected from the markers listed in Tables 1-2.
- 56. A method of inhibiting ovarian cancer in a patient at risk for developing ovarian cancer, the method comprising decreasing expression of a gene corresponding to a marker selected from the markers listed in Tables 1-2.
- 57. A method for determining whether ovarian cancer has metastasized in a patient, the method comprising comparing:
 - a) the level of expression of a marker in a patient smaple, wherein the marker is selected from the group consisting of the markers listed in Tables 1-2, and
- b) the normal level or non-metastatic level of expression of the
 30 marker in a control sample

30

wherein a significant difference betweent he level of expression in the patient sample and the normal level or non-metastatic level is an indication that the ovarian cancer has mestastasized.

- 5 58. The method of claim 57, wherein the marker corresponds to a secreted protein.
 - 59. The method of claim 57, wherein the marker corresponds to a transcribed polynucleotide or portion thereof, wherein the polynucleotide comprises the marker.
 - 60. The method of claim 57, wherein the sample comprises cells obtained from the patient.
- The method of claim 60, wherein the patient sample is an ovarian tissue sample.
 - 62. A method for assessing the aggressiveness or indolence of ovarian cancer comprising comparing:
- a) the level of expression of a marker in a sample, wherein at least one marker is selected from the markers of Tables 1-2, and
 - b) the normal level of expression of the marker in a control sample, wherein a significant difference between the level of expression in the sample and the normal level is an indication that the cancer is aggressive or indolent.
- The method of claim 62, wherein the marker corresponds to a secreted protein.
 - 64. The method of claim 62, wherein marker corresponds to a transcribed polynucleotide or portion thereof, wherein the polynucleotide comprises the marker.
 - 65. The method of claim 62, wherein the sample comprises cells obtained from the patient.

66. The method of claim 65, wherein the patient sample is an ovarian tissue sample.

TABLE 11/467

Sequence 1

Sequence 2

CGTCCGGAAAGCTGGTGGGAATGCTAAGTTCCGAGAGTTCCTGGAGTCTCAGGAGGATTA
CGATCCTTGCTGGTCCTTGCAGGAGAAGTACAACAGCAGAGCCGCGCCCTCTTTAGGGA
TAAGGTGGTCGCTCTGGCCGAAGGCAGAGGTGGTCTTTGGAGTCATCACCTGCCCAGAA
CTGGACCCTACCTNAGCCCANGACGCTGCCGTCCATGGTGCACCGAGTCTCTGGCCAGCC
GCAGAGTGTGACCGCCTCCTNGGACAAGGCTTTTGAAGACTGGCTGAATGATGACCTCGG
CTCCTATCAAGGGGCCCAGGGGAATCGCTACGTGGGGTTTTGGGAACACGCCACCGCCTCA
NAAGAAAGAAGATGACTTTCTCAACAACGCCATGTCCTCCCTGTACTCGGGCTGGA
Sequence 3

Sequence 6

CGTCCGCGTCCTCGCTGCGAAAGTTGGGGCAACCTGTTGCTAGTCTGGTCGTTGGTGAC
AGCGAGGCTTCCGCGCTGCTGGTGAGCAGCCCCGGCGTGCCCCGCGGGCTGGAAGA
GGCGGCGGGCGTGATGCGGCCCGTGGACGCCCCGCGCCCGCGCCCGCGAGAACCTGGCCTC
CCTGGAGCGCGAGCGCCCCGGGCGCCCCGCGGAGAACCTGCCA

TABLE 1 2/467

Sequence 7

Sequence 8

Sequence 9

Sequence 10

TABLE 1 3/467

TGGCATCTCCAGCAAAAGATGTGCTATTTACTGATACCATCACCATGAAGGCCAACAGTT
TTGAGTCCAGATTAACACCAAGCAGGTTCATGAAAGCCTTAAGTTATGCATCATTAGATA
AAGAAGATTTATTGAGTCCTATTAATCAAAATACCCTGCAACCGATCTTCCTCAGTGCGG
GCCATGGNGTCCAGTGCCACATNGGGGGGGTCAGAATGATTACATTGGGCTTGCTCTCCC
GGNGGATATAAATGATATATTTCANGGTAAGGGTATTTCTTATTTTTAGACAAAAAACAT
CCCCNCATGATGATCCAGGNGCCAGAGCATTTGCCCTGAATGCAGGAGGGCTTTCATNTG
GNACTGGGNGGGGCTTTGNAAAAAATTTTTT

Sequence 12

Sequence 13

Sequence 14

Sequence 16

NGCCCCGCGTCCGTTTTAATTATTTTGTTNGAGCCTGCANAGTAANGTTNTTAAAAATA TAACGTTCATACGCATTTTAATTAACTTTGAAAGTTCATATGCATCAGAAAATTTATGAA AATTTGAATGAAAAAAATTTCATCTATTTATTTTTCTAATTTTAATGGCAAATTTACACT ATTATGGCTGATAATTCTGTGAACTTACCTTCTTGTTGACTGATTCTTTTTCCCTTAATC

TABLE 14/467

CCAGCTTTAAGGAGATAGGTGAAGTTATTGTACAAAGTTAAGTGATACCATAAAGTATAT ATTATAAAGTCATACATGGCTTTTGGACAGTNTTATATTTCAGTTGCAGTGCTGCATTCC ATTAAAATTTCATAAAATGCTAGGGAAAATGTTTTGATAAAATTTTNTGCAGTGAGAAAT GACAGACTGAGTGCCTGACAATTTAAGCCACATATGAAAGTATGCAAGTAAAAGANTTCAG GTCCTTAATGTCATCATGTATACATGGTATAAAAG

Sequence 17

CCACGCGTCCGGACGAGACGAGCCCACTAGTGTCCCCCGAGCGGGCCCAACCCCCGGACT ACACCTTCCCGTCGGGCTCGGGCGCTCACTTTCCGCAGGTGCCCGGGGCGCGGTCCGAG TGGCTGGCGGCCGGCCCCTNTCCGCCGGGCTCGCCGGGCCACGACCGCTGA GCGCAGCCACTGTTGGATCGGCCCGGGGCGCGGNGGCCCAGGGCCAGACCCAAACCGT GGCGGCGCAGGCCCAGGCTCTGGCCGTTCANGCCGNGGCGGCAGTCCACGCCGATCAGGC CCACCGNGAGCGGAACGAG

Sequence 18

Sequence 19

NATGTNGNNCNAAAAAGGCCNGCNTTANAGGCCAGGAAACNCGTAAAAAGGGCNCGCGTT
GCTGTGCGTCTTTTCCATAGGCTCGCGNCCCCCTGACCNAGTCATCAAAAAATCCGA
CNGCTCAAGTCATGAGGTTGGCCGAAAACTCCGACAGGGACTTNTAANAGNATACCCANG
GGCGNTTTCCCCTGGGAAGGCTCCCTTCGTGGCGCNTCTCNNTGTTTCCAGACCCCTGC
CCCGCTTTACNCGGNATTACCCTNGTCCCCGCCNTTTTCTTCCCTTTCGNGGAAAGCGGT
NGGGCGCCTTCTCNTCAATTAGGCTTCACCGCCTGNTAANGGTATTCTCAAGTTNCGGNT
GTANGGGTGCCGTTTTCGCTTCCAAAGNCTGGGGCCTTNTGTGCCACCGGAAACCCCCC

Sequence 20

Sequence 21

Sequence 22

TABLE 1 5/467

Sequence 23

CGCGTCCGGCTGGGCGAATNAGGGATTCCGGTTCACAATGGATGCTGATAAAGAGAAAGA
TTTGCAGAAATTTCTTAAAAATGTGGATGAAATCTCCAATTTAATTCAGGAGATGAATTC
TGATGACCCAGTTGTGCAACAGAAAGCTGTCCTGGAGACAGAAAAGAGACTACTGCTTAT
GGAGGAAGACCAGGAGGAGGAGGATGAATGCAGGACCACCTTGAACAAGACTATGATCAGTCC
TCCACAAACTGCTCTGAAGAGTGCAGAAGAAATAAACTCAGAGGCCTTCTTGGCATCTGT
GGAGAAGGATGCAAAGGAACGAGCCAAGAGAAGAAGGAAAAAAGTCTTGGCGGATGC
CCTAAAAGAAAAAGGGAATGAAGCATTTGCTGAAGGCAATTATGAAACAGCTATCCTGCG
CTACAGTGAGGGGTTTGGAGAAAGTGAAAGTGCTGTACACCAACCGAGCCC
AGGCTTATATGAAACTTGAGGA

Sequence 24

GGGAGTCGACCNCGCGTCCGCTCCCTCTGAGTTGCGCTGGGCTTGGCTGCACCATGA
CCCTGGAGGCGATCCGCTACTCGCGGGGCTCCCTGCAGATCCTAGACCAGCTGCTGCC
CCAAGCAGAGCCGCTACGAGGCGGTGGGCTCGGTGCACCAGGCCTGGGAGGCCATCCGCG
CCATGAAGGTGCGGGGCCCCCGGCCATAGCCCTGGTGGGCTGTCTCAGCCTCGCCGTGG
AGCTGCAGGCGGCGCCGGGGGACCCGGGACTCGCCGCGCCTCGTGGCCTTCCTGCGCGACA
AGCTGAGCTTCCTCGTCACCGCCCGGCCCACCGCTGTCAACATGGCCCGCGCCCCCGCG
ACCTGGCTTGATGTTGCAGCCCGGGAGGCCGAACGGGAGGGGGCGCTACGGAAGAGGCCGG
TCCGGGAGAGAGAGTGATCTGCTGCACCGAGGACATGCTGGAGAAAGACCTCAGAGACAACC
GAAGCATTG

Sequence 25

Sequence 26

Sequence 27
NCCNCGCGT

NCCNCGCGTCCGGCCGCGCCCCCGGGCCGGGCTGTAGCGGGGCCGCGGCTGGACGTGTGCGCCGGGCAGGCGGGCCGGGCTGCAGCGGCCTGCGGGCCGGGCCGGGCCGGGCGCGGGCCTCTCTTCGAAGGCCACGACATCAACGGTGCCCTGGAGCCCTCCAACATAGACACCAGCATCCTGGAGGAGTACATCAGCAAGGAGGATGCCTCCGACCTCACACTGCCGGACTCTCCCCC

TABLE 1 6/467

AGACTCGGGCTCCGAGGCCTACTCCCCCCAGCAGGTGAATGAGCCCCACCTNCTGCGCACGATAACCCCTGAGACACTGTGCCACGTGGGGAGTGCCCTTC

Sequence 28

Sequence 29

Sequence 30

Sequence 32

NCGTCCGGGAAACTGGTTCNGATGGTGTCTGCCCAGGAGCGCCTGACACGCACCTTCACA CGCAGCAGCCACCCTACACCCGCACGGAGCGCACGGAGATCAGCAAGACGCGGGGCGGG GAGACAAAGCGCGAGGTGCGGGTGGAGGAGTCCACCCAGGTCGGCGGGGACCCCTTCCCT GCTGTGTTTGGGGACTTCCTGGGCCGGGAGCGCCTGGGATCCTTCGGCAGCATCACCCGG CAGCAGGAGGGTGAGGCCAGCTCTCAGGACATGACTGCACAGGTGACCAGCCCATCGGCC AAGGTGGAAGCCGCAGAGATCGTNGAGGGCGAGGACAGCGCCTACAGCGTGCCCGGC CCCAGGAAATGGGGCCCCATACGGTCGCTGTCAAGTACCGTGGCCNGCACGTGCCCGGC AGCCCCTTTCAGTTTACTGTGGGGCCGCTNGGTNGAAAGGTGGTGCCCACAAGGTGCCGGG CCCGGAGGCAC

Sequence 33

CCGCGTCCGCAGGAAATTGTTAAAAATAATTTGGGGGTGTTTATTGGGGAAGGAAACAGG GCCTTGACAGTGGAGGACTTGGAAGACATGTAATTTAAGATATAGAGTATGATTGTTGGA AAATAAGCATGGAGATCCAGAAGGAATCTTAAGAGTTTTTCTATGCAAGTGAAGATGGAA GAAAATATGTATTTTACAAAAGATAAATTACAAGTACCTTATTTGCTTTGCAAAATAACT TATCATGTTCTTCCACTATTTTTATTATATTTTAATTTTAATGAAACTTATATAACATTT

TABLE 1 7/467

ACACTAAATTTTAAATACATGGCTCAAGACAAAAAAATGGGGAAAATATTTTTTAAAAAA TCACCCCAAATCCTGGTACTCAGACATAACCACTATTCAAACTTGGCAGAGTAATATTTT TCCTGTCTGCATGTGTGCCACNATGTGTGCATGCATACCACAAAGTAGATGTTTTACTAT ATCTCCTGGGTTATTATCTGCTTTTTTCCC

Sequence 34

Sequence 35

CCCCGCGTCCGGTAGATTGCTTGTGGCTGGCAGTGAAGATGGTGGAGTTCAACTTTTTGA
TATAAGTGGGAGGCTCCCCTCAGGCAGTTTGAAGGCCATACAAAGTAAGAGACAGTTGG
TTTCTGTGTGTTCTGGTTTTATTTTGTTGTAAGCTCTTTTTTTCTCTGGACTTTGGTTAA
AAAGATAGAGATCAGTTTTATTGGAGATTATTTGCCTATAGGTACTATATTTCCTGATTGT
TCTAAGAGTGCTTAACTTGGGTTCCGTGGTCCAGTTTCATGGGGCTTATGAATTCCCTAG
AATTGTATGTGATATTTTAGGAAATACACGTTTATCTAGGGAGCTACTCTGTAGCTTTTG
GTTAACTTTAGTGGGGTCTGTGGCCCAGCTGAGATTATGAATTACTGACCTGAAGACAAC
CTTACAGCTGGTAATGACAGCTCTATAGGCCTGTACTGTCTTAGAGGCTCTTATGTTGAA
GTCAAGTANGAAGGTGGATTTTCTTCTTGAATTATAGTGTTTTGCCCCTTAATAA
Sequence 36

CNCGCGTCCGCGACGCGTGGGGGCGAGGGCCGCTGGGGCCGCGAAGTGGGGCGGCCGGG
TGGGCTACGAGCCGGGTCTGGGCTGAGGGGCGCGCTTCGCGGTGGACCCCAGCCGGCA
ACGGGAAGGCGAGCTCTCCTCCACCGTCCAAAGTAAACTTTGCCGCTCCTTCCGCGGCGC
TCCCGAGTCCTCGCCGCGCGGGCCGCCGCAGTCCGCGAAGAGCCGTCCTGCGTCAGGG
CCTCCTTCCCTGCCCCGGCGGGGCCACTGCGCCATGGACGCCACAGCACTGGAGCGGG
ACGCTGTGCAGTTCGCCCGTCTGGCGGTTCAGCGCGACCACGAAGGCCGCTACTCCGAGG
CGGTGTTTTATTACAAGGAAGCTGCACAAGCCTTAATTTATGCTGAGATGGCAGGATCAA
GCCTAGAAAATATTCAAGAAAAA

Sequence 37

TABLE 1 8/467

Sequence 40

Sequence 42

Sequence 43

Sequence 44

CGTCCGCGAGACTCCCGCGCCCACCACCCCCGGCGAGCTGCTGAGCCACTCAATCT GAGCCCTGGCTACTAATAAAGTTCGTTTAAAAATCATAATCATTCTTAAGAGAGCGAAAG

TABLE 1 9/467

Sequence 45

Sequence 46

Sequence 47

CGCGTCCGCGGACGCGGGGCCGGGGCCGGGGCCGGGCCATCCCGN CTCGGGGCCGNCGGGGCCCCTGCTGAGCGCTACCCACGTGCGTCCGCGCCACCTCGCG GGCGACCCCGCGGCCAAGGCCCCCGGCGGAGCGGNTCCCGGGCGCCCCCAACTAGCCCCC AACTTTGGGCGAAGTTTGCCTGCGCCTCTCCCCGCCCCCACGCGGCGCCGGGGCCGCG GACGGNAGCGGCCCCCGGGGATGCGCCTTCCCGGGGTACCCCTGGCGCGCCCTGCGCTGC TGCTGNTGCTGCCGNTGCTCGCGCCGCTGATGGGAACGGGTGCGCCGGCCGAGCTGCGGG TCCGNGTGCGGCTGCCGGACGGCCAGGTGACCGANGAGAGCCTGCAGGCGACACCGCCG CGGACAGCATCAAGNCTCGAGCTGCGCAAGCCNGACGGCACCCTCNTNTTCTTNACCGCC GACTTTAAGA

Sequence 48

Sequence 49

TABLE 1 10/467

CTTCGTATAAGTCCCAAAGAACTCAGGCTTATAGCACTAAGCAAATTACCAGTGGGAGGA GGAGGACCTGCCACGGAGCTGGATAATTACATTTAAATATTTTTGCCANTCTGTTGGAGA C

Sequence 50

Sequence 51

Sequence 52

Sequence 53

Sequence 55

TABLE 1 11/467

ACCNCGCGTCCGGACCTGTTGGCGACATGGTGGCACCCGTGCTGGAGACTTCTCACGTGT
TTTGCTGCCCAAACCGGGTGCGGGGAGTCCTGAACTGGAGCTCTGGGCCCAGAGGACTTC
TGGCCTTTGGCACGTCCTGCTCCGTGGTGCTCTATGACCCCCTGAAAAGGGTTGTTGTTA
CCAACTTGAATGGTCACACCGCCCGAGTCAATTGCATACAGTGGATTTGTAAACAGGATG
GCTCCCCTTCTACTGAATTAGTTTCTGGAGGATCTGATAATCAAGTGATTCACTGGGAAA
TAGAGGATAATCAGCTTTTAAAAGCAGTGCATCTTCAAGGCCATGAAGGACCTGTTTATG
CGGTGCATGCTGTTTACCAGAGGAGGACATCAAGATCCTGCATTATGTACACTGATCGTT
TCTGCAGCTGCAGATTCTGCTGTTCGACTCTGGTCTAAAAAGGGTCCAGAAAGTAATGTG
CCTTCAAACTTTAAACTTTGGAA

Sequence 57

Sequence 58

CCNCGCGTCCGGGGAGCAGGATCAACGGTGGTCCCCGTAAACCTGACAGTAAACCTGAC
AGAGGCTGCAGGAGTGCATTTCCACCCAGGGTGCACTCAGCGAGTGGAACTCCACCCG
TTTCTTTGGAGTCAAGGCGCGACCTCTCAGGGAGGAGACTGCTCCTGGTTGCCCACTGCC
GGGTCATCCCAGCTTGCAGTGGAACCCTCCGCAGCCTGGCCTCTTCCAGGGTAGCCCTC
ACTCCCCTCTCTCTTGTCCTAGGATAAGGCCGAGGAAGGCTGACGAGTTCCAGCTCTGGG
GATGCCCTATCAGCTGTGCACCTTGAACAAATCATTTCTCCTCTTTGGGTCTCTTTCC
TCCAGTGTGAAACGTGGTGAAGGCATGAGGGGCTATGGGAGCCCCAAGGCCTCTTTCAGA
GATCTCCTCTGGGTCCCATGTGACCCCGTGGCTATCCCCAAAGGCAAGAGGGTCCCCAGC
CCTGCACCAAGGCCCTGGG

Sequence 59

Sequence 60

CGCGTCCGGTGGGAAGCCAGAAGATAAAACCAAATGGCTGGGCACGTCTTTAGGTTATTC
CTAGCTAAGAGTTAAGAGTTGTAAGCTCTCTCATTCTTTGTTCTCAGCCTTAAACTATC
TTTCCTTCTATTAACTTTATTTGTCTCAGTTACAATGATAGAGGTAACTTCACATACTAA
AAGAAATTAGGTTACCATGTGAAACATTCTTCTTGGCTTGTGCTAATGTTATCAGATCCA
AACAGCATCTGAAAGAAAATTTTCCAAGTACGATGTTGTTCTCTTGTTTTCTGAAATACA

TABLE 1 12/467

TATCATATGTTAAAGTGAGAGTTTTTATACATGTTGAAAGAAGTTGAATGACATAACAAA TAGTTACTGAGGCCTCCATTTTCTTACTTCACAGTTAAAATTCCTGTTTCTCTTTGGGTA TAGGAGGGTAGAAAGAAGTGGGAGAGTAATAGCATTTTAAAACACAGAATCAAAAATCAT ATTAAAAGTAG

Sequence 61

Sequence 62

NCCACGCGTCCGCCAGNCTGTGAAGGATCCCAGACTGGCATATGCAGGAGGAAATGGGGC GGGCGAGGAGTAAGGACCCCAAAAAGCAGGGGTAGGGAAGGGCCCTCCCAGCGCCCCACT GTAATAGGGGCCTCATCAATGCCCCATGCTCACTGAATAAAGCACTGCCAGCGAAAGGTG AAAAGAGGAACAAAGAACATTCTCCTGGACGCCACCCACAGAAAGCCACGTGCAGGCTTG GCCCTCACCTTGGGGACCTTGGACACGGAGCTGGTTATGTCACATCTGGCTCTCAGAGCT GGGGCAGCGTCTAGGAGGCCTGATGTAGAAAGCACTCAGCTAAGCCCTAGTTACCGGCAC ACGGGCACCAGCGCCCCCTCTCAGCAAACTTNCACGTCTTATGAAATTAGCACTGGATTT CCACTTCAATTGGA

Sequence 63

CCCACTGTAATAGGGGCCTCATCAATGCCCCATGCTCACTGAATAAAGCACTGCCAGCGA AAGGTGAAAAGAGGAACAAAGAACATTNTCCTGGACGCCACCCACAGAAAGCCACNTGCA GGCTTGGCCCTCACCTTGGGGACCTTGGACACGGAGCTGGTTATGTCACATCTGGCTCTC AGAGCTGGGGCAGCTGTCTAGGAGGCCTGATGTAGAAAGCACTCAGCTAAGCCCTATTTA CCGGCACACGGGCACCAGCGCCCCCTNTCAGCAAACTCCACGTNTTATGAAATTAGCACT GGATTTCCACTTCAATTGGA

Sequence 64

NCGCGTCCGCTTCATCTTAGGATAAAGTCTAAATCTTTGTTTTTTTGCTATTGTACTAAAC
TCATAAATCCTAGGTTATAAAGATAAAGCCTTAAACTTTATCTCATCATCCAGCCCAATT
TCCAGCCACAATGAAGTACTTAAAACTCTGTGTCTTTGTACTTGCTGTTCTCTTGGCCTC
CAATTCCTTTTCATCTTTTCCATTCGGTAAAGTTTGTTTATCCCACAGGCCCTATCTTGG
AAGCCTCCAGCAACTTCTCCAGACAGAGGTGTTAGCAGTGTAGGATCAGATTTCTCAACC
ACGTCACTCCCATGTCTGGGTAGATATCTCTGCCCAAGTGTTCTCATAGCACTTGAGCAG
TACTCTCTAAGCGCCCAGGATCTACCATGTTGCTTTTTTAAAATTTGATTATTTT
TTTATACTGCTCCTTGTGGAGCANGGAGTGTTCCCAGAGTAGCCCACCATGTTATATTGA
ATGGATCTGTGTGCATAATGCAGCTGTCCATCTACATCGTATATTTTTTTCTCTCCTCAAGG
GTAGGGA

Sequence 65

WO 01/070979

TABLE 1 13/467

Sequence 66

Sequence 69

ACCCANACCTGGGAGGAATTAATGGAATGCTTGNCCCTGGGCAGCCTTAGAAACAGACCC NAGCTTATCTAANGCTGCTCCGAGGCAGTGACCCAACTANGGCTCAGGAAGTCAAGAANA TTGACCAAGCTTATAGTGATCACCTCTTGACCTTTGTGTCACAGTCNTTTTGCTTTTTAA AACCCTTTTGTGAACCGNTTATGGCCTTTGATCTGACAGGCATCNTAGTTGTGAAGGGG AACANGGGCAGGATATAATGTTTCGTTTACCAAATACAANAAAATCNGANGTACCCAGNT AGATCACAANATTTTTTGGGAGAAGGNCTNTTGGGTCTCTTCCAGGAGNTCACTTCANNN TTGGNAACTTGACAGGGGCTTGGGGAATTTANTATTCCCCTTGGGCGCAGGGNCNCAAAN GGGTGGCANTTTCCCTCCTTGGAGNTTTTTTTTTCAAGAANTCCTTGCNTNGGGGAAAGA TGGTTACNANNATCCCGGAATTTCCAACCCCCTTCCCTATTTTTTTGGTTTAAGG Sequence 70

TABLE 1 14/467

TGTCTCTTCCCAGTGCCATCCCAGTGCTGTCTCTGCCCCCTGCTGCTTCTGTAAAGATTT
TCTGACACAAGTAACTGCCTCATAGACCTTCCTTTTTATGAAATCCTGAGTTTTGGTTTG
GGTACGTCCTTTTTAGAT

Sequence 71

GCGCGGCTGTCGCGAGGGCGGGGGTCGGGGCTGCAGGCCGGGGCAGGGCTGGGGGGCCCCAGCCCCAAGCACTGCGGGGCCCCAGCCCAAAGCACTGCGGGGCCCCAGCCCAAAGCGGACCTTGA

Sequence 72

- Sequence 73

Sequence 74

Sequence 75

CCCGCGTCCGGGCTGGCATGGCTCTATATAAGATTGTTGCANAAANTCCCTACTACTTTT GGTCTGTGATGAGCTTAATTATGCAATCTATATNGGCACAGGATGAAAACCTCTCAAAAA CAATGTTTCTGCCCCTTGCTGAGAGAATGGTCGAAAAAATGGTGAAAGAGGACAAGATAG AAGCTGAGGCTGAAGTTGAACTTTATTATATGATCCTGGAACGTTTGGGAAAGTACCAGG AGGCCTTGGATGTCATCAGAGGGAAATTAGGAGAGAAGTTGACAAGTGAGATTCACAGTC GGGAAAATAAATGCATGGCTATNTACAANAAGCTGAGCAGGTGGCCAGAGTGCAATGCCC TTTNCCGGCGCCTCTTACT

Sequence 76

GNTGGAGGAGCTTTGCTACTCTGCTCTTTGGCATGACTCCAGGATTTTTTTCTGGAATCC
AACCTCTGTCCTCTTAGGAGAAGGAACCTGTCCTTGGTTCAGATGGCTGGGCATGAGGAG
GAAAATTTCCATTAGTGTAGAAAAGTGCTGGACAGAATCCGGTTTGGAAAATTACAAATC
CAGTTGGTCAAAATAGGCCATTTCCTATGTGTGACCTATTCGTGGTATGCCAACTGGACT
GCTTCCTAAACAGGACGAGGAAAGTGAGGAATATTTTTATATGAAAGCCTTAGCCTGTCT
GGCACCCATGAAAAAAACTATTTATGCACTCCTACTTTCACCCGTCTTTTTTGCATTCTCT

TABLE 1 15/467

ATTTGTAGCACAACAGAGTTGAATGCCACAAAACACCCCGTTTATAGTGAGCTGTTTTCA GTGACCAATATCAGAAGGAGGCTTGCTTCTGGACTAGCCTACTAATTGCCAGCAGCCACC ATTTTCATG

Sequence 77

GGAGAGTGCCTTGCCGGACCCTCAGGACGAGCTGCTGGGCTGCTACAGTGACCAGGACT
TTCTGGCCAAGCTGCACTGTGTGCGGCAGGCCTTCCGAGGGGCTTCTGGAAGACAAGAGTA
ACCAGCTTTTCTTCGGGAAAGTGGGCCGACAGATGGTGACAGGCCTGATGACCAAGGCTG
AGAAGAGCCCCAAAGGCTTCCTGGAGAGCTACGAGGAGATGCTGAGCTATGCCCTGCGGC
CCGAGACCTGGGCCACAACACGGCTGGAGCTGGAGGCCGAGGGGTGGTATGCATGAGCT
TCTTCGACATCGTGCTGGACTTCATCCTCATGGACGCCTTCGAGGACCTGGAGAACCCTC
CGGCCTCGGTGCTTGCCGTCCTGCGGAACCGCTGTCANACAGCTTCAAGGAGACCGC
CCTTGGCCACTGCTTGCTGGTCGTCCTGAAAG

Sequence 78

Sequence 79

Sequence 81

CACGCGTCCGCAAAATAGCCCCACATCCNGGCAAAAGGGGCCTTTCCCTTGGCCCAGAAG
AAAAAGGAACAAGTGGAGTGCAGAAGAAAATCTGTACTGAGAGACTTGGGCCTAGCTTGT
CTTCCAGTGAGCCAACCAAGGCTGGTGCTGTCCCATCCAGTCCCTCGACGCCAGCACCAC
CCAGCGCCAAACTTGCCGAGGACTCAGCTCTGCAGGGTGTGCCCTCTCTGGTGGCAGGTG
GAAGTCCACAGACTCTTCAGCCGGTATCCAGCAGTCACGTGGCTAAAGCTCCCAGTCTGA
CCTTCGCTTCCCCGCCAGTCCTGTCTGCGCATCAGACAGCACTCTCCATGGGTTAGAGA
GCAACTCTCCCCTTTCACCACTGTCCGCTAATTATAGCTCACCTTTATGGGCTGCAGAGC
ACCTCTGCCGCAGCCCAGATATCTTTTCAGAGCAGCAGCAACATAGGCGCTTTC
AGAATACCCTAGTAGTCCTACATAAAATCTGGGTTGCTGGAGATCACTTTTGAAAACCAA

G

TABLE 1 16/467

Sequence 84

GTCCGCCGCTTCCGGTCTCCCCGGGCCGGCGCTGGCCTGACTGCGGCCCCGGTCCG
TAGCACTCCGCCTTCTCCCGCCCTGTAGCCGCGAAGACTGCTTCAGCCTTTCCC
TGTGCTGCCCCTGCCGCGATGGAGACGAGCTCGAGCTGCGAGAGTCTTGGCTCCCAGC
CGGCGGCGGCTCGGCCCCCAGCGTGGACTCCTTGTCCAGTTAATGTGTTAAGAGCCATT
GACATTTGAAGATCATCAGAAGTGAAGATAAAACATCTCAAAAATTATAATTGCCTCCAC
TTCTCATTCAGAGAATTCAGTGCATACAAAATCAGCTTCTGTTGTATCATCAGATTCCAT
TTCAACTTCTGCCGACAACTTTTCTCCTGATTTGAGGCCCATGCAGTCCAGTTCGGGAGC
TAAGT

Sequence 85

Sequence 86

Sequence 87

TABLE 1 17/467

NACAAGTTGCANGGGTCACAAAAACATCGTGAATTTTGATNGGAGTGGTTACAATCCAC Sequence 88

CGTCCGTTTAATTATAACCTAGATTGTCTGGGCAACGGCAGGAACGGAGTGCCACTGTGG
AGCAGATAACTGCAGTGGTTTTCTAGGAGTGCGGCCAAAGTCGGCATGTGCGTCAACAAA
TGAAGAAGAGGCAAAAAATGCTAAGTTAAAACAGAAGAGACGAAAGATCAAAACAGAACC
AAAGCAGATGCATGAAGATTACTGTTTTCAATGTGGAGATGGTGGAGAGCTGGTCATGTG
TGACAAAAAAGACTGTCCCAAAGCATACCACCTCCTATGCCTTAACCTGACTCAGCCACC
ATATGGAAAGTGGGAGTGTCCGTGGCATCAGTGCGATGAGAAAGGGGGGCCCTGGTTTC
CTTCTGTGAATTCTGTCCACATTCATTTTGTAAAGATCATGAAAAGGGGGCCCTGGTTCC
CTCTGCACTGGAAGGCCCGCCTCTGCTGCTCGGAACATGACCCCATGGCTCCTGTGTCAC
CAGAATACTGGAGCAAGATAAAATGTAA

Sequence 89

Sequence 90

WO 01/070979

PCT/US01/09126

TABLE 1 18/467

TGAAGGCTGCAGTACCGTTGGTTCGTGCTGGACTACAATGCAGGACTGCTCTCCTACT ACACGTCCAAGGACAAAATGATGAGAGGGCTCTCGCAGAGGATGTGTTAGACTCAGAGGAG CTGTGATTGGTATAGACGATGAGGACGACACCCTTCACAATAACTGTTGATCAGAAAA CCTTCCATTTCCAGGCCCGTGATGCTGNTGAGCGAGAGAAGNGGA Sequence 94

ACGCGTCCGCGGACGCGTGCGGTCCGGCCCGCCNCCCTGGACGAAAGAAGAGGGCCCCTC CAGGCCAGTCTGGGCACCCTGGGATAGCGGCTGCAGCCAGGCATGGCCGACTCTGCACAG GCCCAGAAGCTGGTGACCTGGTCACAGGGGGCTGTGGCTTCCTGGGAGAGCACGTGGTG CGAATGCTGCAGCGGGAGCCCCGGCTCGGGGAGCTGTGAGCACACACCTG GGTCCCTGGCTGGAGGAGCTGAAGACAGGGCCTGTGAGGGTGACTGCCATCCAGGGGGAC GTGACCCAGGCCCATGAGGTGGCAGCAGCTGTGGCCGGAGCC Sequence 95

CCCCGCGTCCGAGGTGACCTCCTTGGCCCAGATCATCTTAGAGCCAAGAAGCAGGACCAT
TCGTGGTTTTGAGGCCCTGATTGAAAGAGAGGTGGCTGCAGGCTGGTCACCCATTCCAGCA
GCGCTGTGCACAGTCAGCCTACTGTAACACCAAGCAGAAGTGGGAGGCTCCTGTATTTCT
TCTCTTCTTGGACTGCGTGTGGCAGATCCTTCGTCAGTTTCCCTGTTCTTTTGAGTTTAA
TGAGAATTTCCTCATCATCATCTCTTTGAGCATGCTTATGCCTCACAGTTTGGAACATTTCT
GGGCAACAATGAAAGTGAAAGATGTAAGTTGAAGCTACAGCAGAAGACGATGTCTTTGTG
GTCCTGGGTTAATCAGCCCAGTGAGCTGAGTAAATTCACCAATCCCCTCTTTGAAGCCAA
CAACCTTGTCATCTGGCCTTCAGTTGCTCCGCAGAGTCTTCCACTGTGGGAAGGTATTTT
CCTACGTTGGAATAGATCCTCTAAGTATTTGGATGAAGCATATGAAGAAATGGTTAACAT
CATTGAATATAAAAGAATT

Sequence 96

CGCCNCGCGTCCGGCAAAGCAAAAGGGAAATTATTTGGTGGATGGTAGCTCAAAATTGGA
ACTCTTGTTCTAATTCAGTTACATTGGCTTTACCCTCCTTAGATTTTTCATCAAAGGGCT
GTCCCATTGCAATCTTACTAAAACATTTTGTTAAAATAAACTCTTTTCCTTTTTATATTA
ATAATTAGGCTTTTAAATAAAGATGTTATTCCTTTAAAATGGTGGGCTTACCATCATTGA
AGATGTCACTCAGGTGGCCTTGCTTGATCAAAACGCCTTTTTTAAAAACCAAGCTTTAAA
AACATGTTTATAATTTCATGAAGTACATATATTTGTTCCCATAGTCTTCAGCTTTAAAA
CTATAAATATGCCCAAATTTTGTTATTTGCCCTACTTTAAGTAGGTTTATTGNGTTTGTT
TTTTTCAAGTACTTGTTTTTCTCTGATAAGACTCAGGAATTCTGAAATGTGAAAATGNCT
CAATT

Sequence 99

WO 01/070979

TABLE 1 19/467

CNCGCGTCCGAAATCGTTGCTACCAANTATTCAAAACCCTTTGAGTTTACATACTAGTTACCTTAAAAATTANTNCCTGACNCTCNTGANTTTGGGNGGAAAGCCCTTGTNTCNNCTCTCTNATGNACTCTCATGGGTTTTTTTGTATGATTTGAATATNAATGTGCCTAAAGAATTTTTGCTCTTAATCTATGNATACATACTTGAACAAATCATTCTTGCTTAACTGCTGATCTTTTTGTAAAAACTATTG

Sequence 100

Sequence 101

Sequence 102

Sequence 103

Sequence 104

TABLE 1 20/467

GCAATCCTGGCGGCGAGCAAGTATGAAAGAAACGAACCGGCGGAAGTCGCTGCATCCCAT

Sequence 105

Sequence 107

AGAATTGTGTATGCCTTGCCTATCACGGTACAGCACGAAGCCAGGCTCCTTTCTCCACCA
AAGAAGATGGAACCAGACTGGAATTCTGTCTCCAGAGAGAAACCCAGCTGTTTGGGTCAA
AGACAGATGCTTCAGACTTGGGTGGGAAGGTGAAAGATGGCTATTTAGAAAGCTGGTGGC
ACGTTTTACATAAGGGAATGTCAGATGGGAGATGCTAGTTGCCATTTTAACAAAGCAGGT
AAATCGGTAAATTTTAAACTCTGTCCATGTTCTGTTAGAACTCAGGGACAAGGGATCCAT
GAAAAAG

Sequence 110

WO 01/070979

PCT/US01/09126

TABLE 1 21/467

Sequence 111

Sequence 112

CGCGTCCGGGCGCGGTACGCCTGGTCCCCGCGTGGAGTCTTTACTCAAAACAGCTCCCG CCTCAGGCCGAGATGAGGAGCCCTTCANAATAGCTGCTGTCTCTGGGNGGACCCGGGCGT CCTTGGCAGCCCAGCTGNTCTGGACAAAGCCCTGCCAGTCAGGCCTCCGCTGGCAGGAAC CATGGCAGAGGCTGGGGATGCTGCGCTATCGGTGGCCGAGTGGCTGCGGGCATTGCACCT GGAGCAGTACACGGGGCTCTTTGAGCAGCATGGCCTGGTGTGGGCCACTGAGTGCCAAGG CCTCAGCGACACCCGCCTGATGGACATGGCCATGCTACTCCCT

TGTCGACCCCGCGTCCGCGGGANGTTCATGGAAACGCAGGACACGACAGAATTGTGTNTG
CCTTGCCTATCACGGTACAGCACGAAGCCAGGCTCCTTTCTCCACCAAAGAAGATGGAAC
CAGACTGGAATTCTGNCTCCAGAGAGAAACCCAGCTGTTTGGGTCAAAGACAGATGCTTC
AGACTTGGGTGGGAAGGTGAAAGATGGNTATTTAGAAAGCTGGTGGCACGTTTTACATAN
GGGAATGTCAGATGGGAGATGCTNGTTGCCATTTTAACAAAGCAGGTNAATC
TTAAACTCTGTCCATGTTCTGTTAGAACTCATGGACAAGGATCCATGAAAAAAGACCTGTG
ATGTTTCNTCTGGCGCTTTACTGGCCTGGGCACACCTACCAATCTTTTAGGATTTGACTG
GTTCCATTACATTTCCT

Sequence 114 ·

Sequence 115

AGTTCAGTCTGCAGCAGTCCCTGCACCCACTTCCCAGTTGCTTTCATCTNTGGAAAAAGA
TGAGCCCCGTAAAAGTTTTGGCATCAAGGTCCAGAATCTTCCAGTACGCTCTACAGATAC
AAGCCTTAAAGATGGCCTTTTCCATGAATTTAAGAAATTTGGAAAAGTAACTTCAGTGCA
GATACATGGAACTTCAGAAGAGAGGTATGGTCTGGTATTCTTTCGGCAGCAAGAGGACCA
AGAAAAAGCCTTGACTGCATCAAAAGGAAAACTTTTCTTTGGCATGCAGATTGAAGTAAC
AGCATGGATAGGTCCAGAAACAGGAAAGTGAAAATGAATTTCGCCCCTTGGATGAAAGGA
TAGATGAATTTCACCCCAAAGCAACAAGAACTCTNTTTATTGGCAACCTTGAAAAAAACC
Sequence 116

CCCGCGTCCGCACCAGGCCCGAGTCTTCCCTTCATGGAGGGTGACGTGAGCAGCAAGGAT
AAGATGGGCAAAGGATGGGACATATAAAAAAAGCTCTTCAGGAAGCTGCAGCAAGG
TTTGAGGAATTAAAGGCCCAAAAAGAGCTAAGACAGCTGCAGGAAGACCGAAAGAATGAC
AAGAAGCCACCACCTTATAAACATATAAAGGGTCTCCCTCTGTGACCCAGGCTAGAGTGC
ATTGCTGCAATTTTGGCTCACTGCAACCTCCGCTTCGTGGGCGCAAGTGATTCTCCTGCC
TCCTGCCTCAGTCTCCTAAGTAGCTGGGATTACAGACATGAGCCACCAACGCCTGGCTAA
TTTTGTGATTGGCAAAAAAAGAGATTTTGTGACACATAAAGATGATATGAAATTCAACTTT
CAATCAAGTATCCAGAAAATTTTA

Sequence 117

CCACGCGTCCGGCCCTTGCCCCTGTCNCACANGAATGGACCCACGGCCCCACCCAGCGCC

WO 01/070979

PCT/US01/09126

TABLE 1 22/467

Sequence 118

Sequence 119

CACGCGTCCGGTTTTACTGCTCTTTGCCATGTGGTAAAAAGAGGGCTGAGACATATTTAAG
AATTCCAAGAGGATATTATGTGTCAGAATTTCAGACACTGATGAGAAGTTTTTAATTGTT
CTTTTTTATTTGATTTTGGAATTCAGGTGCACTCTATTCAAGTGCAAGGATATCAGAAGT
TTTTTTTTATTTAAAAAATTTTTTTTCGAGATGGAGTTTCACTCTGTTGCCCAGGCTGG
AGTGCAATGGCAGCTTACTGCAACCTCCACCTCCTGGTTCAAGCGATTCTCCTGCCTCAG
CCTCCCCAAGTAGCTGGGGATTACAGGCACCGCGCCAACACACCTGGGCTTATTCTAATT
TAAGTAAGAAAATGGGAAGTCTTACCCATNTTTGGTCAAGCCTTGGGTCTTCGAACCTNC
TGACCTTAANGGTGATNCCACCCCANCTTTGGCCTCCCAAGCCGTGCTNGGGATTATAGG
GCATGAAGCCCACCCANGCCCGGNCCCAGGATTTTTATATTTAAGCCCTTCTTGCTCTTN
AAAAAAAAAAAAAAAAGGT

Sequence 120

Sequence 121

TABLE 1 23/467

TGGAGCGGGGGGGACTGAAAGCCATTTCCTTTCCCGTGAAGAATTTTTATCAGTGCAAGTAACAAAATATT

Sequence 123

Sequence 124

CCNCGCGTCCGTGCTGATAAAACTCCTTTGACCTGACGATTGCTCTAAGTCCTAATTGCC
ATATTTATATTCCCATAGTAAGAGTGTTTGGAGATAGTGTTTGAGCTTTTTTGCTGGTGT
TAAAAATGCATAATGAAAGATGGCACNAGAGAGGCATATTATATCCAATTCATGAAGTTG
TTTGTGTTAACAGAAAGCTTATTTTAATCACTTAACATTGTTGATTTGTCTAATCACAGT
AGCGCTATTGATTAGGAGCCTGACCTTTANATGGTTGACTTGTGAGTGTATTCAATATGG
TGAAATAANGGTGTTTGATATATGGCTGCAGATTTTAGAAGGTGTCATTAGCAAAGGTAT
ACGGAATAAAATANGGGTTATAGTATTCCTTACTCAAATTCTGTATGTGCTAGAGCTGGC
TGGAGTCTGTTGGCATGCTCATTTGGTGTAAGGNCCGNTAAGGACTATGCT

Sequence 125
GCCCGCGTCCGCACTTTGTATTGATAACTTAAAATGGCATCAGTTTATCTTAGACATCA
GCTTGCTTTTTATCTCCTTTTTTAGTGAGTGAAATAGAGCAACTAGCATGCCTGTGTTCC
CAGCTACTTGGGAGGCTAAGGTGGGAAGATCAATTGAACCTAGGAGGTTGAGGCTATAGT
GAGCTGTGATTGCACGACTGCACTCCAGCCTGGGCAATGGAGTGAGACTCCTGTCTCTAA
AACAGCAACAACAAAAATAAAGCAACCATAGTGCATAAGGGAAATTAAATGTTCCCTATA
GAAATATGTGTATGTCTGTGATAAGTGGTATGCAAATGCTAATTATTTTATAAAATAAAA
GTTCAGAACTATTCTTATCATTGCCACTTGAACAATTAAAGGGTTTGCTTTATTTCCTAA
TGTTTAATAGGAACCCTTTGCTTCAAACAGCCTTTGTTGAAAATCATGTAAAAAATTTGTTA
ATAG

Sequence 126

Sequence 127

CNCGCGTCCGCGGTCGCGGGCGGACGCGNGGGTTCGTCCTGGACAAGTCTGGGAGTGT GGCAAATAACTGGATTGAAATTTATAATTTCGGNNAGCANCNGGGCGGAGAGATTCNGTG AGCCCTGAAATGAGATTATCTTTCATTGTGTTTTCTTCTCAAGCAACTATTATTTTGCCA TTAACTGGAGACAGAGGCAAAATCAGTCAAGGCTTGGAGGATTTAAAACGTGTTANTCCA GTAGGAGAGACATATATCCATGAAGGACTAAAGCTAGCGAATGAACAAATTCAGAAAGCA GGAGGCTTGAAAACCTCCAGTATCATAATTGCTCTGNCAGATTGGCAAGTTTGGACGGTC

Sequence 128

TABLE 1 24/467

Sequence 129

Sequence 130

GCGTCCGGTGGCATCATGACTTCTGGGGCAGTAGACTGAGCAGCAACACCAGCCACAAGT
CCTACCGGCCTCTCACCGTCCTGACTTTCAGGATTAACTACTACCTCTCGGGAGGCTTCC
ACCCGTGGGCTTTCACGTGGTCAACATCCTCCTGCACAGTGGCATCTCTGTCCTCATGG
TGGACGTCTTCTCGGTTCTGTTTGGCGGCCTGCAGTACACCAGTAAAGGCCGGAGGCTGC
ACCTCGCCCCCAGGGCGTCCCTGCTGGCCGCGCTGCTGTTTGCTGTCCATCCTGTGCACA
CCGAGTGTGTTGCTGGTGTTGTCGGCCGTGCAGACCTNCTGTGTGCCCTGTTCTTCTTGT
TATCTTTCCTTGGCTACTGNAAAGCATTTAGAGAAAGTAACAAGGAGGAGCGCATTCTT
CCACCTTCTTGGGTGCTGCTGAGTATCTTTCTGGGAGCAGTGGNCATGCTTGTGCAAAAG
AGCAAGGGATCACTTGTGCTGGGTTTAAAATGCCGGAATTTGACAATCTTTTGGGTGATAG
GC

Sequence 131

Sequence 132

CGCCNCGCGTCCGAACAGGCCGGGCACCAAGGCGCAGGATTTCTATAATTGGCCTGATGA
ATCCTTTGATGAAATGGACAGTACACTAGCTGTTCAACAGTATATTCAACAGAACATAAG
AGCAGATTGCTCCAATATTGACAAAATTCTTGAACCACCTGAAGGCCAAGATGAAGGTGT
GTGGAAGTATGAACATTTAAGGCAGTTCTGCCTTGAGCTAAATGGACTTGCTGTCAAACT
TCAGAGTGAATGCCATCCAGATACTTGCACTCAAATGACAGCAACTGAACAATGGATTTT
TCTTTGTGCAGCTCATAAAACTCCAAAAGAGTGTCCTGCTATAGACTATACTAGACACCA
ACTTGATGGTGCTGCATGTCTTCTGAATAGCAATAAATATTTTCCCAGCAGGGTTAGCAT
AAAGGAATCATCTGTAGCGAACTAGGATCAGTATGCCGTAGGATTTACAGAATATTTTTC
ACATGCTTATTTTCATCATCGGCAGATATTTGGATGAAAATGAAAAC

Sequence 134

TABLE 1 25/467

GCGTCCGCGAAAGCTGGGAAGCCAGGTCTACCTGCCCCAGACGAATTGGTGTACCAGGTG CCACAGAGCACAAGAAGTATCAGGAGCAGGAAGGGATGGGGAATGTGTTTTTAAA GAAATCCTTTGAAGATGATGCTGCTTTTTACAAAGCATCGTTTTAAAGCACATGGCCTTT TTTTTTTTAATTATTAGTGGTAGTAATATATAGAATGTATTACATAACTGTCACTGAAGT GGTTGGGGAAAATGTGGTGACTGAGGTACAGGAAACTACTAATCTTGCCATCTTGCTTTA AGGTGTTATGGTGGCACAGTTACTGCTCGCCTGTTAAATTTCAAATGTCCTGTTTGATAC TACTGGAGAACACTATTTTTAATACAGAAAAAGCTCCCTATAATGCACTTCAGAGAAATT AA

Sequence 135

TCGACCACGCGTCCGGGAGTCCCCCCTGCCCCCCATCAAATGCTTCCTGCAATACTTTG
CACACCAGAGACTGGGCCTCCCAGATCCAGGGGGACAGGGGTCCCTGGGGGAGTCCCCA
GGGCCAGCCCCTCCAGGCCAGCTGCACACACTTGACACTGATTTGCACAGTCTTGCACAA
ATAGGGGGTAAGAGCCCAGTGGCTGGGGTGGGCAATGGGGGTAGCCTCTGGCCTAGGGAG
TCCCCTGGCACTGCCAATGGGCACAGTCCCGAGCACACCCCCTGGCCCTGGACCCCA
GGCCCCTGCCCACCAAGCGAAGGCTGCTTCCTGCTGGAGAAGCCCCAGATGTCAGCTCT
GAGGAAGAGGGGCCAGCCCCTCGGAGGCGCCGGGGATCCCTGGGCCCCAAAGAG
CCTGTTTTGGACCCAACAGCTGCGGTCCCATGGGGCGAGGCTGAAAGGAGCCCGTCGC
CTGAAAGCTTGAGCCCCCTTCGAAAGCCTNCGGAAGGGCCCAGGCCTGCTGAGCCCCCCC
AGT

Sequence 136

Sequence 137

TCCGATTTTTAAATCTATTGGCCGTGTTGTCCTACCTGAAGTTCTTCAACTGCCAAAAGC
ACAGCCCTTTTTCTCTGAGCTGGTGGTTCTCGCTAACACTGACAGGGGTCGCTTGTTCCT
GTGCAGTGGGCATCAAGTACATGGGTGTTTCACGTACGTGCTCGTGCTGGGTGTTGCAG
CTGTCCATGCCTGGCACCTGCTTGGAGACCAGACTTTGTCCAATGTAGGTGCTGATGTCC
AGTGCTGCATGAGGCCGGCCTGTATGGGGCAGATGCGGATGTCACAGGGGGTCTGTGTGT
TCTGTCACTTGCTCGCCCGAGCAGTGGCTTTGCTGGTCATCCCGGTCGTCCTGTACTTAC
TGTTCTTCTACGTCCACTTGATTCTAGTCTTCCGCTCTGGGCCCCACGACCAA
Sequence 138

Sequence 139

CGACCACGCGTCCGGGCTGGCGAGCCCGGCTGAGGAGCCTCTTGGGTCGCACTTACCGCC GCGTCCGCTCCCGGTCCCTCAGCGCCATGGCGTGCGGGGGGACGCTGAAGCGG CCCATGGAGTTCGAGGCGGCGCTGCTGAGCCCC

Sequence 140

TABLE 1 26/467

Sequence 141

Sequence 142

Sequence 143

Sequence 144

Sequence 145

TABLE 1 27/467

GGCAGAGGCGGCGGGGGGAGGACAGCACGGCCGAGGCTGCCCAGAGGCGCCTCCTC CACACCCCCGCGCAGCACCACCGGCGACAGATTTTTTAAAAAATGGATTTGGCCAACC ATGGACTTATTCTACTGCAACAGTTAAACGCTCAGCGAGAGTTTGGTTTCCTGTGTGACT GCACGGTTGCAATCGGCGATGTATACTTCAAGGCACACAAATCAGTTCTTGCTTCATTCT CCAATTACTTTAA

Sequence 146

CCACGCGTCCGATCCTCCCAAGGCAGAGGTGTGCGGGAACCATGTCCAGCCCTACA TCCCATCCATCCTGGAGGCCTGATGGTCCCACCAGCCAGGGCTTCACTGAGGTGCGAG ATGTCTTCTTCAAGGAGGTCACGGACATGAACCTGAACGTCATCAACGAGGGCGGCATTG ACAAGCTGGGCGAGTACATGGAGAAGCTGTCCCGGCTGGCGTACCACCCCCTGAAGATGC AGAGCTGCTATGAGAAGATGGAGTCGCTGCGACTGGACGGGCTGCAGCAGCAATTGATG TGTCCAGCACGTCCGTGTTCAAGCAGCGAGCCCAGATCCACATGCGGGAACGAAATGGACA ATGCCGTGTATACGTTCGAGACCCTCCTGCACCAGGAGCTGGGGAAGGGGCCCACCAAGG AGGAGCTGTGCAAGTCCATCCAGCGGGTCCTGGAGCGGTGCTGAAGAAA Sequence 147

Sequence 149

Sequence 150

CACGCGTCCGGCCTGTTNACCTGCGGGACCCCAGGAACCTGGACTTGTTTCTCAAAG
TGGTTCATGGAGATGTCACCCCCTACGACCTGGTGCGGATGAGCTCGATGCAGCTGGCCC
CCCAGGAGCTGGCCGGGGACCAGGAGGAGAAAAGGGGCCTGAATATCATTGAGC
AGCAACAGAAGGAGCCGTGCAGACTTCCAGCCTNCAAAATGACCCACAAGGGCGAAGTGG
AGATTCAGCGGGACATGGACCAGACACTGACCCTGGAGGATCTGGTGGGACCGCAGATGT
TCATGGACTGCAGCCCACAGGCCCTGCCCATCGCATCAGAGGACACCACGGGGCAAGCAT
GACCACCACTTCTTAGACCCCAACTGCCACATCTGCAAGGACTGG
Sequence 151

TABLE 1 28/467

TGGGTGCCACAGTAGGAATGAAATGATGGGGACTTTTGGAAGCCCCTGGACTTGTGGCCC CTGTAGAAGAGCAGCTTGGGCAGGGTGTGATGGCCATCTCTGTCTCTAGGGGCCCTGTGG

Sequence 152

GTTCGACCCACGGGCGTCCGCGGGACCGCCGTGGGNNNNACATACTATGCGNACAGGCGC
GTTGNACACAANGGCCCATTCCTGTAGCCTCACACTTGACTACACATGGGGGANTCACT
CGGATTCGGNTCTCCACGTGGNNGNTCTTTGTTCTGTACTCTACGTAGCTTTGGCTTTTG
TTTCTCGTCGCAACAGGGCATGAGACTTCGTCGACCTTNGGGGTCTGTATAGTCTTTGA
CTTACTACGTGTAGGTCTCAATACAAAGTGGGANATANTCATATCCGTCCGCGAAAAGTA
ATTCTTGGAAAAATTTACCCTTGTCTCCCGCNTTATGAAACGTGAACTAAGCTCACT
TTGCCCCTGGGGCGCCTCTNTTTAACANTGTTCTTTTGNCGAAATCATCATAACCTTCAA
CTGAAAACAATGTGGTCAACAAACTGACTATGGAGGTCTTAGGCTCNGTCTCTAAGATCT
TTAACCTTGTTTATCGGCGCGTGCGGCGTNGTCCGAACGAAGAGACTATAACCCGCACTA
TAACNAAAACTCTTTTTTTAATCCCACCACCTCGTGAGGGANGGGCCCTAAGACTGAAACT
GTAGTAAGTCCTATTGATTTGCGTAGGAGGANTTAGGAAA

Sequence 154

Sequence 155

Sequence 156

Sequence 157

TABLE 1 29/467

Sequence 158

CGACCACGCGTCCGGGGACTCAGGCATGCACCACCACGCCCAGCTAATTTTTGTATTTTT
AGTAGAGACAGGGTTTCTCCATGTTGGCCAGGCTGGTCTCGAACTCCTGACATTCGGTGA
TCCACCCGCCTCGGCCTTCCAAAGTGCTGGGATTACAGGTGTGAGCCACTGTGCCCAGCC
CCTTCCTGTTGAGTAAAAGGAAGAACTTCAGGGGTAAGACACTGTACAGTGCCCAGCATCT
GGAGAGCCGCCAGCATTACCCCTGCCTTAGGAGGTAGTCGTCTCCTCATCACTACAAGGT
ATTGAAGCCTGAGGGCCCCTGGGCAGGACGATAGAGTGAGATTGCCCTGGGGACTCAGGA
AAGGAAACATGCCGTATTTNTAGGGAAGGAGCTGCTGCTGCCTCTCAGTGACTCTGGTTC
CAGGAGGGAAGAGCCGAGAGCTAGGGTTCCCTTTCATAGGGAAAACCCAGCAGGGTTTG
GGGTGTTCT

Sequence 159

CGTCCGGAAAAATATTAAACAACTCATTTTAAGATTCAAATTAACTAATTCCTGCATATA
TGACATTCCTTACATAAGCGAACACTAAACAAAAATGGCTAGAAATGTCTTTTTCT
TTTCTCTCTTTGTTGTTTAAGGTATTAAGCACCGAATTATTACATGAGACTGGCAGATAG
CTATTAATCCTCTTACAGATTTGAGAAAGTTGATTCTCAAATATTTATGCACCTTCTCCT
TCATTGTTTTCTTAAATCTGTCCTCTTAAAAAGCTTCTTAAGAGCTCAGTTAATGCTTT
TGACTTAACTAGGAGAAAAAGGCATGATAATACAGGCAAGATGGCATTGTTAGCAATTCT
GGTAGGTGGTTTTGGAATGAATCCTAAGAGGCAAGGGGATCTTAAAGGACAAGGAAGAA
GAGAGAGGGGGNGGGATCCCTTTGATCTCTTTCTCTGGNAATCTTAAATGCNTAATTTTA
CTAAAACATGTTCTCAATTCATAT

Sequence 162

TABLE 1 30/467

TTCCCAGCAGACCTCTGAGGTAGGGTACTAGTATGATCCCCATTTCGTACATGAGGAAAC TGACACTAAGGGACATAAAATAAGTTTTTGAAGTCACAAAGTGAATAAAAGGAAGACCAG GGTTTTAATTGGAAGCCCATA

Sequence 163

TAGACTTTTGCAGTGTTAAACACAGCTTCCTTAACTCTTAGAACTGGAAGTTGTAGAGCT
CTCCTTTTGGTGCCTTTCCAGCCTTTATACACACACTATTGTAGCTTTCTTAGGTTTGATAG
GTAGCGTTTCAAGTAGTTTAGCTGAGACAGNGAATGTATTAGGTTCAACATGACCTTGTG
TTTTATTTGTGTTTGCCAACAGGATGCCTTATTTGTTTGAGAAAAAAGATGTACTAGTGTC
ATTCTAAACTATCTCCTTTTTTAGGATTCTAAAGAAGTTAATCATCCTCTTTTGTTTAT
TTTACCACCATTTAGTGCCTTAAATCCTATCAAGAAAGCAGTGTTACTGCTCAATGCCCA
AATAAGACACGCGGATATTGCTATTGCTTTTTTTAGGTTAACAGGCCNACTTTTTATAC
TTAAAACCTCA

Sequence 164

Sequence 165

Sequence 166

Sequence 168

TABLE 1 31/467

Sequence 170

Sequence 171

TTTAGGGAGCCGACCCACGCGTCCGCTTGGCAAACCTCCGGGGACTGTCAGAGGAGGAGA GGAGCGAGAAGGCTATGCTTCGCTCCCGCATTGAAGAGCAGTCCCAGCTCATCTGCATCC TGAAGCGGAGGTCAGATGAGGCCCTGGAGCGCTGCCAGATCCTAGAGCTGCTCAATGCAG AGCTGGAGGAGAAGATGATGCAGGAGGCTGAGAAGCTCAAGGCCCAGGGTGAGTACAGTC GGAAACTAGAGGAACGCTTTATGACCCTAGCAGCCAACCACGAGTTGATGCTCCGCTTCA AGGATGAATACAAGAGTGAGAACATCAAGCTGAGGGAGGAGAATGAGAAGCTGAGGCTGG AGAATAGCAGCCTCT

Sequence 172

Sequence 173

CGTCCGGTGACCCATTAAGTATATTTCGTGACCCANAGTTTGAAAGAGATTATAGGTGTA GCTTTGCTAGTTTGTAATTGATATAGAACAGTGACTATCAGGGAAGNTGAAGAACGGCNA ATTGAATGTAAATCATGTCTGGATGGTGAAGATTCTAAGAATGCANCTAGGGAAAGGGCT GCAAAAAGAAGGTGGCAGACTAATGTAGAATGGTGCAACCAGATGAAGACATGGGTGGCT TTAGGAATTCCAAAGTGGCCGTGAAGGCCAGGCACGGTGGCCCACGCCTGTAATNCTAGC ACTTTGGGAGGCCAAGGTGGGTGGATTGCTGAGCTCGGGAGTTCGAGACCAGCCTGACCA ACCAGGTGAAACACCATCCCTACAAAACAT

Sequence 175

GGCGGCGGCGGCGGCGGGCCGGGCCAGCGGGCCAGGTGGGGACGCGCGTNGCGGGTGCGGAGATGCCGTGCGGGACTGGGGCCACNTTGAGCCGCCCGNCTCGTCCCCGCCTTC

TABLE 1 32/467

TGTGGGAAGGATGTCCCCGGGATGCCCGGTCGCACAACAGCGCCCCTCGGGGGCCCTA CGGCCCCTGGCTCTCCCTGGTGGCCCTCGCCCTGGACGTCGTGAGAGTGGACTGTGG CCAGGCTCCCTGGACCCTGTC

Sequence 176

Sequence 177

CCTTGTNAGGGGACACAAAGAAAAATTGAATAAACTGTATGATTTAAAAGATTATCGGGA GAGTTACCTCCCGATATAAAAGGAAGGATTTACAGAATGTGACCTAAGGTCTGGCGTAAA TGTGCACCGGAACCGAGAAGGCCCGGATTGTCATGGACGATGAGATACACCGGAATATCA TGGACATATTCTTTAAAGCGCCCTTTATCTTCAAATGCGGCACGGAAACCGGAGGCTTTG AAGAACTCAAGGAAGCGCGGCACGATACCGCCCGCAATAAACACGCCGCCAAATGTCCCG AGATTGAGCGCCAGATTGCCGCCAAAACGGCCCATAATGACGCAAAACAGCGACAATGCG CGGCGGCAATCGGTGCAAGCTGTCAGCCAGCGCCGCGTTCGGTAATATCTT Sequence 178

Sequence 179

CGTCCGGAAAACTGTTCATCTACTCACTGTAGTGCCCTCCTTGAAATGTGTGTTTTGTTCA TTCAACTAACAATATTTGGGGATCCCTGTAGTAAACACTGTATGAATTTTACACAGTCTG GCCATCAAGAAAGATCACGGAGTATATTCTAGATGGGGAGGCTACTAAGTGAATAGGAAT CACCACGCTGGGCTGTTTATTAGGTACAGTAATAAACATAAGTACTGGTTGCAAAANAAA ANAANAAAANAAAAA

Sequence 180

CCNCCGCGTCCGAAAAGACAAGACAGCATACTGTATTTTTCCTCTTAAAATTCAATGTTA
CAATTAAATGATTGTTNTCTGAGAATAAGTTAGCTTCAGCTTTCTAATCGATGTGTCCC
ACATCTACAAATTGATATGAAAAAATTATTTTGAAATGCACACTGCAAAATGGTGAGAATA
TGAAAGTTACCTGGGAATTAAATCAGAACTGTCTCCATATGACTATTCCAAGTCACAAT
CATAACTTTCTTAATAGCAATGGTTATATATGTGGCCAGATAGTATTCAGTTTCACAGTA
ATGTCTCGGTCACATAAAGATAGCANAGCATAGACATAGTACAACAATTTATTATTTCTG
CTGATTGCCAAATGTGCATAAAACTATAAAGATATATTTTCCAGCCCAGGTGACAGAGAC
CCTGTCTCCCNTTTNAAAANCTTCATGNTAAAGGTGCGGCCGCTAGACTAG
Sequence 181

CGCGTCCGCTAATCAACTTTTAAAAATAATGTTTTACGGCCGGGCGCGGTGGCTCACGCC

TABLE 1 33/467

Sequence 182

Seguence 185

GTCGCCCGCGTCCGGGCATTTGTATTTTCAACAATTGTTCTCAAATTTAGAAAAGAGAC ATCGCAAGATGGTAAAATAGGAAGCCCTGGGCCCTCCTTCCCTCACAAACACACTGATT TGACAACAGTTCATGGACAGATTCCCTTTATAAGAAACCAAGAAACTGTTAAGAGGCTCT TATACCCCAGGTGAGTGCAAAATCATCCACATCAAAGATAGCTGGGAAGTTCAAGACACC TTCTTTCCGTAATTTCTAAACTGGCACAGTACTATATGATTGAGATGAATCTCCCACAT CCAAGCTTCCTGCTGGGGAGGAGAGGGGGGGGGTATACCATTATGTCCAATGTTCCAACTC CTCTAGGAGCTACCCAGGTAGGAGGTGGGTCCAGCTCTGTCAGGCTTGTCTTAAGAGCAC TGATTGAGGGTCTGGTATTCTCTAAGTGGCCCAGGACCATAAGAGCAGTGGATGGTGCTG

TABLE 1 34/467

GGGNTNNGNNGTGGGTTACCCATAACCCCCTGGTTTTTGG

Sequence 186

Sequence 187

Sequence 188

Sequence 189

Sequence 190

CNACACATGCGGAATCATAGGCCTGCAAAGCTCCTGCTATTCACTATAACTCTGCCATGC
CTTAGGCACTTCCTAACCTAGAATTCTGAGTGAAGGACAACAATAACTATACTTTTGAT
TCAGGTATTACAAAGAAGTTAAGAGTTCATAAGGCACCTAAGTAAAGTCACATTGGTTAA
GAGTACATGTCTCCAGATACTCTTACATTTGCAAAGNAATTGCATTTCTGNATCTATGGT
CTGTAAATAAAATTGAAGAGTTGNGAGAATAAAAGCATGTTGTCTTTGATAAATTGTTTT
TACAAAACAGGCACAAGAGAGGCTTGAAGGGTCCTTGCTATCTTTTAACCTATTTTATAA
TCTTTGCTGCATAAGAAACAAATATGCTTATTTACATTCTATACTTAAACATATTATCAA

TABLE 1 35/467

Sequence 191

Sequence 192

Sequence 194

Sequence 195

CGCTCCCTGGTTTCTTGTCTCATGAANAAGAAAAAATCCTAACTGTTCTTGATGATCTTT
AAGGCTCANAATGATCTGGACAGAGGTATTTACCTTGAAGCTCATAAAGCATAGGCCTTT
CTCACTTGCAGAGTATCTTTCTGAAGCTGGACTAAATTGGTTAAGGCCACTGTACTTTTC
CACTTTGTCTTCCTGTCACACACCCTATCCTTTCAGGCTGTGTTGGGATGACAAA
AGCAGTTCTGGAGTCCTAAGGAGAAGATGAGTGGGATATGTTTCTGTGACCTGCAGTCAT
TTTAAAGTTTAGCTGTTGCTAGCTGACTCCATGTAAGAATACCTTCCAGGAATTTGATGG
CTGTGCACTCTGGCAGTGCAACTGGCATGGT

Sequence 196

CNCGCGTCCGGCCCTGATTGATGAAGCACAGTCAGTAAATCATCTCTTCATTCCCCAGTT CTTAAGCCAACATCAGCAACACTGAGAGAACATTAGATTAAAGGCAGGTATAGAAGAGAG ACTTAGGGTAACAAGTTAGTGGGTGCCTGAAGGCATGTGGGAAGAGATGTGGTAAAGGTG

TABLE 1 36/467

CTAAGCTGTTATTTTCCCTAAAAATGCTTCCCTTGCATTTATACTTATTAAGAATAGATA ATAGCTAACATCTATCCACTGCCTTTGATTCATGAGGCCCTCACGAATTGCCTCATTAGG TCTCCGACAGTATGGTACAACTACTCTTTATATTTTACAGATGAAGAAACTGAGGCTGGA CTGNTACCTTTTTGCTACACATCCTAATG

Sequence 199

AACCTGTTTTGTTAGATGTGAATCTAGGAAATACAATATATTTTTAATGTAAAAGNACTC
TTGCTTTACTTGTAAACTGATTTTCGTTTTTTTCCCCTCAGGCCATCAAGCCCTGTCGTC
CTATGACCAACAATGCTGGCAGACTTTTCCACTACCGGATCACAGTCTCCCCGCCTACGA
ACTTTTTAACTGACAGGCCAACTGTTATAGAATACGATGATCACGAAGTATATCTTTGAA
GGATTTTCTATGTTTGCACATGCCCCCCTGACCAATATTCCACTGTGTAAAGTAATTAGA
TTCAACATAGACTACACCGATTCATT

Sequence 200

Sequence 201

CGTCCGAAAAGCAGTCTTTCTTGCTCAAAGTATTAANGGTGAACAATTGAATAGAGTACT GTGGTCGGGAGACTGATTTGAGACTGCAGAGCTGATGCTGGGTAGAGGGTCTGGACTTGT ATTCATGTTCTCAGGGCAGCCCCTGGAGCAGGAGTAGCCAGAGGCATTTACAGCTG CAGAAAACAGGGAGAATGGAATCTGAGGTAGCCCTGGCCTCAAAATTCAGGCCTGGCTG TATCATTTACAGAGATTTTTCTGGAGGGAAAAAGTCTCATTTCTGAGGAAGGCAAGGNGG GCTAATCATTATTAATTTTTTTTAAACTTTTTG

Sequence 202

GCGTCCGGTTGAAGAGGGCAGGGAATAGGGGTGAGCGTGAACAGAGTCAGGCTGAT
TGCTGCAGGGTCCCTTGCATTAGTTCAGGTGAGAAGAGACCCGAGTAGGCCAGTGAGCCT
GGAGGAGAGGCTCTCTGTGTTTTAATTGGTTTCCAGCTTTTTTTCTCTATTCATGTAGG
TTATACACGTTTCTTCTGTGAATTTTTATTTAAATGATTTTTTTGTTACTGGATCTAC
AAACAGCCCAACTCCAAGGAATCTGGCATCTCTCAGTGGAGCATACAGGTGACTTCATAA
TCTAACCGCATTAGTAACTGCCAAAATCGGAAGTAATTTTCTCTCTGTTTAAAAGGCAGTG
AAACAATTTTCAGAGCAGGTTTCTTCAACTGAACAAAATATTTTGGACCTTAAAGGTGG

TABLE 1 37/467

TATGGCTCTCCTGATCAGGGAGGGACAGTGAAAGGTTTGAGCTCTGACACTGNCCAGCTCTCTGGATACAACCAAGTGACTTTTTTTTG

Sequence 203

Sequence 204

CGCGTCCGCTGGGAGGCTGTGGGGTCTGCCACCCAGCAGATCTGTGTCACGGGAGTGGCG CTGTCACTCGTTGAGGTGGCCTGGTTCCTTTGGCCTTAGGGAAGGACAAACTTCAAC TCTGAGCCTTGATTGAGTGACCTTGGCCAAGTTACCTAGCTTTTCTGAGCCTCACTTTTT TGGCNATTAGATGAACCAGAGGTTTATTTCACTCAGAATCCTGTTCACGATGCTGGTATT TGGACCAGCCTGCGGGTTTATCCTGGGCTCTTTCTG

Sequence 205

Sequence 206

CCNCGCGTCCGGTTATGTACTTTTGGAGACTTCCATTAGAAATATTGGCAAGTCCCTGCT
TCGTGGCCATAGATTTAAAAGGCCTATCAATTTTAAATGTTTCGGTCATTGAGAGCTAAA
ACATGTAACATATCACAGTGTTATTCACCAGAAATAAAAAATCAAGAGTCTGCTCAGAGT
AGGTTAATATGAGTTCCTTTCTTCAGTCCAGCTGATGGTTTTTAGTAAGATGAACTGCCA
AGGAGACAATGAGCACTGACTTCTCGATGCATGACTTCATCTTGTTAGAAGGTGGGTTGC
CGGGCCGCGGTGGCTCACGCCCGTAATCCCAGCACTTTGGGAGGCCGAGGCGGCCGGATC
ACCGAGGTNGGGGGGATCGAGACCATTCTGGCTACACGGTGACACCCCGTCTCTACTAAA
TATACAAAAAATTGCCCGGCCGTGGTGG

Sequence 207

Sequence 208

CGTCCGGGAAAACAAGGGTTTCCGCCAACAGGCTGAGAGCAAAGGAGGACGCAGGAAAA CTATTTTAAAAATTGACCCAAGAGTTCAAAAGGCATATGGAAGCATTTAATGGGGGTGGG AGGTATCCTTGTAATAAGAATACCATGCATGTATTCCCACACTGCTCTTGGTGGTCTGCA AAGTGATTTCATATGTATTTTATGTCAACACCAGCACAATGAGGTAAGTAGGACTGTATA

TABLE 1 38/467

CCTCAGAGGCATTTGGTGATTTGTCAGAGTGGAGTGTAGTGTTGGTGCCCAGATTTGA ATAGGATCATTTGAGTCTGATATCATCATGTTGCCCACCGCCTACTCAGCCTCTACACCC GATGAGGCCAATCTGCAGCTCACTACAGTCAATAGAGAACAGGCAATTAACCCTTAAGTT ATATTTTAGAAAGATTTCTGTCTAAAATAGATAAACTTGAAAGTATAGCTCTTCAAAATA ACGTATTCCTGTGTTGGCAAATATTTTCCAAACTCACAATCAACACATAGGTGTATTTCT TAGACTACTAGAAGTGGGGACTTACCCCAA

Sequence 210

CGCCNCGCGTCCGGGAAAAACAAGGGTTTCCGCCAACAGGCTGAGAGCAAAGGAGGACGC
AGGAAAACTATTTTAAAAATTGACCCAAGAGTTCAAAAGGCATATGGAAGCATTTAATGG
GGGTGGGAGGTATCCTTGTAATAAGAATACCATGCATGTATTCCCACACTGCTCTTGGTG
GTCTGCAAAGTGATTTCATATGTATTTTATGTCAACACCAGCACAATGAGGTAAGTAGGA
CTGTATACCTCAGAGGCATTTGGTGATTTGTCAGAGTGGAGTGTAGTGTTGTGTGCCCA
GATTTGAATAGGATCATTTGAGTCTGATATCATCATGTTGCCCACCGCCTACTCAGCCTC
TACACCCGATGAGGCCAATCTGCAGCTCACTACAGTCAATAGAGAACAGGCAATTAACCC
TTAAGTTATATTTTAGAAAGATTTCTGTCTAAAATAGATAAACTTGAAAGTATAGCTCTT
CAAAATAACGTATTCCTGTGTTGGCAAATATTTTCCAAACTCACAATCAACACATANGTG
TATTTTCTTAGACTACTAGAAGTGGGGAC

Sequence 211

NCGCGTCCGGTTTCNTTGGGATAGATTTTACCTATGAATTCCTCCTTAGAATTCTGAAAT
TGCTCAGATTTACCCAAATGACAGCCAGTTTCTCATTTCACATTTGGGGGCTGTAGAATC
TTCCAACATTGAGAACCTGTTTTAATCAAAGGATGCTTTGTGGAATCCTGAATGAGGAAC
AGCATGTTGCAGGAAGAAGAAGAAGAAGGATCCTGATGCCCTAATGGGACTGATTTCCTTTTGG
GGGGCAGGAAGATATATATTCGTTGGGTGCTTATAAAAGGTTAATTCCAAAGATTGTGTA
TGGTTAAAGGACTGAAAGTCACACTTAGCCTCATACTTCACTTAGATGAAAAACAAAAGC
CTTCCTCTCCCATTACCTTGTAAGATCTTCCTTGTGTCTTGTGCTGAGTGGACCTGGAA
TAATGGATAGCCCTCACTGAGTACCTAGAAGGGGACTAGGGGTGGTGATGAAAGGGGGT
TCACACCGAAGATCTAAGTGCTAGCTTGGGTA

Sequence 212

CACGCCCGTGGCCTTGCTAGAGATCCATATAATGCAGTCATGCTGTTTCTTNCTCCATA
GTATGTGGGGCATGAGGAGAGAGAGAGAGAGAGGGTGGCTTCATTGNGCAAANGNGGAATG
GCTGTGCTTTTGGGGCCAAGGAGATGCTGTCCTGCTGTAGCTGCTCTTGTAAAGGTCAGGC
CTGCCCCTNTGAGGCTCCCTTTATCCTCCTAAATTCTGGGGCATCTACATGACGCTTTCT
AGTCCACCTTTGCCTNCGCAGATCATGGCTACTAACCTGACCTTTGTCTGTACTTGAGCA
CCCTTCGCGATTTAACTTNCATGTANCGTCCGACTTCTAATATGGATTTGAATTTNTTGA
CTGTTACTGCTCANAACAATCACCCTTTTTTGAGCAGNGAGCTGGNAGGATAATTGCCGA
CAAATGACATTNGGANCCGTTTTNAACCACAGGGGGCATGGGG
Sequence 213

CGATCATTTATTAGAGTNATGTATTTAAGAACTGATAAATCATGGGCTTACCTACACAA TGTCTAGACACATGAGCAATGAACAAATAGCAAGGTCTGTGATATCTCATATGGCAATAC TAGGACTGAGATTATTTTTGTTACAATTAAATAATTGTCAGTAAAAAATCCACAGAGATCA TTTAGAATGGGAAAAAAGTCTGATATATTTTGTTTCAGATTATAATCATTAATAGGGTAC CTGACAGTTTCAAAGTTGTTTAATGTTTTTTTAGGTCTTTAACCTTCCTAATCCTACAAG GTGGTTACAATCCCACATATTATCCTTGTGTCAGGGGTCTCCAGCACCTGCCTTAGGGTC AGTGATTTGCTAGAAAGTACTTACAGAACTCAG

Sequence 214

TABLE 1 39/467

Sequence 216

Sequence 217

Sequence 219

Sequence 220

TABLE 1 40/467

ACAGCCTGGTGGAGCTGGGCGACCTGGTGGTGTCGCTGACCGAGTGCTCGGCCCACGCGG CCTATCTGGCCGCTGTGGCCACGCCGGGCGCCCAGCCCGCGCAAGN Sequence 221

GATTITGGCTNCTGCAACCTCCGCCTTAGGGGTTCAATGCAATTCTCCTGCCTCAGCCTC
CAGATTGGGATTACAGGCATGTGCCACCGTGTCTGGCTAATTTTCTTGTAATTTTAGTAC
AAAAGGGGTTTCACCACATGGGCCAGACTGGTCTCAAACTCCTGGCCTAAAGCGGATCCA
CCTGCCTCGACCTCACAAGGTGCTGCGATTACAGGGATTACAGGCTGGGATTACAGGCAT
AAGTCACCACACCCAGCCTAAAAATTAAAAGTTTATACTGTATTGTTCACATTGTGATGC
AACTTTCCATATGTATTTCCAGAATCAACTATGTATCAAGGAATATTGAAAGCATAAAAT
GAGATCATGGTGAATTCTCTCCCATTGTCATTCTTGNGGTAAGGGAATGAATGGTGG
Sequence 222

CNTCCGCAATTACTGCCTTAGGCTAGATTCCCATGAATANGAATTGCTGAGTCAAAAGGT
TGACACATTNTTTAAAGGTTAGATACATATTAGTCAAAGTTTTTAAGCAANATGCTTTCT
AAGCCTNTTTGATCTTTATAANNCATTGNTCCTTTCTAAAAATATATAACTGTCTTCTGC
GTNCCAAGGATAATTNTTTTTATTAATATGGGGCTTCTTGTGTCTACTTCCTCCCCTTTC
GTTATTTCTTCAAAATGTTTAACAAACTAATACATTTCAGAACACATTATGCTTNCATCT
TGTCACTATTTGCAGTACCTTGTATCTCCTGGACTTTATGCAATGCGTGTGTGCACAG
ATGGAATATGTTNCACCATTTGGCT

Sequence 226

GCAGTGCCGGCGCAGTTGGGAATGGGAGTGCGCTTGCACAAGCGCCGACGAGCGATA GCGACGCTATGCCCTCTCTCGCCAGGCGCCGGGTGGCGCGGGATCAACCTGCTCTCGCAG CAGCCCCTGTGGTGGCCGCCGGTGATGATGCAGGAATCGTATTTCGACGGTGGNCAGCTT CGCTTTCGATCAACATCTTCGNCGAAGTTCCGCGTGAACCGTNCGGNATCGACATCGTGG WO 01/070979

TABLE 1 41/467

CGCTGGCATCTGCCGCTATACCAATCATCGAAACCGCGCTGGAAGGTCGGGTCCAGCGCC CTGCAGAAGAGACGCCTCCAGCAGGACAAGGTGGCCTGCTCGACGAGCAGGCTACCCGAG TGTCGTTGAACAAGTATCGCCTTGGGTCT

Sequence 227

Sequence 228

CCNCGCGTCCGCAAGACAGGAGATTTCTTAAGGTCATATATGCACGATTTGCTTAAACGT CATATAGCATAACTGGAAGAATATAGAATCTACCCAAAGCCTATGCTCTTTCTACTGNAT TATTTGCTTATAATAGAGAATGCTAATCAGAATCACCTGAATAGTCTTGTAGAGGGTCAG TACACAAGCCTAGGTCCTATCCTTCAGAGAGGTGAAATGGAGGCAAATATATTCTGAAAG AGTTTCCCAGTTGATTCTGATGAGCACTCACAATTAAGAAGTGCTGCATTAAGAGCTGTA CATGGTGGCTTATGCCTGTAATCCCAGCTATTCCTGAGGCTGAGGCTGGAAGATCACTTG AGCCTGGAAGATCACTTGAGCCTGGGAGTTGGAGACCAGCCTCGGCAACGTAGTGAGACC ATGTCTTTTTT

Sequence 229

TTGGGAGATATGGCANGGTGAGAATGTTTGGGAAAGGAAGTAGAGACAGACATTGGATTT
TTGTCAGTCAANTTTCTTTTGATTTTAAATTATTTATTCATTACATTGTCTACATGGCAG
TTAATATTCTAAAACTATAAACAAAATTTAATATAGAAAAAATATTATGCTTTTCTTTTT
TGCCTTTGCATGCTCTTATTTCAAAATAGATTTAAAATTCATGGCATATTATACTAGAAA
ACAAGTCTGTCAATGATCTAAGCTTCTATCTTTAGATACTAGGAAAAAAAGAGAAAAAACCC
AAAGCAAGCAGAAGCAAGGAAATAAGAACAGAAATAAATGGAATTGANAAGAACACTTCA
GAAAATCAGTCAAACTGAAGCTGATTTTTATAAAGATTA
Sequence 230

NCTAGACTCCCCTCTCGTATCATGGATCCCAACATCNAGGNATATGGNCATTTACGTGTT GGGATCTGCCCTTGCCATTGNACACAGCTATATTCNATTGCCCCGGGNGTTGTGTATNTTT CCAAAAACGTTGAAAGGGAGGTTCAGAAGTATNCAGTTATTNGTATTATTAGTCGTTTTG AAACTGAGTNGAAAGACTCATTNANGAAAGNTCCATATGCCTTCTTGTCTGTCTATGGCT GGNNTGCTCNNGAGAAAAGTCCNCANTTATACAATTGTA Sequence 232

TABLE 1 42/467

AATACAAAAANATTGGCGGGGTGTGGTGGCAGGTGCCTGTATTCCCAGCTACTTTGGAGG CTGGGACGGGATAATTNCTTGAGCCCCGGAGGCGGGGTTTCCGGTGAGCCCGGGATTGC GCCCCTTGCACTACAAGCCTGGGGCACANAAGCGAGGACTNTGTCAAAAAAAAA Sequence 233

Sequence 234

Sequence 235

Sequence 236

Sequence 237

TGTTNACCTTTGGGATTACACAATACTTGCAATCCAGCTCTGCCATGGGGGACATCATTA CACAAAGCACTCCTCACCAGTAGTCAGATGGCACTTGATAGCTACAGGCATGTGAATATT CTTTACTGTCAACTTTTGTTGTGATTTCACCTAAAATATGATAAGCTCCTTGAGGATAA AGGCTAAGTCTTACTTCTTCGTATTTCTGGTAACCGCTTGTACCAAACACCTGCCAAGCA TTGTTGATTGCACCTATGAGGAGGTGAGAAAGTGCCAGGCCGTCATGCCCCTCTATACAA

WO 01/070979

TABLE 1 43/467

Sequence 240

Sequence 241

TABLE 1 44/467

Sequence 242

Sequence 244

Sequence 245

TTCCGTACCTAAGAATTGTACCCTTTCATAACAGCACCACTTGGATATGTAGAAAGAGTT
TGTTGTGAGATCAGATGTAAAACAAATAAAAGTTATTCGTGAAATGATATGGAAGACTGG
GATTAGAAACTGTGGCATTCAAGAAGCCAGTTAAGCTGTTCTCAGAATTGACAGAGATTC
TAGAGATGGTGTAGTGCAGATGGTGTAGTGCAGGGATTCTCAGCCTCACTGCACATGGTA
ATCTCATAGGAAAATTTTAACAAGGACAGATGCAGAAATTCTTATTAAACTGTCAGGACT
GAAGTCCAGAGGTCACTATATTTTAAAAAGGTCTGCAAGTGATTGTAACATGCATCTATG
GAGGAAAACATCANCGTAGGAGAAAAAGGGAAAACCAACTGGAGTAAAGGCTCTGTC
TTGAGCACTGTGCTGGCTCCTGTCATTCTCCATCTTTTTTATCTTCATAGTAAGTGAGA
TGGGTTTGACAAATAGGGA

Sequence 246

GCGTCCGGNGTAACTTGAACNAAAGTATTCTCCTTCTTCTGTATATTTGTTCTCAACCCC

TABLE 1 45/467

€7

Sequence 247

TGTCGACCCGCGTCCNTNGTATTTATAAANATAATNCTGNTAGATAAATAAGTGATTCA
TATTTGTCAAANCTATTTTAAAATTTCAATATTTAAAATATTNTTGAATCACTGGGTGT
CGNTAAGTGGCATCATNNATGAGATTTGATTCCATGTACCATATAATNTTAGATTGGTCC
TNTCTCACCCCTTTTAAACTCCTTCAAGCATTGCTATTACTGGGGTTGCCTTTGGGAAAA
CTTACTTCTAGATACTACCATATATCTGAAATAGTAGAGGTGGATGTTAATAAAATTCAT
AAAATNATCATGTATTACTTTTTTTGATTTACCACTGGAAGGAAATACAGNCATGTGCAA
TATAATGACCGTTTTGGTCATNGAGACCCACATGTGTGACAGTGGTCCCATAAGGATGNG
GCTGAAAANNTCCTGTTGCNGCCTAGTGACACTGTAGCCATNGNAACNCCATAGCACGAC
ACGTNACTCACCTNTTCATGGTGATGCTGGTGT

Sequence 248

Sequence 249

Sequence 250

TCGACCACGCGTCCGGGTGAACGTGGTCACCAAGGCCATGGGTACCCTGGGGGTGAGCTT
ATCCTCCTGCAGCGTCCCTGGTTCCAAACCCACCTTCGAGCTCCAGCCGACGAGGTGGA
GCTGGGCCTGGGGATCCACGGGGAAGCTGGTGTGCGCCGGATAAAGATGGCAACCGCCGA
TGAGATTGTGAAACTCATGCTCGACCACATGACAAACACCACCAACGCGTCCCATGTGCC
TGTGCAGCCCGGCTCCTCAGTTGTGATGATGGTCAACAACCTGGGTGGCCTGTCATTCCT
GGAACTGGGCATCATAGCCGACGCTACCGTCCGNTCCCTGGAGGGCCGCGGGGTGAAGAT
TGCCCGTGCCCTGGTGGGCACCTTCATGTCAGCACTGGAGATGCCTGGCATTTCTCTCAC
CCTCCTGCTGGTGGATGAGCCTCTCCTGAAACTGATAGATGCTTGAAACCACTGCAGCAG
CCTGGCCTAACGTGGCTTGCAGTCTTCATTACTGGGCGGAAAGCGGAGCCGGGTAAGCCC
CTTGCCGAGCCCCAAGAAG

Sequence 251

TABLE 1 46/467

CCGGTGAAACCTGGAGCTGAAGTGAATTCTCTTAGAGTATATTTTGAAACTGTACTAGGA CTTTAAACACTTTTGGAATTTAAAACAGCCATAAAAATTCTTGTTATACTGAAGGAGTTC CTGAGGCAGTGTGCCTCTCATTTTACCACCTAAAGTTGCCATAGAGGTCCAAGGAGACAC TGCTGATAGCAGAAAGTCTTCCAGAAAGAAATTAGGCGACCCACACCAAGCATGTATGGC TTTGAGTCTTACAGATGGCTTTTTAATAGTTTAGTCTCTTAACCTAAGGAAGTTTCTGAA GTTCCGGTCAGAGAGTCTAAAAATTCACATTTTACCTAATAAATGATAATGAGGCTATTT ATCTTGTCTGTCTGGATTTTTTCACTTGACATTTAATGAAATATCCCATATTACCTATAA

Sequence 253

CCCCCGCGTCCGAGATAATGCTGTTTGCTTCCGGCCGCTGTAAATCATAGGTGAAAACC
AGTAGCANGTGCTCACTCAGTGCCTCCCAGAAGCGGTCTGCGGGTCTCAGCTGGGCTGGG
GGCAGTTTTCATTGGGCAAGGCTTGGGCTTAGCTTCGAAGCANGGGCTGGGAGAGGATGG
ATGGGGGTGTGAGAGCAAAAGAACCTGGCTTTGCAGTGATGGCANCCCACGTTCAAA
TNNNAGCTCACCACTGACCNGTCGNNTGACGNGCGCCAGGNGTTAGGAGACTGNAACTGN
TTNTGNGTNNNGNNTCCGGNCGTNCATNNNNNCTGCTCAGCATACANANCCTNTTNCTNA
TCNTAATCCTCATACNCATGNCTGNNNACTNTACACTGTTCTACTTATCAATGACAGGTC
AAAAGTGTTATCATNTGTGACNTAGAATGAGTGAAAAATC

Sequence 254

Sequence 255

GCCCACGCGTCCGCAAGANAGCTCCTCAGATTTGTCATAGACTATATTTAAAGAAAGGCC ACATTTTTCTTATTTAAAATGCATTAAACAATGCANCCAATTAAAAGAACTGAGNTGGAT TTGTACAAAAGCAGGGACTAGGTCTGNTTTGTTCACTGCTATATTCCCAATGCCTAGAAC CATGTCTGGCAAACATACTGGCATGGGAAGAACATTTCCATAACCCCTGAATGTTCTGTG CCCCTTTCCAATTAATCCCTACCCTCAGAAGCAACCACTATTCTCATGCTTATTACATTA GTTTTGCCTCTTCTTGACTTTCATATAAATGAAATCATACATCTAANAAAAAANANAAAA

Sequence 256

TCGACCCCGCGTCCGATTTGATATAAATAGTTATGTTACTCATATAGAAATCTCTTCCCC ATTACACACATACAAACATTTATCTATGAGTGGCTTATAATTGCAAATAAGATGTAAATC ATGCTCATGATCATTGTCAAAATTGTGAAAGATTTTTTTCTATACCTCTTTTAGGTTTGT



TACTTCTACTCCCAAGTCACTAGTTTGCTGAATTTAATTGAGTTAAAGAATTGTATCAGT CCAGAATTGAAGGATGGATAAAATGAGAAAGAGAAGTAGTTCTTCATATTATTAAAATAA AGAGTTAAATTAGACACTTTGTTGGACTCTTTGGTCTTAATAATTCCTACTCTTTTTGAG GTCCAAAAGTTTTGTCTTTGATAAATATAATTTTAATGGG

Sequence 257

AAGTTGGGAAAATAATTCATGTGAACTAGACAAGTGTGTTAAGAGTGATAAGTAAAATGC TGAGAGGACAGGATAGTGCATGTTCTTTGTCTCTGAATTTTTAGTTATATGTGCTGTAAT GTTGCTCTGAGGAAGCCCCTGGAAAGTCTATCCCAACATATCCACATCTTATATTCCACA AATTAAGCTGTAGTATGTACCCTAAGACGCTGCTAATTGACTGCCACTTCGCAACTCAGG GGCGGCTGCATTTTAGTAATGGGTCAAATGATTCACTTTTTATGATGCTTCCAAAGGTGC CTTGGCTTCTCTCCCAACTGACAAATGCCAAAGTTGAGAAAAATGATCATAATTTTAGC ATAAACAGAGCAGTCGGCGACACCGATTTTATAAATAAACTGAGCACCTTCTTTTAAAC AAACAAATGCGGGTTTATTTCTCAGATGATGTTCATCCCGTGAATGGTCCAGGGAAGGAC CTTTCACCTTGACTATATGGCATTATGTCATCACAAGCTCTGAGGCTTCTTCTTT

Sequence 258

GAGTCGACCCGCGTCCGCTCTGGAGGAAGCATAGATTAGAATCATGATTTTATCTATT TTAAGAGAATAGAAGAACAGAAGGGGTTACAATCTTGCAATATTATGCAACTCTTCTGCT CTAATATATCAAAAACTTGATGATCCAAGATCATGCAGAACAGCTGAGAAGAAATCAAAG TAAACAGTGTACCTTGCAGCCAACAGATCCTGCCAATATGAGATTAGAACTCTCCATCCT AGCAAAAAAAAAAAAAAA

Sequence 259

CTGGTACCTGCGAGTCGCTGCAGCAGCTGTGGCAATTGTCACCTTCATCCAGGCCCATCC CGCTTTGAGGGCCTAGAGAGAGTGGGCCAGAGGTTAACCCCCGATTCATCTGCCTCCCCA CGCTGGGCATCTGGGTGTCCCGGGGCATTCCCCCGCTGGTCAGACAGGTTTTTGGGCCAG GGCGGGGCTGACCAGGGTTAATTAGAGGGAACTGGCTAGGAGGGGGCTGGGGAGGGGGCTG GGCAGAGTCCAGGCCTNCAGAGCCCCTGGGACACAGCAGGTGTGTGCTGCCATGGGCCGG GGCTTGAACTCTGCCAGACTCAGGCGCCCAAAAACGGCGCTTGCGACCTCAGGTCCAGAAG **CCCCGGCAGCAAGCTG**

Sequence 260

TCGACCCCGCGTCCGAAACTCTGTCTAGTCTAAACTATTATTCTATACTTCTCATCTCTA ATGCTCTGTTGCCCAGGCTAGAGTGTAGTGGAACAATCATAACTCACTGCAGCCTCGAAC TCCTGGGCTTAGGTGATCCACCTGCCTTGGCCTCCTGAGTAGCTGGAATTCCAGATGCAA GGCACCATGCCTGGCTAACTTTTTAAAATTTTTCATAGAGATGGGGTCTTACCATCCTGC CCAGGCTGGCCTCGAGCTCTTCACCTCAAGCAGTCCTCCTGCCTCAGCCTCCCAAGGCAC TGGTATTGCAGGAGTGAGCCACCACGCCCAGACCAAAATAATTNTTTTTAAAGCAAGAT CCTGTACTCTGNACATAGGATCCACAGAAAACTTCTAATGGATGGTTATCCCTGNGGN GGGAAACTGGGGGACAGGGAATGATGAAGCAGGAAAATTTTTACTGGATAAACTTTAGTT CTGGTGGCTCTTTTTCTTCTATCATGNGNATGGTAACTT

GTCCCGCAAAGCCTTTAAAAAGAGTCCGAATTTCACTTTTCACCTTTTGTAGATGTGCAC GTGTAGCTGTAGAGCTCATACTTACGTTTCACATGGCATAGTTGATGGATATGTAGGTGT AAAGTTTATGGTAGTGGACAGGCTGAGAATGGTGTATCTGTGACAAAAAATCTGATGGAA GTGATATTTGATATGAAAGTGAACATTTTCTTAGTTGGGTGTTTATAACTTTTTTTG GTAAATTGTTTTTAGTTTTTATCCTTATTTTACTTATGCTTGGCAATAGATGGTCTTTTT GGTTCATTCTTTCTCCACTCCCATTTATTTGTTTTCCATTTTGTAACTTCTATAAAGCA

TABLE 1 48/467

GATAAAAATCTGGAACTTCTAGATCTGACCTTCATGCCTTGTCTTTTCTATGGTACTTAT
TCTTTCTGTCTCCCTTCTCATTTTGGATTGGGCTTATGAGAGAAATCTTGGGGTTGATCTT
CCAGCTCACTAATTTGATATTCATTTGTGTCTCTTCAGTTACTTAGCTTGCCTGAAAACT
TTTTTTTCAGCAATTGTGTACTTAATTTTCATA

Sequence 262

Sequence 264

Sequence 265

Sequence 266

Sequence 267

TABLE 1 49/467

AGAGCAAAAACCTATATATAAAGCAATTTTTAAGATTTTGGTTCTATAAGGGTAGAATGT TCGATCCATTAGTGTATTCCCAAAGTCCTATACACATGTCAAGATCGGGAAAGCTCACAC ACACAATAATGCCCAAG

Sequence 268

Sequence 271

ACCGCGGNGGCTTCATGCAAGCTGTGGGCATGGNCAACGATCACGAAAATCATTNTTCCT
TTAAATAAAATACAATCCTATNNAAAGGAGTNCTTCCATGAGCAACAATCAAATACGTGC
TTATGCTGCGATGCAAGCAGGTGAACAACTGGTTCCTNATCAANTTGACGCAGGCGATTT
ACAAGCCCATCAAGACGAAGTCAAAGTTGAATATTGTGGATTATGTCATTCAGATATTTC
AAGTGATTAATAATGATTGGCCGATCATCTACTTATCCTGTAGNCGCAGGTCATGAAATC
ATTGGAACCATCACTGCTCTTTGGTTCATGAAGCGAAAGGACTCAAAG
Sequence 272

Sequence 273

TABLE 1 50/467

Sequence 274

Sequence 275

Sequence 276

CCCTTTCGAGCGNCCGCCCGGGCAGGTACGCGGGGAAATGCAAAAAAATCAAATCAATTT
AATAGAATACATCAGAGATGTTAAAGATTTCCCAATTGAAGGATTGTATTTAAAGATAT
TTCACCACTTTTAGCAAATGGAGAAGTGCTAAATTACACAATTAATCAAATGGCTGAGTT
AGCTAAAGATGCAGATGTTATTATAGGTCCAGACGCAAGAGGTTTCTTGTTTGGGACACC
TACTGCAGCTTTTTTAAAAAAACCTTTTATTATGGTAAGAAAACCTAAAAAATTACCAGG
AGACGTTATTAGTTTTGAGTATGATTTAGAATATGGTAAATCAACTCTAGAAATCCAAAC
TAATATGTTGAAAAAAAGGCCAAAAAGTAGCAATTATTGATGATGTTTTAGCTACTGGCGG
AACAATGAAAGCGATTATTAACTTAATCGAATCTCAAGGTGCTGGTTGNTCATAAAGTAA
TCTTTTTACTTGAATTANGATTTTTAAACCGGAATTGAAAAACTTAAAA
Sequence 277

Sequence 278

CCCTTAGCGTGGTCGCGGCCGAGGTACAAGATAGTNNTCTCAGTAAAAGGTCTATTATCT AACTTGCCAAACTTGTTTACTGAGAGCCCTAAGGAACTAAAACTGCCATAATGCCGTGCA CAGCTTGAAAAGCAATTAGAGTAAGCAAGATTAGTTTTTCCTCCCTTCCAGTTCCTCAGC AGGCCTGGAGGCCCAGGAGGGAAGGAAATATAAGANCCAACAATAAAAATAGCACT AGCAATAANAAGAATGCCATCCCATGGAGCACACCATAAT

Sequence 279

CCGAGGTACTAAACTCTNTTTAATGNNCTAACGTCATATTTTTTAAGTTTTTCAATTCCG TTTAAAAATCCTAATTCAAGTAAAAAGATTACTTTATGAACAACAGCACCTTGAGATTCG ATTAAGTTAATAATCGCTTTCATTGTTCCGCCAGTAGCTAAAACATCATCAATAATTGCT

TABLE 1 51/467

Sequence 280

TATTTGGTGAAGATCAGCGTTATCAGCATTTTCTACGATTAAACGCTGGCCATGCTTTGA CTGATGAAATCCGCCAAGCTATTCAGCAGTTGGCGGATTGGGTCAGAGAAAGTCTCAAGT CGAAATTGAGTTAGTCGAAGTCTGCTTTCAATACGATGCGATAACGTGCTTGACCTGAAT GAAGTCGCTCAATGGCATCGTTGAGCTGTGACATAGGATAGAGTTCAATTTGCGGGGCGA TATTTTTACGTGCTGCAAATTTGAAGAAGTTGACGAAGTGCTAAAGGAGAACCCGTCGGT GAACCTGTTACTGATTTGGCACCATCAATCAAAGCACCCGACTGAAACTGGGAATAGGTT CTAAAAGTCAGACCTAGAAAAATG

Sequence 281

CGANAAGCANGATTTTNAATTNTTGCAGCCCGGGGGATCCGNGGAGNGGGGAGAGCCCAC CGCGGGGGAGCGCCAACACGACNNAGAGCGAGNCGNAATACGCGCGCACACNGACCGCNG ANNAACAAACGNNGAGACGGGGAAAACCCNGGCGNCCNCAACAAAAACGCCCGNGCAGCA CAGNCCCCAAAAGCCAGCNAGGCGGAANANCGAACAGGCCCGCACCNAGCGNCCCA ACAGNAGCACAAGCCCCGAANGGCGAAAAGGG

Sequence 283

Sequence 285

CGTCCGTNAGGCCTGTNCTTACGGCTGGGTTTAGAAACCAGCCCATTCAGAAAGACTGAA TCAGAACATGGATNAAGTGAACTNATTCTAAGATGACTCGNNTATCCATGTNGATTAATC

TABLE 1 52/467

TNCTGGNTCATAATAGGCCTCTTCCCTTTGATTGAAGGGTCACGTNTAAGTATANAAAAC
ATAAAACTGTAAGGTAGAGGAAGCGAAGGATAGCTTNGTATTAATGTTGCGTTAAAGCTT
CAGAGACAAGAACAAGAACACTCCTCCCACGTGACAGCATTTGAATAGGAGGCGGNGGGT
GCNGCAGCCTGGGCAGCTTCAGTCCCGATTTACAATAAAGTACCTTGNGNGTNATTAGTT
CTTAAATGTTTATTTAGAAATGGCATTGATGTT

Sequence 286

Sequence 287

Sequence 288

Sequence 289

NGGAAAGCCGGCATAAGTGACATNGTTTGGGCAGTTGCCNGCTGGACTGAAGGGCNAACC CANACCACCTTAAGCCATAAAAGCCCGTGACACTGCTANCNAAGGTGCCTTGCCCACCGC TTTGCCACCNGTCCCGGAAATGNAAAAAAAGTCGCGTGCCNTAAAAAAGCTGCCGGAAGG NCCTGGGTGNACNTTTGGGCCACCCCCACCCCGCTGGCAAGGNCTTGAATTGNGTNACNC CAAAAGACGCCCANGCCGGACCTTGGNAAANNATTGTTNTTTNGGGANAAAAAAAAATG GANCCCGNTGGGGGAGGCCCTTGGGGGCATTGNGNAAGCCCCCGGAGGTTCCCCGNTGT TGGCNGGGGTCAAATTCAAAGGCCAGTGGTNGGCCACCCCGGGGAACCTGGNNGCTGTTG CAAGNACCNNGGTGGGGAACCGTTTCAAGGAATACCCCAACCAACCCANGTAGCCACCTT AAGGTAATTTGGCCCACCTTGCCCACCANAANGNGCCATTGGGGAAGAAACCACCAAAAA CGTTCCCCCGGGT

Sequence 290

WO 01/070979

PCT/US01/09126

TABLE 1 53/467

AAGACCCGAA

Sequence 291

TCTTGCAGACTCAAGCTCCGCGCGCAGCCGCTCCTGGTGCGGGCCCACAGCAGCCTGGGCCCCGGNTCGGCCCCGGAGCCCCTGGCCTGCGACGACTGTTCCCTTCGATCGGCCAAATCCCCTTCAGCCTCCTGGCGCCCATCCGCAGCAAGGACGTTCGCAGCAGGAGTTACCTGGAGGCAGCCTNCTGGCCAGNGGGGCCCTGCTGGGGGCAGACGAGCTGGCCCGCTACTTCCCAGACCGGTACGTGGCGCTCTTCGNGGCCACCTGGAACATGCAGGGCCAGAASSequence 292

NGGCCCGCCCGGGCAGGTACTAAACTTTAATTAATGAGCTAACGTCATATTTTTTAAGTT
TTTCAATTCCGTTTAAAAATCCTAATTCAAGTAAAAAGATTACTTTATGAACAACAGCAC
CTTGAGATTCGATTAAGTTAATAATCGCTTTCATTGTTCCGCCCAGNTAGCTAAAACATC
ATCAATAATTGCTACTTTTTGGCCTTTTTTCAACATATTAAGTTTGGATTTCTAGAGTTG
ATTTACCATATTCTAAATCATACTCAAAACTAATAACGTCTCCTGGTAATTTTTTAGGTT
TTCTTACCATAATAAAAGGTTTTTTTAAAAAAGCCTGCAGTAAGGTGGTCCCAAACAAGA
AAACCCTCTTTGCGTCTGGGACCTATAATAACCATCTGCATCTTTAGCTAACTCAAGCCC
ATTTGATTAATTGGNGTAATTTAGCACTTCTCCATTTGCTAAAAGGTGGTGAAATAATCT
TTÄAAATACAATCCCTTCAAATTGGGGAAATCTTTTAAACATCCCCCGGCGGTACCTCGG
GCCCGCTTCTAGAACTAGTGGGGATCCCCCGGGCCTG

Sequence 293

GCTCCCGCGGTGGCGCCCCCGGGCTGGTACGCGGGGAAATGCAAAAAATCAAATCAA
TTTAATACGAATACATCATGAGATGTTAAAGATTTCCCAATTGAAGGGATTGNNTTTAAA
GATATTTCACCACTTTTAGCANATGGAGAAGTGCTAAATTACACAATTAATCAAGTGGCT
GAGTTAGCTAAAGATGCAGATGTTATTATAAGGGCCAGACGCCAAGAGGTTTCTTGTTTGG
GACACCTACTGCAGCTTTTTTAAAAAAAACCTTTTATTATGGTAAGAAAACCTAAAAAATT
ACCAGGAGACGTTATTAGTTTTGAGTATGATTTAGAATATGGTAAATCAACTCTAGAAAT
CCAAACTAATATGTTGAAAAAAAGGCCAAAAAGTAGCAATTATTGATGATGTTTTAGCTAC
TGGCGGACAATGAAAG

Sequence 294

Sequence 295

TATAGGGCGAATTGGAGCTCCCCGCCCGNGGTCCCAAATGGAAGTGTGAAAACCANGGCC CATCCCCNNTTTTNTAGAGGGGTGGTAAAAAATAAACCCANANATCAAGGGGAGAAAGG AAAAGGATGAAAGGACAAACTGCCAAAAAAATTNCCCAAAGTGGCGACTTTTTTAANTN TGGGAGCCAGAATTCTGAGGGCTTTGCATTGTCTTTGCAATTCNCTCAAGGAGCCTGAAA TTGAAAAAAAATGCCAACAAGGCCAAATNAACTACTTTTTAGGAGGGGGTTTTGGAGGTC TTGGGAAGCCTCATTCCCNTTCAACCNNTCNAATTCTGGGAATGGGGAAATGGAAAANTTNCT NCACCCAAGGTTGGGTACCACAAAAAATTGTAATGGACTGGTATTGGCAAAAAGG Sequence 296

GGCGAATTGGAGCTCCCCGCGGTGGCGGCCCGAGGTACAGGTGGGTCCCTTTTCAGAGGT TGGGCCTTCTAGACCTCACCTGTTCTCACTNCCCTGGTTTAAATTCAACCCCAAGCCATG

TABLE 1 54/467

Sequence 297

Sequence 298

TAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGNCAGGTACGCGGNGAAATGCA
AAAAAATCAAATCAATTTAATAGAATACATCAGAGATGTTAAAGATTTCCCAATTGAAGG
GGTTGTATTTAAAGATATTTCACCACTTTTAGCAAATGGAGAAGTGCTAAATTACACAAT
TAATCAAATGGCTGAGTTAGCTAAAGATGCANATGTTATTATAGGTCCAGACGCAAGAGG
TTTCTTGTTTGGGACACCTACTGCAGCTNTTTTAAAAAAAACCTTTTATTATGGTAAGAAA
ACCTAAAAAAATTACNAGGAGACGTTATTAGTTTNGAGTATGATTTAGAATATGGTAAATC
AACTCTAGAAATCCAAACTAATATTTTGAAAAAAG

Sequence 299

Sequence 300

Sequence 301

Sequence 302

AGGTACTTTGATATCTNCGCCCTCTCGTGTGTTCCTTGTGGNGNTAACCAGAGGCAAGAT GCCCGAGGAACTTCATGTGTATGTCTACCAGGATTTCAGATGATCTCTAATAATGGAGGA CCTGCTATTATTTGTAAAAAGTGCCCAGAAAACATGAAAGGTGTTACAGAAGATGGCTGG AACTGCATTTCTTGCCCTAGTGACTTAACTGCCGAAGGAAAATGTCACTGTCCCATTGGC CATATTTTAGTGGAAAGAGACATTNATGGAACATTGNTGNCTCAAGCAACTNGNGAGCTC

WO 01/070979

TABLE 1 55/467

PCT/US01/09126

TGNGATGGAAATGAAAACTCTTTTATGGTAGTAAATGCTTTAGGAGACAGGNGCGTNCGA TGTGAGCCAACATTTGNTAATACCAGCAGGTCCTGTGCATGTTNCGAACCTAACATTTTA ACAGGGGGATTATGTTTCAGNAGCACAGGGAATTTTTCCTTGTACGTANAATTTCACCTG CACGTTATGGAGAAGTTTGGCAT

Sequence 303

Sequence 304

GCGGTGCCGAGGTACCTTNTCCGAATGCACCTTNAAAGCGGGTATTAGCCTATACA GGCTGTTTTAGTCGAATGCAGACCATCAAGGAAATTCNNGAATATCTATCTCAAAGACTG CGCATTAAAGAGGAAGATATGCGCCTGNGGCTANTCCANAAGTGGAGAANTACCTTACTC TTTCTGGGNTGATGAGGAATCATAAATCTGGAATATTTNGAAAAATCCAGGATGAACAACA C

Sequence 305

GCNGNCGCGGGGAAATGCAAAAAAATCAAATCAATTTAATAGAATACATCAGAGATGTTA
AAGATTTCCCAATTGNNGGGATTGTATTTAAAGATATTTCACCACTTTTAGCAAATGGAG
AAGTGCTAAATTACACAATTAATCAAATGGCTGAGTTNAGCTAAAGATGCAGATGTTATT
ATAGGTCCAGACGCAANGAGGTTTCTTGTTTGGGACACCTACTGCAGCTTTTTTAAAAAA
ACCTTTTATTATGGTAAGAAAACCTAAAAAATTACCAGGAGACGTTATTAGTTTTGAGTA
TGATTTAGAATATGGTAAATCAACTCTAGAAATCCAAACTAATATGTTGAAAAAAAGGCCA
AAAAGTAGCAATTATTGATGATGTTTTAAGCTACTGGCGGAACAATGAAAGCCGATTATT
AACTTAATCGAATCTCAAGGNGCTGGTGNTCATAAAGTAATCTTTTTTACTTGGAATTAG
GGATTTTTNAACCGGAAATTGGAAAAA

Sequence 306

ATAGGGCGAATTGGAGCTCCCCGCGGTGCCGCCCCGGGCAGGTACGCGGGGCAATTA
TGAAATTATTGCAGAAAGAAGATCACTCTCACCTGATGAATAAGTGTTCATAGGTNAAG
GCTACAAAATACTAATTTGTTATTTTTAATAATAATTTTTTGTTTTGCTGAGAAAGTG
GATTTACCACTTTTTTATTTTTTAATCCAAGGAGGAAAAATTATTTCCAAACCAAATCCT
AAAAATTTTTCACGTTCTAAACCAGTTCAAGAACATTGAGTAAACAGAAATATTCCATTT
GTCAAAGTTTTTCTTATCGGCTCAGATAATGAAAAAATTGGGATAATTGAAACAAGAGA
GCTATTGAAATGGCAAAAGAACAAAA

Sequence 307

CGAATNGGAGCTCCCCGCGGTGGCGGCCGAGGTACGCGGGGGCAGCAAGCGGACGTGAGCGATAATGGCGGATATGGAGGATCTCTTCGGGAGCGACGCCGACNGCGAAGCTGAGCGTAA AGATTCTGATTCTGGATCTGACTCAGATTCTGATCAAGAGAATGCTGCCTCTGGCAGTAA TGCCTCTGGAAGTGAAAGTGATCAGGATGAAAGAGGTGATTCAGGACAACCAAGTAATAA GGAACTGTTTGGAGATGACAGTGAGGACGAGGGAGCTTCACATCATAGTGGTAGTAAA TCACTCTGAAAGATCAGAACAATAGATCAGAAGCTTCTGAGCGTTCTGACCATGAGGACAA TGACCCCTCAGATGAGATCAGCACAGTGGATCAGAAGCCCCTA

TABLE 1 56/467

CCGCGGTGGCGCCCCGGGCAGGTACTGACCCTCCTTGATGGTTTACTTTGCAAGCTA
TGGTGACCTCCGCAAGTTGTGTCTGGGCCCATCCAGGGCTCTGACTAATTGTATTCAAAT
CAAGGCAGGAGCGGCCAGCTGGCGTTGACTTAACCCAAGCCATTTTATAAGCCTCCCGAT
CATTTTTAAGCCACTCTAAGTCGTGTAGTAGGATCTGGTCAGAGTTATGTATACTCTGAT
GGGCATGTGCTGTGTCGTCTAAAATGTCCAGAAGTTCTGAAACACTTTTAGATCTTCCAG
AATTTCTTGAGGAAGTCTGCCTAAGTAACTGATGCACATCAAGTTCATCACCGGAGGAAT
CAAAAGAATTTCCATTTTCTATTTCTCTACAGAAAAGAAAAGGATCTTCCTTTAAGATGG
AAATATTATTTCTCTTC

Sequence 310

Sequence 311

TTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGNCAAGGTACCTGACTGTGGC TCANATCTGCGTCGCAGCAGCAGAGAAAATCACTCCATATCCGATGAGAGGAAGGGT GGCACAGANATGGTGTCTACAATTAGAGACATTTCTGACTCCACCTTAGCCTAAGCAAAC TTTATATACTGAGTAACATTTGAAGGTTGTCTTTTAATGGTGGGGGGGTGNTTTTTCCTTT TTAAACTACAGT

Sequence 312

CCAAAANGGGNCCTGGGGCGTGGTCACGGCCNAGGTACAAAATTATGACTGTTTTAGCTC CAGGAACAGATTAAAAGTAATTGAAGACGTTTTAAAATCTGTTTTTGATGCTAAGAACA TCGAAAAAAATTGAAAAACTTGAAAGAACAGAGTTAGCATACGAAATTAANNAGCACAAA CAAGGAATTTTTGTTTTAGCTAACTTAAAATCTGAGGAAAGTTTAATCGAAGAATTTGTC AGAAGAGTAAATATTCTCAAAAAAACAAGTTTTAAGATTTTTAGTTATTAATCTAGATTCT GAAAGAGGGAATGCACAAAACTTTCAGACCTAGAAAAAAATGATAAACACAAATTTTTCTCT TCTAAAAAAACCA

Sequence 313

AATNGGGCCTNGCGTGGTCACGCCCAGGTACNAAATTATGACTGTTTTAGCTCCAGGAAC AGATTAAAAGTATTGAGCNTTTTAATCTNTTTTGATCTAAGACATCGAAAAATTGAAAACT TGAAAGACAGAGTTAGCATACNAATTTAAANGCACAACAGGATTTTTTGTTTTACTAACT TAAATCTGGGGAAGTTTAATCNAAGATTTGTCAGAAGAGGTAAATATTCTCAAAAAACAAG TTTTAAGATTTTTAGTTATTAATCTAGATTCTGAAAGAGGGATTGCNCAAAACTTTCAGAC CTAGAAAAATTGATAAACACAAATTTTTCTNTTTTAAAAAA

Sequence 314

NGGGCCTNGGNGTGGNNACGANCCAGGTACTTTTACCAAAGAATCTACTAGAACTCTCTG CTATTCAAAACAAAGAGCTCATACTTGTTGGAGTAGGGAAAAAATTAGAAATTTGACCAA AAGATAGATTCAATCAACTACAAAGTCAATTCCAAGATGCTGNTAACATCGAAACTCTTG AAAAAGAACTATTANAATCTGGAGTTGAACTTTAATGGATCATATACCTGNTTTGCTTGA TCAAGCGGATTGNTCAGCTTAATATTAAAGAAGATGGNATCTATTTAGATCTTACTTTAG GACGNGGNGGNCATTCGAGNCAAATTTTAAAAAAAACTTACTA

TABLE 1 57/467

CCCTTTCGAGCGGCCGCCCGGGCAGGTACTTGTCCATAATTTGTGAATATATTAACTAAT
TTTTCTTTTGAGTATTCATTTACTAACTCATAAGCTGAAAAGCTTTGAGCTTGATTCATT
CTCATATCCAAACGAGCTTGTTTGTTGTATGAAAATCCTCTATTGGCTTGATCTAACTGA
GGTGAAGATACTCCTAAATCAAGTAATACACCATCTACTTTGTTGATTTGAAGTTTTTT
AGTTCTTGATCAAAATCTTTAAAATCAGATCAAATAAATTCAATATTTGAAGAAATTTTT
AAGAGTTTTTCTTTTGTTTGTTCAATTGCTTGTTTGTCTTTATCAAAGACTA
Sequence 316

Sequence 317

Sequence 318

Sequence 319

CCCTTAGCGTGGTCGCGGCCGAGGTACGCGGGGCAATACGTAGAGATAATAACAGTTTTT
TAAAAAACTTAATATTTGTTATTGAATGTATATTTTTGAGTATTGCATCTTTTCTATACT
AATAAGGAGGTGTAATTTGAACGCTTTTAGAAAGAAAAAAGAAGAAGTTAGTGCAAGAAT
TAAAGATTTGATTAATTCTTCTTCTTCATTAGTTATAGCTGAATATCGTGGATTAACAGT
TGCTGAAATTGAAACTCTTAGAAATGAAGCTTAAAGAAGCAGGTGTTTTTGTAAAAGTTT
ATAAAAAATAGACTATTTAAAATAGCATCTAAAGAAGCAGGTTTCGGAGATTTAGAACAAT
CACTAGTTGGTCCAAAATTTTTTTGCTTTTTGGTTCTACAGATGCANTAGCTCCAGCTAAAA
TTATTTCAAAATTCGCTAAAAAACAAATCCAGTAAGTTGTATTAAAAAGGCGGTATTTTTTG

Sequence 320

Sequence 321

TABLE 1 58/467

TGCCTGGAGTTTGAAATACATGTCTCTTTAGTTTCTTTTGCACATGCTACATTGTGCTTT
AGACCGGAGATAATACAGTGACTTTACCTCACAAATCATATTCTGTCAACACACAAATCTAT
GAATTTAGTTTATTTAAAATCAGAACAATTTCCTACAAAATTTTTCTGGAAAATAGACTC
CTAACAGACCTACCAGAATCATGCTTAAAGGGCTCCCTTGACACTTATTCTATACTGAAG
GATAAATTTTAAAAAAAT

Sequence 322

Sequence 323

GCGGTGGCGCCCCGGGCAGGTACAAGGTAAAGCAAGAGCTGGCTCTCTACGTTCACC AATTTTTGTAGGTGGTGGTCGTGCATTTGGGCCTACAAATAAAAAATTACAAAATTAA ATTAAACAAAAAAGTTCGCAAATTAGCTTTTGCCTCAGCTTTTAAGTCAACTTGCTCAAA ATAATCAAGTACCT

Sequence 324

NNCTTAGCGTGGTCGCGGCCGAGGTACGCGGGGAAATGCAAAAAAATCAAATCAATTTAA
TAGAATACATCAGAGATGTTAAAGATTTCCCAATTGAAGGGATTGTATTTAAAGATATTT
CACCACTTTTAGCAAATGGAGAAGTGCTAAATTACACAATTANNCAAATGGCTGAGTTAG
CTAAAGATGCAGATGTTATTATAGGTCCAGACGCAAGAGGTTTCTTGTTTGGGACACCTA
CTGNAGCTTTTTTAAAAAAAACCTTTTATTATGGTAAGAAAACCTAAAAAATTACCAGGAG
ACGTTATTAGTTTTGAGTATGATTTAG

Sequence 325

CCCTTTCGAGCGGCCGGGCAGGTACTTGTCCATAATTTGTGAATATATTAACTAAT
TTTTCTTTTGAGTATTCATTTACTAACTCATAAGCTGAAAAGCTTTGAGCTTGATTCATT
CTCATATCCAAACGAGCTTGTTTGTTGTTGATGAAAATCCTCTATTGGCTTGATCTAACTGA
GGTGAAGATACTCCTAAATCAAGTAATACACCATCTACTTTGTTGATTTGAAGTTTTTT
AGTTCTTGATCAAAATCTTTAAAATCAGATCAAATAAATTCAATATTTGAAGAAATTTTT
AAGAGTTTTTCTTTTGTTTGTTCAATTGCTTGTTTGTTTATCAAAGACTA
Sequence 326

Sequence 327

Sequence 328

TABLE 1 59/467

TGTGTGAGGCCACAACTGTCCCATTATGCATATCANAAACAGAAATTTGTTGAGGATAAT TTTGGATATTCAGCAGNGGCTGNGAAACTGGATTTGAATTACCGGGATACATGCATGCTT CTTGGTT

Sequence 329

Sequence 330

Sequence 331

Sequence 332

Sequence 334

CCGGGCAGGTACTAGGAGATATTGATTCTAGTCAATTAGGCATTGTAGACTGTCATGACC ACTTAATAAAAAATTATGGACCTGAAGCTCACGAGCATCCAGATTTTATTATGATGTCAA AAGATGCTGCAATTAAAGAAATGAATGAATATGTAGCAAAAGGAGGAAAAACTGTTGTTA

TABLE 1 60/467

CAATGGACCCTCCTAACGTTGGGCGTGATGTTTATCAAATGTTAGATATTGCAAAGAAAT TAGAAGGAAAAGCTAACATTATTATGGCAACTGGTTTTCATAAAGCTGCATTTTATGACA AAGGTGCTTCTTGACTTGGCTTCGAACAAGAAAAATTGNAAAAATGGTTGTAGCTG AAATCGAAGAAGAATGGATGAATATAACTACAGCGGACCAGTTGTAAAAAAGATCTAAAT CCAAAGCCGGAATTATTAAAGC

Sequence 335

CTCCCGCGGTGGCGGCCGAGGTACCGCGGGGAAATGCAAAAAAATCAANNCAGTNNANT CNAATACATCACAGATGTTNAAGATTTCCCAATTGAAGGGATTGTATTTAAAGATATTTC ACCACTTTTAGCAAATGGGAGANGTGCTAAATTACACAATTAATCAAATGGCTGAGTTAG CTAAAGATGCAGATGTTATTATAGGTCCAGACGCAAGAGGTTTCTTGTTTGGGACACCTA CTGCAGCTTTTTTAAAAAAAACCTTTTATTATGGTAAGAAAACCTAAAAAAATTACCAGGAG ACGTTNTTAGTTTTGAGTATGATTTAGAATATGGTAAATCAACTCTAGAAATCCAAACTA ATATGTTGAAAAAAAGGC

Sequence 336

- CCGGGCAGGTACCTGGAAGACTTCTCCACCTCGGGGGCCTGGCTGCCTCACAGGTATGAA GACAACCACCATAACTGCTACTCTTACGCACTCACTTAACTGCGTTCTGATGGCA GAAGGTAGACAGCAACTGGACAAGGGTGAATTTACGGAGAAGTACCT Sequence 339

ATAAACTGCGGGATCTCAATGGCTTCTATGATCGTATTGAGGCAGTAGTTCCCACACTCT GCCCGGTGCCAGCATGAAAGAGAACAGGGAGAGTCAGCCTTTCACAGTCCTTGTCAAATC CCAATTACTCTGGTTGCAGATCACTTGAAGCCTGCCTTGTTTCTCTCACAAAGCTCTGCC CGAGAGTCCAGCCCCGCGTACCTGCCCG

Sequence 340

GCGAATTGGAGCTCCCCGCGGNGGCGGCCGAGGTACAAGATAGTCATNTCAGTAAAAGGT CTATTATCTAACTTGCCAAACTTGTTTANNGAGAGCCCTAAGGAACTAAAACTGCCATAA TGCCNTGCACAGCTTGAAAAGCAATTAGAGTAAGCAAGATTAGTTTTTCCTCCCTTCCAG TTCCTCAGCAGGCCTGGACGGCCCAGGAGGGAAGGAAATATAAGAACCAACAATAAA AATAGCAATAGCAATAAGAAGAATGCCATCCCATGGAGCACCATAATTCTGGAACCAC CTNTCCCGGATCAGGCTTCCATTGCTCACGATGCTCACGCTGGGCAG

TABLE 1 61/467

TTAAATGGTGTTGATATGGCTAGATCAGAAGGATATTCTGAAGGTGAAATGAAATTACAC ACACTTAGACAAGATGTTAGTTATGCAACAGCAACAGCAAGAACAACTTATGGAGCACTT GGAGTTAAAGTTTGAGTTTCATTAGGCGAAAGTATTTGCAAAGCAAAAATCAAGCATATAA TGAAGAAGAACCAACNCACAAAAAAGGGCCAAAAAGGGCAGCAAGAGTTAAAAAAGAA Sequence 342

CCGGGCAGGTACCGCTGTGTCCGGGTGGTGGTCATGAATGCCGTGCTCCAGGTGTTCAC AGCTGCTTCGTGGAAGACCATGTGCTCCGATGACTGGAAGGGTCACTACGCAAATGTTGC CTGTGCCCAACTGGGTTTCCCAAGCTATGTGAGTTCAGATAACCTCAGAGTGAGCTCGCT GGAGGGGCAGTTCCGGGAGGAGTTTGTGTCCATCGATCACCTNTTGCCAGATGACAAGGN GACTGCATTACACCACTCAGTATATGTGAGGGAGGGGATGTGCCTCTGGCCAC Sequence 344

Sequence 345

CCGCGGTGGCGCCCCGGGCACGGTACCACTTGAATTATCTATTGAAAGAACTACTAC
ATCGAGTTTTTGTTCTTTTGCCATTTCAATAGCTTCTCTTGTTTCAATTATCCCAATTTT
TTCATTATCTGAGCCGATAAGAAAAACTTTGACAAATGGAATATTTCTGTTTACTCAATG
TTCTTGAACTGGTTTAGAACGTGAAAAATTTTTAGGATTTGGTTTGGAAAAAATTTTTCC
TCCTTGGATTAAAAAAATAAAAAAGTGGTAAATCCACTTTCTCAGCAAAACAAAAATTATT
ATTAAAAATAACAAATTAGTATTTTGTAGCCTTTACCTATGAACACTTATTCATCAG
GTGAGAGTGAATCTTCTTTCTGCAATAATTTCTAATTGCCCCGCGTCCTTGGCCGCTCTA
GAACTAGGTGGG

Sequence 346

CACTACTATAGGGNGAATTGGAGCTCCCCGCGGTGGCGGCCCCCGGGCAGGTACTAGGA
GATATTGATCCTAGTCAATTAGGCATTGTAGACTGTCATGACCACTTAATAAAAAAATTAT
GGACCTGAAGCTCACGAGCATCCAGATTTTATTATGATGTCAAAAGATGCTGCAATTAAA
GAAATGAATGAATATGTAGCAAAAGGAGGAAAAACTGTTGTTACAATGGACCCTCCTAAC
GTTGGGCGTGATGTTTATCAAATGTTAGATATTGCAAAGAAATTAGAAGGAAAAGCTAAC
ATTATTATGGCAACTGGTTTTCATAAAGCTGCATTTTATGACAAAGGTGCTTCTTGACTT
GCTTTGGCTCCAACAGATAAAATTGTAAAAATTGGTTAGCTGAAAATCGAAAGAAGGAATG

Sequence 347

GGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTACCGTAGAAGAAGAAGAAGAAGAATACCTAAAGAAACAGACATAGAAATCATCCCAGAAATCCCGGAAACTCTAGAGCCACTGTCCCTTCCAGATGTGCTGAGGATCTCGGCAGTTCTGGAGGACACCACAGGCCAGCTCTCTATTCTGAACTACATCATGCCCGTTCAGTACCT

Sequence 348

TABLE 1 62/467

AGATTACTITATGAACAACAGCACCTTGAGATTCGATTAAGTTAATAATCGCTTTCATTG
TTCCGCCAGTAGCTAAAACATCATCAATAATTGCTACTTTTTTGGCCTTTTTTCAACATAT
TAGTTTGGATTTCTAGAGTTGATTTACCATATTCTAAATCATACTCAAAACTAATAACGT
CTCCTGGTAATTTTTTAGGTTTTCTTACCATAATAAAAGGTTTTTTTAAAAAAGCTGCAG
TAGGTGTCCCAAACAAGAAACCTCTTGCGTCTGGACCTATAATAACATCTGCATCTTTAG
CTAACTCAGCCCATTTGATTAATTGTGTAATTTAGCACTTCTCCATTTGCTAAAAGGTGG

Sequence 349

TCTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCCCCGGGCAGGTACTAAAACAGGT GCTCCTGTTAAAATAGAAGATCTTGCAGCTACTTCTAGAGATTTAAATTCTAAACGATCA ATAGCAGCGTATCCTGTTCCGGCTTTAATAATTCCGGCTTTGGATTTAGATCTTTTTACA ACTGGTCCGCTGTAGTTATATTCATCCATTCCTTCTTCGATTTCAGCTACAACCATTTTT ACAATTTTATCTGTTGGAGCCAAAGCAAGTCAAGAAGCACCTTTGTCATAAAATGCAGCT TTATGAAAACCAGTTGCCATAATAATGTTAGCTTTTCCTTCTAATTTCTTTGCAATATCT AACATTTGATAAACATCACGCCCAACGTTAGGGAGGGTCCATTGTAACAACAGTTTTTCC TCCTTTTGCTACATATTCATTCTTTAATTGCAGCATCTTTTGACATCATAATAAA ATCTGG

Sequence 350

TAGGGCGATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTACATTCTTCACTATCA
CTGTCCTGTAAATTTAGTAGCCTTGGCTGGAAACACTGTAGTCGACATGATCTGATATTG
CTTAATATTTCAGAAAGAGACAGTCTATTTTCACAATGTTTACTGGAAGCATTGGTCCGA
GAGAAATTAGAAGAAAAGTCTATAGTTTGGGAAGAGCTTGAAAAACTATTCAGCATTTCA
GGGTCTATCTGTTTCAGGACTGGGTCATGTTCTGTGGATATTCGGTCCATTATGACCCTT
CCACCTCTGCCAATTCGCCTCCTTGCAAATCCTATACATCTTCTTGGGACTGTAAGTGTT
GTAAGGC

Sequence 351

Sequence 352

Sequence 353

TABLE 1 63/467

Sequence 354

Sequence 356

GAATGGGAGCTCCCCGCGGTGGCGGCCGAGGTACAAGATAGTCATCTCAGTAAAAGGTCT ATTATCTAACTTGCCAAACTTGTTTACTGAGAGCCCTAAGGAACTAAAACTGCCATAATG CCGTGCACAGCTTGAAAAGCAATTAGAGTAAGCAAGATTAGTTTTTCCTCCCTTCCAGTT CCTCAGCAGGCCTGGCTGAAGGCCCAGGAGGGAAG

TABLE 1 64/467

Seguence 360

CCGCGGTGGCGGCCGAGGTACAAGATAGTCATCTCAGTAAAAGGTCTATTATCTAACTTG CCAAACTTGTTTACTGAGAGCCCTAAGGAACTAAAACTGCCATAATGTCGTGCACAGCTT GAAAAGCAATTAGAGTAAGCAAGATTAGTTTTTCCTCCCTTCCAGTTCCTCAGCAGGCCT GGCTGAAGGCCCAGGAGGGAAGGAAATATAAGAACCAACAATAAAAATAGCAATAAAGAATAAGAATGCCATCCCATGGAGCACCATAATTCTGGAACC Sequence 361

AGGTACTAAACTTTAATTAATGAGCTAACGTCATATTTTTTAAGTTTTTCAATTCCGTTT
AAAAATCCTAATTCAAGTAAAAAGATTACTTTATGAACAACAGCACCTTGAGATTCGATT
AAGTTAATAATCGTTCATTGTTCCGCCAGTAGCTAAAACATCATCAATAATTGCTACTTT
TTGGCCTTTTTTCAACATATTAGTTTGGATTTCTAGAGTTGATTTACCATATTCTAAATC
ATACTCAAAACTAATAACGTCTCCTGGTAATTTTTTAGGTTTTCTTACCATAATAAAAGG
TTTTTTAAAAAAGCTGCAGTAGGTGTCCCAAACAAGAAACCTCTTGCGTCTGGACCTAT
AATAACATCTGCATCTTTAGCTAACTCAGCCATTTGGATTAATTGTGTAAATTTAAGCAC
TTCTCCATTTGCTAAAAGTGGTGAAATATCTTTAAATACAATCCCCTTCAATTGGGAAA
TCTTTAAACATCTCNGGATGGTATTCTATTAAAATTGAATTTTTTTTGGC
Sequence 365

TABLE 1 65/467

Sequence 366

CCGCGGTGGCCGCCCGGGCAGGTACGCGGGGAAATGCAAAAAAATCAAATCAATTT
AATAGAATACATCAGAGATGTTAAAGATTTCCCAATTGAAGGGATTGTATTTAAAGATAT
TTCACCACTTTTAGCAAATGGAGAAGTGCTAAATTCACAATAATCAAATGGCTGAGTTAG
CTAAAGATGCAGATGTTATTATAGGTCCAGACCCAAGAGGTTTCTTGTTTGGGACACCTA
CTGCAGCTTTTTTAAAAAAAACCTTTTATTATGGTAAGAAAACCTAA
Sequence 367

Sequence 368

Sequence 369

Sequence 370

Sequence 371

AGGTACTATTGACTAAAGTCAGTTGGGGGAGAGAGAGGCGGAAGTATATTACTTTTATGC TTGGTTATACTAGAGAACAAATAGAAACTGACTAAAGAAACATTAGATCAGTGGTTCTCA GAGTATTGATATCTGGGAGTCCCAGCAACAGTCTGAGGAGGTTCATGAGTTCAGAATATT TTGATAATAACACTAAGATGGTATTTACTCTTCTAACTGGGTAGATATTTGCACTGGT Sequence 372

WO 01/070979

TABLE 1 66/467

CCCCTCTGTGCGGACTTCTGGGCATCCTCCCAGATACTCAATACTCTTGAGGGCCTG AGGAAAGTCTCTATGAAAGGTCTTGCAATTTTGGGTGCAATGGTTTCCGTGACAGAAGGT TCCTGAGAAAGCACCACAAACTCCTCAGCTTTGACCGGGAAGCCAGCATCACGGACGCGT GGGTCGAAGCTTGACCT

Sequence 374

Sequence 375

Sequence 377

CGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTCAAGCTTCGACCCACGCGTCCGTGATG CTGGCTTCCCGGTCAAAGCTGAGGAGTTTGTGGTGCTTTCTCAGGAACCTTCTGTCACGG AAACCATTGCACCCAAAATTGCAAGACCTTTCATAGAGACTTTCCTCAGGCCCTCAAGAG TATTGAGTATCTGGAGGAGGATGCCCAGAAGTCCGCACAGGAGGGGGTGCTGGGACCACA CACTGATGCTCTGTCATCAGACTCTGAGAACATGCCGTGTGATGAAGAACCATCCCAATT AGAGGAGCTAGCTGACTTCATGGAGCAGCTTACACCAATTGAAAAAATATGCTTTAAATTA CCTGGAAATATTNCATACTTTNTATTTGNGGCNAAAAAAAA

Sequence 378

Sequence 379

TABLE 1 67/467

Sequence 380

TAGGGCGAATTGGAGCTCCCGCGGTGGCGGCCGCCCGGGCAGGTTACAAGTCGACCCAC GCGTCCGCTTCAGAATATCCAATTCATGTGAACTACAGGAAATTATAGTTTAGATATTTT TAAATGATTTGCCTGTCACCGTATAACACAAGGGTGTCATGACCAAGCTAGATCTCTTTA CCATATCATTAATAAAAGTCAAATTTTAAATTTGTGCCCAATTTGGCTGGGTGTGGC TCATTCCTGTGATTCCAGCACTTTGGGAGACCT

Sequence 381

CTACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTCTTCGACCCACGCGTCC
GCATTTATTAAGGCTTGTATATGTTCAAGATCCAGTGAAGACTGTCTTGGGCGTGTATAA
TTGATCTTAACCACAAGGCTGAGAAGTTATGTGCAGGGCTTATGATGCTACTTCCAAAGT
ATTAAATCCTCCAGAGAAGCCTGTAGTGTGGGATGCAAACTATTTTAAGTGTGACCATGA
GGTGTTTTTTTTGTGGACCATTTTAAAGCCAATGATAGGTTCTAAAGCAATCTCAACCTGA
GTTAGGTAGAATGGGTTGGTTATCTGCACTCTAGCGCCCTTCATAGCTATTGTATTCTG
GATTTCAATTCGGCACTTTATGTATTAGCTAAAAATTTCATGACCAGATCTTTTGAAGTA
TACAAAGTAAATCTTCAAGGTGGATAGTTTATCCAAGTGTAAAATGTGTTGCACTAGGTC
AGCTTGGAATTTTGAGATGACTTTTGGCATCATTGCATACATCTGGTTTGTACCTGCC
CGGGCCGGCCGCTCTAGAACNGTGGATCCCC

Sequence 382

Sequence 383

CTACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACTATTGACTAAAGTCA GTTGGGGGAGAGAGAGCGGAAGTATATTACTTTTATGCTTGGTTATACTAGAGAACAAA TNGAAACTGACTAAAGAAACATTAGATCAGTGGTTCTCAGAGTATTGATATCTGGGAGTC CCAGCAACAGTCTGAGGAGGTTCATGAGTTCAGAATATTTTGATAATAACACTAAGATGG TATTTACTCTTCTAACTGGGTAGATATTTGCACTGGT

TTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACATATCTGCATATACACCAT
TAATTTTACATCGTTGAGGTAGCCAAAACTGCTCGTAAGTGGGCTTTTATTAAATAATAT
AATGTTCTTAATAGAGGAAAAAGGAATTGAATACATTTTTAAAAAACAAAATCCATTGTCCCACAAAAGGAAATCAGTGGAGACAAAAGCAGTTTAATTTGCTGGATTC
TTTTGTGGCTTATTTTTTGAGTATTATTTACAAAATGTTAGACTAATTTTTAAGCAATAT
TAATAATAAGCAACATACAACTCCAAGAATAATAAAATAAAATAAAACTGCGGACGCGT
GGTTCGAAGCTTGCTCGNNGGGGGCCGGGNCGCTTCNAGGCCCNCCCGGGCAGGTACCCA
GTNATCACATAAATTCTGCAATCATNTGGNTATTNAGCTTNACNTGNTTTTTTTATTTGN
NGAANTTGTTGTTGTATTCAG

Sequence 384

ACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTTACAAGTCGACC CACGCGTCCGCTTCAGAATATCCAATTCATGTGAACTACAGGAAATTATAGTTTAGATAT TTTTAAATGATTTGCCTGTCACCGTATAACACAAGGGTGTCATGACCAAGCTAGATCTCT TTACCATATCATTAATAAAAGTCAAATTTTAAATTTGTGCCCAATTTGGCTGGGTGTGGT GGCTCATTCCTGTGATTCCAGCACTTTGGGAGACCT

Sequence 385

TABLE 1 68/467

Sequence 388

Sequence 390

Sequence 391

TABLE 1 69/467

Sequence 392

Sequence 394

Sequence 396

AGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTCTTCGACCCGCGCGCTCCGCATTT
ATTAAGGCTTGTATATGTTCAAGATCCAGTGAAGACTGTCTTGGGCGTGTATAATTGATC
TTAACCACAAGGCTGAGAAGTTATGTGCAGGGCTTATGATGCTACTTCCAAAGTATTAAA
TCCTCCAGAGAAGCCTGTAGTGTGGGATGCAAACTATTTTAAGTGTGACCATGAGGTGTT
TTTTTGTGGACCATTTTAAAGCCAATGATAGGTTCTAAAGCAATCTCAACCTGAGTTAGG
TAGAATGGGTTGGTTATCTGCACTCTAGCGGCCCTTCATAGCTATTGTATTCTGGATTTC
AATTCGGCACTTTATGTATTAGCTAAAAATTTCATGACCAGATCTTTTGAAGTATACAAA
GTAAATCTTCAAGGTGATAGTTTATCCAAGTGTAAATGTGTTGCACTAGGTCAGCTTGGA
ATTTTGAGAT

Sequence 398

Sequence 399

CCGCGGTGGCCGAGGTAGCTTGAGTCGACCCACGCGTCCGTTCAGATCCGTTTCAGA

TABLE 1 70/467

AACGTGAGTCTCTAGCTCAGGAGATTTCCACAACTGTCCTTAGTAACCTGATCTTATTCT
CATGTTTAACCTTGGCAGTGGGAAGTTCTTCCTGGTATCCTGCCTAATTTACTGGAGTTG
GCATTAATGCCATTTCCCCCTAAGGCGTGGCTCTTGGACCAGTATCACCTGAGAATTTGA
TAGACATAGACCCAGAGTTACTGAGGCAGGTGCTCTGTTTTGGGGACCAGCAATCGGTGC
TTTAGCAAGTTCTTTGGGTGATAGGGTTTGGAAACTACTGCTCTAAAGCATCATCTGTTT
TGACTTTGCCATGCACAATCTGAACTCACTCCCGTGAGGCCCTGCTCCTGATACTTTAAA
TCGTCCTGTCTCTTTTTCTGCCTCTCTGTGGAG

Sequence 400

Sequence 401

TACTATAGGGCGAATNGNAGCTNCCCGCGGTGGCGGNCGAGGTATTCAACAAGGGCCCTG
AGAGAGGGACAGCAGCCCCTGTGAATCTTGCTGTTCAGCAGAGACAGGAGTCAGCACGT
GTGAGGGCAGCAGGAAGTCTTCCTGGAGGAGTGAGACCTGGCGATGAGGAGGCACGGCA
GGGAGGTGGAACAGGCAGGAGACTCTTCAGGAATTGAGGAGATAGAATAGAGGACACT
AAAGCCTTAGAGAGGCCAGGGGTGGTGGCTTGGCAGGATCATCGCTTGAGGCTAGGAGTT
TAAAAGCAGCCTGGGCAACATAGCGAGACCCCATCTCTAAACACAAAAAAATAAAAACCTG
CCCG

Sequence 404

TABLE 1 71/467

Sequence 406

Sequence 407

Sequence 408

Sequence 409

TAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCCCCGGGCAGGTTACAAGTCGACCCAC GCGTCCGCTTCAGAATATCCAATTCATGTGAACTACAGGAAATTATAGTTTAGATATTTT TAAATGATTTGCCTGTCACCGTATAACACAAGGGTGTCATGACCAAGCTAGATCTCTTTA CCATATCATTAATAAAAGTCAAATTTTAAATTTGTGCCCAATTTGGCTGGGTGTGGC TCATTCCTGTGATTCCAGCACTTTGGGAGACCT

Sequence 410

CTATAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGACCAGTGCAAATATCTACCCAGT TAGAAGAGTAAATACCATCTTAGTGTTATTATCAAAATATTCTGAACTCATGAACCTCCT CAGACTGTTGCTGGGACTCCCAGATATCAATACTCTGAGAACCACTGATCTAATGTTTCT TTAGTCAGTTTCTATTTGTTCTCTAGTATAACCAAGCATAAAAGTAATATACTTCCGCCT CTCTCTCCCCCAACTGACTTTAGTCAATAGTACCT

Sequence 411

CTATAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTCTTCGACCCACGCGTCCGC ATTTATTAAGGCTTGTATATGTTCAAGATCCAGTGAAGACTGTCTTGGG Sequence 413

AGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTACAACTTGTGATGCTT TTGGCAGGAATTACAGAACAACCAATGCCATTCAAGTTGTGGAGATTATACTNGCAGGTG AACTCGTAAAGAGAAGATTCTGGAATGCCTATATCTGAAAGCTTGAGTCGACACCTN

TABLE 1 72/467

Sequence 414

Sequence 415

CTACTTAGGGCGAATTGGAGCTCCCCGCGGTGCCGAGGTCTCCCAAAGTGCTGGAA TCACAGGAATGAGCCACCCACCCAGCCAAATTGGGCACAAATTTAAAATTTGACTTTTA TTAATGATATGGTAAAGAGATCTAGCTTGGTCATGACACCCTTGTGTTATACGGTGACAG GCAAATCATTTAAAAATATCTAAACTATAATTTCCTGTAGTTCACATGAATTGGATATTC TGAAGCGGCCCCNTGGGTCGACTTTGTAACCTGCCCGGGCGGCCGNTCTAGAACTAGTGG GATCCC

Sequence 416

TATGGCGAATTGGAGCTCCCCGCGGTGGCGGGNCGAGGTNAAGCTTCGACCCACGCGTCC GATTATTCTCTCCATTTAGGCTATAAATCTTTCAGTGTAGGGTGTTTCTAATGTCNTATT CTTCCAAAAAAAAAAAAAAAAAAA

Sequence 417

CTACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTGCCAAAGCCT
TAACTTAGATTGTTACTTATGTTTCTAAATCTGNGGAAGCACATTTCCTTTTNTTNTNNT
TTTCTTTTACTGTTAATATCCTTATTCTCTATTTTACCAGTGGAGAATGNTTAGTATTAA
TTTCCATTTANCTCANGATTCAAGAAATGCAAAGTGCTATTTTTATCAAATTTCTGAAAG
CCTACTGTCTTCTGNTTTGGAAGTCCCACAACAGCTCTTTAATTTCCTTAAGCCCCACTT
TCCTCATCAGCAAGTTGGTGTGGCAATGGATCATAATAGGTTGCTGGGAGGATGAAGTGA
GCGGACCGCGTGGGTCGAAGCTTGTACCTN

Sequence 419

CCGCGGTGGCGCCCCCTTTTTTTGTATTACTTCAACTTTTAAAAATTCTAAAGAAAAC CATCATCTCAGACCAGCATTTCCGGACGCGTGGGTCGAAGCTTGACCT Sequence 420

TACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTGTCAAACATCT CCCTCGTCCGGATCCTTCTAACGCAGGAGTCTCAGACGCAAATGCCGGCAAGGGCCAGGC AGGTGATGTAAGATGCGTGGAGCAGATGCCAAGCCACAGGGAGTGGTGGAGACTGGGGTG AACTGGAAAGCACCT

Sequence 421

CCGCGGTGGCGCCCCGGGCAGGTACACAAACCAGATGTATGCAATGATGCCAAAAGT CATCTCAAAATTCCAAGCTGACCTAGTGCAACACATTTACACTTGGATAAACTATCACCT TGAAGATTTACTTTGTATACTTCAAAAGATCTGGTCATGAAATTTTTAGCTAATACATAA AGTGCCGAATTGAAATCCAGAATACAATAGCTATGAAGGGCCGCTAGAGTGCAGATAACC AACCCATTCTACCTAACTCAGGTTGAGATTGCTTTAGAACCTATCATTGGCTTTAAAATG GTCCACAAAAAAAACACCTNATGGTCACACTTAAAATAGTTTGCATCCCACACACACAGGCT TCTCTGGAGGGATTTAATACTTTGG

Sequence 422

GGTGGCGGCCCGGGCAGGTGTCAAACATCTCCCTCGTCCGGATCCTTCTAACGCAGG AGTCTCAGACGCAAATGCCGGCAAGGGCCAGGCAGGTGATGTAAGATGCGTGGAGCAGAT

TABLE 1 73/467

GCCAAGCCACAGGGAGTGGTGGAGACTGGGAAAGCACCT Sequence 423

Sequence 425

Sequence 426

CCGCGGTGGCGCCCCGGGCAGGTCAAGCTTCGACCCACCGTCCGGCAATGATGAGCA AAAACAAGTTTGGTCCCCCTGTTATAGNGCCTGGTAAAGGTTTTTGTTGTTGTTTTGCAG GGGTGGGGAACCAGGAAATCAGATCATCACAACAATATATACTTATCTGTAACTATGGT AACTGCTACAGCAAAGGGGCGTATCATACTATTAGCATACTAAGTTTCACTTAAAGAGGT CGGA

Sequence 427

AGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCCCCGGGCAGGTGTCAAACATCTCCCTCGTCCGGATCCTTCTAACGCAGGAGTCTCAGACGCAAATGCCGGCAAGGGCCAGGNAGGTGATGTAAGATGCGTGGAGCAGATGCCAAGCCACAGGGAGTGGTGGAGACTGGGGTGAACTGGAAAGCACCT

Sequence 428

Sequence 429

CCGGGCAGGTCAAGCTTCGACCCACCGTCCGGCAATGATGAGCAAAAACAAGTTTGGTCC CCCTGTTATAGAGNCTGGTAAAGGTTTTTGTTGTTGTTTTTGCAGGGGTGGGGGAACCAGG AAATCAGATCATCACAACAATATATACTTATCTGTAACTATGGTAACTGCTACAGCAAAG GGGCGTATCATACTATTAGCATACTAAGTTTCACTTAAAGAGGTCGGA Sequence 430

TABLE 1 74/467

Sequence 431

TTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTATTCAACAAGGGCCCTGAGAGAGGGCAGCAGCAGCAGCCCCTGTGAATCTTGCTGTTCAGCAGAGACAGGAGTCAGCACGTGTGAGGCAGCAGGAAGCCCCGGGAAGCAGGAAGCCTGGCAGGAAGCCTGGCAGGAAGCAGGAAGACACGCAGGAAGACTCTTCAGGAATTGAGGAGATAGAATAGAGGACCTAAAGCCTTAGAGAGGCCAGGGGTGGTGGCTTGGCAGGATCATCGCTTGAGGCTAGGAGTTTAAAAGCCCTGGGCAACATAGCGAGACCCCATCTCTAAACACACAAAAAATAAAAACCTGCCCG

TABLE 1 75/467

Sequence 439

Sequence 440

Sequence 441

Sequence 442

AGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTTACAAGTCGACCCACG CGTCCGCTTCAGAATATCCAATTCATGTGAACTACAGGAAATTATAGTTTAGATATTTTT AAATGATTTGCCTGTCACCGTATAACACAAGGGTGTCATGACCAAGCTAGATCTCTTTCA TATCATTAATAAAAGTCAAATTTTAAATTTGTGCCCAATTTGGCTGGGTGTGGTGGCTCA TTCCTGTGATTCCAGCACTTTGGGAGACCT

Sequence 443

CGCCCGGGCAGGTACACAAACCAGATGTATGCAATGATGCCAAAAGTCATCTCAAAATTC CAAGCTGACCTAGTGCAACACATTTACACTTGGATAAACTATCACCTTGAAGATTTACTT TGTATACTTCAAAAGATCTGGTCATGAAATTTTTAGCTAATACATAAAGTGCCGAATTGA AATCCAGAATACAATAGCTATGAAGGGCCGNTAGAGTGCAGATAACCAACCCATTCTACC TAACTCAGGTTGAGATTGCTTTANAACCTATCATTGGCTTTAAAATGGTCCACAAAAAAA CACCTCATGGTCACACTTAAA

Sequence 444

ACNGNCAGGTACCAAGATTAAGGACAGAGTTCCCTCCATTGGTCATTGATTTGNAAACCA AAATGTATCTGTGACAGGTATTAATCCGGACGCGTGGTCGAAGACGAAAGGACACGAGAA ATANGGACCTANNCCGCTCTANAACTAGGNATCCCCNNNNCTGCAGGAATTCGATATCA

TABLE 1 76/467

Sequence 445

Sequence 446

CGGGCAGGTACCCTTATTTTCCCTGATACAGCACAACTCTGCCTATTCTAATCATGACCT AGACACATTCAATGAACTACAAGTTCTCCTTTACACGGACGCGTGGGTCGACTCCGGACG CGTGGGTCGAAGACCTCGGCCGCCT

Sequence 447

Sequence 448

GCGGCCGGCCGGCAGGTTACAAGTCGACCCACGCGTCCGCTTCAGAATATCCAATTCATG
TGAACTACAGGAAATTATAGTTTAGATATTTTTAAATGATTTGCCTGTCACCGTATAACA
CAAGGGTGTCATGACCAAGCTAGATCTCTTTCATATCATTAATAAAAGTCAAATTTTAAA
TTTGTGCCCAATTTGGCTGGGTGTGGTGGCTCATTCCTGTGATTCCAGCACTTTGGGAGA
CCT

Sequence 449

CGCGGTGGCCGACCAGTGCAAATATCTACCCAGTTAGAAGAGTAAATACCATCTTA GTGTTATTATCAAAATATTCTGAACTCATGAACCTCCTCAGACTGTTGCTGGGACTCCCA GATATCAATACTCTGAGAACCACTGATCTAATGTCTTTAGTCAGTTTCTATTTGTTCTCT AGTATAACCAAGCATAAAAGTAATATACTTCCGCCTCTCTCCCCCCAACTGACTTTAGT CAATAGTACCTCGGCCG

Sequence 450

Sequence 451

CTATAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACAAGCTTCGACCCACGCG

TABLE 1 77/467

TCCGATTATACCCTAAAAAAGTAGAAAGATGGAATAATTAGGAGTAAAATTAGTGAAATG GAAAGATATGTTATAGAAAAGACGAAAAGACGCAAAAGTTGGTATTTGAAAAGACTGAAA AAATTCATGAAACCTGTGAAAACAGTGGTCAAGAAGAAAAGAGAGGCATATTTTGATCTCT GTTTTACATGTTACTCAATGTTCATTGCTGCCTCCCTTGTCCATAAAGTGCCTTTAGTGT GTATGTTACTTTAGATTATCTTGGTGTCATCAAGCTTTACTCAGCAAAGAACCACTTTGT TGTCTACTTTAAAACATAAGTTATCTTTAAAAGAATGGGTATCTTTTATAGTTCCATATT AATGGCGAAGAAACTGCAGGTAACAGTGCCTTACCAGCTGGGTTTTGCTAACTTTTCTC Sequence 452

CCGCGGTGGCCGCCCGGGCAGGTTTTATATTTTTTTCCTCTTTTAAAAAAATAATTTG GTTTGAATATTAAATTTACATATTTCTAAGTTAAATCAACATTCGTAGAGGAATTATCA AAAAAAACTAGTAAGTCTGAAAAAAAAACCATATTTTATATTCTGAGGTCCCGGACGCGT GGGTCGAAGCTTGACCT

Sequence 453

TATAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCGCAGGTACCCAACACAAACTA
TTCAATAAAGTAATCTGCTTTAAAAATAAAACACACTGAAAGGCCGAGGCAGGTGGATCA
CCTGACATCATTAGTTCAAGACCAGTGTGGCCAAACTGGTGAAAATTAGTCTCGACTAAA
AATCAACATTAGCTGGGCGTGGTGGCAGGCGCCTCTAATTCCAGCTACTCAGGAGGATGA
GGCAGGAGAATCACTTGAAGCAAGGAGGTGGAAGTTGCAGTGAGCTGAGATCGTGCCATT
GCACTGCAGCCTGGGCAACAGAGTGAGACTCCGTCTCAAAAACACCACCACCAACAAAAT
AAACACAACAGAATTATTCTGCAAATACAGATATTGGAGTAGCTGAGTTCCATCTCAAAT
TTGACTATGCAGGTTGACAGGTGATCTTGGCAAACTACTTATCCTTTCTGAAGTTCAACT
TTTTCACCAAATGGTATTGGGATACAACACTTGCTCTTGCCTATCTCACATGAATTATCC
ATTTTGGACAACTTGGTAAACTATA

Sequence 454

Sequence 456

CCGCGGTGGCGCCCCGGCAGGTACAACATTTTACATTTCCAGGGACTGCAAAAATGT
TAGTTCCTTCCCCCATCATTTAGTTTGAAAATTCTTAGATAATTCTTTGCTGGTAAATTC
CAACAGAATAGTTAGCACACAGGTTCCACACACACACAGTTCTAGATAGGAATCTGAAGCA
CCACAATGAAAAGAACATTTAACATCTTTTAAAAATGTTTAATGTTATCAGAAAGATGTT
TGGTATATGTGTTCCATGCATGCTCCTGCTGGTTCTATTTGAAAAAGAAGTTTTTACAGT
TATCTGTTGTCACCATATTGTAAACGGACGCGTGGGTCGAAGACCT
Sequence 457

TABLE 1 78/467

CATCTCCCATTTATTTTCATTTGAAATAAAACTTTTGAATTTTATCTTCTACCTAAATA ACATATTTTGTTTTATGTTTCAAGATGAAGCTCACACTGAGTTGGAAAAAAGGAAAAAGC AAAGGATCAAAGCTGGGGGAAAATACTGGACCATGTGCTTCACCTCATGGTGCCAAATAA AGAGAAAATGGGGAGAAGATAGGGACAGATAAAGATCTATTTGCTCGGATTGNGCTCTCA TCCTTGGCAACATGTTGACAATGCCCTGGAAATA

Sequence 459

Sequence 458

Sequence 460

CCGCGGTGGCGGCCCGGGCAGGTCTTCGACCCACGCGTCCGTGATTGCCTATTGTT
TGTTGATTGACTGATTTATGCCTCTAAGAGGAACTATCTTTTGATAATAATAAAAAAA
GTCCTAATACAAAACTGATAGAGTTCAGAAATAATAAGAATCTCCTGGCCAGGCGTGGTG
GCTCACGCCTTTAATCCCAGCACTTTGGAAGGCTGAGGTGGGCGGATCACGAGATCAGGA
GATTGAGACCATCCTGGCTAGCATGGTGAAACCCTGTCTCTACTAAAAATACAAAAAAA
TTAGCCCGGGTGTGATGGCGACCT

Sequence 461

Sequence 462

Sequence 463

Sequence 464

WO 01/070979

PCT/US01/09126

TABLE 1 79/467

ACTATNGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTGTCGACTCAAGCTTTCAG ATATAGGGCATTCCAGAATCTTCTCTTTACGAGTTCACCTGCTAGTATAATCTCCACAAC TTGAATGGCATTGGTTGTTCTGTAATTCCTGCCAAAAGCATCACAAGTTGTACCTGCCCG

Sequence 465

Sequence 466

CCGCGGTGGCGCCCCGGNCAGGTTACAAGCTTCGACCCACGCGTCCGGGAAATTTTA ATTAAAAATAGGTGAACATTTTAAATGACCTAATACATATTTAGTCCACATTGAAACTTT GGCATTTTGTCATTGCCATTAAAATTTTGATGGCATTAAAATTTGATGCCATTAAAATTT TGAT

Sequence 467

Sequence 468

Sequence 469

GACCTCTTTAAGTGAAACTTAGTATGCTAATAGTATGATACGCCCTTTTGCTGTAGCAGT TACCATAGTTACAGATAAGTATATTGTTGTGATGATCTGATTTCCTGGTTCCCCCACC CCTGCAAAACAACAACAAAAACCTTTACCAGGCTCTATAACAGGGGGACCAAACTTGTTT TTGCTCATTGCCGGACGGTGGGTCGAAGCTTGACCTGCCCG

GCTCCCGCGGTGGCGCCCCGGGCANGGTTACAAGCTTCGACCCACGCGTCCGGGAA ATTTTAATTAAAAATAGGTGAACATTTTAAATGACCTAATACATATTTAGTCCACATTGA AACTTTGGCATTTTGTCATTGCCATTAAAATTTTGATGGCATTAAAATTTTGATGCCATTA AAATTTTGAT

Sequence 471

GCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTCAAGCTTCGACCCACGCGT CCGTGATAACTTCTCCTAAGTGCCAGGCATTGTATTACATGCTGGGAGCACAAAGATGAA TAATAACAATAGGTTCACAGAAAAGATGAATTGATTGAGAGAAAAAGAACCCTCCAGGAG CCCTCAGCGTAGTAGGGGGTTGGTGTTGGAGGGTNGGAGGAATGGANAAAGGCCCTGAAA TGCAGGCAGAGAAATGATGAAACAATTCAGGGGCTGTGGTGAGGTTAAATGAATATCTT Sequence 472

TABLE 1 80/467

CGAAAAAAGAAAAAAAAAAACTTTCTCTTTGCCANTTCTTCTTCTTTNTT Sequence 473

Sequence 474

CCGCGGTGGCGCCCCGGGCAGGTACACAAACCAGATGTATGCAATGATGCCAAAAGT CATCTCAAAATTCCAAGCTGACCTAGTGCAACACATTTACACTTGGATAAACTATCACCT TGAAGATTTACTTTGTATACTTCAAAAGATCTGGTCATGAAATTTTTAGCTAATACATAA AGTGCCGAATTGAAATCCAGAATACAATAGCTATGAAGGGCCGCTAGAGTGCAGATAACC AACCCATTCTACCTAACTCAGGTTGAGATTGCTTTAGAACCTATCATTGGCTTTAAAATG GTCCACAAAAAAAACACCTCATGGTCACACTTAAAATAGTTTGCATCCCACACTACAGGCT TCTCTGGAGGATTTAATACTTTGGAAGTAGCATCATAAG Sequence 475

CTNCTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGACCNGTGCAAATATCTACCCAGTTAGAAGAGTAAATACCATCTTAGTGTTATTATCAAAATATTCTGAACTCATGAACCTCCTCAGACTGTTGCTGGGACTCCCAGATATCAATACTCTGAGAACCACTGATCTAATGTTTCTTTAGTCAGTATAACCAAGCATAAAAAGTAATATCTCCGCCTCTCTCCCCCAACTGACTTTAGTCAATAGTACCT

Sequence 476

Sequence 477

Sequence 478

TATAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTACTTATACTAGAA GATGCTCCAAGGTTTCAGAAAGGAATTAATTACTTTCAATTTGCACAATTTAGAACAAAT ATCTGGCTTTTCCCTAAGCTTAATGATTTTCCATTTCACACAACTAAAATATAATAGCAT TATTTTATAATCAAGTTTAACTGATGGTCTATGATAGTAGTAGGGCGATTTAGTATTTTGACA AAAATCTTATGAGACATGAAGTCATTCAATTTGCCGGACGCGTGGGTCGACTCAAGCTAG ACCTN

Sequence 479

TABLE 1 81/467

AGGGCAGAGGTATGTGCGAGCTCAGATACCTTAAATTCATATGCCTTTAATACAATCC AGGCAGATTTCTAAATGAGGGATGCTTCCCCACAAATGGAGAGTGAAAGTGGGCCAGCCT AAAAGGACCTCCATAGCACTGTGCATGGCCAGCTGTTTTGTGGCTGTACC

GACCTCTTTAAGTGAAACTTAGTATGCTAATAGTATGATACGCCCTTTTGCTGTAGCAGT TACCATAGTTACAGATAAGTATATTGTTGTGATGATCTGATTTCCTGGTTCCCCCACC CCTGCAAAACAACAACAAAAACCTTTACCAGGCTCTATAACAGGGGGACCAAACTTGTTT TTGCTCATCATTGCCGGACGGTGGGTCGAAGCTTGACCTGCCCG Sequence 482

Sequence 483

Sequence 484

Sequence 487

Sequence 488

CCGGGCAGGTACAAATCAAGTCATTAACATTTTCAATGTCAAAAATACAGCACGCTGTTA AGAGTTCTGTCAGTGCTCATTATCCCACTAGATCCCACAAAGGGCAAACTCAAAAGATGA AACAAAGGCAACGCCATCAATAACCACCATATTCCACAGGCTTTCTCCCCTAGGACGTAC

TABLE 1 82/467

CTN

Sequence 489

Sequence 490

Sequence 491

CCGGGCAGGTACAGCCTCACATACACAGATGCAGGTGAAGTCACCAAAGCTGATCTCTCA
TTCGTTCTGGGGACAGTTAGCAGCGTAGTGGTCCCACTGCAGCAAAAGTTTGAAATTCAT
TTTCTTCAGGAAAATACCCAGCCAGTCCCTCTCAGTGGAAACCCTGGTTATGTCGTGGGG
CTCCCATTAGCTGCTGGATTCCAGCCTCATAAGGGTGGAGCTCTCCCGTGTCAGCTCGTA
GCACAGAAGGTGAAGAGCCTGCTGTGGGGCCCAGTGCTCCCAGATTACGTGGCCCCTTTT
GGAAATTCCCAGGCCCAGGGACATGCTGGACTGGGTGCCCATCCACTTNATCACCCAGTC
ATTCAACAGGGA

Sequence 492

CCGCGGTGGCGGCCGAGGTACTATTGACTAAAGTCAGNTGGGGAGAGAGAGAGGCGGAAGT ATATTACTTTTATGCTTGGTTATACTAGAGAACAAATAGAAACTGACTAAAGAAACATTA NATCAGTGGNTCTCAGAGTATTGATATCTGGGAGTCCCAGCAACAGTCTGAGGAGGTTCA TGAGTTCAGAATATTTTGATAATAACACTAANATGGTATTTACTCTTCTAACTGGGT.AGA TATTTGCACTGGT

Sequence 493

ACTACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGTTAAAGGAATAATCTGCAGA ACATCTTGATTTACAAGGGACAAAATGATGCAAATTATATGCTGTCCAACCTACTGGTGA ACTGGATCAGAATGGTCCAAGGACTGTTAAACAGAGGAAGTATTTACATTTTGAAAAACTT GCGGACGCGTGGGTCGAAGCTTGTACACCT

Sequence 494

CCGCGGTGGCGGCCGTTAAAGGAATAATCTGCAGAACATCTTGATTTACAAGGGACAAAA TGATGCAAATTATATGCTGTCCAACCTACTGGTGAACTGGATCAGAATGGTCCAAGGACTGTTAAACAGAGGAAGTATTTACATTTTGAAAAACTTGCGGACGCGTGGGTCGAAGCTTGTACACCT

Sequence 495

Sequence 496

TABLE 1 83/467

Sequence 497

CTACTTAGGGCGATTGGAGCTCCCCGCGGTGGCGGCCCCCGGGCAGGTACCCCCAGGTC
AGCACTTTGAACACTCTATGAAATCACATAGTAAAGTGATAGGAGATGGGGCT
AAGCTTTAATGGCCTTTAGACATAGCATTAGACATAACCTAAGCTTGAAAGGCTTTGGGA
AGTTGTTGTTTAAATCCCCAACACACTCTCGTGTTTTCTTAGGACTTGCCTNTTATTTA
AAAAAAAAAAAAAAAAAAAAAGTTGCGGCCCGCTCTAGAACTAGTTGGATCCCCCGGGCTTGCAG
GN

Sequence 498

Sequence 500

Sequence 501

CCGCGGTGGCGCCCCGGGCAGGTCAGGAGTGTCCCAAAGATTTCCCAAGTCCAGCCC AGAGAAGCTGAAAGCCTTTCCCCCAGGTGTGGGGCTGAGTTAGATGTGGGTCATAAAGGA TGTGGCCTCGAGGCTGGGAGGCAGCTGGGCAAAGTGGGAAGCCTCCCTACTCCTGAGACA GTGATGGCTCAAATCCAGGCCAACCTGGAACATGATCCTCAACTTCTCTAAGTTCACCTT TCCCAGGTGTGAAATGGGTTGTTCTGGGAATTGAGTGAGCTAATGATACACTCCCTGGCA CACAGCGAGCCTNAAAACGCTTGTGTCCCCTCCCTACCTCACAGCCCATTTTAGAAGTTT GCTGTCACTTA

Sequence 502

Sequence 503

TABLE 1 84/467

Sequence 504

Sequence 505

CCGCGGTGGCGGCCGCCCGGGCAGGTACTACTGATACAAATAGCATGGATGAAACTCAAA ATCATTATTCTAAGAGCCAGATACTATAGCCTGTATTTTATGATTCACTTTCAATGAAAT TCTACAATAGACAGAACTATCTATCAACAGAAAGCAGATCAGTGGTTTTCTGCAGCCAGA GGTATGAAAGGTTTGAAACATGTGGCACCAGTAGGACATATGGAAACTTTTTTGGTGTGA TGGAAGTATTTTTTTATCTTGATTGTGTGTGTTTTTTATCAGTGGACTTTTTTGACC

Sequence 506

GGGGCGCCCCGTTCAGGTACACGTNTTTNCCAACCAATTTTATANGNATATATATT TCTACTTCCAACACCCNTNTTCATCCTGGTNCAATCAAAGCCTGGTTNTGGCCAACAANA AACTCGTCAGGAGATCGAAGGNTGTAGATGTCTGCACGTGGCTTCCTTGGAGGTCCAGNG GNGACTCCCTCTTCCAAAATCCATTCTGTACCCGCTGGCTGCTCTAACGGGCAGGACAAC AGCGTATGAAGCCTGACTGCAACTAGGAGAAGTACCACACTCCCGGACGCGTGGGTCGAA GCTTGTACACCT

Sequence 507

CCGCGGTGGCGGCCGAGGTCAAGCTTCGACCCACGCGTCCGCTTTTCAATTTTATTGTAT
AGTTTTTGATAATGTTAATGTCTGAGATCTTTATGGGTGAGTCTGCTGTCATTTCTGCTA
TTTCTCGTAGTGATTTGCTTGTATGGTTTATGATTTTTTAAAAACTGAATGTGTATTAGA
ATTGTGTCTGGTAATTCTTTAGGGACCCATTGTAGATGTATTTCTTCAAAGAGCATTTGT
GGTTATTATATTTTGGGTGCTTGGGGCACTGCCAGTACCTGCCCG
Sequence 509

CCGCGGTGGCGGCCGAGGTATTGAACCAGGTCAAAACATTGTTGAATATCAAACCCAATC TATTTAATCTGTAAGAAACAAGGACCCTGAGAAAGATTCTGACCAAGGGTATGTGATCGG AAACTTGACAGATAAATGTAGTATACTTGTAAAGCCATACTGTGAAAAACTTGGGGATTA TTTGAACACAAATTATCACCTGGAAAAAGACAGAAAACAAGGCAGAAGACTGTGCAAAGA GGTTGGAATATTCAAAACTTCAGATTAGAAG

Sequence 510

TABLE 1 85/467

Sequence 511

CCGCGGTGGCGGCCGCACCACGCTTGGCCGCCCGGGCAGGTCAAGCTTCGACCCACGCG TCCGAAATTAATGAAATGTTTTACATTCTTTTAAAAACCTTTGAAATATGGTGTGTATTT TATGCTTTAGCAAATCTCAGTTTGGACCATTTCAGGTGGTCAGCAATTACACATGGCTAG AACTAAGAGCAATCAGTTTTNTTCCACAGTTTTTCTAAAATTTTCTTGTCAAAAATCTTG ATGGTATGAATTACTCTTTTAAAAAGTGCACTTNACCAGCAACAGAAAANAACCCTGGAG GGGTATGGGTTTTAAAGCTGGTACCTNGGCCCGNTCTAGAACTAGGTG Sequence 512

CTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTCTCCCAAAGTGCTGGAATCA CAGGAATGAGCCACCCACACCCAGCCAAATTGGGCACAAATTTAAAATTTGACTTTATTA ATGATATGGTAAAGAGATCTAGCTTGGTCATGACACCCTTGTGTTATACGGTGACAGGCA AATCATTTAAAAATATCTAAACTATAATTTCCTGTAGTTCACATGAATTGGATATTCTGA AGCGGACGCGTGGGTCGACTTGTAACCTGCCCGGGCGGCN Sequence 513

Sequence 514

Sequence 516

Sequence 517

TCGCGGTGGCGGCCGAGGTCAAGCTTCGACCCACGCGTCCGGAGAAATACCATTTGCACA GTCAATCACTTCTGACCAAGCTTATCAGAAAAAGGAGAAAAGAATGTCTCCCCACTAAAT GTTCTAGGGNGGGNGAGGAAANCTAGGGTGGNTATCTAAATCAACAAATATTCTAGATAT TCCAATATCTAAATTATTGTTGGAAATACTCNTCCTGAAGNGNTCATTTGAACNCTAAAG CAGGAGNACAGCNTTTGTTGTATCAANATGGGCAGGGGTTTTTAAAGGGTNTCCATTTTT TNTTANTTTCCNCATTATTAAATTCCNTTNTAAATNNTTTTTAGGACCAAAAATTTTTCC CNTTTCTTNGAGGTNTTTAAAGGGGGGTTT

TABLE 1 86/467

Sequence 518

Sequence 519

ATTGGAGCTCCCGCGGTGGCGGCCGAGGTACAATGCTTCGACCCACGCGTCCGCTCACT
TCATCCTCCCAGCAACCTATTATGATCCATTGCCACACCCAACTTGCTGATGAGGAAAGTG
GGGCTTAAGGAAATTAAAGAGCTGTTGTGGGACTTCCAAAGCAGAAGACAGTAGGCTTTC
AGAAATTTGATAAAAATAGCACTTTGCATTTNTTGAATCTTGAGCTAAATGGAAATTAAT
ACTAAACATTCTNCACTGGTAAAATAGAGAATAAGGATATTAACAGTAAAAGAAAAGAAA
AAGAAAAGGAAATGTGCTTCCACAGATTTAGAAACATAAGTAACAATCTAAGGTTAAGGC
TTTTGGCACCTGCCCGGGCGGCCCGCTCTAGAACTAGTGGGAT

Sequence 520

CACTACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTCTTCGACC CACGCGTCCGAGCTATGGACCTAAGGCAGCGAGTGGATTCATTAGTCCTCTTTCAGCTGA ATGCATGCTACAGTATAAGAAAAAAGCTGCTGCCTATATGAAGTCTTTGAGAAAGGTTTG TTAGCTGCTGTTAATATTTAAATCAGAGGAAACATCAGGAGTCATTCTAGAGAATGGCAA GAGTTTTTCTGCAGTTTATATTGTTGACTTTTTATACGATATTGGGGTACCTCGGCCGCT CTAGAACTAGT

Sequence 521

CTACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTTCGACCCACGCGTCCGC
TAGGAACTATGTTAAAAAAAATTCAAGAAAGAATTTAAGGGAGATTACAGTGTTACTGTG
ACACCAGGAAAACTTAGAACTTTGTGTGAAATAAGACTGGCCAGCATTAGAGGTGGGTTG
GCCATCAGAAGGAAGCCTGGACAGGTCCCTTGTTTCAAAGGTATGACACAAGGTAACCCG
TAAGCCAAGGCACCCAGACCAGTTTCCATACATAGAACCTGCCCG
Sequence 522

CTNCTATAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCCCGGGCAGGTCCCAGAATA ACTAAATAAAAAAGGCTAAAGAAAACTGGAACAGTACTGCGTCTCCATCTGAGACGCA NTCTTCTACTTCCAGCATCGNAGAGAAGGGCTAGGGACAATTTTTTTTCAAAAGATTTAT ATACAGGCTTGAATCCAGAAATTAAGGNTAAAAGCATAAATATTGATAATTTCAACTAAA TTCAGAATGGNTTCAGAAAGATATGATACAACAATTTAGAATAAAACAAAGCAGAAGACC ATNATATTTTGCGGACGCGTGGGTCGAAGACCT

Sequence 524

CCGCGGTGGCGGCCGAGGTGTACAAGCTTCGACCCACGCGTCCGCTTAAAAGATTTTTTT
TTTATGTAAACTGTTGAATATTTGAAATAGTCCACTTCACCTTAATGGGTCTTGTCTATC
TTCATTAGTCTTCAAAGAAAAACCATTTGCTACCAAAGTAAATCAGTATTTTTGAATGTGC
TTCTCTTGTTTTTTGTTTATTAGCTAGTTCCTGTAAGCATTTCCACCAGAACTTGAGGCA
AATCGTAAGGAAGCTGTTTCTTTTAAAACACAAACCACCACCAAAAATTTAAATGTACCT
GCCCG

Sequence 525

CTACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTTTCAAGACCCGCCTGGC

TABLE 1 87/467

Sequence 526

Sequence 527

Sequence 528

Sequence 530

Sequence 531

CTACTTAGGGCGATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACTTTAATCCCGTCTTAC

TABLE 1 88/467

Sequence 532

CGCTACTTAGGGCGATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACAAATAAGCCCACCC CACTAGGAACTATGTTAAAAAAAAATTCAAGAAAGAATTTAAGGGAGATTACAGTGTTAC TGTGACACCAGGAAAACTTAGAACTTTGTGTGAAATAGACTGGCCAGCATTAGAGGTGGG TTGGCCATCAGAAGGAAGCCTGGACAGGTCCCTTGTTTCAAAGGTATGACACAAGGTAAC CCGTAAGCCAAGGCACCCAGACCAGTTTCCATACATAGAAAGTTACAGCTGCTTTTATAC CCCCTTGCCCCGCCAACGTAGT

Sequence 533

Sequence 534

CCGCGGTGGCCGCCCGGGCAGGTGTCCCCATGAGGGCCACGGCCCAGGCAGAACCCA TCCCATTTTATCCTTAAACTCAGAAGGAAATTTGTCTAAATATTAAAGGATTAATATGGG AATAAAAAATGAACCTTAAA

Sequence 536

Sequence 535

GAANTGGAGCTCCCCGCGGTGGCGGCCGAGGTCCAGTAGATTTGGAGAGTAATACAAATC
CTTTCTTTCTGGTTAGAACACACTGCCAAAAGCCACCTCTTTCATCTAAGGAAAAGATTA
AAAATGCATGTTGATATCTCCTAACTATCACACAACTTCCACTATTACAATGAAAAATCT
GGTCCCCTTTCATTGCCTTTGAAAACCNTTTTGCCGAGGTGGNTTTCAAAAAAACNCGNG
ANTTTNAAAAANTTGGNTTTGGTTTTACCNGGGGAAAGGGGACNTTTNNCNNTTTTTT
TTTTTTTTTTTTTTTTTTTAAANGGNGATTNGGTTNNGGTTNTNCCTGGGGCCAAAATNCC
NTTTTGNGGAACCTTTTTTGGGGTCCNAAAANNNACAAAANAAAGGGNTTGGGACNATNT
TTTTGNATNCNCNCNAAAAAAATTTTTTTTTTTT

Sequence 537

ACTTAGGGCGAATTGGAGCTCNCCGCGGTGGCGGCCGAGGTTCGACCCACGCGTCCGCTA GGAACTATGTTAAAAAAAATTCAAGAAAGAATTTAAGGGAGATTACAGTGTTACTGTGAC ACCAGGAAAACTTAGAACTTTGTGTGAAATAGACTGGCCAGCATTAGAGGTGGGTTGGCC ATCAGAAGGAAGCCTGGACAGGTCCCTTGTTTCAAAGGTATGACACAAGGTAACCCGTAA GCCAAGGCACCCAGACCAGTTTCCATACATAGAACCTGCCCG Sequence 538

TABLE 1 89/467

AGGCCCTGA

Sequence 539

AATTGGAGCTCCCGCGGTGGCGGCCGAGGTGACAAGCTTCGACCCACGCGTCCGCAAGT
TTTCAAAATGTAAATACTTCCTCTGTTTAACAGTCCTTGGACCATTCTGATCCAGTTCAC
CAGTAGGTTGGACAGCATATAATTTGCATCATTTTGTCCCTTGTAAATCAAGATGTTCTG
CAGATTATTCCTTTAA

Sequence 540

TACTTAGGGCGATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACTCCCATTTCCCTGAAAC AAGCAGCCAGCAACTATCTCAGAAATGTGTCATTTTTACTGGTTATAATTCTTAAAAAGC TTGTTTTCCTAAGATATGAAATGCCTGCCAGTATACAAACTGTTGTAACTACTTCCCTTT TTGCTTTTAGCGGGGAAAAAATAGCTTAATGACAGCATAGAATCATGTAGTAAATAAT TCATTTTTGAAAGGTTCAGCTATATCCTCTTCCATTTGTTTATTTTAAATGATCTAATT GCAAACATGTCATCACTCCCTT

Sequence 541

ACTNCTATAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTACATTGGA TTGTTAAAAGAGGAGTCTAGAAAAATTAATCCTGAACCCTAAAGAATAAATCTTAAGTGG TGGATACATGGGTTGAATAGTGTCCCCAAAATTCACATCCACTTGAAACTTCAGAGAGT GGCCATATTTGTAAATAAGGTATTTGCGGGTGTAATCAGTTAAGGATCTCAAGATAAATT CATCCTGAATTATAAGTTGTCCTTAAATCCAATTACTGGTATCCTTACAAGAAGGTGAGA GGAGACAGAATAGAGCCATCTGAAAAGGGTCAGAAA

Sequence 542

CTACTATAGGGCGATTGGANCCTCCCCGCGGTGGCGGCCGAGGTACTTCCTGGAAATCAA TTAACTGAGTCTTTTGAAACCCCTAGAGAAGATAGGAGAAAATTGGTTCAGANCGAGCAT TTAAATTAAGTCAGCAAAGTCAGAATTTAAAATTGGGCAATTCCTTGTCTACATTTTCTT TACACTCAA

Sequence 544

CTNACTATAGGGCGANTGGAGCTCCCCGCGGTGGCGGCCCCCGGGCAGGTGCCAAAGCC
TTAACTTAGATCGTTACTNATGTTTCTAAATCANGTGGAAGCACATTTCCTTTTCTT
CTTTTCTTTTACTGNNAATATCCTNATTCTNTATTTTACCAGTGGNGAATGTTTAGAATT
AATTTCCATTTAGCTCAAGATTCAAGAAATGCAAAGTGCTATTTTTATCAAATTTCTGAA
AGCCTACTGTCTTCTGCTTTGGAAGTCCCACAACAGCTCTTTAATTTCCTTAAGCC
Sequence 545

ACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACCATCACACAGAAGGAGGAGGAGGCTAATCCAGTAACAAAACATTCAAAGATTAAATTGTAGATATGCACCTCTGTATT
TGGCACTGTTGATTAATATTATAACACCTTCCTCTCAAAGACAGGCATTCTTAAGCGTTA
GTCACAATATACCAGAATTTGCTATTCATATTAAAACCACCTTTTAAACTTTATAACAGT
AACCAATTATTATAGTTTTAAGAAACAAAACGCAATGAGAACTGGGAATGGGAATTCAAAT
CCTCCAAATTCTTGCTATGCTCCAAGCTGCCATCCATAAAACAGGTTTAATTTGGGTAAT
TTTTCCATTGTGGGGAAGGGTCAACAAGAAACAATTTAAAGACAATATTTTCCAATACAA
ATAAAGACATACACTTTTTGTT

Sequence 546

Sequence 547

TABLE 1 90/467

Sequence 548

CTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGCCCCGGNAGGGTCGCGGTGGGTCGA CTNANGCTAGAGAATTGTAATACGACTACTATAGGGATCTAGATCACGAGC Sequence 549

Sequence 550

CTATAGGGCGAATNGGAGCTCCCCGCGGTGGCGGCCCCGGGCANGTGCTTCGCCCCAC
GCGTCCGNAATAATTGGAAANGGCCTATAGATTAAAAAGCTGAGAAAGTATATGGTAGGG
AGCACACTCCCCACAAGTATGAACTCTGNGATTACGACATCTCATAAATNCATGAGCACT
CATGTTGGCTTGCTTTGTAGCTATGAACTTACCCTGTATTATTGAAACGTCAGCATAATG
ACTGGAAGGAGAAATTGGTCCATTTTAGAGCATTACTATTATGCTATCTGTCCATTTAAA
TTAATAATTGCATTAAATTCATTTTAGAAGGNGCTATTACATTNGTAGTAAGAAAGTAAA
TTCATATATAAATATTTGATTATCAGATGGTTTACTTACAGATACTTATTTTCCTGTAAA
ATAGGAGAGAGTTTACCTGAAGAAAAATAAAACTTTTNACTTTTCTGGGAAAAAAA

CTACTTAGGGCGAATTGGAGCTCCCCGCGGNGGCGGCCGCCCGGGCAGGTACCAAGTGAA
TTTAAATAATTGGTGTGGATTGGCCAGTAGCTAAGAAGTGGGCTTTTAAAGAGTNTTGAA
NATNGAANGGGTTTTTNTTTCTTTTTTAAAAAAAGAAAACAAACTATTGATTGTCTATAA
TGAAAAGCTAGGNNTTGCCCTNTTCATGTNTACTCTCCTTCCAAATAGTTATATCCAAAA
CTGTTTTTCCCTCCCCTACCTTGTCCCCCCTATTAAAATANAAACNGGGATTGATTAA
TGTCCCGCTCCTGAATACATGTAAAATTTGTACCTCGGCCGNTCTAAAACTAG
Seguence 553

CACTACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGTTAAAGGAATAATCTGCAG AACATCTTGATTTACAAGGGACAAAATGATGCAAATTATATGCTGNCCAACCTACTGGTG AACTGGATCAGAATGGTCCAAGGACTGTTAAACAGAGGAAGTNTTTACATTTTGAAAAC Sequence 555

TABLE 1 91/467

CTACTTAGGGCGAATTGNANCTCCCGCGGGGGCGGCGGCGCTAAAGGAATAATCTGCAGAA CATCTTGATTTACAAGGGACAAAATGATGCAAATTATATGCTGTCCAACCTACTGGTGAA CTGGATCAGAATGGTCCAAGGACTGTTAAACAGAGGAAGTNTTTACATTTTGAAAACTTG CGGACGCGTGGGTCGAAGCTTGTACACCTT

Sequence 556

Sequence 557

Sequence 558

ACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTCTTCGACCCACGCGTCCGC
ATTTATTAAGGCTTGTATATGTTCAAGATCCAGTGAAGACTGTCTTGGGCGTGTATAATT
GATCTTAACCACAAGGCTGAGAAGTTATGTGCAGGGCTTATGATGCTACTTCCAAAGTAT
TAAATCCTCCAGAGAAGCCTGTAGTGTGGGATGCAAACTATTTTAAGTGTGACCATGAGG
TGTTTTTTTGTGGACCATTTTAAANCCAATGATAGGTTCTAAAGCAATCTCAACCTGAGT
TAGG

Sequence 559

Sequence 560

CTATAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTGTACAAGCTTCGACCCACG CGTCCGCAAGTTTTCAAAATGTAAATACTTCCTCTGTTTAACAGTCCTTGGACCATTCTG ATCCAGTTCACCAGTAGGTTGGACAGCATATAATTTGCATCATTTTGTCCCTTGTAAATC AAGATGTTCTGCAGATTATTCCTTTAA

Sequence 561

Sequence 562

TTAGGGCGATTGGAGCTCCCGCGGTGGCGGCCGCCCGGGCAGGTGCCAAAGCCTTAACT TAGATTGTTACTATGTTTCTAAATCTGNGGAAGCACATTTCCTTTTTCTTCTTTTTTCTTTTTTACCTGNTAATATCCTTATTTTACCAGTGGAGAATGTTTAGTATTAATTTCC ATTTAGCTCAAGATTCAAGAATGCAAAGTGCTATTTTTATCAAATTTCTGAAAGCCTAC

WO 01/070979

PCT/US01/09126

TABLE 1 92/467

TGTCTTCTGCTTTGGAAGTCCCACAACAGCTCTTTAATTTCCTTAAGCCCCACTTTCCTC
ATCAGCAAGTTGGTGTGGCAATGGATCATAATAGGTTGCTGGGAGGATGAAGTGAGCGGA
CGCGTGGGTCGAAGCTTGTACCT

Sequence 563

Sequence 564

CTTAGGGCGATTGGAGCTCCCCGCGGTGGCGGCCGAGGTCAAGCTTCGACCCACGCGTCC
GTGCAAATTTGACTTTGTAAATGGCCCTTGGGCTCTGGGAGGAAAGCAACTGTTGGGCCA
TGTGGTTGTATCTTTAGTTTTGTAAAGAATTGCCAAACTGTTTTATAATGTGGGTATATC
TTTCCACACTTCCAGCACAATGTATGAGTGATCCAGTTTCTTAGCACCATAGTCAGAATT
TACTGTTGCTACTATTTTTTAGCTATCCTGATAGATGTGATAGTGATATTTTATTCTGGTT
TTGAAGCAGTGTCATTGTCTGGGGTAAATCCTTGAGGTTTGTTGTCTCAGTCAAGGGGAA
TCAAGGGACATGGACACACAAGTAGTGAATTTAAGAGTGGAAGTTTAATAGGTGA
Sequence 566

Sequence 567

Seguence 568

Sequence 569

CTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTACGAGCGGCCGNCCGGGCAGGTACACAAACCAGATGTATGCANTGATGCCAAAAGTCATCTNAAAATTCCAAGCTGACCTAGTGCAACACATTTACACTTGGATAAACTATCACCTTGAAGATTTACTTTGTATACTTCAAAAGATCTGGTCATGAAATTTTTAGCTAATACATAAAGNGCCGAATTGAAATCCAGAATACAATAGCTNTGAAGGGCCGCTAGAGTGCAGATAACCAACCCATTCTACCTAAC

TABLE 1 93/467

Sequence 570

Sequence 572

TTAGGGCNATTGGAGCTCCCGCGGTGGCGGCCGAGGTGTACAAGCTTCGACCCACGCGT CCGCAAGTTTTCAAAATGTAAATACTTCCTCTGTTTAACAGTCCTTGGACCATTCTGATC CAGTTCACCAGTAGGTTGGACAGCATATAATTTGCATCATTTTGTCCCTTGTAAATCAAG ATGTTCTGCAGATTATTCCTTTAA

Sequence 573

GAATTGGAGCTCCCGNGGTGGGGCCGCTCGAGGCCGCTCTGACCTCTTTAAGGNANACT TATTATGCTAATAGTTGATGCGCCCTTTTGCTGNANCAGTTACCATAGGTTACATGATAA NTATATTGTTGNGATGATCTGATTNCCTGNNTNCCCCACCCNTGCAAAACAACAACAA AAACCTTTACCAGGCTNTATAACANGGGGACCAAACTTGNTTTTGCTCATCATTGCCGGA CG

Sequence 575

AGGTACTTACCCCAGACACGACGCCGCTTCACCATGATGATGACAACAGGCAACTTTT
TTTTTGGAGTTTCAGCTTGCTTCCAACAGGGACGGTGAGTGTGAGGTTTATTCCCATTTC
TAAGACGATAGAAGTTTTCAGCCTAAGCCGTATTCCTAGGTAAGCAGCTGGATTGCAAGT
TTTGTCTTGGAAATTCTCCTTAATGACTAAAAGTTAAAGAATTAAACAACCTAGCTGGGC
TTAAATTTCTTNCTTACCCATTAGAAGTACCCTTGCCC

Sequence 576

Sequence 577

TABLE 1 94/467

AGGTGTCGACTCAAGCTTTCAGATATAGGCATTCCAGAATCTTCTCTTTACGAGTTCACC TGCTAGTATAATCTCCACAACTTGAATGGCATTGGTTGTTCTGTAATTCCTGCCAAAAGC ATCACAAGTTGTACCTGCCCG

Sequence 579

CCGGGCAGGTTACAAGTCGACCCACGCGTCCGCTTCAGAATATCCAATTCATGTGAACTA CAGGAAATTATAGTTTAGATATTTTTAAATGATTTGCCTGTCACCGTATAACACAAGGGT GTCATGACCAAGCTAGATCTCTTTACCATATCATTAATAAAAGTCAAATTTTAAATTTGT GCCCAATTTGGCTGGGTGTGGTGGCTCATTCCTGTGATTCCAGCACTTTGGGAGACCT Sequence 580

Sequence 583

AGGTCGCCATCACACCCGGCTAATTTTTTTTGTATTTTTAGTAGAGACAGGGTTTCACCA
TGCTAGCCAGGATGGTCTCAATCTCCTGATCTCGTGATCCGCCCACCCTCAGCCTTCCAAA
GTGCTGGGATTAAAGGCGTGAGCCACCACGCCTGGCCAGGAGATTCTTAATTATTTCTGA
ACTCTATCAGTTTTGTATTAGGACATCTTATTTAATATTATCAAAAGATAGTTCCTCTTA
GAGGCATAAATCAGTCAATCAACAAACAATAGGCAATCACGGACGCGTGGGTCGAAGACC
TGCCCG

Sequence 584

AGGTGTACAAGCTTCGACCCACGCGTCCGCATTTTTCTGGTGTTCCCTCTTACGTGCACA CCCCTTGCTCCCCTTTGGGTTGACTTATAATCTGACTTTTGTGACAGATGTTAGGAGGTG GAGCAAAGGAATTCAGACCAATCAGTTAAGAGACTGCTGTGGGGGTAAGAAAAAAATTA GCCTCTTAAAATTACTCTTATCAAAGGAAAAAAAGTTGGAAGCACATGATAGTATAACCA GAAACATGACACAGAAGAATTAAGGGAAGAACCTGCCCG

Sequence 585

CCGGGCAGGTGGAAAGGTGGGTGGGGAGAGGGAGGCTTATTTGTTGCTGCAGTGTAACTA
AGTGAAACCTAATTCATATGACTCAAACTAAGGTATATTTGGTTAGATCTAGGTGAGTTC
TACTTTAGAGGAAATCCTGGTAACTGTTTGTTTGTTTGTAAGTTATAGCTGTAATTATT
TCCCTGTATTCAAAGCCCCCAAACCCTGCATTCAGATACTATGCATTTAGACTTCCTTAG
GCAAAGTCAAGGCAACAAGCTGATGATTCTAAGCTATTATTCAAGGAGTATCTACCATCA
TAAAGGTGGTTTAGTCATATAGATAATATCAATCAATAAT
Sequence 586

TABLE 1 95/467

Sequence 587

Sequence 588

Sequence 589

AGGTACATTGTTAGACAAGTGTTTATCACTAATCTGGAATACATCATCTTCAATAAGGCT CTTGTTTTCCTCCAAGCTGCACTGCTCACACTGCTCAGTTTTCTGTTAAGCAACCTGCTC ATTATAGTAGAGCACCAAGGTGATCTGTTCTTCTGTTCTTCAGAAGTTCACTATTTCTTG TTGCAACAGGGCTACATGATTTTAAGATTCCTCAAAGTCAATACAGAATTAACATTATTTT CCATTTCCATTCTGTATATCTTCACATTCCATAAATATAATACTCATGTATACGTTAAATTTCCTTATAAGTTCAACACACTTGAAAGCTAAAATAAAAGACTTCCTACTAG

Sequence 592

AGGCCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTCTTCGACCCACGCGTCCGTTTA
CAATATGGTGACAACAGATAACTGTAAAAACTTCTTTTTCAAATAGAACCAGCAGGAGCA
TGCATGGAACACATATACCAAACATCTTTCTGATAACATTAAACATTTTTAAAAGATGTT
AAATGTTCTTTTCATTGNGGTGCTTCAGATTCCTGATTCTAGAACTTGTGTGTGTGGAAC
CTGTGTGCTAACTATTCTGTTGGAATTTACCAGCAAAGAATTATCTAAGAATTTTCAAAC
TAAATGATGGGGGAAGGAACTAACATTTTTGCAGNCCCTGGAAATGTAAAATGTTGTACC

TABLE 1 96/467

Sequence 594

Sequence 595

CTATAGGGCCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTGCCAAAGCCTT
AACTTAGATTGTTACTTATGTTTCTAAATCTGTGGAAGCACATTTCCTTTTCTTCTT
TTCTTTACTGTTAATATCCTTATTCTCTATTTTACCAGTGGAGAATGTTTAGTATTAAT
TTCCATTTAGCTCAAGATTCAAGAAATGCANAGTGCTATTTTTATCAAATTTCTGAAAGC
CTACTGTCTTCTGCTTTGGAAGTCCCACAACAGCTCTTTAATTTCCTTAAGCCCCACTTT
CCTCATCAGCAAGTTGGTGTGGCANTGGATCATANTAGGTTGCTGGGAGGATGAAGTGA
Sequence 596

Sequence 597

Sequence 598

Sequence 599

Sequence 600

AGGTCAAGCTTCGACCCACGCGTCCGTGATGCTGGCTTCCCGGTCAAAGCTGAGGAGTTT
TGTGGTGCTTTCTCAGGAACCTTCTGTCACGGAAACCATTGCACCCAAAATTGCAAGACC
TTTCATAGAGACTTTCCTCAGGCCCTCAAGAGTATTTGAGTATCTGGAGGAGGATGCCCA
GAAGTCCNCACAGGAGGGGGTGCTTGGGACCACACTGATGCTCTTGNCATTCAGACTC
TGAGAAACATGCCGCGTGATGAANAAACCATCCCAATTANANGAAGCTAGCTGNNTTNCA
TTGNAGCAGCTTTACCCCAATTT

Sequence 601

CCGGGCAGGTCAAGCTTCGACCCACGCGTCCGTGATAACTTCTCCTAAGTGCCAGGCATT GTATTACATGCTGGGAGCACAAAGATGAATAACAATAGGTTCACAGAAAAGATGAAT TGATTGAGAGAAAAAGAACCCTCCAGGAGCCCTCAGCGTAGTAGGGGGGTTGGTGTTGGAG GGTGGAGGAATGGAAAAGGNCCTGAAATGCANGCAGAGAAATGATGAAACAATTCCNGGG GCTGCGGNGAGGTTANATGAATATCTTTACAGCAGCCTNGAAGACTGATCANGTTACTAT WO 01/070979

TABLE 1 97/467

PCT/US01/09126

ACCCTCTCTCTGTCCACGTGCATTTNA

Sequence 602

Sequence 603

ATTGGAGCCTCCCGCGGTGGCGGCCGAGGTAGCTTGAGTCGACCCACGCGTCCGTTCAG
ATCCGTTTCAGAAACGTGAGTCTCTAGCTCAGGAGATTTCCACAACTGTCCTTAGTAACC
TGATCTTATTCTCATGTTTAACCTTGGCAGTGGGAAGTTCTTCCTGGTATCCTGCCTAAT
TTACTGGAGTTGGCATTAATGCCATTTCCCCCTAAGGCGTGGCTCTTGGACCAGTATCAC
CTGAGAATTTGATAGACATAGACCCAGAGTTACTGAGGGCAGGTGCTCTGTTTTGGGGAC
CAGCAATCGGTGCTTTAGCAAGTNCTTTGGGTGATAGGGGTTNTGGAAACTACTGCTCTA
AAGCATNATCTGTTTTTGAC

Sequence 604

Sequence 605

CCGGGCAGGTACANNTTGTGATGATTTTGGCAGCAATTACAGAACAACCAAGGCCATTCA AGTTGTGGAGATTATACTAGCAGGTGAACTCGTAAAGAGAAGATTCTGGAATGCCTATAT CTGAAATCAGAATCCTAGTAGTTTGTAGTTTGCCTCTTCCTAGAAGTTCAAGAGACTCAA GTCATAGGCTACAGATGTACCTN

Sequence 606

AGGTCTTCGACCCACGCGTCCGCAACTGTTGATCTAACTTTTCCACTTGAATGTCTAATT GGCAAATCAAACCTAACATGTTCCAAACGAGTTCTGAAGCACCCCCTCTGCCAAATCTAC GTCTCCCACAGCCTTCCCTATTTCTCTACCTGGTACCTGCCCGGGCGGCCGCTCGACCTG CCCG

Sequence 607

AGGTCTTGAGTCGACCCACGCGTCCGGAGATGTATACGCCACTATAGGAACTATAAGAAA
AAGTCAAATGGAAATCTTATAAATAAAAACCACAGTCACTATAATGAGGAAATACTTTGA
TAAGGTGTCAGTGAACTCAAAAATCAATCAATAGAAACTACAACTAAAACTCAAAGA
GAAAAAAAAAGATGGGAGATAATTATTTTTTAAGAATTGGTCATCAAAATGTAGCAACAA
GTTTGCCTTATCCTATATCATTTGAATTTTCAAAAAAATAAGCTCATTATACAATCTTTAA
AATATTTTGAATAGAACTGTTTCATGTGTTATTTGT

Sequence 608

Sequence 609

AGGTCAAGCTTCGACCCACGCGTCCGTGATGCTGGCTTCCCGGTCAAAGCTGAGGAGTTTGTGGTACTTTCTCAGGAACCTTCTGTCACGGAAACCATTGCACCCAAAATTGCAAGACCTTTCATAGAGACCTTCCTCAGGCCCTCAAGAGTATTGAGTATCTGGAGGAGGATGCCCAGA

TABLE 1 98/467

AGTCCGCACAGGAGGGGGTGCTGGGACCACACACTGATGCTCTGTCATCAGACTCTGAGA TTACACCAATTGAA

Sequence 610

ACTITITITITITAGCTTGAGTCGACCCACGCGTCCGGGGATCTAGATCACGAGCG GCCGGCCGCCGGGCAGGTACGGAAGCCATGCACTTGCCTCCTTCAGAGCTGGGATTT TTTTCATTTGCTGGCTGTGAGCACACACGCCCACAGGTGCCTAAGCCTCTTGTATG TGTGTTTTGAACTGTGTCCTCTGAGTTCTGTGTCTGGGTGCATGCTCTCCTCTTAGCGTG GGTCTCCCTTCCCCTGTGTAGCACTTCACAATGTTAGGCATTTGTCTGTGATAGCAGCTGT TCAGTAATTTCCTACTT

Sequence 611

AGGTTTCGACCCACGCGTCCGGAATTTATCTGGCCAGGCATTGGTAGTTTACAGAAGTCT ACCAGATGATTCTAATGTGTGGTCAAGACTGAGAACTATGTGTTTAATTGGGTTCATTTC AAGAATACTGTAAAAATTTTATCTAAATACTAAATATCCATAAAAGAAACCTCGGTAATC AGGCCAGGTTTTTGAGTTTTTCCAGATTAGCCCAACTACAGGGGAAAGAGACTTTCGCAC TATATCCCAGAGTCTCTGCTCCTGCTTCCAGCCTCAATGCACTGGGCCTTTCTGCTGCCT TGGAGCACTTAGAGGGATTACAGGAGGAGTGATCTGTGGAGTT Sequence 612

CTAAACAATGCAAAAAAAAAAAAATCTAAAAATAAAAGAATTTTATATTTGAAGTTATTC TGGATATTCGCACCATTTTAGCTTCTGAAAAAAATGCAACTATGAAATGAAGACCTCATA TATTTTCATTATCAATATAATGTTAAAAGTTTCATTCCACCGGGTGTGGNGGCTCACAC TTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCATGAGGTCAGGAGATCGAGA **AAGGAA**

Sequence 613

CGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACATTGTAGTTTTCTTAGCCATTTTTC AATAGTCTACACAGTGTTTATGTTTCCTTTTATTTGTGTATAGTGGAGTAGAGGGGAGGT TTTTTTATTCAAATAGAAGAAGCTAAAACTCAAATGCAATGTCAGATCTCANAATAAACT GACCCAATTTCTGAAACCCAATAAACACATTTCATTTGTAATATTCTTTATTATATAGCT CTATGAAAAGTAATTTGTGACTTTCGATCTTAAAAGAGAGTTTTAAAAATACACAGTAAA TTGAAAGAAAACTACTACATTTAAAACAGTATTTTCCTGAAAACATAGAATGAAAATGC AAGTATTTTGTGCATGGCAGCTGTTTTTAAGGAACCAATGTTATATATGGNGAATTTTGT GGAAGACTATGTCTCTTAAAATATTTCTTATAAAATANCATGGCTTTTTAATAGCTGGGA ATCTGANGNNGGATTTCCCATGAAGACCTTAAATGGCTNNGCAGGAATTATAAAAAAG Sequence 614

ACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACATGCCTGTAATCCCAGC TGTTGGGGAAGCTGAGATGGGAGGATTGCTTGAGCCTGGGATACTGATATTGAGGCTGCA GCGGGCCGAGAATACCACTGCACTCCAGCCTGGATGACAGAGTGAGACACTGGCTCAAAA AATGAAACATTATTGGGAGAGTTATAGTCATAATCATCTTACTGCACTATCAATTAAAAA ATACATCATTTTTAGAGCACAATATATACCATAAAGAATTATTCAAATAGTCTAAATAT TACGATCAAATTTTTAATAGACTTTGTTACTTAAACTAAAACTGTATTAGTCTGTATTAG TCAGCTCAAGTTGGGATTCACACCTGTAATCCCAACACCTAGGGGGGC Sequence 615

TAAATGTCTAACAACAGAGAATGGTTCTCTGTTGATACAAAATTATGATACATCAAAAAA GCGGTGGCTCACGCCTGTAATCACAGCACTTTGGGAGGCCGAGTCGGGTGGATCACGAAG

TABLE 1 99/467

TCAAGAGATTGAGACTACCCTGGCCAACACTGTAAAACCCCGTNTCTACTAAAATACAAA AATTAGCTGGGCCGTGG

Sequence 616

TTAGGGCGAATTGGAGCTCACCGCGGTGGCGGCCGAGGTACTGAATAACTGCCAATGCCA
TCTGCCTGTGGCCTTCTCAAGTTTGTCTGCACCTGTGGTTATCCTGACTTCAAACCCGGG
GAGACAGAGGCTAGAAGAGCAGCAGCTCTTGTGTATTCTCCTGTCCAGTGCAAAGAAC
ATCTGGAACTCTGAGCCCTAACCTTAAATGCAAGACCTNATCTGCAGGTGTTCCTNATCC
TTTTAGCCCCTCAGTGATGTAAGCAACAAACGTCACCCANCTCCTGGGGCACACTTNACT
CCCAGATGAGCTTGTCCTGGATTTGCAGGGAGCCTGGCTCCC

Sequence 617

GCCGGGCAGGTACAGATGGGGTTNCACCGTGTTAGCCAGGATGGTCTCGANTTCCTGACC TCATNANGCATCCANCTCGGCCTCCCAAANTGCTGGAAATTACAAGGGCGTTGAGCCCAC CCGCACCTGGGCCAGAATCTTACATATTTCTTAAACATCATTAAATATATTGTATTTT TTACTTTTTTTTGAATAGGGGTCTTGCTATGTTGCCCAGGCTTGGTTTTGAACTCCTGG CCTTNANGAGATCCTCCCGCTCTCAAACCTCTCAAAAGCAATGGGTA Sequence 619

AGGTACCCCATTTTATGCCATAAGTCAGGTTTCTCCCTCAATAGCCCTTTGGAACTCTCA AGGTCCAGAGTGGCATCAAACCAACTGACACATGAGTTGATACATCATGTGCTGCCAACA GAGAAATTAGTCTGTGCCAAACTCAGCACAATCCTGCAGTTCAAACCAGAATTTCAAAAA

Sequence 620

ACCAAGATTTGAATCATGCTTTCAAAAGCTAATGTGAAGTTAGACATATTTGGTTTCATA ATCACAGAATTTTAAAAACACCAGGTCTGCAATATTCAGAAATCACCATTAACGCTCTCT TGACACATACAATCAATTTCACTTTAGATCGCTGATTTTCTTAACAACTGATTTAGTTAT TTCTGAATACTGCTAGAAAATTCAAAATCTACAATTAAT

Sequence 621

AGGTACATCACCCTGCTGAGGGACATCCAGGACAAGGTCACCACACTCTACAAAGGCAGT CAACTACATGACACATTCCGCTTCTGCCTGGTCACCAACTTGACGATGGACTCCGTGTTG GTCACTGTCAAGGCATTGTTCTCCTCCAATTTGGACCCCAGCCTGGTGGAGCAAGTNTTT CTAGATAAGACCCTGAATGCCTCATTCCATTGGCTGGGCTCCACCTACCAGTTGGTGGAC ATCCATGTGACAGAAATGGAGTCATNAGTTTATCAACCAACAAGCAGCTCCAGCACCAG CACTTCTACCTGAATTTCACCATCACCAACCTACCATATTCCCAGGACAAAAGCCCAGCC AGGCACCACCAATTACCAGAGGAACAAAAGGAAT

Sequence 622

NCCGGGCAGGTACTGGATGACAGCAAGTGCACACATCAAGAGAAAGTTACCATTCAGAGG TGCAGTGAGTTCCCTTGTCCACAGNGGAAATCTGGAGACTGGTCAGAGGTAAGATGGGAG GGCTGTTATTTCCCCTAGGTCATCTCTTACATTCTAGTTCTGGTGCTCTCTATCTGTTTA AGACAAACCCTTGNGCACCTTTCTCCCACCCCTCCCTTTCTCCCTTGTCTCCCTTGAGAA AACAACTNCAGTTCTCTGCCTGCACCATGACTGTCGATACGCGGGGGCAGTTCGGCGGTC CCGCGGGTCTGTCTCTTCA

Sequence 623

TABLE 1 100/467

Sequence 624

Sequence 625

Sequence 626

Sequence 627

Sequence 628

Sequence 629

TABLE 1 101/467

CCCCGCGGTGGCGCCCCGGGCAGGTACATTATTGCTTCCTGGGAGAGCTGACCATGA GTCAATTGGCCCACAATAANTTATNAAATGAAAACCGGCCATCATCTGCATCTTATGAGT GCACGTCATCAGAGATGTCCACTCCAGTTACAAGAAAGTCCTGAGGGCTTTCTTGGAGCC TGANGGGCGCTGGAGGTGAGACCTGGAGGTGAGCAGGAGTTAACTAGGATGAGGGACNGG CGCAGCATACAGGAAAAGCTGCCTGGGGGGAGAAAGGACCAACAGCAAAGACTGAGAAAAA AATGCTGTTGTGACCAGGGTTCAGAGCGGGCATGGAGGACTGAGGGTTCAGAGCGGGCAT GGAGGACTGAGGGTTCAGAGCGGCATGGAGGACTGAGGGTTCAGAGCGGGCATGGAGG

Sequence 632

GCCGAGGTACTTCCCTGAGCAGTCGAAGTGGATGCCCAGACCAATGGCCAGNGCTAATAT NCAANGCAATGATCCCAATGACGATGATTGGAAAAAACTTCAATGGCAGCAGTGACAGGA TCTGTGCAGCAACAGCATCTGCATCTGGTGCAACAGGACTTATTTTCAAATCATCAAGGC CAAAAAGCGATCGGAATGAGAAGGGGGCTTCAACAGCAGCGGATCATTTTCCCCCATGG TGACTATTTCAGGACCTCTGACATCCGGCTCCGCCTCCACCTCTACCTCATAATTCCCGA GTCCCAAAAATGTAGATGGCACCACGGAAGAGATAGTAGGCCACAGTGTTACTGGCTTCC CATAAACACAGCCCTTTCCTGGCTCACACGGGCATGACCTAATTAAGAACCCCCGCGTAC CTGCCCGGGCGC

Sequence 634

CTACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTACAAAAGTGA AATCCCTAAGTCAAACTGTGGCTTATAAGCAGAAATCCTGGTTAGTATTTCAAAGTTCTC TTAGCGTTTTCTCCTGCGACTTAAAAAGACTTAAAAACGTGAAAAGACATGGACGTAAGAC

TABLE 1 102/467

TGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACGGGAGTAAAATAAAAGGGTCG
GATTTTGTAGGATTCTAAGGAAGAGGCAGTGTGCTCTGTCCACAGGCTGCAAGGTGAGAA
CCTAAAAGAATGAGATATATTCCCATTTTGGAATGGCAATCAAAAAGAGGATCTCTCTGT
CAAGTCTTTACATTAATGCTGAGTAACAATCTCAAAAGCCTGCCCATTCCCCTTTAGACA
CATGTGGCAAAAGCAGAACTGAAGGAATGGCCAAGGGGCTTGAACAAGTAGAGAGACCGA
CAGTCTTTCAAATTTCAGGGAACCCCAGATACATTTTGGGGGAGCCACTGTTTTCCCATT
TTCCTGAAAAGTTCTTGCAGGTATAAGAAATAGGAATAGAAATTGAATAGGTTCTGGAGC
CAGGGCTACAAAGGCCCCAGCTCTGATCTGTTAGACTGAAAACCACACATCAGATGAAAT
TATATNCACAAAAAGGAGAGTCCTTAAAAACAGCCATTTCGGTCCCT
Sequence 636

CCGGGCAGGTACCAGGAGAGATCTGAGACANGGTATGAAGTAAAAGATTTAAGATTGGAA GTGGAGAGTGTCATGGACCAGTGCCTTTCGGATGGGTGACTTCTGGAATTCTTGTTAGGC ACAGCGGAGGTTGGTCCTGTGGGAAAGGAAGAATATTTCCGGGGTGAGGAGACTTCGGGG TGTGGGCCGGGTGCCTTTTTAAATTTGGAATGGTGTATACAATAGGGAAAGGATGTTAAC TTTGCAGCAGCGGGGATGGTGAATATAACCTGATAGGGACCCTTCCATTTTGTTGGAAAG GGGAGGAGGGGGTGTGCTACCCAGACCCAGTCTCCTGGNTGTAAGGGTAAGAAAGTGAATT GGGAAGAATCCTCAGG

Sequence 638

Sequence 639

Sequence 640

AGGTACAAAGGTTCAGTGGTGAGAAGAGGGGAGCAAGGCCTTTGGAATAATGAACTCCAGTTGTTCCTCATAGGTGCAGCAGAAATAGCGAGAGGTCAGGATTATGGAGATTAGGTAAGGCGAGATCATCCAAGGGCCTTTTGCTTGGTAAGCCATTTTACTTTAATCTTGAGTGCCATAGG

TABLE 1 103/467

Sequence 641

Sequence 642

AGGTACCTCGTTTCTGAGGATCAANACCTNAGNGACCGNGTGTGTGTGTGTATTTGTG TGTGTGTGAGTCCTATTTGGGCCCCGCCTTTCAGCCCTGTCTTGCAGC Sequence 643

Sequence 644

Sequence 645

GGNCACCACACTCTACAAAGGCAGTCAACTACATGACACATTCCGCTTCTGCCTGGTCAC CAACTTGACGATGGACTCCGTGTTGGTCACTGTCAAGGCATTGTTCTCCCAATTTGGA CCCCAGCCTGGTGGAGCAAGTCTTTCTAGATAAGACCCTGAATGCCTCATTCCATTGGCT GGGCTCCACCTACCAGTTGGTGGACATCCATGTGACAGAAATGGAGTCATCAGTTTATCA ACCAACAAGCAGCTCCAGCACCCAGCACTTCTACCTGAATTTCACCATCACCAACCTACC ATATTCCCAGGACAAAGCCCAGCCAGGCACC

Sequence 646

TABLE 1 104/467

Sequence 648

Sequence 649

AGGTACTAGTATGAAGGAAATAATATCCACACACTGATACTGGTCCAGCNGAAACCAAGA CCGCTCCTGGTGCATTAACTTTTAACAGAGCANGGACTCANTTCTCTGAAAATAGTGCCA TAAAACATGTGCTCCCAGAAGAATAAATATTTGGCTTGCTAGAATTTCTGCNGCTTTTNT GTAAAAGTTGATTATTCGGTATTAAAGAGGAGTATCAAATATGNGTNNATGNANNAAAAA CTTGGAAANAGTANNGGACCNNGGCTTATCTCNTCATTTTCATTCTGCACACTNCAANTC ANTCNTTTTCCCATCTTNNTTCCCNTCTCTGNAATTTATCACCCTCCCCCTCT Sequence 650

Sequence 651

TABLE 1 105/467

ATTTTTNNGNCCAAAAATTNGGCAAAAAAAA

Sequence 653

Sequence 654

CNAATTGGAGCTCCCGCGGTGGCGGTCAGTTNGTCTTAGAGATACCCATGAGGTCACCT
ACTCAAAATGGGGCTCAGAGTAGCCTTGTCCCATTCTTGTCCAGTGGGCGCAGCTACAGT
CTNNCTGGNNNGGAGTGACTGGAGGCTGTCCCCACGTCCCACTTCAGTGAGGCATTCATG
TGCACCCAGCACACTTTCTAGCTTTATTTGCCTGGAGGGGAAGATTCTCCAGAACCTTGT
TAAGATGCACAGNGNGGGCCCTTGGACTGGCAAGTGTGGCCTTNGGCAGTCCCTNGGAGC
TTGTTAGGAATGCAAAATNTTAAGCTTCTTCCTACTGNATCTAAAGGTTGANTTTAAACA
AGATCCAGCTTGTTTCGTTTCACATGAAAGTTGAGGCACACTGCTCTAGAAAGTTCTTTT
ATCTTTACTGGCCCACCAAAGTAATCAAACTTTGNGAAGTACCCTCGGNCCGCTCTAGAA
CTAGTG

Sequence 655

Sequence 656

TABLE 1 106/467

Sequence 658

ACTTAGGGCGAATTGGAGCTCNCCGCGGTGGCGGCCCCCGGGCANGGTACGCGGGGACT TGACTTAAACTCTGGGGCCCGGGAGGCCGCCGGTTTTCTCCCCGCTTGCCGGGGTGGTCC TCTTCCCTTTGTCGGACCAAAGAAGTAAACACTGTGTGGAGAGGGACTGACGTGTTTGGA GGGAAATGGGAATGTACCT

Sequence 662

WO 01/070979

TABLE 1 107/467

Sequence 664

CTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGGGCAGGTACTGCTGGTTTTCTGGT GTTCCTACAAGCTGCCTAGGTCTCTTTTGTTCTCAGCAGTTCCCAGGCATGCAAAAGTTG CCAGTTCTGTCAGCATTCCAAGTCAGGTAAGACAGAAAGCCATCTCTTAGGCAGTCCCCA GAAAAGCTGAAAGGTTGGATATACTTTCTACTCTTTTCTTCATGAGAGAAAGGCC ATGTGGGCATTTTCTCCCAATAACACTGAGTTCTGTTGTCTTCTGTCGGCTGTGCTGCAG GTTCTCAGGTGCTGCAGTTAGCTGCT

Sequence 665

CTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGTAAGATTTCCTGAAGGGATCCATAGCC
AAAACATGTTTGAAGGCCACTGGGCTCGCTAACTTCTAAAAGCACCCCAGTTCTAGCAGA
CATCCTAAGGAACATTCCCAGGAAAATTCCAGCCTAGAACCTCCTGGGGTCTGACAACCT
TAGAGAACAGTGCTGGCTTTGAATGGGCTTGGGGGCAGCCTCGAAACCCTCTTTCCAGTC
TCCATGCAGGCAGGGAGCTCCTTAAGCAACACATAGGACATTTCTGGGAGAAATGGGAT
CCCCAACACAATGAACACTATAGATTTTAATGGTCTATATGGTTAAATACACAAGGCCCC
TCATTTCCAACCCCGCCTGTTCATCTGATTCATCTGTACCTCGGC

Sequence 666

Sequence 667

CCGCGGTGGCGGCCGAGGTACCTGCCCTATCTTGCTGAATGTTTTATAATCTAATAAAAC TCAGATAAAGACCCAGATGTCACACCTGAACAGGAAAAGCTGAAAGGAAAAGATAATTAA AATATAAATCAACAGAATCAAGATTTTGAAAAAGACCTAGAAAACTTGAAGGATTACTGAA

TABLE 1 108/467

Sequence 670

CCGCGGTGGCGCCCCGGGCAGGTACGCGGGGAGGTCATGCCCGTGTGAGCCAGGAAA GGGCTGTGTTTATGGGAAGCCAGTAACACTGTGGCCTACTATCTCTTCCGTGGTGCCATC TACATTTTTGGGACTCGGGAATTATGAGGTAGAGGTGGAGGCGGAGCCGGATGTCAGAGG TCCTGAAATAGTCACCATGGGGGAAAATGATCCGCCTGCTGTTGAAGCCCCCTTCTCATT CCGATCGCTTTTTGGCCTTGATGATTTGAAAATAAGTCCTGTTGCACCAGATGCAGATGC TGTTGCTGCACAGATCCTGTCACTGCCATTGAAGTTTTTTCCAATCATCGTCAT Sequence 671

Sequence 672

Sequence 673

CCGCGGTGGCGGCCGAGGTACTAAATCATTAATTCATCCTGAGCTAGTGGCTTTATTAAT GAGTATCTCACAAAATACCACAAAAATTCAACCTGGCCATGTGGAGCAATATAAAATTATG GCATTTCTTGGTATGTTTTCTCTTTGGCGAGGAGACAACTTGATCTTGTGTTTCCAGAA GCATGTTAATTTGCCCTGCTTGCAGAATCTCTCTGGCTTGAAAGGAGATTATATTCATGG CAGTCTGTGAATTTTCATTTTATTTCATTTATTTTGAAGACAAGAGTCTCACTCCAG CCTGGGTGACAAGAGCAAGACTCCCGTCTCAAAT

Sequence 675

Sequence 676

AGATAATAACATCTGATATCCACATGGGGTCTGGAGGNGCAAGCCACCTTCCTTTCATCC

TABLE 1 109/467

CACGGTCTCACAGCAGCCCTGGAAAGAGGCTGCTCTCTGTTGGAGGCCTAAGGGCCAGTGT TGGAAGGAGCTCGGGTGGAAAGTGTGGTCTGCATGAGGGGCTCCCGTGAATAGAGGAGAG GGGTGGCNGGTACCTGCCCG

Sequence 677

Sequence 679

Sequence 680

AGGTACAAACTGGCTTCTCTCTTTGTCACCAGCACCTGCTTCATAGTCTCTCTGGAGTG CCAGGAACGGGTCATTTAGATTAAATCTCCCATACCGTTCCTGGATAAATACCTCCTTCC TGCGAGCCCGCAGGGCCTCGATGACAAGGTCTCTGGCCTCCAGCTCCCCTTCCATCACGC TGAGGAGCATCCGCAGCTCGGATTTACTGAGAGTATCCACATCAAACTCTTTTTTCAGTT TTACAAGTGGAAATTAAGCAGTCCTCCTCCCCGTTTCTCCTTCCATTGCCAGGCTCAGCT CCTCTCACCCCAAGTACCTGCCCG

Sequence 681

AGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACAGGTGGAAAGTGAGGTGGTTT
TATTTCTAGTTCACCATTGTCCTTAGGCTGTATAGACCTCTGGAATCCCAGCTTATGTGG
AGAAGGTATCCTGTTAGACTTCCCTCCTTTGGTCAGCACTGGGCCTTAACTTCTGGCCCC
TCAAAGCTGCTAAAACTGAAGGCCAGGCTTGCCTGGCTTGGCAAAGGACGTCGGGCAGAA
GCAGCTTCTCCTCTCTTGTTTCTCTGTTTCCCCTCACCATAGGCTTTGGCCTGGGAG
TTTTCCTACA

Sequence 682

TABLE 1 110/467

TNAGAANTNAGTAANCTTAAGGCTTNAAGAATCAACAGNGCCCCTTTGGGNATTAAGGGCCATT

Sequence 683

Sequence 684

Sequence 686

Sequence 687

Sequence 688

NGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGGGGGCCATTGAGACTGCCATGGAAGACT TGAAAGGTCACGTAGCTGANACTTCTGGAGAGACCATTCAAGGCTTCTGGCTCTTGACAA AGATAGACCACTGGAACAATGAGAAGGAGAGAATTCTACTGGTCACAGACAAGACTCTCT TGATCTGCAAATACGACTTCATCATGCTGAGTTGTGTGCAGCTGCAGCGGATTCCTCTGA GCGCTGTCTATCGCATCTGCCTGGGCAAGTTCACCTTCCCTGG Sequence 689 WO 01/070979

TABLE 1 111/467

CCTATAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACTGCTATGAATCTCACA GATGTAATAATGAGTTAAAGAAGCTAGGCACAAAAGAATATTACTGTATGATTCCAATCA TATAAAGTTCAAACCAGATCAAACTAATCAATGAACGAGGAGTCAGGATTCTGGTTATAT TCAGGGATAGTGATGGAAGAGGGCTATAAGGAGGGTGTCTGGGTGCAGGTCATGTTCTAG ATCTTGATCTGAGTGGGGGTTACATAGGTGTATTCACTTCATGAGAATTCAGAGGGCTGC ACACTAATGATCTGTATAATGCTCCTCTATAGTATGTCACACTTCAAAAAAAGTTTACAGA AACAGTTCCTTCCTAATTTTCACAGGGCCTAAGAGCTAAAAAACGCAGCCCCAG Sequence 691

NCTATAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGGGGGCCATTGAGACTGCCATGG
AAGACTTGAAAGGTCGCGTAGCTGAGACTTCAGGAGAGACCATTCAAGGCTTCTGGCTCT
TGACAAAGATAGACCACTGGAACAATGAGAAGGAGAGAATTCTACTGGTCACAGACAAGA
CTCTCTTGATCTGCAAATACGACTTCATCATGCTGAGTTGTGTGCAGCTGCAGCGGATTC
CTCTGAGCGCTGTCTATCGCATCTGCCTGGGCAAGTTCACCTTCCCTGGGATGTCCCTGG
ACAAGAGACAAGGAGAAGGCCTTAGGATCTACTGGGGGAGTCCGGAGGAGCAGTCTCTTC
TGTCCCGCTGGAACCCATGGTCCACTGAAAGTTCCTTATGCTACTTTCACTGAGCATCCT
ATGAAATACACCAAGTGAGAAATTCCTTGAAATTTGCAAGGT

Sequence 693

Sequence 694

GGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTACTGGTCTCTGTCTTTAC AGCTGAAGCATCAGAGGATGGAGTGACCAGGCTGGTTCCAATGACAGTTATACGGCCATG GGGAGTANACATGGAGTCTAATTCAGTGCTTGAGGCTAAGAATGAAGTTGTATGCATTGT GGAAATTGTTCCAGGAGATCTTGCAACTTTCAAGTTTGAAGTCATGTCTGTAGAAGTCATGTCCA GGAATNTGATGCAGCTGTGGAAGACCAGGTGGAAGGGTGTTCTGTAGAAGTTGTGCGCCT CTCTGTGGCCGGGGTGCTGTCCATGGTACCT

Sequence 695

ATAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTACACATGTATCANG GAAAAGAAAACGTTATTTGTCCCACAGATGCTGCTAGGAGCAGCTACCCCAAGACAGGCC TTGCACCTTGGGTCATGACAATGCGTGGCTACTGAGAGCTGTTGACAGAGTGGACAGGGC CCAGACCAGGACAGTCTCTCTAGAGGTCTTCACCTCCTCAACCGTAACTTAATCAGCCCC

TABLE 1 112/467

ATGCCGGGCTAGCCCCATGCCACAAAGGCTCAGAAATGCCCTGCAACATGTGGGACACCT GGTAGTATCTACATAGGGGCCAGCATCCATCCCAGCTGCTGGGGGTGGCTCAAGAGCTGT GAGGGACACCCTTTCCTGCCTGATACCGTGGACCAGTTTGCAAAGAGCTGACTGTCCTGC TAGGCCCA

Sequence 696

Sequence 697

Sequence 698

TATAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACCATCCTATGCAGNCATNC
TGTNAGNACCCATTCCATTNTNCTATCCCTGGNTNGCTGGTGTCAATACTNTNAAGCGAN
TTACTGCNGGNGCTCTNNTTTTTCCCTCANAGATACCNNGTTGATTTCTTTGATTCTCTC
CATCTCTACAGGCATAATAACTCCTAATATTTAAAAACNCTGTAGAGGGATGNANNGAAG
CTGNGGNGAGAGCCCNTGGGCTTTTCNCNTGGGTNAAGATGCACATTCCTGAAAATTNTG
GGCCTTGGCTTAAGCTGNACTAGNGCCGGCCACTCAGCTGATCTCACTAGCGTCACCTGT
CGCAATGGTGCTGAAGCGCACTNCCNAGAGGCCATAAGGCAAAGCGAGAGTNCNTGGCTA
TNGACTGGANCCCATTTAAGCAAAAAAACATGCCTCNCGNANGACAAATTCNATCAACAA
AGGGNGGGCAATACAGGATCTGTACCTGCCCGGGCGGNNCGGGCANGAACCTTTTTTTTT

Sequence 699

TTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACCCAGCCCGCCACCCGGCTT GTGTGTCATCCTGGGCCCAGGCAGGTGATGATGCCAAACACAAGGCCCAGCTATGTAACC AAGTAAAAACTTTCATCAGAATGCCCATCTTTGTGACCCACAGCCCATTGTCAAGAGCCT TCCCTGTGCCAGGAGTTCAGCAGGTTCACCTCCGCCTCCACTAGTCACTAAGACACGGAT ATTTTAAGAATTAAAAGCCTCCACAAGCCAGGCACAATGGCTTACACCTATAATCCCACA ACTTTGGGAGGCCAAGGTGGGAGGATCACTTGAGCCAACGAGTTCGAGACCAGCCTGGGC AACATAGCGAGACCTTGTCTCTACAAAAAAAATTTAAAAGTTAGCCAAGCATGGTGGGGCA

Sequence 700

TABLE 1 113/467

CGGCGCCCCTCTAGAACTA

Sequence 701

Sequence 702

Sequence 703

NGGTTAANTGCCGCCNCTTGGCCGTAATCATTGGGNCATTAAGCCTGGTTTTCCCTNGTG

WO 01/070979

TABLE 1 114/467

TGAAAAAATTTGTTATCCCGCTCCACAATTTCNCACACCAAACATTACCGAAACCCGGGA AGNCAATAAAAAANTGGTAAAAAGCCCTTGGGGGGGTGGCCCTTAAATGAAGGTGGAAGC CTAAACCTCAACAATTTAAATNTTGGCGGTTGCGGCTCAACTTGGCCCCCGCCTTTTTNC CAAGANGCGGGGGAAAAA

Sequence 707

GGCGATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACTGAACATCCATGGCAGACGCTATT CTTTCCCTCTTAGAGATGCAGACACTGAGGCTCAGAGAAGTTGTCCCGCACCCAGTATGT GATGGAGAGGGTAGAGGGTAAAAACATCAACTGAAGGATTTAGCATTTGGGGAAGAAGGAA GAAGCCCAAAATGGAGTAGATCAAAGGCTCCCCCGTGAACAAATTTAAAATTAAGGAGAA AGAAGCAGAATTCAGTCTTCTCCACACCCATAACCAAACAGCTCCTATGAAGGCACCAAG CCTGACGCTCATCCCAATAAAAAGGAACGATCTGGAGAGAGGGGCAGCCGCTGGTGACAA GAGAACCCCCCAGGCAGCCTCGTCATCTGGCCAG

Sequence 708

Sequence 710

TABLE 1 115/467

Sequence 713

AGGTACCGTGTGAGCAGGTGGCGTTCACCAGGGGTGAGACTTTATTGACAGTAAGTTGCC
TCTGCCAAAAAACGCCCTCATATGTCTGCTGATGTTTGAATTNCNNCCNNATGGCAGGAG
GTTTTTTGGTCCTCCCCAGNTTTAAAAAAAAAATTGGTTAAAAATAACCTGGGTTTGGTTN
TTTCTTTTGNTATGGGGAAGGCCCTTCCAAGNAAGNGGAAAATAAANAAAAAAGTAATTA
NANCCTTAACCTTCCTTAAGGGGGAATTAATTGGTAATTTCAAAATTTTTTGGAATGGCC
TTANCTTTTNTTAATTTTTTTAAATTTTTTAAATTTTTGGGANGGAAACCAAGGGGGGGG
TTTCCTTNTGGGCCTTTCTTGGTTTGGCCCCCAGGGGGCNTGGGGNANGGTTGGCCAAGG
NCCAATNTTTNNGCCAAAATTTCCAAACCAAGGGCCCTTTCNAACCTTTGGGCCAAGNTC
CCCCTTTCAAAAAACCCCCTTTCNNCCTTGNTTTGGGCCCCCCAAAA
Sequence 715

CCGCGGTGGCGGCCGAGGTACCGTTTTATGATGATAACATAACTTTAATGCTCCAACCTG
AGAAAGATAAAATAGACTAAGATGACCATTGAATGCAAACAGAAAGTTCTAAATGAACAA
TCAAGNCAGGACCTGGAAATTTCAGGTCCCTGGTGGTTGGAAAANTAAATTAAAATTAAAA
ACCAANTTTCTTGGTTTTTCCAAGGAAAAANTGGNTAAAAAAAAATTAAGGTNTTTAAAAT
AANCCCCAGGGAAAAATTTCCAAATTCAAAATTATTAAAAAGGCCTTAAATTAAAT
ATTTTTTGGCATTTCNAAGGCCCCAAACCTTAAAATTGCCCTTANCCAAAATNGGTTTTT
GGGTAATTAAACCAGGGCCAAATTTNATTAAAAAAAATTCC

Sequence 716

Sequence 717

CCGCGGTGGCGGCCGAGGTACTACAATAAGGACAAATATTCAAAACATTCTGTTAAGTAA
AATAAGACAGTCAAAAAGGAAAGCTGTATAATTACACTCATGTAAAAATATTTAGTCCAA
CNCTCACAGGANAACCAAAGGTGGTCAATAGGTTCCTCAAGCCAGGTGGCCACCCCAAAG
GAATGGTTAAACCAAGGTTCTTCCTTCNGTTAAGGTTCCTGGAAGGAATTAAAACCAATT
CCCCAAGGAGGTTTNCTTTTTGGTTTTCCTAACCCTTCTTAAAGGGGAGGAATTTTAAAG
GGGAGGTGGTTAAAAANCAACCAAAAAAGGGTTTGNAAAGGGNTTTTGGGGGAAGGNTTT
GGGAAAAAAANGNTTTTTAAAGGNA

Sequence 718

WO 01/070979

TABLE 1 116/467

Sequence 719

Sequence 720

CCGGGCAGGTACCGCTGTGTCCGGGTGGGTGGTCAGAATGCTGCTCCAGGTGTTCACA GCTGCTTCGTGGAAGACCATGTGCTCCGATGACTGGAAGGGTCACTGCGCAAATGTTGCC TGTGCCCAACTGGGTTTCCCAAGCTATGTGAGTTCAGATAACCTCAGAGTGAGCTCGCTG GAGGGGCAGTTCCGGGAGGAGTTTGTGTCCATCGATCACCTCTTGCCAGATGACAAGGTG ACTGCATTACACCACTCAGTATATGTGAGGGAGGGGATGTGCCTCTGGCCACGTGGTTAC CTTGCAGTGCACAGCCTGTGGTCATAGA

Sequence 721

CCGGGCAGGTACCGCTGTGTCCGGGTGGTGGTCAGAATGCTGTGCTCCAGGTGTTCACA GNTGCTTNGTGGAAGACCATGTGCTCCGATGACTGGAAGGGTCACTGCGCAAATGTTGCC TGTGCCCAACTGGGTTTCCCAAGCTATGTGAGTTCAGATAACCTCAAAGTGAGCTCGCTG GAGGGGCAGTTCCGGGAGGAGTTTGTGTCCATCGATCACCTCTTGCCAGATGACAAGGTG ACTGCATTACACCACTCAGTATATGTGAGGGAGGGGATGTGCCTCTGGCCACGTGGTTAC CTTGCAGTGCACAGCCTGTGGTCATAGAAGGGGCTACAGCTCACGCATCGTGGGTGAAA CATGTCCTTGCTCTCCAATGGCCCTGGCAGGCCAACCTTTAGTTTCAGGGCTACCACCTG TGCGGGGGCTTNTGTCATTACCCCCTGTGGATATTAATGCTGCACACTGNGGTTATGACT TGTACCTTCGCCCGTT

Sequence 722

GGAGAGGAAATGTGTAGGGGTGAGGGATGATACAAGAAAGCCAAATCCTCATCTTCTATA GTAGAGAGTCAGCGGATAAAACCTAAAAACAATACATCAAGAAATACTTACACTTATGGA AGGAAATACCAGAAGTTAAAAGGGGTTACTTCTGGGACATCAGACACCAGACTGCAGGGA AGGGCTGCCTCTTGTATTAACAAGCTTCCAGTATAATTTGCTTTTTAAAAATAGGTCCAT GCATTATTTTAATAAAAATTANGCTGGGCGTGGTGGCTCAGGCCTGTAATCCCANCACTT TGGGAG

Sequence 723

GGGGCCATTGAGACTGCCATGGAAGACTTGAAAGGTCACGTAGCTGAGACTTCTGGAGAG ACCATTCAAGGCTTCTGGCTCTTGACAAAGATAGACCACTGGAACAATGAGAAGGAGAGA ATTCTACTGGTCACAGACAAGACTCTCTTGATCTGCAAATACCGACTTNATCATGCTGAG

TABLE 1 117/467

TTGTGTGCAGCTGCAGCGGATTCCTCTGAGACGCTTGTCTATCGCATCTGCCNGGGCAAG TNTCACCTTCCCTGGGATGTNCCCTTGGACAAGANACAAGGGAGGAANGGCCTTAANGAT CCTANCTGGGGGGGGA

Sequence 725

TAGGGNGAATTGGAGCTCCCCGCGGTGGCGGCCCGGGCCCGGTACCCATAAAAATTAAA
AACTATTTTAAAAAATAAATTCCATTTGAGCCACTCCTTCAAACCACCCAGAGTGGGTAG
ACGTCTTTCGTGCCTCTAAGAAGCCCCATCTCTATTCTGCGTCTCACCTTGCAGGGCTGC
TCATCTGAATCCTGAAGATGGTGGACACCCATCTGCTAGGACTGAAATGAATAGGACAGA
GGGAGGTGCAGAGTGAATGGACCATACTACCTGTCATCTTGGCAACGTGTGATTGAATAA
AACAACTTCTTTAGAAGTTTGATAGAGTGATTTGATAATTTACAAGTGATCATTT
CTTTTTA

Sequence 726

Sequence 727

Sequence 728

Sequence 729

Sequence 730

TABLE 1 118/467

CTATAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACACTACACCTGGACAAA TACTTTTTTGTGAAGNCAGGTAAAGCCTTTGCGTGCAATATAGCATCTCTATGCAATGCA NCAACTCCTCGTCTATCGCTĀCAGTAAGAAAACAGCCACGGGTCAGGTGTTGNGGCTCAC ACCTGTAATCCCAGCACTTTGGGAGGTCNAGGTGGGTGGATCACTTGAGGCTAGGATTTT GAGACCAGCCTGACCAACATGGAGAAAACCCCATCTNTACTGAAAATACAAAATTCCCGGG TGTGGTGGCNGCATGCCTGTAATCTCAGCTACTCGGGAGGCTGAGGCAAAAGAATTGCTT GAATCTGGNAGGCGGNCGTTTGNNGGTGAGCCAAAAAATCGTGCCATTGCACTCCAGCCTG GGCAACAAGAGCGAACTTTCGTTTCAAAAAA

Sequence 732

Sequence 735

GCGAATTGGAGCTCCCCGCGGGGGCGGCCGCCCGGGCAGGTACTACTGTGTCCTTTAGAT CACTCTGCCTTGATCACTCTGTCCCGTCACTCTGCTATTTCACCTGNCAGNGAAATACCT GGTATCGTCCTGCCAACGTGAAGCATTGAATGCTTNATACGTCTCCATCCTGATTGTTTA GGCTTTGAATGCTGAGAAGTATCTGCACTTTGTTGGTCA

Sequence 736

TABLE 1 119/467

GTGNGGATTAACATAAATAAAATGATGCGCAAATGAACACAAAATTCAAATTGATGATGTGTACCTGCCC

Sequence 737

Sequence 738

AGCTCCCGCGGTGCCGCCGAGGTACATGTAGTTGGATGTCGAGGTTNGATTAGATTCT GGGGTTGGTTTGCTTGTTTTGGTGGATNGTTTNTGAGTCGACTTTACAGAGGGTTGTTTA TCCACCAGAAGGCACATGTGCTTGCCTGTGTCTTTTTTGTTATTGTTTTGAGGCAGAGCC TCNCTCTGTCTTCCAGGCTGGAATGTAGTGGCACAATCTTGGCTCACCTCCACC TCCCAGGTTCAAGTGATTCTCCTGCCTCAGCCTNCCAAGTAGCTGGGATTACAGGTGTGT GCCACCATGCCCAGCTAATTTTTGTATTTTCAGTANANATNGGGTTTTTTGCC Sequence 739

CTATAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCGGGCAGGTACACTTCCACGA GAAGAATTAATATTGTAGTGTTAGGAAAACTAGCAATTTAACTAAACAGCATCAAGTTAC AAACCAGGAAAGTGATTTAAAACTAAATGCTGGCTTATCTTTCTGAAACAAAGCATCTAA ATTTGACAGTCCAAAATGGCACTTATTGAGTGTCCGTGACAATACATGCTGACAAGCAGC ACACCTCTTTTTTTGTTTTTTTAAGACGGCATCTTGTGCTGTCACCCANGCTG Sequence 740

Sequence 741

TATAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACTACAGTATAAATCATGCT CCTGCTGTCTAGAGCTTACCACCCAACGAGGGCTTCAGATAAGATCAGCAACTGCCCTAG AGTGTGGAACTCCTATGACAAGGTGAGCCTGGGGTGTGATGGAAACACGGCGTGCATGGT TACCAAGCCACGCTTCCAGGGAAAGGGGTCCGTGCGGGAAAAACTTCAGAGAGGAAATGA CATGTCAGTCAATAACCTGAAAGAACTGGNTGAGAGTTAAGCANCAGGGAACAAGGGCAC AGTNNTCCACACAGCTTTTTGGAAAGATCATGTTGNTTATAGTGCAAAAAAAATACTGAAT ATGGGAAACAATTTGTTATTATTTTTTAGGAGTNTTGCTTTGTCCCCCAGGCTGGAGTGC

Sequence 742

ACTACTATTGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACTTTGGGGGGAAAA AGAGTTACAATTTGCCCATAAAGAATGGAGAGAACAGAAATGTANCTTTTATGCTGAAAA ACAAAATGCAAGGGCAATCCAGTTTCTAATTCCTGTGCCAAAGCTGCTGTTCTTGATGAC CTCGGTCAAATCATTTAAATTCTCTCAATTTGTTCATAAAAAGTGCTATTAACCTGCAG TTCCTTCAAATACCAATCAATGTTGGCTACTTGATTTTCA Sequence 743

TATAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTATTCACAGGGTATGCATAAA

TABLE 1 120/467

Sequence 744

CCGCGGTGCCGCCGAGGTACGCGGGAGGAAAGGGCTGTGTTTATGGGAAGCCAGTAACA CTGTGGCCTACTATCTCTTCCGTGGTGCCATCTACATTTTTGGGACTCGGGAATTATGAG GTAGAGGTGGAGGCGGAGCCGGATGTNAGAGGTCCTGAAATAGTCACCATGGGGGAAAAT GATCCGCCTGCTGTTGAAGCCCCCTTCTCATTCCCGATCGCTTTTTGGCCTTGATGATTT GAAA

Sequence 745

CCGGGCAGGTACACAGTAAGTGAAGGGCCAAGACTGACGGCTGATAGGACAGGGGTGACC
AGNGGTGGGGAGGGTAGTGGGAGCAGTCCATCCTGGAATCTGGCATTCAAGGGGCGCATT
GTCTGTGGGAGGATTTAAAAATAAAACCAACTAAAGGCAGTCTGCTTTTTATGGTCA
CCAGGCCGCCAGCAATTCTAAATTTCAGTGATAAAATATTCCTCCTCACTGGACACGAGA
AGCTGGCTTTCTCCTTATTCCCCAGTACCTTNGGCCCGCTTCTAGAAACTAGGTGGGATC
CCCCCCGGGGCTGCAGGGAATTTCCGATATTCAAAGCCTTATCCGAATACCCGTCGACCC
TTTNGANGGGGGGG

Seguence 746

Sequence 747

Sequence 748

GCCCGGCATGGTACCTGTGGGAAAAGAATGCTTGCAAAGCTTGTCACCCTCACGAGAA
TTCCTGTGACAGACATTTGCCTTTGACAGTGAAAACAGATATTAAAGTGAAAGGAGAAGA
AACCGAAGAGCATCAGAGGGGACGACTGGGTTACTTAACTGTTGGGGAGCAATCTGAGGA
GTTGGTTACCAGAGAAACTGGCGATGGCGATCCCGTGAGCAACATCTCTCAGACCCATTT
TAAAATGCCGGGGGATACTTAATCATGCTGAAAAACAGCAGAGCCCTTGAGGTTTTTGGA
CTACATGTTGCAGAAAGAAGAAGAAGAAGNAATTTNTACCTTNNCCNAAAAATAAAAATATNNNA
NNNNGGTACCTCGGGCCCGGTTTTNAACTAGTGGGATTNCCCCCGGGCTTGAAGGAATTC
GNTNTTCAAAGCCTTNTTCGATCCCCGTCCNANCCTCNANGGGGGGGGGC
Sequence 749

AGGTACTTTTTTTTTTTTTTTTTTTTTGGNCTAACTGNNNGGAGTATTTCTTTTACCCAA GATAAGTAAAAGCTACAACTCTTAGTATAAATATGNGTCCAAGTGCCTNATAACTGCTAA CCACAGGGATCCTGAGCTCTNATAGCTTAAACACACAGNGTNNATTTTACTGGTCTACTT CTCCTGNAGACCTAAAAGGGCCTATAGCCTCAGTAGTTGACAAAACAACATATTAAAATT

TABLE 1 121/467

CCTCACTGATCACTAACCTAAAATCCCTGCTTTTGACATTAGCATGGNANACATC CTTAGCAGGCCTAAATAGAATGGCCTTATAAGTGGATCCAAAGGGC

Sequence 750

Sequence 751

Sequence 752

Т

Sequence 753

Sequence 754

Sequence 755

GCCGAGGTACANACAAGGGGGCNACTGNCATGGGGGNGGNNTCTGGTCTTGTAGTCNGTT TGGAATTTTCTAAGTCAGGGTGGGGTGGGGGGGACTGTGCACGGGTCATGTGCAGACTGGA ACCCATCTCCCCCTCGGTCTGCAAGTTAAAACAATTGGGTTGTCCTTCTCAGCATCTGCC AATGTCTCTTANTCAATCTTGGATCAAAAGGGCGTTGGAGGAGGGGGAAAT CCAGACAGTTCTCCGCCTCTGACATCAGGTCCAGCTGTTAGCATCGTGCTGTGGGTCCCT GAACAAGAAGCAAAGTCAGGACT

Sequence 756

AGGTACCGCTGTGTCCGGGTGGTGGNGNGAATGCCGTGCTCCAGGTGTTCACAGCTGCT TCGTGGAAGACCATGTGCTCCGATGACTGGAAGGGTCACTACGCAAATGTTGCCTGTGCC

TABLE 1 122/467

Sequence 758

Sequence 759

Sequence 760

Sequence 762

ATAGGCCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTACGCGGGTGAAAAT GGAATAGTTTTCTAATTACAGAAAGAAAGAAGGGGGGNGTGGGNTTNTGCCATGTTGAGC ANGCTGGNCTCGAACTCCTGACCTCAGGNGATCAGCTCGCCTNAGCCTCCNAAAGTGCTG GGATTACAGGCATGAGCCACCACGCCTGGCCAAAAATNTTATNAATAATCCCCTTCTAAT

TABLE 1 123/467

TNCGGNCANCTTAATCACACACCAAATTCCTTTCATGAGATTAAACTNNCACAANTNCTA CACTTNCTTAAATNTTTGATNNTGNCCTATACTTNTTTTTTTATATTNGCAATCTACTTT AGGACAGAAATTTACTTTCCTCTCTCTTGNTTTTTGACCAANGTNCTNTCTTNTGCAAAA TGNANAATNNCTNTTTTTTCAACTTTCTTTACCAAAA

Sequence 763

TTAGGGCGATTGNAGCTCCCCGCGGTGGCGGCCGAGGTACATGTAATGCTCCTGAACTGT
ATGCTNGACACGGCTGTCTACNTAGGTTTTGTTCTGTGTATTTTTATGACTATTTTTTTAA
AAAGTAAACAAAAAAGAATTAGCTGGAAATACCAGCACAGGCAAACCCCTGGAGACAGAA
AGCAGGTGAGTGGTTGCTGGGGCTTGAGCAGGAGGAAGGGCGAGGGACTGCAGAATGGCC
ATGGGCTTTGCCTTCTAGCATGATGAGAATGTTCTGGAATTAGACAGTGGTAACGCTTGT
TCAACACTGCCAGTGTAGTTAATGTCACTGAATTATACACTTTAAATGGCTAACATGACC
AATTTTATGTTATATATTTTTACTACCACAAAAAAAACTAGCTGGCACCTAAAAAACATTC
CATT

Sequence 764

CCGCGGTGCCGAGGTACTTGGATGGGTTTTGTGTGTATGTTTGTGTGCACTNGC GTCCACCCTGTTGGGCTTAGTGAACTTTTTGATTCAGTGATTTAAAGTTTCTCATCAGAT TTGGAAAATTCTCAATTACTTTTTTCTTTAAATATTTCTCTTGCCCTTCCCCTCTCTT CTTCCAGGATTCCAATTTCATCGATGTT

Sequence 765

TACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACGCGGGGGGTTCAAGCG
ATTCTCATGCCTCAGCCTCCCAAGTAGCTGGGACTAAAGGTATCCACCACCACCACGCCTGGC
TAATTTTTGTATTTTTAGTAGAGATGGGGTTTCACCATGTTGATCAGGCTGGTCTCGAAC
TCCGGCCTCAAGTGATCTGCTCGCCTTGGCCTCCCAAAAGTGCTGGGATTACAGGCATGA
GCAGCTGTGCCCAGCTGGATAATTATTTAATAAATTGGGGAGCATAGGAAGCATAGTATT
TGTGAAGTGGGTAGGCAGGTGTGATGGGGGGTAGGTGATGTTACATTTTGGAAGTGGTGGTTCTTCTGAGTTGAGCAGTCACCTCTTCATTTGCTGCACCTTTATCTCA
TTTTAGCCAACAGACATTGAATACCTACCAAGTCTTAGGTATTTGCA

Sequence 766

Sequence 767

AGGTACACACAGTGATTTGGGGTCCTTTTTCCTAAAACAGCTTCTTTATCAGGACTTTGG
AATTCTGGGTGAGATAGAAACACTGAAAACAGGGCGGAAGTTTTTTCTTCTGGCTTCTTA
GTCCATGGAGGGCTCAGCGTGGAGAGGATATGCCGTGGCATTCTCCCTGGGAGACCACAC
ATGTTCCCGACAGCTCAGACCCCAGACCCGCACATGCTTCTTGACAGTTNAAACCCCAAA
CCGNAGGNGCTCCCGACAGNTNAAACCCCANACCCCGCGTACCTGCCCG
Sequence 768

Sequence 769

TABLE 1 124/467

TAACTCAGATGGAAATGCAGAAATCACCCGTCTTCTGCGTCGCTCACGCTGGGAGCTGTA GACCGGAGCTTGTTCTAATTNGGCNATTTGGGTTCNTCCCCCCGGGNNCNTN Sequence 770

Sequence 771

Sequence 772

Sequence 773

Sequence 774

CCGCGGTGGCGCCCCGGGCAGGTACACTACTGGCATAAGAGTAAATTGGTGAGAACT
TTCTGGAGGGGTAGTTTGGCAATGTGTTTCCAAAAAATCTAAAAATTATATTTGCCTCTA
ATCCAGCAATTATACCTCTAGAAATTAATACTAAGGAAAATCTTAAGAATATACCGTAAA
ACTTTAGTTGTAAGAAATTTTTTTGTGGCCAGGCATGGTGGCTCACACCTGTAATCCCAG
ACTTTGGGAGACCAAGGTGGGCGGATCTCCTGACCTCATGATCCACCCGCCTCGACCTCC
CAAAGTGCTGGGATTACAGGCGTGAGCAAATTTTAAATAAGAAGAACAGTCAACAGCAT
CAGACATAGTAGGTATGTCCAACACCATAATGGCTGAAAAGTGCCCCCTAGTCTGGCAAT

TABLE 1 125/467

TAGTAGGTCATTGGTTTATTAATAACCGGCATGTTAAAGTTG

Sequence 776

Sequence 777

Sequence 779

CACTACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACTATGAGAATTTCA
AACAAAGAATGAAGCCATAAAACAAAAAGACTGAATATTTGGCTCTGCCTGGCTCCCAGG
CTTTCTACTATTCTTGTGACTTGGCCTCAACAAAATCTAAAGTGACTTGTTATTTGTGGG
TCAGCTTTGTCCCATCCTTACCAGTCATGGCTTTAGACAAAAGACTCAGCACCACTCACC
CTCTGGGACAGTCTGACTGTGGTCTGAGGCCCCTTGCTTAGATATTAGGCTTCAGCTCAG
TTCC

Sequence 780

TNCTATAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTACACACAGTC AGCATGCGCTGTAGCAATGTGCTTTGCAGCTGGAACTCCTATCAAGCATCCTAGGCAAGG CATGCACCCCAGCGCCAGAGAATCAGGAAGGGGAAGGTGCCCTGAACCTCAGACAAGA ACCCCTTCCAGAACCACCACAAAGCCATCACTGTGTTTCCACCCTCAGACCTGTGTCT CTTTAGCTTCTTGGTAGAAGGAAAGAAGAAGAAGAGGGGGCAG

Sequence 782

CNATTGAGCTCCCGCGGTGGCGGCCGAGGNCTGATGTCCTACAGTCCTCTACCTGATCT ACGTTCACTGGAAAGTGTNGAGTCTCAGCAGGAAGCACCTTGCTCTCGTGTCCGGCTAAT

TABLE 1 126/467

TCGAGTGCTTTACGTAAGTAGAGGAATTGCTGACTTTTGGGACATTTCTGGTCTTGCCAA AGTTCACCTTGTAGTAAAGCCCCCAAAGATACTTCCCAAATAGATGCTCTCTTGAAAATA ACTCAG

Sequence 784

Sequence 785

GCTCCCGCGGTGGCGGCCGGCAGGTACGAAATGAGAGAAATGGTTTAGTAAACGTATAA GACATCAACATAGNAAAGTATTCTATAGGNNTATGTGTTGGAATTACAAAGATGAAGAAA AGATACAGGCAAGTATTTGATATACTNAATTAAAAATAGCAAGATGTAGAGTAGNCATGT ATACAGTGATAGCAAGAACATGGATCCTTAAGGACAAAACTGAAACATAATGCAAAAAAA GAAAAATATGCAAATTATTTTTCGTATGATGTAAGTTGTAAATAT Sequence 786

Sequence 787

CTATAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGNACACANTAAGTGAAGGGCC
AAGACTGACGGCTGATAGGACAGGGGTGACCAGTGGTGGGAGGGTAGTGGGAGCAGTCC
ATCCTGGAATCTGGCATTCAAGGGGCGCCATTGTCTGTGGAGGATTTAAAAATAATAAAAC
CAACTAAAGGCAGTCTGCTTTTTATGGTCACCAGGCGCCAGCAATTCTAAATTTCAGTGA
TAAAATATTCCTCCTCACTGGACACGAGAAGCTGGCTTNTCCTATTCCCCAGTACCTGCC
CG

Sequence 788

GGNGGCGCCCCGGTTTTGGACGCGGGTNTNTGCCCTNACTTTTTTAGCGGAGCAGAG GAAACATTCATAAGGAAATATGCGAGTAGAGCTCAGGAGAAAAAGCAGGACTAGAGGCCCA AGAATCACAGGCCAGAAGAAGAAGCTGTAGCCTCGGGAATGGAAGAGCTCTCTGAAGGGG AAAGGGGAAACAGGAATGTNCCAGGAGCCAAGGCTCATCTATAAGGGACTTNCACATTT AGGATGTAGAAGAAGGAAGCAGAAGCAGGGGATGACCAGAAATGGCCCCAGAGATGAGAT GAAAGTTAGGAGAGCGGNGAGCAAGCCTTTAGGTTTCACAAGGGAAGGAGGGAAAGTAGG TGTTAGGTGCTGCCAAGATCAGGGAAAATAAGCAGAAGACCAGGCCATTTTNANTTGCNG TGG

Sequence 789

CCGCGGTGGCGCCCCGGGCAGGTACTGCCCAAGAGAGACGTCTCTTACTGCCTCATT
AAGCATTTGGAGCTGTTAAACACAAATCAAGGCAACCAGAAAGGGCATCTTGGCTTCAGG

TABLE 1 127/467

CTGGGCATAACCATCCCATTTGCCACATAAAAGTCTAGTGGCTACTCTGCACCCTTTCTG GGTAGAAGCAGAGTTAGTTTGGTCATGGGGGCCCCTGTGGGACAGTGTTGCCCAGACAGG TACCTCGGCCGCTCTAGAACTAG

Sequence 791

Sequence 792

Sequence 793

AGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTACCAAGTATACCTTTT
CATTTAAATCATTGAACAGTTCACAATGGCTGTTGTAAAGTTTTTGCCTTGTTACTGAAA
CCATCATCTCTTGGTCTATTTCTATGGAGTTATTTTTTCCTAGTTATTGGCAGTTTGCTT
ATCTTTTATGTGTCTAATAACTTTTAATTGAATGTAGAACATTATGGATCTTATATTTTT
GAGAATCTGAATGTTTAAAATTCCTTTGAAGAGTTTGTGTTTTCTTCTGGAGGCAGTTTA
CTTACTGGCTGTGAGCTCAGTCCTGTTGAGGCTGTTTNGCGACNNNCTGTGGCTTTGTCA
GGGTGGGGTGGTGGATCAGACATCTGGTCATCAAC

Sequence 794

Sequence 795

Sequence 796

CCCCCCGGAGTTTCAGCGAAAANCCCGGCCGAGGNACCNCNCCNTTACNCCCAGGNTT ANAAACNCCCNGGTNTNGNCCCAGGAGAGGCGGGGGANCACCGCGCCNGGCCAGCANGGN

TABLE 1 128/467

Sequence 798

CGGTGGCGCCCGGGCTTGGTACCCTCTGTCACGGCTTCCCTTTGCTGGAAAAGGGA ATTTCCCAACCCCGGGTGAGGCAATGCCCCGCCCTGCTCCGTGGGCTGCACCTGCTGTCT GTCAAGCCCCAATGAGATGAACCCTGTACGCGGGGCCTGGGATCTCAAAATGGCGGCCC CGTGCGGAAACAGCGTNTGGGAGCAGANATTGTTGCCTCCTGAA

Sequence 800

GGGCGNTTTGGAGCTCCCCNCGGTGGCGGCCGGGCAGGTACTATCTGGAACNTGTAGCTT CCTTTNGCACTGCAGCATGGGAAGCCAGAGTTGATGATTCATACACCAGCATTTACATTT TTCAGCATGAAAGTGGTATGTTCTTCAACTCACAACCCATTGGCCAGAACCAGTAACATG ACTTCACCTAACTGCAAACTAGCTGGAGAATTGTGGGAGAGCTCATGG Sequence 801

Sequence 802

TABLE 1 129/467

Sequence 803

AACGACCGCCCGGGCAGGTACTAAGCCAGGACCTCAGTTAGCACTAAGCACTCTTACTAT
TGCCCCCACCTGGCACAAAGCAAACTGAGATCTTAGTTGGGCCCATCATGTGTCATCTGA
TTGTCTTAGAAGTTCTTTTTTTCTAAGACAGAGTTTTGCTCTTTTTGGCTCAGGCTGGAGT
CCAATGGCACAATCTCGGCTTACTGCAACCTCCGCCTCCCAGGTTAAAAGCGATCCTCCC
GCCTCAGCCCTNCGAGTAGCCGGGACCACAGGCACCCGCCACCACGCCCGGNTAACCTT
Sequence 804

Sequence 805

CCGGGCAGGTACAATGGACTTTGACAGTTCTTCCCAAACAGATCCTAATTTTAAACATTA
GGTTTGCTTTGATTCTTTTCCTTGGGGCTAAGAGCTCACAAAGACTTAGGTTCTGGTCAT
GGCTCCAGAGGCCACACATTCCAGGACAAAGTCTCTCTACAGTCAACGCCTTAGTCCCAC
ATCTGTAAAATCGGAATAATCATCCCTGATCCAGCTATCACATTGCAGTAGAGTGAGACT
CAAATGAGATAATGGAAGACAGTGGGAATGATCATTTCCAACTTGGCCTGGCTGACCCAT
TCCTTGTTCTAAAGTCAGCTCAGGTTTCACCTCTTCCAGNGAAGTTGACCTGGCACTTTC
TTTTAGGATGGCTACTGCTCCTCTGGGTGCCCCGGGGCTCANTGTCTCCCCATCACCGCC
CATGGCACACTTGGAGTGACTGGTCCTTTACTTTGNTT

Sequence 806

TNCGGGCAAGGTACATTGGCCCCAAAGAGNAGGAATTCCTTGTAGAGGAGCTTGTAGATG CTTNCCCTCCAGCGGAGAAGCAGGCCAGAGAAACCTCCGAAGCGGGCCTCCGCCACTTTG AGAGTGTATGAAACCGTCATGGTGCTGGGAGCCTGGGGCAGGAGGTCACAAGAGTTGCCC CCAGGGCTGTCGTTTAGTTCTCCAGACAACCTCCCTTCCACTCTGGTCTCACACACCCCA GCCTTCACCCTGCGTCAGTGGACAAGGGGGTAGGAGCCTGCAGAGCAGAAAAGTACCT Sequence 807

Sequence 808

CCGCGGTGGCGGCCGAGGTACGAGACTTGTCACCATGTGACATGGCAGCTTCAGAAACTT
AGCCACTGCCAAAAAAAGAGCAGGCAGGGATAATGTTGTCCCATTGTCCAGTCAGAGAGA
CCTGTTGAGTCTCTAGTTTGCCAGTCCCCAAGAGACCTTTGGAGCTTTGCTGGAGCCAGA
CATCCTGCTTAGAGATGAGGAAGATCCTGCTGTTCCGTGGGGAGCTCTTGAGACACCCGT
GCCACCACCCACCTTCTCCTGATTGCCACTTGCTGCCCTTTTCCCATTACCCTCTCCTGA
CTCCATAAACATCTTCAAGTCTTCCCTTTCTCCACCCCAAAAAAATGCCCACCTTGGAAAG

Sequence 809

AAATTAATTGGGGTTGNGCTAACTGCCCGGTTTTCAATCNNGNAAACCTTGTGGGGCCCA NNTGAATTAANANAATNGGNCCACCCCCCGGGGAAAAGGGNGGTTTTNNAANTTTTGGG GCCTTTTTCCCCTTTTTTAAAAAA

Sequence 810

TABLE 1 130/467

CCGCGGTGGCGCCCCGGNCACGGTACGCGGGGATGTCTTCTGAGAGAGTCAGGGCAG CTGAAGACTGGGTGAGGGGAAGCCGCTGGTGTCCTCCTCAGTCACCCGTGAGAGG ACTCCTNTGTGGAGCTAATCAACTGCAAGGAAGATTGTTCCCAGTGTCCAGACCTGAAGG AGTCTGGACCCATAGTGCANTGAGATTTGGGGAAGGAAGGATTCCGGATAGGGGTGAGCT TTNTGNTGATAAGCAAATGTGAAC

Sequence 811

CCGCGGTGCCGCCCGGGCAGGTACGCGGGGGTGTTTATGGGAAGCCAGTAACACTG TGGCCTACTATCTCTTCCGTGGTGCCATCTACATTTTTGGGACTCGGGAATTATGAGGTA GAGGTGGAGGCGGAGCCGGATGTCAGAGGTCCTGAAATAGTCACCATGGGGGAAAATGAT CCGCCTGCTGTTGAAGCCCCCTTNTNATTCCGATCGCTTTTTGGCCTTGATGATTTGAAA ATA

Sequence 812

Sequence 814

Sequence 815

Sequence 816

TABLE 1 131/467

GGATGGCGGCTTCATTTTTGTCCCTCCTACCTCTGA

Sequence 817

GAACCTAGGGCGATTTGGAGCTACCCNCGGTGGCGGCCGAGGTACATTTTGGCAAACCGT GAAGGGCTTTCNTTTTNGCAGGTTGGACTTCCCCCCCCTAGTNGGCAGGATTTTTTTTTAG GGGACCACCTGAGAAAGGTCTGTTACCGTGCATAAACCTCCTTTAACACCTTTTAAAAAC TCTTCTGGGGGCCGGACTCAGTGGCTCATGCCTGTAATCCCACCACTTTGGGAGGCTGAG GCAGATGGATCACCTGAAGTCAGGAGTTCAAGACCAGCCTGGCCAACATGGTGAAACCCC GTCTCTACTAAAAATAGAAAAATTAGCCAGGAGTGGTGGCAGGTCCCTGTAATCCCAACT ACTTGGGAGGCTGAGGCAGGAGAATTGCTTGAACCCAGGAGGC

GCCAGGAAACCCGTAAAAAGGGCCCNGTTTGTTGGCGGTTTTTTTCCATAAGGGTTTCCG CCCCCCTTGACCGAGGCANTTAACAAAAAATNGACNGCTTCAANGTCAGAAGGTGGGC Sequence 819

TAGGGCGNTTTGGAGCTCCCGCGGTGGCGGCCGAGGTACATCACCCTGCTGAGGGACAT CCAGGNCAAGGTCACCACACTCTACAAAGGCAGTCAACTACATGACGCATTCCGCTTCTG TCTGGTCACCAACTTGACGATGGACTCCGTGTTGGTCACTGTCAAGGCATTGTTCTCCTC CAATTTGGACCCCAGCCTGGTGGAGCAAGTCTTTCTAGATAAGACCCTGAATGCCTCATT CCATTGGCTGGGCTCCACCTACCAGTTGGTGGACATCCATGTGACAGAAATGGAGTCATC AGTTTATCAACCAACAAGCAGTTCCAGCACCCAGCACTTTTTACCTGAATTTTAC Sequence 821

Sequence 822

CCGGCAGGTACGCGGGAGGTCATGCCCGTGTGAGCCAGGAAAGGGCTGTGTTTATGGGA AGCCAGTAACACTGTGGCCTACTATCTCTTCCGTGGTGCCATCTACATTTTTGGGACTCG GGAATTATGAGGTAGAGGTGGAGGCGGAGCCGGATGTCAGAGGTCCTGAAATAGTCACCA TGGGGGAAAATGATCCGCCTGCTGTTGAAGCCCCCTTCTCATTCCGATCGCTTTTTTGGCC TTGATGATTTGAAAATAAGTCCTGTTGCACCANATGCAGATGCTGNTGCTGCACAGANCC TGTCACTGCTGCCATTGAAGTTTTTTTCCAATCATCGTCATTGGGATCATTGCATTGATA TTAGCACTGGCCATTGGTCTGGGCATNCACTTTCGACTGCTCAGGGAAGTACCTCGGCCG CT

Sequence 823

ACACTACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTACGTGTT
AGCTATTATCATCACCCTCCTTGCTAGGCAGAGCAGGACAGTGGGGAATTGATGTTTCCT
CCCCTCCATCTCACAGGTGGGGCAGGGGTGTGCTGAGAAGAGAACTTGGGACTCTTGGCC
CCTGTTCAATTCTCTGCTTAACCTGCTAGGCAATTTGGGCCTCTGAAAATTCAGTAATCC
TCATAGCAACTTAGACGTCACCTGGGCCTGTGGTCCCCTTCCTAGCCTAGGAGTCAGAGC
ATGAAGCTCCATCTGTCACATTGGTTTGTTCAGAGAACTACACATGCGTTTTATTTTAGC

TABLE 1 132/467

AGCATACAGGTTCCCACTTAGGCATTGAGAGGACATAGGAAGCTGTTTAACTTCCTA
Sequence 824

Sequence 825

CCGCGGTGGCGGCCGAGGTACAGATGTATGGATCTCATAGCATTGAGGGGTCTTTCAGAT TATGTTTTCAAACCCCTCACTTTCTCTTTTCAGATAAGACCACAGCGACCTGGGAAAGTG CAACGTCTTAGCCAAAGACCACAGAACTATTTAGCGACACTGTCTAGACTCTAGTTTCCAT GTCTCCTGACTTCAGTCTAGTGTTCCACCCCTGCCGCCCACCCCTGCCCCATCCTCATTC CTCCTGTAGGAGAGGCCAGACCTTTGCCTGCTGCAGCTTGTGGCTCTTCTCCTGCCTTCA GTTNTTCCATTGCCTG

Sequence 826

GGGNNAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGCAGGTACCTGTCTGGGCAACACT GTCCCGNNGGGGCCCCCATGACCAAACTAACTCTGCTTCTACCCAGAAAGGGTGCAGAGT GGCCACTAGACTTTTATGTGGCAAATGGGATGGTTATGCCCAGCCTGAAGCCAAGATGCC CTTTCTGGTTGCCTTGATTTGTGTTTAACAGCTCCAAATGCTTAATGAGGCAGTAAGAGA CGTCTCTCTTGGGCAGTACCT

Sequence 827

Sequence 828

TTAGGCCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACATCACCCTGCTGAGGGACA
TCCAGGACAAGGTCACCACACTCTACAAAGGCAGTCAACTACATGACACATTCCGCTTCT
GCCTGGTCACCAACTTGACGATGGACTCCGTGTTGGTCACTGTCAAGGCATTGTTCTCCT
CCAATTTGGACCCCAGCCTGGTGGAGCANGTCTTTCNAGATANGACCCTGAATGCCTNAT
TCCATTGGGCTGGGGCTTCCACCTACCAAGTTGGGTGGGACATCCATGTGACAGAAATGG
AGTCATCAGTTTATCAACCAACAAGCAGCTCCAGCACCCAGCACTTNTACCTGAATTTTA
CCATCACCAACCTACCATATTCCCAGGACAAAGCCCAGCCCGGCCCCCCC
Sequence 829

CGAATTGGAGCTCCCGCGGNGGCGGCCGAGGTACCTGATCTACTCCTCTCTACAACAAC
CTTGTGGGTGACGTTATTATCTCCATTTCACAAATGAGGCCACAGAGGTTCTAAAGGGTA
AATGACGATGATGAGAGGTAAGTGATAAAACAATGTCTCCTGACCACAAATCCTGGA
ATTTAAACATAAGNGTAGTAAACATGAACTCTAGGAAGCCTCCTGGGGCTTCTNCCTGTG
TCTGGAGCCCCTGCACATGCCCAAAGGAAGTCCTTTTGGTTCTNCGNTCAGNAGAGAAAG
GGNGCATTTCACTAAAAGGGAGGTGGGGAAACAAGACTGGTGGTAGGG

Sequence 830

CCGCGGTGGCGGCCGAGGTACATTATTCATATCCAGCACTCCCTGCGGCTGCTGCAGGGGGGCGGTTATCCAACAAGGACTGTTTCAACCTCATCGCGTTTGGAAGCACAATTGAAAGC

TABLE 1 133/467

TGGAGGCCTGAGATGGTTCCCGTGAGTCACAACAATTTACAAAGTGCCTGGCGGTAGGTT
ATGGGCAGAGACTTCGTGGGGCTGTGTCTGAGGGAAGGTTTGCAGGCATTGTTTTCTCTG
TCCCCCTCTCCACCAAGAAGTAGCTCTCTAGAGTCCCTGACCCCAAACAGCCATGGGCAG
AAATCAGAAAACAGCTTCCTTCTGTCTGCTGCTCCCCACCTGGCCATCTTCACTTTAT
GAGAGTAATGACATCGACTCCATTCACGTCTGAGATGGAAAAGGCTCTCAGCTACTCCCA
AAAGGTATGCCCTGGGCATGG

Sequence 831

CCGCGGTGCCGAGGTACGCGGGTAACAGGAGTCTTTGCTGAGTGATCATCTGTTTA
TTCTTTACTCCACAAATATCGAATGTTTACAGCGTGCCTGGCACTGAGCAGGGCTGGGG
TTTCCTGACCATATGGACCTTCCTGGGTATATCTGTGGGGCTTGAATGGTGTGACCTT
GTGTCCTGCCCG

Sequence 832

CGGGCAGGTNCGCGGGGGTGTTTATGGGAAGCCAGTAACACTGTGGCCTACTATCTCTTC
CGTGGTGCCATCTACATTTTTGGGACTCGGGAATTATGAGGTAGAGGTGGAGGCGGAGCC
GGATGTCAGAGGTCCTGAAATAGTCACCATGGGGGAAAATGATCCGCCTGCTGTTGAAGC
CCCCTTCTCATTCCGATCGCTTTTTGGCCTTGATGATTTGAAAATAAGTCCTGTTGCACC
AGATGCAGATGCTGTTGCTTGCACAGATCCTGTCACTGCCCATTGAAAGTTTTTTNCA
ATCATCGNCATTGGGATCATTGCATTGGATATTAACCCCTGGNCAATNGGCTTGGGCATT
CAATTTGACTTGNTAAGGGAAGTNCCTCGGCCGNTNTANAACTAGNGGGATCCCCCGGCT
GGANGAATTTCAATTTNAACTTATTGATACCGTCCANCCTTGNGGGGGG

ACCGCNGTGGCGGCCGCCCGGGCAGGTACATCACCCTGCTGAGGGACTTTTNNGGACAAG GTCACCACACTCTACAAAGGCAGTCAACTACATGACACATTCCGCTTCTGCCTGGTCACC AACTTGACGATGGACTCCGTGTTGGTCACTGTCAAGGCATTGTTCTCCTCCAATTTGGAC CCCAGCCTGGTGGAGCAAGTCTTTCTAGATAAGACCCTGAATGCCTCATTCCATTGGCTG GGCTCCACCTACCAGTTGGTGGACATCCATGTGACAGAAATGGAGTCATCAGTTTTATCA AC

Sequence 834

Sequence 833

Sequence 835

Sequence 836

GNGGNGCCGCCGAGGTACTTTAACANGCCATACTCCAGTCCCAACAATGTTAAATGCCA AAGCAGTGTTGGTAAAAGCCTCAAATGGTGAAAAGGACAGAAACTCAAACCCGCCCTTGT GCCAGTAAGTAACTGTTACTTATCTCACAAAGCGCTTGGCTCTGGAAACAATCTAACTCT GAGCTGCACGTGGAGTCTACATGGGAATGTGCAAAGCATGTATTTCCTTTTAGGTGCAGC AGAGGTAACCGAAATTCAGATAAGAGAAAAAAAAATCCAGATTTCAATGCAAGAGGTGGAA

TABLE 1 134/467

Sequence 837

NTTGCGTTGCGCTNACTGNCCCGCTTTCCAGTNCGGNGTAAACCTGTCGTGCCCAGCCTG CATTAATGAAATCGGCNCAACGCGCGGGTGAGAGGCCGGTTTGCGTATTTGGGCCGCTCT TCCCGCTTTCTTCGCTCACCTGACTCCGCTGCGCCTCGGGTCGT

Sequence 838

Sequence 839

Sequence 841

TABLE 1 135/467

CCGGA

Sequence 843

Sequence 844

CCGCGGTGGCGGCCGAGGTACGCGGGGAGGTCATGCCCGTGTGAGCCAGGAAAGGGCTGT GTTTATGGGAAGCCAGTAACACTGTGGCCTACTATCTCTTCCGNGGTGCCATCTACATTT TTGGGACTCGGGAATTATGAGGTAGAGGTGGAGGCGGAGCCGGATGTCAGAGGTCCTGAA NTAGTCACCATGGGGGAAAATGATCCGCCTGCTGTTGAAGCCCCCTTCTCATTCCGATCG CTTTTTGGCCTTGATGATTTGAAAATAAGTCCTGTTGCACCAGATGCANATGCTGTTGCT GCACAGATCCTGTCACTGCCATTGAA

Sequence 845

CCGCGGTGGCGGCCGCCCGGGCAGGTACTTCTAACCCTAAGGGATTCCTACAGCTTTTCT GCATGTTAAATAGTCTGTTTTAGCTTATTCTCTTATTACTTGGTTTTTACTTTGA AAGTTTGCTTAATAATCATGGGAATATTTTAGATTTTAAAATACAAAATATACAAGCTAA ACTTGAGAGCAGTTTTTAGTTGTAGAAACTGTTTCTTGAAGTAATTGACTTAGCGTTTGC TCTGCCTCTTTCTTTCTTACCTAGGTAGGTAGTGGGGACTCCTTCAATTATCTGAGCAA TTCAAATCTCAGAATGTAGTGTTGGGTAAATTGAGGGTT

Sequence 846

Sequence 847

TGGAGCTCNCCGCGGTGGCGGCCGNGGTACTCCAAGCAGTCCCAAAGTGGGAGTNCTTAA AACACCATGGGCAGGTGAATGGCTGACCAGGTGGAGGTGCACAGTGCACCATGACAAGAG CAGTGGAAAATGGGTGAATCTGAGATGCCTGGAGGCGAGGGGGAAAGAGCACATCACAGA GGACAACGTCCANNGGGACACCCTTTTATA

Sequence 848

CCGCGGTGGCGGCTGTGGACTGAAGGGTGACTGGTTCCACTGTGGTCTCCATGGGAACAA GTTGTTTCTGGAGTCTTCCAAGGAGAATTTCTCACAGTGGACCTGATCTCTGGGCTGATG CTGGGTTCCTTGGAGCTCATGATTTTGAGAGTGGTAGACATTTCTGGGCTTCCTGGGGAT GTGCCTGCTGGACTGCTCCCCGTCTCCTCTGCTGGGGCAGGCCACGTGGAATTTCCTTGT GCTGCCTGGCTTGACATCTTTA

Sequence 849

CCGCGGTGGCGGCCGAGGTACCTGAAGAATCTCTCTTCAGCTCTCTTCTCCTGGAAACTT
GAGTGGGGCAGGAGAAAAGCGGAGCTAGGTGTCATTTTAATGAGGAACATACTTGTCTC
CTCCATTTATCTGGCCCTCCCTGATGGCACTCCAGAATTCCAATCCCACACGATTAACAA
CATAGTTTCCCTTTTCTGCTTGAAGGTCCATTCTCCTCTCAATTTCAAATCACCTGAGAT
ACAAAGCTGCATTTCCCCACAAGAACCAGTTCCCTCTCCTTTCCTTCAGTGCTACTGTCC
TTCTCTCAGACCACCAAGCTTAAAAACTCCAGAGGCTCAAACAGCAAAGATGGCAGCCCG
CTCCTCCCTCTGGGGAGTTCTGGCCCAGGGAGTTTTCAAATTTCTGTAGGCGGAAGAATA
CTAGCGGGGGAGTGGCTGGAGACCCCAGTTGGTAGGGNTCCACATTTGGGGGAAGTGAGCC

TABLE 1 136/467

CAAGCTTTTTN

Sequence 850

CCGGGCAGGTACATGAAAGTAAGATCACAACCACAGGAACCACAAAAATTCAAGGCACC
AGAGGAGCCCAGACTTGGCTGGCAATGCCTGTTTTTGGAGCTATTCCACATTTCTGGAAGT
CAATGGGAATACCGGAATATGAAAACACTATGAGGCCGGGCACAGTGGCTCACGCCTGTA
ATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCATGAGGTCAGGAGTTCGAGACTAGC
CTGGCCAACATAGTGAAACCCCATCTTTAATAAAAAATACAAAAAATTAGCCGGGCGTGGT
GGGGGGTGCCTGTAATCCCAGCTACTCCGGCGGCTGAGGCAGGAGAATTGCTTGTACCTC
GGC

Sequence 851

CCGGGCAGGTACTTTTTCTTTTTTTTTTTTTTTTTTGAGTGGGGGCGGGGTTTCGCCA TGTTGGCCAGGCTGGTCTTGAATCTCGGGTGATCTGCCCGCCTCGGCCTCCCAGGGTGCT GGGATTGCAGGCGTGAGCCACCACGCCCGGCCTCGATATATTCTTACAGTGGAATACTGC TCAGAAATACTGATGAATCTTAAAAAACATGATGTTTAGCAAAAGAACCTTGGTATAAGG TTCTTGGTATAAGGGATACATACTCTATGATTCCATTATATGAAATTCTAGAACAGGAAA AACTATAGTGAAAAACAATCAGATTAGTGGTATCTGGGGTAGAAAGTAGGAGGAGATTGA

Sequence 852

CNANAGGGCTTTTTGGGGGCAAAACCGCGGNGGCGCCGCNCNAGAACNAGNGGANCCCT NTTGGGGGGGAAAAAAACCCCAAGCCCACCGANACCGNCGACCNCGAGGGGGGTNCCGG NACCCAGNGNNNGNCCCCTAAANAGAGGGNNAANNGCGCGCNNGGCGNAANCANGGNCAN AGCNNGNNNCCNGNGNGAAANNGNANCCGCNCACAATTTNTCTTTTNTAGNCGAGCCGGG AGCAGAAAGCCCNAAGAAAAAAGN

Sequence 853

Sequence 856

GCCAGGATTCAAACCAGGGANTTTGCTCCAGCACTCCGGCTCTTAACCTCAACCGTCTGC CTCTCCACAAACACCAGGATCAACCACCAAGACCAAAAAAACAGTCTCACAAACCATCAA ACATTGCACTTGGTGGCTCAGGACCTTAGCTTCGTCTTAAAGGTCCCTGTTATGCTTTTT CTTTTTGCCCCAGTGTGGAGTGGTCTTCGTGTTTGTGAGTGCAGGGGTCAGGGGTTGTGT CTTTTCTTCTTGTNCCCTTCCAAGAGGTGACATGTATCCTTGATACTGGAAGGGCCCTT Sequence 857

TABLE 1 137/467

Sequence 858

Sequence 859

Sequence 861

Sequence 862

Sequence 863

NCTATAGGGCNAATTGNAGCTCCCCGCGGTGGCGGCCGAGGACAAATTCAGTCCCAATAC TCAATACGTATTATAGATGACTATGAGTGCAAACCTTAGGATGNGATTNTCTGAATAATN GNTCTTTGTAGGATTTGGTTACATTATTTAAAATGAAAAAGATCTAGTTTTAGTGTGAGC TCAGTAATGNTAATNGGTTAAGTTCATTGCGAATCTTGAGTTTTTAGATAAGTAATTTTTTTCAATATCACTTCTGTTTTTAGTGATATTATATCAAGAACCAACGTATTCAAGAACC ATGGCTGACAGTGCCAGATATACTTAGGGATAAACATCAAAATGCAATTATATGAAACGTTAGATAACGTTAGATAAACGTTAGATAAACTAAAATGAA Sequence 864

WO 01/070979

TABLE 1 · 138/467

TTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTACAAGAGTCAGCAG
AAATGTGTGCTTTAAGCAGAGTCACAGGGGCCTGGGGCTGAACTGAGTCATTTCTCAAAG
ATATCCCTGCCTGGGATGATGATGGCTCTAATTGAAGCTCTGGCATCATCTGGGGCTTTA
TGAGCCAAGGGAGATAAGAAGAGCCACAGCAAAACCCTTGGGTCTACAGTGCAGGCTGCA
ACCAAGGCAGCATTTGCTAGAATATTTGTGATTATGTGTTCAACCTACAACCT
Sequence 865

Sequence 866

ACTTAGGGCNATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACACGGAAATCTGGACAGTG
CTGCACAGATTGATACATTAGCCTTTGCTTTTCTCTTTCCGGATAACCTTGTAACATAT
TGAAACCTTTTAAGGATGCCAAGAATGCATTATTCCACAAAAAAACAGCAGACCAACATA
TAGAGTGTTTAAAATAGCATTTCTGGGCAAATTCAAACTCTTGTGGTTCTAGGACTCACA
TCTGTTTCAGTTTTTCCTCAGTTGTATATTGACCAGTGTTCTTTATTGCAAAAACATATA
CCCGATTTAGCAGTGTCAGCGTATTTTTTCTTCTCATCCTGGAGCGTATTCAAGATCTTC
CCAATACAAGAAAATTAATAAAAAAATTTATATATAGGCAGCAGCAAAAGAGCCATGTTCA
AAATAAGTCATTATGGGCTCAAATAGAAAGAAGACTTTTAAGTT
Sequence 867

Sequence 868

CTATAGGGCGAATTGGAGCTCNCCGCGGTGGCGGCCGCCCGGGCAGGTACAGGATATCAC
CTGAATTATTAATGAATGCCCAGGAAGTAATTTTCTTCTCATTCTTCTAAAACTACTGCC
TTTCAAAGNGCACACACCGCGTNCACATACACTGCATTCGTTGCTCCAGTATAAATTA
CATGCATGAGCACCTTTCTGGCTTTTAAGCCAATATAATGGGCTGCAAAATGAAGACACC
ANAGTGTATGCATACAAATCTCACTGTATTAAAGATGCAGGTTTTCTAATTGTACCT
Sequence 869

Sequence 870

CCGGGCACGGTACAGAGCCCAAGACAAAAGATAGGCCTGTGAGGATAACATCTGGTATAT CTGACCCTTCCCAGCATGGCCAGGAGGCACAGCCAGGCCAGGGAGGCATACTGGGTTTG

TABLE 1 139/467

Sequence 872

Sequence 873

Sequence 874

ACTNCTATAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACAAAGACTTTGTAA
ATGTGATTCAGGGCCCCCAGCACCCCTGTGTCTGCAGAGTGCCTTCAAAACTCAGCTGTT
CCGGCCGGTGCCAACCTGTGAACTTCCCACCATATCCCAGAATCTGCTATTCCCCAAACC
ACTTCCCAGTTTCCTTTCAGTAATCTTTCTGAAGGAGCCAGGACAATAGGGCCTGTTGTT
TAGTGAATTTCTTTATTATTTTCAGCCTTTAAAATGTAATTTCCATCTCTTGCAATGAAT
TTGTTTCCCTTTTTTTTTGCTTCATTTTGTTTAAATTTTCAGGTATTTAGCTCCCCTTTCA
TATTATTTTTAAATTTTTTAATTACCTGTTGTAGGGGTGTTCCTCCAGAAGCAAAGAGCA
AAATTTTACTGTTGTAGATGTACCT

Sequence 876

CTACTTAGGGCGATTGGAGCTCCCCGCGGTGGCGGCCCCCGGGCAGGACGCGGGATTGA
TCAAAAGCTTTGTAACCACAGGAAAAAATAAACTCTTCCATCCCTTAAAGAATAGAATAG
TTTGTCCCTCTCATGGGAATTGGGCTGTATGTATATTGTTCTTCCTCCTTAGAATTTAGA
GATACAAGAGTTCTACTTAGAACTTTTCATGGACACAATTTCCACAACCTTTCAGATGCT
GATGTAGAGCTATTGGGAAAGAACTTCCAAACTCAGGAAGTTTGCAGAGAGCAGACAGCT
AGAGATAACTCGGGA

Sequence 877

TABLE 1 140/467

Sequence 878

Sequence 879

Sequence 880

CNCTACTATAGGGCGATTGGAGCTCCCCGCGGTGGCGCCGAGGTACAATGGCGCAATCT CAGCTCACTGCAACCTCCACCTCCTGGGTTCAAGCAATTCTCCTGCCTCAGCCTCCTGAG TAGCTGGGATTGCAGGCATGTGCCACCATGCTCGGCTAATTTTTTGTATTTTTAGTAGAA ACGGGGTTTCGCCATGTTGGCCAGCTGGTCTCCAACTCCTAACCTCAGGTGATCCACCCG CCTCGGCCTCCAAAATGCATCTCTGGTCTTTAAATGCCCTTTGCTGTATATTCTATAAC ATCAAGTCTCAGATCTGGTTTGACCTCAGTTGGCCTCTTAATAGTTTTCCCCTATGAACA TTCTGGTCTCCCAGTAAGCCTGTAAGCAGCTGAGACCATCTCTTATATCCCA CATCGTCCCATG

Sequence 881

Sequence 882

Sequence 883

CCGCGGTGGCGCCCCGGGCAGGTACTATAATTATAATGATTTCAGATAGAACATGCA

TABLE 1 141/467

ATTAGCCTTTTGAAATCCAACTTCTGTGCAAAATTTTAGTATCAGAAAATACGAGATTTG CAGGGGGAAACATCAGTAAACTACCATTAATGTCAATGCCCAGTTTTGACTTTTGTTAGC CTGACACTCCCAAACAGTTGTAGAATCCGATAGATGACTGATGGCAAAAGATTGTGAACA TGTGGAAGAAAATCAGTGGGATTCGTTGTGATGAATAGGTTGCCTTCAGAGTATTATTG ACAGACAGCTTGTGGAACTAATTCTTTATTTTTGATGTTGTGGGAATTAACACATCAATG GTGGTTATGGGAACTACCAATGGGTTCCTACAAT

CTTAGGGCGATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACTTTAATTCTAAATTATAAG
AAAATATACATTTGCACTTATTAATATAGAAATTCATTTTGTGTATATTTAACATAGCTT
TTAAACTATTTTACATTAGCTACTTTCATTATGGTTTCTTGAACTTCTGAAAAAAATTAG
AAATGTATTAAACTTATCAGTAACATAAAAACTTATTTTGTTTCACCTAACGAATACTGC
GTTTGTAAAAAATAAATTTAATATAGAATATTTTTAAATTAAATATTTTGAATATAAAAT
AGCTCTAAGAAAGAAGCAAATTATCACTGAACATATTTCTTATTTTCTGGCTTTGAAT
TAATACGTAACTTAAATTGGCTTAAATGATCCAGAATATTTGGAGGAATATGATACTTTCA
CATAATATACTATGAACCTGTTCATATAACTCTGGATTGGCTACCTAACCTTCTGNTTTA

Sequence 885

ATG

Sequence 884

Sequence 886

CCGCGGTGGCGCCCCGGGCAGGTACGCGGGGAGAGACATTGTGGCTAGCCAACCACA TGGTCAGCCTCAAAGTTGAGAGGCTCAGTAACCCTCCTATCCCTAGAGAATTCCAAAGTG TGGATGTAATTTAACCTAGGAAAGCCATTGGTGACTATCTGTGATCCTCTGGAAAGTATG CTATGTTGGGGTATATCTTTGCATCCAAAGCCAGAGGGGAACCACAATGGCCTAGTAAAA CCGGTGGGTCCTCAAATGCCCACTTAAGCCTCTGGCCTNTTGGAANTTTGACCCATAGTG GGCCGTTCAGCTTGATTAGAGCCGGGGAAAGAAAGAAAATATTGNCATTTTTTTTNTTGA

Sequence 889

TABLE 1 142/467

CTACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACCTGGATCTATGCTGC
TATGGGTGAGAATCGACATCCTTTGAAACTGGCCACAGGCAGAGCTAAGAGGATGACTA
AAAGGTCCCTTGGGTGGTGCTAATGAGCAGGGGCCCAGGAAAACCTCTGTCTTCCCGGA
GAGCCCTCTTGCATGAGTTTCGGCTTTGCCAAGATTCCAGGGACTTGAGGACAGCTATTG
AGTTATGGTTACGTGACTGCCACATTGGGGCTTGGAGGCATCTGGCAGATGGTTGGGAAT
GGGCTGGCACCACACTAATTAGGCCACGATGATCCAGTTTGACTCAGGGAAACCCAGAAG
TCATAGTNCTCTTTGCAGAATGACACAAGGATGTCAACATGCTTTGNTTGTGTACCTCGG
CCCGCTCTAGAACTAAGTGGGATCC

Sequence 890

Sequence 891

Sequence 892

Sequence 893

CTACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACACAGTTTGGAAGTTT
AGGCAAAAGTCATTTCTTCCCTATATTTTGTCATGCTTATCTCCTGTCTCTTTCTGTTTT
ACAGATTAGCAATAAACTCCTTAAAACCCAAAAGGTTTGGGCTTCTGTTCCTTTCACTTG
CAGTCAGACATGGAGTTAGTGGTAGAAGAAACAGAAGGGGTAACCTGCATGGTGACAGCT
ACTGAGGGGATAGGAAAGCAGGCTGAGTCCCTGGGGCCAGTGGTTACCAAAGCCAA
GGAGAGGGCAAGGGGAGCCCAGTGGGCCTGG

Sequence 894

TTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACAAGGAGTAGTCTAAAACAA

TABLE 1 143/467

Sequence 896

Sequence 897

Sequence 898

Sequence 899

Sequence 900

GCTNCACCGCGGTGGCGGCCCCGGGCAGGTACCCTAAATGTTAAACTGAGGGATGAGT GAAACAATATCAGGATTAATAAATAAACACATTCTTGAATTCCATCACTTAATAGAAGTG GCCATTTGAATGCTGGCAGGTNGGAAGAAAAGAGGGAGGACAAAGAACCCCAAAAGTTTGG CATCATAACTACTGCCACAAG

Sequence 901

GGCAGGTACCCACCTCCTCGGTCACCCACAGAGCCACCAAAGATTCCATGTCCCAGAGCT

TABLE 1 144/467

Sequence 903

CCGCGGTGGCGGCCGAGGTACCATCTACTGAATGCCCAGTTTTGATCTATTTCTAAATGG
AGCAAACCAATTCCATCTCCTAGAGCTGGAGACTGTATCCAGGCAGTGTGTGGACAGAAC
GGACAATCTTTTCTGCCAAGGGCCTATTTGAGTGGAGCACCCCCACACGGGTTAGACGGG
TCGGCACGGGGCTGGTGGGTGAGGAACTCAGGGGTCAGTGCAAGCTGCAGACCCTCATTT
GGGGAACGCTCTCAGCACAATGCTCTTACAACTACAGGGTGCACTCCAAAATGGAGTTCA
AGGAAAAAAAGGCTAATGAGAAATAAAATCTGAAAAAATAACTTAAAAAGTTTTGCT
Sequence 904

CCGGGCAGGTACGCGGGGGCCCTTTGGATACCTGCACTCCCCATCACCGCACTCCCCATC
GTGGCACTTCCCTTGTTGCAGTTTTATGGAGTGTGCGTCTGGCTCCCCAACTAGACTTGA
ACCGCTTGGGTGCATAACTCGGGACTTGACCATTTGCGTCTCCCTACGGCCAGCTCAGCC
TCCGCACACAGGGACCTGCAGAGAGTGGATGTAGCCACTGCCCCAGCGTCCCTGGGCTCT
GAAGAGAAGCCATTGCCCTTCAAGAGCCACCCTCATTTCCTGGGCACTGGTTTGGAAAAA
ACGAAGAAAAAGAGACACCCAGCTCACCTCCA

Sequence 905

CTCCACCGCGGTGGCGCCCCCGGGCAGGTACGCNGGGCAACTCATTCATGATATTGGG AGAAAAGCAAAACCAAAAACTGCAACAAAATCTCAAACCCTTTCTGCAGCAGCAGATGGCA AACAGTGATCAGAGGAGAAGGACCCTTCCAGCATTAGAAGATTTCCAAAGGCTGTTCCAG TAGGGGCTGTGGGCTTCTGGGAGCCCAGATGCCCCCTGATGGTATATTTGAGTTTGTGAG GTGGAGGCCAGGTGGCAAGANACTGCNNGCCAATGTCAATGAAAAGCCTGGGAGGAAAAA GAGATTTCTGGGA

Sequence 906

Sequence 907

Sequence 908

AGGTACTTCCCTGAGCAGTCGAAGTGGATGCCCAGACCAATGGCCAGTGCTAATATCAAT GCAATGATCCCAATGACGATGATTGGAAAAACTTCAATGGCAGCAGTGACAGGATCTGT GCAGCAACAGCATCTGCATCTGGTGCAACAGGACTTATTTTCAAATCATCAAGGCCAAAA AGCGATCGGAATGAGAAGGGGGCTTCAACAGCAGGCGGATCATTTTCCCCCATGGTGACT ATTTCAGGACCTCTGACATCCGGCTCCGCCTCCACCTCTACCTCATAATTCCCGAGTCCC AAAAATGTAGATGGCACCACGGAAGAGATAGTAGGCCACAGTGTTACTGGCTTCCCATA Sequence 909

TABLE 1 145/467

GAAATTAAAAAGAGACTAAGAATATTACAAACAACTTTATTTCATTTAGATGAAATGGAC AAATTTATTTTAAAACACAATTCGCCAAAATTGACAGAAGTGGAAGTAGAAAATCTATTT CTGTATTTATTAAAGATACTGAATCTATAATTAAAAAATATCTTCACACAGAAAATTACAG TTTCAAATG

Sequence 910

Sequence 911

AGGTACAGATCACTATGGCTTGTCTTTTCTCCTAACTAATGTAAAATTCCCAATAATTCA
TAACTTGTATGAGGACAACAGTTGTGTGAATCTACCCTGGTCCTTCTGATNATTTTTAAT
TTTTTNATTTTTTTTTTTTGGGGACAGAGTCGTGCTGTTATCGCCCGGGCTGGAGTGCA
GTGGCATGATCTCGGCTCACTGCAACCTCCACCTCCAGGTTCCAGCAACTCTCCTGCCT
CAGCTTCCCGAGTAGCTGGAATTACTGGTGCCCACTACCACACCCGGCTAATTTTTTTGTA
TTTTTAGTAGAGATGGGGTTTCACCATGTTGGCCAGGCTGGTCTTGGACTC
Sequence 912

AGGTACAAATTGTCGTTTTTATTCCTCTTATTGGGATATCATTTTAAAAACTTTATTGGG TTTTTATTGTTGTTGATCCCTAACCCTACAAAGAGCCTTCCTATTCCCCTCGCTGT TGGAGCAAACCATTATACCTTACTTCCAGCAAGCAAAGTGCTTTGACTTCTTGCTTCAGT CATCAGCCAGCAAGAGGGAACAAAACTGTTCTTTTGCATTTTGCCGCTGAGATATGGCAT TGCACTGCTTATA

Sequence 913

Sequence 914

CGCCCGGGCAGGTACGCGGGGACTTGACTTAAACTCTGGGGCCCGGGAGGCCGCCGGTTT TCTCCCCGCTTGCCGGGGTGGTCCTCTTCCCTTTGTCGGACCAAAGAAGTAAACACTGTG TGGAGAGGGACTGCGTGTTTGGAGGGAAATGGGAATGTACCT

Sequence 916

TABLE 1 146/467

Sequence 917

GGCTGTGGCCAAGAAACGCAGGGACCGCTCTCTCCCCCGGGCTTTCGAAATCTTCACAGA CAATAAAACCTATGTCTTTAAGGCCAAGGATGAGAAGAATGCAGAAGAATGGCTCCAGTG CATCAACGTGGCAGTTGCCCAAGCCAAAGAAAGGGAAAGTAGAGAAGTAACCACATATCT GTAGGGAATTTATAAGTCAGCCATGACAATTATACACCACAGGCATTGTATTATCATTGC CAATGTCAAGAAAAAGAGCTAAATTTACCAAGCCATGGTTGGNTTTTTACTAAATACCAT GGGAATTTGTTGGTCCTTTAAGAAGAAGAGGGCCTTAAAATGGCAGGGATTTCTTAGTNAAA TGNCAATACTCTAACAGCTTTAGTATTGACTTTAGAATATCTGATGCCCACAAAAATT AAATAAAAGGGNTTNGAGGAGGTTTGCCCNAAATAAGTGNGGGGCCCGGAGGGGAA Sequence 918

AGTCNCCACGCGTCCGCGGACGCGTGGGCGAGTGCCCAGTGACCCTTTACGGGGGTAGCT
TTTACTCCGCACTCTCAGCCCCTGCCTCACCCCTCCAGGCCCGGATTGACCATTTC
CTGCTCCAGCACTCCATCCCTGGCTGCCACCTGCTTGGGAGAGCACAGACGGCATTGGCA
GTGATCCCTTCTTCCATTGTTCTGCCCTCTCAGAAAAGGAAGATAGAGCAGGCTGAACAT
GTCCCAGACAGTAACTTTGGTGTAAATGCTTCCTGTTTTTCTGCCACAAGCCCTTTGGTC
TTACCCACTACCTCAGAGCACACTGCTAAGAAAATGAAAGCCACCAATGAGCCCAGCCTG
ACACATATGGGACTGCTCGACAGGTCCACTGTCCCACGAGCAGAAGCTGGTCACAAAGCT
TGGGAAAT

Sequence 919

GGGAGTCGACCACGCGTCCGCGGACGCGTGGCCAGTGACCCTTTCACGGGGGTAGCTTTTACTCCGCACTCTCAGCCCCTGCCTCACCCCTCCAGGCCCGGATTGACCATTTCCTGCTCCAGCACTCCATCCTGGCTGCCACCTGCTTGGGAGAGCACAGACGGCATTGGCAGTGATCCCTTCTTCCATTGTTCTGCCCTCTCAGAAAAGGAAGATAGAGCAGGCTGACATGTCCCAGACAGCATTTGGTGTAAATGCTTCCTGTTTTTCTGCCACAAGCCCTTTGGTCTTACCCACTACCTCAGAGCACACTGCTAAGAAAATGAAAGCCACCAATGAGCCCAGCCTGACACACATATGGACTCCGACAGGTNCACTGTCCCACGAGCAGAAGCTTGTCACAAAGCTTGGAA

Sequence 920

AGTCGCCCGCGTCCGCGGACGCGTGGGCGGACGCGTGGGCGGACGCGTGGGCGGACGCGTGGGCGGACGCGTGGGGACGCGTGGGGACGCGTGGGGACGCGTGGGGACGAGAAAAAAGTTAGTGGAGGGACAAGCAGGGTTGCAGAGAAAAAATGTTCCTGTGAGAAGAAAACTGTCCAAAGAGTNTGAAGAGAAAAAGGGAACAGGGTGAATTTGANGCCCTACAAGAAAAACAGGAGACCCATTCAACAGGAGACGCCCAGGGAGCCAGGTGGCTTTGTGGGCCTGATGTCCAAGAAAAGAAGTNCTGGTGGTAAACAGAGACTTGTGTGGGATTGCAAGCTACTGTTGTCTTTCTATTGAAA

Sequence 921

Sequence 922

TCCGCAGGCTGGGGATCCCAAAGGGTGCGCTCCAGCCCCAACCCAGGCACTGGGACTC TGGTGCACCCTGGGTGCAGGCAGGCATCTGAAATCAAGTGCACGAGCCTTGGAAAGGAG GACCGGGAGAGTTATGGCATTTATGAATGAAGAAGAAAAGAGAAATCACTCGGATGGGAA AAGTTAACTGGATTGTTCCCACCTGCATGGATCACCCGGGTAACTGCAGTGGGACCGAGG GGGCGAGGCTGCGGGGTTGCCGGGTTTCCTTGTGTTGCCACGAACCCAGAGA

TABLE 1 147/467

Sequence 923

Sequence 924

Sequence 926

Sequence 927

CGCGTCCGGTCATATACAATGTCATTGTTTGGGACCCGTTTCTAAATACATCTGCTGCCT ACATTCCTGCTCACACATACGCTTGCAGCTTTGAGGCAGGAGAGGGTAGTTGTGCTTCCC TAGGAAGAGTGTCTTCCAAAGTGTTCTTCACTCTTTTTGCCCTGCTTGGTTTCTTCATTT GTTTCTTTGGACACAGATTCTGGAAAACAGAATTATTCTTCATAGGCTTTATCATCATGG GATTCTTCTTTTATATACTGATTACAAGACTGACACCTATCAAAGTATGATGTGAATCTG ATTCTGACAGCTGTCACTGGAAGCGTCNGTGGAATGTTCTTGGTAGCTGTGGTGGCCG ATTTGGAATCCTCTCGATCTGCATGCTCTGTGTTGGACTAGTGCTGGGGGGTCCTCATCTC

TABLE 1 148/467

GGTCANGTGACTTTCTTTACTCCACTGGGAAACCTAAAGAATTTTTTCATGATGATTGGG TGTATTCTGGGTCACTTTCTCTTGCCATAAGCTATNCTCATTCCAGTAGTTT Sequence 928

Sequence 929

CGACGCCANGGCGCCTCCGAGTTCCCCGCCAGGACTCGGAGGGCCAGGAGGGCGCGACC
TGGGTGGATATTTTTGTTGGACGGCGCAACTCTTGGGGTGGCCCGGGAGCGGCGGAAACC
GAGCGAGAACCAGGAGGCGCTGCGCAGAAGGAGGCCCGGGGGCTCCGAGGCGTTGAGG
GGCTCGATCTGCGTTCTGGGGTTGGCAGCCGAGAGGCCCGGGTCCCTGAGTGCCAGAGGT
GGTGGTGTTGCTTATCTTCTGGAACCCCATGCAGCCAGATCCCAGGCCTAGCGGGGCTGG
GGCCTGCTGCCGATTCCTGCCCCTGCAGTCACAGTGCCCTGAGGGGGACGCGGT
GATGTACGCCTCCACTGAGTGCAAGGCGGAGGTGACGCCTTCCCAGCATGCCACC
CTTCAGCTACACCCTGNAGGGATCATACCAAGCAGGCCTTTGG
Sequence 930

Sequence 931

CACGCGTCCGTGGAGTATGTGCCATCTGCCAAAGTGGAGGTGGTGGAGGAGCGCCAGGCC
ATCCCTCTAGACGAGAACGAGGCATCTATGTGCAGGATGTCAAGACCGGAAAGGTGCGC
GCTGTGATTGGAAGCACCTACATGCTGACCCAGGACGAAGTCCTGTGGGAGAAAGAGCTG
CCTCCCGGGGTGGAGGAGCTGCTGAACAAGGGGCAGGACCCTCTGGCAGACAGGGGTGAG
AAGGACACAGCTAAGAGCCTCCAGCCCTTGGCGCCCCGGAACAAGACCCGTGTGGTCAAG
CTACCCGCGTGCCCCAC

Sequence 932

TABLE 1 149/467

CATCCCAGCTCAAGGTGGTCAGAGCTAGACCTTCTTATTCTGTTGGGGACGGCGGGCCAC GTCTTGAGCCTGGGCGCCAGCAGCTTCGTGGAGGAGGAGCACCAGACCTGGTACTTCCTT GTGAACACCCTGTGTCTAGCTCTGAGCCAAGAAACCTACAGAAACTACTTT Sequence 934

Sequence 936

Sequence 937

GTCCGCCGCATGAGCTGTCCATGAAGGATGAGCTGCTTCAGTTCTACACCAGCGCTGCG GAGGAGAGTGAGCCCGAGTCCGTTTGCTCAACCCCGTTGAAGAGGAATGAGTCGTCCTCC TCAGTCCAGAATTACTTTCATTTGGATTCTCTTCAAAAGAAGCTGAAAGACCTTGAAGAG GAGAATGTTGTACTTCGATCCGAGGCCAGCCAGCTGAAGACAGAGACCATCACCTATGAG GAGAAGGAGCAGCAGCTGGTCAATGACTGCGTGAAGGAGCTGAGGGATGCCAATGTCCAG ATTGCTAGTATCTCAGAGGAACTGGCCAAGAAGACGGAAGATGCTNTCCGCCAGCAATGA GGAGATCACAC

Sequence 938

Sequence 939

CGTCCGGCCGGCGGCGGCAGTGGCGGCCCGGCCTGCAGGAGCCCGACGGGGTCTCTG

TABLE 1 150/467

Sequence 940

CCCGGTCGTGCGGCTCGGGCGCGGCGGCGCGCGCAGTGGCGCTNTCAGGTGATTGA CTGGCCAGCTGCCTGAAGGAGCGCCAGGTCCTCCTTGCTGGCAGGTGGCGAAGCCCATTG GGGCGGCGGTGCAGACCCGCGGCGGCNGCTGCGGCGGTCTGGCTCGGGAGGCGTTCCTGG GGCCAAGGCCATGGCCCCGCGGCTGCAGCTGGAGAAGGCGCCTTGCCGCGTGGGCGGAGAC GGTGCGGCCCGAGGAGGTGTCNCAGGAGCACATCGAGACCGCTTACCGCATCTGGCTGGA GCCCTGCATTCGCGGCGTTGTGCAGACGAAACTGCAAAGGAAATCCGAATTGCTTGGTTG

Sequence 942

Sequence 944

WO 01/070979 PCT/US01/09126

TABLE 1 151/467

CCTCGTTCTCCAACGCTGCTACGAGGGCAAGCCTTCTCAGAGGAAGCCCAAGCATTAGG AAGCCCGCAGGC

Sequence 945

CGCGTCCGGCACGGGGAGTCTGTGGTGGCCNGTTTACCTGGCATCTGGCTGAGAGGAA
GAAAGGCCAACCTGATCCTGAGGGGACCCAGACATATCCTTTGCACTGTCCCTAGAGGGG
CGATGAGCTTTGCAGCATTAAAAAATGGTGAAGGGGGAAATATTTTGAACCAAAGACCA
AATGTTAGGCCGCCGTTATATTTGCAGAAGCTTTGAGAACCATGCGTATAGCCTCCTGCA
TTCTCCCCTCTCCTAGGAGCTCTTTTGTCTCTGTCCTTACGAGGCGTCATACAGAGGCAG
TGGGGTGGGCACAGATGAGCAGAGTGGATGGTTCGGTGGGTCCCCACGAGGGCGAGTGGT
GGTCATATGTGATGGCACCGTGTTCACACACCCTCCTGTGTACCCCCCCAGGGTCACCCG
AAGTCCCCACACGCTGGCTCTCCACACCCCTCCTGTTCCAGAAAGCATGTCCCG
Sequence 946

TCGACCNCGCGTCCGGCACTCCCTCTGGCCGGCCCAGGGCGCCTTCAGCCCAACCTCCCC
AGCCCCACGGGCCCACGGAACCCGCTCGATCTCGCCGCCAACTGGTAGACATGGAGACC
CCTGCCTGGCCCCGGGTCCCCCGCGCCCCGAGACCGCCGTCGCTCGGACGCTCCTGCTCGGC
TGGGTCTTCGCCCAGGTGGCCGCGCTTCAGGCACTACAAATACTGTGGCAGCATATAAT
TTAACTTGGAAATCAACTAATTTCAAGACAATTTTGGAGTGGGAACCCAAACCCGTCAAT
CAAGTCTACACTGTTCAAATAAGCACTAAGTCAGGGAGATTGGAAAAGCAAATGCTTTTA
CAC

Sequence 947

Sequence 948

Sequence 949

CCACGCGTNCGGTCGGCCTGTGCGGCGCGCGGAGCGGGCCATGGCAGTGGGAGGG GGCGAGTGTAGTGCTGCGCGGGGCAGGCGGAGGTGATCGAGAGAGGCAGGGATGGGGGC GCCGGAGTGGAGCGGTTGCGGCGGCACTGGGCACTTGGAATAGTAGCAG GCGCGCGCGGCGGAACGCCAGGCAGTGTATGTTTTAACTGGAAAAAGTCTTCCATGAAAA CCGTCACTTTTAAAAAAATAAGGTAATGCCCATTCTGTTTTTTTCCTAAAAAAAGACCTGAA AATGGGGGGGCCGAACACATTCCTTAGGGGCCCCCGGTGGNTTATTGAAATGTGCCTTTC AAGTTTTCATTAAATGCNCTCCTGGCTTATTGGGCAGGACCATTCCCTTTGAACAATCC TGGGGGCCGGGCTGGGATTTCAACAAGAATTAGGCAATTCTTGGAATGGGCCTTCCAATA ACCCTGNTGGGGAATTTTTCCCNTTTTNGCCCCCAACCTTGGGGGAATTTNATTATTTNC AAGNTTTGGGGAAGGGTTACCCTTCNGGGGGAAANGCTTAACCCAATTTTTC Sequence 950 TTNGGGAGTCGCCACGCGTCCGGCCGCGCGACGGCGAAGTGGCGGCCCGGCCTGCAGGA

TABLE 1 152/467

GCCCGACGGGGTCTCTGCCATGGGGGAGTGACGCGCCTGCACCCGCTGTTCCGCGGCAGC GGCGAGACATGAGGAGACCCCGCGACAGGGGCAGCGGCGGCGGCTCGTGAGCCCCGGGAT GGAGGAGAAATACGGCGGGGACGTGCTGGCCGGCCCCGGCGGCGGCGGCGGCCTTGGGCC GGTGGACGTACCCAGCGCTCGATTAACAAAATATATTGTGTTACTATGTTTCACTAAATT TTTGAAGGCTGTGGGACTTTTCGAATCATATGATCTCCTAAAAGCTGTTCACATTGTTCA GTTCATTTTTATATTAAAACTTGGGACTGCATTTTTTATGGTTTTTCAAAAGCCAT TTTCTTCTGGGAAAAC

Sequence 951

Sequence 952

Sequence 954

CGTCCGGACCCTTATTAAGAATATCCCAGGAAGATGGTGATGAACAGCCTCAGTTTACTT
TTCCACCAGATGAATTCACTAGCAAAAAAATTACAACAAAAATATTACAGCAGATTGAGG
AACCATTGGCACTGGTGAACAATTAACCAGCAAATGTCCTTTTCTAATACCATTTGAA
ACTAGACAGCTTTATTTCACATGTACAGCATTTGGCGCCTCAAGAGCAATAGTATGGTTA
CAGAACCGACGTGAAGCCACTGTGGAGCGAACGAGAACCACAAGCAGTGTTAGGCGAGAT
GACCCTGGAGAGTTTCGAGTTGGTCGTCTCAAGCATGAAAGAGTAAAAGTTCCACGTGGC
GAGTCACTGATGGAATGGCTGAGAATGTCATGCAAATACATGCAGATCGGAAATCAGTT
CTTGAGGTTGAATTTTTAGGAGAAAGAAGAACTGGCTTGGGACCCACATTAGAGTTTTAT
GCTCTGGTG

Sequence 955

TABLE 1 153/467

GGGGTAGAGATCCGGAGCGCCACCGGCAAAGAGGTGTTGCAGAACCTCGGCCCCAAGGAC AAGAGTGACCGTCTNCTTATCAAGGGAGGCAGAATCGTCAATGATCAGTCCTTTTAT GCTGATATTTACATGGAAGATGGCTTAATAAAACAAATTGGAGACAATCTGATTGTTCCT GGAGGAGTGAAGACCATTGAAGCC

Sequence 956

Sequence 957

Sequence 959

CCACGCGTCCGCGACGCGTGGGGCCGGGACAACTGGTCTTATCACGGAGGCTGGGGCCA
NGGCAGCCCTTCGGTTCGGGTGGGCCCATGGACCCCAGTCCAACGCCGAGGGAATAGGAC
CATCCAAAAGCGGAACCTTCGCCTCAGAAAAAGGGTGCGGGACCCCTCCTCACCGTGCGG
TCACGCGTGGACCCTGCCAGCAGCCAGGCCATGGAGCTCTCTGATGTCACCCTCATTGAG
GGTGTGGGTAATGAGGTGATGGTGGTGGCAGGTGTNGGTTGGTNGCTGATTCTAGCCTTG
GTCCTAGCTTGGCTCTCTACCTACTTAGCAGACAGCGGTAGCAACCAGCTCCTGGGCGCT
NTTGTGTCAAGCAGGCGACACATCCGTCCTNCACCTGGGGCATGTGGACCACCTGNTGGG
CAGGCCAAGGCNNCCCCGAAGCCAACTGA

Sequence 961

NCCCCGCGTCCGGGAGGCTCCATGTTGTCCCCTCAGCGAGTGGCAGCAGCTGCCTCAAGA

TABLE 1 154/467

GGAGCAGATGATGCCATGGAGAGCAGCAAGCCTGGTCCAGTGCAGGTTGTTTTGGTTCAG
AAAGATCAACATTCCTTTGAGCTAGATGAGAAAGCCTTGGCCAGCATCCTCTTGCAGGAC
CACATCCGAGATCTTGATGTGGTGGTTGTTTCAGTGGCTGCCTTCCGAAAGGGCAAG
TCCTTCATTCTGGATTTTATGCTACGATACTTATATTCTCAGAAGGAAAGTGGCCATTCA
AATTGGTTGGGTGACCCAGAAGAACCGTTAACAGGATTTTCCTGGAGAGGGGGATCTGAT
CCAGAAACCACTGGGATTCAAATCTGGAGTGAAGTTTTCACTGTGGAGAAGCCAGGTGGG
AAGAAGGTTTGCAGTTGTTTCTGATGGATACCCAGGGGGCAT
Sequence 962

Sequence 964

Sequence 965

TGCGCATGCGCGGGCGCGCGCGCGCGCGCGTTGGCCGTTTCGCCCTGGGA TCCGCCGCCACTCCGCGATCAGACCGCTCTGTGCCGCGAGCCGCCGTGAGCACTCGGATT CAAGCCGGCGCCAACGAGTCCGGGGGCATCGCCGCAGCGGCCAAGCTCATGGCCGGCTG AGCGGGACGCCGCCTCAGCCACCGCCGCCGCCGCCGCCGCCGCTCTCCAGCCG GCGCGCCCCGGGCCCAGCAACCATGGCTGAAGACTACTGGGACGGCGCCTGCGGCGAA CAGGAGGAGAAAGGGAGGTCGCGCGGCCTCATTCCGGGCCGCCCCCAGGCGCCGCCGC GCCGCCCCGCGGCTCTGAGGTTGCTCGCGCGCCCCC

Sequence 966

TGGAAAATNTTTTGGAAAAAATTACCCTTGGGACCTTGNTTTTNAANCCCNAGGTTCCCN GTTNNGGCAAATAAAANAATGNNNGACCCGGGATTTNGGGNTTNNAAACCGGGGGTTTTT AATTTCCCCNNNNCNNGGGNCCTTTTTTTTTTNCCNCCCCCNCAAGGGGGNTTTGGGAAAN NAAANCCCCCCCTTTTTTTTTTNGGGGGNGAAANTTCCCCGGGTNNNNGCCNTTTTTTTT TTTTTAAA

WO 01/070979

TABLE 1 155/467

Sequence 967

GTCCGCGAGGCTCCGCACCAGCCGCGCTTCTGTCCGCCTGCAGGGCATTCCAGAAAGATG
AGGATATTTGCTGTCTTTATATTCATGACCTACTGGCATTTGCTGAACGCATTTACTGTC
ACGGTTCCCAAGGACCTATATGTGGTAGAGTATGGTAGCAATATGACAATTGAATGCAAA
TTCCCAGTAGAAAAACAATTAGACCTGGCTGCACTAATTGTCTATTGGGAAATGGAGGAT
AAGAACATTATTCAATTTGTGCATGGAGAGAAGACCTGAAGGTTCAGCATAGTAGCTAC
AGACAGAGGGCCCGGCTGTTGAAGGACCAGCTCTCCCTGGGAAATGCTGCACTTCAGATC
ACAGATGTGAAATTGCAGGATGCAGGGGGTGTACCGCTGCATGATCAGCTATGGGTGGTG
CCGACTACAAGCGAATTACTGTGAAAGTCAATGCCCCATACAACAAAATCAACCAAAGA
Sequence 968

Sequence 970

GTCCGAGATCGCGAGCCGCCCCTTTTTTTTTTTTTTTTATAAGATTATTAGTATAAAAN
GGGGAGACGAGGTTAGGGCCCTGGGAAAGGTGGGAGATCAGCCAGAGACAGGTTTCCCAG
AACAGAATGTCTGGCCTTTGTGGTGAGGAGGGGACTGTGGTATGAGCCGCAGAAGCGGGCC
AGGGGTAAACCCTCCTGTGCGTCCTTCCTTCAGCCTGGTCCTGAGGGTGACCCTTTGATC
CTGGGTTCTCCAGGTAGGGCTGTGAGCTGTGAGTTGGATCCTTTTTGGTGAAATGGTCTCT
CTCATCTGGCCTGTCACTCAATGTGGAATAGAGTGAGTTCTATGGGTTCTAAGTCC
TGCTCTGGAACCATAAGTAAGTTATCCTCTCTGGGCTTCAGTTTTTCATGGAAAGTTGCG
TTAAGAATCTAGTTTAAGGCCAGGCATGGTGGCTCACCGCCTTGTAATCCCAGCACTTTG
GGGAGGCCAAGGAAGGTGGATCATGANGTCAGGAGATCGAGACCATCCTNGCTAACATGA
TNAAACCCGTGTCTTTACTTAAAAAAATAC

Sequence 971

CCTGCCAGTGGTGAGCACCTTCGGCCTCCAGGTGCCTTTCTTCTTCTCGCGGCCATNTG CTTGGTGAGCCTGGTGTTCACAGGCTGCTGTGTGCCCGAAACCAAAGGGACGTCCNTGGA GCAAATCCGAGTCCTTTTTCCGCACGGGGAGAAGGTCCTTCTTGCGCTAGGTCAAGGTCC CCGCCTGGAGGGGGCCAAACCCCCA

Sequence 972

GCGTCCGCGGACGCGTGGGCGGACGCGTGGGTCAGCCTCCACCTGGAAGAGAGCTANGGG CCGGGCAGGCCGGCCACCCCGCCCGGCCCGACGCCCCGCATGCCCCGAAGTCC CTGGCGCCCACCCGGCCCTGCTGCTGACCCGCGGGTCGATACCTGGCAGCCCCA GTGCTGGGGCGCCCGGCCCTGCTCGCCCAGGAGGAGGGGCCCCACACTGAGTCT CTTGAAGCCTCACGTTTCCCTGGGGGGGTGCTGCATCGTCGGGTGTCCCTCACCCCACCT WO 01/070979 PCT/US01/09126

TABLE 1 156/467

GGGGAACCTCTGTCTTCAGGTCACCCCTTTTCAGGGGCCTGG

Sequence 973

Sequence 974

Sequence 976

Sequence 977

NCTCCAACAATTATGGCTCATCCTTTCTTTTACTCTGTCTCACCTCCTTTAGGTGAGTAC
TTCCTTAAATAAGTGCTAAACATACATANACGGAACTNGAAAGCTTTGGTTAGCCTTGCC
TTAGGTAATCAGCCTAGTTTACACTGTTTCCAGGGAGTAGTTGAATTACTATAAACCATT
AGCCACTTGTCTCTGCACCATTTATCACACCAGGACAGGGTCTCCTAACCTGGGCGCTAC
TGTCATTTGGGGCCAGGTGATTCTTCCTTGCAGGGGCTGTCCTGTACCTTGTAGGACAGC
AGCCCTGTCCTAGAAGGTATGTTTAGCAGCATTCCTGGCCTCTAGCTACCCGATGCCAGA
GCATGCTCCCCCCGCAGTCATGACAATCAAAAAATGTCTCCAGACATTGTCAAATGCCTC
CTGGGGGGCAGTATTTCTCAAGCACTTTTAAGCAAAGGTAAGTATTCATACAAGAAATTT
AGGGGGAAAAAAACATTGGTTAAATAAAAGCTATGTGTTCCTATTCAACAATATTTTT
Sequence 978

TABLE 1 157/467

Sequence 979

Sequence 981

AGGCTGNTACGAAGCGAGCTTGGGAGGAGCAGCTGGCCTGCGGGGCAGAGGAGCATCCCG
TCTACCANGTCCCAAGCGTGTGGCCCGCGGGTCATGGNCAAAGGAGAAGGCNCCGANAG
CGGCTCCNCGGCGGGGCTGNTACCCACCAGCATCCTCCAAAGCACTGAACGCCCGGCCCA
GGTGAAGAAAGAACCGAAAAAGAAGAACAACAGTTGTCTGTTTGCAACAAGCTTTGCTA
TGCACTTGGGGGAGCCCCCTACCAGGTGACGGCCTTCCTCATCATCCTGNTTGTGGG
CCGANCCTGGGATGCCATCACAGACCCCCTGGTGGCCTTCATCATCATCCTGNTTGTGGG
CCGANCCTGGGATGCCATCACAGACCCCCTGGTGGCCTCTCATCACCAAATNCCC
Sequence 980

TNGGGAGTCGACCCGCGTCCGGTTTTTGTGAGGCAGTGAGACCTAAGGTAACCTTTATC
AAAAGGATGGAGTTGGGAAAAGGAAAACTACTCAGGACTGGACTGAATGCGTTGCATCAA
GCAGTGCATCCGATCCATGGCCTTGCCTGGACCGATGGGAATCAAGTTGTCCTAACTGAT
TTGCGGCTTCACAGTGGAGAGGTCAAGTTTGGGGACTCCAAAGTCATTGGACAGTTTGAA
TGTGTCTGTGGGTTGTCCTGGGCCCCACCTGTTGCAGATGATACACCTGTTCTACTCGCT
GTCCAGCATGAGAAGCATGTCACTGTGTGGCAGCTGTGTCCCAGCCCTATGGAGTCAAGC
AAATGGCTTGACGTCTCAGACTTGTGAGATTAGGAGGGATCACTACCTATCCTTCCCCAG
GGCTGTGTGTGGCACCCAAA

Sequence 983

TABLE 1 158/467

CTGCAGTGGGGATTTATTTTT

Sequence 984

CACGCGTCCGGAGTACGGAGTTGTTCCTTTACTGGCTGAAAGATATATTCGAATTGTAAA
GATGCTTTTTCTCATGCATTGAAATTATACATTATTTGTAGGGAATTGCATGCTTTTTT
TTTTTTCTCCCGAGACAGGGTCTTGCTCTGGCGCCCAGGCTGGAGTACAGNGGCATGAT
CTTGGCTCACTTCAGCCTTGACTTGGGCTCAAGTGATCCTCCTACCTGAGCCTTCTGAGT
AACTGGGACTACAGGTGTGCACTCCTCGCCTGGCTAATTTTTTATTTTTTGTACAGGCAG
GATCTTGCCACCTTGCCCAGGCTGGTCTTGAACTCCTGAGCTCATGCCATCTGCCT
TAGTCTCCCAAAATGCTGGGATTACAGGAGTGAGCCACCATGCCCGGCTGGCAGTTGCAT
GGAAGAACACCTNTTTATGGCTTACCCTCTAGAATTTCTAATTTATGNGNNCTGTTGA
AATTTTTGGTTTTTTACCT

Sequence 985

Sequence 986

Sequence 987

Sequence 988

Sequence 989

GTCGCCCACGCGTCCGTTCGTTGTCTGATGGACCTGCTTGCAAAAGGCCAGCTCTGTTGCAATTTTTGACACCACCTCAAACACCAACGCCCGGGGAGAGCATGGAAGATGTTC

TABLE 1 159/467

GTCCGCTGGGACCTCCTCTTTGGGGTCCCCATGAACCCTTCCAGTTCAACCTTTCA GGACGGAACCCCCAGAAACAGGCCCGGACCTCCTNCTCTACCACCCCCAATCGAAAGACA ATGCCTGTGGAAGACAAGTCAGACCCCCCAGAGGGGTCTGAGGAAGCCGCAGAGCCCCGG ATGGACACACCAGAAGACCAAGATTTACCGCCCTGCCCAGAGGACATCGCCAAGGAAAAA CGCACTCCAGCACCTGAGCCTTGTGAGGCGTCCGAGCTGCCAGCAAAGAGATTG AGGAGCTCAGAAGAGCCCACAGAGAAGGAACCTCCAGGGCAGTTACAGGTGAAGGCCCAG CCGCAGGCC

Sequence 991

Sequence 992

Sequence 993

CGCGTCCGGGCAGGAGCACCACTCAAGGAGCTACACCCCTTGCATCGGCTTGACCGCCTT
ACCTCAGGGGTGCTTATGTTTGCCAAGACAGCTGCAGTCTNTGAGAGAATTCACGAGCAG
GTTCGGGACCGGCAGCTGGAGAAGGAGTACGTGTGCCGGGTGGAAGGGGAGTTCCCCACT
GAGGAAGTGACCTGTAAAGAACCCATCTTAGTGGTGTCTTACAAAGTAGGGGTGTGCCGT
GTAGATCCCCGGGGCAAGCCCTGTGAGACAGTGTTCCAGAGGCTAAGCTACAATGGCCAG
TCCAGTGTGGTACGGTGCCGGCCACTCACAGGCCGCACACACCAGATTCGAGTCCACCTT
CAGTTCTTGGGCCATCCCATTCTCAACGACCCCATCTACAACTCAGTTGCCTTGGGGTCC
TTCTCGAGGCCGGGCGGCGCTACATTCCCAAGACAAACGAGGAGTTGCTACGGGACCTGG
Sequence 994

ACGCGTCCGCGACCGCTGGGCATGCGGGTGTTGGCGCGGTATCCCCGCCCTGCCCAGCAT CTGCCCCACGTTTCTTCAGGCTAAACTACCGGGATCCCGGGCTTCTTCCTAAAGTAAAAC TCGCTCCGGAAAGGCCAACAGTCCAGCGGCCAGACGGGCACCTGGGAACGCGGGCCTAAC GCGTACTGGAGACGGAGTGGCGCCCGGCACTGCGCCCTCCTCCCCGCCGGAGACTGCG TGCTAAGCTCAGCAAAGCCCCGCTGTGGAGACGGAGCCATGTCGCCCATTACCTAATGAA ACTGAGAAGGGAGACTCAGTCTCTCTTCTAGCCCCGAGCGCAAGCTCTGCTGGACTTGGC ATCGTCCGCCCTCCACGATCCCACACTCCGGGTTTTCCCCATTCCCAGCTCGGCTGCAAC CGAGAGACAGACGGAAGAAAC

Sequence 995

TABLE 1 160/467

TCCTCCTGGCCCTGTTAATGTCGGGGCCNGGCCGGGGAGGATGGCGCCCTAGAACCCGG CCTTGCTGGGGTAGGGGCGGGAGGGGACGGGGTGGGGACCGGCCATGTCGGAGGTGACCC GGAGTCTGCTGCAGCGCTGGGGCGCCAGTTNTAGGAGAGGCGCCNNACTTCGACTCTTGG GGCCAGCTGGTGGAGGCGATAGACGAGTATCAGATATTAGCAAGACATCTACAAAAGGAG GCCCAAGCTCAACACAATAATTCTGAATTCACAGAAGAACAAAAGAAAACCATAGGCAAA ATTGCAACATGCTTGGAAT

Sequence 996

Sequence 997

Sequence 998

Sequence 999

Seguence 1000

TABLE 1 161/467

Sequence 1001

Sequence 1002

Sequence 1004

Sequence 1006

ACCACGCGTCCGGAAAAGCCCGGAAGTGCCACGGGACTTCCTGTCTAAGGAAGAGCCTC
GTGAAGCTCCTCCACTGGGGAGTCAGTGGCCTTCGTTGTATCTGCCCCGCTTGTCCACCT
CCTAGAGTGAATCCCCGCCTGGAGGCTGGGACACTAACCAAGAAGTGGCACATGCATAT
CACGGGAGCAATGTTGCCGCTGTACGGAGAGTGCTGGACCGAGGGGAGCTGGGAGCAGGT
ACTGCCTCCATCTGANGCCGTCCTTTGAAGGGAGAACCTGGGGTAGGGTTCGAGGAGCCN
GCGAGAACTGTGCACCTCCTCGGGAGGAGCCCCCCTCCTGTGCTTCCCCCTCCC
TTCAATATGCTGGGGGCGGAGACCCTGGCCTCCAAAGTGCAATTCCGGGACCCCAAATCC
CAGCGGACGCACCAGGCTTTAGGTGGGCGTCAAGTTGNTGTGTGCCCCCTGGCTTCTACA

TABLE 1 162/467

CCCCGGGACCCCCTTCCG

Sequence 1007

GCGTCCGGGCNGCGAGTTTTGTCCATAACGTGGCCAACCGCGCAGCTGGAGGATGGCCT CACTCGGGCCTGCCGCAGCTGGGGAGCAGGCGTCGGGGGCCCCG CGGGGCCGCCGCCGCCCTCACCGTCCTCTCTGGGGCCCCTGCTCCCCCTGCAGCGGG AACCTCTCTACAACTGGCAGGCGACCAAGGCGTCGCTGAAGGAGCGCTTCGCCTTCCTCT TCAACTCGGACTGCTGCGATGTGCGCTTCGTACTGGGCAAGTTGGCGGNGCCGCCCCG CTGGGGGCCCGCAGCGCATCCCCGCCCACCGCTTCGTGCTGCGCGCCGCCGCCGCCTC

Sequence 1009

Sequence 1012

WO 01/070979 PCT/US01/09126

TABLE 1 163/467

Sequence 1013

Sequence 1014

GTCGCCCGCGTCCGCGGNCGCGTGGGGTGCTNGTCACCAGACTGCACCCTTGCCAGCAG CTTCGCAGCTCTCGAAGTAANTTATCGCANGATGGCCGGCGCCTCACCTAGGAGAACCAG GAAGGCAGGCCNCGCTAGAACGACGGNATTGAATTTTACTATTGNCAAAACAATCACATT CAAATTCATTCCACTTAAAACCTGAAAACATTGGACCACAA

Sequence 1015

CGCGTCCGCTTTCAGTGAAGAAAAGGGAATTACACATNGAATCGACACATCAGTAATACC
GATACAGTGAAATGGGCCTCTAATAAGAATTTNAGCGNGTTTTCTGATGTGCCATTTTT
TTGTCTTTTTAAAAATATACCATANTTATAAAANTGGNAAATANNTTTTTGNACACCAT
TTAAATTGACCCCCTTANAGNACNCTTGCCGTNATGNTGAAANGCTAGACCTATNGAAGC
TGNCTTGANGATATNTGTTTTTTTAAAAAAATTTTTTACAACTNTACTTGTTGGAAAATA
TAATATGCACTATAAAATATGATCNTATATCCTATTATCTATNATCTAAAAAACACTTCCT
TGGACNCATTTANACGTAAAATTAAAAAATGGGTCTTTAANGAAGANTAATGGGGAGGCCC
CTTTTTTAAAACCTATGGNNCAATCTTTTTATGNCAAAGGGGNGGACCATTTTATTAAAA

Sequence 1017

GCGTNCGCTGCGCCCGTGGACCCGGTAAAGTTCTGGCGACCCGGTACAGAGGGGCCAGGT GTAAGCATCTCTGAAGAGAGACAAAGTCTGGCTGAAAACTCTGGGACAACGGTTGTTTAC AACCCTTATGCTGCCCTTTCCATAGAGCAGCAGAGGCAGAAGCTGCCGGTATTCAAGCTT AGGAATCATATTTTATACTTGATAGAAAATTATCAGACAGTGGTGATTGTTGGTGAAACA GGATGTGGGAAGAGCACACAGATTCCTCAGTACCTTGCAGAAGCCGGCTGGACAGCTGAA GGAAGAGTGGTAGGAGTGACCCAGCCTCGAAGAGTGGCTGCTGTTACACATGATCTTTCT TNCCAAAGGTTGCAGGGAGAGAGAGAGAAAGGGGTGCAGTGCTGGGCCACCAGGTGG

Sequence 1018

AGTCGCCCGCGTCCGGTGGGAATCTTTCNACTTCTTGATCCATCTGGGAGAGAGACGT ACCATTATGTGCCCGAATTCCGAAAAGTGTCCATAGCAGCTACCATCATCTATGCCTATG CCTGGCTGGTTCCTCTTGCACTCTGGGGTTTCCTCATGTGGAGAAACAGCAAAGTTATGA

TABLE 1 164/467

ACATCGTCTCCTATTCTGGAGATTGTGTGTGTCTATGGATATTCCCTCTTCATTT ATATCCCCACCGCAATACTGTGGATTATCCCCCAGAAAGCTGTTCGTTGGATTCTAGT Sequence 1019

GGAGTCGCCACGCGTCGGTGGCACGATCTTGGCCCACTGCAAGCTCCGCCTCCCAGGTT
CACGCTATTCTCCCGCCTCGGGAGCTGGGACAACAGGTGCCCGCCACCACGCTCGGCTAA
TTTTTGTATTTTTAGTACAGACGGAGTTCACCGTGTTGGCCAGGATGGTCTCGATCTC
CTGACCTCGTGATGCACCTGCCTTGACCTCCCAAAGTGCTGGGATTACAGGCGTGAGCCA
CTGCGCCCGGCCAATAATTTTTTTAGTTTAAGTTCATTTTTGTCCCCGCTGATGAAAGTT
ACAGCAGCTGCCCAGTGCCTCTGTCCACACCCACCTCCCTGGTGTACTTGCCCCCTACAG
CAGCAGCCCAGATCCTCCCCTGGATTAAAATTGCAACTGGTGCCCTAACCCAAAACTTGA
GAAAAAATTCTCTATCACATCCACTCTTCTGGCATTTGTAGAATCTC
Sequence 1020

GTCCGGTNGATATATATTTTACCTCCTTAGTAATGCAAGAAGTGTTTGTGGGAAGCAGA GAAGCAAGCAACTGTATTTCTTGTTCTCACCTAAGCATTACTGGAGGATAAGCCACATCA GAAGCAACACGTTTCATACAAACATAATAAGATGTAAAATGGACCAAAAGTTGAAAG CACATTCTTGCAAGTAAGCACCTGTTACTCTCCAAGCAACCATGGGTTTACCATATTTGG GGATTTTTTGAACACTTAGNCACTTTCTTGCTCCCNAAGGGGACNTTTACAAAAAGTGNA NACATTTTTGTANTGTNNCCCGTTATTAAAAAAGCTAACNTTTTGTAACCTNCTTGTTTT CAAAAGGGCTTGGTNTTTTTGGACAAATTCAAAAATGGAAAAATGGATTTTCACCGTTT TAAGCCTCAATTTTAAGCCCCAAGGTTCCCAAAAATTTTTTAANGAAAAAAGCTTATTCGG GTATTAGGTNGGNCCTGGGTTAAAAAAACCAAGAANAAAACCATTNAAAAACAAAGCCCATT CAAAAATTCTTNTGGAAAAAAA

Sequence 1021

CAGGGAGTCGACCCCGCGTCCGAGCATCTTGGGGAATTTATATTCCTTTGTGAGAAATGT
TTTGATCATAAGCCTAGAATGATAAGTAAAAGAAATAAAGATAATTCTACTGCTTGTTCT
CACCCGGTTACAAAGCATGAGTTTGAAGACAATAAGTGCCTTGTCCACATTTTGCGAGAG
ACAACAGTAAAATACTCCAAAATACGTTCTTTTCATGGTCAGTGTCAGCTTGATTTATGT
CGACATGAAGTTCGGTATGGCTGTTTAAGGGAAGATGAGTGCTTTTATGCCCATAGTCTT
GTGGAACTGAAAGTCTGGATAATGCAAAATGAAACAGGTATCTCACATGATGCTATTGCT
CAAGAGTCTAAACGATATTGGCAGAATTTGGAAGCAAATGTACCTGGAGCGCAGGTCTTG
GTAATCAAATAATGC

Sequence 1022

CNCGCGTCCGGCCAACCGCCGAGGAGCAGTGCCCTATTCAGCACAGTGCGCCAGGGCCAC TGGCAGATTGTTGATCTTTTACTCACCCATGGAGCTGATGTCAACATGGCAGACAAGCAG GGCCGCACTCCCCTGATGATGGCTGCTTCCGAAGGCCATCTAGGAACCGTGGACTTTCTG CTTGCACAAGGTGCCTCCATTGCTCTTATGGACAAAGAAGGATTGACAGCCCTCAGCTGG GCTTGTTTGAAGGGCCATCTCTCAGTAGTACGTTCTCTGGTGGATAACGGAGCTGCCACA GACCATGCTGACAAGAATGGCCGTACCCCACTGGATCTGGCAGCTTTCTATGGCGATGCT GAGGTGGTCCAGTTCCTGGTAGATCATGGGGCCATGATCGAGCACGTTGACTACAGTGGA ATGCGCCCTTTGGATAGGGCAGTTGGGGTG

Sequence 1024

GTCGCCCCGCGTCCGAGAAGTCAGGGAGTGGAGGTTCTATAAGGAATTAACAGCTGAGGA

TABLE 1 165/467

Sequence 1025

Sequence 1027

CGTCCGTAGTCTCTCGTGGCCCGGAAAAAAAAAAAAAGAAGAAGGTTGGGGCCAGTCACC CCCACATCCCTTTATGGAGGCTTCCAGATCATGGATCCTGTCACGCGCATCCCGGTGAAG AGAGTCCACCAACAGGCTTTGTATGGGGTCTCGCTCTGTTGCCCAGGCTGGAGTGCAGTG GTTCGATATGGCTCACTGCAGCCTCAGCCTCCCTGGGATCAAGTGATCCTNTCACCTCAG CCTCCCAAGTGGCAGGGACCGCAGGAAGGCCTGGACGACGGCCCGGACTTCCTCTCAGAA GAGGACCGCGGACTTAAAGCAATAAA

Sequence 1028

Sequence 1029

WO 01/070979

TABLE 1 166/467

Sequence 1031

Sequence 1032

TCGCCCGCGTCCGCAATTTCTTTTGAATTTCGATCACTTCTACATTCCCAGCTTGCCAC
ACTCTTTTTTGATGAAGTTGTGAAGCAGATGGTAGCTGCCTTTGAAAGAAGAGAGCATGTAA
GCTGTATGGTCCAGAAACAAATATACCTCGGGAGTTAATGCTTCATGAAGTCCATCACAC
ATAAAGGCAAAAAAGAACTGGTGCCACCTGCTTCTGACTTTAGTTTCACTTTTAGGA
AGTATTTTCATGACATGTTTTCAGAAGCCAGAAAGCATTTGTTAAACCGCAGCTTTGGTTA
TAAACCTGCACCATTGAAAATTTGCACATAGAATATAGACTCACTTGTACAATAATGGG
ATGTCATCACCATTGCTAGAATACTGGCATGATTCTTCTGAGCAGAAGTTGAAACTGTAA
ATTTAAACCTTTTAATTATCACCTTACCT

Sequence 1033

Sequence 1034

TABLE 1 167/467

Sequence 1035

Sequence 1037

CGCCNCGCGTCCGCAAGACTTTGAAAAATNNGATCATGGTTCTTCTCAAAATACCAGCAT
GTCTAGCATCTATCAGAATTGTGCAATGGAGGTTTTGATGTCCAGTTGTTCACAGTGTAG
AGCTTGTGGAGCTTTAGTTTATGATGAAGAAATTATGGCTGGATGACAGCAGATGACTC
AAATTTGAATACAGCTTGTCCATTCTGTAAAAGCAACTTCTTGCCTCTTCTCAATATAGA
ATTCAAAGATTTGAGAGGTTCTGCAAGCTTTTTCCTGAAACCAAGTACCTCTGGTGACAG
TTTACAAAGTGGAAGCATTCCATTGGCAAATGAATCCTTGGAGCACAAACCTGTATCCAG
TTTAGCAGAACCTGACTTGATCAACTTTATGGACTTCCCAAAACATAACCAGGATCATAA
CTGAAGAAACAGGCTCTTGCAGTTGACCCAAGTGATGAAATAAAGAGAGCCAGTGGGAGA
TGTCCAAACTATTGAAAATTTCATCTGTGNCTTAATAGGTTTATC
Sequence 1039

TGANATTAGCATCACTTCGTCTACTAAGAATCTTAATAGATGTAAAAATATCTTTTAAAA ° CATATGGTAGGATGGGTAAAATTTGGCAATACTATCCAGGAAGTCACTAAGTACAGAAATTTAGCCACGAATTTAGTCCTAATTCCAAGAAGTGTGATTCCACCTACTTGACTAGAAATTTATACC

WO 01/070979

TABLE 1 168/467

TGGTAATAACTCCTTGTCCTTGAAGATTTTCAACTAAGGAAAACTGTTTTTCAGCAGGAC CTGATTATGCACTGCTATCTAGGTAGGGTCACTTATGGTTTTATAATATTTAATTGGA TTATAATATTCCTTTTTTCTTGTCTCTTTGGACAAAATCCTAGCTTTACTGTAATTTAAAA AGATGAGTTTAAAATTTCAGGCTTTAAAAACATACCAAACATTGATAAAAATGAAATCTA GATAAAAGTATTTTATCAATGTTCAGTTGCCTGGATTCAATAACTGTATTATGGTTATGT AAGGATAATATCTTAGGAAATCACATTATGGTATTAA

GTCGACCCCGCGTCCGGTAGCTTAGTTGAGTAGATAATCTTTTGTTGTTTCCTCCTTGTA
ATATACAAGCCTTGGCTTCTGTGACATCATACTCTCCTAGATTTCCCCCTGTCACTGTGG
CTTCTTCTCAGTCTCTGTCCATCCCTGGTGCTCCTGAAGGTTCTGTTCTCAGCCTTACAC
ACATTACCTGGGTGATCTCATTCTCTGCCATGACTTCACTTGCCATATATGTGCTGATTT
TCCCCAAATTCCTATTTCTCCCGACCTTTACATCTATTTTATTTGCAGGTCATATATCTA
ATAAGGAATTGATATCCAGTGTACATGTAGAACTCCTGTAATTCAAAGAAACCAAAC
AGTCCAATTAATAAATGGAGAAGAGATTTGAATGAACATTTTTCTAAAGAACATCTCAAG
CTCAAGATTTCCCAGGTAACTTTTCTTCAAAATCTGCTTCTGTGTTTCCTCATCTG
TAGGTGGCACAGCATACATCTGATTTCCCAAGCCAGAAACCTCATAGTTATTCTTGACTC
CAGGAAGAAATATTATTGAGTTTTTAAAAACTC

Sequence 1041

Sequence 1040

CGACCCGCGTCCGTGCTGAACTGAGCTCAGGTGTTTTTCTCCAAGCTTTCTAGCAA
GGTTTCTACTTAAAATCACCTGTGTGCAAGCCCAAAGGACATTTCATCTATTCTAAGCAG
AAAGGCTGTTTTGTTCATTACAGTGAGTGCTGTTCATCTCATGGAGTGGGAGGAGCACTA
AACCAGGAGACAGAGGACATGGATTTGGTTTCCAGCTTAACCAGTTAGGACTCTGTCCTC
TGCATTCTGGAACCATGATGCCTGCCTGCCTCACAGGGCTGTTGTGAGGACCAGAT
GAGATGATGTTCATACTTTTGGAATCTCTAATTTAAAGTCTTAATATTTTGTCTTC
TGAGTGTGAGGGGATAAACCTGGATGTAGACTATTAAGCAGCATAGGAGAAAAGAACAAT
AGAATCTAATGGACTGGGTTTGCAATCTCTCTCTAAATGCACTGCTTCAGACAAAGTGAA
ATCCAAAGGTGTGAAAAAAGTATAGCTGCAAATTGGAAAAATGTGTTTCAAGAGT
Sequence 1042

Sequence 1043

Sequence 1044

TABLE 1 169/467

CCCGAAGGCTCTAGCAAGGACCCACCGACCCCAGCCGGCGGCCGGACTTTGCCCGGTG TGTGGGGCGAGCGACTGCGTGTCCGCGGACGGACGAAGATGTTAGCCTTCGCTGC AGGACCGTGGTGAAGCCTCTGGGCTTCCTGAAGCCCTTCTCCTTGATGAAGGCTTCCAGC CCGCTTCAAGGCACACCAGGATGCACTTGCCACGGNTTGCCGTGCCCCCTNTTCAGCAGT CCCT

Sequence 1045

Sequence 1046

ACCACGCGTCCGCCCACGCGTCCGGGCGGGGGCATGACTACTGACCCATGCGGGGCAGC
GTCCCTGTGACCTGGCCGATGAGGAAGTACTGAGCCTGTTGAGGAACTGGCCCGGAAAC
AGGAGGACCTTCGGAACCAAAAAGAAGCTTCCCAGAGCCGGGGCCAGAGCCCCAAGCGCC
CTCTAGCAGCAACACAGAAGGAGCTCTGTGTGTCGTCTGAGCAGTCGCGAGAAGATTTC
CCTCCAGGACTTGTCCAAGGAGCGCCGGCCTGGTGGGGCTGGGGGCCCCCCATCCAGGA
CGAGGATGAGGGGGAAGAAGGTCCCACCGAACCACCCCTGCAGAACCCTCAA
TGGCGTCTCCTCCCGCCGCACCCCAGCCCTAAGAGTCCCGTGCAGCTTGAAGAGGCCCC
CTTCTCCAGGCGCTTTGGCCTCCTGAAGACAGGGAGTTCTGGTGCCCTGGGTCCCCTGA
AAGGCGGACAGCGGAGGGAGCCCCTGGGGCTTGCAACGCTCGGCTTTCTTCTCT
GGCTGGAAGGGACCTTCACTTANGCCAAGGAGCTTCGTNTTGGCAGAATTACCCCGACCC
CCTTCCCGAAGCTTGCCGGAGCCCTTNTGTCCTTGTCTGAGGGTCACCAAGCCTTCTTCC
TTTGCTTGGGAGAAACTTCCTTGNCTTNCCTTCAGGAATTCCNGAGCCTGGATTCCCAGCG
AANCCNAACGTTCCCACAGGCTTTCACGGGGC

Sequence 1047

Sequence 1048

NCCACGCGTCCGCAAGGCGCTACGTTTATTGCCTCGTCTTATTCACTGACCTTTGTAATG ATACACAGTGAATTCTTTTTGACAAAGAGAAATGCAGTGTAGTATGCAGAGCTGCTGTTT TAATGCCTATGCATTTACTCTTTCCTGATTTAGGCAGAGGTGGCATTTTCTTTATTGCAT TTCTCTATTTTTTAATGTACCCTACCTTCAGTATTCTCTTTGTAAGTTGGTGACTTGCA TCTGTGGCCTTGAATATTTTATTATCACATGTGGCATAACAGTATCCACACTTTTTAGTT

TABLE 1 170/467

CTTTATTTTTTTTTTTTTTTTTGAGCAATTCTCCTGCCTCAGCCTCCCAAATAGCTGGG ATTACAGGGTGCATGCCACCACACCCAGCTAATT

Sequence 1050

Sequence 1051

GACCCCGCGTCCGGGAGGTTGAACGTTCAGGCTAAGACCGTTACTGAATTGGTTACTAAG
AAGAAGCCAAAGGCTGAAGGCTATGCTGAGGGTGACCTCACTCTCTATCACCGTACCTCA
GTCACTGACTTCCTCCGAGCTGCCAACCCTGTTGACTTCCTCTCCAAGGCCAGCGAAATC
ATGGTAGATGAAGAGTTGGCACAGCATCCAGCTACCACTGAGGACATACGGGTGTGC
TGTCAGGACATCAGAGTGTTGGGGCGCAAGGAGCTCAGGTCGCTACTAAACTGGAGAACA
AAACTTCGGCGATATGTGGCCAAGAAGCTGAAAGAACAAGCAAAGGCACTGGACATCAGC
CTCAGCTCTGGAGAGGAAGATGAAGGTGATGAGGAGGACTCAACAGCTGGAACCACAAAG
CAGCCCTCTAAGGAGGAGGAGGAGGAAGAGGAGGAACAACTGAACCAGACCTTGGCA
GAAATGAAGGCCCAGGANGTGGCGGAATTGAAGAGGA
Sequence 1054

GTCGACCCCGCGTCCGCAAGGACCATGTTGTACCACAGCCTCTGCTGAGCTGAGGGACAC
ATGTCCTTGGTGAAGACCTGCACCCCTGGAACCTCCACCATCATCACAACTGNAGTCTC
ATTTGCAGTGGAGAAAAGAACCCGACGTCCCACAGCCAGATATACACCCAGCTCCATGCC
AGCCCTTCATGTTTACCTTTTGCTTTGTTAATTACATGTCAGACTCCTAGAGAGCCTCCA
GACTAATAGGAAGCATTCTGTAACCAACCTGCCACCCACTGATTCAGAAATGGAAATCA
CATTCCACAATCTATGGCTTCCACCAGCTAGCCCAGGAAATACTTGAAATCAGCATTCCT

TABLE 1 171/467

AAAGCAATAGCNTCCAAATTTCCAAATAAAGCATTTTTTTTCACTGNATTCTAGTTGGGG **GGTTGG**

Sequence 1055

CCACGCGTCCGCTGTTCCCGACAGCATGGATTAGCTTCCGTGTTCTGAAGTTGTTCTTTT GTGTTTTGCCTTCTCAGGGACCAAAAATGTATCATTGACTCCTTAACAGTGACCTTCCTC CCAAGGACATATCCGTGTTCATTTTTCATAGGTTTTACTCATATTCATAGGTAGATTCTG TTAATGTGAGTTGGAAAGAAAAGACCAATTTGTACACCAGTCACACCACAAGACAGTTTA TCATATAAAATACCTCAATTTTTTGTATTCCTCATTTCCACCTCACAATTGTACTGGTGA **TGAATTTTAAGGGTCTG**

Sequence 1056

TCGCCNCGCGTCCGGGCAAGGAAGGCTCTGTTAATTTATAGCTGTTTAGAGGGGAAAGCA GTGCAGACCACTTATTAAGCCCGCTGAGGACTAGCTTTCTGTCTTTCATACATTTGGGAA AGATAGGAATGACTGTTTCAAAGAAGAGGGGGCACATAATTTATGCAGGCAAGTATGAT GGAATGTAATATNTGGGATTTAGCCTTAGGCTTTAAGTTTTAGGCTGGCAAAAGAAATGT TATTCAGTGGGTTTGAGGTTTGGACTACTTTCTTCAAACTTAGAGAATTATAACAGGATG GTGTTTACCTTTGTTCACCTGGGATGTCCCCAAGACTCTAGCTTCTTCTATCAAGTGGTT GGGTCTGATAGAAGAGGTAAAAATTGCTCTTGAAAATNNTCTACAATTATGCAGGTTCTT **TGATAAAATTTTCTGGTTAAATCC**

Sequence 1057

GGCTCCCGGCGCCATGTGAGGGGGCTCGGGGGGCCCGGGGGGGCGCCCGGCGG AGGTGTGAACCCACATCCCTGCCCCCAGGGCCACCTGCAGGACGCCGACACCTACCCCTC AGCAGACGCCGGAGAAAATGAGTAGCAACAAAGAGCAGCGGTCAGCANTGTTCGTGATC CTNTTTGCCCTCATCACCATCCTCATCCTNTACAGCTCCAACAGTGCCAATGAGGTNTTN CATTACGGNTNCCTGCGGGGCCGTANCCGCCGNCCTGTCAACCTCAAGAAGTGGAGCAT Sequence 1058

TGGGGCCGGGAGGAAGTCTAACCTTTGGGAGACTCCAAGACCGCAGCTCCGAGGTCGGCG GAGGACGAGGAGGACTAGGTTGGCCCGAGGGGGCGCTTGGCAAAGAAGCCCCTTCC AGCTGACCGCCGAGGACNGTGTATNACATCTNCTACCTG

Sequence 1059

TGGCGATCGCTGAGAGGCACGGAGGGCCGAGGCGGCCCGGAGGTGGG GCGCCGCTGGGCCCGCCCGCACGGCTTCATNTGAGGGCGCACGGNCCGCGACCGAGCG TGCGGACTGGCCTCCCAAGCGTGGGGCNGACAAGCTGNCGGAGCTGCAATGGGCCGCGGC TGGGGATTCTTGNTTGGCCTCCTGGGCGCCGTGTGGCTGCTCAGCTCGGGCCACGGAGAG GAGCAGCCCCGGAGACAGNGGCACANAGGTGCTTCTGCCAGGTTAGTGGTTACTTGGAT GATTGTACCTGTGATGTTTGAAACCATTGATAGATTTAATAACTACAGGCTTTTTCCCAA GACTACAAAAACTTCTTGAAAGTGACTACTTTAGGTATTACAAGGTAAACCTGAAGAGGC CCGTGTCCTTTTTGGAATGACATCAGCCAGTGTGGAAGA

Sequence 1060

CCACGCGTCCGGGGTGTTGGTGCGGCGCTGTTGGGGTCCTCCGCTGGCTCATGGCGCCAG GCGTGGGAGCCCGAGTCCCCAGTGGCGAGCACTCGGCTGGGAGGACTGCCG GGACTCCAGAGTCCGCGAGGCGCTGCGGGGCGCCAGGGAAAACAAGAAGA AGAGTTAATCGACAAACTGGAGGTGGTCACAATGCCTTCCCCATCACCAAAAGGACTGCC

TABLE 1 172/467

AGTGAAGCAATATGCTGTGCAGTCTCAGCTTCCCGTATATGAGTGGCCGGATGTGGGATCTGGAGAATATGATGTTGGAGTAGTGGCTTCGTTTGGCCGACTTTTGAATGAGGCTCTTATTCTTAAATTTCCCTATGGCATATTGAATGTTTCATCCCAGTTGCCTCCCGAGATGGCGTGGCCCAGCCCCTGTAATCCATACAGNTGCTTCACGGAGACACAGTTACNTGGAGTAACAATTTATGCAAATTAGACCTAA

Sequence 1061

GCCGGTTCTTAGGGAGGCAGGTGCTGGCCTGGCCTGGATCTTCCCCATGTTCCTGTTGCT GCCTTTTGATACGCCTGATTGTCAACCTTCTGGGCATCTCCCTGACTGTCCTCTTCACCC TCCTTCTCGTTTTCATCATAGTGCCAGCCATTTTTGGAGTCTCCTTTTGGTATCCGCAAAC TCTACATGAAAAGTCTGTTAAAAATCTTTGCGTGGGCTACCTTGAGAATGGAGCGAGGAG CCAAGGAGAAAACCACCAGCTTTACAAGCCCTACACCAACGGAATCATTGCAAAGGATC CCACTTCACTAGAAGAAGAGATCAAAGAGATTCGTCGAAGTGGTAGTAAGGCTCTGG ACAACACTCCAGAGTTCGAGCTCTCTGACATTTTCTACTTTTTGCCGGAAAGGAATGGAGA CCATTATGGATGATGAGGTGACAAAGAGATTCTCAGCAGAAGAACTGGAGTCCTGGAACC TGCTGAGCAGAACCAATT

Sequence 1062

Sequence 1063

GTCACCACGCGTCCGCCNCGCGTCCGGCGTGCATGGAGGACGCTGGGCACGGGCCCGGC GCGGTCGGGGGCCCCGAGGGGCCCGAGCGCGCGCGCAGCGCCGCACATC CACTCGGGCCGCATCGCCGCGGTGCACAACGTGCCGCTGAGCGTGCTCATCCGGCCGCTG CCGTCCGTGTTGGACCCCGCCAAGGTGCAGAGCCTCGTGGACACGATCCGGGAGGACCCA NACAGCGTGCCCCCCATCGATGTCCTCTGGATCAAAGGGGCCCAGGGAGGTGACTACTTC TACTCCTTTGGGGGCTTGCCACCGTTACGCGGNCTTACCANAACTGCAGGCGAGAAGACC ATTCCCCGCCAAA

Sequence 1064

Sequence 1065

CGCGTCCGAACGGCATCATCACGCCCGCCACCATCCCCAGCCTGGGCCCCTGGGGAGTCC
TGCACTCAAACCCTATGGACTACGCCTGGGGGGGCCCAACGGCCTGGATGCCATCACAC
AGCTCCTCAATCAGTTTGAAAACCACGGCCCCCCACCGGCAGATAAAGAGAAAATCCAGG
CCCTCCCCACCGTCCCCGTCACTGAGGAGCACGTAGGCTCCGGGCTCGAACCACCTGTTCC
GCAAGGACGACTACGCGCTGGGTGAGCGTGCGCAGCAGCTGCCCGTCTGCCAAAAA
GCCTNACGGGACAAGAACACGGCCACGAACCCCCCTGGCCTCACTGGGGTGAGCTTCTTC

TABLE 1 173/467

TTCTTGTCGTCATCGTCCTTCTTCAAGCTTGGCCAGCAACGAGAACGCCACAAGGAAACT
NGTGAGCCCACGTTNGGCCGTCGGGAAAACACGGGGN

Sequence 1066

Sequence 1068

Sequence 1069

Sequence 1071

WO 01/070979

TABLE 1 174/467

Sequence 1072

Sequence 1073

CGCGTCCGCTGAGTTCNAGGATGGTTTTTTCTTGGGACCAGACATGAACAAAAGTTGACC
TCATGAGCACTTCAACCTCTCCAGCTGCCATGCTCCTCCGGAGGCTGCGGCGACTCTCCT
GGGGCAGCACTGCTGCCAGCTCTCATCCTAACAGTGGTGACAGTTTGGCCTGCTGCC
CCCCTGGCCTGTCACCGACTTCTACACTCTTACTTCTATCTGCGCCATTGGCATCTGAAC
CAAATGAGCCAAGAGTTCCTGCAGCAAAGCTTGAAAGAGGGTGAGGCTGCCCTCCACTAT
TTTGAGGAGCTTCCCTCTGCCAATGGCTCAGTGCCCATTGTCTGGCAGGCCACCCCCGG
CCCTGGCTGGTGATCACCATCATCACTGTGGACAGGCAGCCTG
Sequence 1074

GAGCCGNCCCACGCGTCCNCGGNCGCGTGGGCTACCTTGGAAGCAGTCATCTCTCAGTCT
TACATTTGGAGAATGTGGATGGCATGACATCAGAATTCCTTTATATAATTTAACTTCAGA
ATAGTCTGAGATCATCGAAGCACGATGGTCAAGGGAATTCCGTTTTTGTTTTAGAGCAAA
TATGTTTGCTGTTTGTCTTTCATCACAAACATCAGTGGAGTTTCAGCACCTTACAGAGCT
CAGTGAACCCCCTGGTCACCATCAAAGTTAGCACAACAAAGCCAACCACCACGTGTCCCCC
TCACAGATGACAATGGCTGAACTCTGAGTGAAACCACCTGTATGGCCGGGCACAGTGGCT
CA

Sequence 1076

GCCCGCGTCCGCTTTTTGAGAATCTCTGCTCTGTTCCTAGGTTCAGTGCTGGGTCCTGG GAATACAGCAGGACAGACCTCAGCTTATCTCTTCATAGAAATTATACAAAGAGAATTGGG GAGACAGCTAAGAAGAAAACAAAGAAATAAAGCAGTTACAAATTGTGATAAAGTGCTTTT GAAGGAAAGAAGGGGTCTGAGACAACAACAGGGAAGGGGCCTCTCTTGAAACAGTAGTTG GGAAGGAGGCAGACATGCACCAGTGATGTGGTGACAGGTGCTCTGAAGGAGGTCACCAGG ACCTGACCTCTTTGAAGGATCAGAAAATACTTCCCTGAAGGACTGACATTTGAGCCTAGA CCTGAAGGGTGAGCCATCAAGCTAAGACAATTGGGGAAGAGCATTCCANGGAGAGGAG

CGCGTCCGATCTTTGTCTGCTTTCCTATAACTCAGTACTGTAACTCAGTACTCTGAAATA

TABLE 1 175/467

GTTTCCTTTGTTAATAGAGTCACTTTTATAGTACTGNGCTTGAGGNNATATACAGAGTAT TGTGTCCAAATTTATCATTGCACAAAGTGTTTTTGGAAATTCTTGGTTACTCCTTAGTAA ATTACCTGTAAATTGGGTTAAATGCTGGTAGGGTTTAAAATCTGATTGCTAAAGTGAATTC TCTATAAAGTGAGTTTTGATACATAGAAACTTTNCATATAATTCTTAAACTCATGTGTCA TGTATTTTCATTTATAGTTTTTCATATTCATTAACATATTGTTGTTCCTTACCATTTACAG CTCANAATTCTGCANATGCAGATTTTTGCAAACTTTGATGCATTTTGGACAGTCTAGTGGT TCGAGTAATTTTGGAGGGTTT

Sequence 1078

Sequence 1080

Sequence 1082

WO 01/070979

TABLE 1 176/467

NNTGGGNTTTTGGTCCCAAAACCTCATCNAATGGGTANTCTTAATCATGTCCTNGGGATCCCCCCGGGTTACCCGGAGCCTTCGGAAATTAAATTTCCTTCTTTCCGCTTTTCCTTCGCTTCACTTGACCTCCGCTTNGNCTCGGGGTCCGTTTCCGGGCTTG

Sequence 1084

CGCGTCCGGACTGTCGCTCTAAAAGAATGAAGGAAATAATAAAGTGATAGACAGGGAAGG
ATAGAAAAGACTTAACAATATACATATGTTCCGTCTTTGCTGTTTTGGAGAATGATGGAT
AAGTANGTGTTTCCTGATTCTGAAGCATAGCTGAACAATTTAATTGTGGTTTACCATCTT
TTTGGTTCCCTCTTCAGTAATTAACCTATCGAAAATCTGTCCTAAATGTTTGGACTGGGG
CACAGTTCCCTCCATCGCTTTGGGAGAAAATCATTAATATGGCATACTGCAGATTTCCAA
GCAGGACCACTGAGGGTGTCATAGACATTAGCTCTATGGAATTCTGCTAGCAATTTCCAA
GTGACAGTGAGGAATTATGGATATATGTTTGAGGTCATTCAAGCTTCCTGAGTACCACAT
TCCCCAGCTACTTAGACACCGGGTTAAAATATTAAAGATGTCCTAGTTCAACAGCTTGAA
TTCCATTGATTGGAT

Sequence 1085

GACCCGCGTCCGGCTTCCTGGGTTCGAAAGAACCCAGTTCAGGAGTTTCTGTTTTAGTT
TGAGATCTTATAGGCCTGTCTCATCAGGTTGGTGTCAGCCCAGCTAGGATTAGGCAGAAT
TGGGTGGGGGCTGTAGTGCATCTTTGGCACAGCATGTACCTGTCTGACTAATTCTCTGTC
TTTTCTTTCCTGTTGCAATTCATGGGTCTTAGCATCTTCTGAATGGTGTTTAGTAGGTCA
TCCTGTTGATTTCCTGCTAGGGAGTAGCATACTCTGGCTCTGTACCATTGGCCAAGGGAC
TTAAGGATAGGTGAAGGGCTGCAGTTTTGTTAAATGGAACAATATGAAGAGATGGCATTG
TAAAAAAAACTTNTGNCAACTNAA

Sequence 1086

Sequence 1087

TABLE 1 177/467

Sequence 1088

Sequence 1089

Sequence 1090

CGCGCCTGGTAAAATTATATAAGCTTAAAAAAACAAAAACAAAAACACTTGCTTTGAAAA GAGTCTCTCAGCAGCAATTTTGTCCTTGCCCCTACTTCCACAGTTCCTTTTCTTACCATT TCACATCTGGATTACTACATTGGCCTCTTTGCTTAGACTCCCAATATTCATTTGCTTTCC TTCACCCCATTTTATGGAGGACTGTCAGATCAATCTTTTAAAGATAAATTTTATAATGTT ACTACTGTTGCCTATTGGATTAGAGCCCTAGGGGTGCTTTTTGTAGTCTCACTGACAGCT GACATTAGTGATTTTTCACCCTCTTCTTATTGCTACCCTGTGTTGATGGCCAGTTTCCAG GTGGGCACCTGCTCCACTTGCTTTCAT

Sequence 1091

GGGGTATGTGTGGTTCTTCCAGGAAAGTGCTGAAAATATCACCCAGGCCTCTGCGCCACG
CCCTGGGAGAGTACACTCCTGGGCTCACGCCTCTGCATTCCAAGGCTGACAGCTAGAAAT
ATACTTTGTAAAATACCAACAACTTATTCACAAATATTCCAACTATCTACCAGCTCCAAT
GAGCTTGCTGAGGATGGGTATGACCCCAGTCTAAGGGGAAAGAATCTAAAACACAAGTAA
ACCTGTTTAAAGGCCAGATCTCCAGATGGAGATCCAAGCAGATGGCGCCTAAGGTTTGCC
CTTGAAAACTACCAAGGAAGCCACAGAGAGGGATCTTTGGACCTTCTGGAAAATGGTAAG
GCCCCAGGTAGATTATGGCTCCTCTGCCCTGGAGGCTGAGCCGCCTCTGGTTACCTCAC
ATCTTCTGGTTTCTTCTGAGTGGGACTTGATCTCATTTCTGCATTCACAGCAAGGNGGAA
CTGTCTGGCAAGAGCTTAAAATTAGGACCTGNTGGTGGGGACCTTTAATAGCAGGTGGAG
GGTTTGAGATCCCNTGAGATGCCCNAGATTAATTCAATAGGGGGANGAAAGATTTGGCCC
AATTCAAAAGNGCTTAAAAAAAAAATTTT

Sequence 1092

Sequence 1093

CGCCCGCGTCCGATAAAACTGGATTTGATTTCTTTTTATGAAANGTTTCATATGAATGT
AACTTGATTTTTACTATTATAATCTAGATAATATGATATAAGAGGGCTAAGAATTTTTA
AATTGAATCATATATATGATATAATTTGATCCTTCTTGTATCTTGAAGTTTTGTACTTGG
GATTTCTGGACTGATAAATGAATCATCACATTCTTCTGGTAAATATTTTCTTGGAGCTCT
GTGTCAACTTTGATCCTTTGTCTCCCAGGAAGGTGTGACCTCTCTTTGCCTGCATACCT
CAAGGCCAGGGGAATATGCCTCAGTGATGCATTTCTTTGTATATCAGGCCGCATGATT
CCCAACTTTCTGCCACACTTAAATTACGTTCCTCCATTTCAGTTTTGTCTTTTCTGTCTA

TABLE 1 178/467

AAGTTCAGTCAAAGAGTATCAAAAAATTATGTTTCAGCTAGACTGGTGTAATGTATAAGT TTTTGTATCTTGTATTAGAGGATTTCGTAGCTTTTATTAGAGG

Sequence 1094

GCCCGCGTCCGATCCCTAGATGACATAACAGCCTTACAAAAGGACAGGGAGGAGTGTCT
GTTCCTACTCTCACATAGCGGAGGAAAGTTAGAGCCTCTCAGTCTCTGTTTATGAGGACT
CATTAATCTCAAATAATTGATGCATTTTCATACATTAGGGTCTCTGTCCATGTGTCTTC
CTGATATTGTTATAGAAATGGCTTCAGGCTGCTGGTAACAGATGCTGCGGAAAAAGAATG
CCTTAAACAAAGCCAGGCGCGGTGACTCACGCCTGTGATCCCAGCACTTTGGGAGGCTGG
GGTGGGAAGGATCACTTGAGCCTAGGAGTTAGACACCTACCCAGCCTGGGCAACACGGTG
AGACCTCGTCTCTACAAGAAACAAATAATTGGCTAGATGTCGTGGCGCACAAGCTTGTGG
TCTCGGCTACTTAGGGGGGTGAGGCGGGAGGATTATTTGAGCCTGGGGAGGTCAAAACTG
CGGTGGGCTGGGATTGCGCTACTGCACTCCGGGCTGGGAGACCGAGTANGACCCTGCCTT
AAAAAAAAAAAAAAAAAAAAAAAA

Sequence 1095

Sequence 1096

Sequence 1097

GTNGCCCCGCGTCCGAGTNAACAGTGGTAGTNAAATTCAGGGTTGGTAAGTTTTTCCATA GAAGGCCAGATGGTAAATATTGTAGGCTTGCAGACCATGTGGGCTCCACGACTCAACTCT GCCACAGTAGTTTGAAAGCAGCCACAAACAGCCTTGGTGACTTTGTTCCAGTAAACTT TCTTTATAGAATGGGAGAAAATATTTGCAAACAATGCATTCAACAATGGCCTGATGTCCA GAATTCATGAGGAACTTAAAAAACTCAACAACAAAAAATCACCAAATAACATTTAAAAGTG GGCAAAAGATATGAATAGTCATTTTTCAAAAGAAGAAGACATACCGAATGGCCAACAAGCATA TGAAAAAATACTCAACATCTCTAGGCTTTCAGAGGCATGCNAANTAAAACCNCCATTNGA TATTATNTTACNNGANCCCNAAATGGGTTTTTTTTTAAAAGGCCAAA

Sequence 1098

TCGCCCCTGGGCCCTCCTAACCAACCAGGGGAGGGGAGAAGGACCCAATTCTTTTCCTTT
GGTGCACGTAGCCTGGACCCGTTATGGACAGGGCCAAAGGAAGATAACAGTGTGGTGTC
CAGAGATGAAACCAAGTGGTTGATGGGCAGTTCTTTGAGCAACCTTGTTTATGAGCCTAT
TGATATGCAGATATAGAGGCATCCAATACTATTGACTAATTTAAAATCTTATTCAGTGAG
TCAACACTCTAAATAAGCAATGGAGATGTTCCATTCATTTTTTTGCAAGTATCATTTTT
ATAAACATAAATTTCCTGAGATTTTTGTTTTCATCTTAGCCTCTGTGGAGCTGCTTCGTG
GTTATGATAAGTGCTGTGTGATGCTCACCTTGGGAGGTCTGCGACATATATTGAAGTCAT
CTCTAACCTGAAGTACTGACAGACTTTCTGGAAGAAAAGGCTTGTAGGAGGAAACTTCAG

TABLE 1 179/467

AATTCTATTAAATGGTGTAAATGATGAAATTATAGTTGATATATGCTAGAGCATCAGTGC TGGGTATTTTAGAAGGGATGGA

Sequence 1099

CGGGCCTGTTCCTAGAGCCTCATTGGAGACATTGACAATGCCATGAGGACCTTCCTCAAC
TACTACACTGTATGGAAGCAGTTTGGGGGGGCTCCCGGAATTCTACAACATTCCTCAGGGA
TACACAGTGGAGAAGCGAGAGGGCTACCCACTTCGGCCAGAACTTATTGAAAGCGCAATG
TACCTCTACCGTGCCACGGGGGATCCCACCCTCCTAGAACTCGGAAGAGATGCTGTGGAA
TCCATTGAAAAAATCAGCAAGGTGGAGTGCGGATTTGCAACAAAAGATCGCTTTGGCTGC
TTTGTGAAGAATAGATTGAAAGGGTCAAAGGTGAGAGCCATCTCACATCCATGCAGGAAC
CAAGCAGGCAAGATATAAATATGAAAGTAGAAGAAAATAGTCTGGAAGAAAAATCCC
Sequence 1100

Sequence 1101

Sequence 1102

GTCCGTATCCTACAAATTTTTTAAATATGTTCAAAATATCTGGAGGGTGAGAAGTT ACCAAGTTTGTATGTTTGTTTGACTCACCATCTTTATTTTCTGTATATGTAGTAGCTGG CAATTGCATATATTTTCTTGATTAACATATTAGAGACCTGCTTCCATCATCTTATGTAAAC CTGGAAACAAGCTGAAACTAGTCTTTTCTGAAGAACCGTGTATCAGTGTTAGATGTGCAT CCCGTTTTGTCATTCCCTCAGACTTTGAATACAGTCATTACTCTCTGGAAGAACTGTA AGTATATTTTTTTGTTATCTGCAGTATTGGTTAACATGTATTAATAATACACATATGCAGA CTCACTAAAGTATCCCCAGTAATTAGTAAATTCCAAAT

Sequence 1103

Sequence 1104

TGCCNCGCGTCCGAGCATCTCAGGTAACAATTTGAGCATAACTTTAACCATAACTTATGA
TAGCATAATAACATTCATTAGTAATTCAGTAGCCGTATGTGCCAGGCTGTGTTAGGTGCT
TTATATATTGTTTAAATTTTTAAAAACTTGTGGAGTGTACAGATTGGTAAGGTGACATTGT
ATCACAAAGCTAGTCTTTGAGTCCAAAGTTTTGTGGTTTTATGTTATGATATACTTTTAT

TABLE 1 180/467

Sequence 1105

ACGCGTCCGCTCTGGTCAAGCAGGCGGTACTTCTCCTTGGATGTCTCAGCCACAGTGCCT
ATCAGGGTACTGAGGAGAGCACACATGGCCCGAGGCCCTNGGAGCCCTCGGAGGCTGAG
TCAAAAGAGTCTCCCTCGAATTGGTGGGCCTTTAGAAGACTTGGCTTCTTCACTGGAGAG
CTATAAAGTAAACACCACACTGAGGGCCCTCGTCCCAGGAAGGCCTTCAGAGCATTTTCA
TTTCTGAACACGTCCCCTCATCTTTCAAGATTTTCTGGTCCTCTAAAGCTGAGAAACTAC
AAGCACTGAAATGAGATGATATTTGATAAGGATGGTAATGAAGCACAAAAGCGTTATTCA
CATTACTCACTGACTTTAATATATTTTTGAAATATTTTCATACTTTTTGAAAAACAAAATAG
CCTGGGCGACAAGANTGAGACTCCATCTCAAAGGTAAAANAAATTTAANCTGGGTGCCNG
CCGCTTGACTATGTCTAGAGAAAAAAACCTTCCACA

Sequence 1106

Sequence 1107

Sequence 1108

Sequence 1109

CCGTCTCTGGCTTGGCCAGGTTTAAATTAATAAAAATGAAGATGAAAATAAGTTGTCAGA TTTAGGATGTATTTTAGAAACCCAACTGATAATTTGCCAACTAATTGGATGCAGAGAGTA AGAGGGAGACTCAAGAACACCTCTAAGATTTTTACCCTGATCAATGGGATAGGTGAAAGT ACATTAATGGAGATTGAGAATCCTGGTGGAGGTACAAGTTTAGGGGTACTGAAGAGTGCT TTTGGACATGTGAATTCTTAGAAGCCTACTAGATTCTCCAAATGGAGACATAAAACATAA TTGAATACAAAAGTCAGGAGTTCAGGAGAGGGCTGAGCTAAAGATACAAATTTGATAGAC ATGAGCATTTAAAAAAAAACTGCATGAAAATACTAAAGATAGGCTGTCCTGCCTATGGAAT

TABLE 1 181/467

AGCCATTCTTTGATCCCTTTACTTCTTAATAAACTTGGTTTCACCTTACTCTATGGACT TCCCCCAAATTCTTCTTGTGAGGTCCAAAAACTCTCTGTTGGGGTCTAGATCAGACC CTTTTCAAGTACATCTTNCTGATGAACCACAAANGGATTATACTAAAGAGACCCCCCACC

Sequence 1110

Sequence 1111

CCCACGCGTCCGCGGCCATTTCTGTATCCCCCTGCCTGGGTTTGCTGCCCTTTATGCTCC
TACCTCACCAGGTACAAGGAACATGAAGATGGCTATATGCGGCTGCAGCTGGTTCGCTAC
GAGAGTGTAGAGCTGACACGCAACTGCTGCGGCAACCACAAGAGGGATCGGGCCTGGGA
ACGTCGCTGAACGAGAGCAGCCTGCAGGGCATTATTCTAGAAACAGTGCCAGGGGAGCCA
GGACGTAAGGAAGAGGAAGAGGGGCAAGGGTAGCGAAGGGACACCCCTCTCAGCCTCT
CAGGACAACCCCAGTTCTGTCATCCACGTGGTGAATCAGACCAATGCCCAAGGCCAGCAA
GAGATTGTCTACTATGTGCTGTCTGAAGCCCCAGGGGAGCCTCCCCCAGCCCCTGAGCCA
CCTTCAGGGGGCATCATGGAAAAGCTTCAAGGAATAGCTGAGAGACCAGAGATCCAGATG
GTTTGAAGGCCGCAGAGCCAGACCATTTCTTCCCAGGTCTGAAAGTTTGAGCCAGGCAAG
TGGCAGTGCCCCTAGTGGGCAGCCGTTGCCAATGGATGCC
Sequence 1112

TCGACCCCGCGTCCGGTTTTTTGTCCCAGCAGTGGCATTTAAATTACTGTACTTTAAGAC ATGGAATTGCTGAGGGCTTGGAAACTTGAGTGCAATTTCCCTAGTACGACCTCCAAGGAG AATAGAGCAAAACAGTGGTAGGAAAAACTCTCAAAATTTTACCCAATTGTATGTTTTCTA CATTGTCAGTATCTAGTTTTATATAGTTAATATGTACTTCTAAAATTTCTGACAGTGNTT GGTGTATAAAACAGACCAAGCTCAAGATGTAAAAGAAGATTGAGAAATTCCACANTCAACT AATGCGACTTATGGTAGCCAAGGAAGCCCGCAATGTTACCATGGAAACTGAGTGAATGGT TTGAAATGAAGAACTTTTTGTCGTGTACTTAGGAAAGTAAATATCTTTTGAATTAGAGAAAGTG TTGGGACAGAAAGTACTTTATGTAACTAAGTGGGCTGTTCAGAAGCTTAGAGGTCATTTT TTGTAATTTTTTTTAATTACTTTTAGAAAGAGCTAGGGATGCAAATGTTTTCAATTTGGA AAGCCTTTATTTACTTTTTGGAAA

Sequence 1114

Sequence 1113

TCGACCCGCGTCCGATTCCTTCTTCATATATTATGTCAGAAGAGTTTGAGAAGAAATGG
TATTAATTCTTCTTTAAATGTTAGGTTGACTCACCAGTTAATGCAGCTATTTGGTCATAA
ATGTTTCTTTGTTAATCACTTTCGATTACTAATTCAATCTGCTAGGTTATAGGTCTATTC
AGATTTTCTCTTCTTGAGCCACTTTGGTAGTTTGTTCTTCTAGTGATTCGTCCA
TTTCATCCAGGACAGCTAATTTGTTGTTAGACAGTTGTTCACAGTATACTCCTGTAATCC

TABLE 1 182/467

Sequence 1116

Sequence 1117

Sequence 1118

GCGTCCGTTGTCATCTATTTACTTTACATATGTCATAAACCTAACACTACATGGTCATTT
TTGTTTAAACAGTCAATTACCTTTTAAAGGGATTTGAATAATAAGTCAAAATCTAATACA
TTAACTGTGAGTTAGCATTTCTGGTGCTCTTCTTTCTTTTCTGTAGATCCATACTTCCA
TCTGGCATTATTTTCCTACTGCCAGAAGGACTTCCTTTAACATTTCTTGTAGTGTAGATC
TGCTGGTGATGAATTCTTTCAGCTTTTGTAATTCTTTTGTCTTTGAAAGGTATTTTCCCT
GAGTATAGGTTAATAGCTTTTTCCTTTCAGTACTCTAAAGATGTTGCTCCAGGCCAGGCG
CGGTGGCTCACTCCTGTAATCCCAGCACTTTGGGAGTCTTGAGGTGGGCAGAACACTTGA
GGTCAGGAGTTTGAGACCAGCCTGGCCAACATGGTGAAACCCCCGTGCTTCTAAACATAT
TAAAGAAAAAAAAGA

Sequence 1119

NCGTGACATGCTGGCTGCTAGTNAGCTCCCCCATGATTGTCAGCTTCCGAGCCCTCACTAGAAGCAGATACCACCCCACCACCATGTTTCCTTTAAAGCCTGCAGAACTGNGAACCAATT

TABLE 1 183/467

Sequence 1121

CGGCCGAGGTACTATAATGGTCCCCATCTTAATTTGAAAGCGTTTGAGAATCTTTTAGGA
CANGCACTGACGAAGGCACTNGAAGACTCCAGCTTCCTGAAAAGAAGTGGCAGGGACAGT
GGCTACGGTGACATCTGGTGTCCTGAACGTGGAGAATTTCTTGCTCCTCCAAGGCACCAT
AAGAGAGAAGATTCCTTTGAAAGCTTGGACTCTTTGGGCTCGAGGTCATTGACAAGCTGC
TCCTCTGATATCACGTTGAGAGGGGGGGCGTGAAGGTTTTGAAAGTGACACAGATTCGGAA
TTTACATTCAAGATGCAGGATTATAATAAAGATGATATGTCCGTATCGAAGGATTTCGGC
TGTTGAGCCAAAGACTGCGTTACCCTTCAATCGTTTTTTACCCAACAAAAGTAGACAGCC
ATCCTATGTACCTGCCCG

Sequence 1122

CCCTTTCGAGCGGCCNTNCGGGCTTNTACGCGGGGGCAGCGGGAAGCTCGCAGCAGCTGGGGAGGAGCCAAAGCCTCGGCGCTCACCTAAGCCGCAGGGAGATACACCCAACTGGGAGAT GAGGAAACAGCAACCCAGAGAGAGAACTAACCCACACAGGATCATTTCGCGAAGGAGCA AGGCTGAAGAACCAGACCTGGACTTTCTTAGGACAAACTTACTGCAGCTTGAAGGAGCCA ACCATGGATTTGAGGCGTGTGAAGGAATATTTCTCCTGGCTCTACTATCAATACCAAATC ATTAGCTGCTGTGTTTTAGAGCCCTGGGAGCGATCTATGTTTAACACCATCTTACTA ACCATTATTGCTATGGTGGTATACACTGCCTATGTCTTATTCCAATCCACATTCGCCTG GCTTGGGAATTTTTCTCAAAAATAT

Sequence 1123

Sequence 1124

TABLE 1 184/467

NATGTGGTGCCCACTAGGCTACTGNTGAAAGGGAGCTGAAATTCCTCCACCAAGTTGGTA TTCAAAATATGTAATGACTGGTATGGCAAAAGATTGGACTA

Sequence 1125

CCCTTANCGTGNTCNCGGCCGAGGTACCAAATGAAGTGTGAAGACAAGGCCATCCACCAC TNTATAGAGGGTGGGAAAATAAACCANAAATCAAGGGAGAAAGAAAAAGATGAAAGACAAA CTGCAAAAAATTGCCAAAATGCGACTTTCTAAAAATGGAGCAGATTCTGAGGCTTTGCAT GTCTTGGCATTCCTTCAGGAGCTGAATGAAAAAATGCAACAAGCAGATGAAGACTCTGAG AGGGGTTTGGAGTCTGGAAGCCTCATCCCTTCAGCGTCAAGCTGGAATGCGAATGAAGA ATAGAGATGTGGTGCCCACTANGCTACTGCTGAAAGGGAGCTGAAATTCCTCCACCAAGT TGGTATTCAAAATATGTAATGGACTGGTATGGCAAAAGATTGGACTAAGACACTGGCCAT ACCACTGGACAGGGTTATTGTTAACACCTGAATTG

Sequence 1126

Sequence 1127

Sequence 1128

Sequence 1129

TABLE 1 185/467

CACTAGGCTACTGCTGAAAGGGAGCTGAAATTCCTCCACCAAGTTGGTATTCAAAATATG
TAATGACTGGTATGGCAAAAGATTGGACTAAGACACTGGCCATACCACTGGACAGGGTTA
TGTTAACACCTGAATTGCTGGGTCTTGAAGAGAGCCCAAGGAGTTCTGGGAAGAGGGACC
AGATTGGGGGGTAGGGTCACGGGCTTGGGTGATAGAATTATTTCTCGAATGACTTTCTTG
AGTGCCAATTTGAACTGTAACATTTGCTTANTCACCTTTAGNGGAGTAATCTCCTGGGCT
TGGTTCTATATTTATATAAAAG

Sequence 1130

CGGGCAGGTACAGCCTCTCGGCCCGGCTAAACATCATCGTCTTGGTAGGCCATTACCCTA
CCAACTAACTAATGTTCCGCACCCCCATTTTTAAGTGAAGCTGTGAAGCTCCTTTCTATT
ACTCATCATGCGATAAATAACTATATCCGGTATTAGCTATTGGTTCCAATAAGTTATCCC
CAGTCTTAAANGTAGGTTAAGTACCTCNGGCCGGCCACCGGGNTGGAGCTCCAAATTNGC
CCTATAAGTGAGGTCGGATTTACGCCCCGCCTCACTTGGCCCGNNGTTTTACAACCGTCC
GTNGACTNGGGAAAACCCCTGGGCGTTTACCCCAANCTTTAATCCGCCTTGGCAGCACAA
TCCCCCTTTTCGNCCAGGTTGGCGTNAATAANCGAAAAAGGCCCGGAACCGAATCGGCCC
NTTTCCNAACANGTTNGCGCCAGTNCTGGAATNGGCNAAATGGGGACCCCNCCCCTTGTT
AACCGGGGNGCATTTAAACCNCCGGCCGGNTGNTGGTTGGNTTACCCCCCAANNGGTGAC
CCGNNTTCAACTTTGGCAAGGGCCCCTAANGGCCGNTTTCTTTTGNTTTTTTC
Sequence 1131

AGCTCACTCAAAGGGCGGTAATACGGGTTATCCACAAGAATCAAGGGGATAACCGCAGGA AAGAAACATGTGAGCAAAAGGGCCAAGCAAAAGGGCCAGGAACCGTAAAAAAGGGCCCGCG TTGCTGGCNGTTTTTCCATAGGGCTCCCGCCCCCCTGGACCGAAGCATCACAAAAAATCG ACGCTCAAAGTTCAGAGGTGGGCGAAAACCCCGGACAAGG

Sequence 1133

CCCGGGAACAAAGCNGCAACCGNGCCCCCCCCCCCGGGTCNACGGNNTCGANAAGCNCGA AAACCGAATTTTTGNAGNTTTNGGGGACCCACTANTTNGNGAGCGGGGGCCGANNNAGNG CGGC

Sequence 1134

TABLE 1 186/467

GAANCAGAAGAAGGGGCGCCCACNAGGCTACNGCNGAAAGGGAACCGAAAAAACCCCNCA CCAANNAGGNATNCAAAAAANNGGAACGGACCGGGNCANGGCAAAAAAAANGGAACCAA GACACCGGGCCCANACCACNGGACCANGGGGNAANGGAAACACCCCGGAAATGGCAGGGN CCCCGAANAGAACCCCAAGGGAGCCCAGGGAAGAGGGACCCAAGATGGGGGGGAAAGGC CCACCGGGCCNGGGGNGAAANAACAAAGCCACCGAGGGCCAACCGNAAGNGGCCAANNGA ACCCGGAACNANAAGGCNNAANCCACCCTGAAGNGGGAGGAAAACCCCCAGGGCNGGGGG CCAAANANNAAAAAAAAGCNGCCCAAAACCCCCAA

Sequence 1136

NTTTAATTTTTTGCAGCCCGGGGGANCCAGGGGNAGGGNGAGCCCACCGCGGGGGAGCGCCAANCGCCCNACAGCGAGNCGNAANACGCGCNGCCCACNGGCCCGCGNANAAACAACGNCGAGACGGGGAAAACCCCGGCGNCACCCAACNGAAACNGCCANGCAGCACAANCCNCAANCGCCAGCGGGGGAANAGCGAAGAGGCCNCGCACCGAACGCCCANCCCAACAGNGGCGCAACAGAAAGGGCGAAAA

Sequence 1137

Sequence 1138

TTACCCCGCGTCCGGGTAAACAAAACAAAGATCGTTTGTTCTGGAAACAGGTAAAATGGT
AATCAAATAGATTGTGTTCCAGGAGTGCAAAGGTGGCTTAATATTCACAAATCAGTTGCT
ATTGTACACCACCTGTAGAAAAGTAATCTGGCATGCAGAACATTCTTATGGTAAAGTTAA
TGTTCATTTATGATCTTAGCAAATGATGGATTGAAAGGGACTTCCTTAATTGCATAAACA
GACTTCAACAAACAGTATGATGAAATAGTGAACATTTCTCCTAAGATTATAAAAATAAGA
CAAGGATATCTGCTGTCAATGATTTTATTCAGCATTGTTCAGAAGGACCTAACCAGAAAA
CTAATGCAAGAAACAGAAACAAAAGGCATAAAAGATTANAAAAGAAGTAAAATTTTAAAAA
AGAAAAAGAATATAAATCTCTATTTGCATATGCCATGAGTAAATTTTGGTAAGTTCCCTGC
ATAAAAGTTATGCAAAAAGCATTTTTTTTGATATACCAGCCAAAAATCAAGGGAAATGGAA
AA

Sequence 1140

TABLE 1 187/467

AAGCAGATGAAGACTCTGAGAGGGGTTTGGAGTCTGGAAGCCTCATCCCTTCAGCATCAA GCTGGAATGGGGAATGAAGAATAGAGATGTGGTGCCCACTAGGCTACTGCTGAAAGGGAG CTGAAATTCCTCCACCAAGTTGGTATTCAAAATATGTAATGACTGGTATGGCAAAAGATT GGACTAAGACACTGGCCATACCACTGGACAGGGTTATGTTAACACCTGAATTGCTGGGTC TTGAGAGAGCCCAAGGAGTTCTGGGGAGAGGGACCAGATTGGGGG

TAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACCACTCTATCCATCGTGGATA
GAGAAACTGAAGCTCTCTAAAGACCCTGCAGCTGGGAGGTGGCAGAGTCAATGGCAGCCC
TCAGCCCTATCTGCCCTGACATGGCATTCCTCCCATTTCTCACCACCGAACCCTCTAAAA
TAACAATGTGTGGGGTCCTTGGCTGAGAGACTTNCCTTTTGGGAATCAATCTGAATGTAT
GATGACAAAGAAAACAACTTTTGCTTTATACAACCTTCTGGTTAGATTCAGCACCAAGC
AGGACACTTCTTTGTGGCGCTCCAAGAATCTTTCAAATTCTTCATCACCAATAACAAATC
TTTCTGCTTCTCTTAGAGCATCTTCTCCACCAATTCTCCCCTCAATTAAGAGGCACTGGA
ACACTTTCCAGCGGACAGGGTTTAGTGCTTTGATCTGTTCCGTCATGTCCTCTTCCACGT
TGAAACGATTAATGACAGAATTTTTTTTTGGAGGCGACTCTATTAATCCCTACACCACCTN
CTCAGCTTTTGAAGGGTTTNCACATGGGTTCTTTT

Sequence 1144

Sequence 1145

TABLE 1 188/467

ATGGGGAATGAAGAATAGAGATGTGGTGCCCACTAGGCTACTGCTGAAAGGGAGC Sequence 1146

Sequence 1147

Sequence 1148

TTAGGGCGAATTGGAGCTCNCCGCGGTGGCGGCCCCCGGGCAGGTACGCGGGGAGTTCT GCGCAGCTTCCCGAGGCTCCGCACCAGCCGCGCTTCTGTCCGCCTGCAGGGCATTCCAGA AAGATGAGGATATTTGCTGTCTTTATATTCATGACCTACTGGCATTTGCTGAACGCATTT ACTGTCACGGTTCCCAAGGACCTATATGTGGTAGAGTATGGTAGCAATATGACAATTGAA TGCAAATTCCCAGTAGAAAAACAATTAGACCTGGCTGCACTAATTGTCTATTGGGAAATG GAGGATAAGAACATTATTCAATTTGTGCATGGAGAGGAAGACCTGAAGGTTCAGCATAGT AGCTACAGACAGAGGGCCCGGCTGTTGAAGGACCAGCTCTCCCTGGGAAATGCTGCACTT CAGATCACAAGATGTGAAATTGCAGGATGCAGGGGGTGTACCTTGGCCCGCTCTAGAACT

Sequence 1149

Sequence 1150

TATAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTACCAAATGAAGTG
TGAAGACAAGGCCATCCACCACTTTATAGAGGGTGTAAAAATAAACCAGAAATCAAGGGA
NAAAGAAAAGATGAANGACAAACTGCAAAAAATTGCCAAAATGCNACTTTCTAAAAATGG
AGCAGATTCTGAGGCTTTGCATGTCTTGGCATTCCTTCAGGAGCTGAATTGAAAAAA
Sequence 1151

TABLE 1 189/467

Sequence 1152

Sequence 1153

Sequence 1154

Sequence 1155

Sequence 1156

Sequence 1157

ATAGGGCGAATTGGAGCTCCCCGCGGTGGCGCCCCGGGCAGGTACGCGGGGCAGTGGGAAGCTCGCAGCAGCAGCAGGAGACCCAACCCAACTGGGAGAATGAGGAAACAGCAACCCAGAGAGAACTAACCCACACAGGA

TABLE 1 190/467

AGGGCGAATTGGAGCTCCCCGCGGTGGCGCCCCCGGGCAGGTACGCGGGGCAGTGGGA AGCTCGCAGCAGCTGGGGAGAGCCAAAGCCTCGCCGCTCACCTAAGCCGCAGGAGATA CACCCAACTGGGAGATGAGGAAACAGCAACCCAGAGAGGAGAACTAACCCACACAGGATC ATTTCGTGAAGGAGCAAGGCTGAAGAACCAGACCTGGACTTTCTTAGGACAAACTTACTG CAGCTTGAAGGAGCCAACCATGGATTTGAGGCGTGTGAAGGAATATTTCTCCTGGCTCTA CTATCAATACCAAATCATTAGCTGCTGTGTTTTTAGAGCCCTGGGAGCCGATCTATGT TTAACACCATCTTACTAACCATTATTGCT

Sequence 1159

GGGCGAATTGGAGCTCCCCGCGGTGGCGGCCCCCGGGCAGGTACGCGGGGCAGTGGGAA
GCTCGCAGCAGCTGGGAGGAGCCAAAGCCTCGCGCTCACCTAAGCCGCAGGAGATAC
ACCCAACTGGAGATGAGGAAACAGCAACCCAGAGAGGAGAACTAACCCACACAGGATCA
TTTCGTGAAGGAGCAAGGCTGAAGAACCAGACCTGGACTTTCTTAGGACAAACTTACTGC
AGCTTGAAGGAGCCAACCATGGATTTGAGGCGTGTGAAGGAATATTTCTCCTGGCTCTAC
TATCAATACCAAATCATTAGCTGCTGTGTTTTTAGAGCCCTGGGAGCGATCTATGTTT
AACACCATCTTACTAACCATTATTGCTATGGGTGGTATACACTGCCTATGTCTTTATTCC
AATCCACATTCGCCTGGCTTGGGAATTTTTCTCA

Sequence 1160

Sequence 1161

ACTTAGGGCGAATTGGAGCTCNCCGCGGTGGCGGCCGCCGGAAGGTGGGTGACGTGCGGA TCTTCTTCTTTTTGTGGCTGTGGACACCTTTCAACACTGCCTTCTTGGCCTTTAAAGCCT TCGCTTTGGCTTCAGCTTTAGGAGGGGCAGGAGCCCATCGCAAAACCACGCTGCGGAGAG AGGGGCGGGTAATGTAGCCCGGTTGAACATGAACCAGAAGGAAAATGGTTAAAGCTGAGG GCACTAATTCCTTACAGGCCCGGGGACATGGAGCTCCAACCAGTGGATGCATGTAGCTTC CCAGAACCGAATGTCTGCCCCGCGTACCT

Sequence 1162

CCGCGGTGGCGGCCGAGGTACCACTCTATCCATCGNGGATAGAGAAACTGAAGCTCTCTA
AAGACCCTGCANCTGGGAGGTGGCAGAGTCAATGGCAGCCCTCAGCCCTATCTGCCCTGA
CATGGCATTCCTCCCATTTCTCACCACCGAACCCTCTAAAATAACAATGTGTGGGGTCCT
TGGCTGAGAGACTTCCCTTTTGGGAATCAATCTGAATGTATGATGACAAAGAAAACAACT
TTTGCTTTATACAACCTTNTGGTTAGATTCAGGCACCAAGCAGGACACTTCTTTGTGGCG
CTCCAAGAATCTTTCAAATTCTTCATCACCAATAACAAATCTTTCTGCTTCTCTTAGAGC
ATCTTCTCCACCAATTCTCACCCTCAATTAAGAGGCACTGGAACACTTTCCAGCGGACAGG
GTTTAGT

Sequence 1163

TABLE 1 191/467

AGATGAAGACTCTGAGAGGGGTTTGGAGTCTGGAAGCCTCATCCCTTCAGCATCAAGCTGGAATGAGGAATGAAGAATAGAGATGTGGTGCCCACTAGGCTACTGCTGAAAGGGAGCTGAAATTCCTCCACCAAGTTGGTATTCAAAATATGTAATGACTGGTATGGCAAAAGATTGGACTAAGACACTGGCCATACCACTGGACAGGGTTATGTTAACACCTSequence 1164

Sequence 1165

TTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACATCATTTTCTTTNTCCTGT CCATAAATCTTCTTCCACCACGTGGCTGTNCAAGACTCTCTGAACCTNCTCTGGCTCA GGAGGCTTNTAGATNTGTGAATTGTCTGCTCAGTNNAACTCCATTAAATTNAATNTGGCC AAGAANTTTCTTCTTAACAGNGGTATTGATGACCATTAATCCTTCAACCTAAACCTGCTC ATTAA

Sequence 1166

Sequence 1167

Sequence 1168

TABLE 1 192/467

GAGGGGTTTGGAGTCTGGAAGCCTCATCNCTTCAGCATCAACTGGAATGG

Sequence 1170

Sequence 1171

Sequence 1172

Sequence 1173

AGGTACCGCTGTGTCCGGGTGGGTGGTCAGAATGCCGTGCTCCAGGTGTTCACAGCTGCT TCGTGGAAGACCATGTGCTCCGATGACTGGAAGGGTCACTACGCAAATGTTGCCTGTGCC CAACTGGGTTTCCCAAGCTATGTGAGTTCAGATAACCTCAGAGTGAGCTCGCTGGAGGGG CAGTTCCGGGAGGAGTTTGTGTCCATCGATCACCTCTTGCCAGATGACAAGGTGACTGCA TTACACCACTCAGTATATGTGAGGGAGGGATGTGCCTCTGGCCACGTGGTTACCTTGCAG TGCACAGCCTGTGGTCATAGAAGGGGCTACAGCTCACGCATCGTGGGTGAAACATGTCC TTGCTCTCGCAGTGGCCCTGGCAGGCCAGCCTTCAGTTCCAGGGCTACCACCTGTGCGGG GGCTCTGTCATCACGCCCCTGTGGATCGTCACTGCTGCACACTGTTTTATGACTTGTAC CTGCCCG

Sequence 1174

AGGTACCGCTGTGTCCGGGTGGGTGGTCAGAATGCCGTGCTCNAGGTGTTCACAGCTGCT TCGTGGAAGACCATGTGCTCCGATGACTGGAAGGGTCACTACGCAAATGTTGCCTGTGCC CAACTGGGTTTCCCAAGCTATGTGAGTTCAGATAACCTCAGAGTGAGCTCGCTGGAGGGG CAGTTCCGGGAGGAGTTTGTGTCCATCGATCACCTCTTGCCAGATGACAAGGTGACTGCA TTACACCACTCAGTATATGTGAGGGAGGGATGTGCCTCTGGCCACGTGGTTACCTTGCAG TGCACAGCCTGTGGTCATAGAAGGGGCTACAGCTCACGCATCGTGGGTGAAACATGTCC TTGCTCTCGCAGTGGCCCTGGCAGGCCAGCCTTCAGTTCCAGGGCTACCACCTGTGCGGG GGCTCTGTCATCACGCCCCTGTGGATCGTCACTGCNTGCACACTGTGTTTATGACTTGTA CCTGCCCG

Sequence 1175

AGGTACCGCTGTGTCCGGGTGGTGGTCAGAATGCCGTGCTNNAGGTGTTCACAGCTGCT
TCGTGGAAGACCATGTGCTCCGATGACTGGAAGGGTCACTACGCAAATGTTGCCTGTGCC
CAACTGGGTTTCCCAAGCTATGTGAGTTCAGATAACCTCAGAGTGAGCTCGCTGGAGGGG
CAGTTCCGGGAGGAGTTTGTGTCCATCGATCACCTCTTGCCAGATGACAAGGTGACTGCA
TTACACCACTCAGTATATGTGAGGGAGGGATGTGCCTCTGGCCACGTGGTTACCTTGCAG
TGCACAGCCTGTGGTCATAGAAGGGGCTACAGCTCACGCATCGTGGGAAACATGTCC
TTGCTCTCGCAGTGGCCCTGGCAGGCCAGCCTTCAGTTCCAGGGCTACCACCTGTGCGG

TABLE 1 193/467

GGCTCTGTCATCACGCCCCTGTGGATCGTCACTGNTGCACACTGTGTTTATGACTTGTACCTGCCCG

Sequence 1176

CCGGGCAGGTACAACAAGCGTTTGTAATGTTTCCCAAANATTAGCTTTGAAATCCAAATG
TCAAGCAATTAAAGTTCAAAAAACTATAAATGTAATTGTTAATAAAACAATGGATGAAAA
AAGTCATTGAAATTTTTTCTACTTGGATTAAGAACATAAATTAAAAGTGCAACTGCAAA
AATAATATTAGTTTGATAAGTAAAAAAAACAAACTAGATATATTTTGAAAATAAAAAAC
AAATGAAACAAAATAAAAATTTAGGTAAAGAAAATTCAACGTAATTTGTTGTAGCTATATT
TTTTGTAATAATTACAAAAGTAGAAATATAGCTCATAAAGCAAAAACAAAATTTATTCT
ATGTTCTTTTTTCAGTCAATTTGTTTGCGGATTTNGATTTGCCATAAAAATTTATTT
TATTTAATTATTTAATCTTCGTCAGCTTTAATTGCTCTTTTAACAATTTGATCTGA
AATTTGTTTTGGTGTTATTTCATAGTGATCAAATTTGCATTTGATAAGTTCCACGACCTGA
TGTCATAGACCTTAATTGTTTGAGTATCCAAACATTTC

Sequence 1177

TAGGGCGAATTGGACTCCACCGCGGTGGCGGCCGCCCGGGCAGGTACCTACGGAAATCCT
AACTACCACTGGCAGGAAACTGCATATNTTCTGGTTTACATGAAGANGGAGGGCTAANGG
AAATGCCCAAAACCTTCAGAGATTGACACCGCTGTCATTNTCCATNTCNGTTCCTGGAAT
CTACCGGGAGTNTTNATAAGAAGANTTTTGCAAATNGAGGGAAGAAGCAATTGTTTTCAA
ACTATATAACTGGAGNCCTTAATTTATAATTAGGGGATATTTAATCAAAAATATNGTAAA
CCATGGAGGGCCCCCTCAGNGTNCTGGATCAGGATCCTGGGGGTGGCNTCGNCTGGCT
TGTGGCGAANGAACAATTAAGCCCCTTTTAAGTTTATTGAAGCCCTGNGGGGAAACTTTA
AGGGGGTTTCCANAGTTGGGGGANGAAGCANTNGGNNAGTTGGNGAAGGCCATTTTGGGG
GGG

Sequence 1178

Sequence 1180

CCGCGGTGGCGCCCCGGGCAGGTACCTATTGCCAGGAAGATAGGCAGCTCATCTGTG
TCCTGTGTCCAGTCATTGGGGCTCACCAGGGCNNCCAACTCTCCACCCTAGACGAAGCCT
TTGAAGAATTAAGAAGCAAAGACTCAGGTGGACTGAAGGCCGCTATGATCGAATTGGTGG
AAAGGTTGAAGTTCAAGAGCTCAGACCCTAAAGTAACTCGGGACCAAATGAAGATGTTTA
TACAGCAGGAATTTAAGAAAGTTCAGAAAGTGATTGCTGATGAGGAGCAGAAGGCCCTTC
ATCTAGTGGACATCCAAGAGGCAATGACCACAGCTCATGTGACTAGAGATACTGGCAGACA
TCCAATCCCACATGGATAGGTTGATGACTCAAATGGCCCAAGCCAAG

TABLE 1 194/467

Sequence 1181

GACTAAGACACTGGCCATACCACTGGACAGGGTTATGTTAACACCTGAA Sequence 1183

Sequence 1184

ATTGGAGCTCCCGCGGTGCCGCCGAGGTACAAGATAGTCATCTCAGTAAAAGGTCTAT
TATCTAACTTGCCAAACTTGTTTACTGAGAGCCCTAAGGAACTAAAACNGCCATAATGCC
GTGCACAGNTTGAAAAGCAATTAGAGTAAGCAAGATTAGTTTTTCCTCCCTTCCAGTTTN
CTCAAGCAGGCCTGGACGCCCAGGAGGGAAGGAAATATAAGAACCAACAATAAAAA
TAGCAATAGCAATAAGAAGAATGCCATCCCATGGAGCACCATAATTCTGGAACCACCT
NTCCCGGATCAGGCTTCCATTGCTCACGATGCTCACGCTGGGCAGCCGCAACTNTACTTT
GCAGAACCTCACCAACTTGCCCAGGTNTTCTCCCCGGTCTTGAAGAAATGGCTCTCCACC
TGAAAAGTNNGATCTTCTCCATACCAGCTTCTTAAGCAAAAGCAATCCTCTCTTTGCTTC
CTCAAGGGGCA

Sequence 1185

GGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACCAAATGAAGTGTGAAGACAAGG

TABLE 1 195/467

Sequence 1188

CCGCGGTGCCGCCGAGGTACAAGATANTCATCTCAGTAAAAGGTCTATTATCTAACTTG CCAAACTTGTTTACTGAGAGCCCTAAGGAACTAAAACTGCCATAATGCCGTGCACAGCTT GAAAAGCAATTAGAGTAAGCAAGATTAGTTTTTCCTCCCTTTCNAAGTCCTCAGCAGGCC TGGCTGAAGGCCCAGGAGGGAAGGAAATATAAGAACCAACAATAAAAATAGCAATAGCAA TAAGAAGAATGCCATCCCATGGAGCACACCATAATTCTGGAACCACCTCTCCCGGATCAG GCTTCCATTGCTCACGATGCTCACGCTGGGCAGNCGCAACTCTACTTTGCAGAACCTCAC CAACTTGCCCAGGTATTCTCCCCGGT

Sequence 1189

Sequence 1190

TABLE 1 196/467

Sequence 1192

Sequence 1193

Sequence 1194

NGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACACATAAATCACCTGGAACCTTG
TTAAAATGCAGATCCTGACTCAGGAGGTCTGAGTTAGAGCCCAGGATTNCATATTTCTAG
CCAGCTCCATGATGAGCTGCTGGTCCGCAGATCATGCTTGCNGGTTTTGACCAGAGTCAG
TGTTGGTTANAGTAAGAGGATGAGGCANACATNTGGGAAAAGTCCAGCTGGGGCAAGCAT
TTGAAGTCTGCCTTCCTACCANGTCAAAATCAAGGCAACGACCTTCCATAGATAACTATC
AAAGCTTGAGGGGGNGCCTTGAACCCAACTCCTAAATCCCTAAGACCTGCCCACCTCTTG
TGTCTCCTGTNTNAGCAAACATTCCCACACTCTTGCATATTGTTAAAAGTAACCTCTGCT
TACCAGGCTTTTG

Sequence 1195

Sequence 1196

Sequence 1197

ATAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTACGCGGGGAGAGCG AGCTTCGGAGAAGCAGTGGTGGGTTCCATGTGGTGGAGTAGGAGGCAGGTCTCCGCG GTGGTTTCCACAAGAAAAATGGCACAATGTTTCTCAGAAGACAATTACATAAGAATCAGC

TABLE 1 197/467

ATACTITAAATTCACAGCAAATAATCAGACAATTGATGAAAAATACTTACCCAAACACTAA
TTGTAGACTGTGCCTTCTGAATATGTTTTGTCATAAACTTGGAGTAAGGAATCCTCACAG
GCACTGGACAATTCAAAAAACGTAAAGTTTGTTTGTTAGAATACCTGGGTGCTTTTGGAT
AGAAACCCTCATCCATATCCTGGTAAGGCTTGAAGTTGCACAGGAGTTTTCATTTGTCAA
AACCCAGAAAACCATAAGCTTTAGATTTGGG

Sequence 1199

Sequence 1201

TTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCCCCGGGCACGGTACGCGGGGGTAAC
TGAAAATCCACAAGACAGAATAGCCAGATCTCAGAGGAGCCTGGCTAAGCAAAACCCTGC
AGAACGGCTGCCTAATTTACAGCAACCATGAGGCCACTTAAGGATGCAGCAAGAAGGAGC
CATCTGCAATCCAGGAAGAAATTCCTTGCCAGGAACCAAATTGGTTGTCACCTTCATCTA
GGACTTCTAGCCTCGAGAACTTACAAATGGTGATGATCAT
Sequence 1202

Sequence 1204

TABLE 1 198/467

Sequence 1208

CCCTTTCGAGCGGCCCGGGCAGGTACCAAATGAAGTGTGAAGACAAGGCCATCCAC CACTTTATAGAGGGTTAAAAAATAAACCAGANATCAAGGGAGAAAGAAAAAGATGAAAGAC AAACTGCAAAAAATTGCCAAAATGCGACTTTCTAAAAATGGAGCANATTCTGAGGCTTTG CATGTCTTGGCATTCCTTCAGGAGCTGAATGAAAAAATGCAACAAGCANATGAAGACTCT GAGAGGGGTTTGGAAGCCTCATCCCTTCAGCATCAAGCTGGAATGAGAATGA AGAATAGAGATGTGGTGCCCACTAGGCTACTGCTGAAAGGGAGCTGAAATTCCTCCACCA AGTTGGTATTCAAAATATGTAATGACTGGTATGGCAAAAGATTGG

Sequence 1211

TABLE 1 199/467

CCCCCGGGGGGGAAAAAANCCCCCNGGGGGGAAACCCCCCGG Sequence 1212

Sequence 1214

TABLE 1 200/467

GCATTCCTTCAGGAGCTGAATGAAAAAATGCAACAAGCAGATGAAGACTCTGAGAGGGGT TTGGAGTCTGGAAGCCTCATCCCTTCAGCATCAAGCTGGAATGGGGAATGAAGAATAGAG ATGTGGTGCCCACTAGGCTACTGCTGAAAGGGAGCTGAAATTCCTCCCCAAGTTGGTATT CAAAATATGTAATGACTGGTATGGCAAAAGATTGGACTAAGACACTGGCCATACCACTGG CAGGGTTATGTTA

Sequence 1218

CCGCGGTGGCGGCCGAGGTACTTCTTACAGTCTTCAGGAAATTCATTAAATCAGTGCCTC CAGTTCCTTTGGCTGCTTTTGAAGGGTCTTCAGAGGTCTTATTCTCCTTTTGGCTGCT GGCTTGCAGGAATCAGGATGTACTGTTCCTGTTGGCCGAGTGGAGACTGGNGTTCTCAAA CCCGGNATGGTGACCCTTTGCTCCAGTCAACGTTACAACGGAAGTAAAATCTGTCGAA ATGCACCATGAAGCTTTGAGTGAAGCTCTTCCTGGGGACAATGTGGGCTTCAATGTCAAG AATGTGTCTGTCAAGGATGTTCGTCGGGGGCAACNTTGCTGGTGACAGCAAAAATGACCCA CCAATGGAAGCAGCTGGCTTCACTGCTCAGGGTGATTATC

Sequence 1219

Sequence 1221

Sequence 1222

CGACTCCTATAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTACCAAA

TABLE 1 201/467

Sequence 1224

Sequence 1225

Sequence 1226

Sequence 1227

TAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACTTCCAGGAAGTGAAGTAAAA CCTGGTCTTGGTTGATAGGCCCCAGGTTGGCTTGGAGCCATTCCAGGTTGAGAGGCAGGA GCCACAGTATAATTAGTAGGCTGAGAAGTTTGGGCAGTGTAAGTTTGTGCAGGATAATTG CTCGCCTGGTACTCTTGGAAGTCCACCTCGTTGTCCCTGTTGCTCCAAGTTGCTCATC AGCTTCTGGAAAGCAGCTTCACCTGTCCTTTTCCCCAAGAAGCTGGGCAGCTCCCGGGTC AGCAGCTCCTTTAGTTCTGACTTGTTGAGCTTGAACTTGTCACCCTCTTTGCCCGAGTAC CTGCCCG

Sequence 1228

TABLE 1 202/467

TTGAGAGAGCCCAAGGAGTTCTGGGAGAGGGACCAAATGGGGGG Sequence 1229

TAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTACCAAATGAAGTGTG AAGACAAGGCCATCCACCACTTTATAGAGGGTGTAAAAATNAACCAGAAATCAAGGGNGA AAGAAAAGATGAAAGACAAACTGCAAAAAATTGCCAAAATGCGACTTTCTAAAAATGGAG AAGCAGATGAAGACTCTGAGAGGGGTTTGGAGTCTGGAAGCCTCATCCCTTCAGCATCAA GCTGGAATGGGGAATGAAGAATAGAGATGTGGTGCCCACTAGGCTACTGCTGAAAGGGAG CTGAAATTCCTCCACCAAGTTGGTATTCAAAATATGTAATGACTGGTATGGCAAAAGATT **GGACT**

Sequence 1230

TAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCCCCGGGCAGGTACGCGGGGGGTCTTC TAGTCCGGTAAACAGAGGGCCTGCCCCGACAGCTTCTGCTTCCGGGTCACGCCTTGACA GCGGCTTTCAACCCCCACCTCAGCCCAGCAATTCGTTTGGAGCATGTGAACACCTTGAGC CTTGATGAGTTCCAGTNTGTGGTATATTATGCAGNGCNTTCAGNGAAAATNCTTTTNTN CGGGNNTTNAANNAAAAANANTNGGGTGCCATGNTNTTNCCCCCNNNNNNTNGGGGGGGG GCCCCCTCAAANGGGGGGGGGGACTATNANNNNCCCTNTTTTTTGGGGNNCNANNTNN ACNCCNTTTNNTTNGGGCCCCNTTTTTTGGGGGNAAAAAAACCCCCCCCCTNNGGGGGGG GTATTTTCNTTTTNNGAAAAAAAAAGGCCCCGGGGNNGACCCCCCCCCGGGGGNTTAN ANAAAAAAAAAAANTCNCCCNNTTNTTTTTTTTAAAA

Sequence 1231

AGGTACGCGGGGCTTTTCCGTGCTACCTGCAGAGGGGTCCATACGGCGTTGTTCTGGATT CCCGTCGTAACTTAAAGGGAAATTTTCACAATGTCCGGAGCCCTTGATGTCCTGCAAATG AAGGAGGAGGATGTCCTTAAGTTCCTTGCAGCAGGAACCCACTTAGGTGGCACCAATCTT GACTTCCAGATGGAACAGTACTCTTGGAAGTCCACCTCGTTGTCCCTGTTGCTGTCCAAG TTGCTCATCAGCTTCTGGAAAGCAGCTTCATCTGTCCTTTTCCCCAAGAAGCTGGGCAGC TCCCGGGTCAGCAGCTCCTTTAGTTCTGACTTGTTGAGCTTGAACTTGTCACCCTCTTTG CCCGAGTACCTGCCCG

Sequence 1232

TACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCCCCGGGCAGGTACGCGGGGAAA CAAAAAGGAACCAGAGGCCACTTGTATATATAGGTCTCTTCAGCATTTATTGGTGGCAGA AGAGGAAGATTTCTGAAGAGTGCAGCTGCCTGAACCGAGCCCTGCCGAACAGCTGAGAAT TGCACTGCAACCATGAGTGAGAACAATAAGAATTCCTTGGAGAGCAGCCTACGGCAACTA AAATGCCATTTCACC

Sequence 1233

GCNATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACCAAANTGAAGTGTGAAGACAAGGCC ATCCACCACTTTATAGAGGGNGTAAAAATAAACCAGAAATCAAGGGAGAAAGAAAGATG AAAGACAAACTGCAAAAAATTGCCAAAATGCGACTTTCTAAAAATGGAGCAGATTCTGAG GCTTTGCATGTCTTGGCATTCCTTCAGGAGCTGAATGAAAAAAATGCAACAAGCAGATGAA GACTCTGAGAGGGGTTTGGAGTCTGGAAGCCTNATCCCTTCAGCATCAAGCTGGAATGGG GAATGAAGAATAGAGATGTGGTGCCCACTAGGCTACTGCTGAAAGGGAGCTGAAATTNCT CCCCAAGNTTGGTATTCAAAATATGTAATGACTGNTATTGGCAAAAA

Sequence 1234

GCNATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTACCAAATGAAGTGTGAAGAC AAGATGAAAGACAAACTGCAAAAAATTGCCAAAAATGCGACTTTCTAAAAATGGAGCAGA AGATGAAGACTCTGAGAGGGGTTTGGAGTCTGGAAGCCTCATCCCTTCAGCATCAAGCTG GAATGGGGAATGAAGAATAGAGATGTGGTGCCCACTAGGCTACTGCTGAAAGGGAGCTGA AATTCCTNCCCAAGTTNGGTATTCAAATATGTAATTGCTGGTATGGCAAAAGATTGGACT AAGACACTGGCCCTACCACTGGACAGGGGTTATTNTTTAACCCCCTGAATTTGCTTGGGT

TABLE 1 203/467

CTTTGAGAGAGCCCCAAGGGGGTTTTGGGAGAGGGGACCCANAATTGGGGGGTAGGTC Sequence 1235

Sequence 1237

Sequence 1238

Sequence 1239

Sequence 1240

TABLE 1 204/467

Sequence 1241

Sequence 1242

Sequence 1243

Sequence 1244

Sequence 1245

TGGTACTGCTAAAGTCATGACAGCCCAACAGGTGATGTTTTACTGGATGAAACTCTGAAACACTCAAAGCAACTGAAACCCACAGAAACTGTCCAAACATGGATAGAGCTACTCACTGGTGAGACCTGGAACCCCTTCAAATTACAGTACTGTTCCTGTTGGCCGAGTGGAGACTGGTGTTCCCAAACCCGGTATGGNGGTCACCTTTGCTCCAGTCAACGTTACAACGGAAGTAAAATCTGTCGAAATGCACCATGAAGCTTTGAGTGAAGCTCTTCCTGGGGACAATGTGGGCTTCAATGACAAGAATGTGTCTCAAGGATGTTCCGTCGTGGCAACCGTTNCTGGTGACAGCAAAAAATGACCCCACCAA

Sequence 1246

Sequence 1247

TABLE 1 205/467

GGACTAAGACACTGGCCATACCACTGGACAGGGTTTATTGTTAACACCTGAATTGCTGGGGTC

Sequence 1248

Sequence 1249

Sequence 1250

Sequence 1252

TACTTAGGGCGATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACAATCTTGAGAAGGATTT GAAGGACAAGTTTGTGGCCCTGACCATAGATGATATCTGCTTCTCGCTCAACGACAACTC ACCAAACATCAGATATTCTGAGAACGCCGTGAGGATTGAGCCAAACTCCGTGAGTCTGGA AGACTGGTTGGACTTCCCAGCACCAATGTGGAGAAGGCTGACAAGCAGCGAACAACTC CCTGATGCTGAAAGCCCTGGTGGATCGAATCCTGTCCCAGACAGCCAATGGATCTGTGCA AGCCAGTGTGATTGTGGACACCGGCATTCAAGAATGGGCCTGAAGGGATCAAAGGGA TGCCAGGGACAAGCTGGGCTTGATCATCTGGCCCAAGGTATTNGGAAAGAGTTGCTTCC CAGGGAAGAAAA

Sequence 1253

TABLE 1 206/467

CTGAAATTCCTCCCCAAGGTTGGTATTCAAAAATATTGTAATGAACTGGGTATTGGCAA

Sequence 1254

CCGCGGTGGCGCCGNGGTACAATGATTGTCATCTCAGTAAAAGGTCTATTATCTAACTT GCCAAACTTGTTTACTGAGAGCCCTAAGGAACTAAAACTGCCATAATGCCGTGCACAGCT TGAAAAGCAATTAGAGTAAGCAAGATTAGTTTTTCCTCCCTTCCAGTTCCTCAGCAGGCC TGGCTGAAGGCCCAGGAGGGAAGGAAATATAAGAACCAACAATAAAAATAGCAATAAGCAA TAAGAAGAATGCCATCCCATGGAGCACACCATAATTCTGGAACCACCTCTCCCGGATCAG GCTTCCATTGCTCACGATGCTCACGCTGGGCAGCCGCAACTCTACTTTGCAGAACCTCAC CAACTTGCCCAGGTATTCTCCCCGGTCTTGA

Sequence 1255

Sequence 1256

Sequence 1258

Sequence 1259

TACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTACTCTTTGTTT
TGGCACACTTTTCCTGACAAACAGCCAGTGTTCTCAATACATAAATACTAGTCCACGTTA
ACAACAATAGCATATGAGACCGCTCTCCGTAAAGATGCCAGATTGGATGCAAATGGACTG
GAAATACCTTGGAGGGTTTCACAAAAATAAGACAAAGGGCAAAGGAACTTTGCCAAAGGA
GATGGAGAGCAATTCTTTAAAGATAGTGGGAGGAAGCAAAGAGCTCATAAATACAA
GCCTCTTAAAATGGGACGCATTTGCCTCGCGCCTCTGGGGTGTCTGCAGCTCAGCNTTGG
TGCCCCACACGGGACACCCGACTTTT

Sequence 1260

TABLE 1 207/467

Sequence 1261

Sequence 1262

Sequence 1263

TGGCGCCGCCGGCAGGTACGCGGNGCAGAAGAGGAAGATTTCTGAAGAGTGCAGCTGCC
TGAACCGAGCCCTGCCGAACAGCTGAGAATTGCACCTGCAACCATGAGNGAGAACAATAAG
AATTCCTTGGAGAGCAGCTACGGCAACTAAAATGCTTTCACCTGGAACTTGATGGGAGGG
AGAAAACTCCTTGGATGATTTTGAAGACAAAGTATTTTACCGGACTGAGTTTCAGAATCG
TGAATTCAAAGCCACAATGTGCAACCTACTGCCTATCTAAAGCACCTCAAAGGGCAAAAC
GAGGCAGCCCTGGAATGCTTACGTAAAGCTGAAGAGTTAATCCAGCANGAGCATGCTGAC
AAGGCAGAAATCAAAAGTCTGGTCACCTGGGGAAA

Sequence 1264

GGCGAATTGGACTCCACCGCGGTGGCGGCCCGAGGTACAGAGATTTATAATGTGCTGCTC
TAGGTCCTATCGGGTAAAGGGATCAGCAGATGTGAAGTCAAGAGTCTCCTGTAAGATTTG
ACTTTCTTGGAAACATATTTTAATCCTGGGCCTCCTNTTTCAAATCACCTATTTCTTTTA
GTTTTTTGCAGTGATACTGTGTTGCTTCTAACAGAGGTTCAGTTTCACAGCCTTTCCC
TCAAGTGTCTTATCCTAAAAGTAAAACCTAGATGATCTAAGGTGGTGGNTTTCAACAGGG
TGCAAATTTGCCTCCTATACTCGCAACACCCAGNGACAGTTGGCTAATGTCTNGGAGACAT
TTTTGNGTTNTCACACCTGGANNNAGGGTGGGGGAGGTGGNGCTAATGACANCAAGNTGG
CCNTAANCCAATNATGCTGATANAAATNCTACANTGCACAAGGATAGGNTCCCACANAAC
ANAAGNCTTANCCAAACCCCAAATACTAACAAT

Sequence 1265

CCGCGGTGGCGCCCGAGGTACAAGATAGTCATCTCAGTAAAAGGTCTATTATCTAACTT GCCAAACTTGTTTACTGAGAGCCCTAAGGAACTAAAACTGCCATAATGCCGTGCACAGCT

TABLE 1 208/467

TGAAAAGCAATTAGAGTAAGCAAGATTAGTTTTTCCTCCTCCAGTTCCTCAGCAGGCCT GGCTGAAGGCCCAGGAGGAAGGAAATATAAGAACCAACAATAAAAATAGCAATAAGAATAAGAAGAATGCCATCCCATGGAGCCACCATAATTCTGGAACCACCTCTCCCGGATCAGG CTTCCATTGCTCACGATGCTCACGCTGGGCAGCCGCAACTCTACTTTGCAGAACCTCACC AACTTGCCCAGGTATTCTCCCCGGTCTTGAAGAAATGGCTCTCCACCTGAAAAGTTGATC TTCTCCATACCAGCTTCCTTAAGCAAAAGCAATCCTCTCTTTGCTTCCTCAAGGGGCAGC ACAAAGGATGTTTTGGCTGTGTGGAAACAGAAGCCCGCATTTGTAGTTGCACTGGCGAGT GAAGTGATAGTTGACGCTGGTTGGGGTGGT

Sequence 1266

Sequence 1268

Sequence 1269

CTACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTACTTCTACAG
AGATCCTGAAGAGATTGAAAAAGAAGAGCAGGCTGCTGCTGAGAAGGCAGTGACCAAGGA
GGAATTTCAGGGTGAATGGACTGCTCCCGCTCCTGAGTTCACTGCTACTCAGCCTGAGGT
TGCAGACTGGTCTGAAGGTGTACTCTTTGGTTTATCAATGGGACGTTCCAGCAATCCACAC
AAGAGCTCTTTATCCCCAACATCACTGTGAATAATAGCGGATCCTATATGTGCCAAGCCC
ATAACTCAGCCACTGGCCTCAATAGGACCACAGTCACGATGATCACAGTCTCTGGAAGTG
CTCCTGTCCTCTCAAGCTGTGGCCACCGTCGGCATCACGATTG

Sequence 1270

TABLE 1 209/467

Sequence 1271

Sequence 1272

Sequence 1274

Sequence 1275

TABLE 1 210/467

ANTGGNTGGTTCCTTCCATTAGGTTTAAAGGGGAGGAGGNANNATTAAAAAAAAATTAAAA AAATTGGTTCATTTTAAAACAAGGTTTNGAAATTTNAAGGGAA Sequence 1277

AGGTACAAAATTATCATCATTTAGAGTTGATTTTTTTCACCAGCCCTGAATTTTCAAACT
TGTAATATGCTGTTTCACAATCTTTTTATTAAAATTACTTAATGATTCCAGTNTGGCAAAT
GAGCCATAGACTTTTGCTCTGCTTGTTATAAGATCANTTGGAATTGGGNGGGGGGGANAA
CCANTAGTTAAGNCTAAATCTAATCCGGTCACTTGGCTTCATTGTAAAAGAACCCCACAA
TTGGTCTGAATTAATTTTTTGCCCAGGCACCANGAAAGNAANATNGNTGTACCAAAGNTN
GAANTACATTCCTTGGCAAANTGGGGCCCTCTTTGGCCCAAATCCTTTTTTCCAATTATC
CTTATTGGTTAAAACCCTTTTTTTGGTTAAGTNTNACCTTGGGTGGTTGGAATNTTTAAA
GCCGGNCTTGGNNGGCCTTAATTTTGGTAAAAAATTTCTTTTGGGGGATTTTAAAATTTA
AACCCAANAANAACCANACCAAANAAATANTTCNTNATTNCACCCCTTGGGGNAAATTNA
TTTTGGGAAAAAGGAAAANATTTTCNAAGTTTAAAAAACCCAAAGGAANTGGGTNGTTCC
TCCAATTANGGTNTTAAAAGGG

Sequence 1278

Sequence 1279

GTGGCGGCCGAGGTACCAANTGAAGTGTGAATGACAATGGCCATCCANTANTTTATAGAG GGTGTAAAAATAAACCAGAAATCAAGGGAGAAAGAAAAGATGAAAGACAAACTGCAAAAA ATTGCCAAAATGCGACTTTCTAAAAATGGAGCAGATTCTGAGGCTTTTGCATGTCTTGGC ATTCCTTCAGGAGCTGA

Sequence 1281

CCGCGGTGGCGCCGCTCGGGCAGGTACCATTCCTCTACATCCATTTGGTAGCAGAACCT CAAGTGTAAGCAGTCAGTGTAGCATGAATATGAACTGGCTCAGTTTATCACTTCCTGTTT NGACCTGAAGCACCACCCAGCTATGCAGAAGTGGTAACAGAGGAACAAAGGCGGAACAAT CTTGCACCAGTGAGTGCTTGTGATGACTTTGAGAGAGCCCTTCAAGGACCACTGTTTGCA TATATCCAGGAGTTTCGGTTCTTGCCTCCACCTCTTTATTCAGAGATTGATCCAAATCCT GATCAGTCAGCAGATGATAGACCATCCTGCCCCTTTTGTTGAAGGAACACTTGGTTGA Sequence 1282

TABLE 1 211/467

Sequence 1283

Sequence 1284

CGCGGTGGCGGCCGGGCAGGTACCCCGGGAGAGCCCGCTTCCCCCTCCCCTGTG
CTGTCTGCACCCGAGGAGAGCGGCCTGCCCGGAAGTGGGCCACCATATCTGGAAACTACA
GTCTATGCTTTGAAGCGCAAAAGGGAATAAACATTAAAGACTCCCCCGGGGACCTGGAGG
ATGGACTTTTCCATGGTGGCCGGAGCAGCAGCTTACAATGAAAAATCAGAGACTGGTGCT
CTTGGAGAAAACTATAGTTGGCAAATTCCCATTAACCACAATGACTTCAAAATTTTAAAA
AATAATGAGCGTCAGCTGTGGAAGTCCTCCAGAATAAGTTTGGCTGTATCTCTACCCTG
GTCTCTCCAGTTCAGGAAGGCAACAAGCAAATCTCTGCAAGTGTTCAAAAAAATGCTGAC
TCCTAGGATAGAGTTATCAAGTCTGGAAAGATGACCTCACCACACATGCTGTTGATGCTG
TGGTGAATGCACCAATGAAGATCTTCTTGCATGGGGGAAGGCCTGGCCCTGG
Sequence 1285

TCGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCCGCCCGGGCAGGTACAGGTAAGATATA
CTGGAGTCACAGAGCAATATGCATTAACAGGATACAACAGTTCATAAAAACTGAGTAACT
ATGCACACAAATTTCTTAAACAGCCACCTAAAGAGAAAATGCACAGATGTATGGTGGAAA
CTGTATCTAACACTGAAACTACTACAGGACTCCATCAATGAGTCCAACTTTTAGTGATAA
AAAACTACTGTACACTACATGAAGAACCATATGTTTATAATTATCCAAAATAAAAATGAAG
TTATTAAACTTCAAGATAATATGGTAATTTGCATTGAACCGATGATTTTACAAAATTCTG
CAAAGGTCAAAATTTTAAAAGATGGCTGAACAGTAATTGCAGCATCTAATAAAAACCGCAG
CTCATTACCGAGCAAACGGTTTTAATTAAAAATTCAAAAGGAATAATCCTGACAGGAGAA
ATAAAAAAAATAGATGTCAAAAGAAGATAAATTTTTTCAAAGGAGTAACTCAAGTT
TTAACACC

Sequence 1287

Sequence 1288

CCGGGCAGGTACAAGATAGTCATCTCAGTAAAAGGTCTATTATCTAACTTGCCAAACTTG

TABLE 1 212/467

Sequence 1289

AGGTACCAAATGAAGTGTGAAGACAAGGCCATCCACCACTTTATAGAGGTTGTAAAAATA AACCAGAAATCAAGGGAGAAAGAAAAAAAGATGAAAGACAAACTGCAAAAAAATTGCCAAAAATG CGACTTTCTAAAAATGGACAGATTCTGAGGCTTTGCATGTCTTGGCATTCCTTCAGGAGC TGAATGAAAAAATGCAACAAGCAGATGAAGACTCTGAGAGGGGTTTGGAGTCTGGAAGCC TCATCCCTTCAGCATCAAGCTGGAATGAGGAATGAAGAATAGAGATGTGGTGCCCACTAG GCTACTGCTGAAAGGGAGCTGAAATTCCTCCACCAAGTTGGTATTCAAAATATGTAATGA CTGGTATGGCAAAAGATTGGACTAAGACACTGGCCATACCACTGGACAGGGTTATGTTAA CACCTGAATTGCTGGGTCTTGAGAGAGACCCAAGGAGTTCTGGGAGAGAGGACCAGATTG Sequence 1291

Sequence 1292

TABLE 1 213/467

CCGGGCAGGTACCAAATGAAGTGTGAAGACAAGGCCATCCACCACTTTATAGAGGGTGTA
AAAATAAACCAGAAATCAAGGGAGAAAGAAAAAGATGAAAGACAAACTGCAAAAAATTGCC
AAAATGCGACTTTCTAAAAATGACAGATTCTGAGGCTTTGCATGTCTTGGCATTCCTTCA
GGAGCTGAATGAAAAAATGCAACAAGCAGATGAAGACTCTGAGAGGGGTTTGGAGTCTGG
AAGCCTCATCCCTTCAGCATCAAGCTGGAATGGGGAATGAAGAATAGAGATGTGGTGCCC
ACTAGGCTACTGCTGAAAGGGAGCTGAAATTCCTCCACCAAGTTGGTATTCAAAATATGT
AATGACTGGTATGGCAAAAGATTGGACTAAGACACTGGCCATACCACTGGACAGGGTTAT
GTTAACACCTGAATTGCTGGGTCTTGAGAGAGCCCAAGGAGTTCTGGGAGAGGGACCAGA
TTGGGGGGTAG

Sequence 1294

Sequence 1295

Sequence 1296

Sequence 1297

TABLE 1 214/467

TTCTGGGGAGAGGGACCAGATT

Sequence 1299

Sequence 1300

Sequence 1302

Sequence 1303

Sequence 1304

Sequence 1305

AGGTATTCGACCCACGCGCCCGTAGTTTTTATCTTTGACCAACCGAACATGACCAAAAAC

TABLE 1 215/467

Sequence 1307

ACTITITITITITAAGCTGCTCCTTGAGGATAAGGGCTAACTCACAGGCAGTGCA CCAAGAGCCACTATAAAAAGATCCTTAATGAGCAAAATATATCCCCTATTATTTTCCTAC AAGTTGCTTTTTACTTGAGTAGGAACCCTTGATTGATTTTTGCGGACGCGTGGGTCGAAG CTTGACCT

Sequence 1308

Sequence 1310

WO 01/070979

TABLE 1 216/467

CTGTCTATGCATAGAAAACTGCTTTATGCCTAAGATAATTACTGGGATTTAAGAAAGTGA GAAAAAAGAATAGGTGGGATTGAGAAATTAGGTAAAAACAGAAGAGGCCAACTAAACCCA AGTGCTGCCCTTCAAGGGCTCTAGTAACCGGACGCGTGGGTCGAAGCTTGACCT Sequence 1311

Sequence 1312

Sequence 1313

Sequence 1314

CTACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACTTAGATGACAACATC
AAAACATACTCTGATCACCCCGAGAAAGTAAACAAAGATGATGAGGAATTCATAGAAAGC
AATAAAATGCATGCTATTAATGGAAGAATGTTTGGAAACCTACAAGGCCTCACAATGCAC
GTGGGAGATGAAGTCAACTGGTATCTGATGGGAATGAGAATGAAATAGACTTACACACT
GTACCTGCCCGGGCGGCCGCCCGGGCAGGTCCGGGCAGGTGCTGTGAGTGCTCTGG
CGAAGTTTGGAGCCCAGAATGAAGAGATGTTACCCAGTATCTTGGTGTTGCTGAAGAGGT
GTGTGATGGATGACAATGAAGTAAGGGACCGAGCCACCTTCTACCTAAATGTCCTGG
AGCAGAAGCAGAAGGCCCTTAATGCAGGCTATATCCTAAATGGTCTGACTGTCCATCC
CTGGTCTGGAGAGGGCTCTGCAGCAAGTACCT

Sequence 1315

Sequence 1316

CTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTCTTCGACCCACGCGTCCGCGAAAAGATGAGGCAACAAGTAAGAGAAAACAGCATTGAGCTTAGAGAATTGGAGAAGAAAT

÷

TABLE 1 217/467

TAAAAGCAGCTTACATGAATAAAGAAAGGGCAGCTCAGATTGCTGAAAAGGATGCCATTA AATATGAACAAATGAAACGTGATGCTGAAATAGCCAAAACCATGATGGAAGAACACAAGA GAATAATAAAGGAAGAATGCTGCAGAAGACAAACGAAACAAAGCGAAAGCACAGTACC TGCCCG

Sequence 1317

CTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTACAGCGTGCATAG GGACTCTTGCCTTAAGGAGTGTAAACTTGATCTGCATTTGCTGATTTGTTTTTAAAAAAA TGGCAAAAAAAAAAAAAAAAAAGTGCGGCCGGCCCGGGCAGGTACACTTGTTGAT AAGAGTTTTCTGAAAACAGTCTATCAAATATAAAGAATGGTTTCTATCCAAGAATCAGCA GTGAGGGAAGAATACTAAACACCTGTCAAGAAATCAGTTATTCATTTTAAAAAAATAACA GTAACATTATATTCCCCACAGAGGCCTTCAATCCTACTTAAAGATA Sequence 1318

AGGTCAAGCTTCGACCCACGCGTCCGGTTACTAGAGCCCTTGAAGGGCAGCACTTGGGTT TAGTTGGCCTCTTCTGTTTTTACCTAATTTCTCAATCCCACCTATTCTTTTTTCTCACTT TCTTAAATCCCAGTAATTATCTTAGGCATAAAGCAGTTTTCTATGCATAGACAGTTCATT GCGGCCGCCCGTGATCTAGATCCCCGACCT

Sequence 1319

GCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTCAAGCTTCGACCCACGCGTCCGGTTT GGGTGGAATTATAATATTTTAGATAAGATTTAAGAGGGATTCTAATTCTAGCTACTTGATA ATTCTGTAATTGAAACAGAGTTTCAAGTCCTTTGGTCAAGTATTACCCTTATTCCTTCAG TGAAATTATTTAATTTGCATTTAACTGTGTTTTCACACCTGCCCGGGCGGCCCTCTTACC TGCTTCTGACCTTATGCTCAAGAACTCCCCTAACTCTGGCCAGAGCTCAGCTTTGGCAAC TCTGACCGTTGAGCAGCTCTCATCCCGGGTTTCCTTTACGT Sequence 1320

AAGCTGCTCCTTGAGGATAAGGGCTAACTCACAGGCAGTGCACCAAGAGCCACTATAAAA AGATCCTTAATGAGCAAAATATATCCCCTATTATTTTCCTACAAGTTGCTTTTTACTTGA GTAGGAACCCTTGATTGATTTTTGCGGACNCGTGGGTCGAANCTTGACCT Sequence 1321

GGGCGAATTGGAGCTCCCGCGGNGGCGGCCGAGGTCAAGCTTCGACCCACGCGTCCGGT TTACTCTCATCGCTTAGCGCCCCAGGTGGGATGTTTTCCAAAACACATTTTTGTATTTA TAAGGAAATGTAGTTAGGATTAATTTTATTGTCCTAATTAGAACTCACATTTTGGTTAAA ATTTAATTTTCTGCTTGCCCAAGAAACAAAGCTTNTGTGGAACCATGGAAGAAGATGAA AATGAGACTGGCAAAGAACAAATGCTGAATCTGAAGAAGATTTGGGCAAATAATCTGCAT ACTITTAATTGGGAATAAGATGGAAAATATGAATGCTAAATCAAATTTTTTA

Sequence 1322

CCGCGGTGGCGGCCGAGGTACAAGCTTCGACCCACGCGTCCGCTCACTTCATCCTCCCAG CAACCTATTATGATCCATTGCCACCACCTACTGCTGATGAGGAAAGTGGGGCTTAAGGAA ATTAAAGAGCTGTTGTGGGACTTCCAAAGCAGAAGACAGTAGGCTTTCAGAAATTTGATA AAAATAGCACTTTGCATTTCTTGAATCTTGAGCTAAATGGAAATTAATACTAAACATTCT CCACTGGTAAAATAGAGAATAAGGATATTAACAGTAAAAGAAAAGAAGAAGAAAAAGGAAA TGTGCTTCCACAGATTTAGAAACATAAGTAACAATCTAAGTTAAGGCTTTGGCACCTGCC **TGCAAACAACTTAAA**

WO 01/070979 PCT/US01/09126

WO 01/070979 PCT/US01/09126

WO 01/070979

TABLE 1 218/467

Sequence 1323

Sequence 1324

CTATAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTCACGCGTCCGCAGAGGCCC
AGGCTCCCAAACCGACAAGTGAAAAGAGACCAGAGAGGCCAAGCATATTGACTGGTGCT
GTTCAGGGCCTGCTCTTTTCCACTCACCACTTGTTTTGCTGCTTGTCACGAGGAGAGTTG
TTCCTGTATGTGGCTGCTCTCAGATCTTTCCAAGCAAGCCAGTCATTTGAAGAGGGTTTTC
TTTTCATGCTGGAGGGCAGGCTAAGATCAATGAGTGGAAGAGAGAAAGGCTGTTTTAGCT
CAAGTTAAAGGAACACCTTCTAGCCATCAAAGCCGCCCAACAGAGGCAAGGGCCACCACA
CATGAGAGAGCGCTCTNTCCTTAA

Sequence 1326

GCGAATTGGAGCTCNCCGCGGTGGCGGNCGCCCGGGCAGGTACCAAAATAATTACCAACA NTACATTATGTACACCATTTACAGGAGGGTAACACACACCTTGACAGGTAGTAACTTTTC ACCCCACATNACTGAACGCTTAACACTCCTGGCTGTTAATTGTCAGTTCAGTGTTTTAAT CTGACGCAGGCTTATGCGGAGGAGAATGTTTTCATGTTACTTATACTAACATTAGTTCTT CTATAGGGTGATAGCGGACGCGTGGGTCGAAGCTTGACCT Sequence 1327

TTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACATCTGTAGCCTATGACTTG
AGTCTCTTGAACTTCTAGGAAGAGGCAAACTACAAACTACTAGGATTCTGATTTCAGATA
TAGGCATTCCAGAATCTTCTCTTTACGAGTTCACCTGCTAGTATAATCTCCACAACTTGA
ATGGCCTTGGTTGTTCTGTAATTGCTGCCAAAATCATCACAAGCTGTACCTGCCCGGGCG
GCCGGCCGCCGGGCAGGTCAAGCTTCGACCCACGCGTCCGGATGGGAATTCAGGTATGA
AAGAAAACAGGCAAGGAGCACTGAGGGAGAAAGACACAGACTTTATCGCTCTGTGGCTC
ATTGTTACTGGAATATTCTAAAACTCTTGTTCACATGCTATTATGACTTATAAAGCAGCA
ACAGCTGAGGCGCACCAGGACACAGCTTCCATTTCTTTAACGT

Sequence 1328

TABLE 1 219/467

Sequence 1329

Sequence 1330

AGGTCAAGCTTCGACCCACGCGTCCGTGAACTTTTATCAAGGCTTTTGCTCTTTTAGACT
TGAGTTTATCTTTATAATTAAGGAGAATGGTTTTTAAAATTTAGTTCCTCTGACACCCCA
AAATTATCAAAATTATGTTGTAGTGAATCTGTTTTTGAAAGTCATTGATAGGACT
TATATGAGTCAAAATTTTATGGATTATAAACTAGGCTTTATCTGGTTGGAAATAATTGCA
ATACAAGAAGCAACTTTATTAAATTAGACCTAAAGTCACAATCTTCTTCTTTTGCTGCTTT
TTAAAAATTACCTATTACCTTTAAAAGATCCCAAATTTAGAAGAGGAATTAAAATAAAAG
TTAATGCAATAAAACACTTCCACAATATTCTATTACTTCAACCTCTAATCAATGAAA
Sequence 1331

ACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTTTCCTGCATTTC
TAATGAAGAAATAGGCTGGTCCTCAATTTTGCAGAAGTTGTATCATCATAGGTCATACCT
AACATTCGTTTGTCAAGAGCAAAAAAACCCCCTTGGGTTCTCTGGATCTCACACAGCCCA
CAAACCTTCAGAATGTGGTTCCTTCCCGCAGGCTTTGTCACACTTAAGATCCAAGAACAA
ATCAGCCTGGCTTTAACATGGGGTAGATGGCAAGAAGGATAATGCGGACGCGTGGGTCGA
AACTTGACCT

Sequence 1333

Sequence 1334

TABLE 1 220/467

TATATAAACTTCTGCTTTGGTCTAAAACTGATATCTTCACGTTGAGGTTTCATCTGAA ATGCNCCACCGTTTGCTGACTTGCTTCAATATGAATTTGGATGGCTATAAAATTGACCTC GGCCGCTCTAGAACTAGTGGGATCCCC

Sequence 1335

TACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCGGCCGCTCGAGGCCG ACTITITITAACCTTTCCTTATGAGCATGCCTGTGTTGGGTTGACAGTGAGGGTAATAAT GACTTGTTGGTTGATTGTAGATATTGGCGGACGCGTGGGTCGAATCTTGTACCTGCCCGG GCGGCCCATAGTTTGTCAACCACTGGTGTAAAACCTTAGTTATATATGATCTGCATTTTC TTGAACTGATCATTGAAAACTTATAAACCTAACAGAAAAGCCACATAATATTTAGTGTCA TTATGCAATAATCACATTGCCTTTGTGTTAATAGTCAAATACTTACCTTTGGAGAATACT TACCTTTGGAGGGAATGTATAAAATTTCTCAGGCAGAGTCCTGGATATAGGAAAAAGTAA TTTATGAAGTAAACTTCAGTTGCTTAATCAAACTAATGATAGTCTAACAACTGAGCAAGG ATCCTCATCTNGAGAAGTGCTTAAAAT

Sequence 1336

TATGTTTTTGCTGACTCCAAAGTAAGTGACAGCAAACTTCTAAAATGGGCTGTGAGGTAG GGAGGGGACACAAGCGTTTTGAGGCTCGCTGNGTGCCAGGGAGTGTATCATTAGCTCACT CAATTCCCAGAACAACCCATTTCACACCTGGGAAAGGTGAACTTAGAGAAGTTGAGGATC ATGTTCCAGGTTGGCCTGGATTTGAGCCATCACTGTCTCAGGAGTAGGGAGGCTTCCCAC TTTGCCCAGCTGCCTCCCAGCCTCGAGGCCACATCCTTTATGACCCACATCTAACTCAGC CCCACACCTGGGGGAAAGGCTTTCAGCTTCTCTGGGCTGGACTTGGGAAATCTTTGGGAC ACTCCTGACCTGCCCGGGCGGC

Sequence 1337

CCGCGGTGCCGCCCGGGCAGGTGTCCCCATGAGGCCAGGCCAGGCAGAACCCAT CCCATTTTATCCTTAAACTCAGAAGGAAATNNGTCTAAATATTAAAGGATTAATATGGGA ATAAAAAATGAACCTTAAACCCTGCCACTGATACACAAGCTGTCTCTTTAGAGTTCAAT GAACACTTCAGGAGAGTATTTCCAACAATATTTAGATATTGGAATATCTAAATATTGTTG ATTTAGATAACCACCCTAGATTTCTCACCACCCTAGAACATTTAGNGGGGAGACATTCTT TTCTCCTTTTTCTGATAACTTGGTCAGAAGTGATTGACTGTGCAAATGGTATTTCTCAGC TAAAATCTCCCTTATGAACCCTTCCTCGAAATCCCAAGGT

Sequence 1338

TAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTGCTTCGACCCACGCGTCCGCTT GGGGATTTCGAGGAAGGGTTCATAAGGGAGATTTTAGCTGAGAAATACCATTTGCACAGT CAATCACTTCTGACCAAGTTATCAGAAAAAGGAGAAAAGAATGTCTCCCCACTAAATGTT CTAGGGTGGTGAGAAATCTAGGGTGGTTATCTAAATCAACAATATTTAGATATTCCAATA TCTAAATATTGTTGGAAATACTCTCCTGAAGTGTTCATTGAACTCTAAGAGAGACAGCTT GTGTATCAGTGGCAGGGTTTAAGGTTCATTTTTTATTCCCATATTAATCCTTTAATATTT AGACAAATTTCCTTCTGAGTTTAAGGATAAAATGGGATGGGTTCTGCCTGGGCCTGGCCC Sequence 1339

CTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGATTCTCTGATTAGATTTTAAACTT TTTTGATGAAATATTGAGTCTTAACTACTTTAAGATGCCATAATACTGAATACAGNGCTA AGCAAAATAAATATTGACTAGTTCTCATTTCTATCTTTCAAATATTTCTAATGCTCCTCT TTTATAGCATGGCCTCAGGTATCAGATGGCGTAGGTCAAGATCTTGGCTCTACTGTTTAC TTACGGGAAATACTTTTATGTTGCTAAATCTCAGTTTTCTCTTCTGTAAGACGGGATTAA **AGTACCT**

Sequence 1340

TAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTCTACTCAAGTAGTCT TTACCCCCTACTCAAGTAGGGGGTAAAGTGTAGAACAAGGAGTTTGATNTGTGTTNGCTG

TABLE 1 221/467

AAAAGCCAAGAGTGAAGCAGGGTTGTTTTTCATCCAATTCTTGGTCTTTTTGTTAAAGGC AGCAATAAGATAGGGTGGTTTCGGGCAATCACTTAGCTAATTGGCTCTCTATAGTCATAC CTGGATAATATTTGTAGTCATACCTGGGATAATATTTAAAGGGAAGAAACTAAACATAGT CCTTAAGTAGGAACCAACTACAAT

Sequence 1341

CCGCGGTGGCGGCCGAGGTCCTAGCTTGAGTCGACCCACGCGTCCGGCCGCTGTTCGTAT
TTCTTATTCTACAACAAGGGNGCAGCCTANAGGCAAAACACATCCCATTGTCATTTTTT
GTAAATAAAGTTGTATTGGAACATGGCCACTCTCATTTGTTTTCTATTATTATGGCTGC
TTTCACTTACAACCTGAGTGGTTGCCACAGAAACTGTATGGCCTGCAAAGTCTAAAATAT
TTACTATGTAGCTTTTTCTTTTTTGGAGACAGTGTGCCACTCTATTGCCCAGGCTG
GAGTGCGGTGGTGTACATGGCTCATTGCAGCCTCAAACTCCTGGGCTCAAGCAATCCT
CCCGCCTCGGTCTCCCAAGTAGTTGGGACTACAGGCATGAGCCACCATACCCGGCTAATT
TTTTTAAAGTTTTTGGTAGAAATGGAGTTTTTTAATGTTGCCCAGGCTGGTCTTGAACTC
CCTGGTCTTAAATGACCCTTTTCCCATCAG

Sequence 1342

Sequence 1344

CCGCGGTGGCGCCCCGGGCAGGTACCAAGTTTGAGTTGAAACGGTATGTGACTTCCC CAGCTGCACCCTGGGCAGTGACTGCATCACTGAGAGGTCCTGTCTACAGCAGATAA AACTCCACAGATCACTCCTCTGTAATCCCTCTAAGTGCTCCAAGGCAGCAGAAAGGCCC AGTGCATTGAGGCTGGAAGCAGGAGCAGAGACTCTGGGATATAGTGCGAAAGTCTCTTTC CCCTGTAGTTGGGCTAATCTGGAAAAACTCAAAAACCTGGCCTGATTACCGAGGTTTCTT TTATGGATATTTAGATATAAAAATTTTTACAGTATTCTTGAAATGAACCCAATTAA ACACATAGTTCTCAGTCTTGACCACACACTTAAGAATCATCTGGTAGACTTCTGTAAACTA CCAATGCCTGGCCA

WO 01/070979 PCT/US01/09126

TABLE 1 222/467

Sequence 1346

Sequence 1347

Sequence 1348

Sequence 1349

Sequence 1350

Sequence 1351

Sequence 1352

TABLE 1 223/467

Sequence 1353

TATAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGATTCTCTGATTAGATTTTAAACTT
TTTTGATGAAATATTGAGTCTTAACTACTTTAAGATGCCATAATACTGAATACAGTGCTA
AGCAAAATAAATATTGACTAGTTCTCATTTCTATCTTTCAAATATTTCTAATGCTCCTCT
TTAAGCATGGGCTCAGGTATCAGATGGCGTAGGTCAAGATCTTGGCTCTACTGTTTACTT
ACGGGAAATACTTTTATGTTGCTAAATCTCAGTTTTCTCTTCTGTAAGACGGGATTAAAG
TACCT

Sequence 1355

Sequence 1356

TABLE 1 224/467

Sequence 1358

Sequence 1359

CCGCGGTGGCGACGTCAAGTTTCGACCCACGCGTCCGCATTATCCTTCTTGCCATC
TACCCCATGTTAAAGCCAGGCTGATTTGTTCTTGGATCTTAAGTGTGACAAAGCCTGCGG
GAAGGAACCACATTCTGAAGGTTTGTGGGCTGTGTGAGATCCAGAGAACCCAAGGGGGTT
TTTTTGCTCTTGACAAACGAATGTTAGGTATGACCTATGATGATACAACTTCTGCAAAAT
TGAGGACCAGCCTATTTCTTCATTAGAAATGCAGGAAACCTGCCCG

Sequence 1361

CCGGGCAGGTCTACTCAAGTAGTCTTTACCCCCTACTCAAGTAGGGGGTAAAGTGTAGAA CAAGGAGTTTGATCTGTGTTCAACTGATTGTGAACCATCAATTGAGATAACTCACTACCT TCAGGCCAGCCAGTTACATACTTTTGAAAAGCCAAGAGTGAAGCAGGGTTGTTTTTCATC CAATTCTTGGTCTTTTTGTTAAAGGCAGCAATAAGATAGGTGGTTTCGGGCAATCACTT AGCTAATTGGCTCTCTATAGTCATACCTGGATAATATTTGTAGTCATACCTGGATAATATTTAAAGGAAGAAACTAAACATAGTCCTTAAGTAGGAACAACTACAATTTTAAC Sequence 1362

Sequence 1363

Sequence 1364

CCGGGCAGGTCAGGAGTGTCCCAAAGATTTCCCAAGTCCAGCCCAGAGAAGCTGAAAGCC TTTCCCCCAGGTGTGGGCTGAGTTAGATGTGGGTCATAAAGGATGTGGCCTCGAGGCTG GGAGGCAGCTGGGCAAAGTGGGAAGCCTCCCTACTCCTGAGACAGTGATGGCTCAAATCC AGGCCAACCTGGAACATGATCCTCAACTTCTCTAAGTTCACCTTTCCCAGGTGTGAAATG

TABLE 1 225/467

Sequence 1365

CTNCTATAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTCTTGAGTCG ACCCACGCGTCCGGAGCTGCTCAATAGTGAGAATCAGGTGATATAATGCATGTGGAAAAA GAATGTGAAAAATCTAACACTTTAGATTGTATACAGTGTTTTTTTAAAAAGACACAAAAAA ACTGTCAACATGAGAAACATAAGCAAAGTTTTACTCAAGACAAACATCCACGAGTCACAA CTTCAGTTATTCCCAGTCTTCAAAATAACAGAAGGGCAAAGCAAAGGTAAACATGCAAA Sequence 1367

GACTNCTATAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGATTCTCTGATTAGATTTT
AAACTTTTTTGATGAAATATTGAGTCTTAACTACTTTAAGATGCCATAATACTGAATACA
GTGCTAAGCAAAATAAATATTGACTAGTTCTCATTTCTATCTTTCAAATATTTCTAATGC
TCCTCTTTTATAGCATGGGCTCAGGCATCAGATGGCGTAAGATCTTGGCTCTACT
GTTTACTTACGGGAAATACTTTTATGTTGCTAAATCTCAGTTTTCTCTTCTGTAAGACGG
GATTAAAGTACCT

Sequence 1368

CCGCGGTGGCGGCCGTTAAAGGAATAATCTGCAGAACATCTTGATTTACAAGGGACAAAA TGATGCAAATTATATGCTGTCCAACCTACTGGTGAACTGGATCAGAATGGTCCAAGGACT GTTAAACAGAGGAAGTTTACATTCTGAAAACTTGCGGACGCGTGGGTCGAAGCTTGTA CACCTCGGCCGAGGTACCTTCTGTCACAAAGACCCAAGCTTCCTCCAGCTTCCAGGATAG CAGTCAGCCAGCTGGAAAAGCCGAAGGGATCAGGGAGCCAAAGGTGACTGGGAAGCTAAA GCAACAATCACCTAAATTACAGTCCTCCAAGAAAGTTGCTTTCCTCAGGCAGAATGCCCC TCCCAAGGGCACACACACAACACCGGCTGTGTTATNCCCATCCAAGACTCAGGCCAC CCTGAAACCTAAGGACCATCATCAGCCCCTTTGGAAACCTAAGGACCATCATCAGCCCCTTTGGAAACCTCAGGACCC

Sequence 1369

CCGGGCAGGTCGAGCGCCCCCGGGCAGGTTTCCTGCATTTCTAATGAAGAAATAGGCT GGTCCTCAATTTTGCAGAAGTTGTATCATCATAGGTCATACCTAACATTCGTTTGTCAAG AGCAAAAAAACCCCCTTGGGTTCTCTGGATCTCACACAGCCCACAAACCTTCAGAATGTG GTTCCTTCCCGCAGGCTTTGTCACACTTAAGATCCAAGAACAATCAGCCTGGCTTTAAC ATGGGGTAGATGGCAAGAAGGATAATGCGGACGCGTGGGTCGAAACTTGACCTN Sequence 1370

CCGCGGTGGCGCCCCGGGCAGGTGTCGACCCACGCGTCCGACGACTCACTATAGGGA TCTAGATCACGAGCGGCCGGCCCGGGCAGGTACAGAGATTTAAATGAAATCTTCGAA AGAATAAATTTGCTTTTCAGTCCACTGTATTTTCAAAATTT Sequence 1371

TABLE 1 226/467

Sequence 1372

Sequence 1373

CCGCGGTGGCGCCCCGGGCAGGTTATAGACAATATGCTCCTTAAGGTCCCTTTCAGT CCCGTTCTATGGATCTGTGTAGTTTCGCTTCTTTTTTCAATATGCTCAGAATTAGGACAC CAATGTTAATGGAAGATAAGGAAACTATACCACCTATCCCTTATAGAAGATTTGTGCACT AACTAATATGAGCCCTGGAAGATCAAGCCAGTAGAAGATGAAGATCTATCCCTGCTTTA TACTTTGGATCATTTATTTGTGAAGATCACAACTTTCAAAGTTTTATTATTTCTTAGGTC TTCATGGAAGTTCGGGGAAATTAACTGGATCTACTTCTAGTCTAAATAAGCTCAGTGTTC AGAGTTCAGGGAATCGCAGATCTCAGTCATCTTCCCTGTTGGATATGG Sequence 1374

Sequence 1375

TACGACTNCTATAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTCAAGCTTCGAC CCACGCGTCCGGCCACATTTTCAATTTAGCCATTTTTCTCTTATTCACCTTTTTCTGCTA ATTACTCTGTAATTCCACTAAGAAAAGTCAATAGATAATTCCAATAATGACTTCACTCCT GAGAATTTTATTAGCTGCTAACGCTTGTCTCATCATAAGCACTCATATGTTCATTGAGTA AATATTTATTGAGTATTTGCTATGGTCCAGGCACTGTGCTAAGTATTGAGGATAAAATGG TGATTGAAACATTTTCCCTTCTTGATTTTAACATCTACAAAATAAAA

Sequence 1377

WO 01/070979

TABLE 1 227/467

Sequence 1378

Sequence 1381

Sequence 1382

Sequence 1383

Sequence 1384

TABLE 1 228/467

Sequence 1385

Sequence 1386

CTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTCAAGCTTCGACCCACGCGTCCGAGAAGAGTTTGCAAATGCAACAAAATATTTAATTACCGGTTGTTAAAAACTGGTTTAGCACAATTTATATTTTCCCTCTCTTGCCTTTCTTAATTTGCAATAAAAGGTATTGAGCCATTTTTTAAATGACATTTTTGA

Sequence 1387

Sequence 1388

Sequence 1391

Sequence 1392

TABLE 1 229/467

Sequence 1394

ACTTAGGGCGATTGGAGCTCCCGCGGNGGCGCCGNGGTACAAATAAGCCCACCCACT AGGAACTATGTTAAAAAAAAATTCAAGAAAGAATTTAAGGGAGATTACAGTGTTACTGTG ACACCAGGAAAACTTAGAACTTTGTGTGAAATAGACTGGCCAGCATTAGAGGTGGGTTGG CCATCAGAAGGAAGCCTGNACAGGTCCCTTGTTTCAAAGGTATGACACANGGTAACCCGT ANGCCAAGGCACCCAGACCAGTTTCCATACATAGAAAGNTACAGCTGCTTTTATACCCCC TTGCCCCGCCAACGTAGTTAAGAGAACAGCAGCATAAGCGGCTGGCAGAGGCAAGGAAAG ACCAGTNGAGAAAAAAAAAAAAGGCCATCTATACCAATTCTAAGTTAATTTAGACTAAACA A

Sequence 1395

CCGGGCAGGTACAAAAGGGTTCCTCTATATGCCAACTAATTCCAAATTTTTACTTTTACT GCAAAAAAACCTTTTTGGCATCAAAACTCCATTGTTTCTCTGCACTCTGACACCATCATT TCAAAGGGGCTCACATAAATGATCACTACTGCTCTCTCCCTAATTTTTGAAAAAGGAGTT TTGAGAATAAAACAGTGCTTTTATTATTAGCCAACACAAAGTGTGAGAAAATCATTCCTG AGAATTAACATTTTAAGCTAACAGAAATTCAGTATACTTAAAACATAATTATATTTAATG AGTCATTATTTGGATCTAAAACGGACGCGTGGGTCGAAGACCTCGGCCGCTCTAGAA

CCGGGCAGGTACCAGTTTGAGTTGAAACGGTATGTGACTTCCCCAGCTGCGCCCTGGGCA GTGACTGCATCACTGAGAGGTCCTGTCTACAGCAGATAAAACTCCACAGATCACTC CTCCTGTAATCCCTCTAAGTGCTCCAAGGCAGCAGAAAGGCCCAGTGCATTGAGGCTGGA AGCAGGAGCAGAGACTCTGGGATATGTGCGAAAGTCTCTTTCCCCTGTAGTTGGGCTAA TCTGGAAAAACTCAAAAACCTGGCCTGATTACCGAGGTTTCTTTTATGGATATTTAGTAT TTAGATAAAATTTTTACAGTATTCTTGAAATGAACCCAATTAAACACATAGT Sequence 1397

AGGTACTTTAATCCCGTCTTACAGAAGAGAAAACTGAGATTTAGCAACATAAAAGTATTT CCCGTAAGTAAACAGTAGAGCCAAGATCTTGACCTACGCCATCTGATACCTGAGCCCATG CTATAAAAGAGGAGCATTAGAAATATTTGAAAGATAGAAATGAGAACTAGTCAATATTTA TTTTGCTTAGCACTGTATTCAGTATTATGGCATCTTAAAGTAGTTAAGACTCAATATTTC ATCAAAAAAGTTTAAAATCTAATCAGAGAAT

Sequence 1398

TABLE 1 230/467

TTTACCATCTTCATANTTTTTCTTTCCCTTCCCTTCAAAAAAACTNAANTTTTTC
NAAGGTGGAAGAANTTTTAATTNAANTGGAAAGGGANGCTTCCCTTCTTCCCCAGTTCC
CTTCTTAGCCNATGGGAGGGGAAACCGGG

Sequence 1400

Sequence 1401

CCGGGCAGGTACCAGTTTGAGTTGAAACGGTATGTGACTTCCCCAGCTGCACCCTGGGCA GNGACTGCATCACTGAGAGGTCCTGTCTACAGCAGATAAAACTCCACAGATCACTC CTCCTGTAATCCCTCTAAGTGCTCCAAGGCAGCAGAAAGGCCCAGTGCATTGAGGCTGGA AGCAGGAGCAGAGACTCTGGGATATAGNGCGAAAGTCTCTTTCCCCTGTAGTTGGGCTAA TCTGGAAAAACTCAAAAACCTGGCCTGATTACCGAGGTTTCTTTTATGGATATTTAGTAT TTAGATAAAATNTTTACAGTATTCTTGAAATA

Sequence 1402

Sequence 1403

Sequence 1404

AGGTGTTACCACTTCATTACTGGAGGGCACTGTCACAAACTTCTGACTATCCAGAC
TTGAAGCTGGAAGCAAATACAAGTCTGAGGGGCTCTAAGCTGGGAGGTTCTGGCCTCTCC
CTAGCTCTCATGGCTCTACCTCTCTGCTTGAAGCTCCCTGCACTGCACTCCCATTACTC
TGACTGGGGATAGGACCACTGCTGACAGGGCCCCACCTTCAACTTCTTTCATTGCTCCTC
TTTTCAGGAAATCCCCACCCTGGGGATACTTCAAAAGACCT

Sequence 1405

AGGTGATTCAGCAGGTCTGGGGTGGGACTGAGAGCTTGCATCTCTAACAAGCTCCCAGCG AGGCTGATCCTGTTGCTCCAGGGACCACCCTTGAGAACCACTGGTTGGGCATTGATGAG GTCAACCAGGAGAAGCAGTGTCCCCTAGAACTGGCAGGAGAAAAGGACAAGGCTAAGAA ACAGTGAACAGGAGTCAAGTAAATGCAGCTGCCAACAGGCGGGGGTCCTTGAGTTCACAT TCTTGGTTCCAGGTGACGTTTCCTGGGAGTCAACACCCTTCTCCTATGAAAAAGAAAAG GGCCAGACACAGTGGCACACGGCTGTAACC

Sequence 1406

TABLE 1 231/467

AGGTACTCAATCTAATCCAAAATTTTCTTTCTTAGCAATCTATTTTCTGTATTTAGAAAA
ATGTTTTTATTTCAAAGAGCCTCTCAAAGAGCATTTCACGTATCTTTTACTGTTTTTCT
CTCCACCTCCAAGGGGTCTGTCTAGATCAGTGCGGACGCGTGGGTCGAAGACCTGCCCGG
GCGGCCGGCCGGCCGGGCAGGTACTGAGGACAAATCAGTTCTCTGTGACCAGACATGAGA
AGGTTGCCAATGGGCTGTTGGGCGACCAAGGCCTTCCCGGAGTCTTCGTCCTCTATGAGC
TCTCGCCCATGATGGTGAAGCTGACGGAGAAGCACAGGTCCTTCACCCACTT
Sequence 1408

AGGTACATATCACACATTTCCAAATTTGAGACCACTAATGTTTTTTAATTTCAAATATGT
ATATAAATATGTATTCTTATTTCCAATTATTTCCTTGGCATGAATTCCTAGAAATTGATC
TATTTAGTATAAGTGCTTTTTTAGCTATATGTCCACTAGTATGGTATGAGAATGCCCTGT
TTATGCCAGTATTATCATCATTGAATATATTACTGCTGATGTTGTGGTAATACATTTAAA
CCAATGTGATGGGGCAAAAAAATTATATTTTTTACTTACATCTTTAAAATTACTGGNGATC
TCTGNTATTGACAAGCTGGGCATANAAAAAGTAAATTAATAGAATT
Sequence 1409

AGGTCTTCGACCCACGCGTCCGTTTTAGATCCAAATAATGACTCATTAAATATAATTATG
TTTTAAGTATACTGAATTTCTGTTAGCTTAAAATGTTAATTCTCAGGAATGATTTCTCA
CACTTTGTGTTGGCTAATAATAAAAGCACTGTTTTATTCTCAAAACTCCTTTTTCAAAAA
TTAGGGAGAGCAGTAGTGATCATTTTATGTGAGCCCCTTTGAAATGATGGTGTCAGAG
NGCAGAGAANCAATGGGAGTTTTGATGCCAAAAAGGTTTTTTTTGCAGTNAAAGTAAAAA
TTTGGAATTAGTTGGCATTATAGAGGAACCCTTTTTTTGTACCTGGCCCGGGCGCC
Sequence 1411

AGGTGATTCAGCAGGTCTGGGGTGGGACTGAGAGCTTGCATCTCTAACAAGCTCCCAGCG AGGCTGATCCTGTTGCTCCAGGGACCACACCTTGAGAACCACTGGTTGGGCATTGATGAG GTCAACCAGGAGAAGCAGTGTCCCCTAGAACTGGCAGGAGAAAGGACAAGGCTAAGAA ACAGTGAACAGGAGTCAAGTAAATGCAGCTGCCAACAGGCGGGGGTCCTTGAGTTCACAT TCTTGGTTCCAGGTGACGTTTCCTGGGAGTCAACAACCCTTCTCCTATGAAAAAGAAA

NCNGNCCAGGTCTACTCAAGTAGTCTTTACCCCCTACTCAAGTAGGGGGTAAAGNGTAGA ACANGGAGTTTTGATCTGTGTTCAACATGATTGCGAACCATCAATTGAGATAACTCACTA CCTTCAGGCCAGCCAGNTACATACTTTTGAAAAGCCAAGAGTGAAGCANGGTTGATNTTC ATCCAATTCTTGNNCTTTTTGTTAAAGGCANNAATAAGANAGGGTGGNTNCGGGCAATCA CTTAGCTAA

TABLE 1 232/467

Sequence 1415

Sequence 1417

TTAGGGCGAATTGGAGCTCCCCGCGGTGGCCGGNCCGAGGNNCAAAAGAGAGACAAAAGGGTTCTCTTGGAAACAAGAGAGACTCCCAGATGTGGCCTGAATAATTGCCATGTTAAGT TAATGCAAAAGATCAGAACAGGGCTACATTTGCACAGGCAGTTTCTCTCCCGGCCGTAGT TTTCACTGATGATCACCTTTCACAGCATTTTCCCCAACCAGCATTTCACTTAGTCTTCTC TATACCCAGCACCTCCCCCGGCACCCCCGGCAAGCCCACTATCACTTCCGACTTCCAACG TGGCATCCGTGAGATCTGTCCACATTAGGCGAAGCAGGAGAACACTGAGAGCAGGAT GGGTTTGGAAAGAGCATGCCTCTGGAAACACAGCTTCCTGGGAATTCACATGAGGCCAGT CCTACAGAGAGCAAGATGCCCCCAGGATTTCTTCATTTTCTAATAGATGTGGGAGTGCT CCATTTTCCCCGACAGCGAATTTCCCCTGAGAAACGATACTAGACCCTGGGTTTGCCCAC CTTGTAACTCTTCCTTATCTNCTCCTTTTCATCCCTAATTCA

Sequence 1419

TABLE 1 233/467

TGTCTCCAGCTGTGAGACCGCTTCATTGACACCACTCTTGCCATCACCAGTCGGTTTGCCCAGATTGTACCTGCCCGGCCGCTCTAGAACTA

Sequence 1421

Sequence 1422

CGGGCAGGTACGATGGGAGGACAGCTTTGTAGAAAGGACATTATCCAGCTAATAGCAAAC
TTTGTGGATCCCAATCCGAGATTTCCCTTGCTGAAAGACAAGAAAGTATCTCATATAAAA
GTGCTGTAGCAAGTATTTGTATACTCCAGAAATAAGCTTCTGTAATTCTTAGCTGCCAAT
GTGTTCAGGCGTGATGACTCGGTTTCTGTTTCTCTGAACATCAATACTAGGGTCTGTATA
ATTTCAATGCATGCCACCAGCTTCATCAACCCTT

Sequence 1423

AGGTACAATCAGAATGCTGCATTCTCCAGCCATAAAGATCGCTCCCTCTTCTTTTCAAAC
ATCCCTGTCCCTCAAGGTCTAGCTCAAGACGGTCACCTTAAGAAAAGCTCCCTTTGTCGA
GCAGTGACTCCATACCAGGCCCTGCTTTAAACGCTTTATCTGCATTATCTTACTTGATTC
TCGCAATAGCCCTGGGTGGTAGGTGCAATTATTATCTCCAGTTTATAAAAGAAGATACTG.
AGGGTCAGAGAAGTTAAGTGACCGGCTCAAGGTGTCACATTCAGTAAGCGTTGAAGGGGC
CTGTGTTGGTCTTCCTTGAAGATGCCCCCCTACCGACTACACTTTCAATGATTTTCTGCC
TTGAACCTGGCCCCATGACTAAA

Sequence 1424

NNCAAACCTCCTATGCTTTCCTTGGCATCGGCTACACATCATAGTATTCATTGCCTCCTT GAGGTCATCTTGCAGCTTGGACAGAAACTCATTTACTGACCGGCTCAGCTCATTCTCTGC CATTCGTTTCATCTCATACTCCTTTCGCTTTTCAGCATTGCTGACAATGTCCCAAGCTGC TCGCAAAACCTTGAAGGCCTCCTCAGCCCGGGGATGATGATTTTTGTCAGGATGAACCAT CACTGCCAGCTGTCTATAG

Sequence 1425

Sequence 1426

CTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACTTGGGCCAAGGCTGCAAT CAGTGATTCAGCCGACTGCTCTTTGAGTCCAGATGTTGATCCAGTTCTTGCTTTTCAACG AGAAGGATTTGGACGTCAGAGTATGTCAGAAAAACGCACAAAGCAATTTCAGATGCCAG TCAATTGGATTTCGTTAAAACACGAAAATCAAAAAGCATGGATTTAGGTATAGCTGACGA GACTAAACTCAATACAGTGGATGACCAGAAAGCAGGTTCTCCCAGCAGAGATGTGGGTCC TTCCCTGGGTCTGAAGAAGTCAAGCTCGTTGGAGAGTCTGCAGACCGCAGTTGCCGAGGT GACTTTGAATGGGGATATTCCTTTCCATCGTCCA

Sequence 1427

AATTGGAGCTCNCCGCGGTGGCGGCCGAGGTACATCACCCTGCTGAGGGACATCCAGGAC

TABLE 1 234/467

AAGGTCACCACACTCTACAAAGGCAGTCAACTACATGACACATTCCGCTTCTGCCTGGTC
ACCAACTTGACGATGGACTCCGTGTTGGTCACTGTCAAGGCATTGTTCTCCTCCAATTTG
GACCCCAGCCTGGTGGAGCAAGTCTTTCTAGATAAGACCCTGAATGCCTCATTCCATTGG
CTGGGCTCCACCTACCAGTTGGTGGACATCCATGTGACAGAAATGGAGTCATCAGTTTAT
CAACCAACAAGCAGCTCCAGCACCCAGCACTTCTACCTGAATTTCACCATCACCAACCTA
CCATATTCCCAGGACAAAGCCCAGCCAGGCACCACCAATTACCAGAGGAACAAAAGGAAT
ATTGAGGATGCGCTCAACCAACTCTTCCGAAACAGCAGCATCAAGAGTTATTTTTCTGAC
TGTCAAGTTTCAACATTCAGGGTCTGTCCCCAACAGGCACCAC
Sequence 1428

Sequence 1429

NCNGNCCAGGTACTCNNNNACANTGNAAACTNNTCANGNGCCCATCATTGCTGGATTTGT
ATTTAACATTATGTTTCACCCAGACAACAGCTCAGAGAACTGGGCAATGGCTGCTNATGT
GTTGAGCCGGGGCATACAGGATGAAGAGGGGACAATGAGAGGGAATCTATTCTANA
CACCCTGAGTTTGAGGAACCTATGGAAATGTCCAGGAGGCAACTAAATGAAACAGCCTGT
GGTAGACAGAATAATGGCCCCAAAGATGTCTACAGCCTAATCCCAGGAGCCTGTGAAAAT
GTTCCCTTCGCATGGTAAAGGGATGTGGCAGATATGATTAAGCTAAGGATCTTGAGATGG
AGAGTTTATCCAGGATTATCCAGGTGTGCCCAGTATAAT

Sequence 1430

AGGTACGCGGGACACAGGGTCCTGTGCAACANGGNGGACTAACAGTAACACCGCCACGCCGCCACGCCGCCACACAAGCTCATTTTGGTCCCCGCCCCGTTCCTCTTTTTTAACTCCTTCCCTCTTTTGCGGATTCTAGAACGGAACCTTTTTTTAATTCTTCCCAGTAGAAACGTAGGAACAATTTCGTGAACGCAATCNGGAGTGCCCAACATGGC

Sequence 1431

Sequence 1432

TABLE 1 235/467

GNAATGGTTTTNTGGNNAAAAAGCCCATGGAAATACTGAGCCCATGCCNCTCACGTTGNA AAAGCCCCGTTCCTTGCC

Sequence 1434

Sequence 1437

CTACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTACTGCCAGGC
ATGCTCCTCCCTTGGGCAGAGTGTATATGTGTGAGTGCACCTGCCCTTCCCACAGCCTAG
AACGTTCCTCCCAGACAGCACATATGGCCTGCTCTCTCACTTCCTTAAGGTCTTTATT
CAAAAGTGACTTTCTCAGTGAAGCCCTGTCTGCTCACCCTGCGTAAAATTTCAGCTCTTC
TTTCTATCTCTCTTCCCAGATTTTTTTTCTCCTTCATGTTCGTTGGTGTCTAAGGTTTAT
CATCTATTTCGCTAATGGTCAGTAGAATGTAACCTCCACGTAAGCAAGGAGTTTTGTCTG
TTTTGTTCATGTCTATGTCCTTAGTGCCTGGAGCATTCCCTAGTATGCAGTAGGTGCTCA
ATAAATGTCAGTTGGATTAATGGCTGAAAGAAAGGTCACCGCTATAAGGATGGAGTCAGA
GAACAAACACAGTTAATTCCTGGTCCACTGTTTTTGCTTCCACTAAATTGTATTTGGTCT
ACGGCTTCTCCGCTTGCCCTGGAACCCTGCTCAGAACACTGCTCCCTTCTCTTCTT

TABLE 1 236/467

CTCCCTCCGGATAAATTCT

Sequence 1439

Sequence 1440

Sequence 1441

Sequence 1442

CTATAGGGCGAATTGGAGCTCCCGGGGTGGCGGCCGCCCGGGCAGGTACAAAGACCAAT
TCCTTCCTAACCTGGATTCCACTGTCCTTGGTGAAAACTACTTTGATGGAACCTACCAGA
TGCTTTATCTTTTGGTTAAAGGAACTATACCTGTNGAAATTCACACTGCCACAGNGATAT
TTGTTTCCAATTATNTGTTGCAACANAAGATGACTTTTATACCTCTCACAATCTGG
NTAAAAATCTTGCCTTGTTCCTAAAGATACCAAGTGACAAAATCCGTATCAGCAAAATAA
GAGGGAAGAGTCTGAGGAGGAAGAGTCCATGGGATTCATAATTGAAATAGAGATTGGAG
ACCCTCCTATTCAGTTCATAAGCAATGGCACCACAGGTCAGATGCAGTTATCTGAACTCC
AGGAANTTGCTGGTTCTCTTGGACAAGCTGTNATTTTAGGAAA

TABLE 1 237/467

Sequence 1445

AGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACGCGGGGAGAGTCACTCCTGCC TTCACCATGAAGTCCAGCGGCCTCTTCCCCTTCCTGGTGCTGCCTTGCCCTGGGAACTCTG GCACCTTGGGCTGTGGAAGGCTCTGGAAAGTGTAAGTTGGAGTCACTCTGGTCTAATCTG GGCTGCAGGGTCAGAGGTGGGGTCTCCTTGTGGGTGTGGGTGTGCCCCTTCTGTAGGCTC TCCAAGGTTTGTGTGGCAGTTTGAGCTTCTGGAAATGCTTCCTCTATGCAGCCATGCTGT

Sequence 1446

GGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTACTCTTAATCCAAGACAA AAGAATAGCTCCTTTCAGAGTTCTCATCATTTCTTCACCCCAGCCTTAATGGGTATATTC CTTTTCCCCAGGTGTCCAGAGTTTTCCAGAATTGTCCCAAGGCTCAGTCCACACCAGTTC TTCTCCAGTGTGCTCTCCTGAGAGGCCAGGCACACTCAACAATTATCTAGATGAGTTCCC ACTTCTTTCCAAGTGAAGGTTCTGCTATCCTAGCATAGTCAGAATAAGTTAAATTATGTC TCTTAAGAGGCACTGTTCCACTCCTTTTCAAGGNGTGTGGCATATTTGAAATATGTGACT TAAAAGTCTACAGTCTCTTACCAAAAGCCTTGGGCCAAATACATGTCAAAATTCAGAATT TTNCAGATTTTAGAAAAGTGACCCATATACCATACATTGCA

Sequence 1447

ATAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACATCACCCTGCTGAGGGACA TCCAGGACAAGGTCACCACACTCTACAAAGGCAGTCAACTACATGACACATTCCGCTTCT GCCTGGTCACCAACTTGACGATGGACTCCGTGTTGGTCACTGTCAAGGCATTGTTCTCCT CCAATTTGGACCCCAGCCTGGTGGAGCAAGTCTTTCTAGATAAGACCCTGAATGCCTCAT TCCATTGGCTGGGCTCCACCTACCAGTTGGTGGACATCCATGTGACAGAAATGGAGTCAT CAGTTTATCAACCAACAAGCAGCTCCAGCACCCAGCACTTCTACCTGAATTTCACCATCA CCAACCTACCATATTCCCAGGACAAAGCCCAGCCAGGCACCACCAATTACCAGAGGAACA AAAGGAATATTGAGGATGCGCTCAACCAACTCTTCCGAAACAGCAGCATCAAGAGTTATT **TTTCTGAC**

Sequence 1448

TAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACAAATTGTCGTTTTTATTCCT CTTATTGGGATATCATTTTAAAAACTTTATTGGGTTTTTATTGTTGTTGTTTGATCCCTA ACCCTACAAAGAGCCTTCCTATTCCCCTCGCTGTTGGAGCAAACCATTATACCTTACTTC TGTTCTTTTGCATTTTGCCGCTGAGATATGGCATTGCACTGCTTATATGCCAAGCTAATT TATAGCAAGATATTGATCAAATATAGAAAGTTGATATTCAACCTCACAAGGGCTCTCAAA GTATAATCTTTCTATAGCCAACTGCTAATGCAAATTAAAACATATTTCATTTTAACATGA TTTCAAAATCAGTTTTTCATACTACCCTTTGCTGGAAGAAACTAAAAATATAGCAAATGC AGAACCACAAACAATTCGAATGGGGTAGAAACATTGTAAATATTTACTCTTTGCAAACCC TGGGNGGTATTTTATTTTGGCTTCATTTCAATCATTGAAGTATATTCTTATTGGAAATGT ACCTGCCCGGCCG

Sequence 1449

CCGCGGTGGCGGCCGGGCAGGTACATCACCCTGCTGAGGGACATCCAGGACAAGGTC ACCACACTCTACAAAGGCAGTCAACTACATGACACATTCCGCTTCTGCCTGGTCACCAAC TTGACGATGGACTCCGTGTTGGTCACTGTCAAGGCATTGTTCTCCTCCAATTTGGACCCC AGCCTGGTGGAGCAAGTCTTTCTAGATAAGACCCTGAATGCCTCATTCCATTGGCTGGGC TCCACCTACCAGTTGGTGGACATCCATGTGACAGAAATGGAGTCATCAGTTTATCAACCA ACAAGCAGCTCCAGCACCCAGCACTTCTACCTGAATTTCACCATCACCAACCTACCATAT TCCCAGGACAAAGCCCAGCCAGGCACCACCAATTACCAGAGGAACAAAAGGAATATTGAG GATGCGCTCAACCAACTCTTCCGAAACAGCAGCATCAAGAGTTATT Sequence 1450

CCGCGGTGGCGGCCGAGGTACAAATTGNCGTTTTTATTCCTCTTATTGGGATATCATTTT

TABLE 1 238/467

Sequence 1451

CCCCGCGGTGGCGCCGNGGNACAAATTGTCGNTNNTATTCCTCTTATTGGGATATCATN
TTAAAAACTTTATTGGGTTNTTATTGTTGNTGTGGGNTCCCTAACCCTACAAAGAGCCTT
CCTATTCCCCTCGCTGNTGGAGCAAACCATTATACCTTACTTCCAGCAAGCAAAGTGCTT
TGACTNCTTGCTTCAGTCATCAGCCAGCAAGAGGGAACAAACCTGGTCTTTNNCATTTTG
CCNCTGNGATATGNCATTGCACTGCTTATATGCCAAGCTAATTTATAGCAAGATATTGAN
CAAATATNGAAAGTTGNTATTCAACCTCACANGGGCTCTCAAAGTATAAATCTTTCTATAG
CCAACTGCTAATGCAAATTAAAACATATTTCATTNTAACATGATTTCAAAATCAGATTTT
CATACTACCCTTTGCTGGAAGAAACTAAAAATAT

Sequence 1452

Sequence 1453

Sequence 1455

CGAGGTACTGACCTCGTNTGTCCCTTCCCCTNCACCGNTCCCCACAGCTTTGCACCCCTT

WO 01/070979

TABLE 1 239/467

Sequence 1457

Sequence 1458

AGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCCGCCCGGCAGGTACTGGAACAGGGATAA
GTTCTTGGATAAGGNGCCAACATACCTATAAAAGCTGATTTTTGAGTAAATTATTGATTC
TAACATATGTAATGGATTTGGTGTGATAATTTTCTGATCTTTAACTATAAGTGACTTTTT
ATTCTCCACCAGAAAAGATAAATGACTGAGAATGTAAGTCTGCGCTCTGATTAACACAAT
GGAGAAACGGAAAAACTATCTCTGTTAAAAACTGATTCCTGTCATTCTTCTGATATCAAA
TAAGAGGAAGGAAAATAAACTTTTTGTGTGTAGATAGAAAAAACATACCTGAGGCCAGGTG
CAGTGGATCACGCCTGTAATCCCAGCACTTTGGGAGGCCAAGGCGGGCAGATCAGCTGAG
GTCAGGAGTTCGAGACCAGCCTGGCCAACATGGNGAAATCACGTCTCTACTAAAAATACA

Sequence 1459

Sequence 1460

TABLE 1 240/467

AGGTACGCGGGGCTCAAGAATAAGCTGAAATATGGCCAGACTATCAGGCCCATTTGTCTC
CCCTGCACCGAGGGAACAACTCGAGCCTTTGAGGGCTTCCTCCAANCCTACCCACTTTGG
CCCAGTCANACCAAAAAAGGGGAAAGNAGGCCTGGCTTCCCCTTGNCAACAAGGGNATTA
ATTCCAAAAAGNCCTTCCTGGTTTTTTGGNTGGTNCCTTGAAGGGNAAGGGNAGGAAAAA
AAAAGNCCTTGNAACCTTCGGGGAAGGGGNAGGGTTCCTTAACAATTCAAAAGGAAATTG
GGGGGGGGAATAAAAGGAAAAANGGGGCCAAGNCCTTGGTTTGGAAGGAAGGNAGGTATG
GCTTCAAATTAATGGCCCCCCAANGGCTTAATTGAACCAAAAAAGGGTNCAAAAGGGAA
CAATTCTTCAANAAGGGTTGGGGTTCCACCCCCCCNTTCGGGGTTTTCCCCTTTTTTGGTT
ACCCCTTGGCCCCCGGNNNCCGGGCCCNGCCTTCCTAAGAAANCNTAGGGTTGGGGNANT
NCCCCCCCCNGGG

Sequence 1462

Sequence 1463

Sequence 1464

TABLE 1 241/467

AAAGGNNTTGGGGGGNAATTTCCCCCCCCCCGG

Sequence 1465

Sequence 1466

AGGTACACTGAAACATAAATCCGCAAGTCACCACACATACAACACCCGGCAGGAAAAAACAAAAACAGCAAGTTTACATGATCCCTGTAACAGGCCATGGNNCTNCAANNCTTCAGGAAT GCCTTNCCNTCNCATTCTGGCCCAAAGNTGGTTGTTTNCNTGGGAATNACCAGGNAGGCC ACCAATTCGGTGGGGCCTNTCCTGGGGGGNGGTTCAACCAACCTNCAAGNCTTTTAAGGG CTTGGTTGGGGGTTCCCCACCANGAGGCCACCTTNCAATTCTTGGGCTTGGGGGACCTAA TTGNGGNTGGGGTTGGGNTTGGGACCTTCCTTAACCTTCCAAAAGTAAGNCAANAAGCNT GTTTAACCCAAGCCAACAATTTNCAAAAAACCAAGGTTGGTAATTTGGNAAACCANTCCT TTTTTTNAAAAAATNATTCCAAAAAAGTTNGAAGGAAAAAACCANAGGAAANGGGNCAAAC CATTAAANTTAAAATNGGTTTAATCCAAGNAAAAAG

Sequence 1467

Sequence 1469

CCGGGCAGGTACTTTTTTTTTTTTTTTTTAACTGAAGCTTTATCTGGAGTGGGGGAA TGGGGGTGTGGTCAGTTGGGGCACCCAAAGNACAACTCATGCCTCCTNCNNNGAAAGGNC GGCCCAAGGGTCCCTGGGCCAATTTGGTTTTCNTGGGATTTCTTTTTCGGNTACATCG GGNCAATTTTCCGNTACACCTNCNCCTNCNAAGGGNCCCNAGGTNTGGCTTTCNCNNCGC GCAANAGNTNGTNCCCTTTTCACCCGGAATGGAATGGTTAAGACCTTGNAAGNGGATTTT GGGNGGACCTTTTNCATTANCTTACCCCCCCCAANGTAAAAAAATTTCCGGTNNTAAGGG

TABLE 1 242/467

GNAAGAAAAGGAACCCNCCCAACAATTGAAGGNGGTTAAGGTTGGGTATTTTCCTTTTCC
TTTCCCCCTTTCCCCAAAGGCCNTTTTTCNAAGGGGGGGGCCTTTTTNCTTTCATTAACC
AACCTTTTTGGNAATTGGGGGGGGGGNCCTTGGGAATTGGGAAAAAACCGGTTTNCCCGG
CCTTTNTCTTTGNGTTCNCCAAAAACCCCCTTGGGCCAAACC

Sequence 1471

Sequence 1470

Sequence 1473

TABLE 1 243/467

CCCAGCCCGCNTGCTTCACNTTTCCACCNCTTTNTTTCTCACCTTGCCTTCTTGGGCT
TTTCTNCAAGGGCCCCTNNTGGCCTTCTCCCCGNACCCCTTTGGTTCTTCNCTTCTGG
AAANAACCCNCTTCNCTNCCAACCAAACCTNNGCAGNCTCCCATTNNCTTTCCCCGGGCT
TCCCCCNTCNCCTTAAGGTTCTTGGTTCCCCTTGGCCGGTTCNCCTTCTTGGTTCCCCCG
GGGTTTTTCAAGNAGNAACAAANCNTTNCCCCAAAAANGCCAACAAAAAAGGCCAAGATT
TTTTTTTTCCCCCCCCTTAAAAGNGGGNNTGGGGGGGAAGGGGGAAAAGNCCAAAAAAAA
GGAACCTTCTTGGTACCCCTTTTTNGGGGCCCCGGGCTTCTTAAAGAAAAACCTAAGGGTG
GGGGAAATNCCCCCCCCCC

Sequence 1475

Sequence 1476

Sequence 1477

Sequence 1478

Sequence 1479

WO 01/070979 PCT/US01/09126

TABLE 1 244/467

Sequence 1480

Sequence 1481

ATTGGAGCTCCCGCGGTGCCGCCGAGGTACATGATTGTCCTTTATGCATTAAATTCAT
GCTTTTACATACTTGTGTTTCCTTTTCATTTCGTCCTTCCAAATCATTATTTTAGGAATA
TAGAGAAAAGGGTTGGCCAGGTGCAGTGACTCACACCTGCAATCCCAGCACTTTGGGAGG
TCGAGGTGGGTGGATCACTTGAGGCTAGGATTTTGAGACCAGCCTGACCAACATGGAGAA
ACCCCATCTCTACTGAAAATACAAAATTACCCGGGTGTGGTGGCGCATGCCTGTAACCTC
AGCTACTCGGGAGGCTGAGGCAAAAGAATTGCTTGAATCTGGGAGGCGGAGGTTGTGGTG
AGCCAAGATCGTGCCATTGCACTCCAGCCTGGGCAACAAGAGCGAAACTCCGTCTCAAAA
AAATTAAATAAATAAGGCTTATGTGCAGTTATTCTCAATGAGCTAAAAAAGCTTCCTGAGG
CTAGAAATTCTTGTCATTTTTGGCTGGGA

Sequence 1482

Sequence 1483

GCTGCCATCAGCTCCCTAGGAGCTCTCCCTCCAGGAAGGGAATGTGTCCACCGTCAGACA CTCAGACCCAGCATGTGGGGACAGAGGCTGATGGCCTGTCTGGCCATTCCTCTCAGTTCC TCTCCTCACTAGCTTGTGTCCTTGTGCAAGTCACTTACCCTCTCTGAGGTTCAGTTCCCT CCTCTTTGAAGTGGGTTTAATAATAAGTACCTGCCG

Sequence 1484

CCGCGGTGGCGCCCCGGGCAGGTACTGCCCTTTCGTTAGAAGGCAGTGACTCCTTTC
TGTGAAGCCGATTTAGTGAAGTGTCCTGTGCAGAAAAGAGTCCAGGGCTGTCAGTTAATT
TCTTCCGGCCACTGGAGTTAGGGTTTGAAACTCTGCAGCTGCCTATTGCACTTGTGAAAA
GGTTTGTATGTTCATCACTGCTGGCTGGCTCAGAGTTGGGAGTGAATCCTCCAAGGGATA
AGCTTGGAGAACTTTCTGAACAGTCAATCTGTAAAGGTGTCTGCAATCCCAAGGCCAATG
GACTAGATTCTGAAGGCTCTCGGTGGACCCACTGTTCCTCTGTTTATTAAGCTTTTTG
AAGGAGAGAGAGAGAGACATGTGACAACGGTGCTTTTCCTTATGCTTATATCGCT
CTCCAACAGCATCCTT

Sequence 1485

AGGTACATGCAAGTTGCATGATTATAATGACGTGATCCTGGGATTTAAGTTGATTATGAC
AGGAACAGAAGGAACTTGGAGATTAGGGACAATGAAAAGGTGGTAGTGAAAGGAGTGTTG
GAGTTAAGTTACTAGATGTCTGGAAGACAGACTGTGGTGGTCAGATAATGAGATAA
TGGAGGGGTTACAGTTTTTGGTAATAACGAGAGAGATCTAAGGTATGACTGAGAGTGAAT
GGATGAGAATAGCAGAGAACAAGGTCAGTGGAAAACTACTCTTCAAAGAACCTATAGTCA
GGGTGTTGAAAGATTAAAAATTGCTAAGAATTAAATCAGGAAGTAGTGCTGCGGGAAATG
AAATGAGCAGTGAACTAAACTTACTGAGAAATGAGAGGGGATGACCCAAGGGTTTGTAGA
TTTTGTAGATGATGACA

Sequence 1486

WO 01/070979

TABLE 1 245/467

AGGTACATGACATCCGACGAAATGAGACGCCACCTAATTGATTTCCGGGAGTCCGCACCA GGGGCCCTCAGGGAAGAGCCCCGCAAAGATCCTGGGAGACCAAGGTGGGGACCCTGGTG AGAAGAGAGAGTTCAGGGGAGTCTCTCTTCATTGCCCTTCTGCTAACCCAAGCATTAATT TGCTAAGTATTTACCAGGGGAGTGGGAAAAAGAGTTGAGCGGGATTCTCTTAGGCTATGA GAGAGTCAGGCAGCCCCCAAGATAAAATAATGAACTAGAAAATCTGGAACCTTACTTCTC TGGGAATNTTACCTATCTGGCACCGTGGGAAGAAAAAAAAGGCTACTGAGTACCTGCC CG

Sequence 1487

GCGGTGGCGGCCGAGGTACTGACCTCTGCCAGTCAGCTGCGTAACTCCAGGCCCTAGGGT GCCCCGTCTGTCCAGCCAGGGATTGCATGGATATGCTGTGATCTCCCTTTTGGTTCTGAT TGAGTTGGACCTTGTGGGAGGAGAAACATAGATGTTGATACATGAACACATATGTTGGAG AGAGAAAGTTTTATCTTGGCATAGGACTTTTAAAACACAAGGTAATTTTTAATCAGTTTT GGGACCAAAAAACACTCAATATGGGAAAAATCCAAATTCTGCCAAAATGTCTAAAGAGGT TTATTCTGAACCAGTATAAGTGACTGTGGTCTAGGTTACACAATTTCAAGAGATCCTGAT AAAGCGTGCATGAGAGAGTTGGGCTACAGCTTGGTTTTACACATTTCAGGGAGACAGGAA TTGTANGGTAAAATTATGGCACAGGACTTTTAAAATGAAGCTGTGAAAGTTTACAGTCCA

Sequence 1488

CCGCGGTGGCGCCGAGGTACTTGACACGACATATGGTAAATGAATAAGACAAAGGCTCT GATGGCTTCTCACAGCCCTGTGGATCAAACTCAGATTCTTTTCTAGAACCCCAAGGCCCT GTCAGTCTCACTAGCCTCTCTCCAGACACACCAGCCTTTTTCTACCTTTCCAACATCCCA AGTTCCTTTTCTCTTACAGGACTACATACACTCTCTCTTCTGCCAGAAACCATGTTCTAC CAGCTAATTTCCACTCAACTTTTAAGTCTCANCTGAAATGTTACTTCCAAAGAGAGGCCT CCACTGAACCCCAAGCCTGGGGTTCACAGCACCTGTCTCCATAACTACATAATAATCTCT CTGATGTTTAGGCTGGGCATGGTGGCTCACGCCTGTAATGCCAGCACTTTGGGAGGCCAA GGCG

Sequence 1489

GGGCGAATTGGAGCTCCCCGNGGTGGCGGCCGGGCAGGTACCCAGAGTTGCGAGGAGTTT
TTTAACTGATTTAGCCAGGTGGCAANCATNAGTGAATGGATGAAGAAAGGCCCCTTAGAA
TGGCAAGATTACATTTACAAAGAGGTCCGAGTGACAGCCAGTGAGAAGAATGAGTATAAA
GGATGGGTTTTAACTACAGACCCAGTCTCTGCCAATATTGTCCTTGTGAACTTCCTTGAA
GATGGCAGCATGTCTGTGACCGGAATTATGGGACATGCTGTGCAGACTGTTGAAACTATG
A

Sequence 1490

GATNAGCTCGATATNGAATNNCNNCANNCNNGGGGANNCANNNGNACAAGAGCGGANNCC NNCGCAGAGGAGCTNCAANTTTACACACTGTTTAAATGAGGGAATANGCNGCAGCGCTTG GATGTAACTGAAGAAGACAGTNNGAGCNNCAAGGAGGGACAACCACGACCTATGAGGACA CCATGCCAGAGAGGCCTGGACCCCACGCTAGGCTCAGTGCCTGTTATACTCTTGGGACCC AGCGCTTTCCTTCTCCATCACGTGGCATACTTGGCATTATTTGTTGNTTAAAATATTGCC CTTAGTTTTNACCTTTCNTAAGGAGACACAAGGNNGACCTTTGNGACATTAACAGTTGCC CCAAGTNGGGGGNANANAAANAATTTTTGGGGGGNGNAAAAANCTTTTGGCTTTTTNNAAA AAATTTTTTTTTTNAAANTTT

Sequence 1491

CTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACCTGGTGACCCTTGCTGGT GCTTTCATGTTTTGTGCCGAGGCAATTAGACTTTGTGCTGAATNTGTTTTGTGCTGCCACC TCAGGGAAGGGTGGAATGTGCAGCGTGGTTTCCATTTGACATTGTTTTCCCTGAGAGAT GGGAGGGCTGAACGTTACCTCTTGACAAGTCTTAGTGGACAGAGGGGCCCGGATACCCAA GCGCCTTAGTTCTTAGGGCTGGGTATTAGTTCATTTTCACACTGCTGATAAAGACATACT CGATACTGGGAAGAAAAAGAGGTTTAATTGGACTCCCACATGGCT Sequence 1492

TABLE 1 246/467

Sequence 1493

Sequence 1494

ATAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACTAATTTGAATTTGTAATGA GTCTGATGGTATATTTCAATTTTTTGCTTTGAGGGACTGGCTGCTACATTGCAGAATATC TTATATCCCTGACTGCTTTCCACTAAATGTCAGTGGTGACCCCAATCCAATTATTATGAC AACTGAACATGCTTATGCATCCCTCATGCCTTTATTTTTTATTTTGGGAAATCTTTCAGC TTCAGTTTTGCTGATATTTATGTGATTCTTTGTTCTGCAATTCAAATTTCTGGGAGCCA AACAGTCTCCTTGGTTCAGATTACTGTTTTTTTGACTAGAGCTTCTCGCTTCAGATTCTGT CATAAGATTATGGCTTAACCTATGGTTGTCCTTTGATTTGGTGCCATATGAAATAAAACA TTATTT

Sequence 1495

Sequence 1496

CGGGCAGGACCATGGGAAATAAGAGCNGGCTNNNGGCATTCTGNGTANGGAGCCTGAGCC
AAACTCTAAAGCTGTCTTTATAAAGGGAGGTCATGTGATGGCCAGAAATTGCCTTTGCTT
CATGGTGCACTTGGTGGGGAGTCAGGTGTGGGGTGTCACATCATCCCATTTTC
TTTTNNGNNTTCAGACCTGCAATGCTTCTTTTGCAACCCGAGACCGTCTGCGCTCCCACC
TGGCCTGTCATGAAGACAAGGTGCCCTGCCAGGTGTGTGGGAAGTACCT
Sequence 1497

AGGTACTTTTNGAAGTAACTGGACATGNGGGAGGNNAGGGGAANGGAAGTATTGNTATGGACTGAACTGTGCCCCCAAAATTCATATGTNGAAGCCNTGAGCTCTGACATGATTGNATNTGAAGTCCTAAAGCCAGGAATGAGGAAGGCTGTGAATGTNCATTGTTCCATGCAAGAATGACTCTGGNGNGGGCTATTTAGAGATCATGAGGGATACTGCCCCAGTTTCCACAGGCCAGATGGNCTCCAACAAAAGCCACGGGGGAGTCACCCCTGCCTGGCAGATCTATCGGGTCAGGACCACCGCCCAGGGGGTCCTGGAGAGGACCAAAGAGGGTCACGGAGACCAAAGAGGGTCACGGAGACCAAAGAGGGTCAGGACCAAAGAGAGGAT

TABLE 1 247/467

Sequence 1499

Sequence 1500

TABLE 1 248/467

CNTCTTNTTTATAAAANAAAAAA

Sequence 1503

Sequence 1504

Sequence 1508

CCGCGGTGGCGGCCGAGGTACGCGGGAGAACAGCTCAGAAGGAGACCCACAGTGAGCAGC TCCCCTGTGTCGGCGGGCAGGTCGTCCCTCAAGTGTTCAGCTCTCAGCAGAGAAAAGGCC CTGGAGAGGGTGACTCCTCTCAGCTCTCAGCAGAGAAGCAGCCCTGGAGAAGGTAGCTTC TGTTCGCAGGCAGATTGTCCAGAGGTCCTGCTGCTCTCAGACGGGGCCCTGGAGAGGATA GCTTCTATCCATAGGCAGG

Sequence 1509

TABLE 1 249/467

CCGCGGTGGCGCCCCGGGCAGGTACGCGGGGACAGAAATGGAGTCATCAGTTTATCA
ACCAACAAGCAGCTCCAGCACCCAGCACTTCTACCTGAATTTCACCATCACCAACCTACC
ATATTCCCAGGACAAAGCCCAGCCAGGCACCACCAATTACCAGAGGAACAAAAGGAATAT
TGAGGATGCGCTCAACCAACTCTTCCGAAACAGCAGCATCAAGAGTTATTTTTCTGACTG
TCAAGTTTCAACATTCAGGTCTGTCCCAACAGGCACCACCCCGGGGGTGGACTCCCTGT
GTAACTTCTCGCCACTGGCTCGGAGAGTAGACAGAGTTGCCATCTATGAGGGAATTTCTG
CGGATGACCGGAAATGGGTACCTCGGCCGCTCTANAACTAGGTGGGATCCCCCCGGGCTG
NAAGGAATTTCGATATCNAGCTTATCGATACCCGTCCGACCCTCGAGGGGGGGGCCCGG
GTCCCAGCTTTTTGGTCC

Sequence 1513

ACTACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACGCGGGAGGCCAAGC

WO 01/070979

TABLE 1 250/467

Sequence 1516

Sequence 1517

Sequence 1518

Sequence 1519

Sequence 1520

Sequence 1521

CCGCGGTGGCCGCCCGGGCAGGTACATCACCCTGCTGAGGGACATCCAGGACAAGGT



CACCACACTCTACAAAGGCAGTCAACTACATGACACATTCCGCTTCTGCCTGGTCACCAA
CTTGACGATGGACTCCGTGTCGGTCACTGTCAAGGCATTGTTCTCCTCCAATTTGGACCC
CAGCCTGGTGGAGCAAGTCTTTCTAGATAAGACCCTGAATGCCTCATTCCATTGGCTGGG
CTCCACCTACCAGTTGGTGGACATCCATGTGGCAGAAATGGAGTCATCAGTTTATCAACC
AACAAGCAGCTCCAGCACCCAGCACTTCTACCTGAATTTCACCATCACCAACCTACCATA
TTCCCAGGACAAAGCCCAGCCAGGCACCCAATTACCAGAGGAACAAAAGGAATATTGA
GGATGCGCTCAACCAACTCTTCCGAAACAGCAGCATCAAGAGT
Sequence 1522

Sequence 1523

Sequence 1524

CCGCGGTGGCGGCCGGCCAGGGTACACCACTGTGCCTGCTTTGAATCCTTTACGAA GAGAAAAAAAAATTAAAGAAAGCCTTTAGATTTATCCAATGTTTACTACTGGGATTGCTT AAAGTGAGGCCCCTCCAACACCAGGGGGTTAATTCCTGTGATTGTGAAAGGGGCTACTTC CAAGGCATCTTCATGCAGGCAGCCCTTTG

Sequence 1526

Sequence 1527

TAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACCTGTGGATATTGGTTGAACA
AACAGGTGGGCAAAGTGAGGAAGATAAGAAGTCCATCCGTTCAGTTTCCCCACTGCGGAG
GGAATAACACTGTCTTTCCACAGGTCACAGACTGGGATGAGCAACGGGCTGAAGGCACGT
TTCCCGGGAAGATCTGAACTGGCTGCATCTCCCTTTCCTCTGTCCTCCATCCTTCTCCCA

WO 01/070979 PCT/US01/09126

TABLE 1 252/467

AGATGGTGAAGGGGGACCTGGTNCTG

Sequence 1528

AGGTACGCGGGATGGCACATANGACATCAGCTAGGCTTTTGGGAATCGTTTGTGTTCTTT GTGGAAATGTCCTTTAGAAGCACCCATGAAGTAGTGTGTCAGACTGTGCACACAGAAAA CAGGCTCTGCCTTCACATGTGAGACGGTGGACTTTTCCTNTGGACAAAATGACAGCATNC TGGCGACTCCACAGTGGAGCTGAGCGCCACTCCCTGTAGCCCGATCTGGGACTGAAACGC TTACACCTCTGCCTTAGAAGGAGTCCCCCNTGCC

Sequence 1529

Sequence 1530

Sequence 1532

Sequence 1534

TABLE 1 253/467

GACTITCTTTCCTTGTCTAGGACCAGTTGAAGCTCATTATTAACCTGCTGCAGCTCCTCA CCATTCTCCTCATCGGNGCCTCCATTTACACGAGCAGGGCGTGCCTGCTGCTCACTGTGA TCCAAAATCTCCTNGACTTGCTCAGGGGCATNTGTAGCCTCC

Sequence 1535

Sequence 1537

Sequence 1538

Sequence 1539

Sequence 1540

Sequence 1542

TABLE 1 254/467

GGAGCTAAACCCCGGNGGCGGCCGAGGTACTTACCCTCAATTTCAATGTTAACAATTTCT
TTAAAAAGGCAAAAGACACAAAAGNTTAGCATTTACCAAACCAGTCTGTACGCGGGGCCT
GTGGATGCTGCGCCCTCCCGAACGCAGCATGAAGGTGCTCCTTGCCGCCCCCCCTCATCGC
GGGGTCCGNCTTCTTCCTGCTGCCGGGACCTTCT

ANAGGATCAANANCAGGGGGTGGGCCCTGCTGCGGCTTCAC
ANAGGATCAANANCAGGGGGTGGGCCCTGCTGGGCTTNCACTGGGATTTTTTGAGCATTN
CTTTCCCNGGNGGCNCGGNAAGGGGNGTGGNGTGAGCCCNAGGGNGGAAAAAATTT
Sequence 1543

Sequence 1546

Sequence 1545

GGCGGCGGCCGAGGNACAAGNANCNNTTGGNGGAGGGGGGGGAAACCCAANACCCGAACN NGGGACTGNGCAGACAAGCTATATCTTAANCCCNCNCCGGGCCAGACCNCNAGCAAGGGN GAGGAAGCAAAAGNCCACAGNNACNGGGGCAGGNAANNGGNANAAANGAGGGNGNGGGGC

TABLE 1 255/467

Sequence 1547

Sequence 1550

Sequence 1551

GGCGGCCGCTCTAGAACTAGNGGANCCNTTTTGCGGGGGGAAAAAAACCCCAAGCCCANC GANACCGNCGACCNCGAGGGGNNCCCGGNACCCAGCGNNNGCCCCCNAAAGAGAGGGNN AANNGCGCGCNNGGCGNAANCANGGNCANAGCNGNNNCCNGNGNGAAANNGNNANCCGCN CACNTTTTNNTTTNNCNGACGAGCCGGGNGCANAACCCCCAAANANA Sequence 1552

TABLE 1 256/467

Sequence 1553

Sequence 1554

Sequence 1556

ATAGGCGAATTGGAGCTCNCCGCGGTGGCGGCCGTCCACATCCCGAAGGCCATAGCGTC
GAGCAAGGTCACATGGATGGCAGCACCTTACCACTCAGGCTCAGGATATTGGGATCTGTT
GCCAAAGCCACCACACATTTGCCACTCAATTCTGTGGTTTCCGCAGATGAGAAGGCTGAT
TTGAACTGCTTCAACACAGGATCCTGCAGGACCTCCTCTTTGCCATATGCTCCTTCAGC
AGTTCTGTCTGCACAATCCCCGGCCACAGAGACACACAGCTGACCCCATGGCGCCGCAGC
TCGTGGGCACAGTCAGCAGCTTGTCACACGCAGCTTTGCCCACACCATAGGGGACA
TTGAACATATACTGCAGGCTTCCTGGGGAGGAGATGACCACGATNAGCCCCTGGCCAGCT
GGTACCT

Sequence 1557

Sequence 1558

CCGCGGTGGCGGCCGGGGCCATTGAGACTGCCATGGAAGACTTGAAAGGTCACGTAGCT GAGACTTCTGGAGAGACCATTCAAGGCTTCTGGCTCTTGACAAAGATAGACCACTGGAAC CAATGAGGAAGGAGAGAATTCTACTGGTCACAGACAAGACTCTCTTGATCTGCAAATACG

TABLE 1 257/467

ACTTCATCATGCTGAGTTGTGTGCAGCTGCAGCGGATTCCTCTGAGCGCTGTCTATCGCA TCTGCCTGGGCAAGTTCACCTTCCCTGGGATGTCCCTGGACAAGAGACAAGGAGAAGGCC TTAGGATCTACTGGGGGAGTCCGGAGGAGCAGTCCCTTCTGTCCCGCTGGAACCCATGGT CCACTGAAGTTCCTTATGCTACTTTCACTGAGCATCCTATGAAATACACCAGTGAGAAAT TCCTTGAAATTTGCAAGTTGTCTGGGTTCATG

Sequence 1559

Sequence 1561

CCACTCACTATAGGGCTGAATTGGAGCTCCCCGCGGTGGCGGCCGGAAGAGCAACCGAGA TGAAGGTGAAGATGCTGAGCCGGAATCCGGACAATTATGTCCGCGAAACCAAGTTGGACT TACAGAGAGTTCCAAGAAACTATGATCCTGCTTTACATCCTTTTGAGGTCCCACTGAGAA TATGTAAGAGCTTTAAATGCTACCAAACTGGAACGAGTATTTGCAAAACCATTCCTTGCT TCGCTGGATGGTCACCGTGATGGAGTCAATTGCTTGGCAAAGCATCCAGAGAAGCTGGCT ACTGTCCTTTCTGGGGCGTGTGATGGAGAGGTTAGAATTTGGAATCTAACTCAGCGGAAT TGTATCCGTTACCT

Sequence 1562

GGGCGNGTTGGAGCTCCCCGCGGTGGCGGCCGAGGTACTCTTCCTGCCTTCCCCCATATA CTGAAGTTTGAGAGGCTGGGAAGGTGCGGAATGGGAAAAGGAGCAGCTGCTTATGTTCAG TTTAACATTCTCTGGGTTTCTCCATCTAGGTCTTGAGTTCATTCTCTTCCTGTCCTTTTG GCTTCCTTGTTTAACCTGGTCCCTGTTTCAGGAGAGAGCCTCATCAGTGCCAAGTCTGT GGGGAAGACCTTCTCTCAGAGTGGAAGCAGGAATGTGCATATGAGAAAGCATCACCTGCA GCTGGGAGCAGCTTGGGAGTCAAGAGCAGGAGCAAACTGCTGAGCCACTAATGGGGCAGT AGTTTGCTTG

Sequence 1563

CCGCGGTGGCGGCCGAGGTACAAATTGTCGTTTTTATTCCTCTTATTGGGATATCATTTT
AAAAACTTTATTGGGTTTTTATTGTTGTTGTTTGATCCCTAACCCTACAAAGAGCCTTCC

TABLE 1 258/467

Sequence 1565

Sequence 1567

TCGCCNCGCGTCCGGGCAACTGCAGTTGGAAAAAAAGATTCAACTTCAAAGCAGAGGATT
TTTGATGAAGAACCAGCTAATGGAGTGAAGATAGAAAGGTTTACAAGGGATGATCCTTGG
TTATCTTCATGTGAAGAAGTGGATGATTGTAAAGACCAGTTGGAGAAGCAACAGGAAAAA
CAAGAGATACTTTTGCAGGAAGTGGCATTCACTCAAAGGAAAGCAGTTATTCATGAGAGA
GTCTGCAAAAGTGATGAAACTGGGGAGAAGAGTGGTCTGAATTCCAGTCTATTTTCATCC
CCAGTTATACCCATAAGAAACCATTTTCATAAACATGTATCACATGCTAAAAAAATGGCAT
CTTAATGCTGCTGTAAACAGTCATCAGAAGATTAATGAGAATGAGACCTCAAA
CA

Sequence 1568

Sequence 1569

CGCGTCCGTTTCTCCTGGCACCCTGTATTCATGGCCTTGGCGTTCTGCCTCTGCATGGCTGAAGCCATCCTACTCTTCTCACCTGAACACTCCCTGTTCTTCTTCTGCTCCCGAAAAGCA

WO 01/070979

TABLE 1 259/467

PCT/US01/09126

CGGATCCGGCTCCACTGGGCAGGGCAGACCCTAGCCATCCTCTGTGCAGCTCTGGGCCTG GGCTTCATCATCTCCAGCAGGACCCGCAGTGAGCTGCCTCATCTGGTGTCCTGGCACAGC TGGGTGGGAGCCCTGACACTGCTGGCCACTGCTGTCCAGGCACTGTGTGGGCTCTGCCTC CTTTGTCCCCGGGCAGCCAGGGTCTCAAGGGTGGCTCGCCTCAAGCTCTACCATCTGACA TGTGGACTGGGTGGTCTACCTGATGGCTACAGTAACGGTGCTTCTGGGCATGTACTCAGT ATGGTTCCAGGCCCAGATCAAAGGTGCGGCCTGGTACCTGTGCCTG Sequence 1570

Sequence 1572

CCGAACAANGTGGCCACCCAGGTTTTTAACCCAAGTCTAGTGGTCATCCTATTCTTTCCA CACCAACATGCCAAAAGCCTTACCTNGAAAGAAAATATAATTTGCAAGAAGCATCACAGT GCCGGGGTCTATATTCTCGATCAGGTTGNTAATTTTCCCATGGGTTTTTTTGACTGATAAA GNCATTGATCTGCTTCTGAGCCATTTCCAAATTCTGAAAGTTGGTAAGGATGGTTTCGGN ACTGTAAAAGTTCTTGGCATCTTCC

Sequence 1573

CGCGTCCNGGNCGGAGAAGACAGTAGGGATACTGGATATGGGAGGAGCCTCTCTCCAAAT TGCTTATGAAGTTCCTACCTCAACCTCTGTCCTTCCTGCAAAGCAGGAAGAAGCTGCCAA GATCCTGCTGAGTTCAACCTGGGCTGTGATGTGCAACACACTGAACACGTGTACAG GGTTTATGTCACAACTTTTCTGGGTTTCGGAGGCAACTTTGCCCGGCAGCGCTACGAAGA CCTTGTTCTGAATGAAACTCTTAACAAAAACAGATTGCTTGGTCAGAAGACAGGTCTGAG TCCCGACAATCCATTTCTGGATCCCTGCCTGCCAGTGGGACTCACAGATGTGGT Sequence 1574

CGCCGTCCNGTTTACTTGGAGTGTCCAAAACTGCAAGCAGTAGAGAAATAAGACAAGCTT
TCAAGANNNTGGCATTGAAGTTACATCCTGATAAAAAACCCGAATAACCCAAATGCACATG
GCGATTTTTTAAAAATAAATAGAGCATATGAAGTACTCAAAGATGAAGATCTACGGAAAA
AGTATGACAAATATGGAGAAAAGGGACTTGAGGATAATCAAGGTGGCCNGTATGAAAGCT
GGAACTATTATCGTTATGATTTTGGTATTTATGATGATGATCCTGAAATCATAACATTGG
AAAGAAGAAGAAATTTGATGCTGCTGTTAATTCTGGAGAACTGTGGTTTGTAAATTTTTAC
Sequence 1575

Sequence 1576

GACCACGCGTCCGCGCACCGCTTCATTGAGGCTGCAAGAGCACACGGGCACCCACGTGCT

TABLE 1 260/467

GGTCCACTGCAAGATGGGCGTCAGCCGCTCAGCGGCCACAGTGCTGGCCTATGCCATGAA GCAGTACGAATGCAGCCTGGAGCAGGCCCTGCGCCACGTGCAGGAGCTCCGGCCCATCGC CCGCCCCAACCCTGGCTTCCTGCGCCAGCTGCAGATCTACCAGGGCATCCTGACGCCAG CCGCCAGAGCCATGTCTGGGAGCAGAAAGTGGGTGGGGGTCTCCCCAGAGGAGCACCCAG CCCCTGAAGTCTCTACACCATTCCCACCTCTTCCGCCAGAACCTGAGGG Sequence 1577

CTACACTCAACTTCACCATCTCCAATCTCCAGTATTCACCAGATATGGGCAAGGGCTCAG
CTACATTCAACTCCACCGAGGGGGTCCTTCAGCACCTGCTCAGACCCTTGTTCCAGAAGA
GCAGCATGGGCCCCTTCTACTTGGGTTGCCAACTGATCTCCCTCAGGCCTGAGAAGGATG
GGGCAGCCACTGGTGTGGACCACCTGCACCTACCACCCTGACCCTGTGGGCCCCGGGC
TGGACATACAGCAGCTTTACTGGGAGCTGAGTCAGCTGACCCATGGTGTCACCCAACTGG
GCTTCTATGTCCTGGACAGGGATAGCCTCTTCATCAATGGCTATGCACCCCAGAATTTAT
CAATCCGGGGCGAGTACCAGATAAATTTCCACATTGTCAACTGGAACCTCAGTAATCCAG
ACCCCACATNCTCAGAGTACATCACCCTGCTGAGGGACATCCAGGACAACGTCACCACC
TTTTACAAAGGCAGTCAAACTACATGACACATTCCGCTTCTGCCTGGTCACCAACTTGAC
GATGGACTTCCGTGTTGGTCACTGTCAANGCATTGGTCTTCTTCAATTTG
Sequence 1578

GCGCCGCCGGCAGGTACCTAACCTACCTTTAAGACTGGGATAACTATTGNNNTNCAAT AGNTTTATACCGGATATAGTTATTTATCGCATGATGAGTAATAGAAAGGAGCTTCACAGC TTCACTTAAAAATGGGGGTGCGGAACATTAGTTAGTTGGTAGGGTAATGGCCTACCAAGA CGATGATGTTTAGCCGGGCCGAGAGGCTGTACCT Sequence 1579

CTCCCGCGGTGGCGGCCGAGGTACAGCCTCTCGGCCCGGCTAAACATCATCGTCTTGGT
AGGCCNTTNCCCTACCAACTAACTAATGTTCCGCACCCCCATTTTTAAGTGAAGCTGTGA
AGCTCCTTTCTATTACTCATCATGCGATAAATAACTATATCCGGTATTAGCTATTGTTTC
CAATAGTTATCCCAGTCTTAAAGGTAGGTAGGTACCTGCCCG
Sequence 1581

Sequence 1583

Sequence 1585

TABLE 1 261/467

Sequence 1586

Sequence 1587

Sequence 1588

CGGGCAGGTACCTAACCTTCAAGACTGGGATAACTATTGGAAACAATAGCTAATAC CGGATATAGTTATTTATCGCATGATGAGTAATAGAAAGGAGCTTCACAGCTTCACTTAAA AATGGGGGTGCGGAACATTAGTTAGTTGGTAGGGTAATGGCCTACCAAGACGATGATGTT TAGCCGGGCCGAGAGGCTGTACCT

Sequence 1589

TACCNCGCGTCCGGGGCCCGGATGCTGGGGGCCACCAGGGCCCCGGGGATGTGCTGTCT
TCATGGATGCCCACTGCGAGTGCCACCCAGGTTGGCTGGAGCCCCTCCTCAGCAGAATAG
CTGGTGACAGGAGCCGGGTGTATCTCCGGTGATAGATTGACTGGAAGACTTTCC
GGTATTACCCCTCGAAGGACCTGCAGCGTGGGGTGTTGGACTGGAAGCTGGATTTCCATT
GGGAACCTTTGCCGGAGCATGTGAGGAAGGCCCTCCAGTCCCCAATAAGCCCCATCAGGA
GCCCTGTGGTGCCCGGAGAGGTGGTGGCCATGGACAGCATTACTTCCAAAACACTGGAG
CGTATGACCCTCTTATGTCGCTGCGGGGTGGTGAAAACCTCGAACTGTCTTTCAAGGCCT
GGCTCTGCGGTGGCTCCGTTTGAAATCCTTCCCTGCTCTCGGGTAGGGCACATCTACCGAA
ATCAGGATGCCCCGTCCCCGTTTGACCAGGAGGCCACCTTGAGGAACAAGGTTCGCATTG
CTGAAGACCTGGCTTGGGGTCA

Sequence 1590

GGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACTGTGATATCCACATATTTTTGAG
AAAAATTCCCAAGCCAGGCGAATGTGGATTGGAATAAAGACATAGGCAGTGTATACCACC
ATAGCAATAATGGTTAGTAAGATGGTGTTAAACATAGATCGCTCCCAGGGCTCTAAAACA
GCACAGCAGCTAATGATTTGGTATTGATAGTAGAGCCAGGAGAAATATTCCTTCACACGC
CTCAAATCCATGGTTGGCTCCTTCAAGCTGCAGTAAGTTTGTCCTAAGAAAGTCCAGGTC
TGGTTCTTCAGCCTTGCTCCTTC

Sequence 1591

TABLE 1 262/467

CCACCGTAAGATTCATATAATCTAATCAAAGATCTACCAACTGGTTGTTTTACCCTGGAT CCAGATTCACCAATTAAACCTAAAATTTTTCCTTGTTGGATCTAAAATTTTACCGTTATC AACAGCTTTGACAACCCAAANTTATTGGAAAAATATTTTTTTAAGCTTTGAACTTTTAAG GGTGGGTTAACTTGCATTA

Sequence 1592

Sequence 1594

Sequence 1593

CCGCGGTGGCGCCCCGGGCAGGTAGGCTGTCTACACTGACATCATCCAGGGCAAGCT GGACCAGCGAAACCAGCTGCTGGAAGTGGATTTCTGCATTGGCCGTGACATCCGAAAGAA GGATATCAATAATATTGTCAAGACCCTGCATGAATGGTGTGATGGCTGTGAAGCAGTTCT ACTGGGCATNGAGCAGCAAGTTCTGAGAGCCAACCAGTACCTT Sequence 1595

Sequence 1597

AGGTACGAAGAAAGGAATCAAAGCCTACTANCTCAAAAAATTGTCAAATTGCAAATGA GGACATCTAGAGAGGAAGAAAGGAAAAAAGGAACTAAAAAAACAGAAACAATTAACAGTAA GTTCTTAACTATCAATAATTATTTTAAAAGTAAATAGATTAAATTATCTAATCAAAAGAC ATTGAATGGCTGAATGGATTAAAAAACAAGATCAACTATACATTGCCCATCAGAGATTCA TTTTAGCTTTAAGGATAAACACTGGTTGAAAGTGAAAAAAGTCAAGGCTGGGCATGGTGG CTCATGTCTATAATTCCAGCACTTTGGGAGGCCAAGGTGGGCAGATAATCTGAGGTCAGG AGTTTGA

Sequence 1598

CCGGGCAGGTACCACCTGAAGACCCTCACACTCAACTTCACCATCTCCAATCTCCAGTAT
TCACCAGATATGGGCAAGGGCTCAGCTACATTCAACTCCACCGAGGGGGTCCTTCAGCAC
CTGCTCAGACCCTTGTTCCAGAAGAGCAGCATGGGCCCCTTCTACTTGGGTTGCCAACTG
ATCTCCCTCAGGCCTGAGAAGGATGGGGCAGCCACTGGTGTGGACACCACCGGCACCTAC
CACCCTGACCCTGTGGGCCCCGGGCTGGACATACAGCAGCTTTACTGGGAGCTGAGTCAG
CTGACCCATGGTGTCACCCAACTGGGCTTCTATGTCCTGGACAGGGATAGCCTCTTCATC
AATGGCTATGCACCCCAGAATTTAT

Sequence 1599

CTTAGGGCGAATTGGAGCTCCCGCGGTGGCGGCCCGAGGTACACAGGACCAATGCTGCC

TABLE 1 263/467

CATCCACATGGAATTTACAAACATTCTACAGCGCAAAAGGCTCCAGACTTTGATGTCAGT GGATGATTCTGTGGAGAGGCTGTATAACATGCTCGTGGAGACGGGGGAGCTGGAGAATAC TTACATCATTTACACCGCCGACCATGGTTACCATATTGGGCAGTTTTGGACTGGTCAAGGG GAAATCCATGCCATATGACTTTGATATTCGTGTGCCTTTTTTTATTCGTGGTCCAAGTGT AGAACCAGGATCAATAGTCCCACAGATCGTTCTCAACATTGACTTGGCCCCCACGATCCT GGATATTGCTGGGCTCGACACACCTCCTGATGTGGACGGCAAGTCTGTCCTCAAACTTCT GGACCCAGAAAAGCCAG

Sequence 1600

TCNCCGCGGTGGCGCCCCGGGCAGGTACGTTCACTGTCTCATATAATCNCAGCCTCC
TGTGTGATAGCTGGTGTCATCTCCACTTACAGATGAGGAAACTGAGGATAAGCAGGGTTG
AATAACTTGCTCGAGATCACCAGAGCCACGGGTGGNGAAACAGGATACAAACCTGGTTCTG
TTTGACTCTAAGACCATTCATNTTTCCTCTGAAACTCAGTATTGCACAGTGTAGAAATGC
AGTTTTTAAGACCTCCCAAAGTGACGTGCTGNGTCACTGCCCATCATTAGCTANATTGAG
TAAATTGCTGCTTAGCCCCANTTGTTTTGACAGAATCAATAGCCCTTGCTGAGGGGCCAN
CAGCCTACGGACACAGGAGCATGCTTCATGGGCAAGACCACCATGCACACTCAGAGGGGA
AGCCACAAGGCAACCTCCACGCCACTTAAGATTTGTAGGGCTCTGAACACATCACCAGAT
ACAGACCACCTACTTATTTTTTTNCACTGTAATANCAAAGGCAGGAATCTTTTTNCTGTAG
GGTAAAGTTTGGGGG

Sequence 1601

GGCAGGTACAAGGCCCCAAAGAGGAGGAATTCCTTGTAGAGGAGCTTGTAGATGCTTCCC CTCCAGCGGAGAAGCAGGCCAGAGAAACCTCCGAAGCGGGCCTCCGCCACTTTGAGAGTG TATGAAACCGTCATGGTGCTGGGAGCCTGGGGCAGGAGGTCACAAGAGTTGCCCCCAGGG CTGTCGTTTAGTTCTCCAGACAACCTCCCTTCCACTCTGGTCTCCACACCCCAGCCTTCA CCCTGCGTCAAGTGGACAAG

Sequence 1602

Sequence 1603

CCGGGCAGGTACTGTGATATCCACATATTTTTGAGAAAAATTCCCAAGCCAGGCGAATGT GGATTGGAATAAAGACATAGGCAGTGTATACCACCATAGCAATAATGGTTAGTAAGATGG TGTTAAACATAGATCGCTCCCAGGGCTCTAAAACAGCACAGCAGCTAATGATTTGGTATT GATAGTAGAGCCAGGAGAAATATTCCTTCACACGCCTCAAATCCATGGTTGGCTCCTTCA GGCTGCAGTAAGTTTGTCTTAAGAAAGTCCAGGTCTGGTTCTTCAGCCTTGCTCCTTCGC GAAATGATCCTGTGTGGGTTAGTTCTCCTCTCTGGGTTGCTGTTTCCTCA Sequence 1604

AGGGCGAATTGGAGCTCNCCGCGGTGGCGGCCGAGGTACCACCTGAAGGCCCTCACACTC
AACTTCACCATCTCCAATCTCCAGTATTCACCAGATATGGGCAAGGGCTCAGCTACATTC
AACTCCACCGAGGGGGTCCTTCAGCACCTGCTCAGACCCTTGTTCCAGAAGAGCAGCATG
GGCCCCTTCTACTTGGGTTGCCAACTGATCTCCCTCAGGCCTGAGAAGGATGGGGCAGCC
ACTGGTGTGGACACCACCTGCACCTACCACCCTGACCCTGTGGGCCCCGGGCTGGACATA
CAGCAGCTTTACTGGGAGCTGAGTCAGCTGACCCATGGGTGTCACCCAACTGGGCTTCTA
TTGTCCTGGACAGGGATAGCCTCTTCATCAATGGCTATGCACCCCAAAATTTATCAATCC
GGGGGCGAGGTACCTGCCCCGGGCGGCCGCTTAAAACTAGGNGGGATCCCCCNGGCTTG
CAGGAATTTCGATATTCAAGCTTATCGATACCCGTCCNACCTTCGAGGGGGGGG

CCGGGCAGGTACCACNTGAAGACCCTCACACTCAACTTCACCATCTCCAATCTCCAGTAT

TABLE 1 264/467

TCACCAGATATGGGCAAGGGCTCAGCTACATTCAACTCCACCGAGGGGGTCCTTCAGCAC CTGCTCAGACCCTTGTTCCAGAAGAGCAGCATGGGCCCCTTCTACTTGGGTTGCCAACTG ATCTCCCTCAGGCCTGAGAAGGATGGGGCAGCCACTGGTGTGGACACCACCTGCACCTAC CACCCTGACCCTGTGGGCCCCGGGCTGGACATACAACAGCTTTACTGGGAGCTGAGTCAG CTGACCCATGGTGTCACCCAACTGGGCTTCTATGTCCTGGACAGGGATAGCCTCTTCATC AATGGCTATGCACCCCAGAATTTATCAATCCGGGGCGAGTACCT

Sequence 1606

Sequence 1607

CGAGTTACCAGAAGGAGAGATCACCACCATCGAGATCCACCGCACTAACCCGTACATCCA GTTAGGAATCAGCATCGTTGGCGGCAATGAGACGCCACTGATCAACATCGTNATTCAGGA AGTNTACCGGGATGGGGCCATCGCCAGAGATGGAAGGCTCCTTGCCGGAGACCAGATTCT TNAGGTCAACAACTGTGATATCATGCAACGTGTCCCATAACTACGCCCGGGCTGNCCTTT CCCAGCCCTGCAGNACCCTGCACCTGACAGNGCTTCGGGAGCGGCNGCTTNGGCAGTCGT GCAAA

Sequence 1608

CGAGCCTTTAGATGGCGTCTCCTCAGGGGGGCCAGATTGCGATCGCGATGAGGCTTNGGA
ACCAGCTCCAGTCAGTGTACAAGATGGACCCGCTACGGAACGAGGAGGAGGTTCGAGTGA
AGATCAAAGACTTGAATGAACACATTTGTTTGCTGCCTATGCGCCGGCTACTTNGNGGAT
GCCACCACCATCACAGAGTGTCTTCATACTTTCTGCAAGAGTTGTATTGTGAAGTACCTN
CAAACTAGCAAGTACTGCCCCATGTGCAACATTAAGATCCACGAGACACAGCCACTGCTC
AACCTNAAACTGGACCGGGTCATGCNGGACATCGTGTATAAGCTGGTGCCTGGCTT
Sequence 1609

Sequence 1610

CGCGTCCGGCGGCGGCGGCTGAGGAGGGCCCGGCCTGCGAGAGCCTCAGTGGGAGCCGGC TCAGCCCTCGGCCACCATGTCGGCGCCGCGCGAGGAGGAGGAGGAGTACTGCGCGGCTGGTGA TGGAGGCGCAGCCGGAGTGGCTGCGCGCCNAGGTGAAGCGGNTGTCCCACGAGCTGGCCG AGACCACNCGTGAGAAGATCCAGGCGCCGAGTACGGGCTGCTGGCGGTGCTCGAGGAGAAGC ACCAGCTCAAGCTGCAGTTCGAGGAGCTCGAGGTGGACTATGAGGCTATCCGCAGCGAGA TGGAGCANCTCAAGGAGGCCTTTGGACAAGCACACACACACACAAGAAGGTGG Sequence 1611

CGCGTTCGAGTCTGGAGACGACGTTNCGAAATGGCACCTCGCAAAGGGGAACGGAAAAĠA AGGAATGAACAGGTCATCAGCCTTGGACCTCAGGTGGCTGAAGGAGAGAATGTATTTGGN GTCTGCCACATCTTTGCATTCTTCAATGATACCTTTGTCCATGTTANTGAACTTTCTGGC NAGTGAGTACTTCAGAAAGGCATNAAACANGCCTCAAAGGGAC

Sequence 1612

TABLE 1 265/467

CCAGACCGAGCAGAGGCGACCCAGCGCGCTCGGGAGAGGCTGCACCGCCGCCCCCGCC TAGCCCTTCCGGATCCTGCGCANAAAAGTTTCATTTGCTGTATGCCATCCTCGAGAGC TGTCTAGGTTAACCGTTCGCACTCTGTGTATATAACCTCGACAGTCTTGGCACCTAACGT GCTGTGCGTAGCTCCTTTGGTTGAATCCCCAGGCCCTTGTTGGGGCACAAGGTGGCA GGATGTCTCAGTGGTACGAACTTCAGCAGCTTGACTCAAAATTCCTGGAGCAGGTTCACC AGCTTTATGATGACAGTTTTCNCATGGAAATNNGACAGTACCTGGCACAGTGGTTAGAAA AGC

Sequence 1613

Sequence 1614

Sequence 1615

Sequence 1616

GGNCGAGCGCCTTGCGGGGGGCGGTATCCCGGCGCCCTAAGACCCCACGACCNCNNGCA CCGGCCGNTGCTGCNAGACCCCGGCCCGNGTCGGTCCGATGTCGCCCCCCGGNCCCGGCG GAAACGCCTCCCTNCTGGCCAGGCTGTTCNAGCACCCGCTT

Sequence 1617

Sequence 1618

Sequence 1619

TABLE 1 266/467

Sequence 1621

GTCGCCCGCGTCCGGGGCCCGCGGCCTCGCCTCCGCCACCTCGAGCTGCGG
TAGCAGCGACTCATGAGAGCGCGGCCGGAGGACAGATTTGATAATGGGCTGCATTAAAAG
TAAAGAAAACAAAAGTCCAGCCATTAAATACAGACCTGAAAATACTCCAGAGCCTGTCAG
TACAAGTGTGAGCCATTATGGAGCAGAACCCACTACAGTGTCACCATGTCCGTCATCTTC
AGCAAAGGGAACAGCAGTTAATTTCAGCAGTCTTTCCATGACACCATTTGGAGGATCCTC
AGGGGTAACGCCTTTTGGGAGGTGCATCTTCCTCATTTTCAGTGGTGCCAAGTTCATATC
CTGCTGGTTTAACAGGGNGGNGGTACTATATTTTGNGGCCTTATATGATTATGAAGCTAG
AACTCCAGAAAGACCTTTCATTTAAGAAGGGTGAAAGATTTCAAATAATTAACAATACNG
AAGGAGATTGGTGG

Sequence 1622

Sequence 1623

GGAGTCGACCNCGCGTCCGAGCCGGGCCGGGCCGATGTGGAGCGCGGGCCGCGGGGGC TGCCTGGCCGGTGCTGTTGGGGCTGCTGCTGCGCGCTGTTAGTGCCGGGCGGTGGTGCCGC CAAGACCGGTGCGGAGCTCGTGACCTGCGGGTCGGTGCTGAAGCTGCTCAATACGCACCA CCGCGTGCGGCTGCACTCGCACACTCAAATACGGATCCGGCAGCGGCCAGCAATCGGT GACCGGCGTAGAGGCCGTCGGACGACGCCAATAGCTACTGGCGGATCCGCGGCGGCTCGG AGGGCCGGGTGCCCGCGCGGGTCC

Sequence 1624

TABLE 1 267/467

Sequence 1625

Sequence 1628

CCTAAGGGCAACAAGGGCGGTCCTGGCCAGCCGGGCTTTGAGGGAGAGCAGGGGACCAGA GGTGCACAGGGCCCAGCTGGTCCTGCTGGTCCTCCAGGGCTGATAGGAGAACAAGGCATT TCTGGACCTCGGGAAGCGGAGGTGCCGCTGGTGCTCCTGGAGAACGAGGCAGAACCCGG TCCACTGGGAAGAAAGGGTGAGCCCGGAGAGCCAAAAGGAGGAATCGGCAACCG GGGCCCTCGTGGGGAGACGGGAGATGACGGGAGAGACCAGAGTTGGCAGTGAAGGACGCA GAGGCAAAAAAGGAGAAAAGAGGATTCCCTGGATACCCAGGACCAAAGGGTAACCCAGGTN AACCTGGGCTAAATGGAACAACAGGGACCCAAAGGCATTNAGAGGCCCGAAGGGGA Sequence 1629

AGTCGCCCGCGTCCGCTGTGCCTGAAGGAGACTGGTTTTGTCCAGAATGTCGACCAAAG CAACGTTCTAGAAGACCTCTCTAGACAGAGACCATCCTTGGAAAGTGATGAAGATGTG GAAGACAGTATGGGAGGTGAGGATGATGAAGTTGATGGCGATGAAGAAGAAGAAGATCAAAGT GAGGAGGAAGAGTATGAGGTAGAACAAGATGAAGATGACTCTCAAGAAGAAGAAGAAGAAGTC AGCCTACCCAAACGAGGAAGACCACAAGTTAGATTGCCAGTTAAAACAAGAGGGAAACTT AGCTCTTCTTTCTCAAGTCGTGGCCAACAACAACAAGGAACCTGGAAGATACCCTTCAAGGAG TCAGCAGAGCACACCCCAAAACAACTGTTTTCTTCTAAAACTGGGTAGAAGCCTAAGAAAG ATAAACTCTGCTCCTCCTACAGAAACAAAATCTT

Sequence 1630

TABLE 1 268/467

AGCCCAGAGCAACAAGCTTTCAGCAACACAAGAAATTCAGGAAGCTGCTTTCAAAAAAGAA

Sequence 1631

Sequence 1632

CGTCCGTTTGTTTAATATTTTTTTTTCTCTCTTGAACAAAACTGAGATAATTTAGAAAACA GGTGCTTAATTGCAATAAAATTACTATGAAGTATATTAAAAATCACGACATTGTAAAATC TCACTTTAGATCATCAAAGAAAACCATTGTTACTATCTCCTTTGAGCTTAGGAAAATGTA CAAGAGAACAAATTAAAATTGAAAAAATTGATTTCACTTAGAAAAACTTCTAGGAACAGGG TGAACCACTGATTTAATTTGCCTAATTATCTTATGACAAGTATCAAATTAAGATGACAC TTAAAGGATCCTTAGCATTTAACTTAATGATGGAGAAAGAGTGCTCAATAGGACAGTTCC CCAGTTAAGGGGTAATGGAGATGCCCATTTTCAGGAGGACCATTCTAAGAAGATATTTTT GGATTCATTAAAAACATTTAAATAAAAAGCCCTTCTTCAAGATTGGGAAC

Sequence 1634

Sequence 1635

Sequence 1636

CCNCGCGTCCGCGGACGCGTGGCCGACGCGTGGGCTTCTGCAGCAAGCTCAGGAGAGCT GCTGTCTTCCCTCCCGCCCACCAGCAACGCACCCTCTGACCCTGCCACAACTACTGCAAA GGCAGACGCTGCCTCCTCACTCACTGTGGATGTGACGCCCCCACTGCCAAGGCCCCCAC CACCGTTGAGGACAGAGTCGGCGACTCCACCCCAGTCAGCGAGAAGCCTGTTTCTGCGGC TGTGGATGCCAATGCTTCTGAGTCACCTTAACTTTGAACCATTCTTTGGAATTGGCGTGG TATATTTAACCACGGGAGGCGTGTCTGGAAACGCAAACTATCATTAATTTCATACTAGGT TTGTACCGTATCTGTAGGCATTCCTGTAAATAATTCCAAGGGGGGAAAACTAAACNGGGAC

TABLE 1 269/467

GTGGGGTTGTATCCTGCCAGGTTTGAGTGGGGGGCTCACACCTAGGGTGAGAAGTCAGAAA GCGCTTGTATTTTAAACAACCAAAAAGAATTGAAAGGGTG

Sequence 1637

CGCGTCCGGCTCCCCGCACCCCTCGCACTCNCTCTGGCCGGNCCAGGGCGGCCTTCAGC CCAACCTTGCCCAGGCCCCACGGGCGCCCACGGAACCCGCTNGATCTCGCCGCCAACTGGTA GACA

Sequence 1640

GTCGCCACGCGTCCGGCCGGGCCGGGCCGGGCAGCCGGGAAGCGGGTGGGGTGTGTTA CCCAGTAGCTNCTGGGACATCGNTCGGGTACGCTCCACGCCGTCNCAGCCACTGCTGTGG TCGCCGGTC

Sequence 1641

Sequence 1642

CGCGTCCGGAGGGGCTAAGAAGGTTGTCCTTGCCTAATGCTCTGATCTGTAAGTGAATAG GGCAGAACAGTTCAGCCTTGAGGTTAGAATTTAGCAGGAGCTATCCTGACTTAATATCCA GTTGTGGGGTTTGCAAAACAAACAGCTGTATGTAATCATTGCCACTAGTTCCATCTAGA ACTCCTTTCTAGTTTGTTATTTTTAAAATGTTTATACATAAAACCACCAAAATACATAGC TTCGACAAGATGGAAGTTTATTTCTCTCTCCCATAACAGTGCAGTGATAGTCAGCTGGTC

TABLE 1 270/467

CAGGCCAGGCAAGGGGCTGGTCCATGATGTCATCAGGCACCCAGGTTCCTACTGGCTTTGCATGTGGCCACAGTTAGCAACAAANGGAGGCTGTAAATTT

Sequence 1644

Sequence 1645

Sequence 1646

Sequence 1647

GGTGTCGCCCCGCGTTCCTGTTTCCTAATTTATATTTCCGATACATANGTGTAGAACA
GGAATTTGCAGAAGCCATTTAAGTTATCTTTTGAGGTAANGCTCTGATTTAGCATTTATT
CTGATAAAATCTAATACATCATGGGATATATATAAAGCAACTTAATTCTTGTGGTGTAGT
CTTAATAGTTTTGAATGTTGACTGAATGTCTATAAAATTGTGAGTTTGTCTTTGTTACAT
TCCAGTGTTTCTGCCTCTTGGCATGCTTAAAGCACGGCTTACTTCATCTGCTCCTTACAC
ACTAAAATGCTGTTAGTGTGCTCAACTACAGAAATAGCCGCTGCTAAGTTGATGTAGATT
TTCTACTTGAATATTTTTATGGTTGTAGGAACCTCAGGAGGGTCAGTGTTTACTGGTTTA
TATATGCCTTCTTTTTCCTGTTTGAGCTTCTCTTTTGAAGGGATTCTAACAGAACAAAA
GCTGCTGATCACCCTAAGTTGGAAACAGNAAAGGNGTAATTAATATAACTTAATGC
Sequence 1648

TABLE 1 271/467

ACTGCGGTATTCCAGTTCTTCTGACACCGGATGGGTGCTTGGGAACCGTTTGAGCCTTAT
AGATCATTTACATTT

Sequence 1649

Sequence 1650

Sequence 1651

Sequence 1653

TABLE 1 272/467

Sequence 1654

CGCGTCGCTGACATTTCCTAGGAAGCTNGGAAAAGGAAAGTGAAGGAATGGTCTAAAGA
AATGACCATTCACACTGATTTTGTCTGGACAGTCTGGCCGCAGGTTATTCATAGATTATT
CAGCCTTTGCAGGACTTGGATTCAGGGTTTTACTCAGTCCCTTTACCTTAGGTGGAATCT
TCTTAAATTGAAATTTTTGGTAAGGAATTCATTTCACAGGTAGTGTTTCAGACTCTGAAA
GCCCTGACTTGGTTCTTGGCTTCTACTGTACTAGTTACTAGTTACTGGTACTGTTGCCAA
GCAATCTGCTTGGAATTTGTGGATCCCTGCTGTTCCCTAATCCCACCCCCTGCCCTGAGA
CAGTGAATGTAGTCCGTGAAGGGAGTGCCTCTCTGGGACCCCCTGTGTTGTTACAGGCTG
TGCAGTGCAACAATTCCAGCAAAAATACCCTATCCCCGCACTTAGTCATTCGTGGTAACT
AACAATTTTGAAATACTCATATAAAATGAACAGGAAAGTGGTTAGTG
Sequence 1655

Sequence 1656

CNCTAACCCCGAACTCTAGATCGTCTTGCTTGTTTGTCTGAAGAAGAGGGAATGAAATAGAA AGTGGAAAAATATTTTCAGAGCATCTTCCCTTAAGTAAGCTACAGCAAGGCATAAAA TCTGGTACATACCTTCAAGGAACATTTAGAGCTAGCAGGGAAAATTACTTGGAAGCTACA GTATGGATTCATGGCGACAGTGAAGAAAATAAAGAGATAATCTTACAGGGACTTAAACAT TTAAACAGAGCTGTTCACGAAGATATTGTGGCTGTGGAGCTTCTCCCCAAGAGTCAGTGG GTAGCACCATCTTCTGTGGTTTTACATGATGAAGGTCAAAATGAAGAAGATGTGGAGAAA GAAGAAGAACGAATGCTTAAGACTGCTGTAAGCGAGAAAATGTTGAAGCCTACA GGTAGGAGTTGTAAGAATAAAAAAGGAATTGGA

Sequence 1657 CGTCCGCGGAC

Sequence 1658

GTCGCCCGCGTCCGTTTGATATACCACTCTGATAACTCATATAAAAAATATCATCATAAA
AAGCTTAATTTCATCCCTTTTATGTTGGTTTTAAAAGGTAAATGCTTACCATATTTTATA
ATTGAGAACTCTTACATAGTAGAATCCATTCTATAATACATGTGTTGACAAAGCTTTAGA
GAAAGTTTCCTATTCTCTTCCATTTCCCCTGCCCAAAGTGCTGACATAGGCAGTGATGAA
GAATCTTTACCAAGATTTTCAGGGTGTACCTATGAAATTGCTTTAAATGCACTGCTGGTG
TAAATAATTAGCAAGCAAAAGCGTTTCTGTGACTTCAGGTACCAGGCTTAAAGAGCACTAG
GGATGGGGAACGAATGCCAAATCAGACTCCACCTAGAGCACCAGGAAACAGCTTGTCCCT
GGTAGGGAAATGGTGTTGCTGAAAG

Sequence 1659

CGACCNCGCGTCCGGCTGNTGACCCCATGCTGAGTGGCCNGTGGGGAGCGGCGCCCGGCA

TABLE 1 273/467

Sequence 1660

Sequence 1661

Sequence 1662

GACCACGCGTCCGGAAGGAAGGGACGGGCTGAGTTCCCCGACGAGAGACACACCCAGATT
TTCCTGCAGCTTGGGGAGAGGTCCTCCCAGGAGCCTTGGTCCCTCCTGGCCTGCCGGAGT
CCTTAGCCAGGATGGAGGCTGTTGTGAACTTGTACCAAGAGGTGATGAAGCACGCAGATC
CCCGGATCCAGGGCTACCCTCTGATGGGGTCCCCCTTGCTAATGACCTCCATTCTNCTGA
CCTACGTGTACTTCGTTCTCTCACTTGGGCCTCGNATCATGGCTAATCGGAAGCCCTT
Sequence 1663

CCGCGTCCGGGGGTTGGTACCCGAGCGCCTTCCCCTCACCTCAACCAGAGAAGAGCATCCGGTTGCTTTTAAAGCTTTTAGCCTGCCCTAGCAAGGACAAAGCATGTTAGATTAGAGAT GCTTCTGCTGATCGCAGGGGTTCTTATTTGAAAACATCTATGATGGGGGTGGGGTGGGAG GAGACAGGTTGTGGTTATGCAGGAAAATCTTGTCCTAAAAATATATGAGTTTGGGGGTAA GGGGTGGGATAGCCAAGCAAAATCAGTAATTATTTTAAAATGAACATATGTATTTTATT AACTTTTAGTTAAATACAGATTTTTACAACGAGGTCAGCATAAGCCTAAATCTATATAGAG GGCTAACTCAGGCATTGTCTTGTTTATTTGTAGACTGGATTAAAAACAACCTGTCCTGTT TTGTNAGTTCCCAGCTTCTTTCGTTTAGAATAAATTAGACCAAAAGAA Sequence 1665

WO 01/070979

TABLE 1 274/467

Sequence 1667

NCGCGTCCGACACTATTTAGAGAGCTCCCTTCCCACCTCTCTGCCCAGCCTTGTTACCTC
ACTTCTGCTCTGGCCATGGCTGTGAAGGGCCCAGCCAGCTCCCTGTTTTGATGTTCTGTG
CAACAGCTCCGGGGTCTTGTGACTGGAGATCCTCAACAGGCCCTGGAGCCAGGACTGGAG
TCTTGGCAGCTGATGAGCACCCTTGCCGGCCAGGAGGAGCTGATGCTGACGATCTCCC
CAACATCTGAAGGCTTAAAGAACATTGTCGTTCTTCAGCCCTCCTTGCTTCTCTCAATAC
AATAAGACATTGCAGAAGCAAAAGGGTGGCCTCTGCTCCAGGCAAGGCAGCTGGCTCTGT
CTGGGGGCGTCGGCCTGGGGCTTGGGTGCCACGTGCTGAGATTGCATAGTCAAAACAAGC
CATTTTTGCCAACAATAGCTTGTGGCTCCCACATTTTTCTACCCTTGCACTNAANGGCCA
GACCACTCTNTGCATGGACCAANACCATNTTTCCAAACCCATGGGGCTTTTTTTNCC
Sequence 1668

Sequence 1670

CGACCNCGCGTCCGGTCTGAAGGGTCTGGCTGGTGAGCCAGGTTTTAAAGGCAGCCGAGG GGACCCTGGGCCCCCAGGACCACCTCCTGTCATCCTGCCAGGAATGAAAGACATTAAAGG AGAAAAGGAGATGAAGGGCCTATGGGGCTGAAAGGATACCTGGGCGCAAAAGGTATCCA AGGAATGCCAGGCATCCCAGGGCTGTCAGGAATCCCTGGGCTGCCTGGGAGGCCCGGCCA

TABLE 1 275/467

CATCAAAGGAGTCAAGGGAGACATCGGAGTCCCCGGCATCCCCGGTTTGCCAGGATTCCC TGGGGTGGCCCCCCTGGAATTACGGGATTCCCAGGATTCATAGGAAGCCGGGGTGA CAAAGGTGCCCCAGGGAGAGCAGGCCTGTATGGCGAGATTGGCNCGACTGGTGATTTCGG TGACATCGGGGACACTATAAATTTACCAGGAAGACCAGGCCTGAAGGGGGAGCGGNGCAC CACTGGAATACCAGGTCTGAAGGGATTCTTTGGAGAGAAG

Sequence 1671

Sequence 1672

Sequence 1673

GTCGACCACGCGTCCGGCCAGAGCTGAGTGGCAGCCGCCTCCCTTATGCAGGACATGTGC
TCTCGGCTTCACCAGGGTTCTGACCGGGTCTGCTTCTGCATTCACAGCGCCTCCTGGACC
TGAAGGCATCTGAGTGTGAGACCCTGTTCTAACTCTTAGAAGTGACATTGTAAGAGGTGG
TGGGGACCAGCTAATTGGTCCAACCCAGCCTGAGTGCACCACCCTTTGAACAAATGTATC
AGTGATGAAAATTTGCCTTTGCCCCGGCTTGCCTGTAATCCCAGCACTTTGGGAGGCCGA
GGTGGGCGGATCACTTGAGGTCGGGAGTTCAGGACCAGCCTGGCCAGCGTGGCGAAACCC
CGTCTCTACTAAACATAAAAAAATTAGTCAGGTGTGGCGGTGCCTGTGCCCAGC
TATTCAGGAGGCTGAGGCACCAGAATTGCTTGA

Sequence 1674

Sequence 1675

TABLE 1 276/467

GGGACATGGGCGGCTTTGCCATTCTGGTGCAAGAAGGCCA

Sequence 1676

TCCCTCTGCTGATGATGGATGCCCCTAACACCTGTGCCTAACACCCCTACTGAACCCCAC
AGCTCCAGCCTTAGTTTTTGGAGTCAAGTGTTAAAGGTTTCTGGCCAGAGGAATTGGGGT
CTTGCCATCCCTGCAATAGCCCTTTTATGGGCTCTGGGAGACAGCTTTAGGGAATAAATG
GGGATTTTCCCCTTTTTCTACCCACTCCTTTGCTTCCTCCAAGACTTACCCAACTCCTTC
CCCCTCAGAGAACCAAATAGCCTGAGGAAGCAGGAGAGTTCCTGGTTATGGCAGATTCTT
GGTGATTTGGGGCTTCAAGACAGTAGGTGAGAGAGTGCTGTCAGGGACGTATCTTCTTCAT
ACCAAAGTCACTGGTCCTTTCTCAGCCTCTCTCGTGCTTTTCTCCTAATGACCATATTTT
TGCCAAAAATTGGGAATATGTTATCTGACAGACCAGAATATTTTGAAGGTTTGGGCTG
Sequence 1677

GCGCCGCGATATNCGGATCAACCTATGGTNTCAATATTGTNAGTTATTCAGCATAAACA GAATTATTTCCCAANACTTGATCTGAAATATTNNTAATGGTCNTACTNGAAACTTATATT CTTNCTGGGAGNGANGTNTTTATCATTTTTCCATGGAGACAGGTTCTAACTCTGTTGCCC AGGCTGCANTGCAGTGATGTGATCATAGCTCACTGCAGCCTGAAACTCCTGGGTGTCAAG TGATCTCTGGCCTCAGCCTCCCAAGTAGTTGGAACTTCAGATACGTGCCACCACAACCAG CTAATTTATTTTTAGAGATGAGGTNTCGCTATGTNGCCCAGTCTGGCCNNCTAGCCNCA AGTGATCTGGCCATCTNAGCCTTCAGTTGGAGATGTCTGATTTATGTTAATATAAGAAAG CTGTTGATCGTTTATCATAAANGCATTT

Sequence 1678

GTCNCCNCGCGTCCGCTCCTCCGCCGGCATGCAACTCGGCGCCCGCGGTCCATGGACCGG
AACCTCGGGCCGACGGACGGGAACCCGGGCCGCGCTCCCCGCCTCAGGCTCC
TCCTCCTCGCTCTCCGCCGCCTCCGCCGGACTCCCGCAGGCCCTGCACCGCCGCCAG
GCTAGCGGAGCTGCCCCGGGAAGCTGGGTGACGGGTTCGCGGCTGCCCCGCAGCTACTCCGCCGCCTCCAGTGCTATTGTCCCTGGGCCTTGAGCGGGTCCACTGGG
GAAGGCNCGTGTGCGCCGGCTCCGCGGAAGATGCCGGACCAAGCCCTACAGCAGATGCTG
GACAAGAAGTTGCTGGGTTTGTTTTGCTACTGATGAAGATGATAGAACAGCTGAATGGGT
GAGGACCATGGCAGGTGCAGGAGGATCTACAAAATGGGTTCACCAGGGCCTGTCTACAAC
GCTGGGTGGATGAAAAGCAAAGAG

Sequence 1679

Sequence 1680

Sequence 1681

CCGGCAAAGCAGGACTCCTGATTTATATGTCCCTCCTCGGCAATCCTCTCACCCCACCTCCCCGAGAACCTCAGTTCTTCCTAAATTGCTAAAGCTGAGGGGAAAGGGATGCTTTG

TABLE 1 277/467

TCACCNCGCGTCCGAAAAACGCAGATGATATACCTGCAACATCNGTCATGGCTGCGCCCT GTGCTCAGAAGCAACCCGGGTGGAATATTGCTGGTGCAACAGTGGCAGGGCACAGTGCCA CTCAGTGCCTGTCAAAAGTTGCAGCGAGCCAAGGTGTTTCAACGGGGGCACCTGCCAGCA GGCCCTGTACTTCTCAGATTTCGTGTGCCAGTGCCCCGAAGGATTTGCTGGGAAGTGCTG TGAAATAGATACCAGGGCCACGTGCTACGAGGACCAGGGCATCAGCTACAGGGGCACGTG GAGCACAGCGGAGAGTGGCGCNCGAGTGCACCAACTGGAACAGCAGCCGCGTTGGCCCAG AAGCCCTACAGCGGGCGGAGGCCAGACGCCATCAGGCTGGGCCTGGGGAACCACAACTAC TGCAGAAACCCAAGATCGAGACTCAAAGCCCTGGTGCTACGTCTTTAAGGCGGGG Sequence 1683

Sequence 1684

NCCCATACTGGGGGCCCCCTTCCTGCAGGCCCCATCAGGTGCAGAGCTGTGGGTCTGGTT CCAAGACACTGTCACTGATGTGGATAAATCTTGGAAGGAGCTCAGTAATGTCCTCTCAGG GATCTTCTGCGCCTCTCTCAACTTCATCGACTCCACCAACACAGTCACTCCCACTGCCTC CTTCAAACCCCTGGGTCTGGCCAATGACACTGACCACTACTTTCTGCGCTATGCTGTGCT GCCGCGGGAGGTGGTCTGCACCGAAAACCTCACCCCCTGGAAGAAGCTCTTGCCCTGTAG TTCCAAGGCAGGCCTCTCTGTGCTGCTGAAGGCAGATCGCTTGTTCCACACCAGCTACCA CTCCCAGGCAGTGCATATCCGCCCTGTTTGCAGAAATGCACCGCTGTACTAGCATCTCCT GGGAGCTGAGGCAGACCTGGCAAGTTGTATTTGATGCCTTCATCACGGGGCAGGGAAAGA

Sequence 1685

Sequence 1686

TABLE 1 278/467

AAACATAAAAGAATGTATCCTTAGTACTGGTTCTTAAACAGCCCATAAAAAACCCATTGGC CTGAAGCTTATATCTCAGGCCTATGCCCATCTTATAGTCTTGGAAGACAAAA Sequence 1687

Sequence 1689

Sequence 1690

Sequence 1691

Sequence 1692

ACAGAATTTAGGGGTGGAAAGCACTTGNGCTTTAGCTNTTTCATATTAAATATAT CTATATTTAAACATTCATGGCATAGATGATGATTTACAGACAATTTAAAAGTTCAAGTCT GTACTGTTACAGTTTGAGAATTTGTAGTATTACATCATTACATAAGTCATTTAGTAACA

TABLE 1 279/467

Sequence 1693

CGGTTAACATGGCCGTCACCGACAGCCTCAGCCGGGCTGCGACTGTCTTGGCAACTGTNT
TGCTCTTGTCCTTCGGCAGCGTGGCCGCTAGTCATATCGAGGATCAAGCANAACAATTCT
TTATGAAGTGGCCNATCAAACAANCTGGGCCTGTTCTTGGTGTGTACATCCCCGATTCTG
GTATTAATTATCGACATGTTGCAAATACCCTTTCTGTTTATAGAAGTGTCAAGAGGCTAG
GTATTCCTGACAGTCACATNTGCCCCTAATGCTTGCAGATGATATGGCCTGTAATCCCTA
GAAATCCCAAACCAGCTACAGTGTTTTAGTTCACAANCAATNTGGAACTAAATGGTGTAT
GGGAGAATGATGTGGGGAAGGTGNNATTATAGAAGTTTNTTGAGGTAAACNGGTGGGAGAA
NNNTTTTTTTTACCNGGGTAATTTAANCTGNGGGAGGGANTCCCCACCCTAAGTANCTTCC
TTCGGG

Sequence 1694

GTCCGCAAGATGACGCAGCTCTCTGACCTACGACACTCTCCGGTTTGCTGAGTTTGAAG
ATTTTCCTGAGACCTCAGAGCCCGTTTGGATACTGGGTAGAAAATACAGCATTTTCACAG
AAAAGGACGAGATCTTGTCTGATGTGGCATCTANACTTTTGNTTTACATACAGGAAAAAC
TTTCCAGCCATTGGGGGGACAGGCCCCACCTCGGACACAGGCTGGGGCTGCATGCTGCGG
TGTGGACAGATGATCTTTGCCCAAGCCCTGGTGTGCCGGCACCTAGGCCGAGATTGGAGG
TGGACACAAAGGAAGAGGCAGCCAGACAGCTACTTCAGCGTCCTCAACGCATTCATCGAC
AGGAAGGACAGTTACTACTCCATTCACCAGATAGCGCAAATGGGAGTTGGCGAAGGCAAG
TCCATAGGGCCAGGTGGTACGG

Sequence 1695

Sequence 1696

TTCGGGAGTCGACCCGCGTCCGGGCCAGCCGGCTCGCCGGGGGCCATGGCAGCAGCGGCTACTGCAGCCGAGCGGGCCCCAGACTCCCAGAGCCCAGACTCCTCGCAGAGCCCCCAGACTCCTCACCTGGATCCCAGACTCCTTCTTCTCCCAGTCTTCTCAGCGCACCCTCCAACTCCTCAACTCCCAGACCCAAAGACTCCAACTCCCAGACCCAAAGAGTTCATCCACCAGGGACCCTACAGTCTTCCACCCCCATCCTCAACTTCCTGCGCACCAAAGAGTTGGATCCCAGGGGTCCACCGCAGCCTCCTCCATGAAGCCCAGTTCTATGGGCTCACTCCTCTGGTTCGTCGCCCCCACCAGAGAGTTCGATCTCTTCTTGTGGAAACGTCCTCTCTCAATGGTTACCTGCCCCCACCAGTGTTCCAGTGAAGCGGCGGAACCGCCCACCAGCCCTAGTGGGGCCCCACCAGCCCTCCTCCAGTGAAGCGGCGGAACCGGCACAGCCTAGTGGGGCCTCA

Sequence 1697

CGTCCGAAGGAAGGAAGGACGGGCTGAGTTCCCCGACGAGAGACACACCCAGATTTTCC
TGCAGCTTGGGGAGAGGTCCTCCCAGGAGCCTTGGTCCCTCGGCCTGCCGGAGTCCTT
AGCCAGGATGGAGGCTGTTGTGAACTTGTACCAAGAGGTGATGAAGCACGCAGATCCCCG
GATCCAGGGCTACCCTCTGATGGGGTCCCCCTTGCTAATGACCTCCATTCTCCTGACCTA
CGTGTACTTCGTTCTCCACTTGGGCCTCGCATCATGGCTAATCGGAAGCCCTTCCAGCT

TABLE 1 280/467

CCGTGGCTTCATGATTGTCTACAACTTCTCACTGGTGGCACTCTCCCTCTACATTGTCTA
TGAGTTCCTGATGTCGGGCTGGCCTGAGCACCTATACCTGGCGCTGTGACCCTGTGGACTA
TTCCAACAGCCCTGAGGCACTTAGGATGGTTCGGGTGGCCTGGCTCTTCCTCTCTCCAA
GTTC

Sequence 1698

Sequence 1699

ACGCGTCCGGAAGAATCTACACTTCTTTGCACCAGAGTATGGAGAAGTCACTAATGTGAC
AACAGCAGTGGACATCTACTCCTTTGGCATGTGTGCACTGGAGATGCCAGTGCTGGAGAT
TCAGGGCAATGGAGAGTCCTCATATGTGCCACAGGAAGCCATCAGCAGTGCCATCCAGCT
TCTAGAAGACCCATTACAGAGGGAGTTCATTCAAAAGTGCCTGCAGTCTGAGCCTGCTCG
CAGACCAACAGCCAGAGAACTTCTGTTCCACCCAGCATTGTTTGAAGTGCCCTCGCTCAA
ACTCCTTGCGGCCCACTGCATTGTGGGACACCAACACATGATCCCAGAGAACGCTCTAGA
GGAGATCACCAAAAACATGGATACTAGTGCCGTACTGGCTGAAATCCCCCAGGCCCTGAT
CTGCGCTGTGGCTGCCCTGGGACGTGCTGCAGCCCTCCTGTCCCCCCAGTC
Sequence 1700

Sequence 1701

CCCACCGTCCGCGCGCGCCCTCGCCTCGGCCGCGCCCTAGCAGCCGACTTAGAACTGG TGCGGACCAGGGGAATCCGACTGATAAATTAAAACAAAGCATCGCGAAGGCCCGCGGCGG GTGNTGACGCGANTGCGATNTNCTGCCCANNGCNTCTTGAATGTCAAAGTTGAANAANC CAATGAAGCGCGGGTAAACGGCGGGAAGTAACTAATGACTTCTCATTAAGGGTAGCCAAA NGCCCTTCGTCATCTNAATTAAGTTGGACCGCGCANTGAAATNGGATGAAACCNAGANTT CCCACNTGTCCCTACCTACNTAATCCAAGGCGGAAAACCACAAGCCAAAGGG Sequence 1702

Sequence 1703

TABLE 1 281/467

Sequence 1704

Sequence 1705

Sequence 1706

Sequence 1707

Sequence 1708

CACGCGTCCGGGAAGCGGTGCGCTCCGTCACCACGGGAGTGCGGGAATCCGCCGTTTGCG

TABLE 1 282/467

Sequence 1710

Sequence 1712

CCACCGTCCGGCCGCCAGAGGTGCGAGAAGGCCGAGGAGAAGGCCAAGGAGATTGCGAA
GATGGCAGAGATGCTGGTGGAGCTGGTCCGGCGGATAGAGAAGAGCCAAGGAGATTGCGAA
GATGGCAGAGAGCTGTCCGGCGGATAGAGAAGAGCGAGTCGTCGTGAGC
GCGGTCGGCGGTTTCCAGCCAATGGATTCTGGTCAACTGGTGGAGATTGGCTGACACCCT
GGAGAAGCCGAAACCAGAGAGCCTTTTGTTTTCTCTTTTTTCCTGTCTATGCTCTGCTC
ACTTAACACTACGTTTTCTGCTATGGTCTGTGGTTGATGACCTCAATATGAGTTTCGATT
GTTAACCGTGTTTTTGTTTGGGAAGTAATTTTGTTTGAAAATGCTCTCACATACAGGAAT
TAGGGCCTAGATTGTAAGCTCTTGCAGCAGTCACATTTGTTCCCGGGCTTTGGTGGTTAT
TTTCTAAATTTTTGAGGTGCCTTTGCTATTTCTTGTGTGACCTGATAGCTTCCCCTG
Sequence 1713

GCGTCCGAGCCTCTGGGGGTGGATCCTGAAAGGTGGTCCAGCCGCCTGGCCCTGCGTGGGACCCTCCACCTGGCAGCAGGGTCTCGCTCTGTCACACAGGCTGGAGTGCAGTGGTGTGATCTTGGCTCATCGTAACCTCCACCTCCCGGGTTCAAGTGATTCTCATGCCTCAGCCTCCCGAGTAGCTGGGATTACAGGTGGTGACTTCCAAGAGTGACTCCGTCGGAGGAAAATGACTCCCCAGTCGCTGCTGCAGACGACACCTGTTCCTGCTGAGTCTCCTTTCCTGGTCCAAGGTGC

TABLE 1 283/467

Sequence 1714

GTCGCCACGCGTCCGCAGAAGATTGACAAATCTGAGGGCCGCTTCCATGTCCAGAACCTT
AGCCAGGTGGAGCAGGATGGGCGGACGGGGCATGGACTCCGCAGATCTTCCAAGTTCTGC
TTGAAGGAGCACAAAGCCCTCAAGACGTTAGGCATCATCATGGGCACTTTCACCCTCTGC
TGGCTGCCCTTCTTCATCGTTAACATTGTGCATGTGATCCAGGATAACCTCATCCGTAAG
GAAGTTTACATCCTCCTAAATTGGATAGGCTATGTCAATTCTGGTTTCAATCCCCTTATC
TACTGCCGGAGCCCAGATTTCAGGATTGCCTTCCAGGAGCTTCTGTGCCTGCGCAGGTCT
TCTTTGAAGGCCTATGGCAATGGCTACTCCAGCAACGGCAACACAGGGGAGCAGAGTGGA
TATCACGTGGAACAGGAGAAAAAAAAAC

Sequence 1715

CCCCGTCCGCTTTGTTNATCTAAAGGCTTNAGTCCCATTTTTTATACGTTGTATTTT
AAAAACGTTTGAAAGGAGTCTTACACCTGTATCATGAAAACTGAATCCTTTTGAAATACC
ACTATATGAAGAGAGAGAGATGAAATTTAGTGAACAGAATTTGGAAAAAGGTGCTCATAATTTC
ACTATGCAAACTTACCCCAGTCTCTAAAAAAGTAATTTAGATTTAAAGTTCTTTGATGTA
TTTGATTTTCTAAATCTTTATGGTTATGATTTGGAATAAAATGTGCCTAATCCTGTGTTA
CATTCTGTTCTTAAATCTGAATGCCTTCTCATTTAATTCTGAGGAAAATATCACACAAGTG
TCTTCATTGACCTTGAAGAAATGTATATACAGTTGCCTTATAAAACAACATAAATTTAGA
CCATAACTTTTATAGAGAAAAGGGTTTTGTCAAATGTTTTCTGAAAAATCTGAGTAATTCAA
AGCATGCCTCTGCCCCCTTTAATA

Sequence 1716

Sequence 1718

CGGACGCGTGGCGCCGCCGCCGCCGTCGTTGTCGTAGTCGCCGCCGCCGCTGCCGAGA
AAGAGCACGAGCGGGAAGCCCCAGAGTGAAATCTAGCATCCTGCCGGCTGGTCTGCCCG
CCCTCCTTTTCCCCCCGGCCCCNGTCCCCTCCCNCCGCAGGTGCCATCCGTCGCC
ATNCGCCTCTCACCCTCNCATCCCCAGGTGAGGGGGGTGAGTTCAGGAAGCGGNNACCC
CNAGGAACCCANCAGGGTCACCATTTGCAGCGCAACATGGCAGGAGCTGGAGGAGGGAAT
GATATTCAGTGGCGTTTTTTTCAGGTGAAAGGAGCAGTATGATGATGATGTAGCAGNAAG
CANGATATNATTTCTACAGTANAATTTAATCNTTTCTGGGAGAAATTCTAGCAACANGAA
GATAAAAGGTGGGTAGAGGTTGTCATTCTTTCAACAGGGAGCAGGAAAC
Sequence 1719

TABLE 1 284/467

Sequence 1720

CTGANGCTCGTTTTCGTGAAATTAAGCTTCAGAGGGAAGCCCGNGAAACACAGGAGAGCG AGCGCAAGCCCCACCATACAAGCACATCAAGGTGAATAAGCCTTACGGGAAAGTCCAGA TCTACACAGCGGATATTTCAGAANTCCCTNAGTGCAACTGCAAGCCCACAGATGAGAATC CTTGTGGCTTTGATTCGGAGTGTCTGAACAGGATGCTGATGTTTGAGTGCCACCCGCANG TGTGTCCCGCGGGCGAGTTCTGCCAGAACCAGTGCTTCACCAAGCGCCAGTNCCCAGAGA CCAAGATCATCAAGACAGATGGCAAAGGGTGGGGC

Sequence 1721

Sequence 1722

TCGCCACGCGTCCGCTCTTAACACAGAGTCTGCAGCCCCTAACTGACACCCTGTCCTTCC
TCCTAGGAAGTGCTGGACTCCCTGGTCAGCAATGTCAACATTGAGCTGCTCAATGCCCTC
CGCTACCATATGGTGGGCAGGCGAGTCCTGACTGATGAGCTGAAACACGGCATGACCCTC
ACCTCTATGTACCAGAATTCCAACATCCAGATCCACCACTATCCTAATGGGATTGTAACT
GTGAACTGTGCCCGGCTGCTGAAAGCCGACCACCATGCAACCAA

Sequence 1723

Sequence 1724

Sequence 1725

TABLE 1 285/467

Sequence 1726

CCNCGCGTCCGGAGCCGAGAGTGTGTGGAGCAGTTACAGCTGGAAGACCGGGTCCTCTGC
CTCCACAGTAGATGGCTGAATCCTCTATGCGGGACTGGCAAATGGCACTGTGGTCACCTT
CAACATAAAGAACAACAAACGACTTGAGATCTTTGAATGCCATGGCCCTCGGGCAGTCAG
CTGTCTTGCTACAGCTCAGGAAGGTGCCCGAAAACTGCTGGTCGTGGGGTCTTATGACTG
CACAATTAGTGTACGCGATGCCCGGAATGGACTGCTCCTCAGAACTCTGGAGGGCCATAG
CAAAACCATTCTTTGCATGAAGGTGGTGAATGATCTCGTGTTCAGTGGCTCCAGTGATCA
GTCAGTCCATGCTCACAACATTCACACTGGTGAGCTCGTGCGGATCTATAAAGGTCACAA
TCATGCAGTGACTGGTGGTGAATATCCTAGGAAAAGTGATGGTGACTGCTTGCCTGG
Sequence 1727

CNCGCGTCCGGATNAATATTTTCATCCCTGAGGTTAACAATTACCATCAAAATGTTTTGT
GGAGACTATGTGCAAGGAACCATCTTCCCAGCTCCCAATTTCAATCCCATAATGGATGCC
CAAATGCTAGGAGGAGCACTCCAAGGATTTGACTGTGACAAAGACATGCTGATCAACATT
CTGACTCAGCGCTGCAATGCACAAAGGATGATGATGCAGAGGCATACCAGAGCATGTAT
GGCCGGGACCTGATTGGGGATATGAGGGAGCATCTCCAAAGATGTGATG
GCTGGCCTCATGTACCCACCACCTGTATGATGCTCATGAGCTCTGGCATGCCATGAAG
GGAGTAGGCACTGATGAGAATTGCCTCATTGAAATACTAGCTTCAAGAACAAATGGAGAA
ATTTTCCAG

Sequence 1728

TCGACCACGCGTCCGATCCTGGATCTGGAGAGAGAGCTCTCCAAGCAAATCAACGTGTGC
CTCTGAGCCAGATGACGGGGTGGGACCCCGGTTAGTAAGGACCGGGCCCCAGTGGCTAA
GGCGGTGCCCTGGTGACCAAGGAGAGCCAGACCTGTTGCTCAGGCCGAGCTCCTGGTTGC
CAGCGAGTTACCACGGGACCAGTCGCGTGTATGGCTGAGACTCATTCCCAGTTTCCAGGG
CCCGGTATTTGGACACTAGTTGCCAAGTCTGGGGCCTGGGGATTTTAGGGACCAGCGGTT
GTGACCATCTTTCCTGAGCACCAAGGGCTTCCCCTTTTGTTGCCAAAAAGGTAGTTCTCG
CGCTTGCTAGGCTGGCCTCTCTTGCCTCCCCTTGGCCGGGGC

Sequence 1730

TABLE 1 286/467

GACTTTTGGGAATAAACAAAAGTTCTAGGAAAAGCACTTTCCTTAATCCCGGTTCCCAC TGATGACAATTGAGG

Sequence 1731

Sequence 1733

Sequence 1732

Sequence 1735

GCGTCCGAAAATACAATACACGGACTCTTTCGAGGCCCTGTAATTGGAATGAGTCCACTT
TAAATCCTTTAACGAGGATCCATTGGAGGGCACTTCCAGAATACCTCCCCCAGCGCC
CGCTGCCAGCCCCACACCAGGTGTGAGAACCAAGGTCTGGTGGAGGCAGCTCCAGGCACT
GCCCAGTCCGACACAACCTGCAAAAATCCATTAGAGCCACTGCCCCCAGAGATG
Sequence 1736

TABLE 1 287/467

GCCCCCGGC

Sequence 1737

ATCCTTTTGCCTAAAGATGTAAACAAAACTCAAGACAGAAGGAATCAGGGAATATGTGCT NTTGTGNGCATCTTGTTTACATTTNGGGATCAANTGATGGCAAAAGAAGTAATGAGACCA CTNNAAATTGTTTTNCANTTGNNTTTAAAANACCAGGGTTCCTCATTTTCTTTGATTTTG NAAGTTTTAACAATTGACCTTCTTAAGNGACATTCTCTTTCAAAAAAGANANGTAAANCA GGNGAAATGAAGGGTGGNTGGGGAAA

Sequence 1738

Sequence 1739

Sequence 1740

Sequence 1741

Sequence 1742

Sequence 1743

GTGATTAGAAGTAAGCGNTGATGAGGCTGAAGAAAAGGAAGACAAAACTGAGTACTTGGA GGAACGAAGAGTAATGGGATATCCAATAAACTGAGAATGTTTCTTCACAATCTCCTTTAT TCTTCGTTCCTCCAAGTACTCAGTTTGGTCTTCTTTCAGGTAGGAACGTGATAAAGAA WO 01/070979 PCT/US01/09126

TABLE 1 288/467

Sequence 1744

CGATTTCTTTGTTGGACAACCCAGCTGGGGCTAGGAATGGTTCAGAAGGTTTAAGGCCGG
AANGGGNAATGAAGGGCCCGGCGCTAACCCTCTAGGGACCTGTTTTGCTTCTGTTTAAA
CCAAATGGGCAGTCTGTCATTACACACACCCCTGNGTCTTCATATGTGGCTCGCCAGTATA
ATGGAATGTGCTTACAAGGGCCAGCAGGAGTGCCTGGTCGAGACGGGAGCCCTGGGGCCA
ATGGCATTCCGGGTACACCTGGGATCCCAGGTCGGATTCAAAGGAGAAAAGGGGG
AATGTCTGAGGGAAAGCTTTNAGGAGTCCTGGACACCCAACTACAAGCAGTGTTCATGGA
GTTCATTGAATTATGGCATANATCTTGGGAAAANTGCGGAGTGTACATTTACAAANATGC
TTTTCAAATAGTTGCTNTAANANTTTTGTTCAG

Sequence 1745

GGACGCGTGGGTGGAAATGTAAACAAGAATAGACTGTTCATTCCTGATGGCTTTTAGTCT
ATACTAACATATTGTTTGTCATGGCATCCGAGACTGAAAAGACCCATGCTTTACTGCAGA
CTTGTAGCACTGAATCTCTTATTTCCAGCCTTGGGTCTGGGGGCATTTTGCCTCGTAGCT
GACAGACTTCTTCAGTTTTCCACAATTCAGCAAAATGACTGGCTTCGTGCTCTCTCAGAT
AATGCAGTACATTGTGTAATTGGCATGTGGTCATGGGCGGTAGTCACTGGAATCAAGAAG
AAGACTGACTTTGGAGAAATCATTTTAGCTGGATTTTTAGCCTCTGTTATTGATGTAGAC
CACTTTTTCTAGCTGGATCCATGTCTTTAAAGGCTGCTTTGACTCTCCCGCGAAGACCT
TTCCTTCACTGTTCTACTGTGATTCCCGTTGTGTTCTGACCCTGAAATTTACTATGCAC
CTTTTCAAGCTCAAAGACTCATGGTGCTTTCTTCTGGGATGGTATTTATATCC
Sequence 1746

TABLE 1 289/467

Sequence 1750

Sequence 1751

GGGCATGCTCATAGGCACAGCTGTTGGTCAGTATGCCAATAACATCACACTTTGGATCTT
TGCAGTCACTGCAGGCATGTTCCTCTATGTAGCCTTGGTGGATATGCTTCCAGAAATGTT
GCATGGTGATGGTGACAATGAAGAACATGGCTTTTGTCCTGTGGGGCAATTCATCCTTCA
GAATTTAGGATTGCTCTTTGGATTTGCCATTATGCTGGTGATTGCCCTCTATGAAGATAA
AATTGTGTTTGACATCCAGTTTTGACCTTTCCCAGTAATCACTGTTGATTACGAGAATGT
TACCATGCAGCTTTGCATCTGTTCCTTGTACTGTATGCACATTGCTCAAAGGAAAGTCAG
TGGCTTGCACTACTTACAAGTTTCATAGATTTGAGCCTAACCACAAGAGGCTGGTGCTTA
GTACTGTTTTCCCTGCACGTAGGGGTCTTTTAAAAAATATAAAGCTTGTGATAAAGAGGGG

Sequence 1752

CTGGTTCAGCAGCCGCCCACCCACCTCTGAGTCTGACCTGGAACCTGCCACAGATGGGCC
AGCCTCCGAGACCACCTACCCTCAGCCCAGAGGCCACCACCTTTAATGACACCAGAATCCC
TGATGCAGCTGGTGGCACGGCCGGCGTGGGTACCATGCTTCTGTCCTTTGGGATCATCAC
GGTGATAGGCCTGGCTGTGGCCTTGGTTTTGTACATCAGGAAGAAGAAGAGGCTGGAGAA
GCTACGCCACCAGCTCATGCCCATGTACAACTTCGACCCCACGGAGGAACAAGATGAGTT
GGAGCAGGAGCTGCTGGAGCATGGGCGGGACGCCGCCTCTGTACAGGCTGCTACTTCTGT
GCAGGCCATGCAGGGCAAGACTACTCTGCCCTCCCAGGGCCCACTCCAGAGACCCAGCCG
GCTTGGTGTTTACCCGATGTGGCCAATGCCATCCATGTGTGAGTGGCCTGGGACAAGC
Sequence 1753

GTCGCCCGCGTCCGGTGCTCTCATGTCATCTCAGAGTTCCAGCTTATCAGAGGCATGTA
GCAGGAGGCTTATTCCAGCCATAACTGGGCTCTACCTCCAGCCTCCAGAAGTAATCCCC
AACCTGCATATCCTTGGGCAACCCGAAGAATGAAAGAAGAAGCTATAAAACCCCCTTTGA
AAGCTTTCATGAAGCAGAGGAGGATGGGTCTGAACGACTTTATTCAGAAGATTGCCAATA
ACTCCTATGCATGCAAACACCCTGAAGTTCAGTCCATCTTGAAGATCTCCCAACCTCAGG
AGCCTGAGCTTATGAATGCCAACCCTTCTCCTCCACCAAGTCCTTCTCAGCAAATCAACC
TTGGCCCGTCGTCCAATCCTCATGCTAAACCATCTGACTTTCACTTCTTGAAAGTGATCG
GAAAGGGCAGTTTTGGAAAGGTTCTTCTAGCAAGACCAAGGCA

Sequence 1754

TCGCCCGCGTCCGGACTGATCATAAACCATGCTGGTATTGCACCTTCTGGAACTATGGG CTTGAGAAAACCCCCAGGATCACTTCTCCTTGGCTTCCTTATTTTCTTGAGGCAGGTCGC ACGTTCTACCTGCCCAAGACGTGTGATATCAGCTTCTCAGATCCAGACGACCTCCTCAAC TTCAAGCTGGTCATCTTGTCCTGATGAGGGCTTCTACAAGAGTGGGAAGTTTGTGTTCAG

TABLE 1 290/467

TTTTAAGGTGGCCAGGGTTACCCGCATGATCCCCCCAAGGTGAAGTGTGAGACAATGGT CTATCACCCCAACATTGACCTNGNGGGCAACCGTCTNGCCTCAACATCCTTCAGGAGAGG ACTGGAAAGCCAGTCCTTACNATANACTCCATAAATTTTATTGGGCCTTGCNGGTATTCT TTTTTTTTTTGNGAGCNCCAAACCCCNNGANGGACCCCCACTTGGAACCNAAGGGAGGGC NCGCAAGAAGGGTTCCTTGGCAAGAACAACCCGG

Sequence 1755

TCCGGCCCGCCCCCCCCCCCACCTACCATGGATGATATCGCCGCGCTCGTNTGTC GACAACGCTCCGGCATGTGCANGGCCGCTACGCGGGCGANGATGCCCCNCGGNCCGTT TTCCCTCATCGTGGGCCCCCANGCNCCAGNTGCGTGATGGTGGGCATGGGTCAGAAGG ATTTCTATGTGGGCACGAGGNCCAGAGCAATGAGAGGCATNCTNACCCTGNATTACCCC ATCAGAGCACGGCATNTNTCACCAACTGGGACCGACATTGGAGAAAATCTGGCACCACAC CTTTCTACAATGAGCTGCGTGTGGCTCCCGAGGAGCACCCCGTGCTGCTTGACCGAGGCC CCCCTGAACCCCCAANGNCAACCCGNCGAGAANGATNACCCCAGATNCATGTTTTGAGGA CCCTTTTCAACACCCCCAAGCCCATGGTTACCGTTTGCCT

Sequence 1756

GCGNNGGGGCCGGGGCTGGGGTCGGGGCCAGGGGTCGCCGGNGGCGGNGGACGGCGTN CGGTGCCTGGGGCTCCCTGAGGCGCCGCTGGGGAGTCGAACCCTGATGATGG GACCTGTGAATTCAGCGGGGTGCCAAGTCGTTTTCTGTGTGGGTTGAGAGACAGGCTGNG CAGCCCACTGTTGCATAGGACTAACTACTACAAATCATGCTGAGACCGAGCTATTTTTGC TGCTTAGAGGCTTTGCAGCCTTGAGAGGAATTTTGTTGTCAGGAGAATAAAAGGAGGTTG TCCATNATTGACTTTAAGCAGCAATCAAGTAAAACATTGAGCTCTTNAGCTCCGCCTTTC TTGCTCTGAAAATTGGAAAACCAANAAGGTTTTGNTGTTATTGTGTGACCCCACCTGAAT TATAAACCAAGATGAACATAACCAAAGGTGGTCTNGGTGTTTTTTCAGCAAAAC Sequence 1757

GAGCCGGCTGGCTCGAGTGGCCTTCGTCGTCCCTTGGCGCCCTGGGAGAGTCGCTGACGG
GTGGACTGACGGCCCTGAGGACGCCGGCCGGCCAGGCCGTGAAAGCGCCAGCCCTATGG
CGCGGTCGCAGTGAGGCGGAAGGCCGAGGACGGCCGGCGCGCCCCGGCGAT
GCGGGCCCCGCCGTCGCCTNAGGTGCCATTTGGATTGTACTTTAGTGGCACCGATGTAC
TCTGAGTGGAGGTCACTGCATTTGGTGATTCAGAATGATCAAGGCCATACCAGTGTGCTG
CACAGCTATCCAAAGAGCGTTNGACGAGAGGTGGCAAATGCTGTAAGTCCGGCCTCTTGG
GCAGGTGTTAAGTACCCCTTCAGTGGCTGGTAGTGAGAATTTGTTAAAAACTGACAAAAG
AAGTA

Sequence 1759

WO 01/070979

PCT/US01/09126

TABLE 1 291/467

Sequence 1760

Sequence 1761

Sequence 1762

Sequence 1763

Sequence 1764

Sequence 1765

TCACCCGCGTCCGACTTGAATCCCGTCAGCTTAAAACTTGTGTAAGGGAATCCTGACTT TTAAAATGTGAGGGTATTTGGATCTGTGTTGAAAGTCGTATATTTTTATCTGTGCGGTGC TGAGTGCAGGCCACCAGCTCCTAAATAGAGGTTCCCTATATGCGCGTATGACATGGTGAA TAAACACAACTCTCCCACTCAGGACATCCGGAGCGTTATGGACCGTGGTAGGTGGTCGT

TABLE 1 292/467

Sequence 1766

Sequence 1767

Sequence 1768

Sequence 1769

Sequence 1770

Sequence 1771

TABLE 1 293/467

AGGAAACCTTTCTGCGAGTACGAGCCAACCGGCAGACCCGACTGAATGCTCGGATTGGGA AAATGAAACGGAGGAAGCAAGATGAAGGGCANAGGGAAGGCTCCTGCATGGCTGAGGATG ATGCTGTGGACATCGAGCATGAGAACAACCACCGCTTTGAGGAGTATGAGTGGTGTGGAC AGAAGCGGATACGGGCCACCACTCTCCTGGAAGGTGGCTTCCGAGGCTCTGGCT Sequence 1772

TNGATGTGTATATGGACTGTTNTGAAGGGTTTTTTCTTTATAGCCCANTTAAGTTNTGT
TTGGCTCGGTGCATTTTCATTTATTTAATTAGTAATTTAAGTAACNGTGTTTGNGTAAA
ATCATTGTGAAGTTTCAAGATTCATTATGGGANGAGTTGATGGTNCANTNANGCATGATG
GTTTAACAAATTTTAACACCAAAAATGTTAAATCCTGCATAAATTCAACTGTANATAATA
AATANGGTGTTTTCNTGTATATGATAGNAATGCAATTAGAAGTACCTNTAGTAAANTCTT
TTGGAATCACCAATNCTTTTTTGGCTTGAAAATTGGGAAAGAATTTCTGTTTATAATNCC
TTTNNAATTAAACCTTGNGNGGGGGGGGGGGGGAAAATAAAAAATTGCAGGAAAAACCTGC
ATGAGNCACCTTAANAACCTTTAAAAGTAAGGGGGGCTTNCCAATCTTTTTANTCCCNGGA
AAACCCTGGTTGCCTNTTTTTTGGCA

Sequence 1773

Sequence 1774

CCCCGCGTCCGCTTCCGGTTGCTAACGGTTCCCAAACAGCCCCCGAAAACGCTACGTGAG CTGGGCCCTGGGCCAGAGGCAGAAACGGACGGAAGAAAGGTCTGGCCGGAGATGGGTC TCACTCTGTCACCCAGACTGGAGTGCAGTGAGTGGTGCGATCATAGCTTACTGCAGCCTG AAACTCCTGGGCTCAAGTGATCTTCTCGCCTCAGCCTCCTGAGTAGCTGGAGCTACAGGT GTGAGCTACCCAGCATGGCTCATTTGAGATTTCTGAGTAGAGAAGTAACATGATTAAAC Sequence 1775

GGAACCTCCCTAGATTTCAGAAGATGTATGGAAACGCCTAGATGCCCTGGCAGAAGTTT
GCTGCAGGGGCGGGCTCTCATGAAGAACCTCTGCTAAGGCAGTGTGGAAGGGAAATGTG
GGGTTGGAGCCCCCAAACAGAGTCCTTAGTGGGGTGCTGCCTAGTGGAGCTGTAGAAGA
GGGCCATCATCCTCCAGACCCCAGAATGGTAGATCCACTGACAGCTTGAACTGTGCACCT
GGAAGAGCCGCAGACACTCAATGCCAGCCCGTGAAAGCAGCCAGAAGGGAGGCTGTACCC
TGCAAAACCACAGGGGCAGAGCTGCCCAAGACTGTGGGAACCCACCTCATGCTTCAGTGT
AACCTGGATGTGAGACCTGGAGTCAAAGGAGATCATTCTGGAGCTTTAAAGTTTGACTGC
CATGCAGGATTTCGGACTTGCATGGGCCCTGTAACCCCTTTGTTTTGGCCAATTTCTCCC
GTTTGGAACGGCTGTAATTACCCAATACGTGTATCCCCATCGTATCTAGGAAGTAACTAG
CTTGCTTTTGTTTTTACAGACTCATAGGTGGAANGGACTTGCCTTGTCTCAAATGAGACT
TTTGGACTGTGGACTTTT

Sequence 1776

TABLE 1 294/467

Sequence 1777

Sequence 1778

Sequence 1780

AGTAGGAACCAAGAAAACTTCTTTTGCCAACTTTACAGGATATCTGGTAAACTATTACAT
NGTCAGGCCAAACATGCTCCTTGCATTTTTGTTGGCTGAATNTGGGTACAGAGTGGTTCT
ATACGATGGTAATAACCAACTTGNAATCAAAGGAAGNATTCCAACAGAAACAGATAGGAN
AANGTCTTGAGAAGATATATNAAGGAATNTGTCACTTGTCACACNATGCCCGATCACCGG
GACACAAATTCCTGCAAGAAGGGACCACACCGGACTCTATTTTCCTACAAGNGCAGGAAA
CCTTGTTCATTCTAAGCATGGTTTCTGNTTGCCCAGGTATTCAAAAAA
Sequence 1781

ACCCACGCGTCCGGCTGCGTTGGGCTTGCGTGCGGCTCAAGACTATGGCGTCCGGGCCTCATTCGACAGCTACTGCTGCCGCAGCCGNCTCATCGGCCGCNNCAAGCGCGGGCGGCTCCAGCTCCGGGACGACCACGACNACNACCACGACGGAGGGATCSequence 1782

CCGCGTNCGTTTGTGTTGAATGGNTTGTATACTTCTTTACACAACCTATCCATTACTTAA GGAATCTGCTCTTATTCTTCTACAAACTGNTCNGGAACAAANTGATATCAGAAATTNGAT AAAAGAACTTCGAAATGNTTGAAGGAGTNGAGGAAGNTCATTGAATTNCATGTTTGGCAA CTTNGCTGGAAGCAGAATCATTTGCCACTG

Sequence 1783

WO 01/070979

TABLE 1 295/467

Sequence 1784

Sequence 1785

ACGCGTCCGGCCAGGCAGTGATGGAATCCCGGGGTCNGCAGGAGAGAGAGAGGGTGAACCAGG
TCTACCAGGAAGAGGATTCCCAGGGTTTCCAGGGGCCAAAGGAGACAAAGGTTCAAAGGG
TGAGGTGGGTTTCCCAGGATTAGCCGGGAGCCCAGGAATTCCTGGATCCAAAGGAGACA
AGGATTCATGGGTCCTCCGGGGCCCCAGGGACAGCCGGGGTTACCGGGATCCCCAGGCCA
TGCCACGGAGGGCCCAAAGGAGACCGCGGACCTCAGGGCCAGCCTGGCCTGCCAGGACT
TCCGGGACCCATGGGGCCTCCAGGGCTTCCTGGGATTGATGGAGTTAAAGGTGACAAAGG
AAATCCAGGCTGGCCAGGAGCACCCGGTGTCCCAGGGCCCAAGGGAGACCCTGGATTCCA
GGGCATGCCTGGTATTGGTGGCTCTCCAGGAATCACAGGCTCTAAGGGTGATATGGGGCC
TCCAAGGAGTTCCAGGATTTCAAGGTCCAAAAGGTCTTCCTGGCCTCCAGGGAATTAAAG
GTGATCAAGGCGATCAAAGG

Sequence 1787

AAGCTATTGTCACACCTTTGAAACCAGTTGACAACACTTACTACAAAGAGGCAGAAAAAG
AAAATCTTGTGGAACAAGTCCATTCCGTCAAATGNTNGTTCTTCCCTGGAAGTTGAGGCA
GNCATATCAAGAAAAACTCCANCCCAGCCTCAGAGANAGATCTCTTAANGCTTTCTGCTC
AGAAGGATTTTGGAACAGAANAGAAAAGCATCATGGTAANAAATGAAAGCCAAGAGATGT
GCCCACTCCTGTTAATTCATTCGATTGAAAATTCATACCCCTTCTAAGAAAAAAATGAAAA
GTTTTNTAAACAACAAAAAAAGAAAGCCCNNNAGGCAAGGAAAGGGCANGTGCTTCATNAA
GNATACCTGNTGNAAAANAGGAAATGGCATCTTCCNCCAAGAAGAAAAAAGCCCAANGGGT
TTGTACCATACCTGGTGCNCTTTGTATGCNCACCCTGCCAAAGGCATAAAGGTTTTCTAA
AAAAAGTTACCTTGAGNGAAGCCAANGAAGCCTGGGAGAAAANAGTANTGNAAAAAATGC
AAGCNAAAGAAGGNTGGGTGGGAAG

Sequence 1788

CCCCGCGTCCGAGCAAACATAAGAAACCTGAGTCATTTTGTCATTTAGAGTATTCTGATA
AAATCTCTTGAAAATACTGAAATCAAAAGGTTAATGATTTTTTGTTCATTCTGATTTGTC
ATTTATTATCTGTCTAGCAGAAAAATCAAATGGGTAAATTAGCACTTTAGACAGCCAAC
ATAGTGAAACCCTCATCTCTACTAAAAGTTGGCAATTAAATCTGAATTTACAGATACAGA
TAACAGTTTATCAGAAATCATATTTTTCCTGAAGAAAATTTAAAATTAGGAGTTGTGGGC
CTGGTGCGGTGGCTTACGCCTGTAATCCCAGCACTTTGGGAGGCTGAGGTGAGCAGATCA
CTTGAGGTCAGGAGTTCGAGACCAGCATAGCCAACATAGTGAAACCCTCATCTCTACTAA
AAGTACAAAAATTAGCCAGGTGTGGTGGCCGTGTGCCTGTAGTCCCAGCTACTCGGGAGG

WO 01/070979 PCT/US01/09126

TABLE 1 296/467

CTGAGGCGGGAGAATCGTTTGGAACCCG

Sequence 1789

Sequence 1791

GGGTTATGAGAAGAACGCTCAGAGCAGAGCACCGAAAGTGGCCACTACCAGCATGAAGAG CCCAACAATTCAAACTGGNAGAAGTGAGAAAAACAGAATGCAGCTTTCAAGGTTCGTTTC AAGCAGTTGGCTTGTGGGACTCTGAGAGATGCTGCTGNCCATGACATGCGGGAATTATCA TGATCAACTACCCAGCTTGGATTTCACCCAGTGGCCAACTAGCTTTGTGTGGGAGACGGC AAGGGTTGGATTTTTCAAAAGAGTAAACCAGACCCGTGACCAAGGTGTNAACTAAGAAGT GGAGTCATGCTTCACACGGNCNTATCNTGCTGGCAGCCATTCCTGGGTCTGGCTGTGGTG

Sequence 1792

GTCCGTTTTACAACCTAGTAATAATGTGGATAAATGTATCTACATGACACATGTCAAGAC
CAAAATAACTGTGAATGACACACCTTGCTGTAAATGAACTGTGCTAACCCTGACTGTGGG
CTTGAGAACAAGATGAACTCTAGAACTCTAGCAGCCTAACTGCTGCTTCTCAAATAACT
GTGTGAACAGTGAGATATTACTGTTTGTTTCTAAAAATCCTACTGTGCCCAGTTTCCTTC
ACTACATGCCCTGCATTTTTTATTTAAATATTTAGCTGTAGCGCCATCAGATATGGATGC
CTTCTAACAATTGCTGTTTGTAAAATAAATCAGGATGGTAGAAAGTGATTATATGGAAAA
TTGGAACCTGGATGAGACCTTTTCGTTGAATTCTGAAGAGTAATGATGTGAAAATTGATA
CAGGGCAAGAGAGTATGATTCTTTTGGGTTTTCTTCTACTTCATGTCCAGAAGAGTAAGAGGG
GAAAA

Sequence 1794

WO 01/070979 PCT/US01/09126

TABLE 1 297/467

TATTTAATTATTGGTAANGGAGTTTAAGACTNGAAAGACTAGAGTGCTTTCTAGTCCAAA TAGAGGGTCANGTGAAACCAGCTTTTTGACATCAAGATTTTCATTTTGAGAAGGGANAAG CCTGTGGGACTGGGCTTAAA

Sequence 1795

Sequence 1796

Sequence 1797

CCGGCNTAGGCGGGGGAACACGCCGCCTGCGCTCTCTTGGGACCCTAGATTTGGGGGAGGAGGTAACGAGAGGCGGAGAGGGTGGCTCCTCAAATATACACCCCTCCTGTCCTCCGCCACCCCACCTTTGATTTCTCTTCCCTCAACCCAGCACTCCAGCCCCACCCCAGGGTCAATTTTTGCCCCCTTCCATCTGAGCAGTGTTACCAGGCCCCAGGGGACCGGAGGATCGGGGGCCGGTGGGGGGTCCCATGGAGTACTCCAGCACACGCAGGGGCTCCCTGCAGACAGGGGGGCCCTTCGCCCTGGAAGCCTGGACGCCGAGATAGACTTTCTGAGCACACGCTGGCCGAGCTGAATGGGGGGGTCATGCCGTCACGGCGACCAGACCGACAGGCATATGAGCC

Sequence 1798

Sequence 1799

GGCGNAGCTCGNCTTCCTCCNCGCCCAAGTTCCGGCGCCCCTCTTGCGGGAGCGTGCCGC ATCACCCCGGGGGCCCCTACGCGAGGATCTCCGGGGCCGTTGGCAGCAGCCTG Sequence 1800

Sequence 1801

GTCGACCCACGCGTCCGGGAGCAGAGTCGACTGGGAGCGACCGAGCGGCCGCCGCCGCCGCCATGAACCCCGAATATGACTACCTGTTTAAGCTGCTTTTGATTGGCGACTCAGGCGTG

TABLE 1 298/467

GGCAAGTCATGCCTGCTCCTGCGGTTTGCTGATGACACGTACACAGAGAGACTACATCAGC ACCATCGGGGTGGACTTCAAGATCCGAACCATCGAGCTGGATGGCAAAACTATCAAACTT CAGATCTGGGACACAGCGGGCCAGGAACGGTTCCGGACCATCACTTCCAGCTACTACCGG GGGGCTCATGGCATCATCGTGGTGTATGACGTCACTGACCAGGAATCCTACGCCAACGTG AAAGCAGTGGCTGCAGGAGATTGACCGCTATGCCAGCCGAGAACGTCAATAAAGCTCCTG GTGGGGCAACAAAGAGCGGACCCTCACCACCAAAGAAGGTNNGTGGGACCAACACCACAA GCCAAGGGAGGTTTGGCAAGACTTCTTTTGGGGCATTC

Sequence 1802

Sequence 1803

CGCGTCCGCGCTTCTGTTACGGCCAGTGCAACTCTTTCTACATCCCCAGGCACATCCGGA
AGGAGGAAGGTTCCTTTCAGTCCTGCTCCTTCTGCAAGCCCAAGAAATTCACTACCATGA
TGGTCACACTGCCCTGAACTACAGCCACCTACCAAGAAGAAGAAGAGGTCACACGTG
TGAAGCAGTGTCGTTGCATATCCATCGATTTGGATTAAGCCAAATCCAGGTGCACCCAGC
ATGTCCTAGGAATGCAGCCCCAGGAAGTCCCAGACCTAAACAACCAGATTCTTACTTGG
CTTAAACCTAGAGGCCAGAAGAACCCCCAGCTGCCTCCTGGCAGGAGCCTGCTTGTGCCG
TAGTTCGTGTGCATGAAGTGTGGATGGGTGCCTGTGGGGGGTGGTTTTTAGGACACCAGAA
GAAAACACAGTCTCTTGCTAGAGAGCACTCCCTATTTTGTAAACATATCTGCTTTAAGGG
GGATGTACCAGAAACCCACCTTACCCC

Sequence 1804

CCCGCGTCCGTAGATTAAATTATGCAAGTTGCAAGAATGTAGTAACTCTGATCAGCTACA
AGGAAAGGAGGAAAGAGTAAATGAAGAAAGTCATCTAACTGAAAAGGAATATATAGAACA
TTGTAACACCCCTACAACTGATTCTGATTCATCTATAGCAGTTAAAGCACTACAAATAGA
TAGCTTTGGTTTAGTTACATGCTTTCAACAAGAGTCTCTTGATGTTTCTCAAATGATACT
TGGAAAATCTCAGCAACCTGAGTCAAAAATGCAATCTGAATTTATAAAAGAAAAAAGTGC
TACTTGTTCAAATGAGGAAAAAAGGTAACTTAAACGAGGTCAGTAATAACTGAAGAAAAG
AAACAGATGGGAGATCACCCTATCTTCATTACTGAACCAAAACTACCNGTTCACAATATA
CCTGGATTCGACAGCATAAAAGAAACC

Sequence 1805

TABLE 1 299/467

TTTCACTGAAGCTGAGATTATTAGTGATCAAAGTTAAAATTTCAATATTTAATTTCTCTA
TATATTATTAATATTAAAATGGTTT

Sequence 1807

GTCGACCCCGCGTCCGGTACTACATCCCCTGAAGAAACATGTGCCCAGGTGATTCGTGAA
GCTAAGAGAACAGCACCAAGTATAGTGTATGTTCCTCATATCCACGTGTGGTGGGAAATA
GTTGGACCGACACTTAAAGCCACATTTACCACATTATTACAGAATATTCCTTCATTTGCT
CCAGTTTTACTACTTGCAACTTCTGACAAACCCCATTCCGCTTTGCCAGAAGAGGTGCAA
GAATTGTTTATCCGTGATTATGGAGAGATTTTTAATGTCCAGTTACCGGATAAAGAAGAA
CGGACAAAATTTTTTGAAGATTTAATTCTAAAACAAGCTGCTAAGCCTCCTATATCAAAA
AAGAAAGCAGTTTTGCAGGCTTTGGGAGGTACTCCCAGTAGCACCACCACCTG
Sequence 1808

CCCGCGTCCGGCCTTTAAAAGAAGACTTGAATTCCTATGGAACAATAAAGACACAGCAG
AAAACAGGGATTCTCCTGTTTCAGAGGAAATAAAAATGACCTGTCAACAATTTATCCATT
ATCACCGTGACCTCTGTATCCGAAACATTGTCAAAGAAGAAGATGTGGTGCAAAGACTT
CTGCTGGAACTTTCTGTGGCTGTGACCTGGTGAGCTGGCTAATTGAAGTCGGCCTTGCCT
CCGACCGTGGTGAAGCTGTGATATACGGAGACAGGCTGGTACAAGGGGGAGTCATCCAAC
ATATTACCAACGAGTATGAATTCCGGGATGAGTACTTGTTTTACAGATTTCTTCAAAAGA
GTCCTGAACAGAGTCCTCCTGCTATTAATGCAAACACTCTCCAACAGGAAAGATATAAAG
AAATTGAGCATTCATCCCCACCCTCACATTCCCCTAAGACCTAAATTATGCAGGGGAAAA
CCCTACATGGAATCAT

Sequence 1809

Sequence 1810

CGCGTCCGGTGCATCTGAGGACTGGTGGGAAGGCANGGCACAACGGGATTGACGGGCTGG TGCCTCACCAGTATATAGTGGTGCAGGATATGGATGATACGTTTTCAGACACTCTGAGCC AAAAAGCCGACAGTGAGGCCAGCAGTGGGCCAGTCACGGAAGACAAGTCCTCATCCAAGG ACATGAACTCCCCGACAGACCGTCATCCTGACGGCTATTTAGCCAGGCAACGAAAAAGAG GAGAGCCACCCCCTCCAGTAAGGCGTCCTGGCAGGACCAGTGAT Sequence 1811

TCAGGAGTCGACCCGCGTCCGGAAGGCCGATGCTGGGGGGTGGGCGTGGAGAGAATTC
TTCTGTGGGTCCTCTGGTGTTGAGTGGTCGGCTTGGTGTGGTGTGCGAGGAGACTCCAGG
CCCGTCGGCGCGGAGTGTCTCACGTGTGAAACATGGCTACAGATTGGCTGGGAAGTATT
GTGTCCATCAATTGTGGAGATAGCTTGGGTGTCTATCAGGGAAGAGTGTCAGCTGTGGAT
CAGGTCAGCCAGACCATTTCTCTCACCCGGCCTTTCCATAATGGAGTGAAGTGTCTTGTT
CCAGAAGTCACCTTCAGGGCAGGTGACATTACGGAGTTAAAAATTCTGGAGATACCAGGA
CCTGGAGACAACCAACATTTTGGAGACCTTCATCAAACAGAATTAGGCCCCTCTGGTGCT
GGCTGCCAAGTGGGCATCAATCAGAATGGCACAGGCAAGTTTGTCAAG
Sequence 1812

CCGCGTCCGCCCAGTCCNAGTGCTGGCTTTCCCTGTATCTGCCTCTGCCAGGCAACACTT ATCATGGCTCCCAATCAGCAGGAGCCTCCATGCTCCACTTTGAACAGCCTCTATGCTCCA GCAATGGGGCATTTGTGAAGAGTGACTTGATTAACTTTTCTGACCATGGGTATAATACAG TTGCTTCAGAGGGCAGTGGTTCTGGGTGTGATTTTTTACACTGTAACATTGTATACAGTGT CATGGATAATTACTATTTTTTTCTGGTCATTAACACTCACCTACTCTAGTACTAGGATTT

TABLE 1 300/467

CAGACCAAGGTCCTCATGACGCCTGGATATTTTAGTATCTATATCCAATAATCTTTTCTC
TCCTACTGAATATCCAGGCAAAGATGAAATCGTTTTCTTTAAAACTGTCAAAATTCTGTAA
AACTCAGGAGCCAGTTCAAAGGGAACAAGCATCTTCACAATAGATGGAATCAAGAGTTAAA
TGTTATAGTGGCAAGCTTGTCTACTGGGCAACAGAC

Sequence 1813

Sequence 1814

CGCGTCCGTTGAAGAATAATATTGTATGTGCATTTTATCCATTAATGTTTCATACTTTCT
GAGAGTATAATACCCTTTTAAAAGATATTTGGTATACCAATACTTTTCCTGGATTGAAAA
CTTTTTTAAACTTTTAAAAATTTGGGCCACTCTGTATGCATATGTTTGGTCTTGTTAAA
GAGGAAGAAAGGATGTGTTATACTGTACCTGTGAATGTTGATACAGTTACAATTTATT
TGACAAGGTTGTAATTCTAGAATATGCTTAATAAAATGAAAACTGGCCATGACTACAGCC
AGAACTGTTATGAGATTAACATTTCTATTGAGAAGCTTTTGAGTAAAGTACTGTATTTGT
TCATGAAGATGACTGAGATGGTAACACTTTCGTGTAGCTTAAGGAAATTGGGCCAGAATTT
CGTAAATGCCTGTTGTGCAGATGTTTTTCCCTGAATGCTTTCGTATTAGTGGCGACCAG
T

Sequence 1815

Sequence 1816

TCGACCCCGCGTCCGCTCTGCTCCTTGTCTCCNTCTNCCTTTTTCTGTCTTTGCCGGGTC TCTGGGTCTCTGACCCCCATCCGGCCCTCATGGCTTTGGGTCNGGAGCTNTTGAAGCAAT GTTCATCAT

Sequence 1817

Sequence 1818

TCGACCCACGCGTCCGGTGAAACACAAAACCAAGGAGTACATTAAGAAGTACATGCAGAA GTTTGGGGCTGTTTACAAACCCAAAGAGGACACTGAATTAGAGNGACTGTTGGGCCAGGG TGGGAGGATGGGTCAGGTAANGACAAGACTCTAGGGNAGAAGGAAANCCTGTGGGCC TTTNTGTCCCACCCCTGTCAGCACTGGTGCTACTGATTGATACATNACCCTGGGGGGNAA TTNAACCCTGCCAGNATGTCAACNTGGAANGGCCACAAAGAAGTGGAACCTCCCATCTAC AAAANNGAGTTTACNCTTANATTTTGTAGAAGCCTNGTTTGGCCATTGTTGCNNNTAGAN

TABLE 1 301/467

AGTCCATNNANTAGGNGGCAAGGGGGCCTNTANTAAAAATGAACCCCTGGNACAGAACCT TGNACTTNCACATTCTTTAAAANCCCTGGGAGATGNTTTGCTTTCTNTGGGNCGNGTTGN TTTGNTTCAAGCTGCTACNAAGTAACTCTCAATGGCCGGCAATTATCCCCAACTCNCACN AAACTCCNTTTTTAACCCCTGGCANGGAATCCTTGCAAATTTAATAATTTTTTAAATGGG

Sequence 1819

GTCCGGCTTTAGTGAATTCTTAATAGATNGTATATAAAAAGTACATTTTAATAGAAAGC CAGGGTTTTAAGGAATTTCACATGTATAAGGTGGCTCCATAGCTTTATTTGTAAGTAGGC TGGATAAATGGTGCTTAAATGGTAATGTACTCCACTTCTTCCTATTGGAAGATTAACATT ATTTACCAAGAAGGACTTAAGGGAGTAGGGGGGGCGCAGATTAGCATTGCTCAAGAGTATGT CAAATTCATAACTGGAAAGCAAAGAGAAGAACAAGTATGATTTGGATGATAAAGCATTGT TTTAATGGTGAAAACTTCACCAGATCACTTAATGTTTCTAGGAGGTTAACTTCAAGTGGG CAANTGGGGGTTTTTAGGTAGGTCAGTGGCCCTAAGTTCCTAAAGCCCACAGATTAGGGA **TTTAAG**

Sequence 1820

GCGTCCGGGAAAAGTTTGCCTTCCANGCCGAAGTTAACAGAATGATGAAACTTATNATCA ATTCATTGTATAAAAATAAAGAGATTTTCCTGAGAGNACTGATTTCAAATGCTTCTGATG CTTTAGATAAGATAAGGCTAATATCACTGGACTGATGAAAAATTGCTCTTTNTTGGAAAT GGAGGAACTAACAAGTCAAAAATTAAAGTGTGATAAGNGAGAAGAACCCTGCTGCATGTC ACAGACACCTGGTTGTCTGGAAATGACCAGTAGAAGAGTTGGGTNTAAAAAACCTNTGGT ACNCATTAGTCCAAATCTGGGACAAGNCGGAGTTTTTTAAAACAAAAATTGACTTGAAAG CCACCAGGGAAAGATGGCTCAGTTCAAACTTTTTTGGAATNTGGATTGGGCCCAGTTATG GTGGTCCGGTTTTNCTATTTCCCNCCTTTCCCTTGTAGCAGATTNAAGGTTTATTTNGTC **ACTITICAAAAAACAACAAACAAACNGATTACCCCAAGCAACATCTTGGGGGGAGNTCTTGA CTTCCAAATG**

Sequence 1821

CGTCCGCGGGTAAAATGTTATGGTAAGCATGCACANGTTTGCAGTCTACAGTTTTTTAT GTAGCACAAAATAGGTGTACCTTTATAAGTACATTCAATTTTATGATTTACATTTATCAT GTAATTTTAAAAAAATCCATCTATCTAGGATATGTTGGATACAAAGTCTGCTTTTGCTA TTCTTTTTGCTTAAATACTCCTATCATTTTCTGAATTACTTGGTATTTAGAACTCCTAGC GAGCATGATTCCACAGCTTTTCTGGGGATGTTTGAGATTCTTTTTTAGTACTAAGCAAAA TTCTCATCACAGGAATGTAGCCCAGGCCAATTTATAACTAAATCTCTATTTTGTTCGGAT GATGCTTCTAAAACAGCATTGATAGGTTAAAGAAGCTTGGGTATTTTTAATTTACTTCAA TGATTAGCTCAATTGCTTCTGGGAGTTTTAATCCTGTGGATATGTCAT

Sequence 1822

GGGCGCCCGCGTCCGCTGATCTCGGGCTCCTATTTCATTTACATTGTGTGCACACCAAC GTAACCAGTGGGAAAACTTTAGAGGGTACTTAAACCCCAGAAAATTCTGAAACCGGGCTC TTGAGCCGCTATCCTCGGGCCTGCTCCCACCCTGTGGAGTGCACTTTCGTTTTCAATAAA TTCAACACGCCAAGAACCTGGACACTCTTCACTGGTAACATATTTTGGCAAGCCAACCAG GAGAAAAGAATTTCTGCTTGGACACTGCATAGCTGCTGGGAAAATGAACATCAGTGTTGA TTTGGAAACGAATTATGCCGAGNTTGGTTCTAGATGTGGGAAGAGTCACTCTTGGAGAGA ACAGTANGAAAAAATGAAGGATTGTAAACTGAGAAAAAAGCAGATGAAAGTGTCTCACG AGCTATGTGTGCTCTGCTCAATTCTGGG

Sequence 1823

CCCCGCGTCCGTTTGGCACTGTCATNTGTGTCCCTCGAGTGAGCNTCACCAGAGCT GCAGTAANNGNGCACCTACTACNGGCTCTGNGCTGAGTCCTTCCAGTGNGCCTCTCACTG AATNCTCACCCCACTGNCATGAGGTTTNCCCCATTTGACTGATGAGGGTGNAGAGCCAGG

TABLE 1 302/467

GAGCCTTGNTCACTGGTTCATTGANTACATTTACAAATATTATTNACAGAGTGGGAGAAG AGCCGTATAGGGNCTTAATGCCATGGTNGGGACTTTGGAATTTAATTCAAGTGATGTGGG AGTACCTGCCAGATGGATGGAGGGTGAAATAATGCTTAAGCCCTCAGCC

Sequence 1825

Sequence 1824

CGCGTCCGGCTGAAGGCTCCCCTGGGNTTNCTGGCCTCCTGGGGCAGAANGGGAGAAA GGCGATGCTGGCAACTCCATTGGAGGAGGGCAGAGGGGGNACCTGGCCCTCCAGGGCTCCCT GGGCCCCCAGGGCCAAAGGGAGAAGCAGGTGTCCGATGGCCAGGTTGGCCCCCAGGGCA GCCAGGAGACAAGGGGAGCGTGGAGCAGCTGGAGAACAGGGACCAGATGGCCCCAAGGG CTCCAAGGGAGACCAGGGAAAGGAGAGATGGTGGATTACAATGGAAACATCAATGAGGC TCTCCAGGAGATCCGGACGCTGGCCTTGATGGGGCCTCCTGGTCTTCCTGGGCAAATTGG CCCACCTGGAGCTCCAGGGATTNCAGGCCAGAAGGGGGAGATTTGACTGCCANGGCCTTT CAGGACACGATGGGGAAA

Sequence 1826

GTCGACCACGCGTCCGGTTTTTTTTTTTTTTTGAGACAGAGTTTTGCTCTTGTTGCCCAGG CTGGAGTGTGATGGCTCGATCTTGGCTCACCACAACCTCTGCCTCCTGGGTTCAAGCAAT TCTCCTGCCTCAGCCTCTTGAGTAGCTTGGTTTATAGGCGCATGCCACCATGCCTGGCTA ATTTTGTGTTTTTAGTAGAGACAGGGTTTCTCCATGTTGGTCAGGCTGGTCTCAAACTCC CAACCTCAGGTGATCTGCCCTCCTTGGCCTCCCAGAGTGCTGGGATTACAGGTGTGAGCC ACTGTGCCGGGCCCGTCCCTCTTTTTTAGGCCTGAATACAAAGTAGAAGATCACTTTC CTTCACTGTGCTGAGAATTTCTAGATACTACAGTTCTTACTCCTCTCTCCCTTTGTTAT TCAAGTGTGACCAGGATGGCGGGAGGGGGATCTGTGTCACTGTAGGTACTGTGCCCAGGA AGGC

Sequence 1827

GGTGTCGCCCCGCGTCCGCTTGTCTTTTTTGGGGGGTGTGAATTTTTTGCATTGTTCTGAT CATATTCTTTATCATGTAATTTATGTTCTTTTTTACTAAGTATTATGTGTGGGTTATTATA GATTTTCACAAAGATATATTGCTGGTAATATTTTATTGTGTAGTCTTATAATTTACTT AACCTTCTTTCAATTGTTAGAAATTTAGGCTATTTCCAGATTTTCAGTATTGTAAATAAT GCTGTGATGACCAATTTTGTGAATAAAATGTTTTTATGTATTTCAGATTATTCCCTTAGG

TABLE 1 303/467

ATAGTCTCTCAGTGCCAAGTTGTCAAAAACATCTCTATTTTGCTTATCTTCCTGCTCTCT TGCTGCCTTAGGGGGTAGTAAACTGAAACATAAAGTAAACATGCATACAAATAAAAAACA TAAAACAAAAATAAGCAACCTGATGGTAATAGGTGAAAGTGGTAACCTGTTTTAACTTTG AATTCTTGCCCGGCGCGGTGGGCTCACGCCCTGTAATCCCAGCA

Sequence 1830

CGCGTCCGGTAAACCAGCCGGAGCGGCGCGGNAGCGGCAGGACCGCCGTGGCGCCTAGAG
TAGCAGACCCGGGGGGAGCGCGGGGCGACGCTGCAGGAACCCGGTGACAGCGTGAC
AGGTTTTGACAAGCTTGCATCATGCGTGAGTATAAGCTAGTCGTTCTTGGCTCAGGAGGC
GTCTGGAAAGNCTGCTTTGACTGTACCAATTTTGTTCAAGGAATTTTTGTAGAAAAATAC
NGATCCTACCGATAGGAAGATTCTTATAGAAAGCAAGTTTGAAAGTAAGATGCACAACCA
GTGTATGCTTTGAAAAATCTTTGGATACCTGCCAGGNAACCGGGAGCCAATTTACANCCA
ATGGAGGGGGATTTATAACATGNAAAAAAATGGGACAAAGGGATTTTGCATTTAGTTTAA
TTNCAATCACCAGACACAAGTTCCCACCAATTTTAAAACGAATTTTACCAAAGAACCCTG
GAGGAGNAACCAAGAANTTCTTTNNGAAGGTTTAAAAAAGGAACCACCTTGAATTGGAATG
GTTTCCCAAATG

Sequence 1831

Sequence 1832

GNGTCGACCNCGCGTCCGCTATTTACTACCTCCTTATGAGGAAGTGGTGAACCGACCTCC
AACTCCTCCCCACCATACAGTGCCTTCCAGCTACAGCAGCAGCAGCTGCTGCCTCCACA
GTGTGGCCCTGCAGGTGGCAGTCCCCCGGGCATCCACCAGGGGGATCCCAGGGGGC
ACAGAGCAGCCCCTTGTCTGAGCCCAGCAGAAGCACCACAAGACCCCCAAGCATCGCTGA
CCCTGATCCCTCTGACCTACCAGTTGACCGAGCAGCACCACAAAGCCCCCAGGGATGGAGCC
CAGTGGCTCTGTGGCTGGCCTGGGGGAGCTGGACCCGGGGGCCTTCCTGGACAAAGATGC
AGAAATGTAGGGAGGAGCTGCT

Sequence 1833

TABLE 1 304/467

TTACTGGGCACCCANCTCCATGTGCANGACTTTTCCCAACACAGCCTTGGCCAGTCAGAT GGTGTGNCAGGGCCNNAGGTTTNCGTANCCTCTTGGGTGATAGAAAGGGGCCCAGGCCCT GGGCTGGGGCTCATAANGGACTCAAANGAGGCACCTTGCCC

Sequence 1836

TCGCCCGGGGGCCATGGCAGCAGCGGCTACTGCAGCCGAGGGGGTCCCCAGTCGGGGGCC
TCCCGGGGAAGTCATTCATCTGAATGTGGGAGGCAAGAGATTCAGTACCTCTCGCCAGAC
TCTCACCTGGATCCCAGACTCCTTCTTCTCCAGTCTTCTGAGCGGACGCATCTCGACGCT
GAAAGATGAGACCGGAGCAATCTTCATCGACAGGGACCCTACAGTCTTCGCCCCCATCCT
CAACTTCCTGCGCACCAAAGAGTTGGATCCCAGGGTGTCCACGGTTCCAGCCTCCTCCA
TGAAGCCCAGTTCTATGGGCTCACTCCTCTGGTTCGTCGCCTGCAGCTTCGAGAGGAGTT
GGATCGATCTTCTTGTGGAAACGTCCTCTTCAATGGTTACCTGCCGCCACCAGTGTTCCC
AGTGAAGCGGCGGAACCGGCACAGCCTAGTGGGGCCTCAGCAGCTAGGAGGACGNCAGC
CCCTGTCCGACGGAGCAACACGATGCCCCC

Sequence 1837

Sequence 1838

Sequence 1839

GCCCGCGTCCGTTTTATTTTGCACTTTTATGGGTGACAGTTTTTACGCATAACCTTTGA
TAAAATACACTCAAGTGACTTGGACTTAGATGCTTATCCTTACGTCCTTGGTACCTTTTT
TGTATTAACAAACACTGCAATTTATAGATTACATTTGTAGGAAGTTATGCTTTTTTCTGG
TTTTTGTTTTACTTTCAACCTAGGTTATAAGACTGTTATTCTATAGCTCCAACTTAAGGT
GCCTTTTTAATTCCCTACAGTTTTATGGGTGTTATCAGTGCTGGAGAATCATGTAGTTAA
TCCCAAAGTGCTGGGATTACAGGCGTGAGCCACCGCGCCCAGCCTACATTCACTTCTAAA
GTCTATGTAATGGTGGTCATTTTTTCCCTTTTAGAATACATTAAATGGTTGATTTGGGGA
GGAAAACTTATTCTGAATATTAACGGGTGGTGAAAAGGGGACAGTTTTTACCCTTAAAGT
GCAAAAGTGGAACATACAAAATAAGACTAAATTTTTNAGAGGTAACTCAAGTAATTTC
Sequence 1840

Sequence 1841

TABLE 1 305/467

CTTCAATTNAAAANTCCGAAAACAATNGGCANCCAAAACCCATNACTTTGGGGAACCATN TAGGAAAAAANNGTACCNATNGGGTTTTTAGGATTCCCAAAACCACNATTGGGAAAAAAAC CTTG

Sequence 1842

Sequence 1843

CGACCNCGCGTCCGGGGGATCTGTGCCTGGCATGGGGACGAGTTCTGGCCTCCTTAGGGT
ACGGGGAGAGCTTGGACTTTGGTCCTGACGTGGTGGACGACACACCTTCGAAGAGTGGAC
GTTACCTCAGTTGTCTGTTAGAGTTTAATCGATCACTCCTCTGTTTTGTTGTTCT
TTCCCAGAAATAACTTTACCAAAGGAAAGCTATTTTGCGAACTATCTTCTCCAGCGGAGA
TGGCCAATGTGCTTTGTAACAGAGCCAGACTGGTTTCCTATCTCCCAGGATTTTGCTCTT
TAGTTAAAAGGGTTGTCAATCCCAAAGCCTTTTCGACTGCAGGATCATCAGGTTCGGATG
AGTCTCATGTGGCTGCACCTCCAGATATATGCTCTCGAACAGTGTGGCCTGATGAAA
CTATGGGACCCTTTGGAC

Sequence 1844

GGGACAGAGCCCCCGATCCGCCAGCACCACCTGAGGATTNNGAAACCGCCCCAGCGATGG AAGAGGGNCAGGAGCTGGAGAGGAAAGCAATAGANGAACTGCTTAAGGAGGCAAAACGTG GGAAAACTAGAGCTGAAACAATGGGACCCATGGGTTGCTTATTACAGGGACAAGATACAA ACTAAAATCAGCCAAAATAAGACACAAAGATTAAAGCCA

Sequence 1845

Sequence 1846

GTCGACCCGCGTCCGCAGCCTGGCCTGTGAGACCCTCGTGGACAACAACCTGCGGGTCA
CCAACTGGAACCGCAAGCTGGGCTGCAAGTGCCAGTACAAGCACATTGTGGACTGGTGTG
GCTGCTCCCCCAACGACTTCAAGCCACAGGACTTCCTCCGGCTGCAGCAAGTCTCCAGAC
CCACCTTCTTCGCCCGGAAGTTCGAGTCGACTGTGAACCAGGAGGTGCTGGAAATCCTGG
ACTTCCACCTGTATGGCAGCTACCCCCCCGGCACGCCCTCAAGGCCTACTGGGAGA
ACACCTACGACGCGGCTGATGGCCCCAGTGGGCTCAGTGATGTCATCCTCACTGCTTACA
CAGCCTTCGCCCGCCTCAAGCCTGCACCATGCCGCCACTGCTGCACCCCCAATGGGCACC
CCACTCTGCAGGTTTGAGCCCAGGGGCTTTGCCGTCCAAGCGTGCACCTGTATTTCTATG
ACGACCATTTC

Sequence 1847

TCCGCAAGAGTTATGCTTAAGACCAGCCAGCCTTGATAGTGGCAGAACATCCACTAGCAA TAGCAATAATAATGCTTCACTACATGAAGTCAAAGCAGGTGCAGTTAATAACCAAAGCAG GCCACAAAGCCACAGCAGTGAGAATTTAGCCTGCTTCATGACCATGAGGCTTGGTCCAG

TABLE 1 306/467

Sequence 1848

Sequence 1850

TCGACCNCGCGTCCGCTCAGGAACCTTNGAGAAGATNAGNNCCCCACTTAGATTNTTAAG GAGTAAAAAGGGCTGAGTTATGCCTTTAAGNGCTGTCAAGAATTCACTTGGGTTTGGGAC ATTTGCTGGTGTAATGCTAGATGCCCACAGCANCATAATATTGNNCTTTGTCAAAGGTNG GTAAATNCTNTGNTTNTCANCANCCCTTTCCCCA

Sequence 1851

AGTCACCACGCGTCCGCGGCTGGTGGTGGGCCCGGGCCCCTTGCCCGTCTTCGCT
TCCGGAGGTCGCTACTGCCGCCTCAGCGGCCCCGGAGCGGGGGCGCCCGGGGGTCCTTCG
CCCCCGGCCACGGTCCCCGCGCGCGGGCTTCGCCCCCCAGTGTCCGAGCTGGATCGTG
CGGACGCCTGGCTCCTCCGAAAAGCGCACGAGACAGCCTTCCTCTCCTGGTTCCGCAATG
GCCTCCTGGCATCGGGCATCGGGGTCATCTCCTTCATGCAGAGTGACATGGGTCGGGAAG
CAGCATATGACCATCCCCCGACCTTGGCCCTGTTGCTACCCTGCCTCTNCCGCAGGCTTC
TTNCTGCTGGGCGGCCTGTGCGTGGTGTGGGGCAAGCGCCTTGTACCCGTGGGCCTGGCG
GCGCTTNGAGGACCCATGCAGCTGACCTGGGGGCCGGCCTGGG

Sequence 1852

Sequence 1853

GCGCCCGCGTCCGGAAATTGACCCCTAGAGAAAATCCCATTAACTTGTTAAATTAGTGGAATTAACAACAAATAAAGCATGTTTGAGACCTGGCAAAAATTCCTCTGGTAGTATTTATAAATAGAGCTGCATGCCTCTAGTATGAAAACCGTATCAGTTGCAAGTGCCACTTCTACAAGTTACTCAGTTTACTCTTGTATCAGTAACTTTAAAGGTTGGATGATCCTTGCTGGTTAAAGCTAAATCTCAACCTAGCAACTAAATGAAAATATTTAGAATCATCAGAATCTGAACAGACTAAAATTATCAGCGATAAGCAGAATCAAGCAGGGTATAAGTTTTATCTCAATTATTTGAA

TABLE 1 307/467

Sequence 1854

TGTCGACCCCGCGTCCGAACCTTTGGGAGACTCCAAGACAGCATGCTCCGAGGTCGGCGG GGGTCTGGGTGGCCATGGAGGAGCCCCCTGTGCGAGAAGAGGAAGAGGAGGAGGAGAGA AGGACNAGGAGAGGGACGAGGTTGGGCCCGAGGGGGCGCTGGGCAAGAGCCCCTTCCAGC TGACCGCCGAGGACGTGTATGACATCTCCTACCTGTTGGGCCGNGAGCTTATGGCCCTGG GCAGCGACCCCCGGGTGACGCAGCTGCAGTTCAAAGTCGTCCGCGTCCTGGAGATGCTGG AGGCGCTGGTGAATGAGGGCAGCCTGGCGCTGGAGGAGCTGAAGATGGATAGGGACCACC TNANGAAGGAGGTGGAGGGGCTGCGGAGACAGAGCCCTCCGGCCAGCGGGGAGGTTGAAC CTGGGCCCAAACAAAATGGTGGTT

Sequence 1855

TGTCTGCCGAACAACTGAAAACTATGCAGGTTATATCATTCCACCAGCACCACCAAGACC
TGATTTTTGATGCTTCAAGGGGAGAAAACTACATGAAGCTTGGNGAAGNGAGAAGGGTC
AAGTGACCGAANNGCAAGNAATTTCACAAANAGAATGAAACNAGGCAACTGGAAAGCTCG
AAATANTTTTGGCAATTATTTCAGAGGANAGCACCAGATTTGCCGTATTGCATNGGAANT
TGNTACCCNGTAGTTCCNTGTTGGANATGTCAACANTCCCCTANTNTTTTGNACGAAACT
AAGGAATTNTAGAAATTTTTGCAATNGTTCCTTTACTTGGGGGAAAATTATTNNAATTCC
AAAGGAATCTTTNAGAGNTTGNNTNGCCGTAANGGCAAGAGAGAGNCNATNNTNGAAACT
NAGGAAGCGGAAACCTTTTGNAAANAACTTTTCTTTTTTA

Sequence 1856

Sequence 1858

Sequence 1859

GCGCCCCGCGCGCGCGCGCGCGCGCGCAGCAGCAGAGGACTCCCAGCGGCTG

TABLE 1 308/467

Sequence 1860

CGACCCGCGTCCGACCCACTGAAGACGTCTGCGTGAGAATAGAGACCACCGAGGCCGAC TCGCGGGCCGTTGCACCCACCGCCAAGGACAAAAGGAGCCCAGCGCTACTAGCTGCACCC GATTCCTCCCANTGCTTANCATGAAGAAGGCCGAAATGGGACGATTCAGTATTTCCCCGG ATGAAGACAGCAGCAGCNTACAGTTTCCAACAGCGACTTCAACTACTTCCTACCCTCACC AAGNCAAGCTTGCTCTGAAAAGCCCANTTATGCCANAATGTAGGATCCTGAAAACCAAGA AACTTTTTTACTTGAAATT

Sequence 1861

GCGTACGGCCTGTTGGGCTGTCTGGGGGGTGGCCATTTAGGGATCGTGGGGACGGGGTCC
ACCCCANNCAAGAAAGAACAGGCCCGTCCACAGGCCCGGCTCTGGGCCACAGTGCCCCGG
AAGCAGGTGTGTCCAGAGTCANGCTTGAATGGCTCTCCCCACAACCACCACAGCNAGGCGC
TGGTGCNTCCTTCTGCCTCATGGGACCAGTCCAGCTTNCAGCCGCTCTGGGCTCGAGGGT
NGGTACTGACCACTTTCCTTCTTGAGNTGGGAGCATTCTCTTGGGGAGANCTCTTCCAGT
GGGCACCTGCCTGGGACNCTTGCCCACCGGTTTTCTTGTAAAAATCAGGAATACCGGTGG
CTTTTAGTAAAAGGCAAGACCANAGNCGCCTTNCGTTGGGCAGGGGAAAAGCCAAGCGTG
CCGGNGGGNAAGGTCACTGGAAAAAAGGTGGCTTGCCCTAAGGGGGAAATTTTTGGCAAAAATA
GTCCCCCTGTTCCAAGAANTGCCTTTGAATTTTTAAAAAACATTTTTGGCT
Sequence 1862

Sequence 1863

GCGTCCGATGGCGTGNTGTCTCACAGAAAGTTCTCCGCTCCCAGACATGGGTCCCTCGGC
TTCCTGCCTCGGAAGCGCAGCAGCAGCATCGTGGGAAGGTGAAGAGCTTCCCTAAGGAT
GACCCATCCAAGCCGGTNCACCTCACAAGCCTTCCTGGGATACAAGGCTGGCATGACTCA
CATCGTGCGGAAGTCGACAGGCCGGGATCCAAGGTGAACAAGAAGGAGGTGGTGGAGGC
CTGTGACCATTTGTAAGAGACACCACCCATGGTTGGGTTGTGNGGCAATTGGTGGGCCTA
CCGTTGGGAAAACCCCTCGAGGCNCTCCGGTACCTTCAAGACTTGTCTTTTGCTGGAGCA
CAATCAGTTGAATGAAATGGCAAGAAGGGCGGTTTNTTATTAAAGTAATTTGGCCATTAA
AAATTCTAANGAAAGGAAAGGGCCTTTACCAAAGTTACCTGCAAGGAAAATGG
Sequence 1865

TABLE 1 309/467

GTAGAGCTGACATCNAGCCAGAGGTTGGCCTCAGAGCCTGAACATGCGCCAGTCACTATC TACCTTCAGCTCAGNAGAATCCATCAGATGGGGAGGAAGGCACAGCTAGTGAACCCTTCC CCCAGTGGCCACACCTGGAAGTTGGCTAGCACCAACACNTGATGAGTCCGGGCNCAGNAT GAAGCNGNGTTCTGATGAACATGTTGACTCCCAAGGGGCTCAAGAAAATCCCCACNTGGG ACNCCACTCTCCTTCAGGAGGGTCATACCCTGGGCCCTGGAACCCAGCTCCCTGGCCCA Sequence 1866

Sequence 1867

Sequence 1869

GGGCAGCGCCTCCGACATGAAGGCTGAGCTGTCGCAACTTATTAGCGACCTGGGCGAGCT CAGCTTCGGCAACGACGTGCGCACCCTGCAGGCCGACTTGCGGGTGACGCGCCTGCTGTC AGGCGACAGCACGGCAGAGAGCTCCATCGAGGGCGGGGGCCCTGACGCCACCTCCGC CACCGCCGGGGACTCGTCCCGCCAGGCCGACGCGCCAGTGCAGACGAGCCCCACTCGGG CTGAGCTCCTCCGCGCGCGCGCCCCAGGAAGGGGGAAATGGGGCATTTGGGGCCCAGACCT ACACTTGGAGCCCAGGTCCAAGCGTTCCCCGACCGCTTTCCCTACTNCCGGNCCCCGCTC

TABLE 1 310/467

Sequence 1870

Sequence 1871

Sequence 1872

Sequence 1873

CCNCGCGTCCGGTGTTCCTCCCTGAGAATTAGTGGTCAGACATTGCAGAGGGCATCAGAA GCGGGTAGATGAAATAGCGAAAGGAAACAGGCTAGCAGACCAAAGAGCTAAGTCAGCAGT AAGAAGGCCCCAAGGTCCCAAAACACTTGAGGCCCCTCTGATTTGGGAGGGCTACATAAG GGAAATAAAGCCTCAGTATTCCCCTACAGAGATAGAATGGGCCACCTCTCGAGGTATACT TTCAACCCTCAGGATGGTTACAATCAGAAGATTGCAAAGTACGCTTGCCAGCCTCCAGC CAATGGAAGATTCTTAAAATCCTCCACTGAGCCTTTCACTTAGGAAAGCATAAGACATCA GTGCATCCAAAGATTGTTCTCAGGAGAAAATCTACTAAAAATGGTCAAATAGGTTGTTAA TACTCGTGAAACCCTCTTAAAAATAATCCCTTTAACAGATGACTTCTTCCCCACCACAAT CAAAGGA

TABLE 1 311/467

Sequence 1874

Sequence 1876

TCGACCNCGCGTCCGGTCTTCGCAGGTGGCCCTCGGGCCGCAGCCGCTGGGTAAGGGTG
ATGCCTAGCCTGGCTTATTGCACCTTCCTTTTGGCGGTTGGCTTGGNGCGAATCTTCATC
TTAGCACATTTCCCTCACCAGGTGCTGGCTGGCCTAATAACTGGCGCTGTCCTGGGCTGG
CTGATGACTCCCCGAGTGCCTATGGAGCGGGAGCTAAGCTTCTATGGGTTGACTGCACTG
GCCCTCATGCTAGGCACCAGCCTCATCTATTGGACCCTCTTTACACTGGGCCTGGATCTT
TCTTGGTCCATCAGCCTTCAAGTGGTGTGAGCGGCCTGAGTGGATACACCTGGAT
AGCCGGCCCTTTGCCTCCCTGAGCCGTGACTCAGGGGCTGCCCTGGGCCTGGGCATTGCC
TTGCACTCTCCCTGCTATGCCCAGGTGCCGTCGGGCACAGCTGGGGAA
Sequence 1877

GTCCGCACAATTGAAAACTGGGAAAAATAATCTCGTGGTTCGGTTTGTTAGTTTGAGACG CAGTCTCACTCTGTCGCCCAGGCTAGAGTACGGTGGCCCAATCTCAGCTCACCT CCAACCTCCCAGGTTCAAGCAATTCTCTTGCCTCAGCCTCCCGGGGTAACTGGGGATTAC

TABLE 1 312/467

Sequence 1880

Seguence 1882

Sequence 1883

Sequence 1884

Sequence 1885

TABLE 1 313/467

CGTCCGCTCCTGAGTAGCTGGGATGACAGGCGTGCACCTGGCAGCTTTTTCAAAGTGTTG
ATGGTAATCTGAGGCAATCTAAGGGAGTCATTTTTTAAGTGACTTTATACAGAAAGATTG
GTAAGAGCCAAGGGGTAGAAGTGGCATAAATGTCTAAAGCAGGGAAGTGACAGGGACTTT
CATTGTTCTTGGCTGAGGAGAAGCGGGAGTGGCTGATGGAAGCACCTAAATGATGCCTTT
GTCTGTGGGAAGGCAAATGATGCCCCAGAGCTCTAACCAAAGGTTTTGCAGCCGCCGAAA
AACAGGAAAGTTGGGAAGCGGGGGTAGGACTACACTGAATCATTAACAGTGCTGTAAACT
ACCCATGTGGCCATTAACAATGGACCTTTGGGGGAGTTTTCCTAAACGATCACTCTGGA
Sequence 1887

Sequence 1888

Sequence 1889

Sequence 1890

TABLE 1 314/467

TAATAAGAACAAAATTAGTTCGTCTAAGGGGACTGGCCGCCACATATTTGTTCCTTGCC CATATGCTTCTACTTCTTGTTCTTATTATGAAATTATGAATTTGAAGCCTCTGAAATGG TGATCAGTTTTCAACATCTTTCAAAAACAAAATTACTA

Sequence 1891

Sequence 1892

Sequence 1893

Sequence 1894

Sequence 1895

Sequence 1896

CGACCCACGCGTCCGCCCNGCGTCCGAGGGGCAACAGCAGAGCCTACAGCAGGGGGCACACCCCGGGNTCCAGCCGCCTGCACGACCTCTACTGGCAGGCCATGAAAACCCTGGGAGT

TABLE 1 315/467

CCAGCGCCCCAAGTTGGAGAAGAAGGATGCCAAGGAGATCCCCAGTGCCACCCAGAGCCC CATCAGTAAGAAGCGGAAGAAAAAGGGATTCTTGCCAGAGACGAAGAAGCGCAAGAAACG CAAGTCAGAGGATGGCACGCCAGCGGAGGATGGCACACCTGCAGCCACCGGCGGGAGCCA GCCCCCCAGCATGGGCAGGAAGAAGAGGAACAGGACAAAGGCTAAGGTCCCAGCCCAGGC AAACGGGACGCCAACCACCAAGAGTCCAGCCCCTGGCGCCCCCAC Sequence 1897

Sequence 1898

GCCTGGAGGCTACTTGTAAATCCTTAGAAGAAAAGCTGGATCTGGTCACGAACAAGCAG CACAGCCCCATCCAGGTTCCCATGGTGGCCGGCTCCCCTCTCGGGGCAACCCAGACGTGC AACAAAGTGCGATGCGCTGGCCTGGGCGTCGGCAGAACACCATTGTGGTGAAGGTGCCG GGCCAAGAAGACAGNCACCACGAGGACGGGGAGAGCGGCTCGGAGGCCAGCGACTCTGTG TCCAGCTGTGGGCAGGCGGCAGTCAGAGCATNGGGAGCAACGTCACGCTCATCACCCTG AACTCGGAAGAGGACTACCCCAATGGCACCTGGCTGGCGACGAGAACAACCCC Sequence 1900

Sequence 1901

Sequence 1902

GTCGCCCGCGTCCGCCCTCCCTGGCAAATAATAAAACCCGTGAATTTTCAGGAATT
TAAAAATTANGCTTTTTTCCACTTAAAGGAGAAAAATATTTGGGACTAGCAGCAGAGGCA
GTAAGAGATGTGAACCTTGGTGAGCTCTGATACAGTGAGAAGAGATTATACTCATGAAAG
AGAATGTTAGTGTTACAGAGAAGCAGCCGATAGCAAATCGACTGTAGAGACTTGGCGGCG
GTGGCATTGCCCCAGGTCGTCAGCAGTGTGGTATTATCTATGAGAACTTGAGCGACAGAG

TABLE 1 316/467

TATTTCTTGATGAATTTATAGATCATTTGAGATGTTGAGTTACTTTAGTTTTGTT
TTGTTTTTCAAATAAGTAGAGACTATTTGTAAAAAACGAGGAAAGGGAAATGAAATGGG
GCGTGTTTGATAGCAATAAATTTGGTTTCTTTTTAAAGAATTCTAAAAAGGGTCTGAGAC
CCTGNTAGCATTAATTTTTTGAGTGCCCTTCCTTTTTNCCCTTCCCCTCCCTTTTTNTTT
TTCTCT

Sequence 1903

GCGTCCGCCCCGCGTCCGGGAAACCCCCTTCGATGACCTCCAGAGCCTCCCAAACGACGT GATCTCTTCCCTGAAGAACAGGCTGAAAAAGGTCTCCACAACCACTGGGGATGGTGTGGC CAGAGCGTTCCTCAAGGCCCAGGCTGCTTTCTTCGGTAGCTACCGAAACGCTCTGAAAAT CGAGCCGGAGGAGCCGATCACTTTCTGTGAGGAAGCCTTCGTGTCCCACTACCGCTCCGG AGCCATGAGGCAGTTCCTGCAGAACGCCACACAGCTGCAGCTCTTCAAGCAGTTTATTGA TGGTCGATTAGATCTTCTCAATTCCGGCGAAGGTTTCAGTGATGTTTTTGAAGAGGAAAT CAACATGGGCGAGTACGCTGGCAGTGACAAACTGTACCATCAGTGGCTCTCCACTGTCCG GAAAGGGAAGTGGAGCAATTCTGAATACTGTAAAGACCAAAGCAA

CGTACGGGGTGCGGTTGGCGGCGGCGGCTGGGCCGGGGGGCTGCCGGCTCGGGCCG TGCGCGGCGCCGTGCGGNCACGCCATGGACTTCAACATGAAGAAGCTGGCGTCGGACGC GGGCATCTTCTTCACCCNGGCGGNGCAGTTNACGGAGGAGAAATTTGGCCAGNCTGAGAA GACTGAGCTTGATGCCCACTTTGAAAACCTTCTGGCCCGGGCAGACAGNACCAAGAACTG GACAGAGAAGATCTTGAGGCAGACAGAGGTTCTGCTGNAGCCCAACCCCAGTGCCACGAG TGGAGGAGTTCCTGTATGAGAAGCTGGACAGGAAGGNCCCCTCAAGGGTCACCAACGG Sequence 1905

CNCGCGTCCGGTGCATCTTGCCCATTGATTTCTAAATGTATTAACTACTTAAATTAATCC
TGAATCTTTTCCCAGGCTTAAGTGGGATAATGTTTTATTGTAGATGCATATTTCCTGGCT
CTACCCAGTCTTTCTTTGAAGACTTTATCATCCTATTTTCTGAATCCAGTGGCTGACTTT
AATCTTCTCGGAGGAACTAGATAATTTCTAGACTAATGCTTACACTCATGATCCAGATT
GTAATTTCTGAACTCCTTCTTCCAAATAGAATCAAAACAAGAAAGGGGAAAGCCTCTCAA
AGCAACTGTGCGTTAATAATGAAACACTCTTTTTTTCTAATCCAAGGAGGGTTTCATACT
TTTTCTTAGTTTCTTGCCCTCTTCCCTTCTGATCAATAATTGTAATAGGGAAATTTGCAA
TTGTGCCAATACTCAGATTCAATACTGAACTACTTTCTTGCATTGGAATTCAAATTCCAA
GGTTAACAACTAGCTGTATGTTTCCAAAACAATCTTATTGGATATGGATTTTCTTAGGGG
GAAGGTTCCAGAAATGATTT

Sequence 1906

Sequence 1907

GTCGACCNCGCGTCCGAACATCGTCAACTACGGCATCCCAGCCCACCGTGACATCGACGA
GTGCATGTTGTTCGGGTCGGAGATTTGCAAGGAGGGCAAGTGCGTGAACACGCAGCCTGG
CTACGAGTGCTACTGCAAGCAGGGCTTCTACTACGACGGGAACCTGCTGGAATGCGTGGA
CGTGGACGAGTGCCTGGACGAGTCCAACTGCCGGAACGGAGTGTGTGAGAACACGCGCGG
CGGCTACCGCTGTGCCTGCACGCCCCCTGCCGAGTACAGTCCCGCCAGCCCCAGTGCCT
GAGCCCGGAAGAGATGGGACGTGGACGAGTGCCAGGACCCGGCCCTTGGGC
GCTGCGTCAACCTGCCGGGCTCCTACCGTGNGAAGTGTCGCCCGCCTTGGGTGCCCGGC
CCTCCGGCCGNGATTGCCAGCTCCCGAGAGCCCGAGCGTGCCCCGGACCGA

TABLE 1 317/467

ACGTGTGCTGGAACCACGCGGAAGAGGACGGNATGTGCCCTTGCCCCTGGCCCGGGCC
Sequence 1908

ACCACGCGTCCGGGCGGCCCGGCCAGGCCCCGGCACTTCCTCGTCCTCGGCCCGGGTGCCCTGCCCCGTCCAGGAGCCCTAGGAGTGCTACGGGGGGGCCGGAGCCTTGCCCGGGCCGCTGCCCCGTCCCTGGATTCGGGGCTGGACGCAGCAGCAGGNGCGCTGTGTCCCCAAGCTCCCGGTCCTCGGGGAGCTTTTGGAAGAGTCCCAGATGGAAGCGACCAGGCTCCGGCAGAAGCAGAGGAGCTAGTGAAGGACAACGAGCTCCCACCCTTNTCCCTCCTTGGGCTCCTTCGACCCCCTGGCTGANCTCACAGGAAAGGACTCAAATGTCACAGCATCTCCCACAGNCCCTGCATGCC

Sequence 1909

Sequence 1910

Sequence 1911

Sequence 1912

Sequence 1913

CGACCCACGCGTCCGCTTTGAAGCAGGAAAAGACACGTCTCTAGAGCAACATGGAAAGGA

TABLE 1 318/467

Sequence 1914

Sequence 1916

Sequence 1917

Sequence 1918

TABLE 1 319/467

GAAACTTTACAAGTGTAATGAATGTGGCAAGACCTTTAGTCGGAAGTC

Sequence 1919

NGACCNCGCGTCCGCGCTCCGCTGCCNGGGGCGGAGGAGGAATGGTTGCTTCACGCCCCGGGGGAAGAGACNGGAAGCTCGGCTCTGGGTTGCGGGCCCCGGGGTCTCCGCGTGGGGCGCCCCGCCCCGCCTCCCGGTGTGCAGCGCCCCGCCCCGCCTTGCCTGGGAGAAGCCCGGCGGGACGCCCGGGCTGGAGTGGGCGGTTATAGGCTTTGAGCTAGGCCGCTTCCGGGAGGGGGGAGGCGGACCCCCATTTCCTTT

Sequence 1920

Sequence 1922

Sequence 1923

Sequence 1924

CCNCAAAAAGGAACCAGAGGCCACTTGTATATATATGGTCTCTTCAGCATTTATTGGTGG CAGAAGAGGAAGATTTCTGAAGAGTGCAGCTGCCTGAACCGAGCCCTGCCGAACAGCTGA GAATTGCACTGCAACCATGAGTGAGAACAATAAGAATTCCTTGGAGAGCAGCCTACGGCA ACTAAAATGCCATTTCACCTGGAACTTGATGGAGGGAGAAAACTCCTTGGATGATTTTGA AAGACAAAGTATTTTACCGGACTGAGTTTCAGAATCGTGAATTCAAAGCCACAATGTGCA

TABLE 1 320/467

ACCTACTGGCCTATCTAAAGCACCTCAAAGGGCAAAACGAGGCAACCCTGGAATGCTTCG TAAAGCTGAAGAGTTAATCCAGCAAGAGCATGCTGNCCAGGCAGAAATCAAGAANTCTGG TCACCTGGGGAAACTAT

Sequence 1925

GCGTCCGGTAAGTATTTTGGAATTCAACCCTCGAATTATTTTTTCTCATTTCAGCATAGT GATAGGGGATGCAATGAGGCTTCATTATTTTTTATGACCTGCCCCTCATTTGCTCTGATG TTCCCTAAATTCTGTAATCATAACTTTTGTTATGAATAGAGAGGAATGGGCTCAC TGAAACCTGACACTAGAAATTGGTGGGTGATGCTCATAACTGCAAACACTTAGCTTATTG AAGTGCCTCTATTTACATGTTCTTTAGTTATAATATGTATTTTTCTAACAGAAATACACG TCTGTAATTGGTATATATATTATACTTTGTATGTGTCACAACAAAAGCTAAACAGAGGCTAA AGTCTTTAGCAGAGAAGAATGAATTN

Sequence 1927

Sequence 1928

Sequence 1929

CCGCACACCCTAAAGAAAATAAGTATCCCAGTCGACATCAGTGACAGTGATATGATGCTG
AACATCATCAACAGCTCTATTACTACCAAAGCCATCAAGTCGGNGGTCATCTTTGGCTTG
CAACATTGCCCTGGATGCTNGTCAAGATGGTACAAGTTTGAGGAGAAATGGTCGGAAAGAG
ATTGACATAAAAAAAAATATGCAAAGAGTGGAAAAAGATACCTGGGAGGCAATCATTGGA
ANGACTTCCTGTGTCTTGCGTGGAGTCATGATTAACAAGGATGTGACCCATCCACGTATG
CGGCGCTATATCAAGAACCCTCGCATTGTGCTGCTAGGATTCTTCTCTGGAATACCAANG
AAAGGAGAAAGCCAGGACTGACATTTGAGATTACACGAGAGGAGGACCTTCACCCCGAA
TTCTCNCAGAATGGAGNGAAGGAAGTACATCCCAGCAGCTNTGTGAGGGACCATTATCCC

TABLE 1 321/467

AACCTGGAAAGCCCGATGTTGGTCANTCACTTGGAAAA

Sequence 1930

Sequence 1931

Sequence 1932

CGTCCGGCGCGTTCGTGCGTCCTAGTTCCAGTACATGCGTGAGGGTTTACGGCAGCGTG
TTCTGATTCTTTGCGGGACGCGAGCGCATTTGTGCTTTGCCCGCCGCGCCCTANGAGGC
CTTTTGAGGCCGCGTAGTCGGTGTTTTTGAACTGACTCTACAGCTTCTGGCAGGCCGTGC
GGCGCCCTGACCCGGCCTCACCATGTTGGTGCTGTTTTGAAACGTCTGTGGGTTACGCCAT
CTTTAAGGTTCTAAATGAGAAGAAACTTCAAGAGGTTGATAGTTTATGGAAAGAATTTGA
AACTCCAGAGAAAGCAAACAAAATAGTAAAGCTAAAACATTTTGAGAAATTTCAGGATAC
AGCAGAAGCATTAGCAGCATTCACAGCTCTGATGGAGGGCAAAATCAATAAGCAGCTGAA
AAAAGTTCTGAAGAAAAATAGTAAAAGAAGCCCATGAACCGCTGGCAGTAGCTGATGCTAA
ACTAGGAGGGGTCATAAAGGAAA

Sequence 1933

Sequence 1934

GCGACGCGTGGGCTCCATCTGAGCTCTTGGGTGACCAGGGTGCATTGTCAATGAGGGTA
ATATTTTGAAAGACATCTTTATTATGAGCAGTAGGTCTCAACAGTGGGCTTAAAATGTGC
AGTAAATCATGCTGTAAACAGATGTGTTGTCATCCAGGTTTTTGTGCCATGTCTAGAGCAC
AGGCTGAGTAGATTTAGCATAATTCTGAAGGACCCCAGGATTTTCAGAATGATAAATGTG
CATTCGCTTCCACTTACAGTCACCAGCTGCATTAACCCCTAACAAGAATCAGCCTGTCCT
TTGTAGCTTTGGAGGCAGGCATGAACTTCTCCTAGATGGCATCTTCCAAGAGGGCTATTT
TTGTCTACATTGAAATTCTGCTTAGTGTAGCCACCTGCTTCAATGATCCTA

Sequence 1935

WO 01/070979 PCT/US01/09126

TABLE 1 322/467

GNGTCCTCCCTTGGGTCCTCCTGGGCCATCTCTGTGGGGAAGGGACAANACTCGCAACAA NCCACATTCTAANGATGANGGCCCTTTTNCCCT

Sequence 1936

CCNCGCGTCCGGAAAATATCCNAGGTTGTACGCAGCAGTGGAAGTTGCTCTCAAGGAGT GGTATTTTACACTATGCTCATGGCGACAGTCAGCAAACTCACCTGTTGAAGCAAGGAAGA AGCTCCATGGGCACTGGTCTCAGTGGTGGGAAACGTCCTAGTCAGGAAGAGGACACACAG AGTATTGGTCCTAAAGNCCAGAGACAGAGCACTAATTAGGTAAATATTTTAGAGCTGTAT TTCTTGCTTTAGAAGAGTATATAATTAACATAAATTAAGATAATTTCAAAAATTGGAGCAA ATCTCTATTTTCAAACCAGAAAATCTTGAGGCATTAATTTTTAAGCAATTTTTACAAACT CAGTTAATTTTTGGTCAAGAGACATGCATCTGTACTGGAGAAATTGTTGCACCAAGTTTT ATATTCATCTGAACCAATGC

Sequence 1937

Sequence 1938
GTCGACCCACGCGTCCGCGGACGCGTGGGCGGACGCGTGGGCTCTCGC

ACTCTGTTCTTCCGCCGCTCCGCCGTCGCGTTTCTCTGCCGGTCGCAATGGNAGAAGAGATCGCCGCGCTGGTCATTGACAATGGCTCC

Sequence 1939

Sequence 1940

CCGCGTCCGCAGAAACATATGTGTAGTGTGCTGCAGCATAAGATGGAAGAACTTAAAGAA GGCCTGCGGCAAAGAGATGAGCTTATTGAGAAACATGGCTTAGTTATAATCCCCGATGGC ACTCCCAATGGTGATGTCAGTCATGAACCAGTGGCTGGAGCCATCACTGNTGTGTCTCAA GGAAGCTGCTCAGGTCTTGGAGTCAGCAGGAGAAGGGCCATTAGATGTAAGGCTACGAAA ACTTGCTGGAGAGAAGGAACTACTGTCACAGATTAGAAAACTGAAGCTTCAGTTAGA GGAGGAACGACAGAAATGCTCCAGGAATGATGGCACAGTGGGTGACCTGGCAGGACTGCA

TABLE 1 323/467

GAATGGCTCAGACTTGCAGTTCATCGAAATGCAGAGAGATGCCAATAGACAAATTAGCCG AATACCAATTT

Sequence 1942

Sequence 1943

Sequence 1944

GCGTCCGGCTGCGGCGGTCGGGGCTCCGGGCCGGGCGCGCCCATCTTGTGCCCGG GGCCGGTGGGAGGCCGGGAGGGGGCCCCGGGGGGCCCAGGGGACTACGGGAACGGCCT GGAGTCTGAGGAACTGGAGCCTGAGGAGCCCCCGGCAGCCAAGAGGAGGAGGAGCCG GGACTGGTCGAGGGTGACCCGGGGGACGCCCATTGAGGACCCGGAGCTGGAAGCTATC AAAGCTCGAGTCAGGAGATGAGGAAGAAGCTGAGAAGCTAAAGGAGCTACAGAACGAG GTAGAGAAGCAGATGAATATGAGTCCACCTCCAGGCAATGCTGGCCCGGTGATCATGTCC ATTGAGGAGAAGATGGAGGCTGATGCCCGTTCCATCTATGTTGGCAATGTGGACTATGGT GCAACAGCAGAAGAGCTGGA

Sequence 1945

CCCACGCGTCCGGCAAACCGGGAAAGGAGAGGATCCCGGAGCCGGTGAGAATTCTCTGTT
TTTTCTCTACCATCCTTTCCAGGCCTTTTCCTCACCTAATGAGTCGTAGAGACGAGGGCC
CAAAAAGTCTGTAAAGGTGGCTGGTGAAAGATTAAGTGNTCCAAGGGCCCTACATTCCNG
GANGNGGTTCGGGATAAAAGAGAACTAGTCNTGGGAACAATGTAAGTGGGAACNTNAAGG
NANNGGNAAAGCGGCCNATAAAGGNGNNCGGAGGNCCCAATGGNANTAAAGCGGACCCTG
TGTAGGTATAGAGTTGAGTCAAGTGGAGTCACTGCCTCTTGTCCCTCTTGGTCAGCGTGA
TGGCCAGAGGCCTGGGGGCCCCCCACTGGGTGGGCCGTGGGGACTGCTGANCCTGGGCCN
ACTTGG

Sequence 1946

Sequence 1947

NCGCGTCCGAAGTGGATGAAAATTGGTACCATGGGGAAGTCAATGGAATCCATGGCTTTT
TCCCCACCAACTTTGTGCAGATTATTAAACCGTTACCTCAGCCCCCACCTCAGTGCAAAG
CACTTTATGACTTTGAAGTGAAAGACAAGGAAGCAGACAAAGATTGCCTTCCATTTGCAA
AGGATGATGTTCTGACTGTGATCCGAAGAGTGGATGAAAACTGGGCTGAAGGAATGCTGG
CAGACAAAATAGGAATATTTCCAATTTCATATGTTGAGTTTAACTCGGCTGCTAAGCAGC

TABLE 1 324/467

TGATAGAATGGGATAAGCCTCCTGTGCCAGGAGTTGATGCTGGAGAATGTTCCTCGGCAG CAGCCCAGAGCACTGCCCCAAAGCACTCCGACACCAAGAAGAACACCA Sequence 1948

Sequence 1952

Sequence 1950

WO 01/070979

TABLE 1 325/467

Sequence 1954

Sequence 1955

Sequence 1957

Sequence 1959

CCACGCGTCCGGGGGACATGGTGGTGAGCAGGACAGAATTCCTGTCCTCATGAGTCTTAC

TABLE 1 326/467

CGCCCACGCGTCCNNCCCGCGTCCGGGAGAAGATGGAAGCAGTGCCCGACGTAGAGCGCA
AGGAGGACAAGCCCGAGGGGCAGTCACCTGTGAAGGCTGAGTGGCCCAGCGAAACCCCGG
TGCTGTGCCAGCAGTGTGGCGGCAAGCCTGGCGTCACCTTCACCAGTGCCAAGGGCGAGG
TCTTCTCCGTACTGGAGTTTGCACCCTCAAATCATTCTTTTAAGAAAATTGAGTTCCAGC
CTCCAGAAGCCAAGAAGTTCTTCAGCACAGTGCGGAAGGAGATGGCGCTGCTGGCTACCT
CACTGCCTGAGGGCATCATGGTCAAGACTTTTGAAGATAGAATGGACCTCTTCTCAGCTC
T

Sequence 1963

Sequence 1965

CGTCCGGCGCCCTCCAGCCCCGTCCGGGAGTCCCCGGCCCGCTGCGGTGCCGGGAGTACC TCCAACCCCCTGCNCCCCNNANGGAGGCCNAGGGGCTTAGCCACCAGGGCTCGGAAGTGG GGGCCGAATCCGGTGCNNGNCNNNNNNAGGNNAGCANAGCCGGAGTTGGGGAGACTGGT TGCTGAAAAGCCAGGAGTCAAAATGACTGAGCGCTTTGACTGCCACCATTGCAACGAATC TCTCTTTGGCAAGAAGTACATCCTGCGGGAGGAGAGCCCCTACTGCGTGGTGTGCTTTGA GACCCTGTTCGCCAACACCCTGCGAGGAGTGTGGGAAGCC Sequence 1966

CCCACGCGTCCGGTGCACTCAACAGAACGGCCCTTCAAATGTGAGAAATGTGAGGCAGCTTTCGCCACGAAGGATCGGCTGCGGGCGCACACAGNACGACACGAGAAAGTGCCATGT

TABLE 1 327/467

Sequence 1968

Sequence 1969

CCCACGCGTCCGCACGCCAGTGCCTCCCTTTACCTACTAATGAGGCAAAACTTTGAGATT GGGAATAACTTTGCCAGGGTTAAAATGCAGGTAACAATGTCACTATCCTCCTTGGTGGGC ACATCTNANAATTTTAATGAAGAATTCTTAAGACNGTCTTTCTAAANNACTATTTNGTAC ATTATGCTTGAAGAANATNTGNGAATTGAGGGAAACA

Sequence 1970

Sequence 1971

CGTCCGGTGAGATTCTCCGTAATGGGCGGGGACAGAGTGCCCTGCAGGAGATTCTGGGCA
AGGTTATCCAGGATGTCTAGAAGACAAAGTGCTCAGCGTCCACACAGACCCTGTCCACC
TCTATAAGAACTGGATCAACCAGACTGAGGCCCAGACAGGGCAAGCGCAGCCATCTCCCA
TATGATGTCACCCCGGAGCAGGCCTTGAGCCACCCCGAGGTCCAGAGACGACTGGACATC
GCCCTACGCAACCTCCTCGCCATGACTGATAAGTTCCTTTTAGCCATCACCTCATCTGTG
GACCAAATTCCGTATGGGATGCGATATGTGGCCAAAGTCCTGAAGGCAACCTTCCTGTACT
ACCGCTTCCTGAACCACTTGTGGTGGCTCCTGACGCCTTCACATTGTGGCCAANC
TGGTGGAGCCCTGGCTGCCCCCCAGCGCCATGCCTTGGG

Sequence 1972

TABLE 1 328/467

GCCGACCCACGCGTCCGACATCCCCAGGCACATCCGGAAGGAGGAAGGTTCCTTTCAGTC CTGCTCCTTCTGCANGNCCAAGAAATTCACTACCATGATGGTCACACTCAACTGCCCTGA ACTACAGCCACCTACCAAGAAGAAGAAGAGTCACACGTGTGAAGCAGTGTCGTTGCATATC CATCGATTTGGATTAAGCCAAATCCAGGTGCACCCAGCATGTCCTAGGAATGCAGCCNCA GGAAGTCCCAGACCTAAAACAACCAGATTCTTACTTGGCTTAAACCTAGAGGCCAGAAGA ACCCCCAGCTGCCTCCTGGCAGGAGCCTGCTTGTGCGTAGTTCGTGTGCATGAGTGTGGA TGGGTGCCTGTGGG

Sequence 1974

CGCGTCCGCGAGAGAGAGGGTACGGTCGAAGCCCGGAGCCAGGCCGAGCGGAGCTGAC
CAGGCTTGACTCGGGTACAGAACGAGGCACCAGTCCCCTTGCGAACCGAAGGGCCTCGCA
GTGGATGGAGGAGGCCCAGCCCTGAGGTCAACGCCAACCAGGCTAGCCTGGCACGGGCC
TACAGGGTGGGTAGGCGGCCGCCGCCAGCCGTCCAGGCCCTCCAGGTCCCGGGCC
GAGGGGCCTACGCTGCGGCCCGGCAACAAGGCCCGACTCGGCCCCTCGGGACCAGAGCCC
CACCCGATCGGAAGCGGATC

Sequence 1975

GGCCTCAGGGGGNAGNNATCCTGCAAAGACNNACATGAGCCCANAGGGGAAANAGAGNCA CCTGNGAGTACNNGCCTTTGGGNNTGACCTTGGCTCTCAGCACAAGATATTTACAGCCTN TGAGCTTGATATTCTAGAATTGNTACAGAGGATAGCTCTGGAAAAGAAATAGACTAGAAGG ATAAAGGGAAGGAATCATAGCTTATGAAGGTTTTTACTCTGCATCAGACCGNTTTCTAGN NCTATGACTTAACGTCCTATAGGCTGTAAGGTTCTCTGCGTGAACACTTCTTTNCTGGCC TCCTTTCTGCCCCATTCCTNTTTAAACTCAGTTGCTGAGTTTATTATNCCCTGTGCATCC CTGGGCATTGNTCATTCACATATGGAAACAATTCANGGAGGACCCTTTGCCTANTTTNCT TTATCCTCTTGAATTNTGGATGGGAAAAATNTTAANTNCTTTTTGGCCGCCTGCANTNGGG GNAANTATTGGGCCTT

Sequence 1976

Sequence 1977

Sequence 1978

TABLE 1 329/467

Sequence 1979

GAGTGTAGTTACTTCGGTCTTGCCTCACTGGGAGGCCACGTTGGTGACGATGCACACGAA GCCCCGGTACTTGTCCAGGTTAACCATGTGCCCGTCCGATGTCCTTGGCGGAAAACTCGT GCATGGAGCGCGCACAGCGCCAGTCGTCCNGGGACGCGCACGGGTCCTGGGACTTGGGAC ATTCGNGGATCTCCGGTCGCAAGCTGCGGGGACAAGGCTTCTTCCGCCGGCGCCCC TCCTGCGCCTGCACGCTGGGGCCTTCCGCCGCCGAGGGGCTCGCGGCCGCTAGACTA Sequence 1980

CGCGTCCGATCGGAAGTGGCGCTCGTGCATTCAACTTGTTCCCGCTCATGGAACCCCTCT
TTAAAAAGACGCAGGGCACCTGTGAGCGCAGGAGCGAGCCTAAGGCCACCCAGCGGCAGC
GCCCGTGTCCTGGGCACTCAGCGTGCTGGGCAGAGCAGGTGCGATGGCCCCAGTCCTAGC
AGCCCTCGCCCATGTCCTGTGCCCTTACATGGCTCCCGGACTGTGCAGGAGCCGATACG
TTTGCTGATAGCAATACTGGAACCACCCGGGTGCGATGGCAGTGAGGAGACTGCCCAGTG
CCTTTGGGGCTGTGCTTGCAATAAAGAAAGAATTTCCTGGAAAGGCAGTCTGCAAAAGAG
GGAACCCGGTGACTCAGAAAGACAGGATGTTTTGGTAATTTACCCCNAAATGTGCCATCC
ACCATAGTGCTTTTTCCTCTTGCCCTTCGGCTTGTTTGAATCTCACAATTATGGTATTTA
ATTCTCAAAGAAATATGTATCTGTTAGCCCGNTTGGTGACACTTATACAGATGATTAA
Sequence 1981

Sequence 1982

Sequence 1983

Sequence 1984

CCGAAAGAATATCTGTGTGCTTAGGGAGGAAACTTTTTGATCTGCAGAAAAGCCAGAAGA CATCTAGGACATCCATAAAAATTCATCAGAGAGCATTTTACTACTGAGCTGCAAAGGGAA AAACTTAAAATGGGATATGAAAAGTGAAGAAAGTGATCATAGGGAGAAAAACCATTTCAG ATGACAAGAGCACCTCAAAGGCAGCCTCAAGGAGCAGCCATGGCCCCAGACTTGTCG CACGGATGCAGAAAACTTAATGGAGGAGGCTGAGGTCAGAATGGGAAGAGTTTTTAAAAA ATAAAAAGGGGAGCTAATATGTGAGGGACCAAAAAAANNNNCANAAAAAANAAAGTGCCG

TABLE 1 330/467

GCCCGCTAGACTAGTCTAGAG

Sequence 1985

Sequence 1986

GCCACGCGTCCGCAGGAACGTGATTAGTGAAAGGAAGATAAACGTGGATGTTACTCCAA
AACTTCGTTTAATGAATGCTTAAAGAATTCAAATTTTATCTGCCTCTCTTGTAATTTGGA
TCTCTTCATATGTACATAGTGCTAACATGAAGACCTTTTTCTGCACTATATGCAAACAG
GGTAACTAACTAAAACAAAGCCACTTTCAATCTTCAATCCTTGAAGGTATATCTAGGTTT
ATGACAGTAATTGTGTTTACATTTTATGGTGCCTAGTATTGACAAAATGTTATTTCCCTA
CATTAAACATGACTCCATAGACCTTTTCATTTGTGGGGTTTTTATTTCCTATGATGTATA
CTGCCACTAACCTTNCAAAAATTACTTAGTATTGCAAAGTCAGGGAATCATCAGGGAACG
TTTAGCTTGGCCAAAATACTTGGTCTGGTTTTAAAAAACCCTGTCNAGGTCTACCAAACCT
GTTCAAGGTCTACCCAATTTTAAGGGGCAAATTTGGGGGNAAAAAGGAAAAAAT
Sequence 1988

Sequence 1989

WO 01/070979 PCT/US01/09126

TABLE 1 331/467

Sequence 1990

Sequence 1991

Sequence 1992

Sequence 1993

TCNCCNCGCGTCCTTGATATTTTGAGAAAAATCATGTGAGTCATTTTTTCTGTTTCTCTT
TTCTCTTAACGATTATCACTGTAATTCTGAATCTGAAAGGTAAAACAATTAGTCAAAATA
TTATTGCCATCATTCTACCTGTGTTATGAAACTACTTATTCATAGTTAATTCTCATTAAC
ACTTACATTTCCATAAAGAAAACTCAAGTATTAAAAAGAGACTTTACTGGCTTAAGAG
GGCTGTGAAAGATTTTTGATAGTGAATCATGACCCTAAGGGAAGAATTTGTGTGATAAAA
GTATTGTATATAATAGATCAGCGATTTTTGTAAGGCAAACAGAATTTGTAAGTTGGCAGA
TCTTCCTAAGTTGCAAAATGTAATGATGAGCTTGGTGGGGAGAAGAATGAGTCTTTTGG
AATACCTATGTGCAGCCACTACCCATCTCAATGTCACCTTGTTTGCATTCTTGGATAGCT
TGTATATGTAGTAGTTGATGAATAATTTAAAGAAAAAACACCTAAAATTTGAAAAATGAT
TGTAGGGATCAAAAAAAGGCAGATGAAATTAC

Sequence 1994

Sequence 1995

TCCGACNAAGGAACAAAGCGAAACACACAAACCAGCCTCAACTTACACTTGGTTACTCA AAAGAACAAGAGTCAATGGTACTTGTCCTAGCGTTTTGGAAGAGGAAAACAGGAACCCAC

TABLE 1 332/467

Sequence 1997

Sequence 1996

Sequence 1998

CCACGCGTCCGCACACTTGACCCCAGAGATCACGCCACTGTCAGCTGCCCTGGCTCAAAC
AATTGCCCAGGGAATGGCACCTCCACCTGTCTCCATGGCTCCTGTGGCTGTATCTGTGGC
TCCTGTGGCCCCTGTGGCTGTATCGATGGCCCAACCCTTGGCAGGAATCACAATGAGCCA
CACCACCACTCCCATGGTGACTTACCCTATCGCTTCCCAGAGCATGCGCATCACCGCCAT
GCCACACTGATGGGGCTAATGGACACTCCCCTGGTATAGCCTCGCAGGGCTGGGGTCAGG
GGGCCCTTGCCCACTCACCTAGCCTTCCCCATCCCTGTCTGAAGGGCTCCCTTGAGAACT
AGGACAAGAGACTACAAGGAGTATGTCCTGAGGAGGGTTGGGATGGTGTGTTTCTCT
CACCTCCCTTTTATGAGGGTCCTCTTGTCCATCTTCAAGCCTCACAGTGGGGGGCTT
Sequence 1999

NNGGCAGGAGAGGTTCAAATGCATTGCATCAACCTACTATAGAGGAGCTCAAGGTAATGG GGCTGGGTGAAGTGGGGTAGGTGGGTCTCAGAGTGCACATGGCTTCTCATATGGAGCTGG AAGGATTGGGGAAATGAGCAGTAGTGTCTTCCCTGTCAACCTGGGGCTGTTTNTGCCACT CTTCCAGCCATCATCATCTTCAACCTGAATGATGTGGCATCTCTGGAACATACCAAG TAAGTGAGCATCCTGCAATATAATGGGAGGCTCCG

Sequence 2000

TABLE 1 333/467

Sequence 2002

Sequence 2003

Sequence 2004

Sequence 2005

Sequence 2006

NCATTTAACTGTAATAGATATAGAACGTATCCTTCAATAACCAACAACAAATGCTTGTTT CCAACAGGCTCTGATGGTTGTATATANGGAAACCTTGATACCAATACGTCCAGCTGACCC

TABLE 1 334/467

GTCTATTAACATACGGAGCTGAATCTGCCGCAGCTNGAAATGCTCAAGAACCAGCTGGAC CAGGAAGTGGAGTTCTTGTCCACGTCCATTGCTCAGCTCAAAGTGGTACAGACCAAGTAT GTGGAAGCCAAGGACTGTCTGAACGTGCTGAACAAGAGCAACGAGGGTATGGGGTAGGCG GGTGAGGGTAACCTAAAGTGGCGAACCTGCTTCTCTCGTCCCACCTCCTAACCCAGTTTT TCTTACCTGAAACGAGAAAATCCATTACATATCGTATACCGCTTCATGAACCCTTTGCAT GTTGCCTGCCTAGAATTGAAAAGTACAGGACATTCCTCTGCTCCTATTGCCCTGTTTCC GTTCTTTTCACACTGTCTGTGGGTGCCTGTTGCACCTTTTAACGTCTTACC GTTCTTTCACACTGTCTCCAGGTGTTGCCCTGTTGGAACTCTCTTTAACGTCTTACC GTTGGAGCCGCTTACCTTCCCAGGTGTTGTCTTCATTGGCTTTCACAAGGGAAAA Sequence 2012

TABLE 1 335/467

Sequence 2013

Sequence 2014

Sequence 2015

CGCGTCCTGAGAGGTCAGGCCGGTCCTGGGGGCAGCAAGCCCGGCCACACTCCCCACCGC
GACCGGGGCTCTGGGTCCTTCCTGCTTCAGTTTCCCCAAGCTCCNGATGAGACTCCGC
TACTACCACCACGTCGATAACGCAAACCTAGAGGGACTCAGGGTAAACTGAGGCACTCAA
ACTGCCGAGGAGCTCCGCCTCCCGAGAGACATTTAATCCGGGGGGATTTGCAGGAAACTT
CTAAATTAAGGGTAGCGGCTGCTGCAGCTGAGGGGGGCCCCAGCCGCCCGGG
CAGCTGCCGTGAGCTCACGCCCCGAAATAGCCCCAGGGGCCCCAGCCGCAGCTGCCACTG
GGTCCGGCTGTCACTCAGAGGAAGCACGGAGCCCCAAGGGTCCCCTCCCCTTCG
CATCGCGGGGTTTTTTCCAGCCGACCGTCGGCCACTTTTTCCTCCGACNGCTGGCAGGGAA
GAGGGGGATTGGGGGCCCCCAAGGGAGCCCCCAATGGGTGGCCAAGGG
Sequence 2016

TABLE 1 336/467

Sequence 2017

Sequence 2018

CCCGCGTCCCGGAACTCTTACCCATAACCCTAATGATGCAAGTCATATGGGGGAACACTT

TABLE 1 337/467

Sequence 2022

ACCACGCGTCCGGTCTGCAGAGGCCCGGGCCTGGGCACAAAGGGAGAGAGGCCTCCATTG
TCCCGCAGGGGCCAAAATGCAGACCGTGCATCCCCGGTGACCTCGGGGACCGTNCTCTGA
TCAGCAGGATTTTCTTGGACTCTGGGGTCCTTGTCCTGCTCAGGCATCCCTGCCCTGCTC
TCCTTGAGGGCCCTCAACACTATCTTCCCTGGACACAAGTCTGGGGACAGCCGGGTGTTG
AGGACCCCAAAGGGGTGACTACCTGCTCCTGGGCCCCACAGAGTCCTTGTGCTCAGTGTA
GTGGCTGAGCTGGGGATGCCCTGGAATTCGGAGCACACAGCACTGGCTTACTGTGGTAC
CTGTGCAGTGAAATTGGAGACAGAATCACCAGGATGGAACACAGGTCTTGCAGGATCACG
GAAAACCTTTTAGAGTTGTCTTGACACCACTTGATGTTTGAGTGTCCGGGTGTTTGTAGGA
TGGCCTGCACTCAGTCCAGGGGCAGG

Sequence 2023

CGCGTCCGCTTGACCCTGTATTTTGGGAGTCGAACGGAGAATGGAAACTGAAAGTGGAAA TCAGGAAAAGGTAATGGAAGAAGAAGCACTGAAAAGAAAAAAGAA ACGGTCACGAGTTAAACAGGTGCTTGCAGATATTGCTAAGCAAGTGGACTTCTGGTTTGG GGATGCAAATCTTCACAAGGATAGATTTCTTCGAGAACAGATAGAAAAATCTAGAGATGG ATATGTTGATATATCACTACTTGTGTCTTTTAACAAAATGAAAAAATTGACTACTGATGG GAAGTTAATTGCCAGAGCATTGAGAAGTTCAGCTGTTGTAGAGCTTGATTTGGAAGGCAC CAGAATCCGGAGGAAAAAAC

Sequence 2024

Sequence 2025

Sequence 2026

ACCNCGCGTCCGGGTGCTGCCAGACCAGAGGCCAGCTCCATGTCCTCCGCGTCGGCAA TGATACCCACTGCCAACCAACAAAAATTGGCTGCAACCATCCCCTACCAGGACCCGGCCC

TABLE 1 338/467

Sequence 2027

Sequence 2028

CCCCGCGTCCGAAAAAGACATATGTACAAGTCTATTTCCTATAGCACTATTTGTAATACC
TAGCACTATTTGTANTATCTAAAGACTGTAAACAACGCAGGTGCCCACAAAGGGAAAATG
GTTTGACAAACTTACGAACATCCTTTTAAAGGAGTACTAGACAGGTCAAAAAGGAAATGAA
GAATGTATATTACTATGGAGTGAATCTTCAGGGTATATGACTAAGTGAAAAAAATGCAA
GGTGAAGTANTATGTAACATATGGTACAGTTTACTTAAGAGAAAAATACAGATGTATATA
CACATTACCTAAAGCAAAATGAGGACCCTACTGGGCTGCCATCCCAGCTGGACTGCTGCT
GTGGAGCTCAGCATCAAGTACT

Sequence 2029

Sequence 2030

Sequence 2031

Sequence 2032

CGACCNCGCGTCCGGCGTTCTACCCTTCCGGCCGTGTTCTATCCGCCGCCTCCACCTTCCATNCGGCGCCGGCTTTCGGCGCGCGCCGTTCCGCGCGCGCCCTTCGG

TABLE 1 339/467

Sequence 2033

CGACCACGCGTCCGCTACCTCAAGGNCCTGGGCACCGAGCGGGCCTACAAATCCGCACTG GACTACACCAAACGAAGTCTGGGGATTTTCATTGACCTCCANAAGAAAGAGAAGGAGGCG CATGCCTGGCTGCAAGCAGGGAAGATCTATTACATNTTGCGGCAGAGCGAGCTGGTGGAC CTCTACATTCAGGTGGCACAGAACGTGGCCCTGTACACAGGCNACCCCAACCTGGGTGCT GGAGCTGTTTGAGGCGGCNTGNAGACATCTTCTTCGACGGGGCCTGNGAGCGGGAGAAAG CTGTGTCCTTCTACCGGGACCG

Sequence 2034

Sequence 2035

CGCGTCCGGAAGAAATTGTGCACCCTCCCAAAACATACAAAGTTTAAAAGTTTGGATCTT
TTTCTCAGCAGGTATCAGTTGTAAATAATGAATTAGGGGCCAAAATGCAAAACGAAAAAT
GAAGCAGCTACATGTAGTTAGTAATTTCTAGTTTGAACTGTAATTGAATATTGTGGCTTC
ATATGTATTATTTTATATTGTACTTTTTTCATTATTGATGGTTTGAACAGTGTATTCTAGAAAAC
AATTCCATAGTTTTTAATATCCCAGAAGTGAGCAATTTGAACAGTGTATTCTAGAAAAC
AATACACTAACTGAACAGAAGTGAATGCTTATATATATTATGATAGCCTTAAACCTTTTT
CCTCTAATGCCTTAACTGTCAAATAATTATAACCTTTTAAAGCATAGGACTATAGTCAGC
ATGCTAGACTGAGAGGTAAACACTGATGCAATTAGAACAGGTACTGATGCTGTCAGTGTT

TABLE 1 340/467

Sequence 2039

Sequence 2040

CGTCCGCGAGATCCGGCACACTGCGGACCGCTGGCGCGTGTCCCTGGATGTCAACCACT
TCGCCCCGGACGAGCTGACGGTCAAGACCAAGGATGGCGTGGTGAGATCACCNGCAAGC
ACGAGGAGCGGCAGGACGAGCATGGCTACATCTCCCGGTGCTTCACGCGGAAATACACGC
TGCCCCCGGTGTGGACCCCACCCAAGTTTCCTCCTCCCTGTCCCCTGAGGGCACACTGA
CCGTGGAGGCCCCATGCCCAAGCTAGCCACGCAGTCCAACGAGATCACCATCCCAGTCA
CCTTCGAGTCGCGGGCCCAGCTTGGGGGCCCAGAAGCTGCAAAATCCGATGAGACTGCCG
CCAAGTAAAGCCCCTAGCTTGAGTCGACCCACGCGTCCGATTTAAATATTTGTCCCATTG
TTTGTGATTAGGATGTAAGCTTTGTGGAATGTAATTAACCCTGCTTTACGAAGTCACCAT
ATTATAATAGGAAAAACACTGCCTAGGAGGCAAAGAGATCTGAATTCCAGTTCTGATGCT
GCCACTGTGTAAGGAAGTAGTTTTATAAACCATGGGCAAATCATCTTGAGCTTTCTCATC

WO 01/070979

TABLE 1 341/467

TGTAAAGTTAGGGG

Sequence 2041

TCGACCNCGCGTCCGAAAAACCAAAACCTGANTGAGATCTTGGAACCGNTGTGCGCCGGC
CGNNCCTCTCCCANGGGACCANCCANCCCCGCGCGGTGGCCGACTGNATAGGCGGGACTG
CGCTTCGAGGCTTAAGGACGNCAGATCGGAGGCATCGTGTGTTGTCTGTGCGGAGAAGCC
AAAANNGTGATTACGTTTATTTGCAAGACCGTTCATGTTGTTTTCAGTTCATGGTATGAT
TAAAACCCGATCCTTTGTTACCATGCCCTTAGGTACGAAAAAAATAATTGTTTNGATATTT
GGCAGTCACCCAAAAATATCCAAAAAGCCATGAAACAGTANAGGTAAACAAGTANGAAGT
GAAANTAATNTTCGTCCTTTGTTTTCTTTCTGGAGGTGCTCAAAACACCCTCTCAAACCA
TTTTCCCAGCATAGAACCAAGTGTGGNCNGGNTANCAGCTAATATTTACNAGGGNAGAA
ACGAACCCTNGCGATATTTAGTCACTTTGTTNCCNGGGANCACANAAAATNTTGAACAAA
CACATGAGAACTGTCACCGATCTCTGTATTGATNACCANGGATACCCGTGAATTTTATGT
AATATTAATCTNNGGNAGGCANGANTNTTTNNTAGGTATTTGCCTTTTCCAAGGTGCNCT
TTCCNTACCAAAGGAAAANGGTTATTTTAAAAACTTTTACCANAANAAAGGGGATGNCTT
ATTTTTTGGTCCT

Sequence 2042

Sequence 2043

Sequence 2045

WO 01/070979 PCT/US01/09126

TABLE 1 342/467

CAAGATNTACAACTCGCAACACCGGGTCAAGCAATCAGCTGCATTCCGGACCGGTGTGNA AGACCGAAGGG

Sequence 2046

CCCCCGAATATCTTATCCTTAACATTAAATTGAATTTTTTGCAAATGATCAAAAGGTCA
TTCCGAGTAAATTCTGTTGTATAGTGCAGATGATCAAGCTGAGTATTTGCCATGTTTTTA
TTTTAGAAAAGAGATGTTGCTATAACATAAGTAAATACGATTCTCGTATGTGGCAGATAA
ATTTACTTGTAATCTGCTCTAGAGTGAAATTATTTTTTACATATAAGCATTGTCATCATT
CTAAGGATTATTGAATAATGAATATAAAATGTTCTTGTGTATTTGTGTATGTGTATATAA
TTTTTGAAAGTTTCTTTATCCTATTGACCCTTCTCATAAACAGNAGCATATATATTA
TATGTAGTAGAATTTATATAGGAACATTGTCTTTTTCCCAGTAATGCTGATTCTAAACTA
GTTATGTCAATTTCATGTAACATGACATTNAGAATAGTGGGGTGCTAAATATATTTAGAA
ATGATTTCCAAAATTGNTGTATTTCTAACATAGAANGATATTTGTCATTTTAAAATAATG
TAAAGAAAAAATGC

Sequence 2047

Sequence 2048

Sequence 2050

Sequence 2051

TABLE 1 343/467

ACAAAAGAAGTCTTCACACCGTTGTGGAACTTTCCTGCAACTTCTGGATGCAGACAAGCC
TCAGAGCAGACTGTTCTGGCTCCAGNGAATATCGGCTGCCAAGCTGTGAGCATCCAGGGA
TCCNCGTCTGCCTGGCTTTCCTGAAAGTCAGAAGGCGCCTTGGTCATACTGTGTGGGGTG
NGTNGGATNTTNAGTTNTGNTCTCTTTTCTTTTTTCTTTTTTAACAGCTTGGCGAGTA
GCCAACACCCCTGACAGCAATTGTGCNGCACTTGGCTTAATTCACACCCTATGAATAATT
TTTNATATTTCAACTTGGAAAAGGTGGTTAAGAAACTTTT

Sequence 2052

GATGGACTGTCATNCAGGACGGCCCTGCTGCATTGGCACCAAGGGCAGGTGTGAGATC ACCTCCCGGGAGTACTGTGACTTCATGAGGGGGCTACTTCCATGAGGAGGCCACGCTCTGC TCTCAGGTAGGTCTGCAGAGTGTCCGTCGTTCCCCCCCAGCTACTGTGATGCTGATA TGCTGCTCTGCAGGTGCACTGCATGGATGATGTGTGTGGGCTCCTGCCTTTTCTCAAC CCCGAGGTGCCTGACCAGTTCTACCGCCTGTGGCTATCCCTCTTCCTGCACGCCGGGATC TTGCACTGCCTGGTGTCCATCTGCTTCCAGATGACTGTCCTGCGGGACCTGGAGAAGCTG GCAGGCTGGCACCGCCATCATCTACCTGCTGAGTGGTGTCACCGGCAACCTGGCC AGTGCCATCTTCCTGCCATACCGAG

Sequence 2053

Sequence 2054

Sequence 2056

CGCNTCCGGAGAGAGCCCAGGGATGCCTTATGGTCAGAACAAATTTATAGACAACAAAGGGGAAGTGACCGTGCAGAAATCAGAAGTGAGGTACAGAAACAGCTGGACTGATTACAGCTC

TABLE 1 344/467

AACATTTGCCTTTTTTGAACAAATCTGAACACTCAGCAGTGTATGAGTGGTTGACCGTAT NGGCTGCTGTGATTGGCCAGACCTCAGCTATTGTTACAGGCACATACTCTTAAGTCAGGT TTTCAATCCTATCTGACTATAAAGTTAGGTTACAGTTTGTCCTCATGGACTCAAATTTAG AAGTATGGCGTCCTTCTCAGGCCATATTTAGTTCAGTTTAACAAGTGCATATGGCTTCTG ACAAAGGTGTGGCCCCTTTAGGACTCCAAAGACGCTGTCACTTACATGGTATTCAGGGAA GACACAGAGGATCTGTGAGCAGCCTGCAGCCAAAGCTTTTGAGATCATATTGAGATTTTT TTGTANTATANGAGGAGGGGTTCTGGCTC

Sequence 2058

CGGAAGCATCGACCTGCGAGCTCACAGAGCTGGGAGCAGAGCACCCCACACCCCGAA TGGCTATGGAAGCTGCAGGGCCCCAGGGACACTGGGAGTCCCTGCTCTCATGGCAAAGCA GGGACGGGGACTTAAAAGCCACCAACAGGAAAATCGGGGAAAAAAGGGAAGATGGTGGT AACAGTTGGACACTATTTCTTGGCAAAACCGTGGAAAAACACGTTCTACACCAGCAGGTG GCAAATTGTGGCCGCCATCTGTGTTTGCAAATAAAGTTTA

Sequence 2059

CCCCTACAATGAGCTGTCCCGCCTCAGTGGCCTGCGAACCCTCAACCTCCACAACAACCT CATCTCCTCCGAAGGCCTGCCTGACGAGGCCTTCGAGTCCCTCACCCAGCTGCAGCACCT CTGCGNGGCTCACAACAAGCTCTCAGTGGCCCCTCAGTTACTGCCCCCGTCCCTCCGNGT CGCGGATCTGGCTGNCAACCAAGT

Sequence 2060

Sequence 2061

Sequence 2062

AAGGGAAAATGTCACGTANACTAGATCAGGGAACAAAATCCTCTCTTGTGGAAATATCC
NATGCAGNNNGNTGATACAACTTANTATCTTATTGCCTAANAAAAAATTTCTTATCATT
GTTTCANAAAAGCAAAATCATGGAAAATTTTTGTTGTCCAGGCAAATAAAAGGTCATTNT
AATTTAGCTGCAATTTCAGTGTTCCTCACTAGGTGGCATTTAAATGTCCCCTGATGTCAT

TABLE 1 345/467

Sequence 2064

Sequence 2065

Sequence 2066

CTTAGCGAGGTCACGNNCNANGAACGCGGGGNGNTCAGGAAGATNTCTGAAGAGTGCAGC NGCCTGAACCGAGCCCTGCCNAACAGCTGACAATTGCACTGCAACCATGAGTGA Sequence 2067

Sequence 2068

CCCTTAGCGTGGTCGCGGCCGAGGTACTTNTCCGATTTCAAGAACTGATGAAATTAGAAA
AAACACCTACAGAACATTGGATAGCCTGGAGCAGACCATTAAACAGCTCGAAAATACAAT
CAGTGAAATGAGTCCCAAAGCCCTAGNTGATACCTNATGTTCTTCCAACAGAGATTCTGN
AGCAAGTTCATCCCACATAGCCCAAGAGGCCTCTCCCCGACCCTTGCTAGTTNCGGATGA
AGGTNCCACTGCCCTAGAGCCCCCTACGTCGATACCTTCACGTTAAGGGCTCCAG
CGGGGCCCCACAGACGAGCAGGATGCCTGTCCCCATGAGTGCCAAGAACAGACCCGGAAC
CCTGGACAAACCCGGCAAGCAGTCCAAACTGCAAGAACCNCGCCAATATCGNCAGGGCTA
ATGGAANTNCTAAGAAATCTTGGNNGGGGACTNTTAAAGCCTACTTTCCCCTACTTACCT
GCTTCTAAAGATTCCAAGGCCNTTCTTCCAAACTTTTGGG

Sequence 2069

CCCTTTCGAGCGGCCGGGCAGGTTCATGGATNNGAGCAGCTTCACCAACCCCTGCA

TABLE 1 346/467

Sequence 2070

Sequence 2071

CCCTTTCGAGCGGCCGCCCGGGCAGGTNCNGGTTANCAGACCCACAACACGAAGCTCCTG CCTTTTAAGACTACAAAGAGGCAGCTCAAAATTAGACTGCACAGGTAAGCGAGGAACTGC AGTCTAAGCCTGGACTCTGCCTTCTGCCCTCCCCCGCGTACTCAAGCAATAAAAT Sequence 2072

Sequence 2073

CCCTTAGCGTGGTCNCGGCCGAGGTACGTGCTTATACAAGATGTCAATTATGTGGTCGTC CACATGCTGTATTACGTAAATTTAAAATTTGTAGAATTTGCTTCCGTGAACTAGCTCACA AAGGACAAATACCAGGTATTAAGAAAGCGAGTTGATAATATGATAATCACAGATCCAATA GCAGATATGATCACAAGAATCAAAAATGCCTTCACACGTAAACACAAAAATGTTATTATT CCTCATTCTAAGAAAAAAGAAATCTTACAAATCTTCTTAGATGAAGGATATAAAAA GGATTTACTGTTATCTGGTGAAGTTAAAAAAAGAAATTAATGTTGAGCTTAAATACAAAGGA AATACAAGTTCAATTGNTGGAATTAAAAAGGATTTCCAAGC

Sequence 2074

CCCTTTCGAGCGGNCGCCCGGGCAGGTGGGCAGGTACTTCAGCAAGTCCTCTTTCTCCTC
AGCAGTAAGCTCAGCCGGCAGGTGCCTGACCAGAAGGGTTCGGTCGCCCCGAGGCGGGA
AAGCGAGGAGGAGCTCGTGCATCCCCTTGATATCGCAAGCGGCTGCTCGGGAGCTGCCAT
TTTCCTTGGAGAAGCAAAAACAGAAATCGTGGGAAGAAGTCTCAGTCAAAATCGCGGCAT
CAACACAAGCTGGGAGAAATATTTTTTCCGCCTCGCGCTAAGGATTCTGGAAACCAGGAA
ATACCGAGAAAGAAAGTCACCTTCTCGCGAGAACTGCGCCACCGAAAAGCGGCAACCCTT
CGAAGACTCTTCGGGGAAGGGCGCGGTGCTAATGATTTAAATTCCAAGGGGTCTNCGGAA
AGACTTACAAAGCCAAAAATTGGCCCAAAAGATGTGCGANGGTTAACACAAGTTGTCAAT
CAAAGAAAGGAAACAGGAACCCCAACCCCTTTAAGGA

Sequence 2075

TABLE 1 347/467

CATTAATATACTTTGCACCAGCAAAAGCGATTTCCAACATATGTGTTTTGGAGGTAATTA AGTAACTCTGTATAAAAATAAATGCACTTTTCCCTCCTTTCCCCAGTGAATGGAAAACTT CCATACTTTCAAAATAATAATAAAAAAAATAATTTTTAAGAGCAACAGCCCTCAACTCTTT GCTGGTGCCTGCCATACTGCCTTTCTTCACTCCATTCTTAGCTCTGCTAGTTTCTTCTTG TATGTCATGATAAAAAGGGAATGTGGGTGTGTAACTTTTGTGTATGTCCCGTTTCCAAAT AAACACAAATAGCATTCCAACAGTT

Sequence 2076

ATCGCCACCTACATTAAAGCTAATATGCCTGATTACTGTTTTTAGAGAACTTATTTTATT AGGGCAGTTCCAAGCTCAAAAATACGCTAACTGGCACCTTGTTAGCTACATAAAAATGCA CCCTAGACCCGAAACTTACTAGACTCATTATAAAATTTTCTTTAAGGTGTCCACGCAGTC CCTGGTCACACTTGAAGCAGTCCGGAGAAATATCAGCCCTACCCCAGTAATCCCCAGAAG GAACTTACACTTTTTTTAATCTTTTCCTACAACTTCATATTTTATAAATAAAAAGACAA AAATGTCAGGCCTGTGAGCTGAAGCTTAGCCATTGTAACCCCTGTGACCTGCACATATCC GTCCAGGTGGCCTGCAGGAGCCAAGAAGTCTGGGAGCAGCCCGAAAAACCACAAAGAAGT GAAACAAGCCAGTTCCTGCCTTAACTAATTAACCCACCTTACGACATTCCACCATTATGA CTTGTCCACCATTATGACTTGTTCCTGCCCTGCCCCAACT .

GATGGAGTCTTGCTCTGTTGCCAGACTGGAGTGCAGTGGTGCGATCTGGGCTCACTGCAA TCTCCACCTCCCGGGTTCAAGCGATTCTCCTGCCTCAGCCTCCCGAGTAACTGGGACTAC AGGGTGCGCCCCCAGCCCAGCTCATTTTNGTATTTATAGTAGAGATGGGGTTTCACG ATGTTGGCTAGGGATGGGTCTCGATCTNTNGGTCAGAGTCTNTTNCTGTAAAATATCCTT GGGTAAAAGAAGCAATTTTANACTGTAAACTGATGNCAANATGCTTTAAGGGAAGAAGGC Ν

TCCCTTNCTTTCTCGCACGTTCGGCCGGCTTTTNCCCGTCAAGCTCTAAAATCGGGGGGG CTCCCTTTAGGGGTTCCGAATTTAAGTGGCTTTACGGGAACCTTCGAACCCCAAAAAA Sequence 2079

CCCTTTCGAGCGGCCGCCCGGGCAGGTNCAGGGTCTGTCAGAAACTGTTGGAATCTTACA TAAAGTCAAGTCTCAGAAATGTCCGATGCTTCACCATATTCTTATATTCTATGCAATTGT TGTCTGTGCACTAATCATCTCGACCTTCTACATGAGATACAGAATTAATACTCTGGAGGA GCAGCTGGGGTTACTAACCTCCATTGTGGACACCCATAATACTGAACAGGCAGCACCATC TGGCCTGAGGTCACAAGTACCTCGGCCGCGACCACGCTAAGGG Sequence 2080

ACCNTATAACGGCCGCAGTGTGCTGGAATTCGCCCTTTCGAGCGGCCGCCCGGNCAGGTA CGCGGGGNTGGTTCCAACTTTTCTGCTNATCTGGGAGGTGNTGGGCGCGGACAGTCNAGA TGTCAGAGAAAAAGCAGCCGGTANACTTAGGTCTGTTAGAGGAAGACGACGAGTTTGAAG AGTTCCCTGCCGAAGACTGGGCTGGCTTAGATGAAGATGAAGGATGCACATGTNCTGGGA GGATAATTGGGATGAATGACAATGTAGAGGGATGACTTCTCTAATCAGTTAACTGAGCTG AAACTAGAGAAACATGGGTTATAAGATGGGAGACTTCATAGCCATCCAGAAGAAGTGCTG AAGTAAACCTAAAACTTGACCCTGCTNAAATACATTGTAGGGGCAAGAAGAACCCAAGGA **ATGGGGACACT**

Sequence 2081

CCCTTTCGAGCGGCCGCCCGGGCAGGTACGCGGGGNAAGTGTCGGCGCCGCCACTGTCCG GCCACAGCCTAACGCTCTTNGCTGTCGTTTGNGGNCTCGCGCAGGGCGGCCCCGGNTCTG GTGTTTGGCNGTCGGAATTAAACAACCACCATGTCCGAGCAAAAAGGCAAAGACCAAGAC CACCATAGAAGCGCCCTTAGCGTGCAACATCCAANGNGTTAGNCATGTTNGACCAANNCA CAGATTNGAGGAGTTCAAAAGAGGCCTNCAACATGAGTTGATCAAGAANANGAGATGGCT

TABLE 1 348/467

TCATTNGANAANGGAAAAATGCCNCAAGGNNNNGCCTNNGCTNACTCTAGGGGAAATAAA CCCCNACCTGANTNNGAAAATCTTGAATGGCCCATGGATGAAATGAGGCCCCCA Sequence 2082

CCCTTAGCGTGGTCGCGGCCGAGGTACTGTGATATNTCACATATTTTTGAGAAAAATTCC
CAAGCCAGGCGAATGTGGATTGGAATAAAGACATAGGCAGTGTATACCACCATAGCAATA
ATGGTTAGTAAGATGGTGTTAAACATAGATCGCTCCCAGGGCTCTAAAACAGCACAGCAG
CTAATGATTTGGTATTGATAGTAGAGCCAGGAGAAATATTCCTTCACACGCCTCAAATCC
ATGGTTGGCTCCTTCAAGCTGCAGTAAGTTTGTCCTAAGAAAGTCCAGGTCTGGTTCTTC
AGCCTTGCTCCTTCGCGAAATGATCCTGTGTGGGTTAGTTCTCCTCTCTGGGTTGCTT
TCCTCATCTCCCAGTTGGGTGTATCTCCCTGCGGCTTAGGTGAGCGCCGAGGCTTTGGCT
CCTCCCCAGCTGCTGCGAGCTTCCGCTGCCCCCGGGCGGCCGCCCCCAA
AAGGG

Sequence 2083

CGGGCAGGTACCAAAGCCTTNTGNCCCCATTTTCCATCATACGAATAGTATTCCCTGTTG CTAAGCCGATGATACATTANCCTTTTCCCAATAGGNGNGAGNGGATGGACTGAATGGAGA A

Sequence 2084

CGCTCACTGCCCGCTTTCCAAGTNCGGGAAAACCTGTCGGTGCCAGCTTGCATAAATGAA ATCGGCCAACCGCGCGGGGGAAGAGGGCGGTTNGCAGTAATTGGGCNGCTCATTCCAGC TTCCTCCGCTTCACTGGACTTNGGANGGCNCTCGGGTCCGTACNGGCTGGCGGGCNGAGC CGGGGNATCAAGCTCAANTTCAAAAGGCCGGGNAAATACCGGGATAACCCACCAAGAANT CAAGGGGGGATAAACGCAAGGGAAAGGAACATGGTGAAGCCAAAAAGGG Sequence 2085

Sequence 2086

TTTNNAGTTTTNGGGANCCACTAGTTCTNGAGCGGCGAGGTACTTATCAANAATGGGGTCCNTAAAGACATAATCTTTGCCAGTAGATGCAGAGTTGCTGGTAGNTTATGACTAATTCCAAGACCGTCCGAAATCCCTGGGCTGTGTTGAAATGTGNNTTCATGCTCCCTCGCTCCCAAGCATAGACCGNCAGGAGCTCCAGGGCATACTGAGGNGGCAAGCTTCCAAGCTTCTTACAATTTTGGACCTGCCCGG

Sequence 2087

Sequence 2089

TABLE 1 349/467

CNTCNCGCCACGGACGCCCGGCTNTCCCCGNCAAGCNCTAAAAACGGGGGCCNCCCACAA AGGGGGCCGANANAAGAGCNNNAACGGGNACCCNCGACCCCAAAAAAACNNGGAAANAAG GGGGGAAGGGGNCAACGCAAGNGGGGCCAANCGCCCCGGANAAAACNGGAGANNACCGCC CCNCNGAACGGANGGAAGACCANCGGCCCNAAAAAAAGGGGNCCCACGGGGCCAAANCAG GGAACAACACACACAAACCCCAAANCCGGGGCCANNNCCNNTGGAANCAAAAAAGGGANANG AGCCGAACACCGNCCCAATGGGGGA

Sequence 2090

Sequence 2091

Sequence 2092

TTAATTGCGCCCCTTGGCGTAATCATGGTCATAAGCTGTTTCCTGTGTGAAAATTGTTAT
TCCGCTCACAATTCCACACCAACATACGAGCCCGGGAGCATTAAAGTGTAAAAGCCTGGG
GTGCCTAAATGAGGGGAGCTAACTCAACATTTAATTGCGGTGCGCCTCACTTGCCCGCTT
TTNCAATTCNGGGAAACCTTGCGTGNCCAGCTTGCANTTAATGAAATCGGCCCAC
Sequence 2093

Sequence 2094

TTCTGCTGAGACGCGTGTGGCTNCCTCCCCGCAACANCCAAAATGNTGAAGCTGATCGAGAGCAAGGAAGCTTTTCAGGAGGCCCTGGCCGCGNGGGAGACAAGCTTGTCNTGGTGGACTTCTCTGCTACGTGGTGGACCTTGCAAAATGATCANGCCCTTCTTCCATTCCCTCTGTGACAAGTNTTCCAATGTGGNGTTCCTTGAAGTGGATGTNGATGACTGCCAGGATGTTNCTGCANACTGTGAATTCNAATGCNTGCCAGACCTTCCAGNTCTATAAAANGGGNCAAAAGGNGGGGGNNNTCTACNGNGCTAACAAGGAAAAGCTTGAAGCCTNTATTACTGAATATGCCTAATCATGCTCTGAAAAAGTGGGACCAGCTNCCAAGCTGNTTNAAACCTCGTACCNTTNTTAATTTGCTAAAAACTATGAAAGTGGGAGAGGGGAGGCTATCCCAACTGNCATCTGATTATTAGTGA

TABLE 1 350/467

Sequence 2095

TGTGTAGCACCTGNGGNGTCCTTGNGTGATTATTCTTGTNCGAGGTACTTAGGGCAAGTC ACATGCCCTCCATCCCNTGGCTCANAGATGAAGAGTAAATCCAAAACATGTGCCTCGCTC TTGGTCACTAACTGCTGNCCTG

Sequence 2096

TCGAGCGGCCCCGGGCAGGTACTTTNTTAATGCCTTNGTTGGAGTCCTNATCCTCATC
TTTAAAAAAAAAAAAAAACAGNTTANCCTAAGCCANATTCACTTTTTTTAGTTNACAAAAA
GGATTAANTNGCCACANTGTGATTT

Sequence 2097

ATTNNCCCTTAATCATCTCACGCCCCATGTATGATTCTCAAAGNGCCTAGCGTGANCANC NGTCCCTNAGACCACACCAATTTCTTNATGTCNCNCTCAAGAAAGCCAAAATGACAATNA TAANGCCATCTCAANCNCAATANCCTACCANAACCACCCCNCGGNCTTATCTANACTTCA ACTCAAACTCTCTGCCTCCTTACTNTCTGGGGAGCTTNAAAACCANNTNACTNATAACTT TAAAAACCTNTCTNTAAAATNTCANAAACCACACACCACATTNNCACAACCACCCCA ACACCAAANANNTTCCCAAAACACC

Sequence 2098

NCCTTAGCGTGGTCGCGGCCGAGGTACACTGGAGGCTGGAGCCTGCAGATGGCATGGCTC TGCGGCTCACCTTGCTGCAGTTGGTGGTGGTGACAGAGACTGCAGCTTGACTGTAGTGAA TTTGGAAATTATCTGTCTGGAAGCTCTGAGTTTATCTTGGGACCTCAAGAGGAGAGGATC ACCCAACTCACAGCAATCAAACTCCAAATGGTGCTATAAACTGAACCACACATGGACACG TCAGTCTTCCGAGGACCCTTAGATCAACCCCAGGAGGAGCCCTAGCTGCTGTTCCCCATT CGACGCCCCTTTCCAGCAGG

Sequence 2101

Sequence 2102

TABLE 1 351/467

TTAAAAAAAAAA

Sequence 2103

Sequence 2104

Sequence 2105

Sequence 2106

TCGGCGTCGCGACCCCGAGGACCTCCTCTNCTCGCTCTGTGGCATACACTAGTCCTGGG CACTCAACCGCGGAGAGCCCCCGACCCCGGGGTAGCGGCTGAGCCTCAGCCGGGACCGGN ACCGGANCCCGCGCGGAGCATGTNATCCGGGCTGGGGCAGCTGGNACAGTGGGCTGGGT TGGCCCTCCT

Sequence 2107

ACCACGCGTCCGAGCTCGCTCAGCACTCCCAGGTCCTTAGCACTCCCAGGTCGTAGCTGG
CGCAGTCAGTAGGAACTGTAACTATGTCTCTGATGCACCACGTGTTTAGACACAGCACAG
TCCTTTTTCTGTTCCTACGGTGGAAGTAGTTTCTCTTTTGGGCATGCTGACAGCACTTTT
TCATAGCCTCACCGATGAGCCCTTTCTGCGGGAGTGACTCCATGCCTGTATACAGAGTAT
TTATACAGATGTTTTAGCATCTTCATATGCGGTGTTAACCCCTAGTTCTGTACAGCATAT
TCTGTTCAAGTATTTTTTTACAAGCTTGTGCTGTAGGCACATGCCTTCCTGCAGAAGT
GGACACCCGTGGCACACCCACCCCCCCCAGTGGGGTGCCATGCCTTCCTGGGACATTGC
CACTTCTGCCCTGGAACTCATGCAGGTACGTAGTAGCTGCTATTGCCAGA
Sequence 2109

NCGCCTATCACATAGTCAAACCCAGTCCCTGGCCACTGACAGGAGCTCTGTCAGCTTTCT

TABLE 1 352/467

Sequence 2110

CGTCCGGGACCTTTATGTCTTGTNAAGATGTCTAGGCCTGGCCGGGCGCGGTGGCTCACA
CCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGTGGATCACGAGGCAGGAGTTTGAG
ACCAGCCTGATCAACATGGNGAAACCCCGTCTCTACTAAAAATACAAAAATTAGCCGGGC
ATCGTGGCACATGCCTGTAATCCCAGCTACTCGGGAGGCCAAGAGAAAAAAANANTTGA
ACCCAGGAGGTGGAAGTTGCAGNGAGCCAAAATCACGCCACTGCACTCCAGCCTGGGCAG
CANAGTGAGACTCCGNCTNAAAAACAAAACAAAACAAAAAGCAAAACCAGATGTCTAGG
CCAATGATAATTATTTTTGATGCATTGTGGATTANGNTCTTTTGTTAACCCCACTGTCTT
GGGGAATGATGCCTGCTGGGAAATTGAGTTTTTTGACTGAAACATGAACCTTNCTGCTT
TTTTTCTGGNTCCTATGAAGGTTTTGGAACATNTGAAAACACAAAAACTCACCTTGAAAT
TTGAGCAGGTCGATGATGGCAAAAAATTATTT

Sequence 2111

GCGTCCGCTGATCTGCTTTGGGACGGCCTTTATATACTTCCTCCTTTCCAGGCCTTCCAC CACCAGTGACCACTATTCGACATCTGGCCCACTCTCAGTCATCCTCCTGCTTATGCTTGT CTNCTCCTTGAAGGCTTCCCACTGCATGTAGGACAAAGGTCAGATTTTGTAACAGGCCAG GCCTGGNCTTNATAGTCTGGNATCCACTAATTTATGGTCTNAGTCTNATCCCTTGGAGGA TTACCTCTGNCCTTNGNAAGCTCTGTGCTCCNG

Sequence 2112

TTGGAGCTCCCGCGGTGGCGGCCGAGGTACCTGCTACTTTTTAAACAATTTCAACTGCA GCTCTCTTTCACTAAGTNAGATGGGNAAAGCATGCCATTTCTGTTTNCTTGNGATTTTTA CTTTTTAGAAACACACATGCTTCCACTGCCATCTGACACTTCTCCACACGCTTTCATNTT GTAAACCTGAATTCTATTTNGAGTACCTATCAAATACTTTCTGGAGGNGGGGCACGCTCC GCTCGGTCATGATGCTGATCCACTTGGGAACATCAGTTCCTTTCCTCTTCACTCCAGCGT CATAGAGATCCCGAGCATCTTGGNNAATCAGTTCATAATCAATGACAGAGCCATCCTCTG CTCTTCTACCCTTTGCCA

Sequence 2114

WO 01/070979 PCT/US01/09126

TABLE 1 353/467

TGGAGGGGTTAATTGCGGCGNTTGGGCGNNAATNATGGGNCATTAGGTGGTTTCCTGGNG TGGAAATNGTNATCCGGGGGGGGGGGGTNCANACAAAATAGCNGAGCCCGGNNAGNATAAN AGTGTAAAAGCC

Sequence 2115

GCTCCCCGCGGTGGCCGCCCGGGCAGGTACCTGTTGTGTCCCTTTCTCTCAAAGAT CCTGAGCAAAACANNGATACGCTTTCCATTACCTNATGGGGGGGNCNNGGACCCAGCTCT TGGCATTGCTANGGNNGGCTANNATCNNGCCACNTGAGGNTGTGGANNN Sequence 2116

CTAACTCACATTAATTTGNGTATGCGCTCACTGCCCCGCTTTCCAGTCGGGAAAACNCTG GTCGTGCCAGCCTGCATTAATGAAATCGGCNCAACCGCCGCGGNNGAGAGGGCCGGNTT TGCGTATATGGGCAGCTCTTCCGCTTTCCTCGGNTCACTTGACTCGCTTGCGCTCGGGTN CGTTTCGGGCTTGCGGGCGAAGGCGNGTATTCAGGCTCACTCAAAGGGCCGGGTNAATACG GGTTATTCCAACAAGAATTCAGGGGGGGATAANCGCANGNAAAGAACCATTGTTGAAGCCA AANAGGGCCCAAGCAAAAA

Sequence 2117

CCGCGGTGGCGCCCCCCCGCTTTTGCATCTTCAGGAGACGCTCGTAGCCCTCGCGC
TTNTCCTCGGCCAGTTCGCGGAAGAAGTGGCTCACGCCTTCCAGAGCCACATCATCGCGG
NCGAAATAGAAGCCCANAGAGAGGTAGGTGTAGGAGGCCTGCAGGTACAACTTGTTGGCC
TACATAAAACACCTAGATGGTAACAACGAGGCAGCCCTGGAATGCTTACGGCAAGCTGAA
GAGTTAATCCAGCAAGAACATGCTGACCAAGCAGAAATCAGAAGTCTAGTCACTTGGGGA
AACTACGCCTGGGTCTACTATCACTTGGGCAGACTCTCAGATGCTCAGATTTATGTAGAT
AAGGTGAAACAAACCTGCAAGAAATTTTCAAATCCATACAGTATTGAGTATTCTGAACTT
G

Sequence 2119 1

Sequence 2121

GGTACCTTGTCTGGAGAATGCAGTGACAGCACCGGCCCATGCTTGAGAACCCANGCGGCT GTGCAGAGGGCAGCCACCACTATAGCCAGCAGATGGCCCAGCAACTGAGGCTCCCCACA GACACGCTCCAGGAGCTGCTGGACGTGCATGCAGCCTGTGAGAGGGAAGCCATTGCAGTC TTCATGGAGCACTCCTTCAAGGATGAAAACCATGAATTCCAGAAGAAGCTTGTGGACACC ATAGAGAAAAAGAAGGGAGACTTTGTGCTGCANAATGAAGAGGCATCTGCCAAATATTGC CAGGCTGAGCTTAAGCGGCTTTCANAGCACCTGACAGAAAGCAT WO 01/070979 PCT/US01/09126

TABLE 1 354/467

Sequence 2122

GGCNAATTGGAGCTCCCCGCGGTGGCGGCCGCCNGGCCAGGTACCCTTGGAAGATGGGAA AGGTGAGGGAAATATNNGAAGCAGGGTCAGAACATCCACTAAGAACATAGCACCTNAGTA NAGCTTACATTATATGAGCCAGGGTAGAGTTANTACTGAAT Sequence 2123

Sequence 2124

GCGAATTGGATCTCNCCGCGGTGGCGGCCGAGGTACCTTTTTAAATCTAGCCCAGTATAA ACATTAGCCTGCTTAATATTTAGACATTTATAGGTAGAATTCTGAGCACTCAACTCATGT TTGGCATTTAAAGTAAAAACAAGTGTGACTTCGAGGACCAAAGAAATTGTCAGCTATAC ATTTATCTTTATAAAACTCATTTATATTCCTTTTAATGACTCGTTGTTCTAACATTTCCT AGAAGTGTTCTTATAAAAGGTCTAATGATCCACAGGCTGTTGTCTTATTAGTAAATGCAA AGTAATGACTTTGTCTGTTTTACTCTAGTCTTTAGTACTGGTTGTCAGGATTCAGCCGAA TGGCTTGCCTCAGAGGGTCAATGGCGTTCTGAGATGGCCAGTTGTCCAGACGGTAGCTTGCTATTGCCAGAGGGTGAATTCTGGGTTCTTTGGCT

Sequence 2125

GCGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACTGGTGAAAGTTCTTGATGAGGG TCTCAATGGCCCTCTCCACATCACTGAATTCCTGAGCATCCTCTGCGTTGGCTGACCGAC ACTGTCCCATGGTGCCCACTGTGTCTGGTCCTTTGGTGAGAGTTCTGTTGTCCTATAGCT GGCCCCAGAGGAGCTGATGGCTCATGATCTGTTGGCAGCCGCTGAGACAAGACAGGAGGC CCCGCGTACCTGCCCG

Sequence 2126

CCGCGGTGCCGAGGTACCCGGTGCGCATAAGAGGAAGATTTCTGAAGAGTGCAGCT GCCTGAACCNANCCCTGCCGAACAGNTGANAATTGCACTGCANCCATGANTGAGAACAAT TAGAATNCCTTGGNGGGCAGCCTACGGNANCTNAAATGCCATTTAACCTGGAACTTGATG

Sequence 2127

Sequence 2128

TABLE 1 355/467

ATAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACNCGGGGNACTGAAANTCCA CACGACANAATAGCCAGATCTCAGAGGAGCCTGGCTAAGCAAAACCCTGCAGAACGGCTGCCTAATTTACAGCACCCATGAGGAAAGGCCACTTANGGATGCAGCAAGAAGGAGCCATCTGCAATCCAGGAAGAAATTCCTTGCCAGGAACCAAATTGGTTGTCACCTTCATCTAGGACTTCTAGCCTCGAGAACTTACAAATGGTGATCATCAGGTCAAGGATAGTCSequence 2130

TAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACGCGGGGAACTGAAAATCCAC
AAGACAGAATAGCCAGATCTCAGAGGAGCCTGGCTAAGCAAAACCCTGCAGAACGGCTGC
CTAATTTACAGCANCCATGAGGAAAGGCCACTTAAGGATGCAGCAAGAAGGAGCCATCTG
CAATCCAGGAAGAAATTCCTTGCCAGGAACCAAATTGGTTGTCACCTTCATCTAGGACTT
CTAGCCTCGAGAACTTACAAATGGTGATGATCATCAGGTCAAGGATAGTCTGGAGCAATT
GAGATGTCACTTTACATGGGGAGTTATCCATTGATGACGATGAAATGCC
Sequence 2131

GAGGTGGTTACATTCGTCGAAGGACACCAGCTGCGGAATTTGCGGNTTTGGCAGATTGAA ATCATGGCNGGTCCAGAAAGTGATGCGCAATACCAGTTCACTGGTATTAAAAAAATATTTC AACTCTTATACTCTCACAGGTAGAATGAACTGTGTACAGAATCCATTCTCATTCTTTACT TGCTACATTATGACCATGAGGAGGGCANAGTAGAGGTGAACTCTCTGTATACTTGCTGAA AGTCTTCTTGTACCT

Sequence 2133

Sequence 2134

TABLE 1 356/467

ACCTGAATCTTTGGAGTACAGGACAATNAAGACTACTCCTATNTGCGGAACAACTAGCTT
TCTATTTAGTTCTAGAATGTTGAAACTGACCGATTGGCTGACATAAAAGTCACATTTTAC
AAAAAAGTGTCTCCAAATGCTTTGACTAGGGGAAAAACCCCTTTTCAATTAGAGGGAGCC
ATTNTGCAACAAATTTCCCACAAATAATTCGCTTATTCCAAGGGGCAANGGCACCATTTG
ATATNGGGAAATTTTTTTTGTTTTTTNGNGCCAAAAATTTAAGGGNA
Sequence 2135

CGAATTGGAGCTCCCGCGGTGGCGGCCGAGGTACCCCAAGACTCAGCACTAGTCTGATG
ACCTGCTAATTCACTGACAGCATAGGGCTGTCTGTTGTTTTTTGCGCAAGTTGGTGTAAC
AAAGTTCACAATATCTGGTCGAATAGGAGCCTTGAATACAGCAGGCAAAGTGACATTTTT
GCCAGATGACTCCCCCTTTTCGGAGTACCTTGTTCAAAAAACACCGCTGAGTCACTTCCA
GGTGCTGTTAAGTTTTCTTTAGTGAAGATGTCTATACCAGAGGGAGCATAGTTCCAGATG
ATTTCCTCAGCGGCAATGTAGTAGTGTCTAACATGCTTCCCACGGATATTATCCTTTTGA
TGAAGACTTTGTTACACTCCTGGACCTGGAAAAAGGCTTGCAAACCGGC
Sequence 2136

TNGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTACCTGAATGTAGAAA CAATGAGGATGGACCTGGTTTAATAATGGAAGAACAGCACAAGTGTTCTTCGAAGAGCCT TGAACATAAAACACAGACACCTCCTGTGGAGGAGAATGTAACTCAAAAAAATTAGTGCCTG GNAAATTTGGGCTGATGAGCTTTCTGGATCCTAAGCCACCTACCGAATTNTTGGANGGTT GGCTGNNGGTGTGGGGAAACACAAGTCTTTTCCAATTTTTACAAAACGAACCAATTGACC CCAGGGACTTNTTTGGTTTATTGGGTGGGG

Sequence 2137

CCGCGGTGGCGGCCGNNGTNCNCGGNGCCNGAAGAGGAAGATTTCTGAAGAGTGCNGCTG TCTGAACCGAGCCCTGCCNAACAGCTGANGAATTGNACTGCAACCATGACTGAGAACANT AAGAANTCCTTGGAGAGCACCCTACGGCAACTAAAATGCCATTTCACCTTGNAACTTGAT GGAGGGGAGAAAACT

Sequence 2138

CTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGNCNGGCCAGGTACCANATGAANNG NNAAGACAAGGCCATNCNCCACTTTATAGAGGGNGTNAAANTAAACCANAGNTCCNGGGA GAAAGAAANG

Sequence 2139 ·

Sequence 2140

Sequence 2141

WO 01/070979 PCT/US01/09126

TABLE 1 357/467

CTGTATCTAGGGGCAGGACCAAGGGG

Sequence 2142

AGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGNGGNGCNNNGCTCTACAGAATAGAGGCN ATNCTTTAGCTTAAGCCTGTCTGCTGACCAGAGAATGGAATTNTGCGTGGNCTCANGGAA CAAAAGGAAACTAGGCAGGGAAGGAAGAAAAGTGC

Sequence 2144

Sequence 2146

Sequence 2147

TCCCCGCGGGGCCGAGGTACATNTGCCTGNCTNCCTNCTGTCCTTCTTTTTATTAT AAGGATACATTTATAGNACCCCATAGAAGGAAAAGATAAATTTCATAGGCTGNTAAAAGA GGCTAGGCCTAAGTTATAATGCCTCCTCCTCACAGNCCAATTTNCCCAAGGGGCNTTANC

WO 01/070979 PCT/US01/09126

TABLE 1 358/467

ACCAGAGCAGNTTTTCTAGCTTGNGGACAATNCCNNCAGGCTTGAGTGATAATGNCCCNG TNGCGGTAGCTCTCCACTTGNTNAAGGACCAAANACACCTTAGCAG Sequence 2148

Sequence 2150

Sequence 2151

CCGGGCAGGTACGCGGGGNANTGCNANANACNCAAANCNNGNTANTACANTGCATCAAAC ATGTTCAAGATTNNCCAATTGACGGGATTGGATTNAAAGATATNCCACCACTTTTAGCAA GATGGNGAAGTGCTAAATNACACAATTAATCAACTGGCTGAGTTAGCTAAAGATGCATAT GTTATTATAGGTCCANACGCAAGANGTTTCTTNCTTGGGACACCTACTGCANCTNTTTTA AAAAAACCTTTTATTATGGTAAGAAAACCTAAA

Sequence 2152

Sequence 2153

TABLE 1 359/467

ATGCAACAAGCAGATGAAGACTCTGAGAGGGGTTTGGAGTCTGGAAGCCTCATCCCTTCA GCATCAAGCTGGAATGGGG

Sequence 2154

GNCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGCCAGGTACTGTGCACGTNGGTTAN AGGCTGCGTGGCAGGANNGNGNTCAGATTNTCCCCTGCACNGNAATTGGGCTTTNAGGGG GAAATGGTGGGGCCATCT

Sequence 2155

Sequence 2156

GAGCTCCCCGCCGTGGCGGCCCCGGGCAAGGTACANGTGTGTGTGGGTGAAATGGAGA TTTGGAATTGAACTCTCTGCCTGTAAATGTTCCCCAAATAATTGTTGTGTGTATGATACC AATAAAGGTTCCTTGGCCCGCTNTANAACTAGTTGGATCCCCCGGG

CGGCCGCCGGGCANGGTACGCGGGGACACAAGACATCATCTTGAAGGAAGGATGGCTTT GGCCAGACCAAGACCGAGACTTGGAGACCTGATTGAGATTTCTCGCTTTGGCTATGCACA CTGGGCCATCTACGTGGGAGATGGCTATGTGGTCCATCTGGCTCCGGCAAGTCACTGGTG CAGTCACGACAGTAGGTGTGGCAGCAGGCCTGCTGGCTGCCGCAAGCCTTGTGGGGATCC TGCTGGCCAGAAGCAAGCGGAAAGGCAATAAATCCAAGAAATTGTCCCAACAACCACCA

ACTGNTTTNTGGTTCATGGAATCTTTATTTTTAATTGGAGTTAAAAANCNCAGGNAAAT GTNTTTTGGAAATTGCACCTTNTTATNGAATTNTTTTTAAAGACACAANTTNGGGCTNTT CCNAAAAAAAAAAA

Sequence 2157

GCACCAAAATGATACGGCTCCGATGACTGGAGGAACACCAGGGTCCTTGGTCTCGCACCA GTTTAGATAAAATGACACAGACACATGTAATGGTTTTAAGGAGTGGAGAGTTTATTAG GAACAAACAGAAACTTCCCCGCGTACCT

Sequence 2158

CCGGGCAGGTACAGCGTCATATAGGCTTTGCCTTTAATGATCTCTTACGGTTAGAAAACA CAATAAAAACAAACTGTTCGGCTACTGGACAGGTTGTATATTACCAGATCATCACTAGCC TTTCTTTGTGGTTTTAATAAGAGTTCAAGGAATTGNTCAGAGTCTTGTAAAATGTTATTT TAATAATCCCTTTTAAATTTTTTATCNTGTTGCTGTTTACCCTCTNTGAAATATGNATTT TATTTTAGATTTGCCTAATGNCCANTTCATTTCAAGGNAAAATTGCCCAAAGAGGGGGTAT TTCCCCTTNGGGGGAAAANNGGGGGNCCNTCTTTACCAAGTGGTAAAANTTTTTTTCCC TCCCTTTTAACCCTTTTTGCTTTAATCATTCCAANTGNGGCANGNAAATTTTTTCCTTT AATNCCCCTTTGGTTGAAGNGGCAANGTTTTGTTTGGAACCTTGGAAGTTT Sequence 2159

TAGGGCGAATTGGAGCTCCCGCGGTGGCGGCGCCCGGGCAGGTACCCATCCTACCCGG CCTGGGCTGACCCATGGGGAAGGCTGGCTAATTTCAGTGCTTCTGCTTGGTTGTTCAGGG CCATTTCAGGTTTTGGGTGTTTTCTGGGGATGTTAACATGGGATTCAGGCTCAACTCACAA GAAACTTTTCCATCTCATGATGGATGCTGTTGGGCATGTCCAATGTATGACTTCATGAGT TACACAGATGCTAATTCGTAGGGGCACTTGGAATCACATGGTTGTTTTGTGTCCCATGGT CAAGCATTCTATCTATCAGGGCCTACAGTAACATGCCAAAAGTTGCTTCCAACATATTT CTCTGCTTTGGATG

Sequence 2160

AGCTCCCGGGGTGGCGGCCGCCGGGCAGGTACATCCCCAGTCGTGGCCCTCTGGACAA GTGGCGGCCCTCTCATGAGGGCTTCCAATGTGCTGCCCCCCTCTTAATACTCATTG TCAATTTGAGAAAAAGGACATATGAGTTTTTTGCATTTATTAATGAAACTTCCTTTGAAAA ACTGCTTTGAATTATGATCTCTGATTCATTGTCCATTTTACTACCAAATATTAACTAAGG

WO 01/070979 PCT/US01/09126

TABLE 1 360/467

Sequence 2161

ATTGGAGCTCCCGCGGTGGCGGCCGCCCGGGCAGGTACCCACGTAAAGACGTTAGGTCA AGGTGTAGCCCATGAGGTGGCAAGAAATGGGCTACATTTTCTACCCCAGAAAACTACGAT AGCCCTTATGAAACTTAAGGGTCGTTGAAAANAAANGANTCANAANTNTANAAAAAAATN ANGNNCCTN

Sequence 2162

NCCGGNCAGGTACGCGGGGCACAGCGGCTTNCTTGATCCTTGCCACCCGCGACTGAACAC CGACAGCAGCATGNCTCACCATGAAGTTGCTGATGGTCCTAATGCTNGNGGTCCCTTTNC CAACNACTGTTTACGCANGGCTTCTGNCATGCTCCCTTTATTTGGAGAATTGNGANTTTT TCAAGNACAATTNCAACTTACAACAGTTGTTCTAATNACCTGAAATATCCAACAGANACN NTTTTTNAANGAAGTTTTCANTAANACCNNACAANTGGCCNACTTTACNAAAATTGGCCA TTATTATTGAAATNTGTAANNGNANATTGTTT

Sequence 2163

GACTACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACGGGACAACACAAA
TTACTGCAACTCCAACAACTATGGCAATAACAATCACAGCAATGACCCAAACATCCCAAAC
TGTCAAGTATTCCTTCCTCAGGTTTAGGATATCCTGGATAATTTGAGACTGGAGGCTTGT
AAGTAGGCCTAGGACCTGGAGCACTGGACGTTTTGTAGTAGGAAGAAGTCGACA
CTTTAAGACACTTTGGAACTGGGGGATCCCAAGTACTTGTGGAAGGTGGACACCATCACA
TCCAGGGCCTTCTCCAGAGGGCACGCCATGACAGCAGTCAGGATCAAACCAAGAAGAAG
AAGCGTTAGGAGAGAGGGGTTGTAGAGAGGGGGAAAGAATTCCCGCGTACCTTGCCCCG
GGCGGCCCGCTCTAGAACTAGGTGGGATTCCCCCNGGCTTGCCGGGAATTCCNATTTTCA
AAGCTTTNTCGGATNACCCGGCGACCCTTNCAAGGGGGGG

Sequence 2164

Sequence 2165

Sequence 2166

CCGGGCAGGTACGCGGAGCGAAGTTCCGGTCCAGGTCTCTGACTTCGGGCTTGTTCGCT GGTGGCNGTCGGAGCCGAGCCGGACTGGTCAGGATGANCACGGACGTGCAGNTCGCCATC TTCGACAACATG

Sequence 2167

TABLE 1 361/467

ATTATGAGNAAGAACTTTTTCAATTGGGGTTANNTTCTAGGGATANACTCAAGTATNTTT GCANCCACCTTAANAAAACTTGCCATTAGAAAAAACCTGNAAAAGGTTTATTGTTTCCCA GNATAACTTTTCCGTTGTTTTACCCAAATTTTTTTTTTAAGAACTTTG

Sequence 2168

AGGTACTCCAGGGCTTCATTCATATTTCCTTCCAATTTGTAGACGAACCCAAGGAGGCTC AAGCTTTCCAGATCTAATGCCTTTCTCCGAAGTTTCCTTAAAACCAATTTCTTCAAAGAA TTTGATACTTTTATCCCTTTGTTAATGATAGCCCTGTTCTATTTTTATAGCTTTTTAAAT AATGGATAATTTGCATTGACTGTCAGATTTCTTTTGAAATTCCTGNAAACNCGACNCATN AGTTGGAAAATTGNTATGTCTCTGCATTGTTTTCTTCTACCACNTGGNTTTCATCGCNAT TAAACAATTTTTTTGAAAAAATTTCTCTTTCAAGCCTTTNTCTGTGGATTGGCCTGCCT TCTAATATTACCAATTTCCTTGGCCANGGGTTCTTAGGATGTAGCCCACCCTCAAAAATG TGGGGCCTTTTTTTTCCCACCTGGCAAGAATTCAAANAATCGGAAAAATAATGGGGCC NTG

Sequence 2169

CGAGGTACATTITNAAAGAGTTGTTTTTTGGCCGGNNTTCAGTGGCTCANGCCTGAAATN CCAGCACTTTGGGAGGCCGAGGTGGGCGGANCACGAGGGCTGGAGATNGAGACCATCCTG GCTAACAAAAGAAGAAANCCCGTCTCTACNAAAAATACAANAAAATTAGCCAGGCGNGGG NGGCTGNGCACNCTAGTAGGCCCCAGGCCTACTTTNGGCAGGCCTGAGTGCAGGNAGTAA TGGNCCGCGCANCCCTGNCAAGNGAAANTAAGGNTNTGCNGGTCGGAGNCCCAAAGNANT GCGGNCCCCTTGCCACNCCCAAGGCNCTNGGGCCAAACCAGAAGGCNAAAGGANCTCCCT ATTCCTCNAANAACNCAAGATATACCNCAANNGCGAGGGAGGTTTNNGGTTNCTTACCTC ANTTGGGCNNCAAATTNATAAGGGNTCAATANNANCNAGGNNTAACCAATAAANNACCCN CACAGGGGNNTCCTTTAACCAAACCCNTAAAANNCACCTGGGGTCAAGTCCNAAATAAAA

Sequence 2170

TCTGAACAACNATATCTGGGATACACAGAAAAGTNTGGAAGANGAGAAAGAAANGCCTAA ATNGGAATGAGATCCAAGACTAAACGCNAGAGCTAGATTGAGCCGCATTTGAAANCTCCT TCCCNTTGGGGCNTTGGCAGAGGGGGAAAAGGCTTCAAAGGAACTNGGTGGCATNANC ACCCCCTCCCCAATGAGGACACCT

Sequence 2171

GGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGGCCCGGGCAGGTACTCACTGAGCTCAAGA CACACTTGGTGCTGCAGTGCTGATACCTGCTCTTTGCCGGCCCCCGCGTACCATCCCAT GTGGAATCTGTGAGTGTCCTCTTAAGTAGCGTGGGCTAGCCAATCTGCTCGTTNATGGGT GTATTTGTAAACTCCGAATTCCATATGTAATANGGATGCAAGTCTAAGCGTTTCATGTGG ACATAAATGTATCTAAATAAAACTTTCCCTAGCACTGTGGCTGACCTCACCCTTACTTTT ATACTTTAGTATGAAACTGATGAGAACTTTGGTAGNGAGTATTTTTTTTATATATATACA TATATATGTATCTATATATATATCTCAAGCATCTTTCAGGTCTTTGTGTNGTGGNT TTTNTTAAAGCCCCTGTTGTAAAAAAAAATTACTATTGTGGGATGGCAGTCTCTCACATC AAAGGTNNCATTCCTNTACTGGNGGNCCAAAAAATCAATNGGTTTTGTNTGNCCAAAAAA AAATATTAAAAATTAAAAATATANTTNTNTTGAACTTAAAAAAAAA

Sequence 2172

AGGGTACATTTTTAAAGAGTTGTTTTTTGGCCGGGCGCAGTGGCTCATGCNTGTAATCCC AGNACTTTGGGNGGCCGNGGNGGGCGGATCACGAGGTCTGGAGTTTGAGACCATCCTGGC TAACACAGTGAAATCCCGTCTNTACTAAAAATACAAAAAAATTTAGCCAGGCGTGGTGGG CTGNNAACCAGTAGTNNCAGNTACTTGGGAGGCTGAGGNANNGANAATGGGCCNTGAACC TGGAAGGAAGAGGTTGCANTGAGCCAAAAANTGCGCCCCTTGCAACTNCAGCCTTGGGCA GGCGGCCCGCTCTANAAACTAGNGGATCCCCCCGGGGCTGNAGGGAAANTCTATANCAAA GCTTANNGAATTCCGCCNACCTNGGAGGGGG

TABLE 1 362/467

Sequence 2173

Sequence 2174

CCGCGGTGGCGGCCGAGGTACGCGGGGACTCGCGTCGGTTGGCGACTCCCGGACGTAGGT
AGTTTGTTGGGCCGGGTTCTGAGGCCTTGCTTCTCTTTACTTTTCCACTCTAGGCCACGA
TGCCGCAGTACGCGGGGGGGGTGAAGAAGGGGCCGGCCTTCAAGCAACAGCGACGCAAGAT
GGCAGCCACCACGGGCTCGGGAGTAAAAGTCCCTCGCAATTTCCGACTGTTGGAAGAACT
CGAAGAAGGCCAGAAAGGAGTAGGAGATGGCACAGTTAGCTGGGGTCTAGAAGATGACGA
AGACATGACACTTACAAGATGGACAGGGATGATAATTGGGCCTCCAAGAACAATTTATGA
AAACCGAATATACAGCCTTAAAATAGAATGTGGGACCTAAATACCCAGAAGCACCCCCCT
TTGTAAGATTTGTAACAAAAAATTAATATGAATGGAGTAAATAG
Sequence 2175

CCGCGGTGGCGGCCGAGGTACTTCTTACAGTCTTCAGGAAATTCATTAAATCAGTGCCTC CAGTTCCTTTGGCTTCCAGTTTTGAAGGGTCTTCAGAGGTCTTATTCTCCTTTTGGCTGCT GGCTTGCAGGAATCAGGATGTACTGTTCCTGTTGGCCGAGTGGAGACTGGTGTTCTCAAA CCCGGTATGGTGGTCACCTTTGCTCCAGTCAACGTTACAACGGAAGTAAAATCTGTCGAA ATGCACCATGAAGCTTTGAGTGAAGCTCTTCCTGGGGACAATGTGGGCTTCAATGTC Sequence 2177

Sequence 2178

CCGGGCAGGTACAAATGATGAAACGGAAAGACAAAGGAAATTTTCCATTTTTGAAGAAAA AGTGTTCAGTGTTAATGGAGCCNGGGGAAACCACATGGACTTTGGTCAGCTCTATCAGTT CTTAAACACCAAAGGATGTGGGGATGTTTTCCAGATGTTCTTTGGTGTANAAGGACAATG

TABLE 1 363/467

ACATCAAGAGTNGTTGAANGTATCTTGCCACTGNTGGCCTTTTGATTTTTTNTCCCACTT TTTCTTGAAAGATTAAGTAATTTTATTTTAGTTCCATTCTAGAATGTTGGGGAGTGNGGC ACAAGAAAAAATANTATANCTGAAATGCATCTGTTAAAAAATGTNATGATTGNAAGCATAA CTGAGTTTCA

Sequence 2180

Sequence 2181

TTTTTTTTTTTTTTNGTTACATAAATTAACCCATTTATTATAGGCCAGTGATGTCTCAAA GAGTAGAGGAGCGTCTACTGGTCTTTCAACTCCTTCAGTCTTCTGATGGCGGACTTTACC GNGACAGCGGAAGTGGTATTGNACCTGATTTTATTTCCAGTTTTCATCCGAATCCACTGG GGAATGGGACGATTTTGCTTTTGTTTCTTGGCCAGGAATCGCTTAATCCT

Sequence 2182

AGGTACTCATCGGCCAGCACGGAGATGCACAGGTTAAATGGTTTACCATCCTGAAAGGGC ATATTGNGGCATGTCACCTCATACTGCCAAGCCCCATTCACGCGGCTGTTCATGACCACC CAATGACCAAAGTACCTGCCCG

Sequence 2183

TAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACGCGGGGGGGCCCGAAGCGTT
TACTTTGAAAAAATTAAGAGTGTTCAAAGNAGGCCCGAGCCGCCTGGATACCGCAGGTAG
GAATAATGGAATAAGGACCGCGGTTCTATTTTGNTGGTTTTCGGAACTGAGGCCATGATT
AAGAGGGA

Sequence 2184

Sequence 2185

CCGCGGNGGCGCCCCGGGCCGGTACGCGGGGAACTGAAAATCCACAAGACAGANTAN CCAGATCTCAGAGGAGCCTGGCTAAGCAAAACCCTGCAGAACGGCTGCCTAATTTACAGC AACCATGAGGAAAGGCCACTTAAGGATGCAGCAAGAAGGAGCCATCTGCAATCCAGGAAG AAATTCCTTGCCAGGAACCAAATTGGTTGTCACCTTCATCTAGGACTTCTAGCCTCGAGA ACTTACAAATGGTGATGATCATNAGGTCAAGGATAGTCTGGAGCAATTGAGATGTCACTT TAC

Sequence 2186

WO 01/070979

TABLE 1 364/467

PCT/US01/09126

Sequence 2187

Sequence 2188

Sequence 2189

Sequence 2190

Sequence 2191

Sequence 2192

TAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCCCCGGGCAGGTACGCGGGGGCCGAGA GAAGCAGTAGTCAATAAAGAGAGTGCCGTATTTCGCAGATTGGAGCTGAGCTGTGGCTGC CAGAAGATAGCGAACGAATGGAAACTGAAAGTGGAAATCAGGAAAAGGTAATGGAAGAAG WO 01/070979 PCT/US01/09126

TABLE 1 365/467

AAAGCACTGAAAAGAAAAAAAGAAGTTGAAAAAAAAGAAACGGTCACGAGTAAACAGGTGCT TGCAGATATTGCTAAGCAAGTGGACTTCTGGTTTGGGGATGCAAATCTTCACAAGGATAG ATTTCTTCGAGAACAGATAGAAAAATCTAGAGATGGATATGTTGATATATCACTACTTGT GTCTTTTAACAAAATGAAAAAATTGACTACTGATGGGAAGTTAATTGCCAGAGCATTGAG AAGTTCAGCTGTTGTAGAGCTTGATTTGGAAGGCACCAGAATCCGGAGGAAAAAACCTCT GGGGGAAAGACCAAAGGA

Sequence 2193

CTATAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACTGTCCATGGGTCCACAA
AATCCTCTTCAGCTTCTGTGGCATCTGGGCCATGATTACTGGTAGGTGCTGGGTTCCCTG
GAGGACAGTCAGCCTTGTAATCCTCCCCGCGGCAGCTTTGTAGCTCATTTTTATGACAC
CAACATCTTTACTGCAGAATCAATTTCATCCCAGGTTGTGGAAGACACTGCAGAGGTGGC
CACTGGTCACGCTGGGCAGTTGAGCTGCTGAGAGTCCCCCGCGTACTATCTTCACTCTTT
TTTTTTCAGAAGCCAATGTTCTCTAAATCTGCAGCTTCATTCCACAGCTTTACAGAATCA
TAATCTCTTGAATATATTTCCAATGTTATTAAAAAAATAAAAAATCATACAAGATATATTT
AGCACATTAAAACTTAAGAGGTTACAGTATAACTGTCCAGACCTCCAGGTACCTGCCCGG
GC

Sequence 2194

Sequence 2196

TABLE 1 366/467

CCATGGANGGAAAAAAGCCCCCCAAATGGGTGGGAACTGGATAATAAGCACTNATGCTTT AAGAATTGGGCACACTTCTCACCTAAGGTGAGCGCATTGNGNCCAGGGGGTGCTTAAATG CTTACATACCTCCAACTGGAAATGGNTAAGGGAAGAAGATTGATNCCAATTTNAAAAAAA AATTTAAAANCCCANTTTNAAAAAAAAA

Sequence 2197

CGCCCGGCAGGTACGCGGGGGTGAGAGAGAGCCTCTAGACTTCAGTTTCAGTTTCCTGGC
TCTGGGCAGCAGCAAGAATTCCTCTGCCCCCCCATCCTACCATTCACTGTCTTGCCGGCAG
CCAGCTGAGAGCAATGGGAAATGGGAGTCCCAGCTGTCCTCGGTGCCTGCTCAGAAGCTG
GGTTGGTTTATCCAGGAATACCTGAAGCCCTACGAAGAATGTCAGACACTGATCGACGAG
ATGGTGAACACCATCTGTGACGTCCTGCAGGAACCCGAACAGTTCCCCCTGGTGCAGGGA
GTGGCCATAGGTGGCTCCTATGGACGGAAAACAGTCTTAAGAGGCAACTCCGATGGTACC
T

Sequence 2198

Sequence 2199

CCGCGGTGGCGCCCGAGGTACAAGATNGNCATCTCAGTAAAAGGTCTATTATCTAACTN GCCAAACTTGTTNACTGAGAGCCCTANGGAACTAAAACTGCCATAATGCCGTGCACAGCT TGAAAAGCAATTAGAGTAAGCANGATTAGTTTTTCCTCCCTTNCAGNCTNAGNAGGCCTG GCTGAAGGCCCANGANGGAAGGAANTNTANNANCCANCANTAAAAATAGCNATATGCAAT NNNAAGAATGCCATCCCATGGAGCACACCA

Sequence 2200

Sequence 2201

Sequence 2202

AGGTACAGACAGGGTTTCTTCATGTTGGTCAGGCTGGACTCGAACTCCTGGTCTCAACTGCCTCAGCCTCCCAAAGTGCTGGATTATAGGCATGAGATACCGTGCCTGGCCTCCATCACT

TABLE 1 367/467

Sequence 2203

CTATAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACTGGTTGNCAGGATTCAA GCCGAATGGCTTGCCTNANAGGGNCAATGGCGTTCTGAGATGGTGGCCA Sequence 2205

ACACTACTATAGGGTGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACTCTTGGTTTAT
CAATGGGACGTTCCAGCAATCCACACAGAGCTCTTTATCCCCAACATCACTGTGAATAA
TAGCGGATCCTATATGTGCCAAGCCCATAACTCAGCCACTGGCCTCAATAGGACCACAGT
CACGATGATCACAGTCTCTGGAAGTGCTCCTGTCCTCTCAGCTGTGGCCACCGTCGGCAT
CACGATTGGAGTGCTGGCCAGGGTGGCTCTGATATAGCAGCCCTGGTGTATTTTCGATAT
TTCAGGAAGACTGGCAGATTGGACCAGACCCTGAATTCTTCTAGCTCCTNCAATCCCATT
TTATCCCATGGAACNCTTAAAACAANGGGTTGGTTTTTGGTTCCTGAAGCCCTTTTTTGCT
GGGGAATGGGGCACCTTAATGGAAAATTTAAAGGGGAAAANCCCTCAGGCCTGNNGGGGG
NGGGGCCCCTTCACAGCCTTTTNCTTAACTNAGAAANCGGGGAAAAATTGNAAACCATTGG
GGGAGAAAATGGACNACTTCNCACTNTTGGACNGGTTTTTTTCCAAAANTGTNAAAACAA
GAATTCTTTATTAATGGAAANGGGGTTTTACCCCCCTTTTAAATT
Sequence 2206

TABLE 1 368/467

TACAGAGCAACTGCGTGACATTCAGCTGGAGAATTACACACCCAAGGAACCCCTCACCCT GCAGGCCAGGATGCCTTGTGAGCAGAAAGCTGAAGGACACAGCAGTGGATCTTGGCAGTT CAGTTTCGGTGGGCAGATCTTCCTCCTCTTTGACTCAGAGAAGAGAATGTGGACAACGGT TCATCCTGGAGCCAGAAAGATGAAAGAAAAGTGGGAGAATGACAAGGTTGTGGCCATGTC CTTCATT

Sequence 2209

AANCCCCGNGGGGGCGGCCGNGGNNCCCCCGACGGNNNCAACCCCGNNGTANAAAACCCCCGAGAACAGAAGAGAGAGAGGGGCGGGNCAAGNNCGAAANCGNGGGGGAAAAGCAGAAGACCCGACNGNCCACGAAGNGGCGCGAAAAAACAAAANCGAGAACCAGAAGGCCCGGGAGGGGAACACCANCCAGGGGNCCACAAAAAAACAGAGAAGCCCNNGCGAGGGCNGGCCGCCNGCAACGCCCCCGGAACCANCGAGAGCNCAAAAGANCCNGGGAAAANACAAAGGCCAGNCCNGGGGAGAANNGCAGNCCGCANCACNGAACCCCAGCAGANAGGGNGNNNGGACAACCGGCCCCGGAAAAANA

Sequence 2212

Sequence 2211

Sequence 2213

TABLE 1 369/467

GAAACGTCACAGGCTGTCTTCCTTTGGATGTAATGGGACGTCCTGATGACCCA
Sequence 2214

Sequence 2215

Sequence 2216

Sequence 2217

Sequence 2219

Sequence 2220

CGACTNCTATAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTACTTTT

TABLE 1 370/467

Sequence 2221

Sequence 2222

TAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCGGAAGTCTCTACTGAGGAAAGC
TATGAGGATACTCTGTTCGTAAGCTCCCGGTGAATTTTGTTCCACAGACTCGGAAGAAAG
GTTGGATAAGAGTTCACTGGAGATTGACAAGTACCTGGAGGAGCCCCTCACCCAAGTGCG
CATCTTAACGGCATTGGTGGAAGCTGGGGTCAGAAAAGAGAAATGACCATTTGGAGGGGC
GGGGCCTCCTAGAAGAACCTTCTTAGACAATGGGGGGAGGATGGGACTTTGTTTTTTCCA
AGAATAAACTTCAACTCCTGT

Sequence 2223

TABLE 1 371/467

AAACAAACCAAAATTTAAATGATCAGAATTGGCAAGCACAAAGAAAACGCCCTNTCCTGA CTTNTATTGTGGGCAGTTCTGAACGCCCCCAGAAAATTTGTGCCAAAGAGTTTTAGAAAA NTAAATATTCCAATAAAAGTAAACACTATACNCCACCAAAACAGGC Sequence 2226

CCGGGCAGGTACGCGGGGCCCTTCTAGAGGCAGAGGGAAGAGAAAGGGTCTGTTGT
TTTTCTCTCCTGTTTCTCGCTCCCTCTCTGCTGATCACAAAGCTGCTGACCGGGTCAGAA
AGTCCTGATGGAAATCCACCAGCGCTGGGCAGGCCCCTCCTCCTCCAGGGAGCTTGTCCT
TGCCTAATTTTCTTCGTCCTGATGAGAACAAAAAAGAGAGAAGAAAAAAACC
ACAAACTTCCTTTGAAAACCAGCTTGTAGTCAGGGCCCGGAGCGCATGCCATAGACTCGG
CGACTCAGGAATCCTGAAGACTCTCTGAGCGACCTTGGAGCACCTTGGGCTGTTCCCTGC
CTGCCTTCACCCTCCTCCAGTGCCCCCAGTACTAAGGAATCTTTCTGTTTTGGGGTT
Sequence 2228

Sequence 2229

TATAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGGCCAGGTACTANAAGATATT GATCCTAGTCAATTAGGCATTGTAGACTGTNATGACCACTTAATAAAAAATTNTGGACCT GANGCTCACGAGCATCCAG

Sequence 2230

NTAGGGCGAATTGGAGCTCNCCGCGGTGGCGGCCGNGGTACCTGCAGNNCTNNTACACCT ACCTCTCTNTGGGCTTNTATTTCGACCGNGATGATGTGGCTCTGGAAGGCGTGAGCCACT TTTTCCGCGAATTGNNCGAGGAGAAGCCGCAGAGGGCTACGAGCAGTNTCCTGAAGATGC AAAACCAGCAGTGGC

Sequence 2231

TTAGGGCGATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTACGTTTCAGAGTTTC
ATAAGACACAGTCTCAACAGGAGTTTTTTTAATAAATGCTCTATCTCTAGTTCCAGAAAC
TGAATTCCAAGAAGCTACACTGAGGATAATTCAGCTCTGATATTGTGATTACTGTGATGT
TCTTTCATTCATACAGTAAGTATCTGCCCAATACGTAACTACCGAGATCTATTGCTTCCT
ACATAATTAGACAAGCTCCTTACACATATGGGCCCATGCCCGGCACATAGCAGGCACTTA
ACAAGGGGTTGCTTAACTACNGGAAGGAATAATATAATTNGCCTTTCCNTTTTTAACTGN
TTTACCCTTTTTCTATACNTTGNTATATTTTGGAAAACNACATGCTTGCAAAAACTAAAAA
TCTAACATGCATTACTAACTTTATAAAAGATCCTTCAGTATTTTTCAAAAAAGGGAAAAAAA
TNATTAAAACCAATCCCCCAAAT

Sequence 2232

TABLE 1 372/467

CCTTGTGCTAGGGCTCCGAGGGCCCAAGGACCCCATGGAACCAGATTTAGTCGCTGACCT CTAGGAGCTCACAGGTGAGTGACTCCCCCCGCGTACCTCGGCCGCTCTAGAACTAGGTGG GATCCCCCGGGGCTGCAGGAATTCCGATATCAAGCTTATCGAATACCCGTCGACCTTCGA GGGGGGGCCCCGGTACCCAAGCTTTT

Sequence 2233

CCGGGCAGGTACCGNTGTGTCCGGGTGGGTGGTCAGAATGCCGNGCTCCAGGTGTTCACA GCTGCTTCGTGGAAGACCATGTGCTCCGATGACTGGAAGGGTCACTACGCAAATGTTGCC TGTGCCCAACTGNGTTTCCCAAGCTATGTGAGTTCANATAACCTCANAGTGAGCTCGCTG GAGGGGCAGTTCCGGGAGGAGTTTGTGTCCATCGATCACCTCTTGCCAGATGACAAGGTG ACT

Sequence 2234

Sequence 2235

TACTTAGGGCGATTGGAGCTCCCCGCGGTGGCGGCCGTCATCACACGTGACAGGATGTCA
ATGACAATCCTCCAGAGTTTACTGCCATGACGTTTTATGGTGAAGTTCCTGAGAACAGGG
TAGACATCATAGTAGCTAATCTAACTGCGACCGATAAGGATCAACCCCATACACCAGCCT
GGAACGCAGTGTACCT

Sequence 2236

TATAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTACAATATGAACCT GTGCTTTGCAGCAGGCCAACTTGTAAAGCTGTTCTCAACCCACTTTGTCAGGTTGATTAT CGAGCAAAACTTTGGGCCTGTAATTTTCTGTTTTCAAAGAAATCAGTTTCCTCCAGCTTA TGGAGGCATATCTGAGGTGAATCAACCTGCCGAATTGATGCCCCAGTTTTCTACAATTGA GTACGCGGNGACAGCGGNTTCCTTGATCCTTGCCACCCGCG Sequence 2237

GGCNAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCGGGTACNCNGGGCCCTGTGCTG
TCTGCACCGAGGAGAGCGGCCTGNCGGAAGNGGGCCACCATATCTGGAAACTACAGTCTA
TGNTTNGAAGCGCANAAGGGAATAAACANTTAANGACTCCCCCNGGGACCTGNAGGATGG
NCTTTTCCATGGGGGCCGGAGCNGCAGCTTACAATGNAAAATNACANACTGGNGCTNTTG
GAGAAAACTATANTTGGCATAATTCCCATTAACCACNATGACTTCAAAATTTTAA
Sequence 2238

TABLE 1 373/467

AATTCCTGCCCCGTGCTCATTTGGGGCTGACGCCATTTTAGACCTCAGCCCATCTGCACC CAGGCGCTCACTGAAACAGTGTGTTGCTCCACACCGCCTTGTTTTGCTTGNTGGCGCGCT CTCAGGGTTCCGACCAATCCAAGAGCCTTGCAGAAAGCATTAACGTGCTTTTNTCTTTGG CAAGAGTTTTTCTTTGCTCTGATCTTGGAGACCATCCCTCTGCCTAGGGGGAAAACATAN GGGAATACAGA

Sequence 2241

ATAGGCGAATTGGAGCTCCCCGCGGTGGCGCCCCGGGCAGGTACACCATGTTAAGA
GATAGCAATGCAACCGCAGCCAAGATGTCTTTAGATGTAATGATTGAACTCTACAGAAGG
AACATCTGGAATGATGCAAAAACTGTCAATGTTATCACAACTGCATGTTTCTCTAAGGTC
ACCAAGATATTAGTTGCCGCTTTGACATTCTTTCTTGGGAAAGATGAAGATGAAAAACAG
GACAGTGACTCCGAATCTGAGGATGATGGACCAACAGCAAGAGACCTGCTAGTACCCTCT
CTTCCAGCACCCAGGCCAGTATTGAGATCGATTCTCTCTATGAAGGAATCGACTTCTATA
CCTCCATTACCCGTGCCCGATTTGAAGAACTGAATGCTGACCTGTTTCCGTGGCACCCTG
GACCCAGTAGA

Sequence 2242

TACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGNCAGGTACCTTCACCTG CTTTGGAGAAATCCTGAATGTGTCCCCAGAAATGAGACGAGAAGTCTTCTCCTGATCAAA GGTCTTTTCTTGATTGAAGGGTTCGTGGTTTCACAGGCTTCAAGGAAAGAAGCCATGGAC CTCAGTGGTGAGTGTTACAGNTCCATTAGAGAAACATGCAGACCCCCCCGCGTACCTN Sequence 2244

Sequence 2245

Sequence 2246

Sequence 2247

TABLE 1 374/467

AATAATTCCAGGTAATTTAAAGCATNTTTTTNAATTGGTGTAAGCTGCTCCATGAAGTCA
NCTNGCTCCTCTAATTGGGATGGTTNTTNATNACACGGCATGTTNTAAGAGTTTGATGAC
AGGANCATNAGTGTNNGGNCCCAGNACCCCCTTCTGNGCGGACTTNTNGGCATCCTCCCT
TCAAANCTCAATNCTTTTNANGGGGCCCTGAGGAAAGTNNTTTATTAAAAGGGNTNTTTG
CAAATTTTTG

Sequence 2248

AGGTCACTTTTTTTTTTTTTTAAAATAATTCTTTTAATTATTGATGCTTTGAATAAN AAGTCCATTTTACTAAATTTAGTATAAATTATCGGACGCGTGGGTCGAAGCTTGACCTGC CCG

Sequence 2249

Sequence 2250

Sequence 2251

Sequence 2252

AGGTCTTCGACCCACGCGTCCGATTTTACTCTGTGTATTCGTGGTGGTGGGTTATAGTNT ACCAAGTTGTCCAAAATGGATAATTCATGTGAGATAGGCAAGANCAAGNGTTGTATCCCA ATACCATTTGGTGAAAAAGTTGAACTTCANAAAGGATAAGTANTTTGCCAAGATCACCTG NCAACCTGCATAGTCAAATTTGAGATGGAACTCAGCTACTCCAATATCTGTATTTGCAG Sequence 2253

AGGTACATGTGCCANNTTTGTTATATCTTTANCTATATNCNNNNCTACTTGCCCCTGATC

TABLE 1 375/467

Sequence 2256

Sequence 2258

GGCGAATTGGAGCTCNCCGCGGTGGCGGCCGAGGTGTACAAAGCTTCGACCCACGCGTCC GAGCAGAACTTGGCAGCAACAGAGGAAGGGCCCCTGGAGCCGGCTGTCGTGGATGCCTTT AATCAAGCCTGGCATTTGGTTGCTCACGAATGTCCCAACTACTTCCGCTAGGCCCATCAT GGCTCAGGCTGCCCAAGGCTTTTCTGTCACCTNTTTTGTTCTCTCACACTGACCAAGTCT TACCTGCCCG

Sequence 2259

CGAATTGGAGCTCNCCGCGGTGGCGGCCGCCCGGGCAGGTCTTCGACCCACGCGTCCGTA GTAATAGGAATTAACTGACCCCTTTNGGATGGGGGAGAGCATCAGGCTGGGGTCAGGTAA GTGTAAATGGCCTTCTGAGCATGCTCTTCTAGGCTGACTCC

Sequence 2260

CCCCGCGGTGGCCGCCCGGGCAGGTACAATTAGTTATCAATTCATGGGCTATGGCCA CTGGTTTGCTGGATGGTCAGGGACTTGGAAGGAACATGACTGGAAAATTGGTGACAAAAC GGTCTGTGGAAGAGGTATATACACAGATCTTTCTGAATGGGTGAAAAATGTGAGGATATT TGTGTCTCATATGAATGCCCCCAAAGAATGACTTCAGCAGAAGAGGGATTTTAATAACCAA GTAGATAGGATGACCTGTTCAGCCCCTTTCTCCAACCATGCAGGTAACTGCCCAATGAGC

TABLE 1 376/467

TCATGAATAAAGTGGCCATGGTGGCAGGGGTTGTTCGGACGCCGTGGTT

Sequence 2261

Sequence 2262

Sequence 2263

CGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTCTCCCAAAGTGCTGGAATCACAGGAAT GAGCCACCACACCCAGCCAAATTGGGCACAAATTTAAAATTTGACTTTTATTAATGATAT GGTAAAGAGATCTAGCTTGGTCATGACACCCTTGTGTTATACGGTGACAGGCAAATCATT TAAAAATATCTAAACTATAATTTNCTGTAGTTCACATGAATTGGATATTCTTGAAGCGGA CGCGTG

Sequence 2264

AATTGGAGCTCCCGCGGTGGCGGCCGAGGTACCGCGTCCGAGCTAACGAATGCTNGACT
AACTAGATNCCAAAGCTTGCTCTGTGAAAATTCCCGNATAACCNNTGAAGTGGGCGACAC
CNTAACCCTGCACACCTTACTCCTGGTNTCAGAGAGCCCAGTNTGAACATAAACTGNGTA
GAGGTGTTAGACTCANCCTACCTAGTAANGCCCAACCTCCGAGACCAACCTTAAACATC
AGTAGACTGCGAGCTGTATGTGGATAGGAGCAGTTTNGNCAACCCCTGCNAAGTGACTCT
GAAAAAGAC

Sequence 2266

CCGGGCAGGTCTTGAGTCGACCCACGCGTCCGCCTAGCAAAGCTGTTTCCACTGAATGCA TCTAAGCANNGATGGANCTATGCCAAAACCACCACAGGNGTTTCACTTNAATGATACCNC GAAACAAGG

Sequence 2267

Sequence 2268

TATAGGGCGAATTGGAGCTCCCGCGGTGGCGGCCGAGGTACAAAGGTATGTAATCCAGG AAGTGACCAGCCTGATGCGTGTTATGACTCACTGNAAGCCTCCCATGATTAAGGAC Sequence 2269

TABLE 1 377/467

TTTTATACTTTGGTTTAAACAGGGGAGAGGGGGGGGGTTTAGTTGAAACAATNTTACAGAAG TAAAGTAGGCAAAAAGTTAAAAGGATAAACGGTTACAGGAAAGTAAACAGTTCCAGGNGC AGAGGCTTTAAGTNTATCCTAAGGNGATGGACCCCGGGCTTTGGGC

Sequence 2271

CNCTACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTCTTGAGTC
GACCCACGCGTCCGGTGATATGTCACAATGCCGTGTAGCCAGAGCCTAGACAAAAGTTAC
AGCACCTGGGAGATCAGTGCAGAGATATGTCACAATGTCCCCAGTAGGCAGAGACCAGGC
AACAGTTGGATCACCTCGGGATCAGTGCAGAGACATGTCTCAATCCCCCTGTGGGCACAG
CCTAGACAAGAGTTAAATCACCTCGGTTAACAGTGCAGAGATATGTCAATATTCCCCTGT
AGGCCGAGCCTACACAAGTGTTACATCACTAAGGTGATCAACGCATAGATATGTCAAAAT
ATTGCCGTGAAAGCAGAGTCTAGACAAGAGTTACATCACCTGGGCGATCAGTGCAGAGGT
ATGTGACAAGGCCCCTTTAAGCAGAGCCTAGACAATAGTTACATCACCTGAGTGATCAGT
GCAGAGGTCTGTCACAATGCCCCTTTAGGCAAGAGCTTAAACACCTCGGC
Sequence 2272

Sequence 2273

Sequence 2274

Sequence 2275

Sequence 2276

CCGCGGTGGCGGCCGGGCAGGTCTCCTGCCTCAGCCTCCTGAGTAGCTGGGACTAG

TABLE 1 378/467

Sequence 2278

Sequence 2277

Sequence 2279

Sequence 2280

AGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTCTTCGACCCACGCGTCCGCTCAG
GGCACAAAGTGATCATTTGGGATCCTAAGTTAAAAAGGAAATGCAAGAGTAGGATACTCC
AATTCCAGAGTCTTTGCAGGAGGCTAATCCCACAAGAAGGGTAGCATCAGAGAAAGTGGC
ATTGGTCTTAGTGGTGGATCATCAGGTAGACAAGTGATAGTGTGTAACCCATCTGAAA
TTCATTTTACCGTCACCACTCTTACAAAGGACAGTTTATTCCCAAGGACAGTGCTGACGG
GGAGGGGGACAGGCAGGGAGTTAGGAGGGTTTTCGAGGATTTCAAACAGGTGGAACCCAT
CCATCCCTATTCCCAAGGGCCACTTACAACTCTAAGGGGTGGTTACAGGATTAACTACCA
GTTCATTTTCAAAATGCTGCTTTGAACTCAGAGGGTTGATACTTTTTAATTTGTAATTTTT
TGTAAAACTTTTTACAAAATAGT

Sequence 2281

Sequence 2282

TABLE 1 379/467

Sequence 2285

Sequence 2284

Sequence 2286

TAGGGCGAATTGGAGCTCNCCGCGGTGGCGGCCGAGGTACGACTCATATAGGGATCTAGA TCACGAGCGGNCGGCCGCCCGGGCAGGTCTCCCATCTTGCGCAAGTTGGTCACGTGGTCA CCCAATTCTTTGATGGCTTTCACCTGCTCATTCAGGTAATGTGTCTCAATGAAGTCACCG GACGCGTGGGTCGAAGACCT

Sequence 2287

GCGAATTGGAGCTCCCCGCGGTGGCGGCCGTTAAAGGAATAATCTGCAGAACATCTTGAT TTACAAGGGACAAAATGATGCAAATTATATGCTGTCCAACCTACTGGTGAACTGGATCAG AATGGTCCAAGGACTGTTAAACAGAGGAAGTATTTACATTTTGAAAAACTTGCGGACGCGT GGGTCGAAGCTTGTACACCT

Sequence 2288

Sequence 2289

AGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTACCATACTTGTCATTG CGTAGACTTCTTATCAAAATTTCACATTNATCTGTAGGAAAATGTAAAGTTGGTAAAAAT TGTTTACACAAATCACACATTTTCCATCCTTGACAATTGCAGNGTTTTTTTTTAAATATT GCTGTATTAAGACAATTTTAACTGAAGTAGGTTGTAGAGGCTANAAACCTGATTAATAGA GCAGTATTAGACAATTCTAACTGAAGTAGGTTGCAGAGGCTAGAAGAAACCTGATTAATA CGGACGCGTGACCT

Sequence 2290

TABLE 1 380/467

AGATTAATGATTTTTCAATCATTAGGGTACCTGCCCG

Sequence 2291

Sequence 2292

ACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCTACCTCCAAGCAGGATGATGGG CTAGACATGGAGCATACATAAACGGGCAAGATTCAGTCCCTGACCGCAAGGCACTTACAG TCTAGTTGGGAAGGGAGACACAAATGTACCT

Sequence 2293

Sequence 2294

Sequence 2295

Sequence 2296

CCGCGGTGGCGGCCCGGGCAGGTCAAGTCGACCCACGCGTCCGCTTGTTTTGCTCTA

TABLE 1 381/467

TCCCATAGGAGTTGGTATGTTGTGTTTCCAATATCATTTACTAAAAGAAATTTTCCTTTT
TATTTCTTCATTGACCAACTGGTCATTTGCATGTTCTTTAATTACTATGTGTTTGTATAG
TTTTCAAAATTTCTCTTATTAATTTCTAGGTTTTCCTGTGGTCAGAGAAGATGCTTGATA
CTACTTTAATTTTTTGAATGTTTTAATACTTGTTTTTGTGACCTAACATATGATCTACCCT
TGAGAATTATCTATATGCTGAGGAAAATAATGTGTATTACACAGCCATTGGATGAAATAT
TCTGTAACTATCTCTTAGGTACCT

Sequence 2298

Sequence 2300

Sequence 2301

Sequence 2302

Sequence 2304

ACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTCAAGCTTCGACCCACGCGTCCGAGAAGAGATTTGCAAATGCAACAAAATATTTAATTACCGGTTGTTAAAACTGGTTTAG

WO 01/070979

TABLE 1 382/467

CACAATTTATATTTTCCCTCTCTTGCCTTTCTTATTTGCAATAAAAGGTATTGAGCCATT

Sequence 2305

Sequence 2306

Sequence 2307

Sequence 2308

Sequence 2309

Sequence 2310

Sequence 2311

Sequence 2312

TABLE 1 383/467

AAAGATTGCTTCAGATCTTAAACTTCTAATGAGGAAAGCTGAGA

Sequence 2313

Sequence 2314

Sequence 2315

CACTACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTGTACAAGCTTCGACC CACGCGTCCGACTTTTTGTCTTAGACCCAGTTAGGGTCACCTTACAGTGCAGGTGGAAAG AAAGCAGGACTGCTGAGAGGAGCTCAGGA

Sequence 2316

TAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTGTACAAGCTTCGACCCACGCGT CCGGATTAAAGTCCTACGTGATCTGAGTTCAGACCGGAGTAATCCAGGNNGGTTTCTATC TACTTCAAATTCCTCCCTGTACCTGCCCG

Sequence 2317

Sequence 2318

Sequence 2319

Sequence 2320

Sequence 2321

TACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTNCATTTACATACAACTGA TCCAAACAGGAAGTAAAAGCNTTATGAAAAAAGAACATGATGCAAATCATTTCCCNNNGA

TABLE 1 384/467

CAAAAGGAGGATCTGCGTGAATTACAGCAAATCAAATGATTTCCACATTATAAAAGCAA GCCATGGCTTCTACAGATATTTTAATTCCTTGGGAGGAAGTTTCACCTNATCGGACGCGT GGGTCGAAGACCTGCCCGGGCGGC

Sequence 2322

Sequence 2323

TAGGGCGAATTGGAGCTCCCGCGGTGGCGGCCGAGGTCAAGCTTCGACCCACGCGTCCG CTGATCTGTGATTAAAGCAGTAATATTTTAAGATGGACTGGGAAAAACATNAACTCCTGA AGTTAGAAATAAGAATGGTTTGTAAAATCCACAGCTATATCCTGATGCTGGATGGTATTA ATCTTGTGTAGTCTTCAACTGGTTAGTGTGAAATAGTTCTGCCACCTCTGACGCACCACT GCCAATGCTGTACGTACCTGCCCG

Sequence 2324

CTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCCCCGGGCANGGTGGCCGCACTTTT
TTTTTTTTTTTTTACTATTCGTTAGGCTTTTATTTTTCTCTATGTTCTGCAGTAACT
AAGGAAAATCATGGTAAATGTCAATCTTCACACAACAGCAGACACAAAGGGTTTCAGAAA
CCGGACGCGTGGGTCGAAGCTTGTACACCT

Sequence 2326

Sequence 2327

TABLE 1 385/467

AAAAAGAAAATTTTTTTTTTTTTTTTAAGCCCNTTTTAACCNCCAAAAAAAANNAAGTGT TTTCCNNNCGNNNCTTTTNNAAAANNGNGGNACCCCCCNGGNGGGGGGGANNTTTTTTAA TTTTTTNNCCCCCCCCTNGGGGGGGGGCC

Sequence 2329

Sequence 2330

Sequence 2331

Sequence 2332

Sequence 2333

AGGTCAAGCTTCGACCCACGCGTCCGTGGTGAACACAGAGAAGACAGTCTTGTATATATT CCTCTGTATTCTGGGGAGCTTTGACCTTGGAGCTTTGTACCTGCCCG Sequence 2334

Sequence 2335

WO 01/070979 PCT/US01/09126

TABLE 1 386/467

TGCATTGGCCCCTAACAAGACAGTCAGCCTGGCCTTTGAAGCGTTGCAGCC Sequence 2337

CTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACTAAACTGCACATATTTAA
AACATATAATTTGATACATTTTGACTCACAAAACAATCACCACAATCAAGANGATGAGNN
TATAGATCACTCCCAAAAGTTTCCCTGTAGTCTTTTGCAGTCCTTTCTTCATGGCCTTCT
TCATCCATCCACCCCATCTCGGTAACCAATGATCTGCTTTCTGTCACCACAAAATTAGTGA
GCACTGTCTAGAATTTTATGTAAACTGAATAATAAAGATTTTACTCTTTCG
Sequence 2338

Sequence 2340

AGGTACTTCTTACATAGTGATTGATGTCTCATGTCTCCCTAAAATGTATAAAACCAAGCT
GTGGCCGGACCACCTTGGGCACATGTCATCAGGACTTCTTGAGGCTATGTCACTGGGCAT
GTCTTCAACCTTGGCAAAATAAACTTTCTAAATTAATTGAGACCTGTCTCAAATTTTGGG
GGTTCACAGGTGAGTGGGCTCAGGCATGTGCACTAGTATGACTAAAGGTCATAGACTATT
AGACTATTAGTCTATGACCTTCCTCTAGAAACACTCGACTGGTAAGGGAAGAATGCCTCA
ACTGAGCATGTGCACAACTCCCATAAACACACTTGTGCTTGCGGAGCCTNTCAAGTGCTG
GCAGGCCACTGCTCAGGTGGATTCTTCCCTCCTACCCGGAGGGAAGAATCAGGGGAGAAG
GGACACAAGCCCCTGAATGCAACACCGTAAA

Sequence 2342

Sequence 2343

ACTACTTAGGGCGATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACAGAGGACTCAAGACC AGATGGCCAACTAGAAGCCAGCAGGAAGAACATCTCTCATGGAGAGACCAGGAATTTGGG AAGACTGGCACACTCTGAGCAGATCTTTTGAAGGAAAACATTGAGGGTGGATGAAGGGAG GATGCAGAGCATGAGGGGCAGGAATCTCAGAAGCCTGCACAGGGCTTCCAAGCA CTAGCATTCCTTACTAGCCCCCATTAACTCCTGGGGAAGGGGTGAGTTGAATAGGTGGNG GAGTGGCCCGCTCTTACCATGAAACTCCAGAATCCTAGCAGCAAGAGACCCCATGACCCC TGTGGACACGAGCTGTCCGGACGCGTGGGTCGAAGACCTGCCCG

TABLE 1 387/467

AAAAATNTNNNGACTCTGGGGATAAAANTNCNAATTAAATNNATNCNANNTTTTAAAGGC TATTAANNANAANAATATTNGCTAAATTNNCCTTNTGCATAACAAACTGTGGNTNTACCA TGTAANGTTTAAAAAAAATGTNTAACCNCAATTTTACGCTCCTCTGTNACANGACAAGGAC TCCATTCANTGNCATTTAAGAACTNAATGGGTTGAN

Sequence 2345

Sequence 2347

Sequence 2348

ACTTAGGGCGATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTCTTCGACCCACGC
GTCCGGGCAATTATCAAAAACACTTGGAAAAAGATTTTTATTCCTACTTTTAAACATACA
TCAAAATCTAAAATAAAACTAGGCACCTTCAGCTGGGCCTGGTGGCTCATGCCTGTAATC
CCAGCACTTTGGGAGGCTGAAGTGGGCAGATCACTGGATGTCAGAAGTTCGAGACCAGCC
TGGCCTACATGGCGAAACCCCCTNTCTACTAAAAATACAAAAATTAGCCGGGCTTGGTGG
TGGGGACCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCACTTGAACCTGGG
AGGNGGAGGTTGCAGTTAGCTGAGATCACACCACTGCACTNCAGCCTGGGCCACAGAGCA
GGACTCCATCTTAGAACAAAAAAACAAACAAACAAACCACCTCATGCACCTTCAAGAAAA
TCAAACAAGTTTTTATCTAATTAAAGAAAGAAACAATTTT

Sequence 2349

Sequence 2350

CTACTTAGGGCGATTGGAGCTCCCCGCGGTGGCGGCCGCCGGGCAGGTAAATCATAGAGC
TGCCCCAACATCTAGACAGTCTCCTACTGATTATAAATGAGTGAAAACTATCAGTTAG
AAAAATCTAATTTAAGTTGTTAATACATGTTTCTTTGGTGAGCACCTGGATATATTTATC
ACAAATTCTTTTATACAAATGTCGAAAATGCTTTCAACAAACCTAAGTGTCCTAATTACA
TGCCACTTTTAAGCATCACTTTAAGGTAAACAAAAATGAAAACCATAATTTTAAATTAAA
ATTTGCGGACGCGGGGGGTCGACTCAAGACCTCGGCCGCTCTAGAACTAG
Sequence 2351

CCGCGGTGGCGCCCCGGGCAGGTGCTTCGACCCACGCGTCCGGATGGCTTGGGTCAT CAGGACGTCCATTACATCCAAAGGAAGACAGCCTGTGACGTTTCAAAAGCAAAAGTCCCC

TABLE 1 388/467

TACCAGCCAGTGAAGCTACCTGATTTCTCAGTATCTTACGCCCAGNGACACGATCTACCC TCAAAACTTAAAAAAAAAAAAAAGGGAAACATAAACACATAACAGCAGACCTN Sequence 2352

GGGCCGNGGNCACAACATTCCCCCTTCCCCAAACAGTAATATGGACACTGATTTAACANG ACTTATAAAAAAATAAGGCNCATTTATTTTGATNTGGTAATTTTAAAATAGAAACCCCTT C

Sequence 2353

Sequence 2354

Sequence 2356

CCGCGGTGGCGCCCCGGGCAGGTACCCAACACAAACTATTCAATAAAGTAATCTGCT
TTAAAAATAAAACACACTGAAAGGCCGAGGCAGGTGGATCACCTGACATCATTAGTTCAA
GACCAGTGTGGCCAAACTGGTGAAAATTAGTCTCGACTAAAAATACAAACATTAGCTGGG
CGTGGTGGCAGGCCCTCTAATTCCAGCTACTCAGGAGGATGAGGCAGGAGAATCACTTG
AAGCAAGGAGGTGAAAGTTGCAGTGAGCTGAGATCGTGCCATTGCACTGCAGCCTGGGCA
ACAGAGTGAGACTCCGTCTCAAAAACACCACCACCAACAAAATAAACACAACAGAATTAT
TCTGCAAATACAGATATTGGAGTAGCTGAGTTNCATCTCAAATTTGACTATGCAGGTTGC
AGGGTGATCTTGGCCAACTACTTATTCTTTTNTGAAGTTCAACTTTTTT
Sequence 2357

CCGCGGTGGCGCCCGAGCAAGTGGGCCTGTAGCCCGACTCTTAATCCAGGTTGGTGCTA
TTCAAAGAGATCATCTTTCACCCGAGGGATTTCTGGGCATCTATTTTGCGGATCAGAAAG
TAGAGAAAGAAGGTAACTTTGCTGAAAGCTAGTCTGGGGAGTTAGTAGCTGATACAGATC
AGCATTTCCTAACTATGAGATTTCATAATATTCTCTCTTGTCTCGATTCTGAGTCACTGG
TGCCTGCTGTGGTGGCATTGTTCATGAACATGTACCTGCCCG
Sequence 2358

WO 01/070979

TABLE 1 389/467

Sequence 2359

Sequence 2360

CGAGGTACACAGCTATGCACTTTCCGTTTCTGACTTTTGCCACCCTGTCAGCCATGGGGA GCCCACTGTGGGACTGAAACCCTGAGCTGAATGCGGCCTCATGTCTCAGAGAAACACTGG CAAGTTGGTCAGAGCCGCGTCTGCATCGAGGCGTAGCTGANCGGCAGGATGGGGGGGCTGC CTGCCCAGGGTCTCTCACCGTGGTGTAAGCAGAGCCATGGCTNGCCTAGGACCCTATAGA TACCATCACTCTTTCTCAGCTCGACTGGAGTTTGCACCTTTGCAGGGGGCAAAGTAACTCC CTGCACCCTGAACCACCCCCCATTCCTGTTCATTTCAGCAGATAATGATGGAGGGGGGG

Sequence 2361

Sequence 2362

Sequence 2363

TABLE 1 390/467

Sequence 2364

Sequence 2365

CGCACTTTTTTTTTTTTTTTTTATAACAACACTTATCCAACACTTAGTATGTGGCA GGCACTGTTTCAAGCACTTTACACATACAAACTCATCCCGGACGCNTGGGTNNAAGCTNG TNCACCNA

Sequence 2366

Sequence 2367

CGAGGTGTCAAGCTTCGACCCACGCGTCCCGACTTTTTGTCTTAGACCCAGTTAGGGTCA CCTTACAGTGCAGGTGGAAAGAAAGCAGGACTGCTGAGAGGAGCTCAGGACCCATTTTCC AGGACTATTGCTTCTCAAAACTTTGGAGAGCAGGAAAATAGATTCCCAAGTGAAAGAGGGT GGCAGAANTAAAAAAAAAAAAAAAAAAAAA

Sequence 2368

CGCCCGGCAGGTACACAGTTCTGACTGCAATACCTTTTTCAGACTGCAAAGGGAGCTCAG GATCCAGAAGTCATTAAAAGAACGGACGCGTGGGTCGAAGCTTGTACCT Sequence 2369

Sequence 2370

CGCACTTTTTTTTTTTTTTTTTTTTTTTTTTTTTAAAAAAAGCCTCATTATCCTG
TAGTCCATTTTGGAAAGTAAAGCCCAAGAAAGCAAAAGATGAAGGTTCTAAAGCTAGTTT

TABLE 1 391/467

GACTGACCTCAGAGTCCTCGGCCGCTCTAG

Sequence 2371

TTCGTGATAACTTCTCCTAAGTGCCAGGCATTGTATTACATGCTGNGAGCACANAGATGA ATAATANCAATAGGTTCACANAAAAGATGAATTGATTGAGAGAAAAAGA Sequence 2372

Sequence 2373

Sequence 2374

Sequence 2375

CCGCGGTGGCCGAGGTATCACGAGCGGCCGGCCCGGGCAGGTCAATCATAGAGC

TABLE 1 392/467

CTATAGGGCGAATTGGAGCTCCCCGCGGCGGCGGCCGAGGTCAAGCTTCGACCCACGCGT CCGGTCTATTTTGATTNTGGGGGGTNATCAGCATTATTCTTCAGAAGGGGACCTGTTTTC TTCAAGGGAAGAACACTCTTATTCCCAAACTACAGAATAATGTGTNAAACATGCTAAAT AGTTCTATCAGGAAAACAAANCACTGTNTTTATCTCCGNAGGCTATTTGNTCAGAGAGGC CTTTTGNTTAAATATAAATGTTTAAATATAAATGTTTGTCTGGATTGGCTATAACATGTC TTTCAGCATTAGGCTTTTAAGAAACACAGGGTNTTTGTATTCTTTACTAAAGATATCAGA GCTNTTAATGTTGNTTANATGAGGGNGANTGTNAAGTACCTGCCCGGGCGGCCGCC CGGNCAGGTCTTNGACCCACGCGTNCGGGCNATTATCAAAAACACTTGGAAAAAAGATTTT TATTCCTACTTTTAAACATACATCAAAATCTAAAATCTA

Sequence 2379

Sequence 2380

Sequence 2381

Sequence 2382

Sequence 2383

TABLE 1 393/467

Sequence 2386

Sequence 2387

Sequence 2388

Sequence 2389

Sequence 2390

AGGTACTATAAGAACACATTAATTCAATGGAAATACACTTTGCTAATATTTTAATGGTAT
AGATCTGCTAATGAATTCTCTTAAAAACATACTGTATTCTGTTGCTGTGTGTTTCATTTT
AAATTGAGCATTAAGGGAATGCAGCATTTAAATCAGAACTCTGCCAATGCTTTTATCTAG
AGGCGTGTTTGCCATTTTTGTCTTATATGAAATTTCTGNCCCAAGAAAGGCAGGATTACA
TCTTTTTTTTTTTAGCAGTTTGAGTTGGNGTAGGGGTATTCTTGGGTTATCAGAATAC
TCATATAGCTTTGGGATTTTTGA

Sequence 2391

GTTCGTATTTCTACCAACAAGGGTCAGCCTACAGGCAAAACACATCCCATTGTCA
TTTTTTGTAAATAAAGTTGTATTGGAACATGGCCACTCTCATTTGNTTTCTATTATTTA

TABLE 1 394/467

TGGCTGCTTTCACTTACAACCTGAGTGGNTGCCACAGAAACTGTATGGGCCTGCAAAGTC
TAAAATATTTACTATGTAGCTTTTTCTTTTTTGGAGACAGTNTGCCACTCTATTGC
CCAGGCTGGGAGTGCGGTGGTGATCATGGGCTCATTGCAGCCTCAAAACTCCTGGGCT
NAAGCAATCCTCCCGCCTCGGTCTCCCAAGTAGTTGGGACTACAGGCATGA
Sequence 2392

Sequence 2394

Sequence 2395

Sequence 2396

Sequence 2397

Sequence 2398

Sequence 2399

AGGTACAAGCTTCGACCCACGCGTCCGATACGACTCACTATAGGGATCTACCTGCTTGAG TCGACCCACGCGTCCGAACACATACAAAAGAATTAAACCCACAAGCTGCCTCTGACAGCA GCCTGTGAGGGAGTGCAGAACACCTGGCCGGGTCACCCTGTGACCCTCTCACTTTGGTTG GAACTTTAGGGGGTGGGAGGGGGGCGTTGGATTTAAAAATGCCAAAACTTACCTATAAATT AAGAAGAGTTTTTATTACA

Sequence 2400

AGGTGGCCGCACTTTTTTTTTTTTTTTTTTTTTTTTAAAGTTTGGGGTCTGTCAGGAGACAGA GGCTTTTTTGAATTCACTGTGAAGAAGAACCCGAACCTTAAGACGGCAGATCCCTGAG AGTCTTCTGGCTGGTTTGAGCGGACGCGTGGGTCGACACCTGCCCG

Sequence 2401

AGGTACTTCAAAGTTATTTGCACATACACTTGTTTACTTTGNATGTTTTGCAGGATTAAA CTTTGTATAATCTTTTTGCAAAATTTTTTTTTCAGTATGCAANGCTTGCAAGATGAAAAT TAAAACC

Sequence 2402

TABLE 1 395/467

ACCGCGGTGGCGGCCGAGGTACAAGCTTCNNNCNACTCGTCCGAGCTTGAGTCGACCCAC GCGTCCGCGTTNATGATTTTTAAAACACACTTGAAATAAAAATGATTGAACTAAATTTTG GTCCGGNGACATCATTNTGCACTGCATAGCCCA

Sequence 2403

Sequence 2404

NTTTTTTGGGGGGGGAAAACCCCNNACCCCCNCCANANAGNCANGNAANAAGGGNTTTT
TNACANNNNAGGGGGGGGCANCCCCCCAAAAAAACNNNCNANGCANGAAGNANANNNAAA
CAAAACANGNANGNAAGNNNNCACGNGCTTTTTTTAAAANATTTTTTTNNNNGGGGGGGG
GGCCCCCCAAAAAAAAANGAGGACGNNGGAGCCCCCC

Sequence 2405

Sequence 2406

CCGGGCAGGTCAAGTCGACCCACGCGTCCGCTTGTTTTGCTCTATCCCATAGGAGTTGGT ATAGTTGTGTTTCCAATATCATTTACTAAAAGAANANTNTCCTTTTTATTTCTTCATTGA CCAACT

Sequence 2407

Sequence 2408

AGGTCAAGCTTCGACCCACGCGTCCGGCCTGGGACAGATCCTTAGTCTTTCCTTGACTTT
TATAGACCCAGAGGTGAAAGGCCAAATGTTTTGTAGAATGTCCTTAAACTTGGGTTTATC
TGAGGTTTCCTTGTGATTGAATTCAGGTTAGACATCTTTGATGGGACTGTCATAGAACTG
ATGCTGTTCTAATTGCATCTTATCAGGTGACTTATGATTTCTGTTTGNCCCATTATTG
ATGCTGNTACTTTAGATCACTTGATTAAGGNGGTGTCTCGCCTGGCTTCTCCAGTGTGAA
ATTTCCTTTTTCTTCT

Sequence 2409

Sequence 2410

TABLE 1 396/467

Sequence 2412

NGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTCTTCGACCCACGCGTCCGATTTT GTGAGAATGATTGTTCTTTCACTTGGGCTGTTTGAGAGCATAATTATGGTAATCATGAGA TTAATGTTTCATGATTTCTACCTCCAAAGTGTGAAGACAAGTNAAACAATGNTTCTAAAT TGTCTTATTTTGTTGGCGGAGAAGATTACAATGGGCTATTAGTGCTACATTTGGTCAAAT GTAATCACTTAAATAGCTTCTTGTCACCTTAACTAAAGCAGAATAAAAAAACCCTGCCCC GGGGCGGCCGGNCCCGCCCCGGGCAGGTACCATTCCCGACGTTTGCAATGGTGGGAGTTG GCAGGTGTG

Sequence 2414

CTATAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACAAGCTTCGACCACGCG TCCGCTTCTCTTAGAATTTTGGGGAAATTGATAGTCCAGTGACTCCTACCCACTTTTGGG TGAAGGACGATTTGGAATTTTGAAGTGTGGGGAGACAGGCCTGTGAAGTCCGAANGACTC ACTTGGGGT

Sequence 2415

Sequence 2416

Sequence 2417

CCGGGCAGGTTTTCTTATGAGTGGGAGGTGACTGATCGTGGAGGTGGATTTCTTATGAGT GGGAGGTGACTGATCGTGGAGGTGGATTTCTTATGAGTGGGAGGTGACTGATCGTGGAGG TGGATTTCTTATGATTGGCTTATCACCATCCCTCCTTGGTGCTGTTTTTTGCAACAGTGAG TGATTTCTTGTGAGATCCGGTTGTTTAAATCCAGAGGCACCTNCCCCTACCCTCTAGCTC CCATTCCTGCCATGTAAGACACCTGCTCCCCCTTTTTCTTACCCCATGATTGGAAGCTTT CTGAGGCCTCCCCAGAAGCTGATGCCAGCCCTATGCTTNCT

Sequence 2418

Sequence 2419

AGGTGTACAAGCTTCGACCCACGCGTCCGGGATGAGTTTGTATGTGTAAAGTGCTTGAAA

TABLE 1 397/467

Sequence 2420

Sequence 2421

CCGGGCAGGTCTTNGACCCACGCGTCCGAGCAAAATTCAACTAAAAATACAATCTGGATT CCATAGCCAAGGGTTTTATTTACAATNTCCTAGTAGGAAGTCTTTATTTTAGCTTTCAAT GTGTTGAACTTATAAGGAAATTTAACGTATACATGAGTATTATATTTATGGAATGTGAAG ATATACAGAATGGAAATGGAAAATAATGTTAATTCGTATTGACTTTGAGGAATCTTANAA TCATGTAGCCCTGTTGCAACAAGAAATAGGGAACTTCTGAA Sequence 2423

Sequence 2424

Sequence 2426

TABLE 1 398/467

Sequence 2428

Sequence 2429

Sequence 2430

Sequence 2432

WO 01/070979 PCT/US01/09126

TABLE 1 399/467

Sequence 2436

Sequence 2437

Sequence 2439

CCGCGGTGGCCGAGGTACCTATTAAGCTCATGAACCATAGAGGTATCTCGGTGGCCC CTCATTACCATCTGCTGTTCTTTCAGCTGTTTAGCTACATCTTTGGCTGAGGAACCAGAC ACTTCAATCCATGTCTTAGAGAAGAATGCACATGACCCCAACATGAAGATGATATAAACA ACGACATGGACAG

Sequence 2440

Sequence 2442

TABLE 1 400/467

CCCCCCGGGGNTGGGGGGAATTTGATNTNAAAGTTTTNTNGATCCCCGCCCCCNTGGGGGGG

Sequence 2444

Sequence 2446

NCACTACTTAGGGCNATTGGAGCTCCCCGCGGTGGCGGCCGAGGTCAAGCTTCGACCCAC
GCGTCCGGGAGAATTACCCGAAAAACAACCACACTGCTTCAATCCTGGACAGGATGCAGG
CAGATTTTAAGTGCTGTGGGGCTGCTAACTACACAGATTGGGAGAAAATCCCTTCCATGT
CGAAGAACCGAGTCCCCGACTCCTGCTGCATTAATGTTACTGTGGGCTGTGGGATTAATT
TCAACGAGAAGGCGATCCATAAGGAGGGCTGTGGAGAANATTGGGGGCTTGGCTGAGG
AAAAATGTGCTGGTTGGTAGCTGCAACANCCCTTGGAATTGCTTTTGTCGAGGTTTTGGG
AAATTGNCTTTGCCCTGCTTGCCTCGTGAAGAGTTTTAANAAGTNNCTTCCNNAGGNTNA
NNTAAGGGTNTCTTNGGTCTTTNTNANNNCCTTCNTTANTTTGGGGGGGNG
Sequence 2448

Sequence 2449

WO 01/070979

TABLE 1 401/467

PCT/US01/09126

Sequence 2450

CCGGGCAGGTACTTTTTCTAATATACTTTTCNATTACACATGAAAGCCATGACAGGAACT
GAGATAAGATTTCTTTGTTTTTTGAAACATCTTATCTACTAANAAAATTTNNAAAATTTNNAAAATTTNACATA
TTNACTTNAAAGCTATTAGTAGTTTTATACTCNCTTAATAAGTATTAATAAATTTACATA
CTNGACTTAGTAANCTAAGCAATTTGGNTAACGTNTTTNTTTATTNGAGNGANTTTTTGC
CANTTGGATATTTTTNCTACCTTACTATTACNTTATAAATATATTTCCCCAAATATATCN
TTCCTCTTTAAAAANTATGTTTTGNCAACNAACCTTNAAA

Sequence 2451

Sequence 2452


Sequence 2454

GAGACACAGTCTCACTCTTGCCCAGGTTGGTCTAAAACTCCTGGGCTCAAGCAATCCTCC CGCTTTCAGCCTCCCAAAGTGCTGGGGTTACAGCCGTGTGCCACTGTGTCTGGCCCTTTT CTTTTTCATAGGAGAAGGGTTGTTGACTCCCAGGAAACGTCACCTGGAACCAAGAATGTG AACTCAAGGACCCCCGCCTGTTGGCAGCTGCATTTACTTGACTCCTGTTCACTGTTTCTT AGCCTTGTCCTTTCTCCTGCCAGTTCTAGGGGACACTGCTTCTCCTGGTTGACCTCAT CAATGCC

Sequence 2455

Sequence 2456

AGGTCTTCGACCCACGCGTCCGGTGGCTTATGCCTGTAATCCCAGCACTTTGGGAGGCCG



WO 01/070979

PCT/US01/09126

TABLE 1 402/467

Sequence 2457

CTATACACTACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTCAAGCTTCGA CCCACGCGTGCGCAATTTTTAGGCCCACAAGGAGTCAAGCACCTCAAGGAGATCTTCAGT TTGAACTTGGTGTAGACACAGGGATACTGATGAATCAATATTCAAATTAGCTGTTACCTA CTTAAGAAAGAGAGAGACCTTGGGGATTTCGAGGAAG

Sequence 2458

Sequence 2459

Sequence 2460

ACTACTATAGGGCGAATTGGAGCTCNCCGCGGTGGCGGCCGCCCGGGCAGGTCTTCGACC CACGCGTCCGGACAGCTCTCCCACAGGGGTCATGGGGTCTCTTGCTGCTAGGATTCTG GAGTTTCATGGTAAGAGCGGGCCACTCCCCACCTATTCAACTCACCCCTTCCCCAGGAGT TAATGGGGGCTAGTAAGGAATGCTAGTGCTTGGAAGCCCTGTGCAGGCTTCTGAGATTCC TGCCCCCTCAGCCCATGCTCTGCATCCTCCCTTCATCCACCCTCAATGTTTTCCTTCAAA AGATCTGCTCAGAGTGTGCCAGTCTTCCCAAATTCCTGGTCTCTCCATGAGAGATGTTCT TCCTGGCTGCTTCTAGTTGGCCATCTGGTCTTGAGTCCTNTGTACCTCGGCC Sequence 2461

Sequence 2462

ACGACTNCTATAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACTGAGCAGGAT TACCATGGCAACAACACATCATCAGTAGGGTAAAACTAACCTGTCTCACGACGGNCTAAA CCCAGTAGAAACAAAGT

Sequence 2463

ACGACTNCTATAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACTTTAAAGTTA TTTTAGTCATGAAATTTTATATGCAGAGAGAAAAAGTTACCGAGACAGAAAACAAATCTA AGTCGA

Sequence 2464

CTACTTAGGGCGAATTGGAGCTCCCCGCGGNGGCGGCCGAGGTTTCAAGACCAGCCTGGCCAACATGGTGAAACCCCATCTCTACTAAAAATATAAAAATCAGCCGGGCATGGTGGCATGTGCCTGTAATCCCAGCTACTCAGGAGTCTGAGGAGGAGAATCACTTGAACCTGGAGGAGAACAGAGGGAGACTCAGTTGCAGTGCAGTGCACTCCAGCCTGGACAACAGAGGGAGACTC

TABLE 1 403/467

TGTCTCAAAAAAAAAAACCTACAGCTGTTCAAGGACCAGCTGACAGGTCAAGTGTGGC CTTTTCTGGTCTTTGAACACATCATAGAAAGTGNCAAATGCTGCAAAGCCATNAAGAACA TGAACTATAAACGGGT

Sequence 2465

CCGCGGTGGCCGAGGTACAAGATAGGTATGGATTCCAGNCTGGAGAAACCCNTAAAC CACTACACCCTGCCTCANAGNAGGGNAGAATTNTCAGTATGTATGTGGAGACAGGCTCGG ACGCGTGGGTCGAAGACCTGCCCGNN

Sequence 2466

Sequence 2467

Sequence 2468

Sequence 2469

CTACTTAGGGCGATTGGNNCCTCNCNGNGGGGGGCGGCCGAGGGCCTGATCTAACTGCTGC CAAGACATGCCAAGGTCACCAGCTTCCCGTCCTGACCAACAGCCACCTCTCAGAAGGCTG GCTTAACTACTCANCCCCAGTCTTNTTAGCAGATGGCAAGGAGCTCTGGCCAAGATTTTA GTCTAAACAGAACCCTAGGCTGCTGATGCAACATCAAGCAC

Sequence 2470

Sequence 2472

CTACTTAGGGCGAATTGGANCTCNCCNCCGGGCGGCCGGCCGAGNACTTACACNCNNGCN ATCGNTTTCNTGNCNGCAGNNGGATNCACTAGTTNTAGCTTCGGNCGCCACCGNANCCNN CNNGAGCATGCATGGAACACATATACCAAACATCTTCTGATAACATTAAACATTTTTAA AAGATGTTAAATGTTCTTTTCATTGTGGTGCTTCAGATTCCTGATTCTAGAACTTGTGTG TGTGGAACCTGTGTGCTAACTATTCTGTTGGAATTTACCAGCAAAGAATTATCTAAGAAT TTTCAAACTAAATGATGGGGGGAAGGAACTA

TABLE 1 404/467

Sequence 2473

Sequence 2474

Sequence 2475

GGGCGAATTGGAGCTCCCGCGGTGGCGGCCGAGGTACCAATTGCTAAAACAGCTCCAGG GNAAGNNATCTTATTTAGCATTAGCTCCCTCACAACTNTTTTCATTCATACTTNTATTGG CCAGNCTCATACCTGAAGTATTTTAAATGAGTTNACAATTATTNCACTTACCNTCAGAAA AAAAAAGGAGCAAAAACTCTTAATGACTGGTNACATGCACATTTGGTGTAGGAAATTATT ATGNGGTAAAATTTATATTTCTATTTATTTTTTATTATTTNTTNACACATTATTT CAC

Sequence 2479

ACTACTTAGGGCGAATTGGAGCTCNCCGCGGTGGCGGCCGAGGTCAAGCTTCGACCCACG CGTCCGTGGTGAACACAGAGAAGACAGGTCTTGTATATATTCCTCTGTATTCTGGGGAGC TTTGACCTTGGAGCTTTGTACCTGCCG

Sequence 2481

CCGGGCAGGTCTACTCAAGTAGTCTTTACCCCCTACTCAAGTAGGGGGTAAAGTGTAGAA CAAGGAGTTTGATCTGTGTCAACTGATTGTGAACCATCAATTGAGATAACTCACTACCT TCAAGGCCAGCCAGNTACATACTTTTTGNAAAAAGCCAAGAGTGGAANCAGGGTTGGTTTT TAATCCAATTTTTGGGC

TABLE 1 405/467

Sequence 2482

AGGNCGACNTTNTCACAGGCAGNNAAACCGGCCAGNTNAAAACACTATGCTANCTCGCGG GGCCANTNTTAGGATGGGTGAGGCAGATGAANCCATTCTCCNANTGGCCAAGGCCGAGGG CATCAGCCTCAAAGAACNTTTGACNGGAGAGAATCACANACGTGNNNTATTCGTCATAAA NAAANAATGAAAAACCNACC

Sequence 2483

Sequence 2484

Sequence 2486

Sequence 2487

AGGTACGCGGGGGAGCCTGTCCAGCTGGCCCGGGCCCTGGCCTGGTTCTCAAGTGTTTCC
TAGACAGAGAGGCACCTGGGTCAGTATTAGTCTATTTATCAGAGGTGTAAATAATCTATG
TATAAGTTTTTCTCCTTTTAGATTATTTTGTATTTGTTTAAAAGAAGTTTTGTCAAAATA
CAAAAATATAAAGAAATGACTGAAAGTTGTTGACAGGGTTTTTAAGAAATAANTTATTCT
AATTGTTTTTGTTTGGTTTGTTTTTGCCTTGTAAACTAGCGCCAAGGAAC
Sequence 2489

CGGGCAGGTACGATGGGAGGACAGCTTTGTAGAAAGGACATTATNCAGCTNATAGCAAAC TTTGTGGATCCCAATCCGAGATTNCCTGCTGAAAGACAAGAAGATTTCTNAAATAAAAGN GCTGTANCAGNATTTGTATACTCCAGAATAAGNTTCTGTGATTCTTANCTGCCAATGTGT TCAAGGCGTGATGACTNGGTNTCTGTTTCTNTGAACATNAATACTAGGGTCTGTATAAAT TTCAATGCATGCCACCAGCTNATCAACCCTTTTGGCTTTGATTTTTGNATGNNGNATTNT TATTCCCTANGANTTCCGGCCAAGTACCTTTGGNCGCCACCCGTGGTGGGAGCTCCAATT TCGCCCTTATAAGTGAAGTCCGNAAATTACGCGCCGCCTCANTTGGNNCGGTNAGTTTTT ACAACGCCNGANGACCTGGGGAAAAACCCTTGNCCGTTACCCCAACTT Sequence 2490

TABLE 1 406/467

GCTTCCTGCCAAANAA

Sequence 2491

AGGTACAGAGAACTGAATTTACACAATAAAGTGTTACCCTATACCAGTGATTCTAAAATT
TTGGTCTGGGGAACCTTTCATGGGGTTCATGAGGTCAAAACTATTTTCATGATAATGTTA
TTTTGCCTGTTATATTCTCATTCTCGAGTATACAGTAGAGTTTTCCAGAGGCCACATGAT
CCATGACATCACAACAAAATGAATAGAGACAGATGAAAATCTAGCTGGCTTCTGCTACAT
GAATCAGACATTAAGGGGTCCAGAGACCATAAAGTGTGACAACCACCACTCTTCACAACC
TATATATAATATCTCAAAATAATGTTAATTCTCTATCCTCAAAGTTTATTTCCTTATATC
TACATTTTCTATGATCAACACACACTCACAAAA

Sequence 2493

Sequence 2494

Sequence 2495

Sequence 2496

AGCTCNCCGCGGTGGCCGNGGACNAGGGNCTGANTGTCTGNGTNTCAGAATGGGATN AGTGNCCTTATAAATGAGGAGCTNGNTTGTCCCTNCCACNACATGAGGTTACAGCAAAA

TABLE 1 407/467

AGATGGCTGTCTATNAACCAGCAAGTTNGCCTTTGNCANACCCCAGATCTGCANACTACC
TTGATNTTGGACTTTNCATCCTGCACAAATCTAAGANANAAATTACTGNTGTTTATCAAC
CACTCNGTTNATGGTNTTNTTCGTTATAGCAGCCTGAACTAAGACAACAGGTNGATCTTA
AGGCATNGCTACNATNAAGTCTTTCCNTGCTCAGAATCTCC

Sequence 2499

CTATAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACTGGGAANTGGATGACTT TTCTTGTCCATATCACCATGGAAATCTGTGTGCTGGGCATGGAGAGTGNGAAGCANGCAG ATGCCAATGCTTCAGTGGCTGGGAAGGTGATCGATGCCAGTGCCCTTCAGCAGCNGCCCA GNACTGTGTCAATNCAAAGGGCCAAGTGTGCAGNGGAAGAGGCACTTGTGTGTGTGGAAG GTGTGAGTGCACCGATNCCAGGAGCAT

Sequence 2500

NTGGGCGAATTGGAGCTCNCCGCGGTGGCGGCCGGCCGGCCGGCCATTNTTCTTT TTTTTTTTNGCGGATGGGGACTTGTGAATTNTTCTAAAGGCGCTATTTAACATGGGAG Sequence 2502

Sequence 2503

CCGGGCAATCTAAGAAGACATGATCACTAAATGTGATGTGGGATCCCAGATGGGATCCTG
GACCAGGTAAAAACTAAAGTAATGTTTCAACTTCAGTAAATAATAATGTATCAATATTGG
TCCATTAATTGTGGCAAATGTGCCACACTAATGCAAAGCGTTAGTAACAGGGAAAACTGG
GAGCAGGGTATATGAGAACTTTTTGAACTGTTTTCACAATTCTCCTGTAAATCTAAAACT
CTTCTGAAAATAGAGTTTATTCTTTAAAAGTGTCTGGAGGATGTGCACAAGGGTGTGGCA
GCAGAGGGGCTACAGGTAAAAAAATCATGACATCTGGAATATTTCCTTCAATTTTTGCTCC
ACACGGTGACTATCTTACCCTGCTCCC

Sequence 2504

CCGCGGTGGCGCCCCGGGCAGGTACTAACAAATGCAGTAGCCAACAAGATTACCATG CAATCATTAAGGAGAACCAAAGTAAGAGAGCCACTCAAACCAGATTTTGAACGCTACTAA AATTAAAGTAGTTCTTTGATGAATATGAATGAGTAGGGAAAGGATTCTTTGTAATAGTGA TACCTCTGTGGTAAGAGAGAGGGTGGTATGTGAGTTTTAGTCTACAGATTATGGCAAATTC AGTGACAACAATCAAATGGTCTAAGATTGACAGTAGCACAGTTTTACTCTGTGAAGGTAA TGTTCAGGACAAATTTCAAGAAAACTAGAAAACCATTCTTTACAGCTGAAATCTTTCCCT

TABLE 1 408/467

Sequence 2506

ACTACTATAGGGCGAATTGGAGCTCNCCGCGGTGGCGGCCGNCNGGCCAGGTACACNTTC
TTAGACCTCAACCTCGAACTNTCAAAATTNAGGATGTCTCANCCCTACTGAGGCCGGGAG
TCACCTNNACACTGANGGCCCTNGGTGNGAAGATGAACCTTNCACCGTCTNTANTGCATT
CTGGAGTGCAAAAATAAAATCCACTNAAGAGTCACAAGGCCCGCTGTGCATAATNGGNTT
CACTTTTACCTTTTTTT

Sequence 2507

CCGCGGTGGCGGCCGGCCGGCAGGTACATGTAATGCTCCTGAACTGTATGCTTCGCACG
GCTGACATGCTAAGNTTTGTTCTGTGTATTTTATGACTATTTTTTAAAAAGTAAACAAAA
AAGAATTAGCTGGAAATACCAGCACAGGCAAACCCCTGGAGACAGAAAGCAGGTGAGTGG
NTGCTGGGGCTTGAGCAGGAGGAAGGGCGAGGGACTGCANAATGGCCATGGCCTTCTAGCATGATGAGAATGTTCTGGAATTAGACAGTGGTAACGCTTGTTCAACACTGCCAG
TGTAGTTAATGTCACTGAATTATACACTTTAAATGGCTAACATGACCAATTTTATGTTAT
ATATATTTTACTACCACAAAAAAAACTANCTGGCACCTAAAAACATTCCATTGAACAGGCC
CCTTCAGATCTGTGTCTTTCCTGCATGCAAATTACNCCACAGAGCAAGCACCTATGGCAN
CGTGGATCACAGGCTCTGTTTTANGATAGANAAAGGACACAAAGGNGTCCCCC
Sequence 2508

Sequence 2509

Sequence 2510

CCGGGCAGGTACAATTGNTTTAGAAGATANTTTGTTTTTCTCTCTCTCAGTTTCNCATATT
ACTAAAGACAAATCATGGTAGGATTGGNTTGTTTATTATACTTGGCCTAACTATTTGTAT
ACAATGCAGCAAGAATGATTATTTTTTACTTAGGCTTTTAAGTAGGCTCTGATGGAACTT
TGTTCCATAGCAGGAATCTCAGATAAGACTTTGTAAAACCCGTAAAACTCANCCGAGCCA
TGGATTTATGCCATTAAATACCCATGAGTTGGGTGAAATTTCCTNTCCTTTNGAGGGCCC
AAGATAAACCTGGGGCGTCTGCACTTGNCAAAAAGTGATATTCTTTACTTACACAG
Sequence 2511

TABLE 1 409/467

Sequence 2512

CCGGGCAGGTACGCGGGGACTGAAAATNGGACTGTTCAACTCACCTGGCAGCCACTCCCA GAGCTCCTGGAACTCTGGCCCAAGGTTCTCTGACTGACTCCTTCTTGGCTTACTGGCTGA AGACTGACGCTGCCTGATCGCCTCAGAAGCCCCGCAGACCATCATGGACGCCGAGCTTTA GGTAACTCACAGTGGAGGCCCGCCTGCACCCAGGTGAAATAAACAGCCTTGTTGCTCACA CAAAGCCTGTTTGGTGGTCTCTTCACACAGACGCGCATGAAAGGGAAGACATACAAAAAC AAGGCCTCTGAGGTAGGTACCT

Sequence 2513

Sequence 2514

Sequence 2515

Sequence 2516

Sequence 2517

TABLE 1 410/467

Sequence 2518

Sequence 2519

CACTACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTACTTGAGA
TTANGGGAGTGGTGATGACTCTTAACAAGCATGCTGCCTTCAAGCATTTGTTTAACAAAG
CACACCTTGCACAGCCCTTAAGCCATTTAACCCTGAGTTGACACAGCACATGTCTCAGGG
AGCACAGGGTTGGGGGTAGGGTTACAGATTAACAGCATCTTAAGGCAGAAGAATTTTTCT
TACAGAACAAAATGGAGTCTCCTATGTCTACTTCTTTCTACACAGACACAGTAACAATCT
GATCTCTCTTGCTTTTCCCCACAACCTCAGCCTCTCAGAGTGCTGGGATTACAGGCATGA
GCCACCGCGCCCAGCCTCCCTTTTAAAGCACTTTCTGAAGTCAAGCCTGATTCAGGATTG
CAAGCCTGCAGAGAACTATGGTGGTAAAGCCTAAAAAGATAGAATCCTTCCCACACCTGA
GAAGGCAGGTATTTTTAGAAGGAAACACCAGAATCACACTTAAGTCACTGCAAAGGCATT
CATGTTTATACATTTCTGAACTGTCTTACTTGGAACTTTATGNGG
Sequence 2520

CTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGGGCATGGTGGCTCACGCCTGTAAT
CCCTCCACTTTGGGAGGCCAAGGCAGGTGGATCACCTGAGGTTGGGAGTTCGAGACCAGC
CTGACCAACATGGAGAAACCCCGTCTCTACTAAAAATACAAAATTAGCTAGGCNTGGCGG
CACATGCCCGTAATCCCAGCTACTCCGGAGGCTGAGGCAGGAGAATCACTCGAACTCGGG
AGGCANAGGTTGNGGTGAGCTNANATCACACCATTGCACTNCAGCCTGGCCAACAAGAGT
GAAACTCCATCTCAAANAAAAAAAAAAAAAGGAAACATGAAGCCTTCCTTNAATGATGATAG
TTTCTAAAGTGAATTATTTGAATCTCTTTGCATGTTTTGGCTCTGTTAATCTAACTCTTG
TCTCTAAATAGATGCTGAAAGTGTAAATCTAGATGACTATAACATACACGTNATTGCAAG
TGTATTCAA

Sequence 2521

Sequence 2522

TABLE 1 411/467

Sequence 2523

Sequence 2524

ACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGNCCGGGGTCCTTTGTCCTNAAAACGT
TAGATCTGGGCTCTGATTCCTAACTGCCACTCGTGATCACAGAGGTGCAGAGAGTCATTA
GCCATTGTTGCACTTCCATTGTTGCAAGCCCCTCACCTTCTGGTTGAAGTGACTTTCAGG
AGAATTAAAAGAGCTGGNGTTTCCCTCCCCACTCCCATTCATTTTTCTCATTTTCCCTT
TTGGGAGCCAGACATAAACACAATTGCNTATATGAGAGAAAATCAGAAAGTCATGGCACAG
CCTAGGGGATGGTGCAGGCTCAGAAAAGACCTCTGAGAAGACCTTAGATTTATACTTCAG
ACTCATCTTAGGCAAAGAGGGCTTACAACAATCAAAAAAACAAAAATAATAAAAACAGTA
ACAAAAACAGCAAACCCTGNAGAAGAGGAAGAATCTGATTTCCAGAGTTAACACATTAGT
AAATTCTAATGTCTGGTTTTCAACAAAAAATATCACAAAGGGATTACCAGAGAAACAGGGA
AAGTGTAACCCCATTCAAATTGAAACCTAAAGAGACTTAANAAACAANAGGGATTTAAAG
GTCAAGAAAATTTTTTA

Sequence 2525

Sequence 2526

Sequence 2528

TABLE 1 412/467

Sequence 2529

Sequence 2530

CCGCGGTGGCGCCCCGGGCATGGTACGCGGGGTCCCTACAAATGCAACGTCTGCAAT AAAGTCTTCACCCAGCGCTGCTCTCTGGAGTCCCACCTGAAGAAAATCCATGGGGTGTAG CAGCAGTATGCCTATAAGCAGCGGCGGGACAAGCTCTACGTCTGCGAGGATTGCGGCTAC ACGGGCCCCACCCAGGAGGACCTGTACCT

Sequence 2531

Sequence 2532

CTACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACCTTGGAAGACCTTAT
TCGATATCTTGAACCAGAGAGATGGCAGTTGGACTTAGAAGATCTATATAGGCCAACTTG
GCAACTTCTTGGCAAGGCTTTTGTTTTTGGAAGAAAATCCAGAGTGGTGGATCTGAACCT
TCTAACAGAGGAGGTAAGATTATACAGCTGCACACCTCGTAACTTCTCAGTGTCCATAAG
GGAAGAACTAAAGAGAACCGATACCATTTTCTGGCCAGGTTGTCTCCTGGTTAAACGCTG
TGGTGGGAACTGTGCCTGTTGTCTCCACAATTGCA

GGAGCTCNCCGCGGTGGCGGCCGNCCGGGCAGGTACCNCGGGGGTGCCCCGNAAGCAGTT GTTGTTGGTTGGGGGCCCTTTGGGCCGGTGACGGANACTGCCCAGGTGTTGGNCACCATGT TCCTCTNCGCGGTCTTTTTTGCCAAGAGCAAGTNANATGNAACAAATAGTCCTTTTCGTG GAAAAGAAAAAATNCGCTCCCTTTNAACGGTGGATTGAAAATGACTNTGNTTTATAAAG AGAANACTGAGGGCGGGGATACTGATTCANAAATNCTGTANCGTGTAATAAAAG Sequence 2533

Sequence 2534

Sequence 2535

WO 01/070979 PCT/US01/09126

TABLE 1 413/467

GACTCCTATAGGGCGAATTGGAGCTCCCCGCGGTGGCCCGGGCAGGACAAAACAAA GACTTTTCATCAACTCTTTTAGATATGCTAGAAGAGCTAAAGGAAACCATGGACAGAGAA CAAAAAAATTAGGAAAGCAATGCCTCATCCAATACAGAATATCAATAAAGAGATTGAAAT TGTAGAAAAGAACCAAATAGAAATTCTGGAGTTGAAAAGTATTATAACTAAAACTGAAAA TTCACTAGAGGTATTCAGCAGCAGACTGGAGAAGTCAGAAGAATCAACAGGCTTCA AGATAGGTCAATTAAGATTATACAGTCTGAGGAGCAGAAAGGAAAAAGAATGAAGAAAAA TGAACAGAGCATAAAAGACCTCTGGGACTCTATCAAGCA

Sequence 2537

Sequence 2538

CCGCGGTGCCGACGTACTAGTCTCAAAAGCTGGGGACTCTGAGCCTTACCTAGAGT CTCAGCAGGTGGACCATTAAGATTAACATTTCTAGTAGGTGAGTTCAATCACAAAAATAT TTCTTGTTCCATAGATTTTATTGTGGCCATGTCAGTGAACACCCCACAAGTTTTGCTCAGA ATATTTTAGGTGTAAGCTAAATCCCTAAATTGTTCAGAGTTCCCACAGCCCTGTAGCAGC AGAGCGAGAACTTTAACCAGACTTTTTCAATCCCAAAGCTAATCTGGAGGCCAACAGTGT TCAAAACCTTGGTGACTGAGGAACCATTTAGAGTTTTTCAGGCTCAGGAATCACATGGG TCGTTGTTGGGCTTGGGGGTAAGTTTCACAGGCGATGAAGCTTGACGTTGAGTCACTTGA CTTCTGGAGCCATAATTTATTTTCTCCCAGCAACCTCCT

TABLE 1 414/467

Sequence 2541

Sequence 2542

Sequence 2544

ACTACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCCCGGGCAGGTACTATTTCA
TATATTGTGTGAGCCCCACAAATGTCTATTTTAAAAAAGAGTATAGTCCCTGGCCAGGCGC
GGTGGCTCACGCCTGTAATCCCAGCAGTTTGGGAGGCCGAGGTGGGCGGATCACCTGAGG
TCTGGAGTTCGAGACCAGCCTGACCAATATGGTGAAACCCCGTTTCTACTAAAAATACAA
AATTAGCTGGGCATTGGGGGAGCATGCCTTGTAATCCCAGCTACTCGGGNGGGTTGNGGN
GNGGAAAANANCTTTGAACCCCCCNANGGCCAAAGGTTTTTTATTTGGGGCCCAAAAAAA
ACCNCCCTTTTGCCCCTTCANCCCNNGGGGNNAANAAAAAAGGNGGAAACCNTTCCNCTN
CCCCCAAAAAAAAAAAATTTTTTTTTAAAAAAAAATTTTAAAA

TABLE 1 415/467

Sequence 2546

Sequence 2547

Sequence 2549

Sequence 2550

CTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACGCGGGGGGTGCTGAAATC CGGCATGTTCTTGTCACACTGGGTGAGAAGATGACAGAGGAAGAAGTAGAGATGCTGGTG GCAGGGCATGAGGACAGCAATGGTTGTATCAACTATGAAGCGTTTGTGAGGCATNTCCTG TCGGGGTGACGGCCCCNTGGGNGGACNNCCCCCANNGGNCNTAAANGGGTNANAACCNTT CCNGTTTTCCCAAANGCCCGNCCCCTTTTCCNTTGGGANAANTTTTTNTTTCTNCCNCA AAANGTTNCCCTAGGNTTTNTTGTCNCANNAANTTTCCCATTTTGTTTNTNTGGGANGAT GTTTNGCCCGTCANNTTCCACCAAATAANANTTNCTTTTTTGGNAAAAAAATNNTAAANTN

WO 01/070979 PCT/US01/09126

TABLE 1 416/467

Sequence 2551

Sequence 2552

Sequence 2554

Sequence 2555

Sequence 2556

TACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACGCGGGGACTCAGAGGCCGCCATCAACCCGCCAGATCAACCTGGAGCTCTACGCCTCCTACGTTTACCTGTCCATGTCTTACTACTTTGACCGCGATGATGTGGCTTTGAAGAACTTTGCCAAATACTTTCTTCACCAATCTCATGAGGAGAGGGAACATGCTGAGAAACTGATGAAGCTGCAAAACCAACGNNGGNGGCCGAATCTTTCTTCAGGATATCAAGAAACCNAACTTGTNATTACTGGGAAAAGCGGGCTTAATCAAGGGGGGTGGGCCTTTANNTTTTTGGNAAAAAAAGGGNGAATTNATTTCTNTTTTTGGGAACAAGNAAAAAACCTGGGCCAAAAAAAAA

TABLE 1 417/467

Sequence 2557

ACTNCTATAGGGCGAATTGGAGCTCNCCGCGGTGGCGGCCGAGGTACTTCTTGTCAAATT CCTTCTTGATATGAGCCGCAATGCCCCTCTCTATGTTGTATTTCTCCAGCGCCTGAGTAG CGCACTCCACCGAGTCCTGTTGCATCTCTTCCGACATGTCCGCATTTTTGATCACGGCCT TTCGGTCGCCCCGCGTACCTGCC

Sequence 2558

CTTAGGGCGAATTGGAGCTCNCCGCGGTGGCGGCCGAGGTACTACTGCTGAGGTCTNCAGGACAGAAGNCACCTCCTNTGGTAGAACATNCATCCCTGGNCCTTNTCAGNCCACAGTTTTGCCCACAGAAATATCCACANGAACAATGACAAGGCTTTTTGCCT

Sequence 2559

Sequence 2560

Sequence 2561

Sequence 2562

TABLE 1 418/467

Sequence 2566

Sequence 2567

TABLE 1 419/467

GGTCTTNGNNCTTNTGCCTAGGACNTNCTTTCCTAGGTANCCACATGCCTGCTCTCATTA
TNTTCATGTCTTAACTCANAGGNCAACTTTGANTTAANGCTTTCTATNACTACATTNAAN
ANNGTGNGACCTTTCNTGTCTNCCCANCTNGCCTGATNTTTNCTTNTCCATTGCACTTTN
CTTNTGACTTCT

Sequence 2568

TATAGGCCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGCAGGTACGCGGGGGGGATT TCCGNTGAGTGACCCTTACAAGTCCTTCTTGATCCTGAACTGGGTAGGTGCCGCTGNTG CTGCTCGTGTTGAATCTAGAACCGTANCCAGACATGGNACTGGAGGACGAGCAAAAGATG CTTACCNAATCCGGAGATCCTGANGAGGANGAAGAGGAGGAGGAGTTAGTGGATCCC CTAACAACAGNGAGAAAGCAATGCNAGCAGTTGNAGAAATGTGNAAAGGCCCGGNAGCGG TTAGAGCTCTGTGATGAGCGTGTNTCCTCTCGATCACATACAG Sequence 2569

Sequence 2571

TATAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCNGGCCGGGTACCCCCATNACAG NNGNCAANCNGNCTGAGGAAGTGGCNNCTACCANGCAGGNGATCTTNCNGGAGCGGTTGG CNGCAGNGCCNGAGTTNCACCGGTNTTGNGCCCCTGTTCAAGTNCTNACCTGANCCCATG GCCCTCACCGNGTCANAGACGGAGTNTGTNATNCGNCTGCACCAANCACACNTTCNNCAA CCACATGGTTTTTNANNTNGNCTGCACAAACNCACTNAATGACCNTACCTTGGANAATGT NNCAGTGCNNATGGAGCCCANTGNGGCCTATGAGGTGCTCTGTTACGTGCCTGNCCGGAG CCTGCCCTACNANCANCCCGGGACCTGCTACACACTGGTGGCACTGCCCAAAGAAG Sequence 2572

TTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGNNGNGCCCGGGACGCACAGNAAANN CNTGTNTTNGTNGGNNTNTCTATNAAAAAGGCAATCAAGAAAGATAATGTGAAAAAGANA GGAATTNATAGGTCGGGAANANATGAATGTCAAGACATTTGAAGAACTATAGTAAAATGA TCAACACTAAATATACTNAGAGAAANCTTTGTTAATATGCCAATGAGGTNGGCCTGATCT TTGAAATAGTGAATAGGAATNCAATGCATTTCCTCAGTGATCACTGATTANGAATGAGTT GGTNNGGATCCTTGGGA

Sequence 2573

TAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACAAGGAAGCCTGGTTGAAGTC
TTTCCTTGAGAGGCCTGGATTTGTTCACATATTCAGATTTCAACTGGCTTTATAACAGG
TTTCCTTATGTGCCTCATATTGGCTCCAGGTTCACTGGGTTTAAAAGGAGCCAAAGCACC
ATAAGGTTTTGGCAAAGGAAGAGTGGCATCTGCTTCTGGGATGTAGGCATTCGGACGCTG
CTCTGCAGTTGTAAAACACCATTGGGCAGCTGGCGATTATCTGCTTCCAAGAACTCCTG
AGACTTTTCAGCGATGGCCAAGGCGTGCATTTCTTCATCTCGAAGGACTTTCAACCATTC
TTTCTCAATTTCCTTATTGAGTGGCAGACCTTTTTCTA
Sequence 2574

TGCCGGTGGCGCCCGCAGTCCGCTTGTCCGTCCTTNCTCTCTGACTGNGGTACNNCGGG

TABLE 1 420/467

Sequence 2575

Sequence 2576

Sequence 2578

CCGCGGTGGCGCCGCGCGCGCGGGCAGGTACCCCGAGTCCAGCGAGACAAAGGAGTTAGAAA GAGACAGAATAAGAGTTTAAAAGGCAGGTCCAGGGGACCGGAGCGTTGGAGGCTTGCTCA TGGCCCAGAGCTCTTTGGCTCCGCCCAATTTATTGATTTACAAGCTCTTTGTTCTTAGGG CAGATGGGAGGGGTAGGAAGGGATGAGGAAAAGGATTAATCAGTGAAGGAGAACTCGTGA GTCATTCAATAATATGTATAGTAGTGGTGGTTTCTGTGAATTTCCTTGAGTAAAGGCGTG TGTCTAAACTACTCAAGATCTTTAACTTATCGGNATTGAAATGGATGGG Sequence 2579

AGGTACGCGGGATAGTGAAACCCCGTCTTTACTAATTTTTTGTATGTTTGGTAGAGACAG GGTTTCACCGTGTTGGCCAATATGGTCTCGATCTCCTGGCTCATGCCTGTGGNCCCAGCA CTGTGGGAGGCTGANGCAGGAGGATCATNTTGAGGCCAAAGAGTTCGGGATCAGCCTGGG CAACATAGTGATACCCTATCTCTTAAAAAAGAAGAAGTTTTTAAATTTGAAATAATAANA GGTACCTTGCCCGGGCCGCCCTCTAGAAACTAGTGGGATCNCCCCCGGGCTGCAAGG GAATTTCGATATCAAGCCTTATCGGATACCGTCCGACCTTCGGAGGG Sequence 2580

CCGCGGTGGCGGCCGGGCAGGTACGCGGGATGATTGAATTTTGTTTCCGCCTAAAATAGT AATCTATAAGATATAAACTCGAGTTAGGGTTTACATTTTTTACTTATGAACACAGGGCAC TAGGGCCACTTCAGTCTAATTTCCTGCTTTTTAATTACTTTAACACTCCACAGGAGGAGG ACTGGTTTTCCTCTGTGACTTCCTAATGTATGGCAAGCAGGACTTCTTCTAATCCACTAC

TABLE 1 421/467

Sequence 2581

Sequence 2582

Sequence 2583

AGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGCCAGGTACGCGGGGGCACTCAG
GGAGCTCAGATTTTGAGACAGTNGCTGGCCGATGCTCCCAGNTGAATAAAGCCCTTCCTT
CTACNAAAAAAGAAANNGAAAAAAGAANACAGGATATCTGAAATTAAGACNGCNGATGGA
GNNGTTTCTNNAAATGACAGGGNCCAAGGNGNGACCACGGGACCAAGNGGCTGAACTGGN
ATGAAGTTAAGAAGCAGNAANAAACATCCNATAATATGGTGATCAGNTCAACAGAATGAC
ATATTNACCATGTNCCCNAGGAGGNGATGACTGAGATTTCAAATT
Sequence 2584

TTAGGGCGAATTGGAGCTCCCGCGGTGGCGGCCGAGGTACGCTGGATAGCCTCCAGGCC AGAAAGAGAGAGTAAGCGCGAGCACAGCTAAGGCCACGGAGCGAGACATCTNGGCCCGAA TGCTGTCAGCTTCAGGAATGCCCCCCCGCGTACTTTTTTT

Sequence 2585

CGGCTGCGGCGAGCCGGTATCAGCCTNACTCAAAGGGCGGGTAATACCGGGTTATCCACA AGAATCAGGGGAATAACCGCAAGGAAAAGAACATGTGGAGCCNAAAAGGCCAGCAAAAG GCCAGGGAAACCCGTTNAAAAAGGCCCGCGGTTGCTTGGGCGTTTTTTCCAATAGGGCTT NCGNCCCCC

Sequence 2586

TATAGGGCGAATTGGAGCTCCCCGCGGTGGCGCCCCGGGCAGGTACGCGGGGGGGATT TCCGCTGAGTGACCCTTACAAGTCCTTCTTGATCCTGAACTGGGTTAGGTGCCGCTGTTG CTGCTCGTGTTGGATCTAGAACCGTAGCCAGACATGGGACTGGAGGACGAGCAAAAGATG CTTACCGAATCCCGGAGATCCTGAGGAGGAGGAAGAGGAAGAGGAAGTTAGTGGATCC CCTAACAACAGTGAGAGAGCAATGCGAGCAGTTGGAGAAATGTGTAA Sequence 2587

TABLE 1 422/467

AGGCTGGAGTGCAGTGGCGTGATCTGCAACCTCTGCCCCCGGGTTCAAGCGATTCTCCT GCCTNAGCCTCCGAGTAGCTGAGATTACAGGTGCGCGCCACCACACTTGGCTAATTTTT GTATTATTAGTAGAGACGGGGTTTCGGCATGTTGGCTAGGCCGGTCTCTCCTGACCTCAG GGGGATCAGCCC

Sequence 2588

TAGGGCGAATTGGAGCTCCCCGCGGNGGCGGNCGNNGNACANAATAANGCCTGTCACATA
TTAAGTNTGTAATAACGCATTTATTATTACTTATCAGGGTATGATTTATGAATTGNGGAA
CCTGNGATTATGGGAGAGTCTGGCTTCAATCAAGGGCTGAAATTCCACTGACAT
CTTTTNCTTCCCCATCCCCGGATTCTGTCCTGCAACAGGGTAACAAGAAGGGGCCCTTAG
GCCGTTGGGACTTTGATACCCAGNAAGAATACAGCGAGTATATGAACAACAAAGAAGCTT
TNCCCAANGNTGCATTNCAGTATGGTNTCAAAATGTCTGAAGGGCGGAAAACCA
Sequence 2589

Sequence 2590

Sequence 2591

Sequence 2592

CTATAGGCGAATTGGAGCTCCCCGCGGTGGCGGCCCCCGGGCAGGTACGCGGGGGCTG
ACTCCTTTTTCGGACTCAGTCTGCCTGCACCCATGTGATTAAAAAGCTTTATTGNTCACA
CAAAGCCTGTTTGGTTATCTCTTCACACAGACATGCGTGACACTTGGTGCTGAAGACCCG
GGATGGGGGACTCCTTCGGGAGACTGGTCCCCTGTCCTCACCCTCACTCCATGAGGAGAT
CCACCTACAACCTCGGGTCCTCAGTCCAACCAGCCTAAGGAACATNTNACCAATTTCAAA
TCAGATCTTGGCTTAGTGGCTGAAGACTGATGCTGCCCAATTACCTCGGAAGCCTCCTGG
ACCATCACAGATACTTTGAGTAATCTCTTATAGTGGAAGGATGCAAAGTTGGAATAA
Sequence 2593

TABLE 1 423/467

CCGGGCANGGTACCATATGTTTCAAAGTAGCTGTTCATCCACAGATAAAGAGATCAAGAA ACTCTCATATACATACACTAGGAAATATTCTCCAGCCATCAAAATAATGAAGCAGTGTCA TTTAGAGCAACACAGATGAACCGCGGAGACCTGCCTCCTACTCCACCATCACATGGAACC CACCACTGCTTCTCCGAAGCTCGCTCTGACCACGCCGCTGCTGCAGGGGCCTCGCAG GAAGTGCAGTCTCCCCCGCGTACCTN

Sequence 2594

Sequence 2595

Sequence 2596

Sequence 2597

CCGGGCAGGTACTTCTTGATTTCATCATACAAGACAAGCACAAAAGCACCACCCATGCCT CTGAGAACATNGGACCATGCACCCTTGAAAAAAAGCTTTGCCTNCTTCATCACGAGCAATC CTGAGAACATNGGACCATGCACCCTTGAAAAAAAGCTTTGCCTNCTTCATCACGAGCAATC TTCCGCCAGCAGCCAGCCTGTGTACAGATGGGGTTTTGCCATGTGGACCAGGCT GGTCTCGAACTCCTGGCCTCAAGTGATGCACCTCGGCCTNCCGAAGTGCTGGGATT ATAGGAGTGAGCCACCACGCCCGGCTACAGAGTTGGGTTTTAACAGAAGAGGACCTTGAA TGCTGAAGCTTNACAGGGCGGCCAAACTAACTCGCTGATTTTTGCAAGACCACACCAT GACCAAGCCTGGGCATGCAGCACCCCAGCTCCCATNCATTCACACTGGTTGCTTTGTGAG GTCATTTTGAGAGAGGGCTTTCANAGCCTTTTAATGAGAA

Sequence 2598

AGGTACCTTTGACCCATCATCTTGGGAGGTGGGGAGGACCNCGAGGGNCCAGGCAGGGTG
TAGGGGAATGTATTAGNCCAANGAGATTTCCCTCTTCATCCGCAGCAGNGTATCTATTCT
ATACCTGGCTATGGGAGAAGACCCCTTGCATGGGAGGGACCCCTTGCTATGGCCCCTTTA
AGCCAGGCAGTGGGGATCTACCTGNGGCCCCGGCCTCCCTAAAGTCATTCACATTGAATG
GGGGGATGAAGGNTCGGGACAGTGGCTCATAAGAGCCCGAGTATTGAGCCCTAANCTGTG

TABLE 1 424/467

Sequence 2600

Sequence 2601

Sequence 2602

Sequence 2603

WO 01/070979

TABLE 1 425/467

GGATCCCCCCGGGCTGGCAGGGAAATTCGGATATCNAAGCCTTATCGATACCCGNCCGAACCCTCGANGGGGGGG

Sequence 2604

CTCCCGCGGTGGCGGCCGCCCGGGCAGGTACAGCGTGGAGGGTTTAGGCAGCGTGTTCT
GATTCTTTGCGGGACGCGAGCGCATTTGTGCTTTGCCCGCCGCGCCCTAGGAGGCCTTT
TGAGGCCGCGTAGTCGGTGTTTTTGAACTTACTCTACAGCTTCTGGCAGGCCGTGCGGCG
CCCTGACCCGGCCTCACCATGTTGGTGCTGTTTTGAAACGTCTGTGGGTTACGCCATCTTT
AAGGTTCTAAATGAGAAGAAACTTCAAGAGGTTGATAGTTTATGGAAAGAATTTCAAAACT
CCAGAGAAAGCAAACAAAATAGTAAAGCTAAAACATTTTGAGAAATTTCAGGATACAGCA
GAAGCATTAGCAGCATTCACAGCTCTGATGGAGGGCAAAATCAATAAGCAGCTGAAAAAA
GTTCTGAAGAAAATAGTAAAAGAAGCCCATAAACCGCTGGCAGTAG
Sequence 2605

Sequence 2606

Sequence 2607

Sequence 2608

CGCGGTGGCGGCCGGGCAGGTCAAACGATGTCCCGTGATGACTGGTGGGGCTCATG
TAATCCCCACCTAAGAAAAGTAGAAAGTGCAACTTTATCTTTTAGGTTAATAAGTGCTGA
GAGATGGAGGTTTTTCCTTCTCATTTTGATGGAGATGCCTAGAAAACCTCGCCTGACACT
CTTTGTCCAACGCAGGATAGAGAACATAGCAACAGAAAGGGTGAGGCAAAAGGCATGGCT
GGTNAAAAGGCACTGCATGTTATTAAGGATGNGGGGCCTGGTCCTGTTCGNTTCACATGT
TTTTCTTNTTTTTATACAGAAATAGGAATCTACCAGACAGTAATAAATGCCACTTCTCAC

TABLE 1 426/467

Sequence 2610

GCTCCCGGGTGGCGGCCGCCGGGCAGGTACAATGAGATGGATACAATTAGTNAAAC CTTAAAATTAAAAAAGCTGTAGACAACAGAAGGNAAACTGGAAATCCATTTACAATTCAA AAGAACTCACTAATAACAAAATTAATGTTCATCAACTTCATTTATAATCCATTTNGGCCT ACATNGCNTAACTAAANTGACACATGTCCCCGGGGGCTGCAGGCGTNGCNCCAATCTTCG CTCTGAGGNGCTNTCTTAACCGNNANACCCTGGAAGCGGGCAAGTCTCTTGCTGTGTCGG GACCTTGCAGNCCCTGGCCCTTCCGCCACCATGGGAATACCTNGGGCCGTTCTAGAACTA GGTGGGATCCCCCGGGCTGNAGGGAATNCNNTATCANGCTTATCGATNCCGTCGACCTTG AGGGGGGGGCCCG

Sequence 2611

CCGCGGTGGCGGCCGAGGTACCAAGTGTGGGAAGATGTTGAGCAACTGGAACTCATGCGT GGCAGGTAGGGATGTAAAATGGCACAAAGACTTTGTAAAATACTTTGGCAAATTNNNAAA AAGNAAACACATAGCTACCATACAACCCAGCCATCCCACTCCAGTATTTAACCCAGGTGA AATGAAAACTTATGTCCAAACAAAGACTTGTACTTTTCTATGATGACCCGGGCCGGCTTC TTTAACGNTTTTNGGTGCGAACCGCNGCCCATGTTGGCGGGTCCTTGGTAAAAGACCCCG CGTCCTGCCCGGGCGGCCGN

Sequence 2612

Sequence 2613

GAAACCTGTCGTGCCCAGCTGCATTTANTGAATCGGCCAACGCGCCGGGGAAGAGGCGGT TTGCGTATTGGGGCGCTCTTTCCGCTTTCCTCGCTCACTGACTCGCTTGCGCTCGGGTCC GTTCGG

Sequence 2614

TABLE 1 427/467

TTGAACCCAGTGCCCGTTCCTTGCAGATCTGCGAACAGTGGGCACCAGCCTCTAGTCTCA AGTGTGAGGTTTGACTCCAGGACGNTGAATTTA

Sequence 2615

Sequence 2618

WO 01/070979 PCT/US01/09126

TABLE 1 428/467

GCAGGCTTAGGGAGCAGGAAAGCATACAGGTGTAGCAGCCTTTCCAGCTGATCCCCATGC CCTGCTGCACCTGGAGGGCTGGAACAAGCTATTCTCATATTGGGGAAAAGGGCTGA Sequence 2620

Sequence 2623

Sequence 2624

WO 01/070979 PCT/US01/09126

TABLE 1 429/467

AGGAAATTAAACGTTTCATGAGTTAAG

Sequence 2625

Sequence 2627

GCTCCCGCGGTGGCGGCCGNGGTACAGATAATAACATCTGATATCCACATGGGGTCTGG AGGTGCNAGCCACCTTCCTTTCATCCCACGGTCTCACAGCAGCCCTGGAAAGAGGCTGCT CTCTGTTGGAGGCTAAGGGCCAGTGTTGGAAGGAGCTCTGGTGGAAAAGTGTGGTCTGCA TGANGGGCTCCCATGAATNAGAGGATAGGGGTGGCNGGTACCTGCCCG Sequence 2628

ACTACTTAGGGCGAATTGGAGCTCCCGCGGTGGCGGCCCGAGGTACCTCATCCCCTCAG
TGACTAAGAATTGCAGNATTTAAGAGGTAGCAGGAATGGGCTGAGAGTGGTGTTTGCTTT
CTCCACCAGAAGGGCACACTTTCATCTAATTTGGGGTATCACTGAGCTGAAGACAAAGAG
AAGGGGGAGAAAACCTANCAGACCACCATGTGCTATGGGAAGTGTGCACGATGCATCGGA
CATTCTCTGGTGGGGCTCGCCCTCCTGTGCATNGCGGCTAATATTTTGCTTTACTTTCCC
AATGGGGAAACAAAGTATGCCTCCGAAAACCACCTCAGCCGCTTCGTGTGGTTCTTTTCT
GGCATCGTAGGAGGTGGCCTGCTGATGCTCCTGCCAGCATTTGTCTTCATTGGGCTGGAA
CAGGATGACTGCTGTGGCCATGAAAACTGTGGCAAACGATGTGCGATGCTT
TCTTCTGTATTGGCTGCTCTCATTGGA

Sequence 2630

TABLE 1 430/467

GGAATCACAAGAGGGAGTTAGGCACTNTACACAACTTC

Sequence 2631

Sequence 2632

GGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACCTGTGGATATCATACGAAAGTGT AGTTTCAAAGGAGTGGACAAACGATACCTACAGTTTGATATTAAGGCCTTTGGNGAAAA TAATCCTGCCATTAAATGGTGTCCTACTCCAGGCTGTGACAGAGCAGTAAGACTAACGAA ACAAGGGTCAAATACATCTGGATCTGATACACTCAGCTTCCCATTGCTGAGAGCTCCTGC TGTTGATTGTGGAAAAAGGACACCTCTTCTGCTGGGAGTGCCTTGGTGAAGCACATGAGCC TTGTGACTGCCAAACATGGAAGAATTGGCTGCAAAAAAATAACCGAAATGAAACCAG Sequence 2633

Sequence 2634

Sequence 2635

CTCCCCGCGGTGGCGGCCGAGGTACTCTCCGCCTAAGTCCATAGAGAGGCTAACACCCT TCTAGTTTATTAGTCTTTGNTAAACCTATGAAATTCTGAATNTAATGGCTANNTTATATG CANNGTGGAGGNCACNCAAAAATGTTTCTCTCAACAGCTGTGATAAGTATAGGCTTATTT TGATGTCTAAAGATCTGNTACCTGTATCTGNTTTCATCTTTCAACACAAATTCATGGGAA NNTTAACTATGNNCCTGTGNTCNGGACAAGTGTGCATGAGAACATCATNCACTAAGTTTA TCATNAAATGGGAAANGAAGCAGACNTTTTAAAAAAGCACCCAAACCGGCCGCTCTAGAAC TAGTGGA

Sequence 2636

AGGTACGCGGGGGCTGACTCTCTCTCAGATTCAGCCCAGTTGCACCCAAGTAAAATAAA CAGTCTTGTTGCTCACACAAAGCCTGTTGGTGGACTCTCTTCATATGGACTCATGTGACA TTTGGNGCCGAAGACCTGAGACAGGAGGACTCCTTTGGGAGACCGGCCCCTGTCCTCGCC CTNTTTCATGAGATCCACCCATGACCTTGGGGTTCCTCANCCCAGCNCGAANGAACTTCT TCACCAANTTTTAAATCGGGGACCGCAAAGCCAACAAGAATGAAGAAGTGNCCAGGTATG GTGGCTCATGCCTGTAATCCCAAGCACTTAGGGAGGCCGAGGAGGAAGAATTGCTTGAGG CCNAGGAATCCCANACCAGCCTTGGACAACATGGCAAAATNCCANTNTTTTCNAATNANA TTAAAGNAAANAAATTAAAGTTACCTGCCTNGGCGGGNCGTTCTAGNAACTAGTTGGANC CCCCCGG

Sequence 2637

TABLE 1 431/467

Sequence 2638

Sequence 2639

TGGGCTCCCGGGTGGCGGCCGAGGTACTAGAAACTTTCCAAGGAGTCTTGGGTGTGTAGCCAAGAGGAGCCATGAGCTATGGACTCCTCAAGCACGGGAAGAGAGGAGTGTGTGCTGAGACAGAGAGGAGCCCTGCCCTCTGTCCACTAGCGAGAATCCCTAGCTGCCCCAGCCCAGTCTTTCTCCCCGGCATTCACAAACTTTGCAAGCGTTGGTCCAGGGCCCTTCTCCAGATCTGTTNCAACTTTGNAGAGTGAAGGGCTTGAGCATACGGGGGAAGAGAGTCTGCATNANGTTAGGGGGAAAACTTTTAAAAGATACCCTCATTGTGTCAAAAGAAGTGTGCCAATCTATTTTTGTATCAGCATTGGGAAGNGCACTTTCCCCTGGGGCCGTGTGGGTGNGTGAATGTGCAAGTGTCTGAGAGAGTACTGCATCAAGCCCTCAAGAGCCAGTCCCGCCCTTTTACAGAGCANTCCCTTATCCTGGGGCCATGGGTCAGGCCTTCAA

CCCCGCGGTGGCGGCCGANGTACGCGGGGGACTTCGGGCTTGTTCGCTGGTGGCGTNNGA GCCNAGCCCGGACTGGTCAGGATNGATCACGGACGTGCAACTCGCCATNTGNNGCCAACA TGCTGGGCGTGTCGCTCTTCTTGNTTGTNGATCTCTATCACTTACGTGGNCNGTCAAACA ATTCCAAGAATGCANGAATGAAAGTTGGCGCTTTCTTCCGCCCCANGGTCCCAGGACATT AGTCTGNGGCANGATNGAGGGGTNTNGAAGGGGCCTTTCACACTTAACTTTATTCCTTTT ACCCTTCACAACATACAAAAGGCAACTTACACCTGGGATTTTTNCAAAACAACCTTTTAT TTCCCTCAGANGNCTTTCCNTTAATCCCTATGGAACAAAGAANGCTNGNCCACTTGAANT AGGGGCCCNAGTATAGGGGGCTTTGCTTTTCTACTTCCNTC

Sequence 2642

Sequence 2641

Sequence 2643

CAATTGGACTCCCCGCGGTGGCGGCCGAGGTACCTTATGTAGCCCAAGAAATTCAAGAGG

TABLE 1 432/467

AAATTGATGGGGCTCCTTCAGGAGCAGCGTGCAGATATGGACCAGTTCACTGCCTCAATC
TCAGAGACCCCTGTGGACAGTCCGGGTGAGCTCTGAGGAGAGTGAGGAGATCCCACCGTT
CCACCCNTTCCACCCCTTCCNAGCCCTACCTGAGAACGAAGACACTCAACCCGGAGTTTG
TACCTGCCCGGGCTGGCNCGCTTCTAGAAACTAGTTGGATCCCCCGGGCTGCAGGGAATT
CGATATCAAGGCTTATCCGATACCGTCCGACCTCGAG

Sequence 2644

Sequence 2645

CCGGCAGGTACCAATCATATAATNTATATAACATTGCTATCAGACTAAAAACACATTCTT
AGCTAAAGATAACTTACCATTTAGAAGTCAAAATGCAGGGAATCTTACTCCTGTTTCCAT
TTTNTGNCCCNCTTGCTTCACTCGNGTATGNCATGCTCTATCTCTTCTCCTATGCAGACT
TTANGNCNGTNGGCCATTAANTCTTGAAGAAATTTCCTTCNNTCTTGCTGTCACNTACCA
NNTTANTTGGTCTGCGTGCAACAAGAAGGNGTATTATANNAAAAAAGTTCTTGCTTAACC
ATTCANGATTAAATAAANAAAAAAATTCCTTTGTTTNAACATTTTGNTATTTTTTGCACA
TACACCAAACTTTTTTAATTGCCTTTTNCANAGNNCCTTTCCCTCCAAAAAAATAAAAAAC
AAAAAATCTTCAATCNACATAAAAATCAAACACCTGTATTGATCCATGTTCATGCTAAGCT
GGGNAA

Sequence 2646

ACTCCCGCGGTGGCGCGAGGTACAAGCGCTTTGAATATCATGGGCACCATGACTGTGA
CCCTACAGGTAGGATTGGATCACTCCATGAGAGTAGCCGGCAGGTTTCTACAATGGCCTG
GGAATGGACTGATTATTTTTATACATTTTCTGGCCTGAGAGAAAGCCAAGGTCCCCTGCT
GTTCACAGCAACCCTGCCTGGGAGCTTGGAATCTTGGTAAATCTGCCCCGTTNGGATCTA
TTGGAGGTAGGCTCACCCTTTTTNGTCTTTTTGTGGGAAAATTAAAGAGAAATAATTNTCA
GACNTATCATCACCTCCAGTGGAACTACAGAANACCTGGACCCANCTGCACTATTTTAAT
GTAAAAATAACAATATGGCCAGGGTGCAGTGGCTCACGCCTGTAATNCNATCACTTTGAG
CAGCCAAGGCGGGCGGATCACGAGGTCAGGAGATTAAGACCATCCTGGCCAATATGGGTG
AAACCCTGTNTTTACTAAAATACAAAAAAATTAACTGGGCATNGTNTTGCGTGCCTGTNG
TCCCANCTACTTGGGANGGCTGNGACCAGGGGAATTGCTTTGAACCCCGNANGGCNTAGA
ATTGCANTGAGCCNNAATCANGCNTCTGACTTCTACCTNGGCGACAGGANTGGGACNTTT
TNTTAAAAAA

Sequence 2647

AGGTACCCTATATTCTTCTTGATTTCTAGCCTTTTATTGGCTCTCAGATTGCCAGAGTTG GGACTCAATAGTAAGCANCCATTCTGGTGAGGCGGAAGNGATNCTACCAGGGTGNGTTNT CATGACAAGCANAATCACTGNGTTTTTCTCTCTACTCTGTGGCATANGACTCTATGCCAT AGAGNGACGTGTGAAAGGCTTGAGGCT

Sequence 2648

Sequence 2649

TABLE 1 433/467

Sequence 2650

Sequence 2651

Sequence 2652

Sequence 2653

Sequence 2654

TAGGGCGAATTGGAGCTCCCCGCGGTGCCGCGCGGGGTACGCGGGGGGGTAAAGGTATAGT
AGTTGGCAGCAGAATGGACCCATTGAGGATAACTATAAAATTACNGAAAATATTTAAATG
CAACTTATTGCTATAGAAGCAAAGAGGACTAAAGGGCAAAATTCTAGAGAGTGGTAAATC
TCAGAAAGCACAAGCATAAAATGCAGCTCTGGGGGCCCTTTCCACTTCTGGCTATAGGGA
AGAACCTGAATACTGAACTTGATTCAGGCAGAGGACCATAACCTGGGGGTCAGGGGAAGG
CATGGGGGGGCCAGAAACCAGAAGAACGATCAAGACTGCAATGAAAAAAATGGATACAT
TAGGAGCTTCAAACACATATAATTTCTCAAGAAATTTCCAGATTCTCATGCTGCATAGGG

TABLE 1 434/467

CAGGAGCCTGAAAAGCTAATTTGAGAAGATAATAAGTTGGATTTTTGNTTTGTTTTGCAT TTTGCAAGTACCTGCCCGTGCCGGC

Sequence 2655

AGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGCCCGGGGAGGTACCACTGAATCCAAGG CTCTCTTGGGTAGCCTATGTGCCTCTTGGATGGTATGTGGAAGCCAAGGACTGTCTGAAC GTGCTGAACAAGAGCAACGAGGGGAAAGAATTACTCGTCCCACTGACGAGTTCTATGTAT GTCCCTGGGAAGCTGCATGATGTGGAACACGTGCTCATCGATGTGGGAACTGGGTACCT Sequence 2656

Sequence 2657

Sequence 2658

Sequence 2659

Sequence 2660

CTACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACTGGAACAGGGATAAG TTCTTGGATAAGGTGCCAACATACCTATAAAAGCTGATTTTTGAGTAAATTATTGATTCT AACATATGTAATGGATTTGGTGTGATAATTTTCTGATCTTTAACTATAAGTGACTTTTTA

TABLE 1 435/467

TTCTCCACCAGAAAAGATAAATGACTGAGAATGTAAGTCTGCGCTCTGATTAACACAATG GAGAAACGGAAAAACTATCTCTGTTAAAAACTGATTCCTGTCATTCTTCTGATATCAAAT AAGAGGAAGGAAAATAAACTTTTTGTGTGTAGATAGAAAAACATACCTGAGGCCAGGTGC AGTGGATCACGCCTGTAATCCCAGCACTTTGGGAGGCCAAGGCGGGCAGATCAGCTGAGG TCAGGAGTTCGAGACCAGCCTGGCCAACATGGTGAAATCACGTCTCTACTAAAAATACAA AAATTATCTGGGTGTAGTGGTGCCTGTAATCCCAGNTACTCGGGAGGCTGAGGCAG GAGAATCACTTTAATTC

Sequence 2661

Sequence 2662

AGTTCGGTGTAGGTCGTTTCGCTCCAAGCTGGGCTTGTGGTGCACNGAACCCCCGTTTT CAGCCCGACCCGGNTGCGCCTTATTCCGGTAACTATTCGTTCTTTGAGTCCCAACCC Sequence 2664

Sequence 2665

Sequence 2666

GGCGAATTGGAGCTCCCCGCGGTGGCGCCGAGGTACAATGAGGCTTGGCTCTGTGTGAT
GCACTCTAACCAGCCCACACTTCAGCAGCGGCATCATTTGGATTCAGGGAGAGTTTCTGC
AGCATGAAGGAGTAGGAAGAACACAGGGTGAGTTCACAGGAATCCCTACTTTTCCATGTG
ACCTTGTTTGGCCTGAAGTGATTTTCTTGACCTCTCTGGGCCTGACTTTCCTCATCTGTA
AAGTGGAGGGTTTGAAAATATCACAGAAAACAAAATACCTTAAAGGATGCTCTGGCACAC
AGCAGGTATTTCCATATAATGATACCTCCCATTCCTTTTTATGTGAGCTATATCCCCTGA
AACCCAGGTTTGACTAAATTGAGACCAACTTTCATAATATACACAATGACTGNTAGATAT
GAATTTTGGTGTGTGAAGATGGGGAGTGAAAAAAAGTAGAAAAAGTCAAATCTCATTGAA
TAAAAAAGGG

Sequence 2667

TABLE 1 436/467

NGCTCTGTTGCCCAGGCTGGAGTGCAGCGGTGCGATCTTGGCTCACTGCAAGCTCCGCCT CCCGGGTTCACGCCATTCTCCTGCCTNAGCCTCCCAAGGAGCTGGGACTACAGGCTCCCG CCACCACGCCTGGCTAATTTTTTTGTATTTTTAGTAAAGACGGGTTTCATCGTGTTAGCC AGGATGGTCTCGATCTCCTGACCTNATGATCCGCCCGCTCTGTCTTCCCAAAGNGCTGGN ATNACAGGGCCTGANCCATTGTGCCCAGCCAAANTGTNCCTTTGNAAAGTTNGCGAAATC AGATTTTGTTTCCCAATAGAACCAAAATTTTTATGAGGGATGCTAGCATTTTTCCAAGGC ATANTAATTAGTTTACAACCTGAANAAATATTATGTTTTGTANTAGATAAATATTAAGGT GNGCATTTTAA

Sequence 2668

Sequence 2669

Sequence 2670

TACGAGCCATTTACAAAAAATCGACCGCTTCAAGTCAGAGGGTGGCNGAAAACCCGACAGGGACTATTAAAGAATACCAAGGNCGTTTCCCCCCTGGGNAAGCTCCCCTCGTGCCGCTCTTTCTNGTTTCCCGAACCCCTGTCCGCTTTANNCGGGAATACCCTGGTCCCNGCCTTTTTCTTCCCTTTTC

Sequence 2673

TABLE 1 437/467

Sequence 2674

CCGCGGTGGCCGACGNACCNGGTNCTCTGTGGGATACNCATTAGAGTTGCTCGNTGG ANATGGAATGATGGTGGGGTGCATTTNANCATGGCTGANTGCTTTCTGCTTAAGGACCTG ATGTATTAATGCTCTCCANGTCATTCATATTTGGGGGAAGGAACAAAGAAGGGTACCTN Sequence 2675

TAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACAGTAGCATGATCTTGGCTTA
CTGCAACCTCCGCCTCCCTGGTTCAAGCAATTCTCCTGCCTCAGCCTNCCGAATAGCTGG
GATTACAGGCATGCACCACCATACCCGGCTAATTTTTGTATTTTTAGGAAGAGATGGGGT
TTCACCATGTTGGCCAGGCTGGTCTCGAACTCCTGACCTCAGGTGATTCACCCGTCTTGG
CCTCCCAAAGTGCTGGGATTACAGGTGTGAGCCACTGTGCCCGGCCTCCATTACACCTCT
TTATTCTAGTTCAACTCAGACCGTGAAGTTAGCATACAGGTCCTCAGGAGTTTGAGGCCA
CTTTCCAAGGATAAGGGCCACCTTCAAGGGCACATCTTGCCCTTAAACAATTAAATTTNT
GAAAGCTTTTGGGAAAAGGGGNNGAACATGCCTTTT

Sequence 2677

Sequence 2676

Sequence 2679

TAGGGCGAATTGGAGCTCNCCGCGGTGGCGGCCGAGGTACTAACANGGGTGTCTGGTCTT
AGAAGCCTCCCTTCAGATCCCAGCTGACCCTGGTGACTGCCTGGCCTTGATGTTGGCTGC
AGCCTTCTGATAGAACCACATGGATTCCACCCACAGCTGGCCAGGCTTGTTACATGGGTC
AAGGGAATACAAATGGCCCCCCCCAGGGAGCAGGTGTTGGCCTCAGTTTTCAGGGACCC
TTGGTGTTGCTCCTTACCTAGAGCCCATTAATCTACCCCATNAACTCTCTTGCCATGAAA
AGCCATCTTCCAGGAGCCCTGTTTT

Sequence 2680

AGGTACTCAAAGACGAATCATGAAAAAGAAAAAAACTTTATTTCAAACAGGTTCAGTGAT

TABLE 1 438/467

Sequence 2681

Sequence 2682

CCTCAGATTTTGGGCCTAGGAAGGTAGGTGATTTAAACTCACTGAAAGCATGTACACCTT GCTGTTGCTGCTGCCACTGCTGCTGTTTCATCTGTTCCTGCCGCTGGAATCGT GGAGGTAAAGACTTCTGAAACTGTTTGAAATAGCCAGATAATACAGC Sequence 2683

Sequence 2684

Sequence 2685

CCGCGGTGGCGGCCGAGGTACTCCAACCCAAGCAACAGAGCAAGACCCTGTCTCAAAACA

TABLE 1 439/467

AAACAAAACAAAACAAAAAAAAAAATGAGGTAGGCATGTTTTATTCCCATCTTACAGAT GAGGAGACTGAGGCAATAATAATTCAATGGCTTATCTAAAGTCACAAAGCTAGTAAGGAG CAAAATCCAGTTNTGTCTGCTTCCAGCCCACCTTGTCCCACTTGCTTCTTTATT Sequence 2687

AACACTACTTAGGGCGAATTGGAGCTCNCCGCGGTGGCGGCCGCCCGGGCAGGTACAGTG GAGAAAGAAGGGGGACCCCACCAGGGCTATGGAGACAGTAGAGGCAGGACTGAACCGT CAGCAAAGATTAAAAGGATGACCTGAGGCTGGCAACCACAAAACC Sequence 2889

Sequence 2690

TATACGACTACTATAGGGCGAATTGGAGCTCNCCGCGGTGGCGGCCGCCCGGGCAGGACG
GGAAGGATTCCTGCCAGGGTGATTCTGGGGGTCCGCTGGTATGTGGAGACCACCTCCGAG
GCCTTGTGTCATGGGGTAACATCCCCTGTGGATCAAAGGAGAAAGCCAGGAGTCTACACC
AACGTCTNGAGATCACGAACTGGGATCCAAAAAACCATTCAGGCCAAGTGACCCTTNACA
TGTGACATTTTACCTTCCGACCTACCACCCCACTTGACTGGTTTCAGAACGTTTTTNACC
TAAACCTTGGCTTTCCCTTNTNTNNTGGCCAGNTTTTNACCCTGATGCGTAAAAAAACGCA
ACCGACGTGAGGGGTCCTGANTNTCCCTGGGNTTTACCCCCAACTCCATNCTTNGATTAAT
GGGGG

Sequence 2691

Sequence 2692

TABLE 1 440/467

ACAATTTCACCTANGTAAAATATTGATGTCATAACCAAACTATATGGCCCCGTTTCATAA AGGTTACTATATTCTATAGAGAGTGAAGAGGTGGCCTTTCTATCCCAGCTTACCCTATTC TTGTTATTGTTCAAATTCTCCTGAAGCTTGCATAACTAGCTGCCATCAGGTAAATGCTAT TGGCTAGCAGAAGACTGCAGTTCTGTTAATATTAGAACCAGCAGGGGGAACTTGGGAACTTGACATTAAAAAATCTAGAAACGGAATTTTA

Sequence 2694

Sequence 2695

GAGCTCCCCGCGGTGGCGGCCGAGGTACACCTGTGGTCCCAGTTACTCCAGAGGCTGAAG
TGAGAGAGTCTCGTGAGCCCAGAAAGTTGAGGCTGCAGTAAGCTGAGCCATGATTGCACC
ACTGCACTGTAGCCTGTCTACAAACAAATAAACGAAAAAACAAAAAGACTTGTGAAAAGT
GCTGATTTTTAATTAGGAAAAGATTAAACATTGGATAGTCATGGAATTGTTTACTGAACA
TTAGAAATTGGTTGCAAGGGTCTATGCTTCTGTAAAATAAA

Sequence 2696

Sequence 2697

Sequence 2698

TABLE 1 441/467

Sequence 2700

Sequence 2701

CACTACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACCTTTGCTCACCAA GCTCTTGAGGCCAAGCTTGATACGGCTGTTTTTTTTCTACATCGTAGCCAGCAGCCGC AAGCGCTTTCTTAAGCGCGGCCAGAGAAAACGCCGCTGCGCTCCTTAGAAGCTGCCACTG CCTTGGTGATAAGCTCAGATACTGGGGGTCCGGATGCTTTGCGTTTCCCAGCAGTTGCGC CTGCCTTCTTCGCCTTTTTCTTCACAAGGTGTTTTTTCTCCGGGTGCAGGAATGGTAGGA GCAAGTGGAGCAGTCTCCGACATGTTTTTGTCTTCCCAGAAAAGACAATAAGTAATCTCA AACTGTCAGAACAGCATGTCCCCCGCGTACCTGCCCGGGCGCCGCTCTAGAACTAGGTG

Sequence 2702

Sequence 2706

CACTACTTAGGGCNATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACTGAGCTNACCACTT CTAAGAAACTCCAANAAAGGAANCATGTGTNTTNTATTCTGACTTAACTTNATTTGTCAT AAGGTTTGGATATTAATTTCAAGGGGAGTTGAAATANTGNNAGATGGAGAANAGTGAATG AGNTTCTACCACTCTNTACTAATCTCACTATTTGNATTGAGCCCAAAATAACTATGAAAG

TABLE 1 442/467

GAGACCGAAAATTTGNGACAAAGGATTGNGAAGAGCTNTCCATNTTCATGATGTT Sequence 2707

NCACTACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACGGGGAGTGGGGG TGAAGCGTGTTCTCTACATAGGCAACACAGCCGCCTAAGTCACAAAGTCAGTGGTCGGCC GAGGTACTTTGGTAAGGAGATAGGGAAGGAATTAAGGCTATTACTCTGAAGAAAGTTGGG GGGCCAGGGCTCCTATTTTTTTTGCTGAGGAGATGGAAGATCAGGGCTTGTATTCAATAAG AATGGGAGGGCCAGGGGATGCCTGGCAAAAGCCTTGCACTGTGAGGTGCAGGTAGAGGC TTTTATTCTGGTGAGAGGACATGGACTCTCTCTCCCCTCAGGTAACTGTGCCCTGTAC CTGCCCG

Sequence 2708

GAATTGGAGCTCCCGCGGTGGCGGCCGAGGTCTNAATTNTTTTNCCCTTNNNNGAGACG ACCTTTTTTGGANATTTTTTTATTTTTTTGGCAAATTTGATCTTACCCTTTACCAGTTCTA TAATTTGGNTAAAAGCTGATTATGTCCTACAATGNCAAAGTCAGCTAACTGNCGTCTACT TAAGACTTNTGGNCATTTCCAACTTATAGAGGAAGGGNGNCTCTAAAATCTCTTCTTCAG AAGGCACCTCACTTNTCANACTTAAAANNCCACATCAAGTGTTCCATTAAAAGAAGATAN GGCATTCTGAGTGCAAACAAATGGGGGCTTNTTAAACTA Sequence 2709

Sequence 2710

Sequence 2711

CCGGGCAGGTACCTTATTACATATGATTTTTATTAGTTTCTGGAGGCAAANGGAATTTTT
ATTTTAAAATCAAAATCTATTTTAAAAGAAATAGTTNTCAAAAAGACAACNGATGACTGG
GTGNGGNGGTGNGTGCCTGTAGNTCAGGCTGCTCGGGAGACAGAGGCAGGAGAACCACTT
GAGGCCAGTTCAGTCTAGCCTGGGTAACATAGCAGGACCCTGTCCCTAAAATAATAAAAA
AATTTAAAAACCACAATAAATGTGAGTTACAAAAAAAAGTGTAACTTATGAAAAGGTCCGT
AATTTTATTATTGGACCCTTTGTTAAGGAGCTCAANTAATTTTCAGGGAAGCAAGGGAGG
TATCACCCATTTCTTGAGTTNAATACCAAATTTTCAAACCTAAATCTTTTAATTTT

TABLE 1 443/467

Sequence 2714

Sequence 2715

Sequence 2716

Sequence 2717

Sequence 2718

TABLE 1 444/467

Sequence 2719

Sequence 2720

AGGTACACTCGCCAGCGGTTTTGCCACAGGAGTGTACGGGAACAAAGGAGACAGGCTCAT
TTATAATCTGACGCGGNCACCCTNCTGCTGCGTTCGGTTTCCATTGGCTGGGACNGNACC
TCACCTTCTGTATTTGTCCCGACTGGCTAGCACTTAGAACTTTTTAAAAGAGGCAAAGGC
ATACAGAGANCAAAGGAAGGAAGGAAGTNACTTGTGGAATATTGAGAAAGGTAAAAACACC
TTTAAATAAGGAAGAAGAACAGGCTATGACCTAATGCTTGTTNGGATCAGTATAAGCATG
TTAGGGCAAATATTTANGCTAAATTGTGGGAGCTAAGAACATAAAGTATATTGATTTTTT
ATTATGGCTAGCA

Sequence 2721

AGGTACAATTTAATTTTTCTGCTTGCCCNGGAAACAAAGCTTCTGTGGAACCATGGAAGA AGATGAAAATGAGACTGGCAAAGAACAAATGCTGAATCTGAAGAAGAAGAACAAATGCTGAATCTGAAGAAGAACAACTTTGGG CAAATAATCTGCATACTTTTAATTGGGAATAAGATGGAAAATATGAATGCTAAATCAAAT TTTTTAANNNATACACCACACGATACGACTCCCCGCGTACATCTTTGCTGTGGGCTCACAG ATTGTTCCTCCCATTCCCCTTGCCGCTTTTTGCCTATCGATGGGTAGCAAGAGTCTTTGA AATAAGCCCATTTGAGCCCTGGATAACAAGGGATAAAGTGGAGCGGATGCACATCACAGA CATGAAATTGCCTCACC

Sequence 2722

Sequence 2723

Sequence 2724

TABLE 1 445/467

Sequence 2725

GCGATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACACAACTCCACTAACCTGGGAACCTT GCCCCCATCCCCCATAGCANCCACAGCGAGACCTGCCCAAGGAGAGTCTGAGCTCAGACA TGCCTAGCCCTGCCCCAACTTGATGGGCCTTCCTATCTACCCTGGTAGCTGAAGGCAAAG GACATATACCCTTGGGAGTTCTAGGGCCCCGCCCATCGCCAGTTCCTCTCCATACTACCA CAGCTGATGCTCTCTGGGAAGTGCCACCTCCCAGCAGCAGCCAATCAGCACAAAAATAG AACATTAAACCACCAAAGCTAANAACCCTCAGAGAATCCATTTACCCCCCT Sequence 2729

Sequence 2730

TABLE 1 446/467

GGAGCTCNCCGCGGTGGCGGCCGCCCGGGCAGGTACTAGTTATTTTAAATTCCACTCATA
ACTTATCGGCCAAAAGTAGTCACATGGGTCCACNTAATNACAAGNGGAGCGGGAAGTGCA
ATCCTACCTTGCCTGGGGAAGGTATAGAGATAGACCAGCNCTAATGACTACCACACTTNG
CTAAGGTNACATAATAAATAAGCATCAGGACATTATGTGTGGNGGCTCATGTCTATAATC
CCAGCNCTT

Sequence 2732

CTATAGGGCGNATTGNAGCTCCCCGCGGTGGCGGCCGTGNGCNCGGAGNTGGTATTGACA TAGCCTTTGTAGAAACAGTGCTTGAGTTCCGCTTCNTCTTCGGAATAAAACTTGGTCTGA TTCACCCCGGGCGTCCCGAGGAGGGTGACAGTGAACAGTGGAGCGATAAATCCGGCATTG GCGGTGAGATTAAA

Sequence 2733

Sequence 2734

Sequence 2735

TABLE 1 447/467

Sequence 2737

Sequence 2738

Sequence 2739

TNTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACTACGAAGCCATCTTGGCT
CTGTGGAACCAGCTCTACATCAACATGAAGAGCCTGGTGTNCTGGCACTACTGCATGATT
GACATAGAGAAGATCAGGGCCATGACAATCGCCAAGGTATGTCCTCAGGGCCACTTAGGC
TGCCTGGAGGGAGGGCAGCGCTGCCCCCGCAGTGCCTGTGTCCAACAGTTCAACCTTCT
TGCTGTGTAGCAGTGCTTTTGTGTCTCGTNAAGCAAGTCAGCTCACCCCTCCTTAGAGGT
TCTGGTCTGTCCAATAGAGAACGGGNGGGATTAGCATATGGCTGATTATGAGAGAAAGAA
GCAATNCTAATTTAGGGTGGCCTGACAAGCAAGCCAGAATTGCCTGTGGAAAAGTTATTG
CACTCCTGTAAGAATTCTGGACCCTATTGCTCCTTTGATGTAATGGAAAGTTAG
Sequence 2740

TNTAGGGCGAATTGGAGCTCCCCGCGGTGGCGCCCCGGGCAGGTACGCGGGAAGTGA ACTGAGGGCCACCCTGGGAGGAAGCCGACTAGGCGAATTCACTTACTGACCGGCCTGGGC TGCTCTGAGACATGGAGGAAGCCAGTGAAGGTGGAGGAAATGATCGTGTGCGGAACCTGC AAAGTGGGGGTGGGGGGAGTTAANANTATTATCCCCANATTGNGGGGCGGGATCCTGCCC CGGGGGGAAAACTTTGGAACATCTCCGCAATAAGACAGA

Sequence 2741

TABLE 1 448/467

GAGATAGGAGAAGAGAGATCCCTTTCTCGGGGAGAGAAATNCAAGCCGTCCCGATCCT CTTAGGGCTNGGAGGTAAAATCNTTTGATAACTTTGTATTNAAAACTTTGCATCCATAGT ATGCTAAGGCNTTNTTTTANCCCAAAAAATTTTNCCTTAAAAGTTTTTTNGAATTNGCNC AAAAAGGGCCCCNAANACCCAAGNNAAAGGGNNGGNNCTTTTTTTTT Sequence 2743

Sequence 2744

Sequence 2745

CCGGGAGGTGTCCGAACAGGCAGGTTGGTGGGTTAAAGGTCTTAATCTTGACTCGAGATC
TCTCCCCGGAGTTCACAGAGTAGGCGACGAAGCCGAAGCAGCTGGAGCGCGACCCGGAGG
AGTCTGACTTCTCGTTGTCTTCATAATTTTCATTCGTTGCTTTCTTCATGGACTTGCGGC
TGGGGGAGGATCCCCGCTGGTCGCCGAGCANGCGGGCGGGTAAAGGTAGGCCGCGAGAGC
CAGGTTATNGAGAGGAGAGAGGC

Sequence 2746

Sequence 2748

TABLE 1 449/467

TTCTANAACTAGTNGNATCCCCCGGCT

Sequence 2749

CCGGGCAGGTACAACATGAGACATGACGCCCTTCGGGACACATGCCTGAGGTAGTGACAA
TCCAACTTTGGAAGAGTGGAAGCCCTAGTTTCAAATTCAAGCATGCTTTGAGTATAAATT
AAGTTTACCTCTTTTTGCACAGCAACATGGCCAATCTTTCCTAAGCTGCTCAGCTTACAA
GAAAAGGAATCATACTGCTAAGAATTCAAACTTCAGCAGTCATAGGTAAAGTAAGGGAAG
TTTTTAAACCNTATTTTTAGCCCCCNTACCCNGAACCCTNGNAAATTTTNGCNAGGGTT
TTTTCAATTTTTCNAGGGACAGGTTGGGGTTTCNCTTTAAATCCANAGGGCCTTTGGAA
NACCNTGGAANAAACCAGACCCTTTTAAAAAAGG

Sequence 2750

Sequence 2751

CCGGGCGAATTGGAGCTCCCCCNGTGGCGGNCGCCCGGGCAGGTACAATGCTTATAAAA TTCAATAATTTGTATTAAAATACAAAATCCNATAACAACCAGGAGTTCTTCGGAAGAAAA AAAAAATCACAAAACAACCCCAACAGTGGTGAAGAACTA

Sequence 2752

TAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCAAAAGCTCCCAGATTATTTGGAAACCA
TGTTTTCTTCCTAGTCCATGGTAACAAGAAAAAGCCANTGGAAGCATCATTCCAAACAAT
AATCTCCAAAGATGGTGGCAACCAAGTGTCAAATGGGGACTGCAGGCACAGAAGACCA
CCCCAAACCCTGCCTGGGTGGACGAAGCAGGTATGCTAGAATAGTCCTGTCCTGCAGAAT
AGGGAACGGCAGCTTGGTCGATCTGTGCCCTGGAAAAAGAAAATGAGTTGCAATAGAAGT
GACTNTAAGACAGACAATGAACCTACTNTTAAGAGAGAGCAGGGCCACGGTGGCTCA
CGCCTGTATCCCAGCACTTTGGGAGGCTTNAGGCGG

Sequence 2753

Sequence 2754

Sequence 2755

TABLE 1 450/467

TAGACTTATTCCTTATGATTGGGAAATTTTACCTAAATCTTCCCTTTCACCCTCTCAGTA
TCTACAGTTTAAAACCTGGTGGATTGATGGAGTACCTCGGCCGCTCTAGAACTAGGGGGA
TCCC

Sequence 2756

Sequence 2757

Sequence 2758

CCGCGGTGGCGCCCCGGGCAGGTACAGAAAATTAGCAAGAGACATTTTCTGCATTGT
GAGAAATCAACATAGACACCTTAAAGACCCCTTTGAGAGTGTGGCTTTTTTGAACTTTTCA
GATTTTGCTCAGTGACCTGCTAACACTTACGTGAGAGGCTCCAGGTGTAAATAGAATCTA
ATGGCAGAATCTGTAAGTGTAAACAAGCATCTTAGGAGTGAGAGATCAAGACCACAAAAT
GTCCAGAGCTATGACCACAGCTATACCTACCCATAAAATACGATACTGGAGTAGGGTATT
TTTGTCTTTTTTTCTTACCTAAGAGCTAGCTAATCAGGACAGGTGATGCAGGTTCTGGAG
CTCTACCAGGGCAAGTTCTATTTTCTTTTTTTTTAGGACAGAGTCTCACTGTCGCCCTG
Sequence 2760

Sequence 2761

AATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACTTGTAGATGTTCTTTGGTATCTGGGCA
TTGAAGAATTAGGTATTTATTATAATCTTCACAGTCTGAGCTTGTTCGTAGTGGTCCTTC
TTGGAAAGGCTTTCTAGATATTCAGAAGGACCGTAGGTGTTGTGATCTAAGCTGTATCTG
CTTTAGAGGGCACCCGAAGCCCCGTAATGCTCTGGTTCTTGCAGACTTCTGGAGATACTG
CCTTGATGGTCTTGGATAAGATTTGGAAGAATCCTCTGGATTATCAGGCAGAGACTCTTA
TTCTCTTTCCTCACTTTTTCCCAGAGTCTTTCTATGCTGAGCTCTCTGGAGCTGGGGGAG
G

Sequence 2762

TNNCCGCGGTGGCGGCCGAGGTACTGTCCAACCAAAACTTTCCACNGNGAAAATTTTCCT GGGTGAGCCTCCCAGAAAAGCCCAGCTTAGTGTAAGCCAAAGACCTCCCAAGTCTGTCAC CAATTTTTTCCCTATTACTCACCTGATCATGTGGGCAATATCCCAGTTGGTCTCTGTAGA CAATGGTCCCTCTATTTCAACACCTTTTTCGGTGACAGTGGCGATTTGAAACTGGAAGAA

TABLE 1 451/467

AGCAGAGCATTCAATAATGCCCACGCCTTAAGTCCTTAAATGAAAGGTCAGGTGGAGGTC TTCCCCAATGTGAAAATAGGAGTCACACAAGTAAGGCGNATCTGTTCTTCAAAGCATAGG CTC

Sequence 2763

Sequence 2764

GCGGNCGAGGNACAANCNACTTGGGGGGGCANAAAAACCNGCCCCCCCACGANGAGAAGG GGACNANGAGAANNNTTTACACACAAGNGGGGGANNNCCCCCNAAAAAACCGGGCGCAGN GGCNNACACNNNGNAANNCCAGNACNNNNGGGAGGCCGAGGCTNTTTNAAAAAAAATTNNT TTNGAGGGGGGGGGCCCCCGN

Sequence 2765

CCGGGCAGGTACGCGGGNTTCCGCGGGGCTTGCTGGGAAGAGAGGCGAAGCCAGGTCACC TTTCAAGGACCCAGAAGTAGGGTTTTGGCCTAGGTAACCGGGGCAGAGATGTGGTTCGAG ATTCTCCCCGGACTCTCCGTCATGGGCGTGTGCTTGTTGATTCCAGGACTGGCTACTGTT TNCCT

Sequence 2766

ATAGGGCNAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACTACCCTCTGCTTTTGCAAGGACTCTACTGTGTCATCTTAAGTGAGACAGGTGCATATGTATACTAGTAAAATTCTCTGCTTTCCTAGCATTGGACAAAAACAAAAATCAACAAAAGAATTGCCTCAGTGTCTTAAACTGGGATCCTTACTAGTTGACTAGGCACTTAGTTACTGAAGGATATGTGTGGAATTCAAGTTCTTTCAACCTATAAGAAATATCCGGCCAGGTGCAGTGGCTCACGCCTGTAATCCCAGCACTTTTGGGAGGCCGAGGCAGGAGGATCACAAGGTCAGGATTNTCAAGACCNGCCTGGCCAACATAGTGAAATTCCTGNCTTCTACTAAAAATN

Sequence 2767

Sequence 2768

CCGGGCAGGTACGCGGGCATCAGCTCCGTGGGAACTCACGAGCCTGGGGAAGAGTTCGTCA TCCCCACATGGAACCTCAGTATGGCCAACAGGCAGCCCTCTGGTGGAAAAAATCAACAATC AGTCCTTGCANCAACTTGATGGAACNCTAGTTGACCACCATAAAGATGTCAAGCCAGGCA GCA

Sequence 2769

Sequence 2770

CCGGGCAGGTACAGTTGGACCTGCTGGCATTCGAGGCCCTCAGGGTTCACCAAGGCCCTG CTGGCCCCCTGGTCCCCTGGCCCTNCTGGATCTCCAGGTGTAAGCNGTGGTGGTTAT Sequence 2771

TABLE 1 452/467

ACAATAAGGCTCTTGAAAAATTGTCATTACTTGTGTTTTCCTATACATTCATCTGTGTGAA AGCCTTTTTCTTCTTTGATTTAAAAAAAATTAACTATACAGTTAATGGTTTAGAACTTAGA ACTAC

Sequence 2772

AGGTACACTCAAAGGCTATGTTCTCTCTCAGGACTCAAGATGAATTACTGGCAGAATTCC
TCACTACATCCTTTAATGGAAACCTCTGTCGGTCCTCATCATCAGTGCTTTCATATTCTG
ATTCTTCACTAGATAATTCCTCATCCTCGTCTGGCAAAGGAGGTTCCTCAGGTGGCTGAG
GAGATGTGGGTGGAAGAGGTGCATGCAATGGCATATAGTCTTCATACATGGGAGGTCGCG
CAGTAATTGGTCCAAAAAGGTGTGGGCAAATTCATTTTATTCATAAGATGAAGGACCTGTN
CCTGCCCGG

Sequence 2773

CCGCGGTGCCGAGGTACTCAATGTTTAGCTCCCACTTAGAAGTAAGAACATGCCCA GCACTTTGGGAGGCCGAGGTGGGTGGATCATGAGGTCAAGAGATCNAGACCATCTTGGCT AACAANGTGAAACCCTGTCTCTACTAAAAACATAAAAAATTGGCCCGGGTGTGGTGGTGG GCACCTGTAGTCCTAGCTACTCGGGAGGCTGAGACAGGAGAATCGCCTGAACCGGGGAGG TGGAGGTTGCAGTGAGCTGAGATGGTGCCCAACAAGAGGGAAACTNCTTNTNAAAAAAAA AAAAAAAGAAAACACAGGTATAATTTCCTACCATGTTCTTACNGGATCATAACTTTAAAT GGTCACCCGCGTNCCTTGCCCGGGGCGG

Sequence 2774

Sequence 2775

TGGCGCCCCGGGTNGGTACCAAAGCCAGATCCTCCTGTTTTGTAGCAGGAAGCCCTT TATTAGTTNNTCTCTATCAATCCATCTTTNATAATNNCCAAAATAGGATAAG Sequence 2776

Sequence 2777

Sequence 2778

Sequence 2779

TABLE 1 453/467

ATTGNAGCTCCCGCGGTGGCGGCCGAGGTACATTGCTGGCCTTTGCCCAAATTATGCTT NCCCCATTTGGTATGACCTGACACCATTGTGATCAGTCTGATGACCTGGCAGCATCCCAT CTGCCTACCCAGTTCACTNTTGCTCCATTTCAGGGCCTCTTACAGGCAACTNCTNACATA TATTTTGACACTGACTCATGCCTTCTNAGGCTNAGCTAACATCAGCCCATTCATTGATN CAGCAAGACAATTTGAGAACCACTATGTGCTCTGCCAGAGTGAATAACAAAACCGCAAGT ACCTNCCNGGGCGGNCGGTCTAGAACTAGT

Sequence 2780

Sequence 2783

TABLE 1 454/467

GAGACGAGTITCACTCTTGTCACCCAGGCTGGAGTGCAATGGCGCAATTAGGGTTCACT GCAACCTCTGCCTCCCGGGTTCAAGCAGTTCTCCTGCCTCAGCCTCCTGAGTAGCTGGGA TTACAGGCATCCACCACCGTGCCCAGCTAATTITTGTATTTTTAGTAGAGACGGGGTTTT GCCATGTTGGACAGGTTGATCTCAAACTCCTGACCTCAGGTGATCTACCCTCCTCGGCCT CCCAGAGTGTTGGGATTACAGGCATGAGCCACCATGCCAGGCTGCTAATTCTCCTTTTTA GTGAGTTAGGGAACTGAGCCTCAGAAAACTTAAACGATTTCTCAGAAAACACTCAAGTGA TAAAGTGGCCCCATTGGAAAGGAGGTTTTTATCTTCTCATTGGCAGGCCCAGNGTTCATT GCACAATATCATGCTACCTCTTGGAATCTTTTAAAA

Sequence 2786

Sequence 2787

Sequence 2789

TABLE 1 455/467

Sequence 2791

Sequence 2792

Sequence 2793

CCGGGCAGGGACCNCGGGATGGTGNCAACTTATGACAGGACCCATGGGCCCTCCCNATGC ACACAGNACTNTTGGAATCTNATCCTTTTCCATGGCTCACACTTNCACAGNATT TACTCCTAAATATGCCCCCTGNGTTCA

Sequence 2794

TATAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACANATTTGAATGGCTTTGA CTTTTGGCAGCTGCACAGNGCTAGGACTGGACCATGAAATATCTNTGGGCTNTGNCAATN ACATTTGGGTTAANCTAANCCTGATCCCATGTGTTCCTGGAAGAGAAGCCCCATGACATT CAAAGTCCTTGACAATNTGACACCAGCTTTTNTAACCNTATAAGGCCC Sequence 2795

Sequence 2796

TACAGAAGCCGGGAGCATAAAGACGTATAAGCCTNGGGGGTTGCTCTAATGTAGGTGAGG
NTAACATNACATTANATNTGNAGTTGNCGCCTNACTTGCCCCGCTTTTTCCAGTTCGNGG
TAAACCTTGTCNTTGCTCAGCNTGCATTTTAATTGTAATTNGGTCCAACNGCGCTGGANG
GAGNAGGCTGGTTTTTGCCGTTATTTGGNGCCGCTTC

Sequence 2797

Sequence 2798

CCGCGGTGGCGGCCGAGGTACTGAGCCCTTCATTCCCCAAACTCAGACTCTTAGCTCTTTTTCCCCAAACTCAGGCCAAACTCTAGCTCTTTTCTCAACTCTGGGCAAAGGTCAGCATTGGAATCGAGCGGCCGCCGGGCAGGTACATTTTC

TABLE 1 456/467

TCTCATCCACTTCCGATTCTCTTCATTGGCTGCAATATCTTTTTCTTCAAATCCTATTTT
GTTGGCTTCTAGGAAACCAAGCACATCTTGTTGTTTCTTCATATCGCTGTAGAGCCAGA
GGAAGATGCAATATATACACCGGATCACCATCCTGGGAACAGCGGCTGCGGTTGTTTGGG
TCCTGAAAAGGGCTGTGGAGCAGCTGCAGCAATGGCTGGAATCCAGCTAGGGGCTGAAAC
AACGGTTGGCAGAAGGGTGGGGGAAGTGGGAAAAAGGAAGAACTCGCCAGAAGCCCCG
CCTTCGNCTTTAGCAAGCTTCCACCGAGCTCTTCTAAGCGCTTGAGTTNCAGCCAAAAAC
CCCCCCCG

Sequence 2799

AGGTACTAACCTCTTACCTTCCAAGGTGGTAGAACATGCTTGAAAAGATAGTAAGTGAAA
AGGGGTAGCCAGTGCTTTACTCACAAGACTGCTTGAACATGAGACTCAAGGAGGGACCTC
AGCAGGCCTGGGGTGTTCAGCAACTATTCCTGGCCGGGGCATCTTGCAAAGGAGTTGCTG
TGACAGTAAGCTCTTCCACTTTGAGACCGTCACCTCAGCCACGGCTCCCACCTGGGCTCA
GGAATGGTCAGGCAACACGTGGGGCCCAGGATGGCGGTGATGACTAAACTGCCGAAGAC
CGCGCCGCTGCGACTACCGAAGTACCTGCCCG

Sequence 2800

Sequence 2801

CTACTTAGGGCNATTGGAGCTCCCCGCGGTGCCGCGCGGTACAGACGGGTGCCTGTAG
TCCCAGCTACTTGGGAGGCTGAGGCAGGAGAACTTGTTTGAACCCGGAGGTGAAAGTTGC
AGGGAGCCGAGGTTGTGCCACTCCAGCCTGGGAGACAGAGCAAGACTCTGTCTCC
AAAACAAACAAACAAACAAAAAAACCCTGTAGCTTGGGATCAGCCTTCTCTTCTGTTGTT
TTTCTTTAAAAAAATAAAAATTAAAAAATAGGCTTCAAGTGATCCTCCGCCATGACCTCCA
AAACTGCTGGGATTGTAGGTGTGAGCACTGCACCCAGCCGTATGTTTTTTTCTACATAAA
AAACAGCACAGGATTATCTTCCAAAGCTAACAAATATGTTCAAATAACCACACCCCAAN
TNNAAAAAAAAAAAATNAAGTACCTGCCCGGGGCGCCCCTCTAAAAACTAANTGGGATCC
CCCGGGGC

Sequence 2802

NCCACCGCGGTGGCGGCCGTNCGGGCAGGTACTCCTTTCAGAGGGTCATCTCCTCCACAA GTATTTTTGTTTCTTTGGCTGGTCTGGGTCCAATGCTGTTGCCATCCCCAGCTTCAGAC TGTTCTCCTTGTTTTGGAGAACTTTCTTTGGACTGTATCTTCAGAGACACTCCTGGTCAA GGGGCCTCAGAGGACCCAAACGCTCTGAAACAGCGTCTTAGCTCATCGCCGAGTGTCAGC TCTAGCTCTTCGGAGCGCTTTCTTCTCCCCCCCGCGTACCT

Sequence 2804

CCGCGGTGCCGAGGTACAGAGAAAATATTTTTTAAAAATCTCATCAGGCTAGGTGA GGTGGCTCGTGTCTGAATCCCAGCACTTTGGGAGGCCACGCTGGGTAGGTTGCTTGAGT CCAGGAGTTCAAGACCAGCCTGGCCAACATGGCAAAACACCCGTCTCTACAAAAATAATAC AAAAATTAGTGAGGCATGGTGGCACACACTTGTAGTCTCAGCTATATTACTTGAGAGGCT

TABLE 1 457/467

Sequence 2805

Sequence 2806

CCGGGCAGGTACATTCTCTGTTCATTACTTAGTTCTTAAGGATATGTGTTCATCCATTCT GTCGCTGGCTCAGAGTTTGCTTCACTCTCTAGACCAGAGTATAATTTCATTTGGCAGTCT CCTATACAAATATGCATTTAAGTTTTTTTGACACGTACGCGGGGGACTCAACAGAAATGGG TTTCCAGAAGAATAATGAAAAGTTGTGGGTAGGAAAATGAATCATTTGGACTCTTCAATG AAATGGAGTGAGCCCAGGAGAGCTCAGCCAACAGAGGCACTCTGGGAACCTGTTAGTAAA GCCAGGCTGGCCAAATGCCATTTGATTTTGAACCTCGTAGGTCCCCACTCACCCTCTGCC AGGAGCT

Sequence 2807

Sequence 2809

AGGTACTGTAAATATTACCATTATTTAAAATGTTGACATTTCTGCATTAAGTAGAAACTT
TCTAAATGCCTAAATACCACTCAAACATGACTTAAAAGAAATTGAATGACTCACCACTAT
GACCTTCAAGAGTCTGATTCATAGAAAGGTTACTGGGGGGCTGCAAGGCCCCTCAATTTTG
CATCATCTGTCTGCGTCTCTAATTTCAAAACTTTCAGTAATCCATCTTCACCACCGCATG
CTATGAACCCTTGTTCCTTGTTCCAGGATACACACTGCAGCTTCACGTTATTGGGAATGG
AAATTTTCTTGCTCAGGTAGAAGAACATCGTGGGATCCCCGAGAGGGTCACGGCGGCCGC

Sequence 2810

AGGTACGCGGGGGGCTCTGAGAGGAGTCTACCTTGCCTTCTTATGGGAAGGGAGACCCTA
AAAAACTTTCTCCTCTTTGTCCTCCTTTTTCTCCCCCACTCTGAGGTTTCCCCCAAGAGAA
CCAGATTGGCAGGGAGAAGCATTGCGGGGCAATTGTTCCTCCTTGACAATGTAGCAATAA
ATAGATGCTGCCAAGGGCAGAAAATGGGGAGGTTAGCTCAGAGCAGAGTAGTCTCTAGAG

TABLE 1 458/467

'AAAGGAAGAATCCTCAACGGCACCCTGGGGTGCTAGCTCCTTTTTAGAATGTCAGCAGAG CTGAGATTAATATCTGGGCTTTTCCTGAACTATTCTGGTTATTGAGCCCTTCCTGTTAGA CCTACC

Sequence 2811

Sequence 2812

CGGTACCCAAGCTTTTGGTTCCTTTAAGTGAGGGNTNAATTGNCGNCGNCTTTGGCCGTA ATTCAATGGGTCAATAGCTTGGTTTCCTGTGGTGNAAATTGGTAATCCCGCTTCAACAAA TTCCCACNCAACATACGNAGCCCG

Sequence 2814

CCGGGCAGGTACGTTCTTTTNGCTTTTCCTTTCNGTAAGATGGTCTTCAGAGCTNCTTAA ACACATTTAGAAAAAAGTTAAACCCCAAGACNCTTTGGGGATAGGTTAATTTTAAGANGC CCAACTTTGGACTNGGATTAAAGGAANTACCTTAAAAAANCCCNGGNAAAACAATTATTTT TTGGG

Sequence 2815

GGCGGCGGCCGAGGTACAGAGAAGCCATCANTTTAGAGGGCAGCANAAAACCAGAAGCCN GNTTTGATCCCTNAACACCAAGANGCCTNTAACAACANGNCACCAGCACCCCCAGGAAGG CCAAGGAGTCCCACAGAAAAACCTAGGGNNAGACCAA

Sequence 2816

Sequence 2817

AGGTACCCTGAGGTGCTCCGCTGGGGACTCTGCTCATTCTGGGGGTGCAGTTGACGGCTGGTCGTGATCTTTCCCCGTAATCTGTCCCCTCTTACGGAACCTAGTCTCCCGTTCTGGCCATGGCCTTTCTTCTTCTTGGACACTGCTTAGGANCCCAGAAAGAAGTATTGTTATCAAATTCTTAAAGCCTTAGGAAGAAAGTCNAGGGAGTGGGAAAACCAGGCTTCTGANAAAGAATACCTGNTTGGCCCACCTGNATCTTCCNAGGNCANCCACGGAANTCCCGGGCCCCTTCCAATCAGGNAAGGTCGGNAATCTCTGATGGTCNATCGGTTCNATGGCCAACCTGGCCAACCAGTTTGAAAAAAAA

Sequence 2818

CCGGGCAGGTACTGTTCCTGTTGGCCGAGTGGAGACTGGTGTTCTCAAACCCGGTATGGT GGTCACCTTTGCTCCAAGTCAACGTTACAACGGAAGTAAAATCTGTCGAAATGCCACCCA TTGAAAGCTTTTGAAGTGAAAGCTTCTTTCCTTGGGGACCAATGGTGGGCT Sequence 2819

AGGTACTTTTTTTTTTTTTTTTGGGTTAGGATGGTTCTAACCTGATGGGTTGTGT

TABLE 1 459/467

TTACAGTGGGGTTTCCCCCAAAGGTTATCTTCCTGCTTTCCTCTGTAAATAGGGCAGTTG CTGCAACAGATTAAATACACTCGGGCCACCTGTGGGTTAGTGGGTCAAGAATTTTTGACA GAAAGGCTATAGGCTGCCGGTGGCCCCCGTGTGTTTTGGGTGAGCACCCCTAGAGCTATCC CTTTATTCACATTGACGAAGAGGTGGAATGGCTGTTCTAGGGAAGGTAGAACTAAGGCAG TTATGAGCAGGTGTTTTAATTCCTCTACTTGTTGGACCTCCCGTGGT Sequence 2820

AGCTTATCGATACCCGTCGACCTTCGAGGGGGGGCCCCGGTACCCAGCTTTTTGGTCCCT
TTAANTGNGGGNTAAATTGGCGCCGCTTTGGGCGNAANTCANTGGNCANTAGCTTGGTTN
CNTGGTGGTGNAANTTGGTAATCCCGNCTTCNACANTTCCACACANANNACGAAGNCCGG
GGAANCNTAAAGTGGNAAANCCTGG

Sequence 2821

CGGCCGCCGGGCAGGTACCATCTCTTGGGAAAACCATGCTACCTCTTCTCTCTGTTCTC
TATTTTGCCACTAGAGAAATAGAAAATAAGGCTGGGAGCAGTGGCTTATACCTGTAATCC
CAGCACTTTGGGAGGCTGAGGCGGGAAGAATCACCTGAGGTCAAGAGTTTNAAGACCAGC
CTTGACTAACANTGGTNGAAAACCCNCGTNTTTTTTTNTTTAAAAAAATACC
Sequence 2822

Sequence 2823

Sequence 2824

Sequence 2825

TTAGGGCGTTTGGAGCTCCCCGCGGTGGCGGCCGCCCNGTCAGGTACCANNNCTTAGCAN
GGAANNTGGACAACANAAGCTNTAAATCCTCTTGCATCGNCACGNTNAATTTGCACTGAC
CAATCTGTTGGCACAGTAACTGGTTATAAGCTAAATTTCTACATTTTGGCTACAAGTATN
CCAAATNCACCTTTTAAAAAAATCCTATGTNAGATGCCATCTGGTGTTAATGATTTGCACA
CCCCTTAAATTGAAANTATTNCAAATAAATCTNACGGATTTATATANNATNATTAATGNN
TNTATTTTAAAAAAGACAATCTGANAATAACACTTCCCCTAATTGTTGTCTTAATAATGAC
CAAGAGCTGNNGAAAAATNATTCACACTGNTACGTCGTTNTGTTGGTTTGCTCACGGGGG
AAGGGGGGTTG

TABLE 1 460/467

Sequence 2826

Sequence 2827

Sequence 2828

Sequence 2829

Sequence 2831

Sequence 2832

TABLE 1 461/467

Sequence 2834

Sequence 2833

GGGGNAAACCCCGGNGGCGGCCGCCCGGTTTGGAACCNGGGTTNAAACCCCCGGNTTTNA ACCNCANAACCGCAAGANAACGGGNGNAAAAAAAGGGAAACANANCAGCNGTCCAAAGAA AACAAAANGNGGGCAAACC

Sequence 2835

TABLE 1 462/467

Sequence 2842

TABLE 1 463/467

TNGGCTTAAATTTTAA

Sequence 2844

Sequence 2846

CCNGGGGCGCCGAGGTACCATNANGCTTGCAGGGGCTGAAGCATGGTTTGTCCANAACC CCAACCACCAGGTCTATCGNNCTCTTTCTGNCACCTTTTTNCTCTTTTTTCCTTCTNCCC TTGCACCTGAGGNCCTGGAAGGCCTTGATGAGGCCCAGCAAACAGGCATTCTCACAGCTG GGTTTATAGTCTTTGGGCCCCTTACTCAGTATCCTGGGAACCCTGGGCCAGGAAGTTAAC AGTGGTCAATCANAAANTNCTGAANAAAATCCCCCTCCCCCTG Sequence 2848

Sequence 2849

GAGATGCAGTCGATTNCATACCTANTGGGTCCCANTCCTNNNTNNGGNCNGTTGNGAAGC CGGATAGTGACTGAGATCACTGGGTAGACCTTGTCCACCTTGGCATTCTTGTCTGCCAAG GTCCATGGCCCATGGGGATGGGGACAATTTGAGTGGG

Sequence 2850

GGCAGGAACTNTTCTTTNNTCTTTTTTTNNAAGTNAGNGGTAATTTAAAAATCTGAAAT ATAGGCTGGGCGTGGNGGCTTACGCCTGNAATCCCAGCACTTTGGGAGGCTGAAAGTTGG GGCNGGATTCATCTGAGCTCGGGAGTTCAGGGACCAGCCTGACCAACATAGAGAAACCCC GNCTCTACTAAAAATACAAAAATTAGCCANGGCGTGGTGNGCACCATGCCTGTAATCCCA

TABLE 1 464/467

GCTGTTTCAGGGAAGGCCCNANGCCANGANAAATTTGCNTGGAACCCCGGGGAGGGCCGG GAANGTTTGTTGGATGGAGCCCCGAAGATCANCCAATTTGNNNANCTNNCAAACTTTTGG GNTTGAACAAAGAAGCCNAAAAANTTCCCCAATTCTTTCATNAAAATACAANGAAAAACNT TANANAAAAATTTTTTGAAAAAATTAATGGGGACCCCNTGGGAAANGAGGCCCNNTAAAAA AAAAAAAAA

Sequence 2851

Sequence 2852

AGGTACGCGGGGATGCGCAGTCGTGAGTCCTCTTGTCCTTGAGCGTCAACCTTCTTTCCC TGAAGTGGCTGGGGTTCCTGTTTCCTTTGATTGACAACTTGTGTTAACCCTCGCACA TCTCTGGGCCAATTTTTGCTTGAAAATGGCAGCTCCCGAGCAGCCGCTTGCGATATCAAG GGGATGCACGAGCTCCTCCTCGCTTTCCCCGCCTCGGGGCGACCCGAACCCTTCTGGTCAG GCACCTGCCGGCTGAGCTTACTGCTGAGGAGAAAGAGGACTTGCCCGAAGTACCTGCCCG GGCGGCCGCTCTAGAACTAG

Sequence 2853

CGGNGGCGCCCCGGGNATGGTACCCTCTGTCACGCTTCCTTTTNCTGGAAAAGGGA ATTTCCCAACCCCGGGTGAGGCAATGCCCCGCCCTGCTCCGTGGGCTGCACCTGCTGTCT GTCAAGCCCCAATGAGATGAACCCTGTACGCGGGGCCTGGGATCTCAAAATGGCGGCCC CGTGCGGAAACAGCGTNTGGGAGCANNCATGTTGCCTNCTGAACAAAGCCGTTGAAGATG AAGAATGGGCAAAATCGCCCCATACGGAACAAGCGCANCCTNGGGAGCCCGATACCTGGC NNGCGAACACCAAACGGGAGAATTTCGCCAATATGGATGTGACAGCGGTTCCCATTAAAG CGGTGATAGGGATTTTT

Sequence 2854

CCGGGCAGGTACGCGGGGTGGCATTCTGGGTAACAGAGCTATTTACTTCCTGCGGGTGC ACAGGCTGTGGTCGTCTCTCTCTTGTTCTTCCCATCGGACGAAGATGGCCCTGGAG ACGGTGCCGAAGGACCTGCNGGCATCTGCGGGCCTGTTTGCTTGTGTTCGCGTGGTCAAG ACTAGTACCACCAGNTTTAGAATATGATGGCTTGTNGACAACATGTTGATGTCATATGNT ATCAAAATCGAAACGGNGTCANCTCCGAAGAAGGATGGGTTATTATTGACTTGCACCTTA GCCTNTTCGCTTTTGCATGGGGATANCCATTTNGCTCATTNATGAAGTTNCCATGTANTG TACAGGCCTTGGGGGNTCNTTTCAAAGGTNTNNNAANCTGCAGNTCCAGTTAAAACCTTT Sequence 2855

CTTTCATGTGATCTTTGTGGCAGTGGGACAGGAAGTAGGCGCGGGCCCTCAGGTTCTCCC
TATCGAAGCGGTCTATGGAGATAGTTGGATACTCGGCCATCTGCCCCTCGAAAGAACTCA
TAGCGCCGTCGATCCCAGAGTCCGGGACCCCAAAACCGCAGCTGAAGCCAAGGCCAGCCC
TGACNCGCCCCCGCGTACCTCGGCCGCTCTAGAACTAGTGGGATTCCCCCGGGCTGCAGG
GAATTNGATATCAAGCTTATCTGATACCGACCGACCTTCNAGGGGGGGGCCCGGTTACCC
AAGCTTTTTTGTTCCCTTATAGTGGAGGGTTTAAATTTGCGCCGCTTGGGC
Sequence 2856

TABLE 1 465/467

Sequence 2857

ACATTAATTTGCGTTTGCGCTCACCTGCCCGCTTTTCCAGTCCGGGGAAACCTTGNCGTG CCAGCTTGCATTTAATTGNAATTCGNGCCCAACCGCTGCNGTNGGAGAGGCCGGCTNTTG CCGTATTTGGGGCGCCTCTTCNCGCTTTNCTCGGCTTCACTTGACTC Sequence 2858

AGGGCGATTTGGAGCTCCCCGCGGTGGCGGCCGGGCANNTACTTTGCGGTTTTTGGGACT
TGATTTTNGCAGAGGGATCGGGCACTGAAGGTGCAGTTCTCAAAATCACACCTGNAGGCT
GGCTCCTCGCTGTGGGTATCCAGGTGCTTCTGGAGGTCAATAAGATTCTTGCAGCTGTAG
TCACAACAGTCACATTTAAAGGGCCGGTCCTCACTGTGACGAAAGCGCATGTGGTTGCGG
AGGGAGGAAGGCAGCGGGCAGGTCATGTCACACAGAGGGCACTTATAGTGATTCACATGG
TTGCGCA

Sequence 2860

ATGCGTTGCNGCTCACTGCCCCGCTTTCCAGTCGTGGAAAACNCTGTTCGTGCCCAGCCT GCATTTAATGGAAATCGGCCAAACCGCCNCCGGGGGAGGAGGGCCGGTTTTGCCGTATTT GGGGNCGCTTCTTCCCGCTTCCTTCGCTCAACTGGACTTCGCTTGCGGCTNCGGGGTTCG NTTCCGGGCTTGCTGGGCCGAGGCCGGGTATTTCANCCTTCAACTTCAAAAG Sequence 2861

TABLE 1 466/467

AGGTACAGCTCTTCTCTTGTCTTTCTGAGCTCTTACCAGAATTGCCTTCCGTGTCTTTTT
TTTTGGAGATGGAGTCTCACTCTGTCACCCAGGCTGGAGTGCAGTGGCGCAATCTCAGCT
CACTGCAACCTNTGCCTCCCTGGTTCAAGCGATTCTCCTGCCTCAGCCTCCCGAGGGGCT
GGGACTACGGGTGCACCACCACCACGCCTGGCTAATTTTTTGTATTTTAGTAGCGACAGGG
TTTCACTGTGTTGCCCAGGCTGGCCTTGAACTCCTGAGCTCGGGCAATCTGCCCGCCTNA
TTCTCCCAACATGCTAGGATTATAGGCATGAGCCACCACGCCCTGCGGTGTCCATATTTC
TAACAGCAGTCACTTCAGAGCCATCTAGGTTTCTTCTAACATGCACCTAAAAACTCTTTG
GCCTNTACTACCTAGNTNTGAAACCATTTT

Sequence 2865

CGGCCGCCGGGCAGGTACAGNTGCATCANCTGCTCGTAGGACATGTCCAGCAGCTGGTCG AGGTCCACGCCGCGGTAGGTGAACTTGCGGAAGGTCCGCTTCTTCTTCTGCTCTACTTCT GCCACCCGCGTACCACGGCTATCCTTATAGCTTTTTAAT

Sequence 2866

Sequence 2868

Sequence 2869

GCGAATTGNAGCTCCCCGCGGTGGCGGCCGAGGTCTAATTTGAATTTGTAATGAGTCTGA
TGGTATATTTCAATTTTTTGCTTTGAGGGACTGGCTGCTACATTGCAGAATATCTTATAT
CCCTGACTGCTTTCCACTAAATGTCAGTGGTGACCCCAATCCAATATTATGACAACTGAA
CATGCTTATGCATCCCTCATGCCTTTATTTTTTATTTTGGGAAATCTTTCAGCTTCAGTT
TTTGCTGATATTTATGTGATTCTTTGTTCTGCAATTCAAATTTCTGGGAGCCAAACAGTC
TCCTTGGTTCAGATTACTGTTTTTTTGACTAGAGGCTTCAGATTCTGTCATAAGA
TTATGGCTTAACCTATGGTTGTCCTTTGATTTGGTGCCATATGAAATAAAACATTATTTT
CTATGGCTATGTATTAAGAATTTTGTGCAATTCTGTTTTTCTTAGAAGGCTGAGGGTGTG
TTGTCAGACACCCATGACTGATGTGACAGGTGTATTTTATTATGC

TABLE 1 467/467

Sequence 2870

Sequence 2871

TABLE 1A 1/599

Sequence 2872

CCCTTTCGAGCGGCCGCCCGGGCAGGTACGCGGGGTGGGGATATTTTGTCTCACAGATTG
TAAGAAAGGGGTATGGAAATCCCCAGGCAACAGTGTGCTCCTCAGCTTGCTGAAACAGAC
CAAAGACTATGTTCTAATCAAACCTTCCAGGAATCTCATGGAAATTTCATTTAATGCCTC
TCCAGGCACTTTTCTGAAAGCCCCCACGTTAGGGATGTCTTGGCTAAGACATCTCTCATG
GTATCCACAGCAACCCTGATGAAGCTCATTTCTGGAGAAGAAAGTCTCTCAACACCT
CTGCTAAGTCATCATTCTCCCATNCTCACTGCAGCAGTTCCTGGAATCTCATGAAGGGAA
GCTTGGGACCCACCGCACACCCTNTGCAAATACCTCACAAGTAAACTTGGNAAATGCCG
Sequence 2874

CCCTTAGCGTGGTCGCGGCCGAGGTACAGTCCTAGCCACAGTAGTAATCACCACTGGCCT GACTGAGCCCTCACCCTTTATACAGTGTCTCCTGCCACCCTCCTGGGAGAGGCTGTTCTC GGCACAGCTGGCCTGGGGTCACACAGCTGGTAGGTGTAAAGCAGGCATTGGAGTCCAGGT AGTCTCACTCCGTAGCCTGTCTCTTTAGCCACTGGAAATGTAGAGCAAAGCGAGAATTGT CCAAAGAGATAAGCTAATAAAGAGGAAAACAGGCTGGGTGCAATGGCTCATGCCTGTAAT CCCAGCACTTTGGGAGGCCAAGGA

Sequence 2875

CCCTTAGCGGCCGCCGGGCAGGTACATCACCCTGCTGAGGGACATCCAGGACAAGGTCA CCACACTCTACAAAGGCAGTCANCTNCNTGACACATTCCGCTTCTGCCTGGTCACCAACT TGACGATGGACTCCGTGTTGGTCACTGTCAAGGCATTGTTCTCCTCCAATTTGGACCCCA GCCTGGTGGAGCAAGTCTTTCTAGATAAGACCCTGAATGCCTCATTCCATTGGCTGGGCT CCACCTACCAGTTGGTGGACATCCATGTGACAAGAAATGGGAGTCATNAGTTTATCAACC AACAAGCAGCTCCAGCACCCAAGCACTTCTACCTTGAATTTCACCATCACCAACCTACCA TATTCCCAGGACAAAAAGCCCAGCC

Sequence 2876

Sequence 2877

CCCTTAGCGTGGTCGCGGCCGAGGTACCTCCTTCAGTGAGTTGTTGGCAACTAGGCAGTG
AAATGAGGGAGTGACCGCTCATGGCTCATGAACTTTGCAAGTTGTGCAACTCAACTGTCC
CACCTTGAAAGGGCTCAGGAAGGTAAAGAGTGTTGTTTTGGGACACAGGGATTGTTGCAT
TTAAATCTTTGTGACTGTGGTTTGGTCTCAGACTGGTTTTTCATGCATAAGTTCTTCTTA
CCCTCAGGCATCTGGGATTTTACCTGTTTTTCTTCCAGTGGTGTGCCCTCTCCGCCACAT
TGTGGAAGCGTGCTTTCTCAATCCTTCAGGAAGAAATTCAAAGACTTTNTTTTTTAA
Sequence 2878

CCCTTAGCGTGGTCGCGGCCGAGGTACATTATTTAGTGTAATGCCTAATGTTAGTCCTCT TTATAGCATATTTTATACAATTTCTATTATTTAACAGGCCTTGGGAATTCAAAGATGAAA TGTGTGTCCCTCAAGTAACTCACTAATCTATTGTTATAAGTAGATTGTAATTCATGAGTG

TABLE 1A 2/599

CTGTAACAGCTATCCTATGACAGCACTGAAGAGGGTTGGACTTCCTAGATGAATATGTA TTGAGTTGTAGGGGAGTAAGAATTCACCTACCAGTGAACTAGTGGACCTGAAGTGGTATT CCAGATTG

Sequence 2879

CCCTTAGCGTGGTCGCGGCCGAGGTACAGTTCTCAGTTTTTCTTATAGGAGAAATATGGT
ATATGTTTATAAGAATCTTTTATGAGATTATAGATTTCAATGCTGTGGATAGTGTCTTGC
ACCCAAACAAGAAAGTCCATAATGGAATGATCTTCCCTCAGCTTCCTATCGATTTAGTTA
CCTCTTGAAAGCACAAAAATTAAAACATTGCCATATGTTGAATTTTTAAAAAGCACTTGG
AGTGAGCGAACATTTCCTGATAAATGCCTTTTAGAGATAGGTTCTTGATATTCAGACATC
TGCAGAAATGTTCTGGTTCCCAAAGTCATTTCACTTCGAAATAAAACACAGCTCCTTCAA
ACAGCACTTTTTCCACATAAATCTAAGTTGCCTCTCCCTGTGGACATTCAGAACTGATAG
AACAAACACTACTCTTTTGAATTTGATGGTTCGTGTCCTTTAAAGTGTTTGAGGACCTAT
GCAGAGCCTGTACACTTGGGGTAGTACCTGCCCGGGCGGCCGCTCGAA
Sequence 2880

Sequence 2881

CCCTTGAGCGGCCGCCGGGCAGGTACAAAATTGCTAATTTTATTCCAGTGATGATTAT
TTTTAACTTTGGTGATTACGTATCAAAATTAAGGTAATTCTATAAAAAATCTACAGCCAGTA
AACTGAAACTATAGCTAAAACTGTAGCTACTGTTTTTATATTTTCTTAGATGCATGTTGT
TTTATTATAATAGTTTAATGTAGTGGTTGAATGGAATATGTGGTTTTCTTCTAGAATACC
TTATGTGATTTATTCTATGACTTTTTTCCTTTGAACCCTTATGACTCTTAGTATGTAAAT
TTTCTTAAATTATACTCTTTTGTTGTTTATTCTAAACTACTTTGAGGCAGATCTCAAAAGT
TGAATAATTACTGTGCATCTCAGAGAATTGTCTTTCAAATATATTTAGTTGTC
TTTAGCAGTAACTCTTACATGGTTATTTGCATGACTTAATAAACATTTCAATGCCCCCAA
GTTACCTAGCAGAAAAAAGTCCACTTTTAAAAGACATCTGTAAGAGAGAACTTTATTTTCT
TAAATTGGAAGCACATCATTTAGTCCT

Sequence 2883

Sequence 2882

TABLE 1A 3/599

Sequence 2885

Sequence 2886

CCCTTAGCGTGGTCGCGGCCGAGGTACCTATTGTATCAGAAAAATGCTAATTATTTTTGCACACATAAAGGGCATTTTAAACTTGGTTTTATTCTTTGTGATAAATATGGATGATGATGGCTAATGTTAAACAGAATTCAAAAGTTATCAGTTTGGCTAGCCAGACACAGTAGTATATGCCTATAGTCCTAGCTACCCAGGAGGCTGAGGCCAGAGGAGCCCGGAAGTTCACGTTTAGCCTGGGCAGCATAGTGAGACACTTGTCTTTTATAAAAACAACAGCAAAAAATGATCAGTTTTGGGGATAAGTAAAGACAAAATGGC

Sequence 2887

Sequence 2888

CCCTTAGCGTGGTCGCGGCCCGAGGTACAAATAAAGTATTCCAAGGGTTCAGAATAGAAA
ATGATTTCTTCCAGCTTGGGGACATTTGGGAAATTGGGATATCCTTTGGGGAAATGTAGT
AATCANTATATTCTGGGAAAACATAGTAGAAGAATGAATAAATTACATTGGAATATG
GAATATGTTGCCATTCTCCCTGTAACTAATGCTATCANGATAAAGTAGAAATACCACATT
TCANAAACAGCTGGAGTAGACAGGTCTTCATAGGCTAGCTTGGGAAACCTAATAACTATT
AATAATGAAATTTTAATTATACTCTTGGATTCTAAACAAATGAACACACAGTGATCTTTT
TGACTTGCTGCTTGGTTAT

Sequence 2889

CCCTTAGCGTGGTCGCGGCCGAGGTACTGATTGTTGAACTCCGAGTCACACTCATTATGA CCTGGGAGGCAGATGTCTAGCCTTCAGCTAATTATGATGGGCAGTATGGAGGAGAGTGTG AGTCAAACCTTCCATGGAGGAAAAGGAGTGAACACTCAGGGAGACTGGAGCCGTTTAAAA GGACATGGGGAGGATCTAATCAGGATCTTGAAAATTTAATGTTCTCAAAAGTTATTTCTA TCAGTCTTAAGTAATAGATGAATTTCTTTTTGCCACTGCAAAGATGATACTGTCTTGATA ACCATTCTCTATCATCATCCC

Sequence 2890

TABLE 1A 4/599

Sequence 2891

Sequence 2892

Sequence 2893

CCCTTAGTGTGGTCGCGGCCGAGGTACAGTCCACAAAATGGTTTGCTTCTGAAAAAGCAG TAGTAGTCTTACATCCAANATTATTCCTAAAATAAAGTTTCGACCCACATATATAATGAA ATTGAAACTGCCTACATTGGCAAAGCCAGAAAGAGAGTAAAAAAGATGGGGTAGGCCAGT TGCGGTGGCTCATGCCTGTAATCCCAGTACCTGCCCGGGCGGCCGCTCGAAAGGG Sequence 2895

CCCTTAGCGTGGTCGCGGCCCGAGGTACTGTCTGTGACAAGAGCAAGAAATACATTTTGA
AGTGGTTTGTTTTAGTAGCTAAAGTTATCCTGACTGATCATTTGATAAAGGATATTTACC
AGCAGTTCACAATGAACATACTACATGTATATATATAAAGATCATAGCCTGCACAATA
AAAAGAAGAAAATAAATTAGAAAATAAATAAGTTTAGAAACAAAGACACAGTATTAG
TTCTAGTTACAGAATATGATTCTCCAAATAGTATATGCTATCAGCTTCATCAACAAGTAA
CCAGAATACCAAAGAAGACATAGAAATGGCTAACAAGTATATAAAAAACATGCTCAACATC
ACTAATTATCAGAGAAATGCAAATCAAAAGCCACAATGAGATATTAAGTCACACCTGACAG
GATCACTATTATCAAAACTACAAAAGTCAATACTTATTGGCAAGGATGTANAGAAATTGA
AACAGCATGGAGGGTTTCTCAAAAATATTAAAAAATAGAACTACCATATGATCTGCAACCAC
TTCTGGGTATTTATCCAA

TABLE 1A 5/599

Sequence 2896

Sequence 2897

Sequence 2898

Sequence 2899

Sequence 2900

Sequence 2901

CCCTTTCGAGCGGCCGCCCGGGCAGGTACTGTAGTTATAAAACTGACACTGTTTACAATT AACAGTGTTCTAGAATCCANTTGTTTGGAGGGTATTTTACATTATGAAATATTGACTTCA GATGGTCACTGCTATTTTCGAGATCTATGACTATGTTTCAAGGAGATCCATTGGTCTGAC

TABLE 1A 6/599

AAAATAAGAGATGTATATTCCTGAAAATTGCATGTCCTCTGGAGTCTGTTGTCTGGATGG TATCAGAGAGGTATTAGAACTGTCCTCAGAGGTCATTACAATTTTCTCATAGTGTTTGTC AAGGAAAGAGTTGGGGTGTGAAAGGTCTTCTATAGTATTGGGTCCTAACCAAGTCAGGGA AGAGAAGCAAATGCC

Sequence 2902

Sequence 2903

Sequence 2904

CCCTTCGAGCGGCCGCCCGGGCAGGTACAGTGACAAGATCTCAGCTCACTGCAACC
TCTGCCTCCCAGGTTCAAGTGATTCTCCTGCCTGAGCCTCTGAATAGCTAGGATTACAGG
CACGTGCCACCATGCCTGGCTAATTTTTGTATTTTTAGTAGAGACAATGTTTCACCATGT
TGCCCAGGCTAGTCTCAAACTCCTGACCTCAAATGATCCACCTGCCTCAGCCTCCCAAAG
TGCTGGATTACAGGCGTGAGCCACTGTGCCTGCCCTAAGCCTGTGTTTTATTCTTCTG
ACTTGCAGGCTAAAGCGGCAGCTCTTCCATATCTCATTGCTATCTCCTAGGGCTTCCGCT
AGGAGACTGATCTGGGGCTAGAGGCCTCCCTCTGTGTACACGAGAATGCTGGAAATGTCA
CCTCTCAGGGCTCTGCCTGCCTCTCAGCCCTGAAAGCCATGGTGGAAAGGGGTGGCGCTT
GACATAGACATCTGAGGAAAAGAAGTGAGGGAGGGTAAAGGGTGGCAGTAAGANGAAG
GGGTNGGGAAGG

Sequence 2905

CCCTTAGCGTGGTCGCGGCCGAGGTACTTCGTTGGTGCCTCAGTCTTTAAGGATTAACTA
GGAAGAATTTTCTTTCTGCATAGAAACTTTATAAAATAACGACATTGTTAATAATTCAGG
CATAATATTACATTATACCTTTCTTGAATGCTGACGTTGCATACAAGGGTGATCTGTAAA
CCTCCATCATTTCCTTGCTCTCACTTTTAGACCTATTTCCTGACATAANAACCTTGGTGG
GTAGTTCTGGATTTTTTTTTTTTCTTCTTCTTTTTNTTATTTTTGAGACAGGGGTCTCACTG
TGTCGCCCAGGCTGGCATGCANTGGNTGCTCAAGTGATCCTCCAGCCTGTGCCTTNCTGA
GTNAGCTTGGGACAACAAAGCACAANGCCACCAGGTNCTGGCTAATTTTT
Sequence 2907

CCCTTCGAGCGGCCGCCCGGGCAGGTACATCACCCTGCTGAGGGACATCCAGGACAAGG TCACCACACTCTACAAAGGCAGTCAACTACATGACACATTCCGCTTCTGCCTGGTCACCA ACTTGACGATGGACTCCGTGTTGGTCACTGTCAAGGCATTGTTCTCCTCCAATTTGGACC CCAGCCTGGTGGAGCAAGTCTTTCTAGATAAGACCCTGAATGCCTCATTCCATTGGCTGG GCTCCACCTACCAGTTGGTGGACATCCATGTGACAGAAATGGAGTCATCAAGTTTATCAA

TABLE 1A 7/599

CCAACAAGCAGCTCCAGCACCTACCTGAATTTCACCATCACCAACCTACCA
TATTCCCAGGACAAAAGCCCAGCCAGCCACCAATTACCAGAGGAACAAAAGGA
Sequence 2908

Sequence 2909

ACCONTANCGCGGTCGCNGCCGAGGTACTATTTGGGGGGATCAAGATNTGNAANATTTAAA CTGTTTTTGGTAAAAACTAGCACTGTTGGGAAGAATGCTGTGGAATACCACAAACTAGTT TNGCAAAGGGGAAAAGAATGTTTNANAAGTGCTGATTGTATTTTAAACATCAGTAGTGAT AATACAAGGAAAGCTTTTA

Sequence 2912

CCCTTAGCGTGGTCGCGGCCGAGGTACAGTTCTCAGTTTTTCTTATAGGAGAAATATGGT
ATATGTTTATAAGAATCTTTTATGAGATTATAGATTTCAATGCTGTGGATAGTGTCTTGC
ACCCAAACAAGAAAGTCCATAATGGAATGATCTTCCCTCAGCTTCCTATCGATTTAGTTA .
CCTCTTGAAAGCACAAAAATTAAAACATTGCCATATGTTGAATTTTTAAAAAGCACTTGG
AGTGAGCGAACATTTCCTGATAAATGCCTTTTAGAGATAGGTTCTTGATATTCAGACATC
TGCAGAAATGTTCTGGTTCCCAAAGTCATTTCACTTCGAAATAAAACACAGCTCCTTCAA
ACAGCACTTTTTCCACATAAATCTAGTTGCCTCTCCCTGTGGACATTCAGAACTGATAGA
ACAAACACTACTCTTTTGAATTTGATGGTTCGTGTCCTTTAAAGTGTTTGAGGACCTATG
CAGAGCCTGTAACACTTGGGTAGTACCTGCCCGGGCCGCCCCTCGAAAGGGGC
Sequence 2913

CCCTTCGAGCGGCCGCCCGGGCAGGTACAATTGGGTAGGCCCAGAAGAGAGAAAAGAGAGCA AAATAGAGTAGTCAGGAAAAGAGGGCCCAGTTTGGGCGCCTGTTAGCTCCTGTGTGGTGT GAAAGGCACTCAGATGTTCCTGCATCTCTGATGGAAAACACAGAACCTGGCTCAGCTGAG AGACAACAGCTCTGTCATGGGGAGGTTGAAGTGACCCCACAGCAAAGTGGAGAAGTT GTTGAACAGAAGCTGTGGCAGAGACTCAAAGAGGCCTATAATGCTGGTGAGAACTATGGT GGCCTGAGTCATC

Sequence 2914

TABLE 1A 8/599

Sequence 2915

Sequence 2916

Sequence 2917

CCCTTAGCGTGGTCGCGGCCGAGGTACATTTACAGAAAGGCCACTGCAGCTGCATCATAG
TTCTATAACTCTTCAAAGTCCCCAGGCACCCTAAGTAGATAGCTTGAAGCTTCACCTTTA
CAAAGTCCAATCCATTGCATCAAAAGCCTACATTATCCCATTTCCTGTGGCCTAGAGATT
ACAAATCACCTGAAGTAATACCAAAACCCAGTGAGTAAAGACGGAAGTAAATCTAGTGAG
TTTCCAACCACCCACCGCCCCCGAGATCTTAAAGGAAGCAGTAACAAGCAACTAGAACTC
ACATGAGAATTTATAGGCCAAGAGAGTTTTAATGTAAGCATTCTTATAATTAAATAACCTCT
TACAAAAAAATGCCATTTAATCAGACAAGGGGAAAAAAAGTANCATCAAAAAGAGATGCTGAC
AAGGGAGACAATGAAATCAAAT

Sequence 2918

Sequence 2919

CCCTTAGCGTGGTCGCGGCCGAGGTACAGAGTATTTTAATCTTTAGGGGATCAAGATGTC AGATGCAAACAAAGCTGCCATTGCAGCAGAAAAGGAAGCTCTGAACTTGAAGTTACCCCC CATTGTCCATCTCCCAGAAAACATAGGCGTTGATACACCAACACAAAGTAAGCTGCTAAA ATACAGAANATCCAAGGAGCAGCAGCAGAAAATTAATCAGGTTAGTAATTGATGGAGCCC AAAAGAAATTTAGACAGAACACTGGGTAAAAAGAACACCTCTATTACCACCACCCTGATT

TABLE 1A 9/599

ATNCCTCAANACTATGACCAGTGAAAATGAAAAAAAAAAG

Sequence 2920

CCCTTAGCGTGGTCGCGGCCGAGGTACTGAGTTTGTGTTGTTAAGAGTTAAGGCCTTAAA CTTGGCTCAAAATAAATTTAACTGTGATTTCTCTAATTTTTAGTGCCTACTGTTTCACCA GACACCTAGAGTCAATAGTGTCCTAGAATCTACGGTGTCCAGGGCTTGAGCAAGATACTT TAGTGAATATAAACACTAACGAGACCTTGCCTTTTCTCAAGCCTACAGGATATCAGCCTA TTTGAAAAGTGACACTGGCTTTACACCCAGAAGCCCACAAAATAGAATGATGTAACTGAA TTTTTGGTAGCTCTCTGGGTAATTTATGTGGTGTTAGGACTCTTTGGGTTTGAAAGNAA AGAGACTCGTGATCCCATTCTGGCATTGACAGTAAACTTCATTGGA

CCCTTAGCGTGGTCGCGGCCGAGGTACAAATTATAATACACATACCAGACAAATTTTATT
AAATAATAAAGAAGGGAGAGAAAGAGCAAGACACTTTTTAAGCACCATGTGCCAGGCC
AGTGCTTGAATCTCTTCCTACGTTACTTCTCCTTATTATTTAACCGTTATTTAAATGTTA
CTACTCCCATTTTACAGATGGAGAAATTTAGCTTAAGGTAATGACAAGATTGAACTTCAA
GTTTTCTGACTCCAAAATATGCCCTCTTTCGACCACACCGTATTATCTCTAAATATGGAA
AACATTTCAAAAGTAGCAAGCGTNTTCAGAACAAAAACNAAAACAATCTAAGGGGGCTTA
CACATTATAAACATGGTTTCGGGGTCAT

Sequence 2922

Sequence 2925

TABLE 1A 10/599

CCCTTNTTGTGGTCGCGGCCGAGGTACAGTCCACAAAATGGTTTGCTTCTGAAAAAGCNG TAGTAGTCTTACATCCAAGATTATTCCTAAAATAAAGTTTCGACCCACATATATAATGAA ATTGAAACTGCCTACATTGGCAAAGCCAGAAAGAGGGTAAAAAAGATGGGGTAGGCCAGT TGCGGTGGCTCATGCCTGTAATCCCAGTACCTGCCCGGGCGGCCGCTCGAAAGGG Sequence 2927

Sequence 2928

CCCTTAGCTTAGCGTGGGCCGGGGCCGNAGTACATTTACAGAAAGGCCACTGCAGCTGCA TCATAGTTCTATAACTCTTCAAAGTCCCCAGGCACCCTAAGTAGATAGCTTGAAGCTTCA CCTTTACAAAGTCCAATCCATTGCATCAAAAGCCTACATTATCCCATTTCCTGTGGCCTA GAGATTACAAATCACCTGAAGTAATACCAAAACCCAGTGAGTAAAGACGGAAGTAAATCT AGTGAGTTTTCAACCACCCACCGNCCCCGAGATCTTAAAGGAAGCAGTAACAAGCCACCT AGAACTNCCATGANGAATTTTNTAGGCCNAGAGATTTTTAATGGTAAGCATTNTTATAAT TAAATACCTTTTACAAA

Sequence 2929

Sequence 2930

CCCTTCGAGCGGCCGGGCAGGTACGCGGGCAAGTCTGCATGGCAAAAAAGGTGTCC
ACAAGTGTGAATGGCTCATTTTTAATGACTAGCCAACAGCCACTTGTAAAAGATGTAATT
GAAATTGTTCAGAGATTAGGTTCCGTCTGCTTTGNCCTCCTTCTCAAAAGTTTTCATGGA
TCCAAGCTATTCTTAAGCATTGTTTAATCTAGGAAATAGCCTTTATGGACTAATNATAAG
AAAGAAAAAGGCANATTTTTAAAAGATATTCCAAATTCAAAAGAAAATAAGTTTGGGCAG
CCTGACTTTTGATTATCTGTAAAAAATCANGGCCAATAGTTTTGAACGGGAAGAGTAAAT
ATGAANGGTTTTCTAAACCAGTTTTTTCTTGGAAGAAGAGGGGTTGGNAGGTTAAGAAA
GTTNTTCTTTTTTTNATCNAGCCATGTGCCCTACCAAAAAAACATAAAATGGTGGTTTCCT
GTGAACCCTCAAAAAAAGTAAAATCAGTGAGTGNGATGNAGGGAATTNGGG
Sequence 2931

Sequence 2932

TABLE 1A 11/599

Sequence 2933

CCCTTTGGCCGCCCGGGCAGGTACTGAAACATCAAAACACCAGAATGAACATCAGGAGGG AAACATGAAAGTAGCCACTCCAAGTAAGGCTCCAGAACATACTCAAATGAAGGAACCAGG GCTTTACTGCGTGACCTAGATCAACAACAGAGCTGTTCTCCTTCTTTCAGCTAATCAGGA GCATTTAGTTGGGATTGGGAAAGAGGCAAAATATACATAGAGGTAGAAAATGAAGATTTA TATGGATAACTTCACAGCTGTTTTCCTGTGAACCACATTTCTAGCAATAAACTAATCCAA TTGGGAGGGAAAACAATATGTGAAGAA

Sequence 2934

CCCTTAGCGTGGTCGCGGCCGAGGTACGCGGGGCAAGCAGGTGTTCCATGAGCTGAGCCA GCAGACCCATGGCATCACCCGGCTGGGCCCCTACTCTCTGGACAAAGACAGCCTCTACCT TAACGGATGGACTCCGTGTTGGTCACTGTCAAGGCATTGTTCTCCTCCAATTTGGACCCC AGTCTGGTGGAGCAAGTCTTTCTAGATAAGACCCTGAATGCCTCATTCCATTGGCTGGGC TCCACCTACCAGTTGGTGGACATCCATGTGACAGAAATGGAGTCATCAGTTTATCAACCA ACAAGCAGCTCCAGCACCCAGCACTTCTACCTGAATTTCACCATCACCAAC Sequence 2936

CCCTTAGCGTGGTCGCNGCCGAGGTACTAAANACTAACATTTATTGAGCACTNACTAGAT NCCATAAACTGANATTGNCNTTGATCTNTGATTAATTAATCTCACAATCCTTTGCTTTTCT GAAGTATNTNATTCAATCCTTTGAATGTCCCTAATGCACAGATAAGGAAATAGGCTGCTC TNCANATAAGGAATACANATCCTTGTGGATTCAACCCAGATCTGACTTGAGGCTAAACTC CTAACCA

Sequence 2938

TABLE 1A 12/599

Sequence 2940

CCCTTAGCGTGGTCGCGGCCGAGGTACCAACTCATTATAAGCAGATCACAGTCATATAGT GAGAGAGAAAGAAAAACCTATGTAGATCTAGAGGAATTACCTAAGAATTCCTAAT TACATAGGATTAAGCTCTGGGCTAACATCAAATTTTAAGTAATTACTAAAATAATTTCTT TTCTTTCTTTTTTTTTGAGACAGAGTCTCATTTTGTCACCAAGGCTAGAGTGTAGTGGC TTGATCTCAGCTCACTGCAACCTCCACCTCCCGGGTNCAGGTGATTCTCCTGTCTCCAAG TAGCTGGGATTACAGGCATGCACCACCACCTCCAGCTCCTTTTTTTATTTTTAGGT Sequence 2941

CCCTTTAGCGGCCGCCCGGGCAGGTACAGTTCTGCTCAGAATGCCCTATCTCCTNANTAA ANNNNAANGNNGGAGANANGNCCTATTTTGGGAGAACTAATTTTGCAATTCCTGCCAATT TTTATGCATTTTGCCCTTGTTTCCATAATTCAGCACCTCCATCATCTCTTCATCACCTCC ATCAAGATACTTTCACTTCCTTTTAAAAGCAAAGATCTCTATTTAATGTAATGCTTCTCA GTTTATTTTTACACTTTTTTTCACCATGCTATCATTTTTACTGGGATTGTCACTG CTTTGGTTAATGCTCTGGTTACAAAGTGGCATTGCTGTGGGGCAGTCAGCTGTAACCC Sequence 2942

Sequence 2943

Sequence 2944

TABLE 1A 13/599

Sequence 2946

Sequence 2947

CCCTTCGAGCGGCCCGGGCAGGTACTACCCAAACCTAAATTTAGAAACAGGATTA
GAAAAATATCATTCCTATTCTTCTTGGCTATAAATTTACCCATCAAAGTTAAATTTAATT
ATACATTCTTAATAGTCTTGGATAGACAGGGCTTCACAGATAAATTGTAATTTAAGCAAG
AATTATTTTTCCTGTTTAACCCTAAACACAATAATGTGGTCTTTACTAGCTCATCTCAA
TTGAATATCATGCCTTAGTATTTGGGCTTTATATAATTTAGTGTGTATATTAATTTCTGC
TCCTGAGCTCTTATAAATGAAACTGCTGGGAGCTGTGCACAAGGCTTAAACTAAAGAAAC
CTCTTAAAGACAGTGTGGATATCACTGAAAGTATTTTGGGGGAAAACTAAATTTTAATGT
AAAAGAGAACAACTTTTAGAAAGAAGAGAACCATAAAAATAAAATGCAGCACCTCTTTGA
CTTTGNCTAATTCCTTGNGTCTTTCTGGGTGGAATTCTGTAGTCAATGNGGTTTAAAAAT
ACATCAGCACCCTTTGCTTCTNCCTATAATGGAAAAATTTAAATTTAAAACAAAA
Sequence 2948

CCCTTAGCGTGGTCGCGGCCCGAGGTACTTGTTTTTGGCCACAGGAATCTTAAGTGACTT
AATTAACAGGTGAGTGGCATTGCTCCTGAACAGAGCTACCTAGTTATAATCTGTGTTACC
TTTGCTTTAAAATGTTCTCTTTACTCCATTTCCTTAGTTGATATGCTTGAGGCATCTTGT
TGAATCCATCATTTATTCACCCACTCATTCATTTCACATGTATTTGCAGTTGCAAAGCAG
GCAGTAGGAATAAAATTAGGATCAAAATAAGGTAAGTAACGAAATTTGCTGAGTATG
TTCTGAGAGAATAGCTGAATATACATTTCTAAATGGACGACAAATCCATTTGGAAGTCTT
TCTCCTCCTGTTATTTTGGTAA

Sequence 2949

CCCTTAGCGTGGTCGCGGCCGAGGTACCGTAAATGGAAATTATCCCGCAAATTACGGCAT CTCCAAATGTAGCGTGGAAACTAATATTGACATGTCAACACAGGATTAATACATAGTAAT CAAAGAGTGCTTAAAAATTCATTAAAAATGAAGTCCCACCTCTAAAAGTGAAATGTGCAA ATTAAAGTAGCAGTTAGATAATGTTTTGTCATTTAGGTAAAAATTACAAAAGAATCGGCC GGGCGCGGTGGCTCACGCCTGTAATCCCAGCACTCTGGGAGGCCGAGGCCGGCAGATCAC CTGANGTCANGAGTTCAAGACCAGCCTGGCCATGGTGAAACCCCGTCTCTACTAAATATA CCANGAAATTAGTTGGGGCCGTGGTG

Sequence 2950

TABLE 1A 14/599

Sequence 2951

Sequence 2953

Sequence 2954

CCCTTAGCGTGGTCGCGGCCGAGGTACAACGTGGGCAAGCATCTGTGCATATGAAATGCT GTTTTCTAAAAGATTTCTCACATTGGCAAACTGAGAGATTTTCTTCTGGAACACAGGAA AGATTATTAATGCTNATAGCCATACCATGTCTGAATATGGGAGGATGACAGACACNGA ACGAGACCAGATAGACCAGGATGCCCAGATATTCATGAGGACCTGTTCAGAAGCAAAGGG Sequence 2955

Sequence 2956

Sequence 2957

TABLE 1A 15/599

Sequence 2958

Sequence 2960

CCCTTAGCGTGGTCGCGGCCGAGGTACAAAATTGCTTGAGTCTGAAGAACCTGCTANGGA GCATATACATCTTCAATTAACCTACAACTGGTCTTCAGTAAAACCTCTGTCCCTGNCACA CTGAATNTGGTGTAAGTCATTTTTAAAACTTCTGGCCAAAACCCAACCATAATATGCTTT CTTGTAAGCCANCTTCATATACCTAAAGAAAACATGTGAAAGGCCGGGCACCGATGGCTC ACTCCTGTAATCCCAGCACTTTGGGAAGACGAGGGGG

Sequence 2961

CCCTTAGCGTGGTCGCGGCCGAGGTACCCACTGATGTCGTCATGGTGGCAAGTCAGTGTT GGCCCTGTCCTAACCACAGGGAAGGGGTTCTCTACAGAAAAGTAGAGTTTAGATCTGAGA AGGTAGTTGAGAATGAGTGCCGTATAGTGAATAATAGTAGATTTTTACCCCATTTTACCC CTTTGTCTTTGGTTGTATATATATTCACATACCATTCTAATTATACATATAGTTTCAAAA ATGCCTCTGCTTCTCCAAACACAACTATACTTTATATATTTTCAAAAACAGTTCTACC TCCTTCTTCCAAAGATAAATATCTGTGTTTTGTGTCCTCCATGGCCACCCCTAAGAGAGG TGCAAGGAGGATTTCATTCCTGGGAATTACCTACTTTAATAGCCT

Sequence 2962

Sequence 2963

TABLE 1A 16/599

AAATGCATTTGGAAAGGATCTGTTNTCTTCCCAGGTTTCCTGCCTGGGTTGAAAATAAAG GGTTCAGGGGATGGAAACAACTTTGAGGAACATAAAGAGGTATTGGGGGTTCATCAATTC ATCTTTGTTTCAAGATGGGTCCCCCCCACCCTCCNCAATGCAAGTTAATTAGGGAGATAA TTTTAGCCTACCTTTGGGAATTNATNTNTAAANATAAAGTTATCTTTTTTTTAANGCTTTG TCACTTTAATTGNCCNCCCCTGNATTTGATAANGAAAAGTAGTTTTTTTTCTTATTTGACC NCTNTTTTNGANTGNCTATTNGGAANNCNTTTTATTTTGGGNACTTTTTTTGGGGGGTGGG AAAGGAAAGTTAAATT

Sequence 2964

CCCTTAGCGTGGTCGCGGCCGAGGTACAAAGAAGCTGAGTGATTTGTTGAGGTCCCAGTG GAGTGTCAGACCTAAACTTCCAGTTTCCCAATTACTTAAATAAGGTTCTTCTCATCAGAC CCTCTTTCCTCATCTCTCTACTAAAAAACTACAGTGAATAACTTCCACTGTCATCAAATA GAAACTTTCTGTGCTGGTTTCCCCTACCCCACCTTTCTGTGCTTGATAACAGAAGCTGTT GGGAGCCCCACCTTCAGTCTTATTTGTCCTTCCTTGCNGGTTTTTCTTTG Sequence 2965

Sequence 2966

CCCTTAGCGTGGTCGCGGCCGAGGTACTGTTGTTCCAGACTGTATGATTGAAATAGCTGT
TATTTTCCCAGTTTCTGTAGATCACATATAGGAAGTTCTGCATAATCATAGTGATGAAAA
CTCATGTTTAAAAAAATCCATATAAATAGCGTGATACAACACAGCATCTTAACACTGAG
GCTTTAAGTTTTAATAATTCTGTTATTCTCAGTAACACTGAAAGTTGCCTGTGCTCTTTC
TGTCACACAATTGATTCCAATGTATTTTAAAATGTGTTTTTCTGAGTCATTTGTTGCCTT
GTTACTTTTTAAA

Sequence 2967

GGNACTTAGCTGGGAATCTGCATCTTTAGAGNTCAAAACTGTGCAGTTTTTCCTCTGATT AGGTATTATNATGTTGAACTCCAAAGGGTCATTTACATTCCTTTATAACACTGGAGCTCT GGTGTATCGAATTGNGTTATGAGATAAGCCACTNGCAGGGACTTGAACATTTCTTTAGATTTTGTNGTATCAGCATGTGAATATGCTGAATACAACTTGTATCCTAAAGCATAC AANCTATAACATTTTCACGTTGGACTCAAATTTC

Sequence 2968

CCCTTAGCGTGGTCGCGGCCGAGGTACCTGGAAGGCCCCACTGTTACTTCTTCATACAGG
CAAAAGCTAATCAACTATTTCACCTTGCAGCTAAGTCAGGACAGAGTGACTTGGAGAAGT
GCAGATGAACTCCCGTGGCTTTTTCAGCAGCAGGGAAGTAAACAGAAGCTGCATGATTGC
CTTCTTAATCTCTTTGTGTCTCAAAACCTTTATAAAAGGGGACACTTTGCTGAGTTGCTG
AGTTATTGGCAGTTTGTTGGCAAAGACAAAAGTGCAATGGCAACAGAATACTTCGATTCA
TTGAAGCAGTATGAGAAAAACTGCGAAGGCGAGGACAACATGAGTTGCTTAGCTGATCTT
TATGAAACCTTGGGGCGATTTCTCAAGGATCTTGTGTTCACTCTTCTCTTTTTCCAAGA
TGTTAATGTGGTTTTCATTTGTTGTGTCATATATTTTAATCAGATGACAGATC
TTGCAGCATTTCACTCACTTTAACTGGCCTTTCACCCCTTT

Sequence 2969

TABLE 1A 17/599

CTCAGCTACTTGGGAGGTTGAGTGGGGAGGATCGTTTGAGCCCAGGAGATTGAGGCTTCAGTGAG

Sequence 2970

Sequence 2971

CCCTTAGCGGCCGCCCGGGCAGGTACGTGTCTGTGGTCCCGACTACTGGGGAGGCCAAGG
TGGGAGAATTGCTTACGACCAGGAGTTTGAGTCCAGCCTGGGCAACATAGCAACACCCCA
TATCTTATTTAAAAAAAAAGCACTCTATGTTTGTTTTTGGGCCTCTTTGAGAACATTTACTA
TGAAATTTTATCTTTGTTTCCTTTCAGTTCTTTTGTTTATTGTGATTATCTTT
CATATAACAATGTGCTTAAATAGCTGGTGGTTCTTGATAGGTCACTCAACAAGTGAGCAA
ACTGATGGATCCTGTGTTTTGTGAGCAGTGTTTATTGGCTGTGATAGAGGGTGGGGACCT
AGATGCTTTTAGGGGGATCCTCCTGTTATCCATTTCTG

Sequence 2973

Sequence 2974

TABLE 1A 18/599

Sequence 2975

Sequence 2976

Sequence 2977

Sequence 2979

ACGCGGCTCCAATITAATTCTTTTAGTTGAATGAGCTTCTTTCTCGCTTGTTACAGACT CACTTAGGGCTCATTCCTCCCTGCCTTAGTCCCAGTATGGTCTCAGTAATGACATGCAGT ATGGGGACTTTGGACTCCTGTTTGAACAAACCAGCTTTGAGATAAAAAATTTGAATAT GAATTGAGTTCTTGAAGATAAGAAATTGTTAATTTTGTCAGGTTTGTTAATGGCATGGTA GTTACTCTAAAAACCAAATTTCTGGGCGAGTGTAGTGGCTCATGCCTGCAATCCTAGTACC TCGGCCGCGACCACCGCTAAGGGCGAATTCC

Sequence 2980

TABLE 1A 19/599

CCCTTAGCGTGGTCGCGGCCGAGGTACTAAAAACTAGTAATGCAAAGGCAGCAATGTTAG CAAAATTTAAAGAGTTATACCGGGGTGAGTTTTACAGAATTAGTAAGACCATTTAAAAGT AATAAATCAACGTGTTGCGATTGGTGTATTGCTGCATTTGGACTTACACCCAGTATAGCT GACAGTATAAAAACACTATTACAACAATATTGTTTATATTTACACATTCAAAGTTTAGCA TGTTCATGGGGAATGGTTGTGTTACTATTAGTAAGATATAAATGTGGAAAAAATAGAGAA ACAATTGAAAAAATTGCTGTCTA

Sequence 2984

CCCTTTCGAGCGGCCGCCCGGGCAGGTACGCGGGGAGCGCCCGGAAGAAAAACCAGCAA GAAGGCGGCGGGGGAAGAAGAAGCCAGCAA GAAGGCGGCGGGGGAAGAAGTGCCGGTCCTGGGGTAGAGTTTGCAAGCTTTCTGACTAGGCT AGTCGAGCAACTATTCGGGTCATGGCGTCAAACTCAACTAAGTCTTTCCTGGCAGATGCC GGCTATGGCGAACAGGAACTGGATGCCAACTCTGCCCTTATGGAATTGGACAAAGGCCTA AGATCTGGCAAACTTGGTGAACAGTGTGAAGCAGTTGTTCCCAGACTTTTTCAG AAGTATCCATTCCTATTCTTATCAATTCTGCATTCCTAAAGTTACCCAACAAAGTGAGAAACAT TTGGAGAAGAATTTTCCTGAGGCTATGTTCTTAAAGTTACCCAACAAAGTGAGAAACAT TTGGAGAAGAGATTCTAAATGTGGATGAATTTGNGAAGAGAATTTTTTCTGGGATTCATAGT AATGATCCTGTGGCAAGAGGCCATCACCCTCCGGAT

Sequence 2985

Sequence 2986

CCCTTAGCGTGGTCGCGGCCGAGGTACCAACAGCAGTGAACCAGGGCCTANTTGTCAGCA

TABLE 1A 20/599

Sequence 2987

Sequence 2988

Sequence 2989

Sequence 2991

TABLE 1A 21/599

CCCTTAGCGTGGTCGCGGCCGAGGTACATTGTATACTGCAGTGTCGTCTACATGGCATTG GACAGGACATAATGTAAAACATAAAAGTGCAATTGTTACACTTACATATGATAGTGAATG GCAACGTGACCAATTTTTGTCTCAAGTTAAAATACCAAAAACTATTACAGTGTCTACTGG ATTTATGTCTATATGACAAATCTTGATACTGCATCCACAACATTATTGGCGTGCTTTTTG CTTTGCTTTTGTGTGTCTTGTGTGTCTGCCTATTAATACGTCCGCTGCTTTTGTCTGTG TCTACATACACATCAT

Sequence 2993

Sequence 2994

CCCTTCGGCCGCCCGGGCAGGTACATTTAAAAGGTGATGCTAATACTTTAAAATGTTTAA GATATAGATTTAAAAAGCATTGTAAAATTGTATACTGCAGTGTCGTCTGCATGGCATTGGA CAGGACATAATGTAAAACATAAAAGTGCAATTGTTACACTTACATATGATAGTGAATGGC AACGTGACCAATTTTTGTCTCAAGTTAAAATACCAAAAACTATTACAGTGTCTACTGGAT TTATGTCTATATGACAAATCTTGATACTGCATCCACAACATTACTGGCGTGCTTTTTGCT TTGCTTTTGTGTGCTTTTGT

Sequence 2996

Sequence 2997

TABLE 1A 22/599

CCCTTCGAGCGGCCGCCGGGCAGGTACATGTTCCTTCCCTTACTTTGGGGAGTCTAGG
TTGTGAATTTGAAACAAAATCAGATTCTTTCATCTTCCCTTTCCCCTCAAATTCCTGAG
AAAACCTCCAACCTTCTAAATTTATAGCAAAATCAACTATAATTATGTGTTTCCATTTGAA
ATTCAAGCTAAAATAACATACTTTAAAAAGTGTATCTTAAAAATCATATTTCGCTTCAAA
AAAACTTGTTAAAAGTAATTTGCATCAGATCCTGGAGTCGACTTGAAGAATTCTCCTACA
TCTGACACCCAGTTAGGCCCTTTGAGAAAGAGAAAAAGAGAATTTTTTAATGCATGTTT
GATTATGGCCATCTCTTTTCTTAGAAGGTAGAAGATAGCACCATGCCGATTCGTCGAACT
GTGAATTCTACCCGGGAAACTCC

Sequence 2998

Sequence 2999

ACATCTGCACATTGTGCAGGTTAGTTACATATGTATACATGTGCCATGCTGGTGCACTGC
ACCCACTAAATCGTCATCTAGAAGTGTTTTCTAATTTTATTTGTAATTTCTTCTTTGTTC
CATTGGCTGTTGAAGAATGTGTTGTTTGGCCGAGCACAGTGGCCCACGCCTGTGATCCCA
GCACTTTGGGAGGCCGAGGCAGGTGGATCACGAGGTCAGGAGATCCCCGCGTACATCTAT
TTAAAAGTCAATACACAGGAAAAAAGGTCTGGAAGAATATATACTAGAAAAGAATGGTTAC
CTCTAGGGGATGGAGTGTCAAGGTGAATTTTGGTTTATTCATACTGTCTAAATGATTGCT
TAATAACTCAGGTATTGCTTTCAAAAAGTAAGAGGAAGGGTGGGAAATACCCTGTTCTCT
CANAATTTTAAGTCCAGAGTGCTGGGGAGAAAAANATGGCAGCACTTGANCGGGACTGAA
AAAGT

Sequence 3000

Sequence 3001

CCCTTAGCGTGGTCGCGGCCGAGGTACAGATGGGGTTTCACTGTGTTAGCCAGGATGGTC
TTGATCTCCTGACCTCGTGATCTGCCCGCCTCGGTCTCCCAAAGTGCTGCGATTACAGGC
GTGAGCCACTGTGCCCAGGCCTATTGGGGGTTATGCAGGTTCCTTTGCTTGGCCATGGTA
GATGGCTAAGTCTTTGCTTCCAAGTTCTTTTGACCATGAGACATGTAGAGCCAGGGAGGA
AAGAGAAAACCCAAACCAGGTCACTGTTACCTGTGAATAACATCTTGATCGAGTTCTGAG

Sequence 3002

Sequence 3003

TABLE 1A 23/599

ATGGCAACGTGACCAATTTTTGTCTCAAGTTAAAATACCAAAAACTATTACAGTGTCTAC TGGATTTATGTCTATATGACAAATCTTGATACTGCATCCACAACATTACTGGCGTGCTTT TTGCTTTGTGTGTGC

Sequence 3004

CCCTTAGCGTGGTCGCGGCCGAGGTACCATGTTCTAAAGGCAATCGAGTCATAATACACT
GAAAGCAGTCCAAGAGCAGCAAGAGACTTTGCTGCAGCTGTAGATCACTGGATCGGTAAC
TCGTAGTTAAAGGAAATCCCTACCCACTCCCATCCAGCCCCTACCCCCTAATTATGGGAC
AAAATAGCCAATTCAATGAGATTTAAACAGGAAGTTCACAAGAGGAACTCTTATACCTAT
GAGGACCCATTAACCAGGGATTCCACAACCAGTAGAATATTATCTACTGGTAGCTATTTA
AGCCTTACCTGACAGGTCTCCAAGCCAGCCGCAGCAGCCACATCCCTCTCTGCGCCATAA
ACGTCTCGCCTCAGTTTCCTGAAATTCCCAACTGAGAANGGAATATAGCCAGCAGGCACT
CCCAACCCTGTTATGATTCTACAGTTCTACTGTTAGTAAATTTCCCAGGGGCATCACAAT
CTGTGTCCTTACACATGCATACACAGAGGAGCTTCCTTTTTANGGATGAGCTCCTCATTA
CAGGGC

Sequence 3005

Sequence 3006

Sequence 3007

CCCTTAGCGTGGTCGCGGCCGAGGTACATGATTCTACACTGAATCTGCATTTCACTCCCA
TATCTATACCAGAAGGTTATCAGTGGAAGAGAAATTCAGTTATCTTGAATGGACATGATC
TTCTCAGGAGCAGTCAGTGGTTAATTGGGACAAGAAAACACAAGTCATTATCATTGAGAA
ATCTGAAGCAAATTGAGGCAGGTTGTCACCTTTCACCAGGAAACAAATTAGCCCTGTCTT
TAAAAAGACTTCTTTCTCTCTCTGCTGACTGGGGATTCCTGTCAACTGCCAATGAAATAG
GGAGAGTGTAGATTAATGGC

Sequence 3008

CCCTTAGCGTGGTCGCGGCCGAGGTACTAACCATATGAAAATAGTTGCTACCTTGTTGGA CAGGACAGATATACAAAGCATTTCCATTTTTACAGAAAATGTGTATGGATACCATGGAGG TTTGAAATAAATGCTGAGTTCATTCAAACTATAGTGAAATACAGCATGTGAAAAAGTAAT TACTTATTGACTATAAATAAATGCTTCATAAAATATAATAGATGCTGATTCTGGCCAAGAT TGACAAAATCTAATGCAGCCTACATGTCTCAGTGGTTAATACTAAGACTCTGAATAAAAT ACAAGCAAATAAACA

Sequence 3009

CCCTTAGCGTGGTCGCGGCCGAGGTACCTTTGCCAGTTTCTGGCATATTAACAGCTGAGA TCAGATAAGTGAACAGCGATAGAGGTAGTGAGGTTTAGGATTCAGGTCTGCCACCGGGAG